0000950170-24-12337210-Q Athira Pharma, Inc. 20241107202411071615281615291615291529 0 0000950170-24-123372 10-Q 70 20240930 20241107 20241107 Athira Pharma, Inc. 0001620463 2836 453368487 1231 10-Q 34 001-39503 241435962 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 M3 Biotechnology, Inc. 20140924 10-Q 1 atha-20240930.htm 10-Q 10-Q Q30001620463--12-31false0001620463atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyFourInducementEquityIncentivePlanMember2024-09-300001620463atha:WangVAthiraPharmaIncMember2024-01-012024-09-300001620463us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001620463us-gaap:AdditionalPaidInCapitalMember2024-03-310001620463atha:ExercisePriceTwoMembersrt:MaximumMember2024-01-012024-09-300001620463us-gaap:AdditionalPaidInCapitalMember2023-06-300001620463202312-31000162046 3atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember2023-12-310001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001620463us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001620463us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001620463us-gaap:CommonStockMember2024-04-012024-06-300001620463us-gaap:AdditionalPaidInCapitalMember2023-09-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001620463202309-300001620463us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001620463us-gaap:RestrictedStockUnitsRSUMember2024-09-300001620463202407-012024-09-300001620463atha:ExercisePriceOneMember2024-09-300001620463atha:JawandhaVAthiraPharmaIncMember2024-01-012024-09-300001620463atha:ExercisePriceOneMembersrt:MaximumMember2024-01-012024-09-300001620463atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember2024-01-012024-09-300001620463atha:WashingtonStateUniversityLicenseAgreementMemberatha:PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember2015-12-310001620463us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001620463us-gaap:RestrictedStockUnitsRSUMember2023-12-310001620463202309-300001620463us-gaap:CommonStockMember2024-07-012024-09-300001620463us-gaap:RetainedEarningsMember2024-04-012024-06-300001620463us-gaap:LeaseholdImprovementsMember2024-09-300001620463atha:SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember2024-09-300001620463202301-012023-03-310001620463us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001620463srt:MinimumMemberatha:ExercisePriceTwoMember2024-01-012024-09-300001620463us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001620463atha:ExercisePriceThreeMembersrt:MinimumMember2024-01-012024-09-300001620463atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember2024-09-300001620463atha:ShortTermInvestmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001620463us-gaap:CommonStockMember2023-03-310001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001620463us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001620463atha:EmployeeStockPurchasePlanMember2023-01-012023-09-300001620463us-gaap:CommonStockMember2023-12-310001620463us-gaap:RetainedEarningsMember2023-04-012023-06-300001620463srt:MinimumMemberatha:ExercisePriceOneMember2024-01-012024-09-300001620463atha:StockOptionsToPurchaseCommonStockMember2024-01-012024-09-300001620463atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember2024-01-010001620463atha:TwoThousandAndTwentyEquityIncentivePlanMember2024-01-012024-09-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001620463atha:LaboratoryAndOfficeFacilitiesMemberatha:BothellWashingtonMember2024-01-012024-09-300001620463atha:AtTheMarketOfferingMember2023-01-012023-01-310001620463202301-012023-09-300001620463atha:TwoThousandAndTwentyFourInducementEquityIncentivePlanMember2024-01-012024-09-300001620463us-gaap:CommonStockMember2023-01-012023-03-310001620463us-gaap:RetainedEarningsMember2023-07-012023-09-300001620463atha:LaboratoryAndOfficeFacilitiesMemberatha:BothellWashingtonMember2024-09-300001620463us-gaap:AdditionalPaidInCapitalMember2024-09-300001620463atha:WashingtonStateUniversityLicenseAgreementMember2015-12-310001620463us-gaap:RetainedEarningsMember2024-01-012024-03-310001620463us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001620463atha:ShortTermInvestmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001620463us-gaap:CommonStockMember2022-12-310001620463atha:FurnitureFixturesAndComputerEquipmentMember2023-12-310001620463us-gaap:CommonStockMember2024-09-300001620463202401-012024-03-310001620463us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001620463us-gaap:FairValueMeasurementsRecurringMembersrt:MaximumMember2024-01-012024-09-300001620463us-gaap:CommonStockMember2024-01-012024-03-310001620463us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001620463us-gaap:CommonStockMember2024-06-300001620463us-gaap:LeaseholdImprovementsMember2023-12-310001620463atha:ExercisePriceThreeMember2024-09-300001620463us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001620463us-gaap:RetainedEarningsMember2024-07-012024-09-300001620463us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001620463atha:SlyneVAthiraPharmaIncMember2024-01-012024-09-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001620463atha:WashingtonStateUniversityLicenseAgreementMember2015-01-012015-12-310001620463us-gaap:RetainedEarningsMember2023-09-300001620463202212-31000162046 3atha:ShortTermInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001620463us-gaap:RetainedEarningsMember2023-12-310001620463us-gaap:AdditionalPaidInCapitalMember2023-12-310001620463202304-012023-06-300001620463atha:AthiraPharmaIncVDrKawasMember2024-01-012024-09-300001620463us-gaap:CommonStockMember2023-04-012023-06-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001620463us-gaap:RetainedEarningsMember2023-03-310001620463202210-12-012022-12-310001620463202304-03-310001620463atha:EmployeeStockPurchasePlanMember2024-01-012024-09-300001620463atha:AtTheMarketOfferingMembersrt:MaximumMember2023-01-310001620463us-gaap:RetainedEarningsMember2022-12-310001620463us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001620463atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember2024-09-300001620463atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember2023-12-310001620463202307-012023-09-300001620463us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001620463atha:TwoThousandAndTwentyFourInducementEquityIncentivePlanMember2024-02-290001620463us-gaap:RetainedEarningsMember2024-03-310001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001620463atha:LaboratoryAndOfficeFacilitiesMemberatha:BothellWashingtonMembersrt:MaximumMember2024-09-300001620463202310-012023-12-310001620463202306-300001620463us-gaap:CommonStockMember2024-03-310001620463202406-300001620463atha:NonVestedRestrictedStockUnitsMember2024-01-012024-09-300001620463us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001620463atha:PhaseTwoClinicalTrailInitiationOfLicenseAgreementMemberatha:WashingtonStateUniversityLicenseAgreementMember2020-01-012020-12-310001620463202303-310001620463us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001620463202301-012023-12-310001620463us-gaap:RetainedEarningsMember2024-09-300001620463atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember2023-12-310001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001620463atha:StockOptionsToPurchaseCommonStockMember2023-01-012023-09-300001620463atha:LaboratoryEquipmentMember2023-12-310001620463atha:LaboratoryEquipmentMember2024-09-300001620463202404-012024-06-300001620463us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001620463atha:NonVestedRestrictedStockUnitsMember2023-01-012023-09-300001620463atha:WashingtonStateUniversityLicenseAgreementMemberatha:LicensedProductsMember2024-01-012024-09-300001620463us-gaap:AdditionalPaidInCapitalMember2023-03-310001620463atha:ExercisePriceThreeMembersrt:MaximumMember2024-01-012024-09-300001620463atha:ExercisePriceTwoMember2024-09-300001620463us-gaap:CommonStockMember2023-09-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001620463atha:FurnitureFixturesAndComputerEquipmentMember2024-09-300001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001620463atha:WashingtonStateUniversityLicenseAgreementMember2024-09-300001620463us-gaap:CommonStockMember2023-06-300001620463atha:LaboratoryAndOfficeFacilitiesMemberatha:BothellWashingtonMembersrt:MinimumMember2024-09-300001620463202401-012024-09-152024-09-150001620463202412-11-040001620463us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001620463us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001620463us-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001620463us-gaap:RetainedEarningsMember2023-01-012023-03-310001620463us-gaap:AdditionalPaidInCapitalMember2024-06-300001620463us-gaap:AdditionalPaidInCapitalMember2022-12-310001620463us-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001620463atha:TwoThousandAndTwentyEquityIncentivePlanMember2024-01-010001620463us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001620463srt:ScenarioForecastMember2024-12-310001620463us-gaap:RetainedEarningsMember2023-06-300001620463us-gaap:RetainedEarningsMember2024-06-30xbrli:purexbrli:sharesatha:Segmentiso4217:USDxbrli:sharesiso4217:USD Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Â FORM 10-Q Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from ____ to ____ Commission File Number: 001-39503 Â Athira Pharma, Inc. (Exact name of registrant as specified in its charter) Â Â Delaware 45-3368487 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) Â 18706 North Creek Parkway, Suite 104 Bothell, Washington 98011 (Address of principal executive offices) (425) 620-8501 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share ATHA The Nasdaq Stock Market LLC Â Â (The Nasdaq Global Select Market) Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act: Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜’ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of November 4, 2024, there were 38,669,073 shares of registrantâ€™s common stock, $0.0001 par value per share, outstanding. Â Â Table of Contents Â Â Page PART I. FINANCIAL INFORMATION 5 Item 1. Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations and Comprehensive Loss 6 Â Condensed Consolidated Statements of Stockholdersâ€™ Equity 7 Condensed Consolidated Statements of Cash Flows 9 Notes to Unaudited Condensed Consolidated Financial Statements 10 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3. Quantitative and Qualitative Disclosures About Market Risk 37 Item 4. Controls and Procedures 37 PART II. OTHER INFORMATION 38 Item 1. Legal Proceedings 38 Item 1A. Risk Factors 40 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 96 Item 3. Defaults Upon Senior Securities 96 Item 4. Mine Safety Disclosures 96 Item 5. Other Information 96 Item 6. Exhibits 97 Signatures 98 Â This report includes our trademarks and registered trademarks, including Athira, Athira Pharma, the Athira logo, and other trademarks or service marks of Athira. Each other trademark, trade name or service mark appearing in this report belongs to its holder. Â 2 Â SUMMARY RISK FACTORS Â Our business is subject to numerous risks and uncertainties, including those highlighted in the section of this report captioned â€œRisk Factors.â€ The following is a summary of the principal risks we face: â€¢We are a clinical-stage biopharmaceutical company with a limited operating history. â€¢Our development of ATH-1105 may never lead to a marketable product. â€¢Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives. â€¢Our approach to targeting neurotrophic factors through the use of small molecules is based on a novel therapeutic approach, which exposes us to unforeseen risks. We have limited data from preclinical studies and clinical trials to date, including for ATH-1105, and we cannot be certain that future trials will yield data in support of the safety, efficacy and tolerability of our drug candidates. â€¢We may not be successful in identifying and implementing any strategic transaction and any strategic transactions that we may consummate in the future may not be successful. â€¢We have concentrated our research and development efforts on the treatment of central and peripheral nervous system degenerative disorders, a field that has seen very limited success in product development. â€¢Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of early, smaller-scale preclinical studies and clinical trials with a single or few clinical trial sites may not be predictive of eventual safety or effectiveness in large-scale potentially pivotal clinical trials across multiple clinical trial sites. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. â€¢We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success. â€¢We are and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations, securities class action litigation and other legal, regulatory and administrative proceedings and face potential liability and expenses related thereto, which could divert management's attention, and insurance coverage may not be sufficient to cover all costs and damages. This could have a material adverse effect on our business, operating results and financial condition. â€¢An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at Washington State University, or WSU. The special committeeâ€™s findings included that (1) our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSUâ€™s dihexa patent, exclusively licensed to us, incorporated certain of these altered images. â€¢Any â€œtoplineâ€, interim, initial, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. â€¢Our reporting of topline or final data for our clinical trials may be delayed and our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented. â€¢If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. â€¢We will require substantial additional funding to finance our operations, complete the development and commercialization of ATH-1105 and develop and commercialize other current and potential drug candidates. If we are unable to raise this funding and access capital when needed, we may be forced to delay, reduce, or eliminate our drug product development programs, commercialization efforts or other operations. â€¢Our success

depends on our ability to protect our intellectual property and our proprietary technologies. 3 Â â€¢If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. â€¢We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the drug candidates we develop, our commercial opportunities will be negatively impacted. â€¢The loss of any of our key personnel could significantly harm our business, results of operations and competitive position. â€¢We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. â€¢The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our drug candidates, we will not be able to commercialize, or will be delayed in commercializing, our drug candidates, and our ability to generate revenue will be materially impaired. â€¢We rely on third parties to conduct our nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our drug candidates. â€¢Even if approved, our drug candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success. â€¢We have never commercialized a drug candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any drug products on our own or together with suitable collaborators. â€¢Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as â€œmarch-inâ€ rights, certain reporting requirements and a manufacturing preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers, which could adversely affect our ability to successfully develop and commercialize our drug products. â€¢If we do not regain compliance with or continue to satisfy the Nasdaq continued listing requirements, our common stock could be delisted from the Nasdaq, which may make it more difficult for investors to sell shares of our common stock and consequently may negatively impact the price of our common stock. â€¢The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors. â€¢We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert managementâ€™s attention. â€¢Actions by activist stockholders have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of our business. Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part. 4 Â PART Iâ€”FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) Athira Pharma, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (unaudited) Â Â Â Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 68,856 Â Â $ 90,584 Â Restricted cash, current Â Â 8,373 Â Â Â Â â€” Â Short-term investments Â Â â€” Â Â Â Â 56,835 Â Prepaid expenses and other current assets Â Â 3,145 Â Â Â 5,682 Â Insurance recovery receivable related to legalÂ Â Â settlement (Note 7) Â Â 1,628 Â Â Â 1,628 Â Total current assets Â Â 82,002 Â Â Â 154,729 Â Restricted cash, non-current Â Â 631 Â Â Â 631 Â Property and equipment, net Â Â 2,687 Â Â Â 3,388 Â Operating lease right-of-use asset Â Â 871 Â Â Â 1,049 Â Other long-term assets Â Â 55 Â Â Â 448 Â Total assets Â $ 86,246 Â Â $ 160,245 Â Liabilities and stockholders' equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 388 Â Â $ 129 Â Accrued liabilities Â Â 16,961 Â Â Â 18,343 Â Accrued legal settlement (Note 7) Â Â 10,000 Â Â Â 10,000 Â Current operating lease liability Â Â 402 Â Â Â 368 Â Total current liabilities Â Â 27,751 Â Â Â 28,840 Â Operating lease liability, less current portion Â Â 912 Â Â Â 1,217 Â Total liabilities Â Â 28,663 Â Â Â 30,057 Â Stockholders' equity: Â Â Â Â Â Â Common stock, $0.0001Â par value; 900,000,000Â shares Â Â Â authorized at September 30, 2024 and December 31, 2023, Â Â Â respectively; 38,669,073Â and 38,172,603Â shares issuedÂ Â Â and outstanding at September 30, 2024 and December 31,Â Â Â 2023, respectively Â Â 4 Â Â Â 4 Â Additional paid-in capital Â Â 448,719 Â Â Â 439,739 Â Accumulated other comprehensive income (loss) Â Â 3 Â Â Â (349) Accumulated deficit Â Â (391,143) Â Â (309,206) Total stockholders' equity Â Â 57,583 Â Â Â 130,188 Â Total liabilities and stockholders' equity Â $ 86,246 Â Â $ 160,245 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 5 Â Athira Pharma, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 17,922 Â Â $ 27,202 Â Â $ 61,312 Â Â $ 70,110 Â General and administrative Â Â 7,572 Â Â Â 7,840 Â Â Â 19,897 Â Â Â 26,342 Â Legal expense Â Â 4,127 Â Â Â â€” Â Â Â 4,127 Â Â Â â€” Â Total operating expenses Â Â 29,621 Â Â Â 35,042 Â Â Â 85,336 Â Â Â 96,452 Â Loss from operations Â Â (29,621) Â Â (35,042) Â Â (85,336) Â Â (96,452) Grant income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 157 Â Other income, net Â Â 880 Â Â Â 2,072 Â Â Â 3,399 Â Â Â 5,908 Â Net loss Â $ (28,741) Â $ (32,970) Â $ (81,937) Â $ (90,387) Unrealized gain on available-for-sale securities Â Â 41 Â Â Â 261 Â Â Â 352 Â Â Â 1,278 Â Comprehensive loss attributable to common stockholders Â $ (28,700) Â $ (32,709) Â $ (81,585) Â $ (89,109) Net loss per share attributable to commonÂ Â Â stockholders, basic and diluted Â $ (0.75) Â $ (0.87) Â $ (2.13) Â $ (2.38) Weighted-average shares used in computingÂ Â Â net loss per share attributable to commonÂ Â Â stockholders, basic and diluted Â Â 38,517,602 Â Â Â 38,054,583 Â Â Â 38,406,709 Â Â Â 37,993,002 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 Â Athira Pharma, Inc. Condensed Consolidated Statements of Stockholdersâ€™ Equity For the Three and Nine Months Ended September 30, 2024 (in thousands, except share amounts) (unaudited) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accumulated Â Â Â Â Â Â Â Â Common Stock Â Â AdditionalPaid-In Â Â OtherComprehensive Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Income (Loss) Â Â Deficit Â Â Equity Â Balance as of January 1, 2024 Â Â 38,172,603 Â Â $ 4 Â Â $ 439,739 Â Â $ (349) Â $ (309,206) Â $ 130,188 Â Issuance of common stock upon vesting ofÂ Â Â restricted stock units Â Â 154,049 Â Â Â â€” Â Â Â â€” Â Â Â â€”

using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.Research and Development ExpensesResearch and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Companyâ€™s drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Companyâ€™s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables. 11 Â Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.General and Administrative ExpensesGeneral and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred.LeasesThe Company adopted Accounting Standards Codification, or ASC, Topic 842 â€“ Leases effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use, or ROU, assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Companyâ€™s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Companyâ€™s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Companyâ€™s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.The Companyâ€™s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Companyâ€™s lease agreements do not contain residual value guarantees or covenants.The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Companyâ€™s leases include variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term. Lease expense is recognized within operating expenses on a straight-line basis over the terms of the leases. Incentives granted under the Companyâ€™s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.Stock-based CompensationThe Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Companyâ€™s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. 12 Â Net Loss Per Share Attributable to Common StockholdersBasic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.SegmentsThe Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Companyâ€™s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.Corporate RestructuringOn September 15, 2024, the Company committed to a workforce reduction that is expected to result in the termination of approximately 70% of the Companyâ€™s workforce, or the Restructuring. In connection with the Restructuring, the Company currently estimates it will incur costs of approximately $2.8 million, consisting primarily of cash severance costs and termination benefits, which the Company expects to recognize in the third and fourth quarters of 2024. The Company expects to substantially complete the Restructuring by December 31, 2024.Emerging Growth Company StatusThe Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.Â Recently Adopted Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures. 13 Â 3. Fair ValueThe Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:Level 1â€”Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2â€”Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.Level 3â€”Inputs are generally unobservable and reflect managementâ€™s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies.The determination of a financial instrumentâ€™s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The following tables reflect the Companyâ€™s financial asset balances measured at fair value on a recurring basis (in thousands):Â Â Â September 30, 2024 Â Â Â Level Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â 1 Â $ 33 Â Â $ â€” Â Â $ â€” Â Â $ 33 Â U.S. government debt and agencyÂ Â Â securities Â 2 Â Â 18,120 Â Â Â 5 Â Â Â â€” Â Â Â 18,125 Â Commercial paper Â 2 Â Â 23,983 Â Â Â 1 Â Â Â (3) Â Â 23,981 Â Total cash equivalents Â Â Â $ 42,136 Â Â $ 6 Â Â $ (3) Â $ 42,139 Â Â Â Â December 31, 2023 Â Â Â Level Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â FairValue Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market fund Â 1 Â $ 63 Â Â $ â€” Â Â $ â€” Â Â $ 63 Â Commercial paper Â 2 Â Â 59,227 Â Â Â â€” Â Â Â (30) Â Â 59,197 Â Total cash equivalents Â Â Â $ 59,290 Â Â $ â€” Â Â $ (30) Â $ 59,260 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Commercial paper Â 2 Â Â 6,431 Â Â Â â€” Â Â Â (4) Â Â 6,427 Â U.S. government debt and agencyÂ Â Â securities Â 2 Â Â 50,723 Â Â Â â€” Â Â Â (315) Â Â 50,408 Â Total short-term investments Â Â Â $ 57,154 Â Â $ â€” Â Â $ (319) Â $ 56,835 Â Â All the commercial paper, U.S. government debt and agency securities, U.S. treasury bills, and corporate bonds designated as short-term investments have an effective maturity date that is equal to or less than one year from the respective balance sheet date.As of September 30, 2024, the Company does not intend to sell any securities in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell such securities prior to the recovery of the amortized cost basis. Based on the Company's assessment, the Company concluded all impairments as of September 30, 2024 to be due to factors other than credit loss, such as changes in interest rates. A credit loss allowance was not recognized and the unrealized losses for available-for-sale securities were recorded in other comprehensive loss. 14 Â 4. Property and Equipment, NetProperty and equipment consisted of the following (in thousands):Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Lab equipment Â $ 705 Â Â $ 688 Â Office furniture, fixtures, andÂ Â Â computer equipment Â Â 712 Â Â Â 712 Â Leasehold improvement Â Â 4,322 Â Â Â 4,322 Â Property and equipment, at cost Â Â 5,739 Â Â Â 5,722 Â Less: accumulated depreciation Â Â (3,052) Â Â (2,334) Property and equipment, net Â $ 2,687 Â Â $ 3,388 Â Â Depreciation expense was $243,000 and $727,000 for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $244,000 and $724,000 for the three and nine months ended September 30, 2023, respectively. 5. Accrued LiabilitiesAccrued liabilities consisted of the following (in thousands):Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Research and development Â $ 7,644 Â Â $ 11,916 Â Employee compensation and benefits Â Â 4,440 Â Â Â 4,545 Â Legal expense Â Â 4,127 Â Â Â â€” Â Professional services and other Â Â 750 Â Â Â 1,882 Â Total accrued liabilities Â $ 16,961 Â Â $ 18,343 Â Â 6. Significant AgreementsWSU License Agreement The Company is party to an amended and restated exclusive license agreement with sublicensing terms with WSU that the Company entered into in 2015. Under this agreement, the Company has an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration. ATH-1105, the Companyâ€™s small molecule drug candidate currently in development for the potential treatment of ALS, is not covered by the WSU license agreement.To keep in good standing, the agreement requires the Company to meet certain development milestones and pay annual maintenance fees. All contractual requirements have been met as of September 30, 2024.During the year ended December 31, 2020, the Phase 2 clinical trial milestone was reached and a payment of $50,000 to WSU was recorded. The Company may also be obligated to pay the following if the related milestones are reached:â€¢$300,000 â€“ At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product; andâ€¢$600,000 â€“ Upon receipt of marketing approval in the United States, European Union or Japan for the first licensed product.Under the terms of the agreement, the Company will pay a royalty in the mid-single digits of net sales, with the first $100,000 of net sales being exempt from royalty payment, and annual minimum royalty payments of $25,000 beginning after the first commercial sale of a licensed product. As of September 30, 2024, no sales of any licensed products had occurred and the Company had not incurred a royalty obligation under this agreement.Additionally, the agreement allows the Company to sublicense the rights conveyed by the agreement, subject to additional payments to WSU based upon the sublicense consideration received in such event. Such amounts are dependent on the terms of the underlying sublicense and range from the mid-single digits to mid-teens of any non-sales based 15 Â payments received, and low twenties of net sales based sublicense royalties. As of September 30, 2024, the Company has not entered into or incurred any liability from a sublicense agreement. 7. Commitments and ContingenciesLegal ProceedingsFrom time to time, the Company is subject to various legal proceedings or claims that arise in the ordinary course of business. The Company accrues a liability when the Company's management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. The following is a brief description of the more significant legal proceedings.Securities Class ActionsOn June 25, 2021, plaintiffs Fan Wang and Hang Gao filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company and the Companyâ€™s former chief executive officer Dr. Leen Kawas, captioned Wang v. Athira Pharma, Inc., et al., No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, or Exchange Act, and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding the Companyâ€™s business. Specifically, the Wang plaintiffs allege that the Company failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU, including the manipulation of data, and that as a result, the defendantsâ€™ positive statements about the Companyâ€™s business, operations, and prospects were materially misleading. The Wang plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneysâ€™ fees. Â That same day, on June 25, 2021, plaintiff Harshdeep Jawandha filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Companyâ€™s then chief financial officer, certain members of the Companyâ€™s board of directors at the time of the Companyâ€™s initial public offering, or IPO, as well as the IPO underwriters, captioned Jawandha v. Athira Pharma, Inc., et al., No. 2:21-cv-00862. The Jawandha complaint asserts violations of Sections 11 and 15 of the Securities Act of 1933, or Securities Act, alleging that that the Companyâ€™s IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawasâ€™s published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to the Companyâ€™s efforts to develop treatments for Alzheimerâ€™s disease, and that the defendantsâ€™ positive statements about the Companyâ€™s business, operations, and prospects were materially misleading. The Jawandha plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneysâ€™ fees. Â Also on June 25, 2021, plaintiffs Timothy Slyne and Tai Slyne filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Companyâ€™s then chief financial officer, and the same members of the Companyâ€™s board of directors and underwriters as in the Jawandha complaint, captioned Slyne v. Athira Pharma, Inc. et al., No. 2:21-cv-00864. The Slyne complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawasâ€™s doctoral research at WSU should have been disclosed in the Companyâ€™s IPO registration statement. The Slyne plaintiffs seek unspecified compensatory damages, reasonable costs and expenses, including attorneysâ€™ fees, and injunctive and other equitable relief.On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel.On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against the Company, Dr. Kawas, the Companyâ€™s then chief financial officer, certain members of the Company's board of directors at the time of the Company's IPO and secondary public offering, or SPO, and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawasâ€™s published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffsâ€™ consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to

dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed 16 Â the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint.On August 12, 2022, defendant Dr. Kawas filed a motion for partial reconsideration of the courtâ€™s July 29, 2022 order. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, the Company and Dr. Kawas filed their individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery. On March 10, 2023, following a mediation and the partiesâ€™ agreement in principle to settle the securities class action, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffsâ€™ motion for preliminary approval without prejudice, citing the motionâ€™s failure to satisfy the courtâ€™s questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023.On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffsâ€™ renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024. In its order, the court preliminarily approved the proposed settlement and certified a class with two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement. On March 29, 2024, the court issued a minute order (i) granting the portion of plaintiffsâ€™ renewed motion for preliminary approval that the court had previously deferred ruling on, (ii) setting a final approval hearing, and (iii) ordering plaintiffsâ€™ motion for final approval of the proposed settlement to be filed on or before September 26, 2024. On September 26, 2024, plaintiffs filed a motion for final approval of class action settlement and plan of allocation. On September 30, 2024, the court issued a minute order requiring additional information related to the claims administration process, to which plaintiffs responded. On October 25, 2024, the court held a settlement final approval hearing and ruled that the terms of the settlement are fair, reasonable and adequate and that notice was reasonable. On November 1, 2024, the court entered a final written judgment and order granting final approval of the settlement and closed the case. As a result of the foregoing, the Company recorded a legal settlement expense of $10.0 million in operating expenses in the fourth quarter of 2022 and an accrued liability of $10.0 million on the accompanying condensed consolidated balance sheets. Additionally, the Company recorded an insurance recovery of $1.6 million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $1.6 million on the accompanying condensed consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by the Company's insurers. The Company has deposited $8.4 million into a settlement fund account pending final payment of the settlement amount, and such funds are legally restricted for use and are included within restricted cash, current on the condensed consolidated balance sheets. 17 Â Shareholder Derivative ActionsOn April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of the Companyâ€™s board of directors, captioned Bushansky v. Kawas et al., No. 2:22-cv-497. Plaintiff purported to bring the action derivatively on behalf of the Company, which was a nominal defendant to the action. The derivative complaint alleged that the Companyâ€™s board of directors breached its fiduciary duties by failing to prevent alleged misstatements in the Companyâ€™s public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint sought unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneysâ€™ fees.On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain current and former directors and officers of the Company, captioned Houlihan v. Kawas et al., No. 2:22-cv-620. Plaintiff purported to bring the action derivatively on behalf of the Company, which was a nominal defendant to the action. The derivative complaint alleged that certain of the Companyâ€™s current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in the Companyâ€™s public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint sought unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneysâ€™ fees.On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. On March 18, 2024, following a mediation and the parties entering into a stipulation of settlement to settle the consolidated derivative action for certain corporate governance reforms and the Companyâ€™s payment of a fee and expense award to plaintiffsâ€™ counsel, plaintiffs filed an unopposed motion for preliminary approval of a settlement of the derivative action. On May 3, 2024, the court entered an order preliminarily approving the settlement. On May 17, 2024, plaintiffs filed an unopposed motion for approval of attorneysâ€™ fees and expenses and service awards to plaintiffs. On July 3, 2024, plaintiffs filed an unopposed motion for final approval of derivative settlement. The settlement final approval hearing took place on July 18, 2024, and no Company shareholders objected to the proposed settlement or attorneysâ€™ fees or service awards sought by plaintiffs. After the hearing, on July 18, 2024, the court entered an order and judgment granting plaintiffsâ€™ motion for final approval of derivative settlement, finding the settlement to be fair, reasonable, and adequate to the settling parties and the Companyâ€™s shareholders, and dismissing the derivative action with prejudice. The Company paid the fee and expense award related to this shareholder derivative action settlement during the third quarter of 2024.Government InvestigationIn November 2022, the Company received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand sought documents and information relating to the Companyâ€™s relationship with WSU, certain of its grant applications in 2016 and 2019 with the NIH, and the Companyâ€™s receipt of an NIH grant in 2020. The Company has been cooperating with the Department of Justice with respect to the Demand.The Company recorded a legal expense of $4.1 million based on developments in the third quarter of 2024 and a corresponding accrued liability on the accompanying condensed consolidated balance sheets. Failure by the Company to obtain a favorable resolution could have a material adverse effect on its business, results of operations and financial condition.Operating Leases The Company has operating leases for laboratory and office facilities in Bothell, Washington that expire in August 2027. The initial terms of the leases range from 6.3 to 7 years and the Company has options to extend the leases for an additional five years that it is not reasonably certain to exercise. As of September 30, 2024, the Company was not party to any finance leases. 18 Â The following table reconciles the Companyâ€™s undiscounted operating lease cash flows to its operating lease liability (in thousands):Â Â Â September 30,2024 Â Remaining 2024 Â Â 123 Â 2025 Â Â 494 Â 2026 Â Â 509 Â Thereafter Â Â 346 Â Total undiscounted lease payments Â Â 1,472 Â Present value adjustment for minimum leaseÂ Â Â commitments Â Â (158) Net lease liability Â $ 1,314 Â Â The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:Â Â Â September 30,2024 Â Weighted average remaining lease term (years) Â Â 3.2 Â Weighted average discount rate Â Â 8.1 % Â Operating lease expense and variable lease expense consisted of the following (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease expense Â $ 89 Â Â $ 89 Â Â $ 265 Â Â $ 265 Â Variable lease expense Â Â 41 Â Â Â Â 42 Â Â Â Â 108 Â Â Â Â 144 Â Â Â Â 8. Common StockEach share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and if declared by the Companyâ€™s board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception.The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Shares issuable upon the exercise of outstandingÂ Â Â common stock options and the vesting ofÂ Â Â outstanding common restricted stockÂ Â Â units granted Â Â 10,785,447 Â Â Â 7,130,956 Â Shares available for future grant under the2020Â Â Â Equity Incentive Plan Â Â 1,426,486 Â Â Â 3,158,094 Â Shares available for future grant under theÂ Â Â Employee Stock Purchase Plan Â Â 1,399,735 Â Â Â 1,128,732 Â Shares available for future grant under the2024Â Â Â Inducement Equity Incentive Plan Â Â 350,000 Â Â Â â€” Â Total Â Â 13,961,668 Â Â Â 11,417,782 Â Â The Companyâ€™s 2020 Equity Incentive Plan, or the 2020 Plan, provides for annual increases in the number of shares that may be issued under the 2020 Plan on January 1, 2021 and each subsequent January 1, thereafter, by a number of 19 Â shares equal to the least of (1) 3,230,000 shares, (2) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Companyâ€™s board of directors. The Companyâ€™s 2020 Employee Stock Purchase Plan, or the ESPP, provides for annual increases in the number of shares that may be issued under the ESPP on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) 646,000 shares, (2) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Companyâ€™s board of directors. Effective January 1, 2024, the Companyâ€™s 2020 Plan and ESPP reserves increased by 1,908,630 shares and 381,726 shares, respectively.In February 2024, the board of directors adopted the Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan, or the 2024 Inducement Plan, and, subject to the adjustment provisions of the 2024 Inducement Plan, reserved 750,000 shares of the Company's common stock for issuance pursuant to equity awards granted under the 2024 Inducement Plan. Â 9. Stock-based CompensationStockâ€‘based compensation expense recognized was as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 1,124 Â Â $ 944 Â Â $ 3,263 Â Â $ 3,228 Â General and administrative Â Â 1,812 Â Â Â 1,550 Â Â Â 5,557 Â Â Â 5,167 Â Total stock-based compensation expense Â $ 2,936 Â Â $ 2,494 Â Â $ 8,820 Â Â $ 8,395 Â Â Valuation AssumptionsThe fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally required significant judgment. â€¢Fair Value of Common Stockâ€”The fair value of each share of common stock is based on the closing price of the Companyâ€™s common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.â€¢Risk-Free Interest Rateâ€”The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. â€¢Expected Volatilityâ€”Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. â€¢Expected Termâ€”The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity. â€¢Expected Dividend Yieldâ€”The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of zero.The fair value of each stock option was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Risk-free interest rate Â Â 4.26 % Â Â 3.54 % Expected volatility Â Â 96.93 % Â Â 99.18 % Expected term (in years) Â Â 6.00 Â Â Â 5.48 Â Expected dividend yield Â Â â€” Â Â Â â€” Â Â 20 Â The grant date fair value of restricted stock units is based upon the fair market value of the Companyâ€™s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market.Â The fair value of options granted during the nine months ended September 30, 2024 and 2023 was $10.2 million and $9.8 million, respectively. The fair value of restricted stock units granted during the nine months ended September 30, 2024 and 2023 was less than $0.1 million and $0.4 million, respectively.Stock Option ActivityChanges in shares available for grant under the 2020 Plan and the 2024 Inducement Plan during the nine months ended September 30, 2024 were as follows:Â Â Â SharesAvailable for Grant Â Shares available for grant at December 31, 2023 Â Â 3,158,094 Â 2020 Plan reserve increase on January 1, 2024 Â Â 1,908,630 Â Shares reserved upon adoption of theÂ Â Â 2024 Inducement Plan Â Â 750,000 Â Options and restricted stock units granted Â Â (4,090,804) Options and restricted stock units forfeited, Â Â Â cancelled, or expired Â Â 50,566 Â Shares available for grant at September 30, 2024 Â Â 1,776,486 Â Â Â A summary of stock option activity under the 2020 Plan and the 2024 Inducement Plan for the nine months ended September 30, 2024 was as follows:Â Â Â Shares Â Â Weighted-AverageExercisepriceper Share Â Â Weighted-AverageRemainingContractualTerm (in years) Â Â AggregateIntrinsicValue(inthousands) Â Balance at December 31, 2023 Â Â 6,820,869 Â Â $ 7.97 Â Â 8.24 Â Â $ 387 Â Granted Â Â 4,088,804 Â Â Â 3.16 Â Â Â Â Â Â Â Exercised Â Â (75,660) Â Â 0.16 Â Â Â Â Â Â Â Forfeited/expired Â Â (50,566) Â Â 11.48 Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 10,783,447 Â Â $ 6.18 Â Â Â 8.27 Â Â $ â€” Â Expected to vest Â Â 5,905,187 Â Â $ 4.27 Â Â Â 8.86 Â Â $ â€” Â Options exercisable Â Â 4,878,260 Â Â $ 8.49 Â Â Â 7.56 Â Â $ â€” Â Â The total fair value of options granted that vested during the nine months ended September 30, 2024 and 2023 was $9.2 million and $8.3 million, respectively.The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Companyâ€™s common stock underlying all options that were in-the-money at September 30, 2024. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2024 and 2023 was $0.2 million and $0.2 million, respectively, determined as of the date of option exercise. As of September 30, 2024, there was $17.7 million of total unrecognized compensation cost related to non-vested stock options. The Company expects to recognize this cost over a remaining weighted-average period of 2.2 years. The Company utilizes newly issued shares to satisfy option exercises. 21 Â Stock options outstanding and exercisable under the 2020 Plan and the 2024 Inducement Plan consisted of the following at September 30, 2024:Â Â Â Â Â Exercise Price ($) Â SharesOutstanding Â Â SharesExercisable Â 0.16Â to 4.22 Â Â 7,703,393 Â Â Â 2,515,358 Â 8.93Â to 19.94 Â Â 2,727,806 Â Â Â 2,084,154 Â 20.55Â to 29.41 Â Â 352,248 Â Â Â 278,748 Â Total Â Â 10,783,447 Â Â Â 4,878,260 Â Restricted Stock Unit ActivityA summary of restricted stock unit, or RSU, activity for the nine months ended September 30, 2024 is as follows:Â Â Â ShareEquivalent Â Â Weighted-AverageGrant DateFair Value Â Non-vested at December 31, 2023 Â Â 310,087 Â Â $ 11.44 Â Granted Â Â 2,000 Â Â Â 2.51 Â Cancelled Â Â Â â€” Â Â Â Vested Â Â (310,087) Â Â 11.44 Â Non-vested at September 30, 2024 Â Â 2,000 Â Â $ 2.51 Â Â 10. Net Loss Per Share Attributable to Common StockholdersThe following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Stock options to purchase common stock Â Â 10,783,447 Â Â Â 7,019,311 Â Non-vested Restricted Stock Units Â Â 2,000 Â Â Â 313,337 Â Employee stock purchase plan Â Â 8,709 Â Â Â 11,373 Â Total Â Â 10,794,156 Â Â Â 7,344,021 Â Â Â 11. Corporate RestructuringThe Company currently estimates that it will incur costs of approximately $2.8 million for termination benefits relating to the Restructuring, substantially all of which the Company expects to recognize in the third and fourth quarters of 2024 and pay out in cash during the fourth quarter of 2024 and first quarter of 2025.The Company expensed the following costs associated with the termination benefit payments resulting from the Restructuring (in thousands): Â Â Nine Months Ended Â Â Â September 30, 2024 Â Research and development expense Â Â 1,007 Â General and administrative expense Â Â 1,309 Â Total severance expense Â Â 2,316 Â As of September 30, 2024, the accrued liability balance associated with the Restructuring is $2.3 million and is included in the accrued expenses line of the accompanying unaudited condensed consolidated balance sheet. 22 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this report and with our audited financial statements and related notes thereto and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or the SEC, on February 22, 2024. Special Note Regarding Forward-Looking Statements This report contains forward-looking statements that are based on our managementâ€™s beliefs and assumptions and on information currently available to our management. This section should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities

Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can identify forward-looking statements by the following words: â€œanticipate,â€ â€œbelieve,â€ â€œcontinue,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œongoing,â€ â€œplan,â€ â€œpossible,â€ â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œshould,â€ â€œtargetâ€, â€œwill,â€ â€œwouldâ€ or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other â€œforward-lookingâ€ information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements include, but are not limited to, statements about: â€¢our financial performance; â€¢the sufficiency of our existing cash, cash equivalents and investments to fund our future operating expenses and capital expenditure requirements; â€¢our expectations regarding the costs and expected cost savings and related benefits from our workforce reduction initiated in September 2024, or the Restructuring; â€¢our ability to obtain funding for our operations, including funding necessary to develop and commercialize our drug candidates; â€¢the ability of our nonclinical studies and clinical trials to demonstrate safety and efficacy of our drug candidates; â€¢the success, cost and timing of our development activities, nonclinical studies and clinical trials; â€¢the rate and degree of market acceptance of our drug candidates; â€¢the timing or likelihood of regulatory filings and approvals; â€¢the potential learnings from our ACT-AD and SHAPE trials, LIFT-AD independent unblinded interim efficacy and futility analysis, and LIFT-AD trial and their ability to inform and improve future clinical development plans; â€¢the potential of our Phase 1 ATH-1105 clinical trial and any subsequent clinical trials to show the clinical benefits of ATH-1105; â€¢the timing and focus of our future clinical trials, and the reporting of data from those trials; â€¢anticipated milestone timelines, such as the timing of data releases, and our ability to meet such timelines; â€¢our plans relating to commercializing our drug candidates, if approved; â€¢our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any drug candidates for which we obtain approval; â€¢our ability to attract and retain key managerial, scientific and clinical personnel; â€¢our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; â€¢the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; â€¢the pricing and reimbursement of our drug candidates, if approved; 23 Â â€¢our reliance on third parties to conduct clinical trials of our drug candidates, and for the manufacture of our drug candidates for nonclinical studies and clinical trials; â€¢the success of competing therapies that are or may become available; â€¢the beneficial characteristics, safety and efficacy of our drug candidates; â€¢regulatory developments in the United States and other jurisdictions; â€¢our ability to obtain and maintain regulatory approval of our drug candidates in the United States and other jurisdictions, and any related restrictions, limitations or warnings in the label of any approved drug candidate; â€¢future agreements with third parties in connection with the commercialization of our drug candidates; â€¢our plans, capacity and capability relating to the further development and manufacturing of our drug candidates, including additional indications for which we may pursue regulatory approval; â€¢our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available; â€¢the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology; â€¢the outcome of legal proceedings which have been or may in the future be instituted against us and certain of our directors and officers, including the legal proceedings discussed in Part II, Item 1 â€” "Legal Proceedings,â€ and elsewhere in this report; â€¢the actions by activist stockholders, which have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of our business; â€¢our plans and ability to regain compliance with the Nasdaq listing rules; â€¢the size and growth potential of the markets for our drug candidates, if approved for commercial use, and our ability to serve those markets; â€¢the potential benefits of any strategic collaborations, partnerships, or other transactions we may enter into; â€¢our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and â€¢our plans and expectations regarding our exploration of strategic alternatives focused on maximizing stockholder value, including whether or not such process will result in a strategic transaction on terms satisfactory to us, or other alternatives which increase stockholder value. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in â€œPart II, Item 1Aâ€”Risk Factors,â€ and elsewhere in this report. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part. In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. This report includes our trademarks and registered trademarks, including Athira, Athira Pharma, the Athira logo, and other trademarks, trade names, or service marks of Athira. All other trademarks, trade names or service marks appearing in this report belong to their respective holders. Solely for convenience, trademarks, trade names, and service marks referred to in this report are listed without Â® or TM symbols, but we will assert, to the fullest extent under applicable law, our rights to these trademarks, trade names, and service marks. In this report, â€œwe,â€ â€œour,â€ â€œus,â€ â€œAthira,â€ and â€œthe Companyâ€ refer to Athira Pharma, Inc. and our wholly owned subsidiary. 24 Â Overview We are a clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Our approach is designed to modulate the neurotrophic hepatocyte growth factor, or HGF, system, that is critical to normal brain function and may play a key role in maintaining the health and functioning of neuronal networks. We believe that by acting on the neurotrophic HGF system and its multiple downstream signaling pathways, we may be able to enhance the bodyâ€™s natural ability to protect and repair neuronal networks by reducing inflammation, promoting regeneration, and reducing disease-specific protein pathologies, thereby positively impacting the course of disease. We aim to achieve these goals by advancing our pipeline of novel small molecule compounds which are designed to and have exhibited properties in enhancing the neurotrophic HGF system in either the central nervous system, or CNS, by crossing the blood brain barrier, or BBB, or the peripheral nervous system, or PNS. Following recent clinical trial developments for fosgonimeton, our previous lead drug candidate, discussed further below, our lead drug candidate is now ATH-1105. ATH-1105 is a novel, oral, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, or ALS, and Alzheimer's disease, or AD. ATH-1105 is currently in development for the potential treatment of ALS. We are conducting a first-in-human Phase 1 double-blind, placebo-controlled trial that is enrolling up to 80 healthy volunteers to evaluate single and multiple oral ascending doses of ATH-1105. The study is evaluating the safety and tolerability of ATH-1105 and includes measurements of pharmacokinetic outcomes. The first cohort of healthy volunteers completed the study in June 2024 and we expect to complete the full study by year-end 2024, with a goal to begin dosing ALS patients in 2025. Our other drug candidate, fosgonimeton, is a small molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases. The effects of fosgonimeton in AD were previously evaluated in our ACT-AD and LIFT-AD clinical trials. 25 Â ACT-AD1 was a randomized, double-blind, placebo-controlled, parallel-group 26-week exploratory Phase 2 clinical trial with fosgonimeton in mild-to-moderate AD, with event-related potential, or ERP, P300 latency as the primary endpoint. Initiated in November 2020, the trial was designed to better characterize the overall effects of fosgonimeton on working memory processing speed and cognitive measures and inform the Phase 2/3 LIFT-AD trial. Topline results for this exploratory Phase 2 ACT-AD trial were announced in June 2022, and the primary and all secondary endpoints were not met by protocoled analysis. However, a post hoc analysis of results from ACT-AD in a pre-specified subgroup suggested positive effects on measures of cognition, function and neurodegeneration in participants taking fosgonimeton alone without background acetylcholinesterase inhibitors, or AChEIs. Additionally, data from post hoc analysis of plasma biomarkers from participants on fosgonimeton without background AChEIs showed descriptive improvements (non-statistically significant) in markers of neuroinflammation and AD-specific protein pathologies when compared to placebo. Fosgonimeton was generally well tolerated in the ACT-AD study, with a favorable safety profile, and there were no treatment-related serious adverse events or deaths observed. LIFT-AD was a randomized, double-blind, placebo-controlled, parallel-group 26-week Phase 2/3 clinical trial with fosgonimeton in mild-to-moderate AD. The primary endpoint for the Phase 2/3 LIFT-AD trial was the Global Statistical Test, or GST, which combines the scores from the co-key secondary endpoints of cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) and function (Alzheimerâ€™s Disease Cooperative Study-Activities of Daily Living, or ADCS-ADL23). Guided by the results from the completed exploratory ACT-AD Phase 2 trial, in September 2022, we proactively amended LIFT-AD to focus on participants not on background AChEIs, and in May 2023, we further amended LIFT-AD to focus on 40 mg dosing, which we had selected for further development and as the potential dose for regulatory approval of fosgonimeton in this indication. In September 2024, we announced the topline results for LIFT-AD, and the primary and key secondary endpoints did not reach statistical significance compared with placebo at 26 weeks. However, both components of GST, cognition (ADAS-Cog11) and function (ADCS-ADL23), directionally favored fosgonimeton treatment, and in pre-specified subgroups characterized by more rapid disease progression (moderate AD and APOE4 carriers), cognition and function improved or stabilized in the fosgonimeton treated group. In addition, data across biomarkers of protein pathology (AÎ²42/40, p-Tau181, and p-Tau217), inflammation (GFAP) and neurodegeneration (NfL) showed directional improvements with fosgonimeton treatment that are consistent with the broad neuroprotective mechanism of HGF modulation. Based on these results, we decided to pause further development of fosgonimeton and to shift our focus to the clinical development of ATH-1105. In July 2021, we announced that we would enroll participants into an open-label extension, or OLEX, trial1 for our LIFT-AD and ACT-AD clinical trials, enabling eligible participants who have completed either trial and elect to participate in the OLEX trial to receive open-label treatment with fosgonimeton. In September 2024, based on the results from LIFT-AD, we determined to stop the OLEX trial. Â 1 The ACT-AD trial and the related OLEX trial for ACT-AD participants have been supported by a grant from the National Institute on Aging of the National Institutes of Health under Award Number R01AG06268. The information presented is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health. 26 Â The following figure illustrates the current development stage of our proprietary drug candidates and early discovery and development programs. Our pipeline consists of both BBB permeable and peripherally restricted drug candidates for CNS, PNS and other indications. In addition, we are exploring the use of our drug candidates in additional indications in the CNS and PNS as we aim to improve neuronal health in multiple neurodegenerative diseases. Our drug discovery efforts are focused on designing and testing new early compounds to enhance the neurotrophic HGF system for a variety of clinical applications. Â We were incorporated in March 2011 and, since our inception, we have devoted substantially all of our resources to our research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. We do not have any drug products approved for commercial sale, and we have not generated any revenues related to our drug products since inception. Our ability to generate drug product revenue sufficient to achieve profitability, if ever, will depend on the successful development of one or more of our drug candidates which we expect will take a number of years. We are focused on the development of small molecule therapeutics which enables us to use well-established and widely available manufacturing processes and infrastructure, formulation processes and drug administration technologies or devices. Our lead drug candidate, ATH-1105, is currently in clinical development for the potential treatment of ALS, and additional drug candidates are in development. We do not currently operate our own facilities for manufacturing, storing, or distributing our drug candidates. We utilize third-party contract manufacturing organizations, or CMOs, to manufacture and supply our preclinical and clinical materials during the development of our drug candidates. We believe the synthesis of ATH-1105 is reliable and reproducible and the synthetic methods can be further optimized to enable large-scale production that continues to avoid use of toxic materials or specialized equipment or handling during the manufacturing process. We plan to continue to optimize the manufacturing process to support future large-scale and commercial supply that may be needed. Our goal is to identify and develop small molecule drug candidates that are cost-effective to manufacture and easily transferable to third party CMOs. We expect to use similar contract resources for commercialization of our drug products, at least until our resources and operations are at a scale that justifies investment in internal manufacturing capabilities. Following our receipt of the topline results of LIFT-AD, we made the determination to explore strategic alternatives focused on maximizing stockholder value. As part of that effort, we have paused further development of fosgonimeton while continuing our ongoing development of ATH-1105 and are exploring partnering options. Despite devoting significant effort to identifying and evaluating potential strategic alternatives, there can be no assurance that this strategic review process will result in us pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. We have not set a timetable for completion of this strategic review process, and our board of directors has not approved a definitive course of action. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value. 27 Â Given our stage of development, we have not yet established a commercial organization or distribution capabilities. To the extent that we successfully develop our drug candidates, we intend to build a commercial infrastructure to support future sales. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities. To date, we have funded our operations primarily through proceeds from the sale of equity securities, including proceeds from the sale and issuance of common stock in our IPO and in a subsequent follow-on public offering, the sale and issuance of convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From inception to September 30, 2024, we have raised aggregate net cash proceeds of approximately $407.4 million primarily from the issuance of our common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes. We have incurred significant operating losses to date. Our net losses were $81.9 million and $90.4 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $391.1 million and cash, cash equivalents and investments of $68.9 million. We expect to continue to incur operating losses for the foreseeable future as we: â€¢continue to advance ATH-1105 and any other drug candidates through preclinical studies and clinical trials; â€¢expand our pipeline of drug candidates; â€¢continue to invest in our drug development programs; â€¢continue manufacturing activities; â€¢attract, hire and retain personnel; â€¢obtain, maintain, expand and protect our intellectual property portfolio; â€¢operate as a public company; â€¢maintain our laboratory and office facilities; â€¢implement and maintain operational, financial and management information systems; â€¢seek regulatory approval for any drug candidates that successfully complete clinical trials; and â€¢incur legal expenses associated with ongoing litigation, as further described in â€œPart II, Item 1â€”Legal Proceedings,â€ and elsewhere in this report. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We will require substantial additional funding to support our continuing operations and further the development of our drug candidates. Until such time as we can generate significant revenue from drug product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include income from collaboration, licensing or similar arrangements, for the foreseeable future. Adequate funding may not be available when needed or on terms acceptable to us, or at all. If we are unable to raise additional capital as needed, we may have to significantly delay, scale back or discontinue development of our drug candidates or other operations. Our ability to raise additional funds may be negatively impacted by potential adverse global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our drug product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to drug candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. Based upon our current operating plan, we estimate that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report. 28 Â Our Collaboration and Grant Agreements We are party to certain collaboration and grant agreements, as described in the section titled â€œPart I, Item 1 â€” Businessâ€”Our Collaboration and Grant Agreementsâ€ in our Annual Report on Form 10-K filed with the SEC on February 22, 2024. Recent Developments Process to Evaluate Strategic Alternatives Following our receipt of the topline results of LIFT-AD, we made the determination to explore strategic alternatives focused on maximizing stockholder value. As part of that effort, we have paused further development of fosgonimeton while continuing our ongoing development of

ATH-1105 and are exploring partnering options. We have engaged Cantor Fitzgerald & Co. to act as an advisor in the process to explore strategic alternatives. As part of this process, we will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger or reverse merger, business combination, equity or debt financing, sale of the Company, sale, exclusive license or other disposition of all or a portion of our assets, a return of capital to stockholders, or other transaction. There can be no assurance that these efforts will result in the pursuit of a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. We have not set a timetable for completion of this evaluation process and do not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or necessary. Workforce Reduction On September 15, 2024, we committed to a workforce reduction that is expected to result in the termination of approximately 70% of our workforce. We took this step to decrease our costs, extend our cash runway, and create a more streamlined organization to support our strategic priorities, including the continued development of ATH-1105. We expect to substantially complete the Restructuring by December 31, 2024. See Note 11 to our unaudited condensed consolidated financial statements included in "Part I, Item 1â€”Financial Statements (Unaudited)â€ of this report for additional information. Components of Operating Results Operating Expenses Research and Development Research and development expenses consist primarily of direct and indirect costs incurred for our research activities, including our drug discovery efforts and the development of our drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables. We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified. As of the date of this report, we cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our drug candidates. Drug candidates in later stages of development generally have higher development costs than those in earlier stages. We expect to continue to incur research and development expenses for the foreseeable future as we continue to invest in research and development activities related to developing our drug candidates, our drug candidates advance into later stages of development, we conduct larger clinical trials, we seek regulatory approvals for any drug candidates that successfully complete clinical trials, we expand our drug product pipeline, we maintain, expand, protect and enforce our intellectual 29 Â property portfolio, and we incur expenses associated with hiring or retaining personnel to support our research and development efforts. We also expect our research and development expenses to decrease in the near term as a result of our decision to pause further development of fosgonimeton and to shift our focus to the clinical development of ATH-1105. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our drug candidates is highly uncertain. Our research and development expenses may vary significantly based on factors such as: â€¢the number and scope of preclinical and IND-enabling studies; â€¢the phases of development of our drug candidates; â€¢the progress and results of our research and development activities; â€¢per subject trial costs; â€¢the number of trials required for regulatory approval; â€¢the number of sites included in the trials; â€¢the countries in which the trials are conducted; â€¢the length of time required to enroll eligible subjects and initiate clinical trials; â€¢the number of subjects that participate in the trials; â€¢the drop-out and discontinuation rate of subjects; â€ ¢potential additional safety monitoring requested by regulatory agencies; â€¢the duration of subject participation in the trials and follow-up; â€¢the cost and timing of manufacturing of our drug candidates; â€¢the receipt of regulatory approvals from applicable regulatory authorities; â€¢the timing, receipt and terms of any marketing approvals from applicable regulatory authorities; â€¢the hiring and retention of research and development personnel; â€¢the degree to which we obtain, maintain, defend and enforce our intellectual property rights; â€¢the impact of health epidemics on timelines and clinical operations, which may lead to increased costs; and â€¢the extent to which we establish collaboration, licensing or similar arrangements and the performance of any related third parties. A change in the outcome of any of these variables with respect to the development of any of our drug candidates could significantly change the costs and timing associated with the development of that drug candidate. General and Administrative General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, business development fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred. We expect to continue to incur general and administrative expenses for the foreseeable future as we maintain our headcount to support our continued research activities and development of our programs. We also anticipate that we will continue to incur expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services. We expect continued legal expenses related to our ongoing legal proceedings and proposed settlement to resolve such claims. We also expect general and administrative expenses to decrease in the near term as a result of the Restructuring and related cost savings. 30 Â Grant Income Grant income consists of income related to the NIH grant and is recognized as qualifying expenses under the grant agreement are incurred. As of September 30, 2024, we had recognized aggregate grant income of $15.2 million in connection with the NIH grant, equal to the total grant amount approved. We will not recognize additional grant income in connection with the NIH grant in the future. Other Income, Net Other income, net consists primarily of interest earned on our cash, cash equivalents and investments and the amortization of premiums and accretion of discounts on our available-for-sale securities. Absent further fundraising, we expect interest earned on our cash, cash equivalents and investments to decrease as we continue to expend our cash balances to fund our ongoing operations. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our results of operations for the periods presented: Â Â Three Months Ended September 30, Â Â Â Â Â Â Â Â Â Dollar Â Â % Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 17,922 Â Â $ 27,202 Â Â $ (9,280) Â Â (34)% General and administrative Â Â 7,572 Â Â Â 7,840 Â Â Â (268) Â Â (3) Legal expense Â Â 4,127 Â Â Â Â â€” Â Â Â 4,127 Â Â Â 100 Â Total operating expenses Â Â 29,621 Â Â Â 35,042 Â Â Â (5,421) Â Â (15) Loss from operations Â Â (29,621) Â Â (35,042) Â Â 5,421 Â Â Â (15) Other income, net Â Â 880 Â Â Â 2,072 Â Â Â (1,192) Â Â (58) Net loss Â $ (28,741) Â $ (32,970) Â $ 4,229 Â Â Â (13) Research and Development Expenses The following table shows the primary components of our research and development expenses for the periods presented: Â Â Â Three Months Ended September 30, Â Â Â Â Â Â Â Â Dollar Â Â % Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â Â Â Direct costs: Â Â Â Â Â Â Â Â Â Â Â Fosgonimeton (ATH-1017) Â $ 10,078 Â Â $ 20,800 Â Â $ (10,722) Â Â (52)% ATH-1105 Â Â 2,438 Â Â Â â€” Â Â Â 2,438 Â Â Â 100 Â ATH-1020 Â Â 135 Â Â Â 249 Â Â Â (114) Â Â (46) Preclinical programs and other direct costs Â Â 439 Â Â Â 1,292 Â Â Â (853) Â Â (66) Total direct costs Â Â 13,090 Â Â Â 22,341 Â Â Â (9,251) Â Â (41) Indirect costs: Â Â Â Â Â Â Â Â Â Â Â Personnel-related costs, including stock-Â Â based compensation Â Â 4,304 Â Â Â 4,405 Â Â Â (101) Â Â (2) Facilities and other costs Â Â 528 Â Â Â 456 Â Â Â 72 Â Â Â (16) Total research and development expenses Â $ 17,922 Â Â $ 27,202 Â Â $ (9,280) Â Â (34) Research and development expenses decreased by $9.3 million, from $27.2 million for the three months ended September 30, 2023 to $17.9 million for the three months ended September 30, 2024. The decrease was driven primarily by decreases in fosgonimeton program costs of $10.7 million and preclinical and other direct costs of $0.9 million, and to lesser extents, decreases in ATH-1020 program costs and personnel-related expenses. The decrease in fosgonimeton program costs of $10.7 million was driven by decreases in contract research organization and clinical site visit costs for our Phase 2/3 LIFT-AD clinical trial and the corresponding open-label extension for our Phase 2 ACT-AD and Phase 2/3 LIFT-AD clinical trials of $5.2 million and a decrease in contract manufacturing costs of $5.5 million. These decreases were 31 Â partially offset by an increase in ATH-1105 program costs of $2.4 million associated with the Phase 1 clinical trial, which commenced in the second quarter of 2024. General and Administrative Expenses General and administrative expenses decreased by approximately $0.2 million, from $7.8 million for the three months ended September 30, 2023 to $7.6 million for the three months ended September 30, 2024. The decrease was due to decreases in general corporate expenses of $0.4 million and in business development expenses of $0.3 million. These decreases were partially offset by an increase in personnel-related expenses of $0.3 million and an increase in professional services expenses of $0.1 million. Legal Expenses In connection with the Department of Justice investigation, we recorded a legal expense of $4.1 million during the three months ended September 30, 2024. For more information, see the section of this report titled "Part II, Item 1â€”Legal Proceedings". Â Other Income, Net Other income, net, decreased by $1.2 million, from $2.1 million for the three months ended September 30, 2023 to $0.9 million for the three months ended September 30, 2024 due to lower income from accretion of discounts on debt securities purchased below par value and held to maturity and lower interest income earned on our available-for-sale securities. These decreases resulted from lower balances of available-for-sale securities held during the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Comparison of the Nine Months Ended September 30, 2024 and 2023 The following table summarizes our results of operations for the periods presented: Â Â Â Nine Months Ended September 30, Â Â Â Â Â Â Â Â Dollar Â Â % Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 61,312 Â Â $ 70,110 Â Â $ (8,798) Â Â (13)% General and administrative Â Â 19,897 Â Â Â 26,342 Â Â Â (6,445) Â Â (24) Legal expense Â Â 4,127 Â Â Â Â â€” Â Â Â 4,127 Â Â Â 100 Â Total operating expenses Â Â 85,336 Â Â Â 96,452 Â Â Â (11,116) Â Â (12) Loss from operations Â Â (85,336) Â Â (96,452) Â Â 11,116 Â Â Â (12) Grant income Â Â â€” Â Â Â 157 Â Â Â (157) Â Â (100) Other income, net Â Â 3,399 Â Â Â 5,908 Â Â Â (2,509) Â Â (42) Net loss Â $ (81,937) Â $ (90,387) Â $ 8,450 Â Â Â (9) Â 32 Â Research and Development Expenses The following table shows the primary components of our research and development expenses for the periods presented: Â Â Â Nine Months Ended September 30, Â Â Â Â Â Â Â Â Dollar Â Â % Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â Â Â Direct costs: Â Â Â Â Â Â Â Â Â Â Â Fosgonimeton (ATH-1017) Â $ 37,602 Â Â $ 49,691 Â Â $ (12,089) Â Â (24)% ATH-1105 Â Â 6,793 Â Â Â â€” Â Â Â 6,793 Â Â Â 100 Â ATH-1020 Â Â 470 Â Â Â 632 Â Â Â (162) Â Â (26) Preclinical programs and other direct costs Â Â 1,419 Â Â Â 4,541 Â Â Â (3,122) Â Â (69) Total direct costs Â Â 46,284 Â Â Â 54,864 Â Â Â (8,580) Â Â (16) Indirect costs: Â Â Â Â Â Â Â Â Â Â Â Personnel-related costs, including stock-Â Â based compensation Â Â 13,229 Â Â Â 13,742 Â Â Â (513) Â Â (4) Facilities and other costs Â Â 1,799 Â Â Â 1,504 Â Â Â 295 Â Â Â 20 Â Total research and development expenses Â $ 61,312 Â Â $ 70,110 Â Â $ (8,798) Â Â (13) Research and development expenses decreased by $8.8 million, from $70.1 million for the nine months ended September 30, 2023 to $61.3 million for the nine months ended September 30, 2024. The decrease was driven primarily by decreases in fosgonimeton program costs of $12.1 million, preclinical and other direct costs of $3.1 million, personnel-related expenses of $0.5 million, and ATH-1020 program costs of $0.2 million. The decrease in fosgonimeton program costs of $12.1 million was driven by decreases in contract research organization and clinical site visit costs for our Phase 2/3 LIFT-AD clinical trial and the corresponding open-label extension for our Phase 2 ACT-AD and Phase 2/3 LIFT-AD clinical trials of $7.0 million and a decrease in contract manufacturing costs of $7.9 million, partially offset by an increase in program consulting costs of $3.0 million. These decreases were partially offset by an increase in ATH-1105 program costs of $6.8 million associated with the Phase 1 clinical trial, which commenced in the second quarter of 2024, and to a lesser extent, an increase in facilities and other indirect costs. General and Administrative Expenses General and administrative expenses decreased by $6.4 million, from $26.3 million for the nine months ended September 30, 2023 to $19.9 million for the nine months ended September 30, 2024. The decrease was primarily due to a decrease in business development expenses of $2.0 million, a decrease in general corporate expenses of $1.0 million, and a decrease in professional services expenses of $0.9 million. Additionally, legal expenses, excluding expenses recognized in connection with the Department of Justice investigation, decreased by $2.4 million. Legal Expenses In connection with the Department of Justice investigation, we recorded a legal expense of $4.1 million during the nine months ended September 30, 2024. For more information, see the section of this report titled "Part II, Item 1â€”Legal Proceedings". Grant Income Grant income recognized during the nine months ended September 30, 2023 of $0.2 million represented the remaining balance of the total $15.2 million approved grant amount available at the beginning of the quarter. There was no grant income recognized during the nine months ended September 30, 2024. Â Other Income, Net Other income, net, decreased by $2.5 million, from $5.9 million for the nine months ended September 30, 2023 to $3.4 million for the nine months ended September 30, 2024 due to lower income from accretion of discounts on debt securities purchased below par value and held to maturity and lower interest income earned on our available-for-sale securities. These decreases resulted from lower balances of available-for-sale securities held during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. 33 Â Liquidity and Capital Resources Sources of Liquidity Since our inception, we have funded our operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From our inception through September 30, 2024, we have raised aggregate net cash proceeds of $407.4 million primarily from the issuance of our common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes. As of September 30, 2024, we had $68.9 million in cash, cash equivalents and investments and have not generated positive cash flows from operations. Since our inception, we have devoted substantially all of our resources to our research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. Material Cash and Future Funding Requirements Our material cash requirements include our operating leases for laboratory and office facilities. As of September 30, 2024, we had lease payment obligations of $1.5 million, with $0.5 million payable within 12 months. For additional information regarding our lease commitments, see Note 7 to our unaudited condensed consolidated financial statements included elsewhere in this report. We are contingently committed to $0.9 million of potential future milestone payments, in addition to sales-based payments and royalties, under our license agreement with WSU. Payments generally are due and payable only upon achievement of certain developmental, regulatory, and sales milestones for which the specific timing cannot be predicted. Refer to Note 6 to our unaudited condensed consolidated financial statements for additional information regarding the WSU license agreement. Additionally, we have purchase obligations and open purchase orders that support normal operations and are primarily due in the next 12 months. These purchase obligations and open purchase orders are generally cancellable in full or in part through the contractual provisions. We anticipate that our research and development expenses and our general and administrative expenses will decrease in the near-term as a result of our decision to pause further development of fosgonimeton and to shift our focus to the clinical development of ATH-1105, and our decrease in headcount as a result of the Restructuring. Based upon our current operating plan, we estimate that our $68.9 million of cash, cash equivalents and investments at September 30, 2024 will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report. However, our resource requirements could materially change depending on the outcome of our ongoing strategic alternative review process, including to the extent we identify and enter into any potential strategic transaction. We will need to raise substantial additional capital to fund the development of our drug candidates. Until such time as we can generate significant revenue from drug product sales, we expect to finance our operations through the sale of equity securities, debt financings, or other capital, which could include income from collaboration, licensing or similar arrangements with third parties, or receiving research contributions, or grants. For example, in January 2023, we entered into a sales agreement with Cantor Fitzgerald and BTIG to sell shares of our common stock having aggregate sales proceeds of up to $75.0 million, from time to time, through an ATM equity offering program under which Cantor Fitzgerald and BTIG are acting as sales agents. As of the date of this report, we have not sold any securities pursuant to this ATM offering. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us or may reduce the value of our common stock. Adequate funding may not be available when needed or

on terms acceptable to us, or at all. Our ability to raise additional funds may be negatively impacted by potential adverse global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our drug product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to drug candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities. 34 Â We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: â€¢the scope, timing, progress and results of our ongoing preclinical studies and clinical trials of our drug candidates; â€¢the number of trials required for regulatory approval; â€¢the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other drug candidates that we may pursue; â€¢our ability to establish and maintain collaboration, licensing or other similar arrangements, and the financial terms of any such arrangements, including the timing and amount of any future milestone, royalty or other payments due thereunder; â€¢the costs, timing and outcome of regulatory review of our drug candidates; â€¢the costs and timing of future commercialization activities, including drug product manufacturing, marketing, sales and distribution, for any of our drug candidates for which we receive marketing approval; â€¢the revenue, if any, received from commercial sales of our drug candidates for which we receive marketing approval; â€¢the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; â€¢the costs related to ongoing legal proceedings; â€¢any expenses needed to attract, hire and retain skilled personnel; â€¢the costs of operating as a public company; â€¢the costs associated with any expansion of our laboratory and office facilities; and â€¢the extent to which we acquire or in-license other companiesâ€™ product candidates and technologies or engage in other strategic transactions. A change in the outcome of any of these or other factors with respect to the development of any of our drug candidates could significantly change the costs and timing associated with the development of that drug candidate. Furthermore, our operating plan may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plan. Cash Flows The following table summarizes our cash flows for the periods indicated: Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net cash (used in) provided by: Â Â Â Â Â Â Operating activities Â $ (71,157) Â $ (74,460) Investing activities Â Â 57,642 Â Â Â 88,698 Â Financing activities Â Â 160 Â Â Â 341 Â Net (decrease) increase in cash, cash equivalents and restricted cash Â $ (13,355) Â $ 14,579 Â Â Operating Activities During the nine months ended September 30, 2024, net cash used in operating activities was $71.2 million. This consisted primarily of a net loss of $81.9 million, partially offset by non-cash charges of $9.2 million, and a decrease in our net operating assets of $1.5 million. The non-cash charges primarily consisted of stock-based compensation expense, depreciation expense, and amortization of premiums and accretion of discounts on available-for-sale securities. The decrease in our net operating assets was primarily due to a decrease in prepaid expenses and other assets and an increase in accounts payable, partially offset by a decrease accrued expenses. 35 Â During the nine months ended September 30, 2023, net cash used in operating activities was $74.5 million. This consisted primarily of a net loss of $90.4 million, partially offset by non-cash charges of $8.1 million and a decrease in our net operating assets of $7.8 million. The non-cash charges primarily consisted of stock-based compensation expense, amortization of premiums and accretion of discounts on available-for-sale securities, and depreciation expense. The decrease in our net operating assets was primarily due to an increase in accrued expenses and a decrease in unbilled grant receivable, partially offset by a decrease in accounts payable and an increase in prepaid expenses and other current and long-term assets, net. Investing Activities During the nine months ended September 30, 2024, net cash provided by investing was $57.6 million. This consisted of maturities of available-for-sale securities of $68.9 million, partially offset by purchases of available-for-sale securities of $11.3 million. During the nine months ended September 30, 2023, net cash provided by investing activities was $88.7 million. This consisted of maturities of available-for-sale securities of $116.7 million, partially offset by purchases of available-for-sale securities of $27.7 million and property and equipment of $0.3 million. Financing Activities During the nine months ended September 30, 2024, net cash provided by financing activities was $0.2 million, consisting of proceeds received from the exercise of stock options and the issuance of common stock under our employee stock purchase plan. During the nine months ended September 30, 2023, net cash provided by financing activities was $0.3 million, consisting of proceeds received from exercises of stock options and the issuance of common stock under our employee stock purchase plan. Critical Accounting Policies, Significant Judgments and Use of Estimates Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Critical accounting policies and significant judgments and estimates are those that we consider the most important to the portrayal of our financial condition and results of operations because they require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. During the nine months ended September 30, 2024, there were no material changes to our critical accounting policies. Our critical accounting policies are described under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Critical Accounting Policies, Significant Judgments and Use of Estimatesâ€ in our Annual Report on Form 10-K filed with the SEC on February 22, 2024 and Note 2 to our unaudited condensed consolidated financial statements included in â€œPart I, Item 1â€”Financial Statements (Unaudited)â€ of this report. We believe that of our critical accounting policies, the following accounting policies involve the most judgment and complexity: â€¢research and development costs; â€¢stock-based compensation; â€¢income taxes. Recent Accounting Pronouncements See Note 2 to our unaudited condensed consolidated financial statements included in "Part I, Item 1â€”Financial Statements (Unaudited)â€ of this report for additional information. 36 Â Emerging Growth Company Status We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company and (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in annual revenue; (2) the last day of the fiscal year in which we are deemed to be a â€œlarge accelerated filer,â€ as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year in which the fifth anniversary of our initial public offering occurred. Item 3. Quantitative and Qualitative Disclosures About Market Risk. As a smaller reporting company, we are not required to provide the information requested by this item pursuant to Item 305 of Regulation S-K. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures We maintain â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissionâ€™s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives. Our management, with the participation of our principal executive officer and principal financial and accounting officer, evaluated the effectiveness of our disclosure controls and procedures at the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date. Changes in Internal Control Over Financial Reporting There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 37 Â PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. From time to time, we are subject to various legal proceedings or claims that arise in the ordinary course of business. The following is a brief description of the more significant legal proceedings in which we are involved. Securities Class Actions On June 25, 2021, plaintiffs Fan Wang and Hang Gao filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against us and our former chief executive officer, Dr. Leen Kawas, captioned Wang v. Athira Pharma, Inc., et al., No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Exchange Act, and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding our business. Specifically, the Wang plaintiffs allege that we failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU including the manipulation of data, and that as a result, the defendantsâ€™ positive statements about our business, operations, and prospects were materially misleading. The Wang plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneysâ€™ fees. That same day, on June 25, 2021, plaintiff Harshdeep Jawandha filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against us, Dr. Kawas, our then chief financial officer, certain members of our board of directors at the time of our IPO, as well as the IPO underwriters, captioned Jawandha v. Athira Pharma, Inc., et al., No. 2:21-cv-00862. The Jawandha complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that that our IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawasâ€™s published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to Athiraâ€™s efforts to develop treatments for Alzheimerâ€™s, that, as a result, and that the defendantsâ€™ positive statements about our business, operations, and prospects were materially misleading. The Jawandha plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneysâ€™ fees. Also on June 25, 2021, plaintiffs Timothy Slyne and Tai Slyne filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against us, Dr. Kawas, our then chief financial officer, and the same members of our board of directors and underwriters as in the Jawandha complaint, captioned Slyne v. Athira Pharma, Inc. et al., No. 2:21-cv-00864. The Slyne complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawasâ€™s doctoral research at WSU should have been disclosed in our IPO registration statement. The Slyne plaintiffs seek unspecified compensatory damages, reasonable costs and expenses, including attorneysâ€™ fees, and injunctive and other equitable relief. On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel. On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against us, Dr. Kawas, our then chief financial officer, certain members of our board of directors at the time of our IPO and secondary public offering, or SPO, and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawasâ€™s published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffsâ€™ consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint. On August 12, 2022, defendant Dr. Kawas filed a motion for partial reconsideration of the courtâ€™s July 29, 2022 order. On October 4, 2022, the court denied the motion. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the 38 Â court entered an order setting certain case deadlines. On November 4, 2022, we and Dr. Kawas filed our individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery. On March 10, 2023, following a mediation and the partiesâ€™ agreement in principle to settle the securities class action for $10.0 million, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffsâ€™ motion for preliminary approval without prejudice, citing the motionâ€™s failure to satisfy the courtâ€™s questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023. On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffsâ€™ renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024. In its order, the court preliminarily approved the proposed settlement and certified a class with two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement. On March 29, 2024, the court issued a minute order (i) granting the portion of plaintiffsâ€™ renewed motion for preliminary approval that the court had previously deferred ruling on, (ii) setting a final approval hearing, and (iii) ordering plaintiffsâ€™ motion for final approval of the proposed settlement to be filed on or before September 26, 2024. On September 26, 2024, plaintiffs filed a motion for final approval of class action settlement and plan of allocation. On September 30, 2024, the court issued a minute order requiring additional information related to the claims administration process, to which plaintiffs responded. On October 25, 2024, the court held a settlement final approval hearing and ruled that the terms of the settlement are fair, reasonable and adequate and that notice was reasonable. On November 1, 2024, the court entered a final written judgment and order granting final approval of the settlement and closed the case. As a result of the foregoing, we recorded a legal settlement expense of $10.0 million in operating expenses in the fourth quarter of 2022 and an accrued liability of $10.0 million on the accompanying condensed consolidated balance sheets. Additionally, we recorded an insurance recovery of $1.6 million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $1.6 million on the accompanying condensed consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by our insurers. Shareholder Derivative Actions On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of our board of directors, captioned Bushansky v. Kawas et al., No. 2:22-cv-497. Plaintiff purported to bring the action derivatively on our behalf, and we were a nominal defendant to the action. The derivative complaint alleged that our board of directors breached its fiduciary duties by failing to prevent alleged misstatements in our public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint sought unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneysâ€™ fees. On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District

Court for the Western District of Washington against certain of our current and former directors and officers, captioned Houlihan v. Kawas et al., No. 2:22-cv-620. Plaintiff purported to bring the action derivatively on our behalf, and we were a nominal defendant to the action. The derivative complaint alleged that certain of our current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in our public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint sought unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneysâ€™ fees. On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. On March 18, 2024, following a mediation and the parties entering into a stipulation of settlement to settle the consolidated derivative action for certain corporate governance reforms and the payment of a fee and expense award to plaintiffsâ€™ counsel, plaintiffs filed an unopposed motion for preliminary approval of a settlement of the derivative action. On May 3, 2024, the court entered an order preliminarily approving the settlement and scheduling a final approval hearing for July 18, 39 Â 2024. On May 17, 2024, plaintiffs filed an unopposed motion for approval of attorneysâ€™ fees and expenses and service awards to plaintiffs. On July 3, 2024, plaintiffs filed an unopposed motion for final approval of derivative settlement. The settlement final approval hearing took place on July 18, 2024, and no shareholders objected to the proposed settlement or attorneysâ€™ fees or service awards sought by plaintiffs. After the hearing, on July 18, 2024, the court entered an order and judgment granting plaintiffsâ€™ motion for final approval of derivative settlement, finding the settlement to be fair, reasonable, and adequate to the settling parties and our shareholders, and dismissing the derivative action with prejudice. We paid the fee and expense award related to this shareholder derivative action settlement during the third quarter of 2024. Government Investigation In November 2022, we received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand sought documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the NIH, and our receipt of an NIH grant in 2020. We have been cooperating with the Department of Justice with respect to the Demand. We recorded a legal expense of $4.1 million based on developments in the third quarter of 2024 and a corresponding accrued liability on the accompanying condensed consolidated balance sheets. Failure by us to obtain a favorable resolution could have a material adverse effect on our business, results of operations and financial condition. Item 1A. Risk Factors. You should carefully consider the following risk factors, in addition to the other information contained in this report, including the â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ section and our unaudited condensed consolidated financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. This report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report. Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part. Risks Relating to Our Business and the Development of Our Drug Candidates We are a clinical-stage biopharmaceutical company with a limited operating history. We are a clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Our limited operating history may make it difficult to evaluate the success of our business. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have not completed a pivotal clinical trial, obtained marketing approval for any drug candidate, manufactured a commercial scale drug candidate, or conducted sales and marketing activities necessary for successful drug candidate commercialization. Our history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. If we do not address these risks and difficulties successfully, our business will suffer. We are currently focusing our efforts on the development of ATH-1105 and we may fail to or be unable to design and execute clinical trials to support marketing approval of ATH-1105 or any other drug candidates we seek to develop. We cannot be certain that our current or planned clinical trials or any other future clinical trials will be completed on time or be successful. We cannot guarantee that the FDA or foreign regulatory authorities will agree with our study design, protocol or protocol amendments, or statistical plan, or that they will interpret clinical trial results as we do, and more clinical trials could be required before we are able to submit applications seeking approval of our drug candidates. To the extent that the results of the clinical trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional clinical trials in support of potential approval of our drug candidates. Even if regulatory approval is secured for any of our drug candidates, the terms of such approval may limit the scope and use of our drug candidate, which may also limit its commercial potential. Our approach to targeting neurotrophic factors through the use of small molecules is based on a novel therapeutic approach, which exposes us to unforeseen risks. We have limited data from preclinical studies and 40 Â clinical trials to date, including for ATH-1105, and we cannot be certain that future trials will yield data in support of the safety, efficacy and tolerability of our drug candidates. We have discovered and are developing a pipeline of small molecule drug candidates to treat neurodegenerative diseases, including ALS and AD. Our drug candidates target an endogenous neurotrophic factor which is expected to protect and repair neuronal networks, which we believe could ultimately result in improvements in clinical outcomes and disease-relevant biomarkers. The therapeutic promise of neurotrophic factors in neurodegenerative diseases had been hampered in earlier therapies by the lack of efficient and non-invasive delivery to the CNS. Our small molecule drug candidates are designed to penetrate the BBB and enhance the activity of a neurotrophic factor, but we cannot be certain of the safety and efficacy of our drug candidates in applicable patients or that our clinical trials will provide sufficient evidence that our design approach results in the intended therapeutic effect. The primary and all secondary endpoints of our Phase 2 ACT-AD clinical trial of fosgonimeton in AD were not met by protocoled analysis. A subsequent post hoc analysis of the data in a pre-specified subgroup from patients on fosgonimeton without background AChEIs showed a meaningful, but not statistically significant, improvement in both ERP P300 latency and cognitive performance compared to placebo at 26 weeks. Although post hoc analyses cannot be used to establish efficacy, these analyses can be helpful in informing the design of current and future clinical studies. In addition, the primary endpoint of our Phase 2 SHAPE clinical trial in PDD and DLB was not met by protocoled analysis. Directionally positive results were observed for the 40 mg fosgonimeton dose group with improvements in cognitive, functional and biomarker measurements. In particular, the five patients in the modified intent to treat, or mITT, population treated with fosgonimeton 40 mg once daily saw improvement in ADAS-Cog13 individually, and collectively improved compared with placebo (n=7 mITT, one-sided p=0.0321). Results for patients in the 70 mg dose group were inconsistent. The topline data from our Phase 2/3 LIFT-AD clinical trial of fosgonimeton in AD showed that neither the trialâ€™s primary endpoint (the Global Statistical Test, or GST, a combination of results from measures of cognition (ADAS-Cog11) and function (ADCS-ADL23)) nor its key secondary endpoints of ADAS-Cog11 and ADCS-ADL23 reached statistical significance compared with placebo at 26 weeks. However, both components of GST, cognition (ADAS-Cog11) and function (ADCS-ADL23), directionally favored fosgonimeton treatment, and in pre-specified subgroups characterized by more rapid disease progression (moderate AD and APOE4 carriers), cognition and function improved or stabilized in the fosgonimeton treated group. In addition, data across biomarkers of protein pathology (AÎ²42/40, p-Tau181, and p-Tau217), inflammation (GFAP) and neurodegeneration (NfL) showed directional improvements with fosgonimeton treatment that are consistent with the broad neuroprotective mechanism of HGF modulation. Based on these results, we decided to pause further development of fosgonimeton and to shift our focus to the clinical development of ATH-1105. Following the readout of topline data from LIFT/AD, in September 2024 we announced our intention to focus on advancing the clinical development program for ATH-1105 as a potential treatment for ALS. We have yet to complete our first-in-human Phase 1 clinical trial in healthy volunteers evaluating the safety and tolerability of ATH-1105, which is under development. We have limited evidence regarding the efficacy, safety and tolerability of ATH-1105 and other small molecules in our drug product pipeline. We may ultimately determine that ATH-1105, or any of our other small molecules, does not possess certain properties required for therapeutic effectiveness. We may spend substantial funds attempting to develop these drug candidates and never succeed in doing so. Our development of ATH-1105 may never lead to a marketable product. We are developing ATH-1105 as a small molecule aimed at restoring neuronal health. We have not received regulatory approval for ATH-1105 and cannot be certain that our approach will lead to the development of an approvable or marketable product, alone or in combination with other therapies. Advancing ATH-1105 as a small molecule aimed at restoring neuronal health creates significant challenges for us, including: â€¢obtaining marketing approval; â€¢if ATH-1105 is approved, educating medical personnel regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating ATH-1105 into existing treatment regimens, including in combination with other treatments for ALS and AD or as a monotherapyÍ¾ and â€¢establishing the sales and marketing capabilities upon obtaining any marketing approvals to gain market acceptance. 41 Â Our prospects are highly dependent on the successful development of ATH-1105. Following the September 2024 announcement of topline results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton showing that neither the trialâ€™s primary endpoint nor its key secondary endpoints were met, we announced our intention to focus on advancing the clinical development program for ATH-1105 as a potential treatment for neurodegenerative diseases, including ALS and AD. Like fosgonimeton, ATH-1105 is a small molecule designed to positively modulate the HGF system. Although we are encouraged about the potential for ATH-1105 based on preclinical data, we may decide to discontinue development of some or all of our product candidates, including if we do not demonstrate the safety and efficacy of ATH-1105 in current and future clinical trials, and may pursue strategic alternatives to maximize stockholder value, which could involve, without limitation, exploring the potential for a possible merger, business combination, investment, a purchase, license or other acquisition of assets or return of capital to stockholders. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives. Our business depends entirely on the successful discovery, development and commercialization of our drug candidates. We have no drug products approved for commercial sale and do not anticipate generating any revenue from drug product sales for the next several years, if ever. Our ability to generate drug product revenue will depend heavily on the successful clinical development and eventual commercialization of ATH-1105 or any other drug candidates we may seek to develop. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives, including: â€¢successful and timely completion of nonclinical and clinical development of our drug candidates and any future drug candidates, as well as the associated costs, including any unforeseen costsÍ¾ â€¢establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the clinical development, both in the United States and internationally, of our drug candidates and any future drug candidatesÍ¾ â€¢timely submission of application for and receipt of marketing approvals from applicable regulatory authorities for any drug candidates for which we successfully complete clinical developmentÍ¾ â€¢making any required post-marketing approval commitments to applicable regulatory authoritiesÍ¾ â€¢developing an efficient and scalable manufacturing process for our drug candidates, including obtaining finished products that are appropriately packaged for saleÍ¾ â€¢establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for drug candidates that we develop, if approvedÍ¾ â€¢successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether inhouse or with one or more collaboratorsÍ¾ â€¢a continued acceptable safety profile following any marketing approval of our drug candidatesÍ¾ â€¢commercial acceptance of our drug candidates by patients, the medical community and third-party payorsÍ¾ â€¢identifying, assessing and developing new drug candidatesÍ¾ â€¢obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally; â€¢protecting our rights in our intellectual property portfolioÍ¾ â€¢defending against third-party patent challenges, derivation proceedings, or interference or infringement claims, if anyÍ¾ â€¢negotiating favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our drug candidatesÍ¾ â€¢obtaining coverage and adequate reimbursement by hospitals, government and third-party payors for drug candidates that we developÍ¾ â€¢addressing any competing therapies and technological and market developmentsÍ¾ and â€¢attracting, hiring and retaining qualified personnel. We may never be successful in achieving our objectives and, even if we are, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase 42 Â profitability on a quarterly or annual basis. Our failure to become and remain profitable may decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our drug candidates on a timely or profitable basis, if at all. Changes in the manufacturing process or facilities will require further comparability analysis and approval by the FDA before implementation, which could delay our clinical trials and drug candidate development, and could require additional clinical trials, including bridging studies and potential confirmatory or Phase 3 registrational trials, to demonstrate consistent and continued safety and efficacy. We have not previously submitted a new drug application, or NDA, to the FDA or similar approval filings to a comparable foreign regulatory authority, for any drug candidate. An NDA or other relevant regulatory filing must include extensive nonclinical and clinical data and supporting information to establish that the drug candidate is safe and effective for each desired indication. The NDA or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the drug product. We cannot be certain that our current or future drug candidates will be successful in clinical trials. Further, even if they are successful in clinical trials, our drug candidates or any future drug candidates may not receive regulatory approval. If we do not receive regulatory approvals for current or future drug candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a drug candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights, as well as the availability of competitive products, whether there is sufficient third-party reimbursement and adoption by physicians. We have concentrated our research and development efforts on the treatment of central and peripheral nervous system degenerative disorders, a field that has seen very limited success in product development. We have focused our research and development efforts on addressing CNS and PNS degenerative disorders. Collectively, efforts by pharmaceutical companies in the field of CNS and PNS degenerative disorders have seen very limited successes in product development. The development of CNS therapies presents unique challenges, including an imperfect understanding of the biology, the presence of the BBB that can restrict the flow of drugs to the brain, a frequent lack of translatability of preclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect that may be too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance. There are few effective therapeutic options available for patients with AD, ALS and other CNS or PNS disorders. Our future success is highly dependent on the successful development of our technology and our drug candidates for treating CNS and PNS disorders. Developing and, if approved, commercializing our drug candidates for treatment of CNS and PNS disorders subjects us to a number of challenges, including ensuring that we have selected the optimal doses, executing an appropriate clinical trial to test for efficacy and obtaining regulatory approval from the FDA and other regulatory authorities. Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of early, smaller-scale preclinical studies and clinical trials with a single or few clinical trial sites may not be predictive of eventual safety or effectiveness in large-scale potentially pivotal clinical trials across multiple clinical trial sites. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. Our lead drug candidate, ATH-1105, is currently in clinical development for the potential treatment of ALS, and we have additional drug candidates in development. It is impossible to predict when or if any of our drug candidates will prove to be effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approvals for the commercial sale of our drug candidates, we must demonstrate through lengthy, complex and expensive nonclinical studies and clinical trials that our drug candidates are both safe and effective for each target indication. Nonclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the nonclinical study and clinical trial processes, and, because our drug candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products. The results of nonclinical studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in nonclinical studies and early clinical trials, they may not prove to be safe or effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and therefore, the results of animal studies may not accurately predict safety and effectiveness in humans. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through nonclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical

trials. For example, in our fosgonimeton Phase 1a/b clinical trial, which enrolled 88 patients, 43 Â including only 11 patients with mild-to-moderate AD, of whom seven patients were treated with fosgonimeton and the other four patients were randomized to the control, suggested improvements in brain network activity including potentially positive effects on brain function. However, our subsequent Phase 2 ACT-AD clinical trial in AD did not meet its primary endpoint of a change in ERP P300 latency for the full study population nor did it meet the secondary endpoints, and our Phase 2/3 LIFT-AD clinical trial in AD did not meet its primary endpoint (the GST, a combination of results from measures of cognition (ADAS-Cog11) and function (ADCS-ADL23)) nor its key secondary endpoints of ADAS-Cog11 and ADCS-ADL23. Based on these results, we decided to pause further development of fosgonimeton and to shift our focus to the clinical development of ATH-1105. Early, smaller-scale studies, biomarker analyses, and clinical trials with a single or relatively few clinical trial sites may not be predictive of eventual safety and effectiveness in large-scale pivotal clinical trials across multiple clinical trial sites. Even if data from a pivotal clinical trial are positive, regulators may not agree that such data are sufficient for approval and may require that we conduct additional clinical trials, which could materially delay our anticipated development timelines, require additional funding for such additional clinical trials, and adversely impact our business. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence nonclinical studies and clinical trials are never approved as products. In addition, in some instances, there can be significant variability in safety or efficacy results between different nonclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in clinical trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. In the future, we may initiate an open-label trial for one or more of our product candidates. An â€œopen-labelâ€ clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a â€œpatient biasâ€ where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an â€œinvestigator biasâ€ where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. We could also encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards, or IRBs, of the institutions in which such clinical trials are being conducted, by a data safety monitoring board for such clinical trial or by the FDA or comparable foreign regulatory authorities. Clinical trials can be delayed or terminated or fail to meet endpoints for a variety of reasons, including delays or failures related to: â€¢the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials; â€¢the FDA or comparable foreign regulatory authorities disagreeing with our clinical development strategy or statistical plan; â€¢changes in governmental regulations or administrative actions; â€¢delays in our ability to commence a clinical trial; â€¢reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; â€¢obtaining IRB approval at each clinical trial site; â€¢recruiting an adequate number of suitable patients to participate in a clinical trial on a timely basis; â€¢the number of patients required for clinical trials of our drug candidates may be larger than we anticipate; â€¢having subjects complete a clinical trial or return for post-treatment follow-up; â€¢clinical trial sites deviating from clinical trial protocol or dropping out of a clinical trial; â€¢protocol deviations or non-compliance with GCP requirements, or other data integrity reasons, that cause us or the FDA or other regulatory authorities to exclude data from non-compliant sites or investigators, which may cause the trial to be underpowered to meet the endpoints; â€¢delays by us or our CROs in qualifying or analyzing patient data at the completion of clinical trials; 44 Â â€¢failure to demonstrate a benefit from using a drug candidate; â€¢addressing subject safety concerns that arise during the course of a clinical trial; â€¢adding a sufficient number of clinical trial sites; or â€¢obtaining sufficient supply of drug candidate for use in nonclinical studies or clinical trials from third-party suppliers. Further, conducting clinical trials in foreign countries, as we may do for our drug candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our drug candidates. If we experience delays in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects of our drug candidates will be harmed, and our ability to generate product revenues from any of these drug candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. If the results of our current and future clinical trials are inconclusive with respect to the efficacy of our drug candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our drug candidates, we may: â€¢incur unplanned costs; â€¢determine to limit or terminate clinical trials, including our open-label extension trial; â€¢be delayed in or prevented from obtaining marketing approval for our drug candidates; â€¢obtain approval for indications or patient populations that are not as broad as intended or desired; â€¢obtain approval with labeling that includes significant use or distribution restrictions or safety warnings including boxed warnings; â€¢be subject to changes in the way the drug candidate is administered; â€¢be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; â€¢have regulatory authorities withdraw their approval of the drug product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS; â€¢be subject to the addition of labeling statements, such as warnings or contraindications; â€¢be sued; or â€¢experience damage to our reputation. We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success. Because we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify for specific indications. As a result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other 45 Â royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. Our long-term prospects depend in part upon discovering, developing and commercializing additional drug candidates, which may fail in development or suffer delays that adversely affect their commercial viability. Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize drug candidates beyond those we currently have in clinical and nonclinical development. A drug candidate can unexpectedly fail at any stage of nonclinical and clinical development. The historical failure rate for drug candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from nonclinical testing or early clinical trials of a drug candidate may not be predictive of the results that will be obtained in later stage clinical trials of the drug candidate. The success of other future drug candidates we may develop will depend on many factors, including the following: â€¢generating sufficient data to support the initiation or continuation of clinical trials; â€¢obtaining regulatory permission to initiate clinical trials; â€¢contracting with the necessary parties to conduct clinical trials; â€¢successful enrollment of patients in, and the completion of, clinical trials on a timely basis; â€¢the timely manufacture of sufficient quantities of the drug candidate for use in clinical trials; and â€¢adverse events in the clinical trials. Even if we successfully advance any other future drug candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this â€œRisk Factorsâ€ section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other future drug candidates. We have been and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations, securities class action litigation and other legal, regulatory and administrative proceedings and face potential liability and expenses related thereto, which could divert management's attention, and insurance coverage may not be sufficient to cover all costs and damages. This could have a material adverse effect on our business, operating results and financial condition. We have been and may in the future be subject to claims, lawsuits, arbitration proceedings, government investigations, securities class action litigation and other legal, regulatory and administrative proceedings. For example, in November 2022, we received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand sought documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the NIH, and our receipt of a NIH grant in 2020. We have been cooperating with the Department of Justice with respect to the Demand. In February 2023, the Securities and Exchange Commission, or SEC, sent us a subpoena seeking documents and information relating to, among other things, our former chief executive officerâ€™s alteration of images in certain research papers. We cooperated with the SEC with respect to the subpoena. On March 29, 2024, we received a letter from the SEC stating that the SEC had concluded its investigation without any enforcement action against us. In the ordinary course of business we have been and may in the future be the subject of various legal claims. Any such claims, investigations or proceedings against us, whether meritorious or not, could be time-consuming, result in costly litigation, be harmful to our reputation, require significant management attention and divert significant resources, and the resolution of any such claims, investigations or proceedings could result in substantial damages, settlement costs, fines or penalties that could adversely affect our business, financial condition or operating results or result in harm to our reputation and brand, sanctions, consent decrees, injunctions or other remedies requiring a change in our business practices. In the past, securities class action litigation has often followed announcement of significant business transactions, such as the sale of a company or other strategic transaction, or of negative events, such as negative results from clinical trials. We may be exposed to such litigation or government or regulatory investigations even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert managementâ€™s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction. Further, under certain circumstances we may have contractual or other legal obligations to indemnify and to incur legal expenses on behalf of investors, directors, officers employees, customers, vendors or other third-parties. For example, our 46 Â amended and restated bylaws provide that we will indemnify our directors and officers, and may indemnify our employees, agents and other persons, to the fullest extent permitted by the Delaware General Corporation Law. We have also entered into indemnification agreements with directors and officers that require us, among other things, to indemnify them against claims that may arise due to their service in those capacities. These indemnification agreements also require us to advance expenses reasonably and actually incurred by them in investigating or defending any such claims, and it may be difficult or impossible to recover any advanced expenses if it turns out the person was not entitled to indemnification. If we are required or agree to defend or indemnify, or advance expenses to, any of our investors, directors, officers, employees, customers, vendors or other third-parties, we could incur material costs and expenses that could adversely affect our business, results of operations or financial condition. An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at WSU. The special committeeâ€™s findings included that (1) our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSUâ€™s dihexa patent, exclusively licensed to us, incorporated certain of these altered images. An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer, Dr. Leen Kawas, in connection with her doctoral research at WSU, including, among other things, an investigation of allegations that Dr. Kawas altered images used in research published by Dr. Kawas in connection with her doctoral studies. The independent special committeeâ€™s primary finding was that our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014. While the conduct that was the subject of the allegations is not related to any of our current drug candidates or clinical research, this finding could have a material adverse effect on our reputation, our in-licensed patents and pending patent applications, licenses and grants, and could lead to further investigation from government agencies, including the FDA, any of which could have a material adverse impact on our business and prospects. As disclosed elsewhere in this report, including in this â€œRisk Factorsâ€ section under the heading â€œâ€”We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert managementâ€™s attention,â€ and in â€œPart II, Item 1â€”Legal Proceedings,â€ lawsuits have been filed against us and certain of our directors and officers, alleging violations of federal securities laws related to alleged false and misleading statements in connection with the alleged misconduct of Dr. Kawas and others associated with us. As a result of these allegations and the ongoing litigation against us and certain of our directors and officers and related matters, we have been the subject of negative publicity. This negative publicity may harm our credibility, reputation and relationships with current and future investors, government regulators, patent offices, courts, current and prospective employees, key opinion leaders, prospective collaborators, advocacy groups, current and future patients enrolled in our clinical trials, physicians and prospective patients and vendors. For example, this negative publicity may adversely affect our ability to recruit and hire talented employees, maintain existing business relationships with CROs, clinical trial sites and other parties, enter into new business relationships, enroll patients in our clinical trials, and maintain a viable business in the future. Also, it is possible that the negative publicity and its effect on our work environment could cause our employees to terminate their employment or, if they remain employed by us, result in reduced morale that could have a material adverse effect on our business. In addition, negative publicity has and may continue to adversely affect our stock price and, therefore, employees and prospective employees may be less inclined to seek or continue employment with us. As a result, our business, financial condition, results of operations and cash flows could be materially adversely affected. WSU has undertaken a review of claims of potential research misconduct involving our former chief executive officerâ€™s doctoral research at WSU. We cannot predict what conclusions WSU will reach, whether or when WSU will share its conclusions with us or the public, and what effect, if any, this investigation may have on our business and reputation. In addition to the investigation of the independent special committee of our board of directors noted above, WSU has also announced that it has undertaken a review of claims of potential research misconduct involving research conducted by Dr. Kawas during her doctoral studies at WSU. We cannot predict what, if any, effect this investigation may have on our business and reputation. It is possible that the investigation by WSU could come to different conclusions, or uncover additional or different information, than the investigation of the independent special committee of our board of directors, the conclusions of which are discussed under â€œâ€”An independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at WSU. The special committeeâ€™s findings included that (1) our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSUâ€™s 47 Â dihexa patent, exclusively licensed to us, incorporated certain of these altered imagesâ€. The conclusions from WSUâ€™s investigation could have a material adverse impact on our business, reputation, scientific credibility, and prospects, as well as our in-licensed patents and pending patent applications, current grants and pending grant applications, and our relationship with WSU, from whom we in-license patents and patent applications underlying certain of our drug candidates. Any â€œtoplineâ€, interim, initial, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we may publicly disclose preliminary or topline data from our nonclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to

change following a more comprehensive review of the data related to the particular study or clinical trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our nonclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. Additionally, we rely on data received from clinical trials, whether preliminary or final, to inform decisions on future clinical trials, including trial design, trial size, and whether or not to initiate additional clinical trials. However, this does not guarantee that our expectations based on earlier data will be realized in future clinical trials. For example, in November 2020, we initiated ACT-AD, an exploratory Phase 2 clinical trial, to better understand the overall effects of fosgonimeton on working memory processing speed and cognitive measures. Topline results of ACT-AD were announced in June 2022. We used these data to help inform strategic decisions around LIFT-AD. In September 2024, we announced the topline results for LIFT-AD, showing that the trial did not meet its primary or key secondary endpoints. Moreover, preliminary or topline results are based on a preliminary analysis of then-available data, and a more comprehensive and full review of the data may result in different conclusions, which could have a negative impact on our decisions regarding any additional trials. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our drug candidates may be harmed, which could harm our business, operating results, prospects or financial condition. Our reporting of topline or final data for our clinical trials may be delayed and our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented. Our projected timeline for announcing our topline data may be delayed, including, among other reasons, due to possible delays in data cleaning, processing or analysis, either on our part and/or on the part of any of our third-party vendors, which could harm our business, operating results, prospects or financial condition. We also may not be able to initiate or continue clinical trials for our drug candidates if we are unable to recruit and enroll a sufficient number of eligible patients to participate in these clinical trials through completion of such trials as required by the FDA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. Patient enrollment may also be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitorsâ€™ programs. Additionally, publicly reported results of our completed clinical trials may impact enrollment of our trials in progress. If we are unable to locate a sufficient number of such patients, our clinical trial and development plans could be delayed. 48 Â If we are delayed or unsuccessful in enrolling the desired number of subjects in our trials, whether as a result of the outcomes of prior trials conducted by us, competing clinical trials, overly stringent eligibility requirements, or other factors, our clinical trial results could be delayed, the costs of our clinical trials could materially increase, and the overall development timeline for ATH-1105 or any other drug candidates we may seek to develop could be negatively impacted. Even if we are successful in enrolling the targeted number of subjects in our trials, the FDA and other regulators may request additional clinical trials with larger numbers of subjects as a condition to any regulatory approval. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Further, to the extent any of our clinical trial sites fail to comply with the approved study protocol, good clinical practices, or FDA regulations, we may be required to exclude such sites, participants such sites may have enrolled, as well as the data collected by such sites. If any of these events were to occur, or if we are required to exclude any data for any reason, we may be required to recruit more sites or more participants than we initially thought. Enrollment delays or other delays in our clinical trials may result in increased development costs for our drug candidates and jeopardize our ability to obtain marketing approval for the sale of our drug candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods. We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the drug candidates we develop, our commercial opportunities will be negatively impacted. The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While we believe that our scientific knowledge, technology and development expertise provide us with competitive advantages, we face competitive pressures from both large and small pharmaceutical companies, emerging biotechnology companies, as well as academic, government and private research institutions. Many of our competitors have access to greater financial resources, market presence, expertise in development, preclinical and clinical testing, manufacturing, commercialization, regulatory approval process, or marketing and sales than we do. Our competitors may compete with us in patient recruitment, use of clinical research organizations, and procurement of operational resources. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do. Drug candidates that we may successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our drug products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our drug candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our drug products. For example, the U.S. Centers for Medicare & Medicaid Services, or CMS, announced a two-part National Coverage Determination, or NCD, under which Medicare will cover monoclonal antibodies that target amyloid (or plaque) for the treatment of AD that receive traditional approval from the FDA under coverage with evidence development. Additionally, for drugs that FDA has not determined to have shown a clinical benefit or that received an accelerated approval, Medicare will provide coverage in FDA or NIH approved clinical trials. In June 2023, CMS announced that Medicare will cover new AD drugs with traditional FDA approval when a physician and clinical team participate in CMSâ€™ registry to collect evidence about how these drugs work in the real world. Current and future CMS coverage restrictions on classes of drugs that encompass our drug candidates could have a material adverse impact on our ability to commercialize our drug candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For additional information regarding our competition, see the section titled â€œPart I, Item 1 â€“ Businessâ€”Competitionâ€ in our Annual Report on Form 10-K filed with the SEC on February 22, 2024. We may develop drug candidates in combination with other therapies, which exposes us to additional risks. We may develop drug candidates in combination with one or more other approved or unapproved therapies. Even if any drug candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our drug product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our drug candidates are replaced as the standard of care for the indications we choose for any of our drug candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The 49 Â occurrence of any of these risks could result in our own drug products, if approved, being removed from the market or being less successful commercially. We also may choose to evaluate drug candidates in combination with one or more therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell any drug candidate we develop in combination with an unapproved therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our drug product. In addition, unapproved therapies face the same risks described with respect to our drug candidate ATH-1105, currently in development, and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our drug candidate we develop, we may be unable to obtain approval of or market such combination therapy. Risks Relating to Our Financial Position and Capital Needs We will require substantial additional funding to finance our operations, complete the development and commercialization of ATH-1105, and develop and commercialize other current and potential drug candidates. If we are unable to raise this funding and access capital when needed, we may be forced to delay, reduce, or eliminate our drug product development programs, commercialization efforts or other operations. Since our inception, we have used substantial amounts of cash to fund our operations, and we will continue to incur expenses for the foreseeable future in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of, and seek marketing approval for, ATH-1105. Developing ATH-1105 and conducting clinical trials for the potential treatment of ALS and/or AD, and any other indications that we may pursue in the future will require substantial amounts of capital. In addition, if we obtain marketing approval for ATH-1105 or any future drug candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing, and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. As of September 30, 2024, we had cash, cash equivalents and investments of $68.9 million. Based upon our current operating plan, we estimate that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months following the date of this report. The amount and timing of our future funding requirements depends on many factors, some of which are outside of our control, including but not limited to: â€¢the progress, costs, clinical trial design, results of and timing of our ATH-1105 and other clinical trials, including for potential additional indications that we may pursue beyond ALS, such as AD; â€¢the willingness of the FDA and EMA to accept ATH-1105 clinical trial data, as well as data from any completed and planned clinical and nonclinical studies and other work, as the basis for review and approval of ATH-1105 for ALS and the potential need for additional clinical trials; â€¢the outcome, costs and timing of seeking and obtaining FDA, EMA and any other regulatory approvals; â€¢the number and characteristics of drug candidates that we pursue; â€¢our ability to manufacture sufficient quantities of our drug candidates; â€¢our need to expand our research and development activities; â€¢the costs associated with securing and establishing commercialization and manufacturing capabilities; â€¢the costs of acquiring, licensing or investing in businesses, drug candidates and technologies; â€¢the cost, timing and outcomes of any litigation involving our company, including securities class actions and government investigations which we may be or may in the future become involved in; â€¢our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; â€¢our need and ability to retain management and hire scientific, clinical and other personnel; â€¢the effect of competing drugs and drug candidates and other market developments; 50 Â â€¢our need to implement additional internal systems and infrastructure, including financial and reporting systems; and â€¢the economic and other terms, timing of and success of any collaboration, licensing or other arrangements into which we may enter in the future. Because we have undertaken a process to assess strategic alternatives, the timing of which is uncertain, our future capital requirements may vary significantly from what we expect. If a strategic transaction is not consummated, we will require substantial additional funding to support our continuing operations and development. In addition, even if we are successful in completing a strategic transaction, we may still need to raise additional funds for any research and development or clinical programs we choose to pursue. Because the time and efforts required for successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities for any product candidates that ultimately may be approved for sale. In January 2023, we entered into a sales agreement with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and BTIG, LLC, or BTIG, to sell shares of our common stock having aggregate sales proceeds of up to $75.0 million, from time to time, through an at-the-market, or ATM, equity offering program under which Cantor Fitzgerald and BTIG are acting as sales agents. We have not sold any securities pursuant to this ATM offering. However, additional funding may not be available to us on acceptable terms or at all. Any such funding may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail or abandon one or more of our research or development programs. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of our technologies or drug candidates or otherwise agree to terms unfavorable to us. We expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. In addition, we may seek additional capital to take advantage of favorable market conditions or strategic opportunities even if we believe we have sufficient funds for our current or future operating plans. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. For example, the current inflationary economic environment and health epidemics have resulted in a disruption of global financial markets. If the disruption persists or deepens, we could be unable to access additional capital, which could negatively affect our ability to consummate certain corporate development transactions or other important, beneficial or opportunistic investments. If additional funds are not available to us when we need them, on terms that are acceptable to us, or at all, we may be required to take steps that could adversely impact our business, including delaying, limiting, reducing or terminating nonclinical studies, clinical trials or other research and development activities or eliminating one or more of our development programs altogether, or delaying, limiting or reducing or terminating efforts to prepare for commercialization of any future approved drug products. We currently have a shelf registration statement effective and an existing ATM equity offering program, however, our ability to raise capital under this registration statement and through our ATM equity offering program may be limited in the future by, among other things, SEC rules and regulations impacting the eligibility of smaller companies to use Form S-3 for primary offerings of securities. We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have not generated any revenue from drug product sales and our drug candidates will require substantial additional investment before they may provide us with any revenue. We had net losses of $81.9 million and $90.4 million for the nine months ended September 30, 2024 and 2023, respectively, and an accumulated deficit of $391.1 million as of September 30, 2024. We have devoted most of our financial resources to research and development, including our clinical and nonclinical development activities. To date, we have financed our operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. We expect to incur significant expenses and operating losses for the foreseeable future, including as a result of the following actions that we may take to: â€¢continue our research and nonclinical and clinical development of our drug candidates; â€¢expand the scope of our clinical studies for our current and prospective drug candidates; 51 Â â€¢initiate additional nonclinical, clinical or other studies for our drug candidates; â€¢change or add additional manufacturers or suppliers and manufacture drug supply and drug product for clinical trials and commercialization; â€¢seek regulatory and marketing approvals for any of our drug candidates that successfully complete clinical trials; â€¢attract, hire and retain additional personnel; â€¢operate as a public company; â€¢maintain our facilities and lab space; â€¢seek to identify and validate additional drug candidates; â€¢acquire or in-license other drug candidates and technologies or engage in other strategic transactions; â€¢make milestone or other payments under our in-license or other agreements; â€¢maintain, protect and expand our intellectual property portfolio; â€¢create additional infrastructure to support our operations and our drug product development efforts; and â€¢incur expenses in connection with legal proceedings, and addressing potential stockholder activism. Our expenses could increase beyond expectations for a variety of reasons, including if we experience any delays or encounter issues with any of the above, are required by the FDA, the European Medicines Agency, or EMA, or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we

currently anticipate. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholdersâ€™ equity. Adverse events or perceptions affecting the financial services industry could adversely affect our operating results, liquidity, financial condition and prospects. Limited liquidity, defaults, non-performance or other adverse developments affecting financial institutions or parties with which we do business, or perceptions regarding these or similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank, or SVB, was closed and placed in receivership and subsequently, additional financial institutions have been placed into receivership. We did not hold cash deposits or other accounts with SVB and did not, and as of the date of this report do not, otherwise have a direct business relationship with SVB or similarly situated financial institutions. However, companies that did have a business relationship with SVB faced: â€¢delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; â€¢loss of access to revolving existing credit facilities or other working capital sources or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources; â€¢potential or actual breach of obligations, including U.S. federal and state wage laws and contracts that required them to maintain letters or credit or other credit support arrangements; and â€¢termination of cash management arrangements or delays in accessing or actual loss of funds subject to cash management arrangements. As a result of U.S. government intervention, account holders subsequently regained access to their accounts, including the uninsured portion of deposit accounts; however, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB and similarly situated financial institutions were unable to access to such sources of liquidity. There is no guarantee that the U.S. government will intervene to provide access to uninsured funds in the future in the event of the failure of other financial institutions, or that they would do so in a timely fashion. In such an event, parties with which 52 Â we have commercial agreements may be unable to satisfy their obligations to, or enter into new commercial arrangements with, us. Concerns regarding the U.S. or international financial systems could impact the availability and cost of financing, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any of these risks could materially impact our operating results, liquidity, financial condition and prospects. The value of our investments is subject to significant capital markets risk related to changes in interest rates and credit spreads as well as other investment risks, which may adversely affect our operating results, liquidity, financial condition and prospects. Our results of operations are affected by the performance of our investment portfolio. Our excess cash is invested by an external investment management service provider, under the direction of our management in accordance with our investment policy. The investment policy defines constraints and guidelines that restrict the asset classes that we may invest in by type, duration, quality and value. Our investments are subject to market-wide risks, and fluctuations, as well as to risks inherent in particular securities. The failure of any of the investment risk strategies that we employ could have a material adverse effect on our operating results, liquidity, financial condition and prospects. The value of our investments is exposed to capital market risks, and our results of operations, liquidity, financial condition or cash flows could be adversely affected by realized losses, impairments and changes in unrealized positions as a result of: significant market volatility, changes in interest rates, changes in credit spreads and defaults, a lack of pricing transparency, a reduction in market liquidity, declines in equity prices, changes in national, state/provincial or local laws and the strengthening or weakening of foreign currencies against the U.S. dollar. Levels of write-down or impairment are impacted by our assessment of the intent to sell securities that have declined in value as well as actual losses as a result of defaults or deterioration in estimates of cash flows. If we reposition or realign portions of the investment portfolio and sell securities in an unrealized loss position, we will incur realized losses. Any such charge may have a material adverse effect on our results of operations and business. Our ability to use net operating losses to offset future taxable income may be subject to certain limitations. As of December 31, 2023, we had federal net operating loss carryforwards, or NOLs, to offset future taxable income of approximately $9.5 million and federal tax credit carryforwards of approximately $12.4 million, which expire over a period of 8 to 14 years. Federal NOLs of $138.7 million generated after the 2017 tax year will carry forward indefinitely and will be subject to the 80% of taxable income limitation. At December 31, 2023, we also had state NOLs of $3.3 million, which expire over a period of 18 to 20 years. A lack of future taxable income would adversely affect our ability to utilize these NOLs. In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an â€œownership changeâ€ is subject to limitations on its ability to utilize its NOLs to offset future taxable income. We may have already experienced one or more ownership changes. Depending on the timing of any future utilization of our NOLs and tax credit carryforwards, we may be limited as to the amount that can be utilized each year as a result of such previous ownership changes. However, we do not believe such limitations will cause our NOL and tax credit carryforwards to expire unutilized. In addition, future changes in our stock ownership as well as other changes that may be outside of our control, could result in additional ownership changes under Section 382 of the Code. Our NOLs may also be impaired under similar provisions of state law or limited pursuant to provisions of the Tax Cuts and Jobs Act amendments to the Code, as modified by the Coronavirus Aid, Relief, and Economic Security Act. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets. Changes in tax laws could have a material adverse effect on our business, cash flows, results of operations or financial condition. We are subject to the tax laws, regulations, and policies of several taxing jurisdictions. Changes in tax laws, as well as other factors, could cause us to experience fluctuations in our tax obligations and effective tax rates and otherwise adversely affect our tax positions or our tax liabilities. For example, many countries and local jurisdictions and organizations such as the Organization for Economic Cooperation and Development have proposed or implemented new tax laws or changes to existing tax laws, including additional taxes on payroll or employees. Any new or changes to tax laws could adversely affect our effective tax rate, operating results, tax credits or incentives or tax payments, which could have a material adverse effect on our business, cash flows, results of operations or financial condition. 53 Â Risks Relating to Strategic Process and Potential Strategic Transaction We may not be successful in identifying and implementing any strategic transaction and any strategic transactions that we may consummate in the future may not be successful. Following our receipt of the topline results of LIFT-AD, we made the determination to explore strategic alternatives focused on maximizing stockholder value. As part of this process, we will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger or reverse merger, business combination, equity or debt financing, sale of the Company, sale, exclusive license or other disposition of all or a portion of our assets, a return of capital to stockholders, or other transaction. However, there can be no assurance that we will be able to successfully consummate any particular strategic transaction. The process of continuing to evaluate these strategic options may be very costly, time-consuming and complex and we may incur significant costs related to this continued evaluation. We may also incur additional unanticipated expenses in connection with this process. A considerable portion of these costs will be incurred regardless of whether any such course of action is implemented, or transaction is completed. Any such expenses will decrease the remaining cash available for use in our business and may diminish or delay any potential cash distributions to our stockholders. In addition, we may not be able to adequately limit or avoid future liabilities, including future costs relating to the lease on our headquarters, which may impair the value of any potential transaction or present additional challenges to completing a strategic transaction. There can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated, lead to increased stockholder value, or achieve the anticipated results. Any failure of such potential transaction to achieve the anticipated results could significantly impair our ability to enter into any future strategic transactions and may significantly reduce or delay any future distributions to our stockholders. We may not realize any additional value in a strategic transaction. The market capitalization of our company is currently below the value of our current cash, cash equivalents and short-term investments. Potential counterparties in a strategic transaction involving our company may place minimal or no value on our assets, including ATH-1105. Further, the development and any potential commercialization of our product candidates would require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, any potential counterparty in a strategic transaction involving our company may choose not to spend the additional resources necessary to continue developing our product candidates and may attribute little or no value, in such a transaction, to those product candidates. If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks. Although there can be no assurance that a strategic transaction will result from the process we have undertaken to assess strategic alternatives, the negotiation and consummation of any such transaction will require significant time on the part of our management, and the diversion of managementâ€™s attention may disrupt the orderly operation of our company. The negotiation and consummation of any such transaction may also require more time or greater cash resources than we anticipate and expose us to other operational and financial risks, including: â€¢increased near-term and long-term expenditures; â€¢exposure to unknown liabilities; â€¢higher than expected acquisition, disposition or integration costs; â€¢incurrence of substantial debt or dilutive issuances of equity securities to fund future operations; â€¢write-downs of assets or incurrence of non-recurring, impairment or other charges; â€¢difficulty and cost in combining the operations and personnel of any acquired business with our operations and personnel; â€¢impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership; â€¢inability to retain key employees of our company or any acquired business; and â€¢possibility of future litigation. Any of the foregoing risks could have a material adverse effect on our business, financial condition and prospects. 54 Â Our board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. There can be no assurance that a strategic transaction will be pursued or completed, and, whether or not such strategic transaction is completed, our board of directors may decide to pursue a dissolution and liquidation of our company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, with the passage of time, the amount of cash available for distribution will be reduced as we continue to fund our operations. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, our board of directors, in consultation with our advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up. Risks Relating to Regulatory Approval and Other Legal Compliance Matters The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our drug candidates, we will not be able to commercialize, or will be delayed in commercializing, our drug candidates, and our ability to generate revenue will be materially impaired. Our drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. Before we can commercialize any of our drug candidates, we must obtain marketing approval. Obtaining approval by the FDA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidateâ€™s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Further, securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our drug candidates, the FDA and other comparable foreign regulatory authorities may approve our drug candidates for a more limited indication or a narrower patient population than we originally requested or may impose other prescribing limitations or warnings that limit the drug productâ€™s commercial potential. We have not submitted for, or obtained, regulatory approval for any drug candidate, and it is possible that none of our drug candidates will ever obtain regulatory approval. Further, development of our drug candidates or regulatory approval may be delayed for reasons beyond our control. Applications for our drug candidates could fail to receive regulatory approval for many reasons, including the following: â€¢the FDA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials; â€¢the FDA or other comparable foreign regulatory authorities may determine that our drug candidates are not safe and effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; â€¢the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; â€¢the FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials; â€¢we may be unable to demonstrate to the FDA or other comparable foreign regulatory authorities that our drug candidateâ€™s risk-benefit ratio for its proposed indication is acceptable; 55 Â â€¢the FDA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and â€¢the approval policies or regulations of the FDA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval or resulting in delays in our regulatory approval, including, for example, legislation or agency policies that aim to reform the accelerated approval process and FDAâ€™s increased scrutiny of post-approval confirmatory studies, which can result in withdrawal of accelerated approval if such studies fail to confirm a clinical benefit. This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our drug candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we obtain approval of our drug candidates, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a REMS. Regulatory authorities may not approve the price we intend to charge for drug products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could seriously harm our business. Of the large number of drugs in development, only a small percentage successfully complete the FDA or comparable foreign regulatory approval processes and are commercialized. The lengthy approval processes as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our drug candidates, which would significantly harm our business, results of operations and prospects. Our current or future drug candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our drug candidatesâ€™ use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. If our drug candidates are associated with undesirable side effects or have unexpected characteristics in nonclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the clinical trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected drug candidate and may harm our business, financial condition and prospects significantly. Patients in our clinical trials may in the future suffer significant adverse events or other side effects not observed in our nonclinical studies or previous clinical trials. Some of our drug candidates may be used as chronic therapies or be used in populations for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our drug candidates are used in combination with other therapies, our drug candidates may exacerbate adverse events associated with the therapy. Patients treated with our drug candidates may also be undergoing separate treatments which

can cause side effects or adverse events that are unrelated to our drug candidate, but may still impact the success of our clinical trials, including, for example, by interfering with the effects of our drug candidates. The inclusion of elderly patients in clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our clinical trials, or we may be required to abandon the clinical trials or our development efforts of that drug candidate altogether. We, the FDA other comparable regulatory authorities or an IRB may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that subjects in such clinical trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage clinical trials have later been found to cause side effects that prevented their 56 Â further development. Even if the side effects do not preclude the drug candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. Further, if any of our drug candidates obtains marketing approval, toxicities associated with such drug candidates and not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the drug product or the withdrawal of the drug product from the market. We cannot predict whether our drug candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on nonclinical studies or early-stage clinical trials. Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our drug candidates in other jurisdictions. Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a drug candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the drug candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our drug products is also subject to approval. We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of drug candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our drug products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential drug candidates will be harmed. Even if we receive regulatory approval of our drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates. Any regulatory approvals that we receive for our drug candidates will require surveillance to monitor the safety and efficacy of the drug candidate. The FDA may also require a REMS in order to approve our drug candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our drug candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations, GLP regulations and GCP regulations for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our drug candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: â€¢restrictions on the marketing or manufacturing of our drug candidates, withdrawal of the drug product from the market or voluntary or mandatory product recalls; â€¢manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation; â€¢revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; â€¢imposition of a REMS, which may include distribution or use restrictions; â€¢requirements to conduct additional post-market clinical trials to assess the safety of the drug product; 57 Â â€¢fines, warning letters or holds on clinical trials; â€¢refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; â€¢product seizure or detention, or refusal to permit the import or export of our drug candidates; and â€¢injunctions or the imposition of civil or criminal penalties. The FDAâ€™s and other regulatory authoritiesâ€™ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. It is difficult to predict how current and future legislation, executive actions, and litigation, including the executive orders, will be implemented, and the extent to which they will impact our business, our clinical development, and the FDAâ€™s and other agenciesâ€™ ability to exercise their regulatory authority, including FDAâ€™s pre-approval inspections and timely review of any regulatory filings or applications we submit to the FDA. To the extent any executive actions impose constraints on FDAâ€™s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. Recently, the U.S. Supreme Court overruled the Chevron doctrine, which gave deference to regulatory agenciesâ€™ statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite more companies and other stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, including FDAâ€™s statutory interpretations of market exclusivities and the â€œsubstantial evidenceâ€ requirements for drug approvals, which could undermine the FDA's authority, lead to uncertainties in the industry, and disrupt the FDA's normal operations, any of which could impact the FDAâ€™s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action. Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the productâ€™s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. The occurrence of any event or penalty described above may inhibit our ability to commercialize our drug candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. Disruptions at the FDA, the SEC and other government agencies caused by the outcome of the 2024 presidential election, funding shortages, global health concerns, or other events could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. The ability of the FDA to review and approve new products can be affected by a variety of factors, including the outcome of the 2024 presidential election, changes in the administration, government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDAâ€™s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. To the extent the FDAâ€™s normal operations are disrupted or delayed, for example due to the outcome of the 2024 presidential election, changes in the administration, travel restrictions, public health or geopolitical issues, staffing shortages, or lack of funding, the FDA may not be able to complete the necessary inspections or provide feedback in a timely manner during our clinical development or review period. If any such delays or disruptions were to occur, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct 58 Â additional nonclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous postmarketing requirements, the FDA may seek to withdraw accelerated approval. We may seek an accelerated approval for one or more of our drug candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsorâ€™s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drugâ€™s clinical benefit. If such post-approval studies fail to confirm the drugâ€™s clinical benefit, the FDA may withdraw its approval of the drug. Prior to seeking accelerated approval for any of our drug candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our drug candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our drug candidate would result in a longer time period to commercialization of such drug candidate, could increase the cost of development of such drug candidate and could harm our competitive position in the marketplace. Further, to the extent the FDA materially changes its policies or regulatory requirements with respect to the accelerated approval program or its internal review process for such program, our clinical development plans and regulatory approval under such program could be materially impacted or delayed. On December 29, 2022, the Consolidated Appropriations Act, 2023, including the Food and Drug Omnibus Reform Act, or FDORA, was signed into law. FDORA made several changes to the FDAâ€™s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements. It is unclear how these proposals, future policy changes, and changes in FDA regulation will impact new drug applications and our clinical development programs. We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our drug candidates or any future drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a drug product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: â€¢changes to our manufacturing arrangements; â€¢additions or modifications to drug product labeling; â€¢the recall or discontinuation of our drug products; or â€¢additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. 59 Â In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA contained provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companiesâ€™ share of sales to federal health care programs. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the U.S. Department of Health and Human Services Secretary, or HHS Secretary, as a condition for states to receive federal matching funds for the manufacturerâ€™s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extending the rebate program to individuals enrolled in Medicaid managed care organizations. The ACA also established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturerâ€™s outpatient drugs to be covered under Medicare Part D. In December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. As discussed above, since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. In June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the â€œdonut holeâ€ under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how additional challenges and healthcare reform measures of the Biden administration will impact the ACA. Complying with any new legislation and regulatory requirements could be time-intensive and expensive, resulting in a material adverse effect on our business. The Bipartisan Budget Act of 2018 also amended the ACA, effective January 1, 2019, by increasing the point-of-sale discount

that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the â€œdonut hole.â€ CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, CMS has published a final rule to give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. The American Taxpayer Relief Act of 2012, or ATRA, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Other legislative changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2032 with the exception of a temporary suspension implemented under various COVID-19 relief legislation. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, â€œPromoting Competition in the American Economy,â€ with multiple provisions aimed at increasing competition for prescription drugs. In August 2022, Congress passed the IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and 60 Â excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Further, the Biden administration released an additional executive order on October 14, 2022, directing the U.S. Department of Health and Human Services, or HHS, to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. Various industry stakeholders, including pharmaceutical companies, the U.S. Chamber of Commerce, the National Infusion Center Association, the Global Colon Cancer Association, and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of IRA are unconstitutional. The impact of these judicial challenges as well as other judicial challenges in view of the Supreme Courtâ€™s overruling of the Chevron doctrine, other legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the government on us and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drug candidates if approved. Current and future CMS coverage restrictions on classes of drugs that encompass our drug candidates could have a material adverse impact on our ability to commercialize our drug candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business. At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our drug products, once approved, or put pressure on our drug product pricing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our drug products. Further, FDA recently authorized the state of Florida to import certain prescription drugs from Canada for a period of two years to help reduce drug costs, provided that Floridaâ€™s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare or impose price controls may adversely affect: â€¢the demand for our drug candidates, if we obtain regulatory approval; â€¢our ability to set a price that we believe is fair for our drug products; â€¢our ability to obtain coverage and reimbursement approval for a drug product; â€¢our ability to generate revenue and achieve or maintain profitability; â€¢the level of taxes that we are required to pay; and â€¢the availability of capital. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. We expect that other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments 61 Â from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drug candidates. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure to what extent the trajectory of these legislative and regulatory proposals will be implemented by the federal and state governments, whether additional legislative changes will be enacted, whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by Congress of the FDAâ€™s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities, and our participation in the federal health care programs and acceptance of federal grant funding, such as funding from the NIH, may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings. Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our drug products for which we obtain marketing approval. Similarly, our participation in the federal health care programs and acceptance of federal grant funding from the NIH may subject us to federal false claims laws, civil penalties and assessments, criminal prosecution, and other administrative, civil, and criminal remedies. The laws that may affect our ability to operate include, but are not limited to: â€¢the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act, or FCA. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. â€¢federal civil and criminal false claims laws, including the FCA, which can be enforced through civil â€œqui tamâ€ or â€œwhistleblowerâ€ actions, and civil monetary penalty laws, impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to â€œcauseâ€ the submission of false or fraudulent claims. The FCA also permits a private individual acting as a â€œwhistleblowerâ€ to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. Under the FCA, a â€œclaimâ€ also includes any request (including grant request) or demand for money or property made to the United States or to a contractor, recipient, if the Federal government provides or will reimburse any portion of the funds claimed. â€œFundsâ€ include money that the NIH awards as part of research grants. Even if a federal grant is not awarded, the grant applicant may be subject to FCA liability if the information contained in or submitted as part of a grant application, including its certifications and assurances, is found to be false, fictitious, or fraudulent. â€¢the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud 62 Â any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. â€¢HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneysâ€™ fees and costs associated with pursuing federal civil actions. â€¢the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. â€¢federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. â€¢analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities, including our advisory board arrangements with physicians, some of whom receive stock or stock options as compensation for services provided, and any sales and marketing activities after a drug candidate has been approved for marketing in the United States, could be subject to legal challenge and enforcement actions. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. In addition to the risks relating to the outcome of the independent special committeeâ€™s investigation noted above, we are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose 63 Â unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also

produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workersâ€™ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. Risks Relating to Our Reliance on Third Parties If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. From time to time, we evaluate various acquisition opportunities and strategic transactions and partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: â€¢increased operating expenses and cash requirements; â€¢the assumption of additional indebtedness or contingent liabilities; 64 Â â€¢the issuance of our equity securities; â€¢assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; â€¢the diversion of our managementâ€™s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition; â€¢retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; â€¢risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and â€¢our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. We may use strategic collaborations, licensing arrangements or partnerships to accelerate the development and maximize the commercial potential of our programs, and we may not realize the benefits of such collaborations, arrangements or partnerships. We own or in-license worldwide intellectual property rights to our pipeline of small molecule candidates. Where appropriate, we may use strategic collaborations, licensing arrangements or partnerships to accelerate the development and maximize the commercial potential of our programs. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our drug candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate safety and efficacy and obtain marketing approval. In addition, the effects to our business and reputation discussed in â€œAn independent special committee of our board of directors engaged in a review of papers co-authored by our former chief executive officer in connection with her doctoral research at WSU. The special committeeâ€™s findings included that (1) our former chief executive officer altered images in her 2011 doctoral dissertation and at least four research papers that she co-authored while a graduate student at WSU, and published from 2011 to 2014, (2) that we cited challenged research papers in certain communications and applications, and (3) that WSUâ€™s dihexa patent, exclusively licensed to us, incorporated certain of these altered images,â€ may discourage potential counterparties from entering into relationships with us. If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a drug candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our drug candidates or bring them to market and generate product revenue. Even if we are successful in entering into collaborations involving our drug candidates, these relationships are subject to numerous risks, which may include the following: â€¢collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; â€¢collaborators may not pursue development and commercialization of our drug candidates or may elect not to continue or renew development or commercialization of our drug candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; 65 Â â€¢collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing; â€¢collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our drug candidates; â€¢a collaborator with marketing and distribution rights to one or more drug products may not commit sufficient resources to their marketing and distribution; â€¢collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; â€¢disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources; â€¢collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable drug candidates; and â€¢collaborators may own or co-own intellectual property covering our drug products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. As a result, if we enter into additional strategic collaborations, licensing arrangements or partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic collaboration, licensing arrangement or partnership, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new strategic collaborations, licensing arrangements or partnerships related to our drug candidates could delay the development and commercialization of our drug candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. We rely on third parties to conduct our nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our drug candidates. We utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs, and strategic partners to conduct and support our nonclinical studies and clinical trials under agreements with us. We expect to have to negotiate budgets and contracts with CROs, clinical trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our nonclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these nonclinical studies and clinical trials and the management of data developed through nonclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for drug candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In particular, protocol deviations or non-compliance with GCP requirements, or other data integrity reasons, can cause us or the FDA or other regulatory authorities to exclude data from non-compliant sites or investigators, which may cause the trial to be underpowered to meet the endpoints. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with pharmaceutical drug product produced under cGMP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. 66 Â Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing, clinical and non-clinical drug candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our drug candidates. As a result, our financial results and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. Switching or adding third parties to conduct our nonclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. We contract with third parties for the manufacture of our drug candidates for nonclinical studies and our clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. We do not currently have the infrastructure or internal capability to manufacture supplies of our drug candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our drug candidates for nonclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. Furthermore, the raw materials for our drug candidates are sourced, in some cases, from a single-source supplier and sometimes involve long lead times from order to receipt of the materials. If we were to experience an unexpected loss of supply of any of our drug candidates or any of our future drug candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. We expect to continue to rely on third-party manufacturers for the commercial supply of any of our drug candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: â€¢the failure of the third party to manufacture our drug candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our drug candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and themÍ¾ â€¢the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of termsÍ¾ â€¢the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for usÍ¾ â€¢the breach by the third-party contractors of our agreements with them; â€¢the failure of third-party contractors to comply with applicable regulatory requirementsÍ¾ â€¢the failure of the third party to manufacture our drug candidates according to our specificationsÍ¾ â€¢the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identifiedÍ¾ â€¢clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost salesÍ¾ and â€¢the misappropriation of our proprietary information, including our trade secrets and know-how. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our 67 Â contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our drug candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our drug candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our drug candidates or drugs and harm our business and results of operations. Our current and anticipated future dependence upon others for the manufacture of our drug candidates or drugs may adversely affect our future profit margins and our ability to commercialize any drug candidates that receive marketing approval on a timely and competitive basis. In addition, there is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. For example, legislative proposals have been passed in the House of Representatives and been referred to the Senate that would limit the extension of certain specific types of government contracts or renewals, loans, or grants, to companies that may do business with select Chinese biotechnology equipment or service providers. If enacted, such legislation will preclude certain U.S. biotechnology companies from using equipment or services produced or provided by those Chinese biotechnology companies when performing on the specified types of agreements with the U.S. government. Further, others in Congress have advocated for the use of existing executive branch authorities to limit certain Chinese service providersâ€™ ability to engage in business in the U.S. Although we do not currently use equipment or services produced or provided by such Chinese biotechnology companies, such changes in applicable trade policy may result in us being unable to obtain or use necessary equipment or services or may cause significant industry-wide supply delays or capacity limitations that could materially disrupt our operations, supply chain, and ability to produce, sell and distribute our drug candidates. Furthermore, the U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. We cannot predict whether any proposed legislation will be enacted, what executive actions may implicate these kinds of service relationships, or what other actions may ultimately be taken with respect to trade relations between the United States and China or other countries,

including countries which the U.S. government has identified as a foreign adversary that poses national security risks to the United States. In addition, we cannot predict what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation, any of which may materially and adversely affect our business, financial condition, results of operations, and cash flows. Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals. In order to commercially produce our drug products either at our own facility or at a third partyâ€™s facility, we will need to comply with the FDAâ€™s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our precision medicines as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our drug candidates, including leading to significant delays in the availability of our precision medicines for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our drug candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our drug candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business. If our third-party manufacturers use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages. Our research and development activities involve the controlled use of potentially hazardous substances, including chemical materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturersâ€™ procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of 68 Â an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Risks Relating to Our Ability to Commercialize our Drug Products Even if approved, our drug candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success. Even if our drug candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance or reimbursement of any of our approved drug candidates will depend on a number of factors, including: â€¢the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatmentsÍ¾ â€¢the timing of market introduction of the drug candidate as well as competitive productsÍ¾ â€¢the clinical indications for which the drug candidate is approvedÍ¾ â€¢the extent of physician acceptance of FDA-approved therapies for target indications; â€¢restrictions on the use of our drug candidates, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor productsÍ¾ â€¢the potential and perceived advantages of our drug candidates over alternative treatmentsÍ¾ â€¢the cost of treatment in relation to alternative treatmentsÍ¾ â€¢pricing and the availability of coverage and adequate reimbursement by third-party payors, including government authoritiesÍ¾ â€¢the availability of the approved drug candidate for use as a combination therapyÍ¾ â€¢relative convenience and ease of administrationÍ¾ â€¢the willingness of the target patient population to try new therapies and of physicians to prescribe these therapiesÍ¾ â€¢the effectiveness of sales and marketing effortsÍ¾ â€¢unfavorable publicity relating to our drug products or drug candidates or similar approved products or product candidates in development by third partiesÍ¾ and â€¢the approval of other new therapies for the same indications. If any of our drug candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from such drug candidates and our financial results could be negatively impacted. We have never commercialized a drug candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any drug products on our own or together with suitable collaborators. We have never commercialized a drug candidate. We may license certain rights with respect to our drug candidates to collaborators, and, if so, we will rely on the assistance and guidance of those collaborators. For drug candidates for which we retain commercialization rights and marketing approval, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. Factors that may affect our ability to commercialize our drug candidates, if approved, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, developing adequate educational and marketing programs to increase public acceptance of our approved drug candidates, ensuring regulatory compliance of our company, employees and third parties under applicable healthcare laws, and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our drug candidates upon approval. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our drug candidates, we may not generate revenues from them or be able to reach or sustain profitability. 69 Â If the market opportunity for any drug candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer. We intend to initially focus our drug candidate development on treatments for various CNS and PNS disorder indications. The addressable patient populations that may benefit from treatment with our drug candidates, if approved, are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these CNS and PNS disorders. Any regulatory approval of our drug candidates would be limited to the therapeutic indications examined in our clinical trials and as determined by the FDA, which would not permit us to market our drug products for any other therapeutic indications not expressly approved by the FDA. Additionally, the potentially addressable patient population for our drug candidates may not ultimately be amenable to treatment with our drug candidates. Even if we receive regulatory approval for any of our drug candidates, such approval could be conditioned upon label restrictions that materially limit the addressable patient population. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any drug candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our drug candidates. We face an inherent risk of product liability as a result of the planned clinical testing of our drug candidates and will face an even greater risk if we commercialize any drug products. For example, we may be sued if our drug candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our drug candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: â€¢decreased demand for our drug candidates or drug products that we may develop; â€¢injury to our reputation; â€¢withdrawal of clinical trial participants; â€¢initiation of investigations by regulators; â€¢costs to defend the related litigation; â€¢diversion of managementâ€™s time and our resources; â€¢substantial monetary awards to clinical trial participants or patients; â€¢drug product recalls, withdrawals or labeling, marketing or promotional restrictions; â€¢loss of revenue; â€¢exhaustion of any available insurance and our capital resources; â€¢the inability to commercialize any drug candidate; and â€¢a decline in our share price. Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of drug products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. The insurance coverage and reimbursement status of newly approved products is uncertain. Our drug candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, which would harm our business. Failure to obtain or maintain adequate 70 Â coverage and reimbursement for new or current drug products could limit our ability to market those drug products and decrease our ability to generate revenue. The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a drug product in a particular country, but then be subject to price regulations that delay our commercial launch of the drug product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if any drug candidates we may develop obtain marketing approval. In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our drug candidates will depend in part on the extent to which coverage and adequate reimbursement for these drug products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as gene therapy products. Sales of these or other future drug candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our drug candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our drug candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payorâ€™s determination that use of a product is: â€¢a covered benefit under its health plan; â€¢safe, effective and medically necessary; â€¢appropriate for the specific patient; â€¢cost-effective; and â€¢neither experimental nor investigational. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our drug candidates. Accordingly, in markets outside the United States, the reimbursement for products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our drug products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not 71 Â be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drug products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drug candidates, and our overall financial condition. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates third-party payors for any approved drug products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drug products and our overall financial condition. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any drug candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. In order to obtain reimbursement, physicians may need to show that patients have superior treatment outcomes with our drug products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. We expect to experience pricing pressures in connection with the sale of any of our drug candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. A variety of risks associated with marketing our drug candidates internationally may materially adversely affect our business. We plan to eventually seek regulatory approval of our drug candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: â€¢differing regulatory requirements in foreign countries, such as the lack of pathways for accelerated drug approval, may result in foreign regulatory approvals taking longer and being more costly than obtaining approval in the United States; â€¢foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials or our interpretation of data from nonclinical studies or clinical trials; â€¢approval policies or regulations of foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; â€¢impact of health epidemics on our ability to produce our drug candidates and conduct clinical trials in foreign countries; â€¢unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; â€¢economic weakness, including inflation, or political instability in particular foreign economies and markets; â€¢compliance with legal requirements applicable to privacy, data protection, information security and other matters; â€¢compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; â€¢foreign taxes, including withholding of payroll taxes; â€¢foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; â€¢difficulties staffing and managing foreign operations;

â€¢complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries; â€¢workforce uncertainty in countries where labor unrest is more common than in the United States; â€¢potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations; â€¢challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; 72 Â â€¢production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and â€¢business interruptions resulting from geo-political actions, including war and terrorism. These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations. Risks Relating to Our Intellectual Property Our success depends on our ability to protect our intellectual property and our proprietary technologies. Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our drug candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our drug candidates, proprietary technologies and their uses that are important to our business. We may also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending applications from third parties. Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or the patent applications of any current or future licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around, found unenforceable or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties or the patent owner before various patent offices or in courts. Thus, the degree of future protection for our and any current or future licensorsâ€™ proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties or limitations in our ability to properly protect the intellectual property rights relating to our drug candidates could have a material adverse effect on our financial condition and results of operations. We cannot be certain that the claims in our pending patent applications or those of any current or future licensors will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our owned or in-licensed patents will not be found invalid or unenforceable if challenged. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our drug candidates by obtaining and defending patents. These risks and uncertainties include the following: â€¢the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; â€¢patent applications may not result in any patents being issued; â€¢patents and patent applications may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; â€¢changes to patent laws in the United States or in other countries may limit the ability to obtain, defend or enforce patents, or may apply retroactively to affect the terms or scope of patents; â€¢our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential drug candidates; â€¢there may be significant pressure on the U.S. government and international governmental bodies to limit the scope or term of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and 73 Â â€¢countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates. The patent prosecution process is also expensive and time-consuming, and we and any current or future licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or any current or future licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed. Certain of these parties may also be subject to public information disclosure statutes and could determine to disclose patentable aspects of our research and development output pursuant to a request thereunder, notwithstanding the existence of a non-disclosure and confidentiality agreement. Any of these actions could jeopardize our ability to seek patent protection. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates or their use might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications and those of any current or future licensors may not result in patents being issued which protect our drug candidates or their use or which effectively prevent others from commercializing competitive product candidates. Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or in-license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged or circumvented by third parties or may be narrowed, invalidated or rendered unenforceable as a result of challenges by third parties. Consequently, we do not know whether our drug candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents or the patents of any current or future licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents or the patents of any current or future licensors may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our drug candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, our patents or the patents of any current or future licensors may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our claim of priority of invention, scope, validity or patentability with respect to our patents and patent applications and those of any current or future licensors. For example, in view of the lawsuits disclosed elsewhere in this report including in this â€œRisk Factorsâ€ section under the heading â€œâ€”We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert managementâ€™s attention,â€ and in â€œPart II, Item 1â€”Legal Proceedings,â€ third parties may challenge the validity or enforceability of our in-licensed patents and patent applications. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Such challenges 74 Â may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar technology and drug products such as other modifications to dihexa not covered by our issued patents. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our in-licensed patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future drug candidates. Further, these proceedings could have a material adverse effect on our business, results of operations and financial condition. Even though we own patents and patent applications covering our small molecule drug candidates, our patents and any future patents we obtain may not effectively prevent others from developing or commercializing products similar to our drug candidates. While the fosgonimeton patent family is distinct from, and not part of the same patent family as, the dihexa patent licensed from WSU, and therefore is not implicated in the allegations that Dr. Kawas altered images in connection with her doctoral studies, third parties may use these allegations to cast doubt on the validity and enforceability of our owned patents or patent applications. Such events may result in substantial cost and require significant time from our scientists and management, and could dissuade companies from collaborating with us to license, develop, or commercialize current or future drug candidates, even if the eventual outcome is favorable to us. We or WSU may in the future file one or more requests for supplemental examination of certain patents for the USPTO to reconsider the enforceability and validity of the patents (including any patents relating to dihexa) in view of the allegations that Dr. Kawas altered images in connection with her doctoral studies. The outcome of any supplemental examination procedure is unpredictable. If a substantial new question of patentability is found, the USPTO Director will order supplemental examination of the patent. An adverse determination in such a proceeding could reduce the scope of, or invalidate or render unenforceable, the affected patent rights. While supplemental examination proceedings that result in our favor would bolster the presumption of validity and enforceability of the examined patents, third parties may still challenge the patents and patent applications in litigation or other legal proceedings. ATH-1105, our small molecule drug candidate currently in development for the potential treatment of ALS, is not covered by the WSU license agreement. Intellectual property rights do not necessarily address all potential threats to our competitive advantage. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: â€¢others may be able to develop products that are similar to our drug candidates but that are not covered by the claims of the patents that we own or license; â€¢we or any current or future licensors or collaborators might not have been the first to make the inventions covered by the issued patents or patent application that we own or license; â€¢we or any current or future licensors or collaborators might not have been the first to file patent applications covering certain of our or their inventions; â€¢others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; â€¢it is possible that the pending patent applications we own or license will not lead to issued patents; â€¢issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors; â€¢our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; â€¢we may not develop additional proprietary technologies that are patentable; â€¢the patents of others may have an adverse effect on our business; and â€¢we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property. Should any of these events occur, it could significantly harm our business, results of operations and prospects. 75 Â Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our drug candidates and drug products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation and other legal actions, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, reexaminations, IPR proceedings and PGR proceedings and oppositions before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing drug candidates. There may be third-party patents or patent applications with claims to compositions, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our drug candidates. As the biopharmaceutical industry expands and more patents are issued, the risk increases that our drug candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents or patent applications that may be infringed by commercialization of any of our drug candidates, and we cannot be certain that we were the first to file a patent application related to a drug candidate, its use, or our technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our drug candidates or their use may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our drug candidates that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any defense to claims of patent infringement asserted by third parties would be time consuming and could: â€¢result in costly litigation that may cause negative publicity; â€¢divert the time and attention of our technical personnel and management; â€¢cause development delays; â€¢prevent us from commercializing any of our drug candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; â€¢require us to develop non-infringing technology, which may not be possible on a cost-effective basis; â€¢subject us to significant liability to third parties; or â€¢require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology. Although no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent our drug candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our drug candidates, treatment indications, or processes could subject us to significant liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our drug candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion for management and other personnel. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or a future strategic partner were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our drug candidates, our treatment indications, or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our drug candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our drug candidates and technology. 76 Â Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. We may not be successful in obtaining or maintaining necessary rights to our drug candidates through acquisitions and in-licenses. Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property

rights from third parties that we identify as necessary for our drug candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property, or if we are unable to maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. We may be involved in lawsuits to protect or enforce our patents or any current or future licensorsâ€™ patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or any current or future licensorsâ€™ patents could be found invalid or unenforceable if challenged in court. Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable, or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our drug candidates or their method of use, the defendant could counterclaim that our patent or the patent of any current or future licensors is invalid or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including allegations of a lack of novelty, obviousness, lack of sufficient written description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent application misrepresented or fraudulently withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include re-examination, PGR, IPR, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents or any current or future licensorsâ€™ patents in such a way that they no longer cover our technology or any drug candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to a validity claim, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or any drug candidates that we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects. The outcome following legal assertions of invalidity or unenforceability is unpredictable, and prior art could render our patents or any current or future licensorsâ€™ patents invalid. There is no assurance that all potentially relevant prior art relating to our patents and patents applications or the patents and patent applications of any current or future licensors has been found. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or the patents and patent applications of any current or future licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Additionally, a finding that issued claims lack sufficient written description or are not enabled could render our patent or any current or future licensorsâ€™ patent invalid. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we may lose at least part, and perhaps all, of the patent protection on such drug candidate. In addition, if the breadth or strength of protection provided by 77 Â our patents and patent applications or the patents and patent applications of any current or future licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates. Such a loss of patent protection would have a material adverse impact on our business. Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented drug product and practicing our own patented technology. Intellectual property litigation or legal proceedings may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline. During the course of any intellectual property litigation or legal proceeding, there could be public announcements of the initiation of the litigation or legal proceeding as well as results of hearings, rulings on motions, and other interim proceedings. If securities analysts or investors regard these announcements as negative, the perceived value of our existing drug candidates, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future drug products, which could have a material adverse effect on our business. Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. Derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of any current or future licensors or of third parties. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other personnel. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our drug candidates to market. Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of any current or future licensors and the enforcement or defense of our issued patents or those of any current or future licensors. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a â€œfirst inventor to fileâ€ system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that filed a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours or our current or future licensors even if we or our current or future licensors had made the invention before it was made by such third party. This requires us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow 78 Â our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we may not be certain that we or any current or future licensors are the first to either (1) file any patent application related to our drug candidates, their use, or our technology or (2) invent any of the inventions claimed in the patents or patent applications. The Leahy-Smith Act also included a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of printed publications to the USPTO during patent prosecution and additional procedures to attack the validity or enforceability of a patent by USPTO-administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims or those of our current or future licensors that would not have been invalidated if first challenged by the third party in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of any current or future licensors and the enforcement or defense of our issued patents or those of any current or future licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future. As an example, European patent applications now provide the option, upon grant of a patent, of becoming a Unitary Patent, which is subject to the jurisdiction of the Unitary Patent Court, or UPC, in member states that have acceded to and ratified the EU Patent Package. The option of a Unitary Patent is a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation in the UPC. European patents granted on applications we file may be subject to loss or revocation via the UPC, which could have a material adverse effect on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time and may adversely affect our ability to enforce or defend the validity of any European patents obtained. We have opted out of the UPC with respect to our European patents to date, and we may decide to opt out of the UPC with respect to any pending or future published European patent applications or patents. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, even if we decide to opt out of the UPC. We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are 79 Â successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time. Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our drug candidates or their use are obtained, once the patent life has expired, we may be open to competition from competitive products, including generic versions of our drug products. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug products similar or identical to ours. If we do not obtain patent term extension for our drug candidates, our business may be materially harmed. Depending upon the timing, duration and specifics of FDA marketing approval of our drug candidates, one or more of our U.S. patents or those of any current or future licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our drug candidates, although the requirements and terms of such extensions vary country-by-country. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products or launch generic versions of our drug products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and nonclinical data and launch their drug product earlier than might otherwise be the case. We will not be able to protect our intellectual property rights throughout the world. We own and in-license patents and pending patent applications in the United States and in jurisdictions outside of the United States. However, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we will not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing drug products made using our inventions in and into the United States or other jurisdictions. Competitors may use our inventions in jurisdictions where we have not obtained patent protection to develop their own drug products and, further, may export otherwise infringing drug products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These drug products may compete with our drug candidates, and our patents, the patents of any current or future licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or any current or future licensorsâ€™ patents or marketing of competing drug products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of any current or future licensors at risk of being invalidated or interpreted narrowly and our patent applications or the patent applications of any current or future licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not

prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. 80 Â Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Geopolitical actions could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russiaâ€™s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have a predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents or applications and those of any current or future licensors. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our drug products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest, and it may be difficult and costly to register, maintain or protect our rights to these trademarks and trade names in jurisdictions in and outside of the United States. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with our employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing 81 Â a claim that a party improperly disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of third parties. We have entered into and may enter in the future into non-disclosure and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners, lessees of shared multi-company property and other third parties. We may become subject to litigation where a third party asserts that we or our employees inadvertently or otherwise breached the agreements and used or disclosed their trade secrets or other information proprietary to the third parties. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our drug candidates. Failure to defend against any such claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. Parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, operating results, financial condition and prospects. We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our drug candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. Our rights to develop and commercialize our drug candidates may be subject, in part, to the terms and conditions of licenses granted to us by others. We have entered into license agreements with third parties and we may enter into additional license agreements in the future with others to advance our research and development or allow commercialization of drug candidates. These and other licenses may not provide exclusive rights to use such intellectual property and other rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our drug candidates in the future. Further, these and other licenses may also include certain restrictions or obligations that limit our ability to engage with third parties, including potential restrictions on sublicensing or outsourcing certain activities. In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering our drug candidates that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our 82 Â business. If any of our current or future licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our drug candidates that are subject of such licensed rights could be adversely affected. Our licensors and any future licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-license. If it is later determined that third parties own the rights to our in-licensed patents, or if other third parties have ownership rights to our in-licensed patents, such third parties may be able to license such patents to our competitors, and our competitors could market drug products similar or identical to our drug candidates. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same rights licensed to us. In that event, we may be required to expend significant time and resources to redesign our drug candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected drug candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our current manufacturing methods, drug candidates, methods of use, or future methods or drug candidates resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant. If we fail to comply with our obligations in the agreements under which we license intellectual property rights or other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. Disputes may arise between us and our current or future licensors regarding intellectual property and other rights subject to a license agreement, including: â€¢the scope of rights granted under the license agreement and other interpretation-related issues; â€¢whether and the extent to which our drug candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement; â€¢our right to sublicense to third parties; â€¢our diligence obligations under the license agreement and what activities satisfy those diligence obligations; â€¢our right to transfer or assign the license; â€¢the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and â€¢the priority of invention of patented technology. In addition, the agreements under which we license intellectual property or other rights from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or other rights, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property or other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize drug candidates covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, drug 83 Â products identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. The patent protection and patent prosecution for some of our drug candidates may be dependent on third parties. While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patent applications and patents relating to our drug candidates and their use, there may be times when the filing and prosecution activities for patent applications and patents relating to our drug candidates are controlled by licensors or collaboration partners. If a licensor or collaboration partner fails to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patent applications and patents covering our drug candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those drug candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling drug products similar or identical to our drug candidates. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as â€œmarch-inâ€ rights, certain reporting requirements and a manufacturing preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers, which could adversely affect our ability to successfully develop and commercialize our drug products. We entered an exclusive license agreement with WSU for certain licensed patents that include intellectual property that was generated through the use of U.S. government funding, and we received a grant from the NIA of the NIH to support our ACT-AD clinical trial. Pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act, the U.S. government may have certain rights in any invention developed or reduced to practice with government funding. In addition, in the future we may discover, develop, acquire, or license new intellectual property that has been generated through the use of U.S. government funding or grants in which the U.S. government may have certain rights pursuant to the Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as â€œmarch-in rightsâ€). Such â€œmarch-inâ€ rights would apply to new subject matter arising from the use of such government funding or grants and would not extend to pre-existing subject matter or subject matter arising from funds unrelated to the government funding or grants. If the U.S. government exercises its march-in rights in our intellectual property rights that are generated through the use of U.S. government funding or grants, we could be required to license or sublicense intellectual property discovered or developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. Reporting of a subject invention and compliance with the Bayh-Dole Act requirements were delayed for the patent family directed to methods of treating AD with fosgonimeton. As such, this patent family may be subject to U.S. government action which may include loss of rights in the subject invention, suspending or terminating the grant or future awards, or withholding further awards. Should any of these events occur, it could significantly harm our business, results of operations and prospects. In addition, the Bayh-Dole Act requires that, in certain circumstances, any products embodying intellectual property generated with the use of U.S. government funds or produced through the use of any such intellectual property be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar

terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property, which could adversely affect our ability to successfully develop and commercialize our drug products and have a material adverse effect on our business, financial condition, results of operations, and prospects. 84 Â Risks Relating to Cybersecurity We are dependent on networks, infrastructure and data, which exposes us to data security risks, including security failures or breaches of our systems or those used by our CROs or other contractors or consultants. We are dependent upon our own or third-party information technology systems, infrastructure and data, including mobile technologies, to operate our business. The multitude and complexity of our computer systems may fail or suffer security breaches. As discussed in the section titled "Part 1, Item 1.Câ€”Cybersecurity," in our Annual Report on Form 10-K filed with the SEC on February 22, 2024, we have implemented various processes and policies for identifying, assessing, and managing material risks from cybersecurity threats. However, despite the implementation of such safeguards and security measures, our internal computer systems and those of our CROs and other contractors and consultants may nevertheless be vulnerable to damage from computer viruses and unauthorized access. Likewise, data privacy or security incidents or breaches by employees or others may pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public or may otherwise be misused. Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our personal, sensitive, confidential or proprietary information and information technology systems, and those of the third parties upon which we rely. For example, in April 2023, CRO Evotec SE faced a cybersecurity attack that temporarily disrupted its systems and operations. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer â€œhackers,â€ threat actors, â€œhacktivists,â€ organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. Increases in remote work impacting how our employees work and access our systems could lead to additional opportunities for bad actors to launch cyberattacks or for employees to cause inadvertent security risks or incidents and may amplify the impacts of any security breach or incident. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entitiesâ€™ systems and technologies. We may rely on third-party service providers and technologies to operate critical business systems to process sensitive information and other company data in a variety of contexts. We may also rely on third-party service providers to provide certain products or services, or otherwise to operate our business. Our ability to monitor these third parties' information security practices is limited, and these third parties may not have adequate information security measures in place. Security incidents or other interruptions suffered by our third-party service providers could cause us to experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy- or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third partiesâ€™ infrastructure in our supply chain or our third-party partnersâ€™ supply chains have not been compromised. Our business partners face similar risks, and any security breach of, or security incident impacting, their systems or that they otherwise suffer could adversely affect our security posture. A security breach or incident or privacy violation that leads to loss of or unauthorized use, disclosure or modification of, or access to trade secrets, company resources, personal, sensitive, confidential or proprietary information, including protected health information or other patient information, or that prevents access to patient information, as well as the perception that any of the foregoing has occurred, could harm our reputation, compel us to comply with federal or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, cause us to provide other notification or take other steps in response to such breach or violation, require us to verify the correctness of database contents and otherwise subject us to litigation, claims, investigations, penalties or other liability under laws and regulations, any of which could disrupt our business or result in increased costs or loss of revenue or company resources. Moreover, the prevalent use of mobile devices that access confidential information, increase the risk of security breaches and incidents. 85 Â Despite efforts to create security barriers to the above-described threats, it is impossible for us to entirely mitigate these risks. To date, we have not experienced any material impact to our business, financial position or results of operations resulting from cyberattacks or other information security incidents such as phishing, social engineering, ransomware or malware attacks; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of such attacks, our business, financial position or results of operations could be adversely impacted in the future. We may be unable to anticipate or prevent techniques used to obtain unauthorized access or to compromise our systems because they change frequently and are generally not detected until after an incident has occurred. If a compromise or other security breach or incident were to occur and cause the loss or corruption of data or interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss, unavailability, or corruption of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any disruption or security breach or incident resulting in loss or unavailability of, or damage to, our data or systems, or inappropriate use, disclosure or modification of personal, sensitive, confidential or proprietary information, could result in us incurring liability and in delays to further development and commercialization of our drug candidates could be delayed. While we have invested, and continue to invest, in the protection of our data and information technology infrastructure, there can be no assurance that our efforts will prevent service interruptions, or prevent or identify vulnerabilities or security breaches or incidents, that could adversely affect our business and operations or result in the loss, unavailability, or corruption of, or inappropriate access to or use of, critical or sensitive information or company resources. Any such interruptions, breaches or incidents, or the perception any have occurred, could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other privacy and security breaches or incidents. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information. As we conduct our clinical trials and continue to enroll patients in our current and future clinical trials, we may be subject to additional restrictions relating to privacy, data protection and data security. The collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals in the European Economic Area, or EEA, is subject to the EU General Data Protection Regulation, or GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to â‚¬20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. Certain aspects of cross-border data transfers under the GDPR are subject to uncertainty, including as the result of legal proceedings in the EU. For example, in 2020, the Court of Justice for the EU invalidated the EU-U.S. Privacy Shield and imposed additional obligations in connection with the use of standard contractual clauses approved by the EU Commission. These and other developments with respect to cross-border data transfers may increase the complexity of transferring personal data across borders and may require us to review and amend our mechanisms relating to cross-border data transfer. Further, the exit of the United Kingdom, or UK, from the EU has created uncertainty regarding data protection regulation in the UK. The UK has implemented legislation similar to the GDPR, referred to as the UK GDPR, which provides for fines of up to the greater of up to the greater of Â£17.5 million or 4% of global turnover. The GDPR and UK GDPR increased our responsibility and liability in relation to personal data that we process where subject to these regimes, and we may be required to put in place or modify policies and measures to ensure compliance with the GDPR, including as implemented by individual countries, and the UK GDPR, each of which may require us to modify our policies and procedures and engage in additional contractual negotiations, and which may cause us to incur liabilities, expenses, costs, and operational losses. Compliance with the GDPR and UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite our efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our activities in the EEA and the UK. 86 Â In addition, in the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). California has enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companiesâ€™ data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The California Privacy Rights Act of 2020 (CPRA), which became operative January 1, 2023, expands the CCPAâ€™s requirements, including applying to personal information of business representatives and employees and establishing a new regulatory agency to implement and enforce the law. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA and CPRA may increase compliance costs and potential liability with respect to other personal data we maintain about California residents. Additionally, numerous other states have proposed or enacted laws addressing privacy and security, including Washington's My Health, My Data Act, and several laws imposing obligations similar to those of the CCPA. The U.S. federal government also is contemplating federal privacy legislation. The CCPA, CPRA, and other evolving legislation relating to privacy, data protection, and information security may impact our business activities and exemplify the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. We may also be bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA/CPRA, require us to impose specific contractual restrictions on our service providers, and we may also be subject to use and disclosure limitations in our contracts with providers who share information with us for clinical trials. Additionally, we may publish privacy policies, marketing materials and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources. These obligations may necessitate changes to our business model, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Any actual or alleged failure to comply with U.S. or international laws and regulations relating to privacy, data protection, and information security could result in governmental investigations, proceedings and enforcement actions (which could result in civil or criminal penalties), private litigation or adverse publicity, harm to our reputation, and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information or impose other obligations or restrictions in connection with our use, retention, and other processing of information, and we may otherwise face contractual restrictions applicable to our use, retention, and other processing of information. Claims that we have violated individualsâ€™ privacy rights, failed to comply with laws relating to privacy, data protection, or information security, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. Risks Relating to Ownership of Our Common Stock If we do not regain compliance with or continue to satisfy the Nasdaq continued listing requirements, our common stock could be delisted from the Nasdaq, which may make it more difficult for investors to sell shares of our common stock and consequently may negatively impact the price of our common stock. We have in the past and we may in the future fail to comply with the Nasdaq listing rules, including, the minimum $1.00 per share closing bid price requirement, the minimum $50.0 million market value of listed securities requirement, and the minimum $15.0 million market value of publicly held shares requirement. From September 4, 2024 to November [5], 2024, our common stock has had a closing bid price below the minimum $1.00 requirement and the market value of our listed securities has been below the minimum $50 million requirement. We received a deficiency notice from Nasdaq with respect to the closing bid price requirement on October 16, 2024. If our common stock ceases to be listed for trading on the Nasdaq 87 Â for failure to comply with the minimum $1.00 per share closing bid price requirement, the $50 million market value of listed securities requirement, or for any other reason, it may harm our stock price, increase the volatility of our stock price, decrease the level of trading activity and make it more difficult for investors to buy or sell shares of our common stock. If we are not listed on the Nasdaq, our ability to raise capital will be adversely impacted. Trading in our common stock may also be halted or suspended in the future on the Nasdaq due to market or trading conditions at the discretion of the Nasdaq. Any halt or suspension in the trading in our common stock may negatively impact the market price of our common stock. We do not know whether an active market for our common stock will be sustained, and, as a result, it may be difficult for you to sell your shares of our common stock. If an active market for our common stock is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our drug product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. The market price of our common stock has been and may continue to be volatile, which could result in substantial losses for investors. The market price of our common stock may be volatile. As a result, you may not be able to sell your common stock at or above the price that you paid for such shares. Some of the factors that may cause the market price of our common stock to fluctuate include: â€¢results of nonclinical studies and clinical trials; â€¢the success of existing or new competitive products or technologies; â€¢the timing and results of clinical trials for our current drug candidates and any future drug candidates that we may develop; â€¢commencement or termination of collaborations for our drug candidates; â€¢failure or discontinuation of any of our drug candidates; â€¢results of nonclinical studies, clinical trials or regulatory approvals of drug candidates of our competitors, or announcements about new research programs or drug candidates of our competitors; â€¢investor reactions to other companiesâ€™ drug development results, including product failures or negative responses from regulatory authorities; â€¢regulatory or legal developments in the United States and other countries; â€¢developments or disputes concerning patent applications, issued patents or other proprietary rights; â€¢the recruitment or departure of key personnel, including in connection with our workforce reduction announced in September 2024; â€¢negative press coverage; â€¢the status of ongoing litigation and government

investigations and potential commencement of additional litigation or investigations; â€¢the results of an investigation into our former CEO, Leen Kawas, by WSU; â€¢the level of expenses related to any of our research programs, drug candidates that we may develop; â€¢the results of our efforts to develop additional drug candidates or drug products; â€¢actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; â€¢announcement or expectation of additional financing efforts, including, but not limited to, under our ATM offering; â€¢sales of our common stock by us, our insiders, or other stockholders; â€¢variations in our financial results or those of companies that are perceived to be similar to us; â€¢changes in estimates or recommendations by securities analysts, if any, that cover our stock; â€¢changes in the structure of healthcare payment systems; 88 Â â€¢market conditions in the pharmaceutical and biotechnology sectors; â€¢volatility with the banking system; â€¢the potential impact of health epidemics on our business; â€¢direct or indirect impacts on our business, our suppliers and other third parties and our clinical sites as a result of geopolitical events, including the Russia-Ukraine war; â€¢general economic, industry, and market conditions; and â€¢the other factors described in this â€œPart II, Item 1Aâ€”Risk Factorsâ€ section. In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a companyâ€™s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert managementâ€™s attention and resources from our business. We and certain of our directors and executive officers have been, and may in the future be, named as defendants in lawsuits that could result in substantial costs and divert managementâ€™s attention. As described elsewhere in this report in â€œPart II, Item 1â€”Legal Proceedings,â€ we and certain of our executive officers and directors were named as defendants in a class action lawsuit that generally alleged that we and certain of our officers and directors violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and Sections 11, 12, and 15 of the Securities Act by making allegedly false or misleading statements and omitting material adverse facts regarding our business. Certain of our executive officers and directors were also named as defendants in derivative actions, which were based on similar allegations, and generally alleged that defendants breached their fiduciary duties to us, among other things. We were named as a nominal defendant in these derivative proceedings. These complaints sought unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneysâ€™ fees, and other relief. Although we have insurance, it provides for a substantial retention of liability and is subject to limitations and may not cover a significant portion, or any, of the expenses or liabilities we may incur or be subject to in connection with any class action lawsuit or other litigation to which we become party. Moreover, any conclusion of such matters in a manner adverse to us and for which we incur substantial costs or damages not covered by our directorsâ€™ and officersâ€™ liability insurance would have a material adverse effect on our financial condition and business. In addition, such litigation would cause our management and board of directors to divert time and attention to the litigation and could adversely impact our reputation and further divert management and our board of directorsâ€™ attention and resources from other priorities, including the execution of our operating plan and strategies that are important to our ability to grow our business and advance our drug candidates, any of which could have a material adverse effect on our business. In addition, additional lawsuits may be filed, the conclusion of which in a manner adverse to us and for which we incur substantial costs or damages not covered by our directorsâ€™ and officersâ€™ liability insurance would have a material adverse effect on our financial condition and business. Actions by activist stockholders have in the past been, and may in the future be, disruptive and could cause uncertainty about the strategic direction of our business. Our business could be negatively affected as a result of stockholder activism, which could be disruptive and cause uncertainty about the strategic direction of our business. For example, in February 2022, an activist stockholder announced his intention to nominate himself and one other candidate for election to our board of directors at our 2022 annual meeting of stockholders. While this proxy contest was unsuccessful, stockholder activism could recur and have an adverse effect on our business, results of operations, and financial condition. For example, at times our market capitalization has been less than the aggregate value of our cash, cash equivalents and investments. Other biotechnology companies in this situation have received proposals from shareholder activists to liquidate and return capital to investors. We strive to maintain constructive communications with our stockholders and welcome their views and opinions with the goal of enhancing value for all stockholders. However, a proxy contest or other activist behaviors could have an adverse effect on us because: â€¢responding to actions by activist stockholders can disrupt our operations, is costly and time-consuming, and diverts the attention of our board of directors and senior management team from the pursuit of business strategies, each of which could adversely affect our results of operations and financial condition; 89 Â â€¢perceived uncertainties as to our future direction as a result of changes to the composition of our board of directors may lead to the perception of a change in the direction of our business, as well as instability or lack of continuity, all of which may be exploited by our competitors, may result in the loss of potential business opportunities, may cause concern for those enrolling in our clinical trials, and make it more difficult to attract and retain qualified personnel and business partners; â€¢actions by activist stockholders may interfere with any efforts that we undertake in the future to raise capital; â€¢actions by activist stockholders could cause significant fluctuations in our stock price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business; and â€¢if individuals are elected to our board of directors with a specific agenda as a result of a proxy contest, it may adversely affect our ability to effectively implement our business strategy and to create additional value for our stockholders. Even if a proxy contest or other activist efforts are not successful, the increased costs that we would bear and the distraction of our board of directors and senior management could negatively impact our business, although we cannot predict with certainty the extent of such negative impacts. A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. In addition, shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available-for-sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act. We also register shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. Our directors, executive officers and significant stockholders own a substantial percentage of our common stock, which could limit your ability to affect the outcome of key transactions, including a change of control. Our directors, executive officers, significant holders of our outstanding common stock and their respective affiliates beneficially own a substantial amount of our outstanding common stock as of September 30, 2024. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock. We are an â€œemerging growth company,â€ and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. We are an â€œemerging growth company,â€ as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditorâ€™s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile. 90 Â Failure to build and maintain our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies. As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, the regulations of The Nasdaq Global Select Market, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. We must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. We may experience difficulty in meeting these reporting requirements in the future. The process of building and maintaining our accounting and financial functions and infrastructure has required and will continue to require significant additional professional fees, internal costs and management efforts. Any disruptions or difficulties in implementing or using such a system could adversely affect our controls and harm our business. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. In addition, we may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systemâ€™s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Anti-takeover provisions in our charter documents and under Delaware or Washington law could make an acquisition of us difficult, limit attempts by our stockholders to replace or remove our current management and limit our stock price. Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, the amended and restated certificate of incorporation and amended and restated bylaws: â€¢permit the board of directors to issue up to 100,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate; â€¢provide that the authorized number of directors may be changed only by resolution of the board of directors; â€¢provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; â€¢divide the board of directors into three classes; â€¢provide that a director may only be removed from the board of directors by the stockholders for cause; â€¢require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be taken by written consent; â€¢provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholderâ€™s notice; â€¢prevent cumulative voting rights (therefore allowing the holders of a plurality of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); 91 Â â€¢provide that special meetings of our stockholders may be called only by the chairman of the board, our chief executive officer or by the board of directors; and â€¢provide that stockholders are permitted to amend the bylaws only upon receiving at least two-thirds of the total votes entitled to be cast by holders of all outstanding shares then entitled to vote generally in the election of directors, voting together as a single class. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any â€œinterestedâ€ stockholder for a period of three years following the date on which the stockholder became an â€œinterestedâ€ stockholder. Likewise, because our principal executive offices are located in Washington, the anti-takeover provisions of the Washington Business Corporation Act may apply to us under certain circumstances now or in the future. These provisions prohibit a â€œtarget corporationâ€ from engaging in any of a broad range of business combinations with any stockholder constituting an â€œacquiring personâ€ for a period of five years following the date on which the stockholder became an â€œacquiring person.â€ Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court in Delaware or the federal district court for the District of Delaware) will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising under the Delaware General Corporation Law, our certificate of incorporation or our amended and restated bylaws; any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or our amended and restated bylaws; and any action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The enforceability of similar exclusive federal forum provisions in other companiesâ€™ organizational documents has been challenged in legal proceedings, and while the Delaware Supreme Court has ruled that this type of exclusive federal forum provision is facially valid under Delaware law, there is uncertainty as to whether other courts would enforce such provisions and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. These exclusive forum provisions may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find either exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could have a material adverse effect on our business, financial condition, and results of operations. General Risk Factors We may fail to achieve the expected cost savings and related benefits from our reduction in workforce initiated in September 2024. In September 2024, we committed to a workforce reduction that is expected to result in the termination of approximately 70% of our workforce, or the Restructuring. We took this step to decrease our costs, extend our cash runway, and create a more streamlined organization to support our strategic priorities, including the continued development of ATH-1105. We may fail to effectively execute on, or achieve the stated goals of, the reduction in workforce. Our plans may also change to the extent we continue to refocus on our key priorities. These actions may take more time than we currently estimate and we may not be able to achieve the cost-efficiencies sought. 92 Â The loss of any of our key personnel could significantly harm our business, results of operations and competitive position. In order to compete, we must attract, retain, and motivate executives and other key employees. Hiring and retaining qualified executives, scientists, technical and legal and accounting staff are critical to our business, and competition for experienced employees in our industry can be high. The loss of one or more of these key employees, or our inability to hire additional key personnel when needed, could have a material adverse effect on our business and prospects. In addition, the Restructuring may negatively impact employee morale for those who are not directly impacted, which may increase employee attrition and hurt future recruiting efforts, hindering our ability to achieve our key priorities. Any failure to achieve the expected benefits from the reduction in workforce could adversely affect our stock price, financial condition and ability to achieve our key priorities, as well as lead to litigation. Our advisors and

consultants are classified as independent contractors, and we can face consequences if it is determined that they are misclassified as such. There is often uncertainty in the application of worker classification laws, and consequently there is risk to us that our independent contractors could be deemed to be misclassified under applicable law. The tests governing whether a service provider is an independent contractor or an employee are typically highly fact sensitive and can vary by governing law. Laws and regulations that govern the status and misclassification of independent contractors are also subject to divergent interpretations by various authorities, which can create uncertainty and unpredictability. A misclassification determination or allegation creates potential exposure for us, including but not limited to monetary exposure arising from or relating to failure to withhold and remit taxes, unpaid wages, and wage and hour laws and requirements (such as those pertaining to minimum wage and overtime); claims for employee benefits, social security, workersâ€™ compensation and unemployment; claims of discrimination, harassment, and retaliation under civil rights laws; claims under laws pertaining to unionizing, collective bargaining, and other concerted activity; and other claims, charges, or other proceedings under laws and regulations applicable to employers and employees, including risks relating to allegations of joint employer liability. Such claims could result in monetary damages (including but not limited to wage-based damages or restitution, compensatory damages, liquidated damages, and punitive damages), interest, fines, penalties, costs, fees (including but not limited to attorneysâ€™ fees), criminal and other liability, assessment, or settlement. Such an allegation, claim, adverse determination, including but not limited to with respect to advisors and consultants that provide services to us could also harm our brand and reputation, which could adversely impact our business. If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If no or few analysts commence coverage of us, the trading price of our stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have hired, and we expect that we will continue to need to hire, additional accounting, finance, and other personnel in connection with our efforts to comply with the requirements of being a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We continue to evaluate and monitor these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. 93 Â If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected. As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of Section 404 of the Sarbanes-Oxley Act, which require annual management assessments of the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to determine that our internal control over financial reporting is effective are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position and results of operations. The potential effects of health epidemics could adversely impact our business, including our nonclinical studies and clinical trials. Our business could in the future be adversely impacted by the effects of possible health epidemics and other outbreaks which could cause disruptions that could severely impact our business, nonclinical studies and clinical trials. Such disruptions may include: â€¢delays or difficulties in enrolling and retaining patients in our clinical trials; â€¢difficulties interpreting data from our clinical trials due to the possible effects of such diseases on cognition of the subjects enrolled in our clinical trials; â€¢delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; â€¢diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; â€¢interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints; â€¢interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; â€¢interruption of, or delays in receiving, supplies of our drug candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; â€¢interruptions in nonclinical studies due to restricted or limited operations at our laboratory facility; â€¢limitations on employee resources that would otherwise be focused on the conduct of our nonclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; â€¢interruptions, difficulties or delays arising in our existing operations and company culture as a result of some or all of our employees working remotely; â€¢interruption or delays to our sourced discovery and clinical activities; and â€¢changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic. Â The trading prices for shares of biopharmaceutical companies have in the past been and could in the future be highly volatile as a result of health epidemics, including the COVID-19 pandemic, and the trading prices for shares of our common stock could also experience high volatility. In the event of an emergence of new disease outbreaks or a resurgence of 94 Â COVID-19, we could face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from a health epidemic, including a resurgence of COVID-19, could materially and adversely affect our business and the value of our common stock. The ultimate impact of a possible health epidemic or other outbreak, including a resurgence of COVID-19, on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. In addition, our business could be significantly adversely affected by other business disruptions to us or our third-party providers that could seriously harm our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our CROs, commercial manufacturing organizations, or CMOs, and other contractors, consultants, and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our drug candidates. Our ability to obtain clinical supplies of our drug candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. Attention to ESG (environmental, social and governance) matters may cause us to incur additional costs or expose us to additional risks. A variety of stakeholder groups, including investors, governmental and nongovernmental organizations, are focused on corporate environmental, social and governance, or ESG, practices. Our ESG practices may not meet the standards of our investors or other stakeholders, and they as well as advocacy groups may campaign for us to change our business, operations or practices to better address ESG-related concerns. A failure, or perceived failure, of us to respond to any such campaigns could harm our business and reputation and have a negative impact on the market price of our common stock. Moreover, if ESG best practices, reporting standards and disclosure requirements continue to develop, we may incur increasing costs related to ESG monitoring and reporting. 95 Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Recent Sales of Unregistered Equity Securities None. Item 3. Defaults Upon Senior Securities. Not applicable. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. During our last fiscal quarter, no director or officer, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or any â€œnon-Rule 10b5-1 trading arrangement,â€ each as defined in Item 408 of Regulation S-K. 96 Â Item 6. Exhibits. Â Â Â Â Â Incorporated by Reference ExhibitNumber Â Description Form File No. Exhibit Filing Date Â Â Â Â Â Â Â Â Â Â Â 3.1 Â Amended and Restated Certificate of Incorporation of the Company 10-Q 001-39503 3.1 November 12, 2020 Â Â Â Â Â Â Â Â Â Â 3.2 Â Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company dated May 23, 2024 8-K 001-39503 3.1 May 29, 2024 Â Â Â Â Â Â Â Â Â Â 3.3 Â Amended and Restated Bylaws of the Company 8-K 001-39503 3.1 November 18, 2022 Â Â Â Â Â Â Â Â Â Â 10.1** Â Employment Offer Letter between the Company and Robert Renninger. 8-K 001-39503 10.1 September 17, 2024 Â Â Â Â Â Â Â Â Â Â 10.2** Â Change in Control Agreement between the Company and Robert Renninger. 8-K 001-39503 10.2 September 17, 2024 Â Â Â Â Â Â Â Â Â Â 10.3â€ ** Â Separation Agreement and Release between Andrew Gengos and Athira Pharma, Inc. dated October 3, 2024. 8-K 001-39503 10.1 October 7, 2024 Â Â Â Â Â Â Â Â Â Â 10.4â€ ** Â Separation Agreement and Release between Rachel Lenington and Athira Pharma, Inc. dated October 1, 2024. 8-K 001-39503 10.2 October 7, 2024 Â Â Â Â Â Â Â Â Â Â 31.1 Â Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â Â 31.2 Â Certification of Principal Accounting and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â Â 32.1* Â Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â Â 32.2* Â Certification of Principal Accounting and Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â Â Â Â Â Â 101.INS Â Inline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document Â Â Â Â Â Â Â Â Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents Â Â Â Â Â Â Â Â Â Â Â 104 Â Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101) Â Â Â Â Â * The certifications filed as Exhibits 32.1 and 32.2 are not deemed â€œfiledâ€ for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Company under the Securities Exchange Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof irrespective of any general incorporation by reference language contained in any such filing, except to the extent that the registrant specifically incorporates it by reference. ** Indicates a management contract or compensatory plan. â€ Certain portions of this exhibit have been omitted because they are not material and is the type of information that the Company treats as private or confidential. Â Â 97 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Athira Pharma, Inc. Date: November 7, 2024 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer (Principal Executive Officer) Â Date: November 7, 2024 By: /s/ Robert Renninger Robert Renninger Vice President of Finance (Principal Financial and Accounting Officer) Â 98 EX-31.1 2 atha-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 Â CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Mark Litton, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Athira Pharma, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15dâ€“15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 7, 2024 /s/ Mark Litton Â Mark Litton Â President and Chief Executive Officer Â (Principal Executive Officer) Â Â Â Â Â Â EX-31.2 3 atha-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 Â CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Robert Renninger, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Athira Pharma, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15dâ€“15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of

internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 7, 2024 /s/ Robert Renninger Â Robert Renninger Â Vice President of Finance Â (Principal Financial and Accounting Officer) Â Â Â Â Â Â Â EX-32.1 4 atha-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 ATHIRA PHARMA, INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Athira Pharma, Inc. (the â€œCompanyâ€) for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Mark Litton, President and Chief Executive Officer (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: (1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 7, 2024 /s/ Mark Litton Â Mark Litton Â President and Chief Executive Officer Â (Principal Executive Officer) Â This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Athira Pharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing. Â EX-32.2 5 atha-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 ATHIRA PHARMA, INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Athira Pharma, Inc. (the â€œCompanyâ€) for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Robert Renninger, Vice President of Finance (Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: (1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. November 7, 2024 /s/ Robert Renninger Vice President of Finance (Principal Financial and Accounting Officer) This certification accompanies the Report to which it relates, is not deemed filed with the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of Athira Pharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing. Â GRAPHIC 6 img106170215_0.jpg GRAPHIC begin 644 img106170215_0.jpg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

]"WTZQM&1K:SMX6CC\!#'$]E4SG:,#@9YQ0!S_A^\N+[X=) M/=3/--]FF1!'.6?:64$GN< 9-ZR02SO)&^+4RH MJQD[5P44#: <9SG)KT>*TMH+;[-#;Q1V^"/*1 %P>3P....W%
'G^B3:LEMH^LRZI:OQ72E[B6;6)9_M09"S!(# M&$5P>0]8QM*\C-066HW<7B#PO<0O?Q6NIR.1]NU5II;J,PEM[0#,<8W$$;#Q MP,#.!Z#;Z+I5I?R7]MIEE#>2EC)
<1P*LCECDY8#)R>34=OX>T2TD\RVT?3X9 M/,$FZ.V13O&<-D#J-S<^Y]: /+M&LXGM=.F+3AAX7O' 6=PN1(H^Z#@CD\8P M3@GD#'2Z##)I-QX.6&]O9%U"R<7*37#NC8B5U*H253!&!M
X/..Z;]$TF1+= M'TNR9+8,L"FW0B(-]X+Q\N>^.M6!96BFW(M80;8;8"(Q^Z&,87^[QQOVH$3T M444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CJ MSE+-6#
[#Y\0SYC)_&O&5!/X=#T/%7JHZLY2S5@^P^?$,^8R?QKQE03^`0]#Q M5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH
S]:&=/'R;_WT1(V.W\:\X4Y_'H.IXI] M,UH9T\?)O_?1$C8S?QKSA3G\>@ZGBGT %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 52U9BFESL'V$?-YC)CD?Q*"1^57:I:LQ32YV#[" /F\Q
MDQR/XE!(.*@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4K!B MTU\"^[%R0!YC-M^1>.1\OT&1W[FKM4K!BTU\"^[%R0!YC-M^1>,1\OT&1W[F M@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 5;0# .A([D[>?LD?.U^?G?O]S\OF]>"*=XDU&ZTC0Y1M(TE-
J5FEC92 M=T(8>9C!X8+N((//3I3;0# .A([D[>?LD?.U^?G?O]S\OF]>"*U(9(TFB>*10R. MI5E/0@)10!R-_P"+;S^T;J#38K:6$3V]C;S2!BIN91O8D@\JJ%3@Z?
=13VT:1K)&JP%P49F*L&0_Q'((Z5T5KX+TNS\-IH MD+W0BCE\^.X\S\)DNI(<-CJ. ..8&#GFAO!UG/YDEW>7MU=2SP3/=:L@<2^2P M9$ 50H7.> HSD\YYH
IS^*:Z+PWJVHK%;^=9ZFUG&I5MI03K'D\]<$_CVJK+ MXHUR*VU34RNG"PT_4C:&$O/YDL8D5=P??A2-W]TYQVK3O?!=I>_:HVU#4(K2 MZN5NY+2-T\OS0RMN!*%N2H.-V,D\59E\+6,VE:AIS2W
AOKHW4K!EW!RP;"\ M=,J\N: .5A\0:KH[ZXTD\=U)<:]]BMP+663YCX*.6VJS,RA%X10.0>#Q M1_:KI;Q1&R#R)U4+YD9VYR0HR&)7D\8-/D\+Q7-G/#>ZGJ5W-)(DJ7,DJ[\# MI]QHPBA%(//"\Y^;(XH
Y^Y\8:W:6DZK:++,)[:.&ZFTZXM(I!+)L92DAW!E MZY#$$,/0BIM5\2ZSH]^;6^N],M441B.ZN:*9+>Z=MQ*^:'*P8 Q\VXYYQCBM MB7PK'=1%:[5=3O'.\,X>61!M.3!E 15"
9')"Y.>O3$NI^'OI3EN"VK:E!;W M,8BGMH9$,O7F@!?$FKS:1H\=[:"*1GN;>+YP2I6254)X M([.<5C^(_%>HZ3>ZM!:06LGV2UM)HA*&&YI9C&P8@],#CC@^O2NAU'1K34M%
M:2I/,BM]I!#$V&C*$%"I.>05!&<].";2Y>]EN]1!#"YGO$A2661HP<12 M:UP%0*.>#@=/?)H HW_BC5=$N[O3[Y;&ZNS#;0:/#&*%I93$%<%FX!P<@\C ML#6;]>K:GX>\5W]_] MKR>+28E@-
M"\:N7N B@IEVX9NQ.1T&>*ZS4_#%A]U MWU2V(1]NT(YD5U(&0P8Y!SV'%5&\%V=Q<7=QJ%_?W\MU;"V=IW1= MJAMRE1&JA2&&01WYH
QKKQEK&GZ=JMR[\1:WI$U[9WZV.]VUDD]CY,3HK2M((O+8%V+8=XN1C.[I6C<>$TO MM/O+/4-9U6\2ZM_LY,LL:[%SDE51%4MT^9@3[\G-W4] L]6U'3;ZX,HET^4R M1:& #9QPW'(RJGMRHH
P(?&%U>P-+;G3[=(M-BGN):QRD<%Q(UT*S9Z+M?*] M2<#(ZUG_/"W0#P M5I:V6H6T:7$?VV\%ZTBLNZ*0.&79D8 ##(!!ZGUI\.1Z=<7VKEM1UF]N+46 MTL,LD0\U,\ #"(N,GI@8R<$GD
L6&JWFKZE]L=E):K9VDL4,4S1-)YC8#2]& M QA@H(Z')YZ5NURVAZ#?:!X)L=-M96%^K1O/(&5LLT@,F2P((+#U('&#BNI MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
HZLY2S5@^P M^?$,^8R?QKQE03^`0]#Q5ZJ.K.4LU8/L/GQ#/F,G\:\94$_AT/0\5>H **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH ****
,.6AG3O\F_]l$2-C-_&O.%.?QZ#J>*?3-:&=/'R M:_WT1(V,W\:\X4Y_'H.IXI] !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %4M68II<[!]A 'S>8R8Y'\2@D?E5VJ6K,4TN=@^P@#YO,9.8S:?
D7CD?+]!D=^YJ[5*P8M-? ONQ8S;?D7CD?+!]D=^YH NT444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6T M _X2.Y.WG()'SM?GYW[_'/R^;UX(J?6]6CT329KZ2-I=A5$B0@-([,%51GC MEB!4%H!_PD=R=O/V2/G:_/SOW^Y^7S>O!%3ZWI,>MZ3-822/%O*NDJ ;HW5@
MRL,\<, <=^E &9=^(=3TR$C4-&C%S+)'#9K;W?F1SR.2 I9D4IC&22I&.F3Q M52^\9W.EFXM;W2% M&*2W"P0W6Y)8YGV*ZN57D,&!!4>'M4U2$;_M]:C\^)XYK0VUF(XM2)(:KW/@Z?49I+S4-
326_>:V;S(K M8I&D4,GF"-4+D\DL22OZ]..4 17'B_5:4:N]=*MR^D1B>[V7Y*F(IO!C)C!9 ML!LJ0HX')SPLGC*^>;5WL]$%O9:65:,8W>UY$,:R\RTVG+!6/!(' P>>+]YX M9^UGO' IFS^V:46 ^KSY.
(V3/7YOO9QOTK T[PW]\NH>)+-;]K.PN98H7+VA M+2QB!%9HG+ *2,KDAP"!QD'(YO&$>EZCKEW+/YL$US:1627%QY42F2 /RS< M(N 6)Q^!-0:KXYNKW2+F/2FL/MMM=VB3/:WXFB:.60 ;) F,[
M4W@M/M%U<6EZ;:4W%O<6A$6X6[11>4 03\ZE<@C0X/7O4] X>U/5M*N+:_ UF M)YWFAFA,5GLBA,;AQ\EV,LV2.)V2XNK.WT]I-2DU1K..&2)\HV M984D=][*?
+0*3PJGD<&++'"S^,KFW"VKZ0#JHU!+&2V6Y_=@R(SI()-O*D >7_ M4$<\<#+QX0F266]BU)$U+^T#?PS?9\OH6B6)Y9-WS*0I_B!&1SQRY?",CW$5
M[=:B);_^T4OIY5@V(X1&1(U7<=H"GJ2QSGUX.-+1=8FU&?4+2[M$M;:RQE6.5 M(YO-0AD#JRL54\@]P.E<]>?$FPM+B\8MI_V2SN#!*'U%5NF*G;S)#CYE!SU8 M$A20#QGI;#2?
L6L:MJ'G[_[0>)_+V8\O9&$ZYYSC/:L^+_P_J5E+-+R6U.HS:*L6E1WS6SE-VW/S CY MN" "9G\'S-JIUK^U/^)T+@.ESY'R+ 1Y&S=RA!)SG.[YNV*R_#WAK4[S2)+ M74+MH=-2Y4[A[-
K4I*P$[,H$A;A"0K?=R03AL&@"=OB38+=,V=/-DMS]GA\ MQ.4^U'YMF\08^[N_VMVWYL=]U8/$&HWTLTVG:/'R1BAVLZIM(M*!@1][ )) /):"]3T[=:V&M+!IANaF6(V@>:,,_VYD60MMV[B<90D
XSP#2 MVOA_4-,EEAT[5TM].ENFN3$;4/*I9MSHLA;;%+9ZH2-QP>F #GM+\<7=EH%B MVK&P^VWMW=)#).<:=GXY34XX8--M;>ZU&2YDM_#_2\!@ =_J&9Q*%)*;67!"YR<$#G#K;P?
=V*6S6FK1)/97%Q):NJH6'E3.7>. M0:QOYQAE*?=''6K<_A_4I_LEX^LHVK6LTCQSFT'DA' #1^6&#;< =7+9YSCB M@*+P9>WU\=?:_#I+%JKQB)I3(L0$47RJ?[N22.!US@$D5T]8WAW1)]%CU W-
M\+R>^O&NW<0^6%)V@9/ V<<]#CG&3LT %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 4=6AXJ]5'5G*6 M:L'V'SXAGS&3^->,J"?PZ'H>*O4 9U_KNF:7?65E>72Q7-
\Y2W0JQWG('4# MY8#G'K)K1KS#6(KSQ-J/B.XM=*OKM8D6QT^YMWA"Q2O-O9L/(I_UH49 /"?A5 M^+4W\5:[X:=;R\M[.\TH>;XM[:X>'B57BOK:>\N+2*97GMMOG(;AE<^Y SC
MZ>HK@9;B[N?"_B'Q+)]E[;ZA97%S]G19V$4(ARB6XE#*@!DW;@HR6VJ0,GIBL5;F^O-4T[1I-7ODMH-W;6UOK>G?9YI)3)+#YI!* MAV))VGD;LD9';%2^(;N\T6+Q9I]E?
WPAALK6Y@:2[DDDA=G*MM=B6 (4<9I? M6@#TVJNI:C:;1IT]_?2^5:P+OD?:6VCZ $FN8L:67Q+J.O276I:C;-:7QM+9 M+2Y:$0JB*VI:#MM7YFPA3@[HR#S5BO)
M=$EN;7PSX1TJV34Y8;W.]S':76R5_+QA%=Y%V+D@>F^Z?4U=N[O51;_P!F M/<7]G$-#=0N=5U_P >WDAEN9?#DIDSE9C$^R6.2-HY(V|&1@&7CGDZ3K$%EK%M;N#!-&)5G@8CAER&
W*OS"N=O=?U>TL-8M;RSL[' M74>RCGU"P&Z.2.;38K@L,@]-P&[//(XH [S4=1M-)L);Z^E\]VBQO?:6OD@# M@ GJ15]N$\9Z*FE^#M5E@OM0DB>.%%X8V=NKIYU#"5?G!<$ XZ<9JC=WVJ:
MG<^([J.+6?-L;EX+.6UO(H;>V\M0P+H\]A\D[FW]PVD#I0!Z317G]E>7E]KN MLZA-V/"-AQE .X/O26\EU8Z)X8UU=5O;B]U&YMDN MEEN&>*99R-P$>=B;@U%;W"7,9>-90
Q7$D31G(.#PP!QZ'H> MU<):/?Z-K%I_PD'IKQSS:@88[^&]\ZSN/,SL1X2?W8Y"#"#! .[DU5L%U4] M-M:E#?ZA9Q:C>QW5O!J#6\[#S2(R'W#+E5 8;-RCD=<< 'I5%8OA2^@OM B,$ MU[+Y+O
_V_'GHKL04?'5ATSSG'4FMJ@ HHHH **** ,OQ#*L&CR3/&72.2-V M 1F. X/12/3KT'4\9K!_X3?3?^>%W_WPO_Q5:_BT$^&;OY-W"\;&;'S#GY>?
MQZ#J>,UY57EYABZE"45#J>MEV#I8B,G/H=]_PF^F_P#/"[_[X7_XJC_A-]-_MYX7?_?"__%5P-%>?_:>([K[CT?[*P_9_>=]_PF^F_P#/"[_[X7_XJC_A-]-_MYX7?_?"__%5P-%']IXCNON#^RL/V?WG??
\)OIO\ SPN_^^%_^*H_X3?3?^>%_MW_WPO_Q5<#11_:>([K[@_LK#^G]YWW_";Z;_,\+O_OA?_BJ/^$WTW_GA=_]\+_\57 T4?VGB.Z^X/[*P_9_>=]_PF^F_P#/"[_[X7_XJC_A-]-_YX7?_?"__M_%5P-
%'|IXCNON#^RL/V?WG??\)OIO\ SPN_^^%_^*H_X3?3?^>%W_WPO_Q5 M<#11_:>([K[@_LK#^G]YWW_";Z;_,\+O_OA?_BJ/^$WTW_GA=_]\+_\57 T M4?VGB.Z^X/[*P_9_>=]_PF^F_P#/"
[_[X7_XJC_A-]-_YX7?_?"__%5P-%'|MIXCNON#^RL/V?WG??\)OIO\ SPN_^^%_^*JM?^,K*>REC@ANO(P&T[A'W_O MDBN*HH_M/$=U]P?V5A^S^\[[_A-]-_YX7?\ WPO_,51_P)OIO_#PN_P#O
MA?\ XJN!HH_M/$=U]P?V5A^S^\[[_A-]-_YX7?\ WPO_,51_P)OIO_#PN M_P#OA?\ XJN!HH_M/$=U]P?V5A^S^\[[_A-]-_YX7?\ WPO_,51_P)OIO_M #PN_P#OA?\ XJN!HH_M/$=U]P?V5A^S^\
[[_A-]-_YX7?\ WPO_,51_P) MOIO_#PN_P#OA?\ XJN!HH_M/$=U]P?V5A^S^\[[_A-]-_YX7?\ WPO_,51 M_P)OIO_#PN_P#OA?\ XJN!HH_M/$=U]P?V5A^S^\[[_A-]-_YX7?\ WPO_M _51_P)OIO_
#PN_P#OA?\ XJN!HH_M/$=U]P?V5A^S^\[[_A-]-_YX M7?\ WPO_,51_P)OIO_#PN_P#OA?\ XJN!HH_M/$=U]P?
V5A^S^\[[_A-]-_YX7?\ WPO_,55:U\9644ET98;LB2;(M[K[@_LK#^G]YWW_";Z;_,\+O_OA?_BJ/^$WTW_GA=_]\+_\57 T4?VGB.Z^ MX/[*P_9_>=]_PF^F_P#/"[_[X7_XJC_A-]-_YX7?_?"__%5P-
%'|IXCNON#^ MRL/V?WG??\)OIO\ SPN_^^%_^*H_X3?3?^>%W_WPO_Q5<#11_:>([K[@_LK# M]G]YWW_";Z;_,\+O_OA? BJW-/OHM2L8[N%76.3. X /!([?2O):I**_\ M(M6G____$-
J[HXSVM_D<&88*E0I*4-[_YFS1117KGCA1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% %6T _X2.Y.WG()'SM?
GYW[_'/R^;UX(J/% M.KRZ%X$I_K<[<%U4YP1V)[TMH!_PD=R=O/V2/G:_/SOW^Y^7S>O! M%1>+[^[U/PO=VEA"LUR[1E(V8*&Q(K')/08!H $\7Z&Z,QNI(IACW+-;2OL! M(V%&VLH.PGC=C:
[UIQZA:S:C/81R[KFW1])4"GY V=N3C&3M/&22),FL/#(:O'))OS(M@DRI&X@A8VSM!['G !U-QXLT:UNGMYKF4%)EMWE%M*T*2$@!6E"[(-%)2ZK:ZA"]G]%S<&[M#6SI>QPVBP++O&
(U<%W*X!\P'D9## STVCZ/?0P:W&\\U@]U]2=P@.^Q6-6(7QD\56F\6Z) M#)#&+QIWG@%$$MK!).7BSC';RV\0M?RIJ^L0S6B0M):WXM M9T='8C<$>)&4A_]"O3DFK/A_0;C3M?
M[G^SEL[5=+\G8+HS]#.SE=[?,QYR M3C&>.F@#6F\4Z-#!;3"[:9+F'SXA;023.8QC+E44D*.@9(SQ4?AS6KC6O"D M,JM#%)/(LA6.$[5?:S!0"2<9P.<]ZYOP]I&N>&_LMVVE2WKO8?99((KB(/"Z
MRNZGYF"E2'YP21CH>V]X5LM0T7P5;V]S9@W\"2M]F21?F8NS!0W3G(Y/KS0! M6_MW6=*U#3(|;%BT=_'.S16T;*]JT<>O#+/Q#K(&CWM]! M:&RUC(AAA1EEMV9#)&K.6(?
*J03A<$CM5:1[#4;VXN+C7M&OQJ5]"\W#/;F M"UC(_P!7&]REMN>IQECR<#@%M]^N36V@V%UI9C713YLDWG1E;IHXVCC$0#9& M[=N,\+C&.:!%Z+6-
=LM2T>+5X[$KJCO']FMT82VK!"XRYY:/,J*K;$[?*&&X\\MC]#5+0H-6FU4ZEK>BZ@FIS* M8EF$EN8+*_PQ@2DGH,MM0)[<4RW\&W>E^(-:.SU/4)M/LEN/,,OV?*%MIP M<1AFWG=N/)
[Y!.2#.WHHHH **** "BBB@ KS[XIW]LIKI'A^XNHK:'5+U!@URI]X+M=6\8C7-5;"]MH[3[/#8S6P9$.O:O M[4 #]3\(ZC)'J-MIUT8.QRG:+#OWQL&0YQE3C![8KG]%\$^'I+ MOQJ[:?EM)F:
[$?.D_=:59A_%\W('7->BZ9X.MM%\7W&M:8\-I:7-L(0:"&V" MIN!R'!! !XZ8[FBP\(?8I/$K ;M_]MNSX\K'DY4K_>^;KI4"/-(/%>WX-'1__M[UT_P"A-
']M%G_HW+'YM^>GOBO2?"NMZ3:^%_#EA<:I90WDFG6H2WDN$61B MT:@84G)R>E+%X.\OX>'PG]OSFW:#[5Y/J2<[-WOTS5S3O"FDV=EIB7%A97=Y M86\,*7DEJGF9C4
,"1D<\4#.+BM=7@^,VE2:QJ$=S+-9W#QO0H5C@3Y@% M7/)/.*%"L<"?, JYY)[DGGMVKLKOPW]J M\:V'B+[7M^R6SP?9_+SOW9YW9XZ],47?AO[5XUL/$7VO;]DMG@^S^7G?NSSN
MSQUZ8H$>1ZHCW.B^)?&S3S#6].UPP6DPD;$42L@" 9QC#G\OIZQJG@^[U;I[&RA7S/M#6ZQKC>SH1CS,;F! Z8YO74WWPQ2\U.ZVZS-%HE[M=B\N],$*D22]3B3.5!..,?TQ-K?PI'FU'5]1N],U^?
3;;546/4;9(%D$X P<, M3\A*Y'0]3ZXH ZG1)[.YT'3YM.!6R>VC,"D\]FT;0>3R!Q5^]VGV%OI>FVUA M:ILM[:8HP3DA5&!GU-6:!A1110 4444 4=6AXJ]5'5G*6:L'V'SXAGS&3^->,J"?PZ'H>*O4 5--
TRSTBQ2RL8?*MT+,%W M%CEB6)))))))/JI9>&M(T^^%[:VGESJ92I\UR%\U@SX4G !(!P!@=L51TK4 MC>:IKNJ7%R\=A82-9QQER$41@-+(1T)W'&>,9.<3PIJ.J1ZW:7&J7%PUO MXBMY+FWAE.
<=/PJK!HD\WC&77KZ.V0Q6WV2T6)R[%Y8NY*C!/ VC..>3FH_"=S/)7UFVT:.&-K.YLWG2W7 M. PD: AMY8\;N,#C&>0#I9 "NC7-[)=2VA+2NLDL8F=8I77!#/$&V.>!R0>@
M]*6]\.:1J.M(=6TCF^B$-NRHJ%)651TRH8#(Q][&?>L*[NY[+P-%K5EK;:HN MGL;E+A&XN(O#1O@D.P3(W'G@M*[.TX;<'9R=SG('WB> M !T&*6^\.:3J.EX]W:>8UY$D.Y\QQO1"64<'C!)Z8K5HH
R+_P .:3J5U+<7 M-O)OG4+.(KB2)9P.)%!@K\\LMW-*T0VE=JEG.%P2-O3VXK=HH Q1X3T46"V0MI1 DWGQ 7,H:%_6 M-MVZ/OPI Y/J:DC\-:1%:Q6ZVI*17OO 6E=G:8'(=G)W.>GWB> !T%:U% &3
M?>&=)U&]>[N:>0S2QB*;R[B2-9D&<+(JL%<&9X94!!! = M"&P<\C.#QZ4V+P_I<=C,<5IT4 8?_"' MZ(T,\4MM-.)T6)WN+J65]BL&"AW8LJ[@#@$ XJ2^\+Z/J-Y+=7-]YDF"B<)/
M)&DX7[OF(K!9,#^CQ>.,E;%%2WTRSM;^YO8(0EQ5 ZGUK8HH QB*/FC6US%/ M%:R#R93-%*;B1H8G.?F6(ML4 _<848SQ2'PEHNR-M9866CDDD22"YEBD!D.Y M_G5@V"3G&<=..*VZ*
*NGZ=::59):64(B@3)"@DDDG))))Y))/)JU110 44 M44 %%%% &)XM!/AF[^3=PO&QFQ\PY^7G\>@ZGC->55ZKXM!/AF[^3=PO&QFQ M\PY^7G\>@ZGC->55X6;_!O]#Z#)O@EZA1117D'LA1110
4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5T,EC81Z3' M)+%!&7L_ -$OG'S6EW$!-W0X_N^O-<]4LUQ+.L0E;<(D\M. ,+DG'ZFM*;5+@6DKG%V(7AC@
V;@Q&WY@"!M.F0-")8UB1'D?YF4A0'P<;2>&/TK.75;U+AYUGO+)*)F;;.6 (ST]&;CIS4G M]M7OG),6A+HH1":>/Y "2-HV\8>SQ"22ET_KH6)-#6'3
MA<2WD4SBMI=*U!GA)N(D5TDWG"Y=5P!^)ZY[= M.\3ZE=26X@D;.10NT-)$C.!G. Q&X=3WHMM1N+2"2&'R=DGWP\"/NZ<98$XX M!Q4BX'/4 MUSV?F"%EVR##HZ*ZL < MC*L"#4AU2\(8>
<.'=P$4 ;E"D#C@:0!@=.<40J022;_#$[A.G4W: IPU>]V*ID0[6+JS1(60DICM8C(Y MYXIN=%[1_K[^O*A76\OZMZ=S5&BQ60F9<;77"(@(HP^-W0=\54CGEBB MFC1L),H5Q@<@$'^8%$JE-2]Q::
[^G^81I57'WWKIMZ_Y&O\ V7;J.^:&EDLV MN?+,1V1C:2 &WY)&.X(]<]*MV6A107=I-(YD#2A)(}HT!&49AD!FOTZ$ UA? MVA=;@WF\B'R/NC[F,8Z>G?K5AM>U)BA,ZY1O("(D!+
%O!%:]9%H! PD=R=O/V2/G:_/SOW^Y^ M7S>O!%:%Y>6^GV4UY=S+#;PH7DD8*U- "W5I;7UL]M=\V5Q!(,/%*@=6[\ M@\&I$1(XUCC5510 JJ, =@*Q$\3QK<6J7FEZC8P7<@B@N+E$".[?
=4A7+H6 M[!U7G@X/%;M %>"QM+:XGN(+6"*:X(::2.,*TI'0L1R<>]6*** "BBB@ HHH MH **** "BBB@ HJI]6HVVDV+WEVY6%65,J"?PZ'H>*O51U9REFK!]A\^(9\QD_C7C*@G\,AZ'BKU M'
3;3=W!\0^%HI8H3?WHO=[LP+VDI7S=N!RP(9<'(R*T]9\$V!MH+CP_I MNF6&J6MQ'<02I L0:;?F1F1<[2I(Z'M7644 EW4%[?R7 M:-)?21,H8*,%1"P_A]>]767O/;WTTL(TZ]M|@K)!/.T#6S8 90ZQ-
YBD\@D* M1[]MVB@#AM4TAM+\&7>B1M$VHZY@[\5Y MI_9&I?\ 0.N ^_+?X5ZIK0SIX^3?^^B)&QF_C7G"G/X]!U/%/KBQ6"CB&FW;
MQW83'2PR:2O<\H_LC4O^@==_]^6_PH_LC4O^@==_]^6_PKU>BN7^R(?S,Z[M9G_*CRC^R-2_Z!UW_P!^6_PH_LC4O^@==_\?EO*]7HH_LB'\S#^V9_RH\H M_LC4O^@==_\?
EO*/[(U+_H'7?_'Y; "O5Z*/[(A_P_MF?\]/*/[(U+_H M'7?_'Y; "C^R-2_Z!UW_P!^6_PKU>BC^R(?S,/[9G_*CRC^R-2_Z!UW_P!^ M6_PH_LC4O^@==_\?
EO*]7HH_LB'\S#^V9_RH\H M_LC4O^@==_\?EO*/[(U+_H'7?_'Y; "O5Z*/[(A_P_MF?\]/*/[(U+_H'7?_'Y; "C^R-2_Z!UW_P!^6_PKU>BC^R(?S,/[9G_*CRC^R-
2_Z!UW_P!^6_PH_LC4O^@==_\?EO\ M*]7HH_LB'\S#^V9_RH\H_LC4O^@==_\?EO*:)IE_#&9)+&Y1%ZLT3 #\<5 MZS5+5F*:7.P?80!\WF,F.1_$%H)'Y4?V1#^9A_:,_Y4>:_P!D:E_T#KO_+\M
M_A1_9&I?] Z[_P"_+?X5ZO11_9$/YF'LS_E1Y1_9&I?] Z[_P"_+?X4?V1J M7_0.N \ ORW^%>KT4?V1#^9A_:,_Y4>4?V1J7_0.N \ ORW^%'D:E_T#KO_+\M A_7J[%']D0_F8?VS/^5'E'D:E_T#KO_
+\M_A1_9&I?] Z[_P"_+?X5 MZO11_9$/YF'LS_E1Y1_9&I?] Z[_P"_+?X4?V1J7_0.N \ ORW^%>KT4?V1 M#^9A_:,_Y4>4?V1J7_0.N \ ORW^%'D:E_T#KO_+\M_A7J[%']D0_F8?VS
M/^5'E'D:E_T#KO_+\M_A1_9&I?] Z[_P"_+?X5ZO11_9$/YF'LS_E1Y1_9&I?] Z[_P"_+?X4?V1J7_0.N \ ORW^%>KT4?V1#^9A_:,_Y4>4?V1J7_0. MN_\
ORW^%-73+]RP2QN6*:P$3':>N#QUY%>LU2L&+37P+[L7) 'F,VWY%XY M'R_09'?N:/[(A_,P_MF?\]/-?[(U+_H'7?\ WY;_H_LC4O^@==_P#?EO\ M"O5Z*/[(A_,P_MF?\]/*/[(U+_H'7?\ WY;_
H_LC4O^@==_P#?EO\ "O5Z M*/[(A_,P_MF?\]/*/[(U+_H'7?\ WY;_H_LC4O^@==_P#?EO\ "O5Z*/[(MA_,P_MF?\]/*/[(U+_H'7?\ WY;__KT'PU#+!X?M8IHWCD7?E74@CYSV-:U M%=.%P,16L+S2J8
MYA$GWI DBN5'J2%(QWS4]H!_PD=R=O/V2/G:_/SOW^Y^7S>O!%7=1U&UTG3Y MKZ]D_=M" 7<(6QSCHH)/["@#%G\9:7.+>WTF6+5+VYD1!:128>-21O:48C M"@DD_QL_L)SY?
_"=C5#M_P"?K/G<>_D^1_P#97>V_B;3+B\AM,W< M$TY(B%U8SVX<@9PID103@$XSGBKVGZA:ZK80WUE+YMM,NZ-]I7(^A - 'F%U
MI5C)IM]]#6R&]/B@PBXY\Q8VN0K(K=54AFR!@VVFV4UY>3I!;0]7DD<#/2M60^'QK>L'Q28EU47B_82^?M'D87R?LVWY_O;O]7SN MW9YS7:RZG9P6,5Y)-B"8H(R%)+E\;0% R2]X@DW&"4P
MR@[04<8)!!B"/4$$<$4^*X2;2;-5D!B8*O>-E!. ?E)&&'/49';J* /+],TRXLK*2R:*TU2Q MO+&;5],C:'2[5H+:)O, ;RVWLI8@C<%/& 3@GGUBL^^US3=-O[*QN[I8KF^8 MI;H5)WD8[@8'4#G']H
\Y\2:;IUJOB>QCL;6+3[>32[I81$HBB9I2LCA>BY1 M<$C'&? ;S[/ROV/(W_=_@VXSC^'/;-:_]H6O]IC3? M-TLP^?Y>T_:]6@@AM8(X M+>)(88U"I'&H55 Z < 5!IVIV>JVS3V15N@ M HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZLY2S M5@^P^?$,^8R?QKQE03^`0]#Q5ZJ.K.4LU8/L/GQ#/F,G\:\94$_AT/0\5>H M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** _.6AG3O\F_]l$2-C-_&O.%.?QZ#]>*?3-:&=/'R;_WT1(V,W\:\X4Y_'H.IXI] !1110 4444 %%%% !1110 4444 %%%% M!1110 4444
%4M68II<[!]A 'S>8R8Y'\2@D?E5VJ6K,4TN=@^P@#YO,9,8S;?D7CD?+]!D=^YJ[5*P8M-? ONQ8S;?D7CD?+]!D=^YH NT M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M %6T _X2.Y.WG()'SM?GYW[_'/R^;UX(JA\0<_\(+JFT@'8F"1G^-:OV@'_ M
D=R=O/V2/G:_/SOW^Y^7S>O!%:5O;07<#07,,CD4,I[\@T 8DFAZI MJ%[8RZMJEI-;V$-0AO;XR7= MX()HVN':(QLLGRB+,T8VKR!G,>3DUZA59=.L4@@A2SMUBMV#PH(E"Q,,X*C'
M!Y/(]30!YO%JER-0\-ZE:S7Z6VHZ@$62\U1F>[C96+'[,.QH@)&,$$8' S5J MPO=0TBZMIKF6YU":\CF%K>6FIFYM;V0J[A6@;'EXV#'E# SC..*[6+P]HD$Y MGAT?
3XYFD$AD2V0,7!R&R!U!YES4EMHFDV5()>VNF64%W)GS)XK=5=\G)RP&3 MD\T <5X=;6'_+"U\1M0E\$]2DO+=)S:VD\T(DY5'\]@&QTR,G!/3M6I;Z+I5I?R7]MIEE#>2EC)<1P
M*LCECDY8#)R>35N6*.>%X9HTDBD4JZ.H*LIX(((44 N=LE^O>'+[5K+4[L:C'KLT4<"W#>6S-1V1MW6VGL9EEMW$>0F 5*XR."C,N,CK[4Z+0M(AOEOHM*L8[Q M2Q6X2W02 MG=AL9YW-
GUR?6@#-MV.7Q#OX8SB.;3()5Q_&)%#?4KQ_P?>E M0QMXBM;?]U,RE8FMU+(O/)R>,YSUKM]TO['?:A>RRB: MXO)0O8)MV1J,(G/Y3DY[EB>.)SIMBTIE-E;F1I1,7,2Y,@& ^ X!ZXH
MP_#C26^NZ_I?VBYFMK66%H1<3-*R!XP2-S$L1D9Y)ZUSxKI>>([[Q#=6>E7M MV(T6STVZMW@"Q21-O9OGD4_27< Y"#Z5Z.EM!%/+/'#&DLV/,D50&? P,GO
M@<F2[22OF6D;8R\U]WO+>Q%U;7826ZLHRB7&44@L"20X4]""3CCG&*Z*H M;2SMK"V2VL[>&WMTSLBA0[IY.3@#@AX]] M5'5G*6:L'V'SXAGS&3^->,J"?PZ'H>*O4 %%%% !1110 4444
%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M &?K0SIX^3?^^B)&QF_C7G"G/X]!U/%/IFM#.GCY-_[Z(D;&;^->+<*<_CT'4\4 M^ @HHHH ****
"BBB@ HHHH **** "BBB@ HHHH "J6K,4TN=@^P@#Y MO,9,*=6N-#\.76HVD4"*A\9:;<;QX4O;"TL8,LTQC 0.%R!(I/)(QP#WH PJ2[K.F7<]A]
M4ND&9K$W<%T=UO!&5=482;F8X!=3D$9Y&!UKGM4\6:G>;3K]E#?0/LT MPV$]KD9(;:'<[@1M*R*V/8UU,G@RTNH+A;[4-0O;B:)(5N9G3S(E1PZ[=]!? MQJ&R022!G(&*1_!5I<7%
[<7VHZC>37ED]C,\SH/W;$'@*@"D%+,RJ!D*,GJ!UXENO&&LV6F:C)]C%Q M+ (7@N9=.N+.)]H8RLO.X9SD,1STX%)>3RW,4"&=F17C: M$L8W0HH
8%LYQC@<<=6EQ;W^K;G>>>8\O+(B[CAP%1$5!R.3MR1QG MI0!S7BW5]=M1)UW2Y[MS%'81W<=Q:P21_(SE&3!D)!X^]GH>E7]0\3ZII>L M_8[ZZTVRB5HDCFN[2:.&\)7=(5GW%
(CIX!6W'*]\UM:MX6L=9FO);F2X5KNR M%DXC8 *@8L&&0?FR>^1QTJ&[*"^CEANM;U:6VN%5;FW:2/9. ,'/R90.."(MR@ZXP3F@";Q1KA..*
,4>+M9OM*LM3TZ"O2WU345M;%+A6++$4?.DA5N3N7.T8P!@G)R' M7WC#4]*N)M*NHK>741=0POSV]M*\9CD1WWF%2SDJ(W&T-R<<@9Q+K?@UI'ME
MTN6ZBBEU:.]F2*5%%L0CAI(\CJ6*DCY@3VY.=)O"%E)!+YUW>RWTEPES]O9U M$RR(,(1A0@ ![QMQ@G(.30!E)XMU7:;,V@-U-=PVMK>3V,]K#)O5F),$\/XDBNM!AFO;!0^K(GF002!9E\IV 9#)P
5/&YLG8V1@@[4G MA>*XMG2[U/4KFX,R3QW4DJAX7084HJ]$7J<_+\V3NS39O"R7,<1N-7U.6YBN MENH[EWC+(Z]4 ";/+ PQSA1G,3SS0!AV_C74[N5;RWLI9K)[KREM(]+NC)Y6 M_89//
\O/5)N,8^7=GFJ?B#4]5UKPY#]2FS32I=5@2.#RV\X(MRJAR^[!)9< M[=HP&^\<<]3%X6BMYV%MJFI6]D9S M?]<<.9DW&/*.=R>C<8S[FL33?%&N36.D:I>+I_V2_OOL9@BB<2*"SJKARY'5
M1\NWH>M=3J.E0:F]BTSR*;.Y6ZCV$#+ ,#D'CYC5&+PM8PZ5[^G+++&&QNA M=1,67<7#%L-QTRQZ8H W**** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****
*.K.4LU8/L/GQ#/F,G\:\94$_AT/0\5>]CJSE+-6#[#Y\0S MYC)_&O&5!/X=#T/%7] "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@#/UH9T\?)O\ WT1(MV,W\:\X4Y_'H.IXI],UH9T\?)O\ WT1(V,W\:\X4Y_'H.IXI] !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %4M68II

4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% %6T _X2.Y.WG[)'SM?GYW[_<_+YO7@BK>]6EQ M?:;+:VMZ]G+)@>>BY95R-V/0E<@'L3GM52T _P"$CN3MY^R1\[7Y^=^_W/R^ M;UX(J?7+&]U+1[BSL-0.GW$HVBY6/>R#/. &&"1D9!R,Y'- '$W^H76F2; ' MHE _=R6,$<%LTT\[W'D7 M9):B5KEH)$=%+*7)(RK],X!&<>MR#PM<'P_+H5U=6*Z>8?+A6QLWA:)@00^Y MI7R9 _=JC,2VXKG*@X'R\ U?\+RP6EY!8 MW<&MVVI26@=?[2O7F6X P'9!YKJ&!*Y&%8!NF,U9T_PW?VFD2:2VI6T-FT3(MK:?:R03(Y.=_F-*^3G).1DD\FIK;1-2-\FH:CJEO=7MO;O!:F.S,4:%\;G== MY+$[5Z,HP#@,: ~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`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`0]#Q5Z@#.O]=TS2[ZRL MKRZ6*YOG*6Z%6.\Y Z@8'+ 2*/:?F5,:CG&!C< M.OK7G6L17GB;4?$=Q:Z5?7:Q(MCI]S:O"%BEB:>S8>13_K0HR >$_"KR:G!X MB\0^%M0=FBBNM*NVEV2-&8S^[#C<""!!!&0W$\=K;2W$S;8HD+NV"< M*!DGBFVEU#?6<%W;/O@GC66-L$;E89!P>1P:Xa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}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}H<1%!MBD?SF*$LJ[5QNR#P,9K M)M+Z"2^\%&'6;2XCCGC465A %BLU:%ALCWD& MFWNC:7I.HZ?K=LMS)'#;RV^R]T2IRSS'((;?5+ M1-4BOXW>QAT]FODG$FYG8F8#!&XERN-K'VKU^B@ HHIKRQOLBNZJTC;4!."Q MP3@>IP"?H#0 ZBHK>ZM)N,R6T\4R!BA:-PP# X(R.X/!%2T 1W%0%:\VEQ.X M2*-2SL>P%>&?$7Q*FK:[!Y$D[V"QX3*856SSQ\LI]1T.[M+9E$T]; M5W`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

>AQ6K?'SKK[9!=1+;&-%5/_8*,#9MSG@CTQWS M4\DMG]KEF/V:1O-NV^?:0W *9]>>GZ4N8=C 6-V1W5&*H,L0.%[<^E-K;9K& M1?,E$ +V\1<(,-Y@#8 Z':.U2!4,],9'L1
JR&%8_(PXSP"2"!VY89X-',% MC#$,A@:<+ ^[5@A,>Y)(D;G_+-OO*|W[%<^7MW;_*;&/7,.E;&JO:"&[CMV MA"F>%@L: C_5G=C'N>PJIYB?\(^8MZ^9]JW;<\XV=<>E.[$4DC>0.41F"C+YDV'!(0
#)['D4N8=CE:[[PY_P @&V X%_Z$:X&N^\.? M\@&V_P"!?^A&I]_"..YJ4445SEA1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%% M% %6T _X2.Y.WG[)'SM?GYW[_<_+YO7@BG>{M621=':YAC26X>6.*!)"F21 MPBY((_MD^PIMH!_PD=R=O/V2/G:_/SOW^Y^7S>O\%6]4TRWUC39K"Z#^5*1D
MHO5E((*LI'0@@$'U%,#AM1U35-!)6WUY?_9+RX32HD@,"-"CE(@H92SD89N M2">*U;W7]>TBYN;">WM=1O&L7N[0VD+O[BC*K*4+,3C>&&#S@C .*N-X+L/B
MXN[C4+^_OY;JV%L[3NB[5#:E*B-5"D,,@COS4L?A6+=<37&J;G M94EA3.<(8U4#D DD'.!G(XIW0&)_PF\T.F7L@N[#4+I;B.VA2"UGAECD=B[\ MVW:=(",C'+<@ =:U_#VMZA?ZAN?
=>*-833M5UN&*R&G:9<20R6KHQFE6)MLC"0,9&4WH3T MYP.1GC9N_#44][=75MJ- 8&[" ;DM'11,0, Y*EE;'&4*G@=P#5>?P98SM<1 M_:+]+"ZE$MS8+(IBF;C)8E2_S8&X]@#WZG+T
R+WQ7KD5MK6HVR:UC<2VD4H254"11S;RRDX(8!F/7L,"A6 S/%.I:BL,NC:H::65+BPNH:BU MC:-61KE5*LC,O# KUW$$,.F.9Y?&NI/+>W%E9R3V!M=/ EI'I=U*\ZHVOF$Z MCRU.0Q P>@!(),-
J7P?:7*3->WM[=W,TD+M=2M&)-L3AT0!4"A=V20%R=QYZ M8D;PM$+FX>VU34K2VN9O/FM;>541W)!8AMOF)N(R=K#]?4T70'+PZ_]NCOKC M23QW4EXQOBV M99/%'OHJ;:K,S*$7A% Y!Y
/&@OBW50KVC6@:ZEN8;.'TNY MK">UAD.@8DF.3YLH$.0&YBQ(SQK3^$+.>6]?[7>1 ;.KI:O1&R#R)U4+YD9VY MR0HR&)7D\8-/D\+O?7-I-%>;]J5U-)(D]7.D]J\+)TQ]A%OS_#SGYLBBZ S M?
#8OE|<^)5U%|>2=;>R DMT**Z_OL':2O4]L9/3/? J3^(K^VU"]@TZSTZ.: M378[R-$PW!H WF/@C]%T NA:G>W5[MJNG:@;=[G3YD3S;=&1)%= X.UF8@\XZGI6W5&TT]"SU+4+ ^-Y#+?,C2AB-H*
M(&&WCT'?-7JE@%%% !1110 5O.O>!1XJ|9Q7VMK!/HMM:&*&V65U7N))ZXSCGTJ33_A_HJO:!=ZE9)-]^FVUO$+A)Y H>)1@@9 (R.XY[UUU M%%V!S-[X=N[GXA:9KZ20"TM;22!T+'>6;.,#&.
<^MK>W2NK?:$;=N94QJ!/('4^GISZ911=@>;ZOX1\7W?C9-F73O7H%%';!E^&]$B\.>';'2(9#*MM'M,A&-[$DL<=LDDXK4HHI %%%% M
!1110!1U9REFK!|A|^(9|OD_C7C*@G\,AZ'BKU4=6AXJ|0!S%OX46:3/$&GZD8W@U2^DN$\HG**P3;>0,,"N>_05A6GP_O MHM$T]+]M.U/4+*^GN&CNE+07*2D[@V5)5NC
[3@CH0:1$HIW8'#GP9>?V?,] MO!!%C=_;K>\@M+2$) ODMD*TBHK/NY))7C. /6+5/"6NZRVOSW#:=#+]5G]: MPQ1S.ZQO-R3N8H,@YSG:.N,<9/>T478&#]>E7Z^(;?7-*^S2SK;-:3V]U(T:
MO&6#!E=58]P8=-!!![8K*@*:G93VNKP3VLVKK=3W-Q%(S)"XF"AD5@"0%") MABISMY SQV=%P//[/ NI7\5_<:C_9DUY+J::C# P:2!@(PAB?*],9&[!Z X
M[4W4O#,=CH^[7]S#I&B[6@DMTL+3S(X6C<.'D=8U=@6P#P%5>?>O0Z*,9@>: M+:,S>.?$,J)-/8FQ?2&L_.TVPMU+W+E=N[EFAD0M]LB+AN!UVD'&>#4% MIX8U$>(=
(O7L=&TZQL8YXVM+!VP3*H!<'RU'}51MQP,G<>E=I11<#B]$*ZI M8?"_+=-9A=&6>)S%*$&560*K %!@YSD=O4T:+X'>QU+66O+A)+"XADM:&* M.G=!!(22*(R>"S!V.1QC.1N^*-
OM3BTQ)%NTUE?QW92XE:-75588W!6(/S#M6[11_M<#G1I6]:KK5A?:O'9V\&GE|(+>VG:;,S)64KO9F1,!03@ 'DYSQBLVT\,ZG9^ M'[/2Y[#0|5@CEGEDM[PL%#/[HRL48<*^""G?@^O:447
|^A^TMK:Z1))#I MNJ3V<4L,EG?Y:#8[;U6-F5RNPX)4Y&?NYXED|$77V.S(M-%E[^DNI=,\D1 M6C*T915RL9W%.H9D)))Z<8[RBCF8%V7AW7+6;7;F2'19?[2>_ 8WWF'RD38
MT1.WCY0N&VD'G*'J9^\LJE]0.&FV?G7<%W:::%F6S1XA@[@57(D'#848 !Y M(KT"BB[Y"Q\-WUE)?WEGIOA[39Y+<0P6MO:AXVY!8R2!$?YONX P.N&Z5-X M=\-3:7KMWJV/3\@F@2'[#ITC-&S
D^8V40!L""^O-=311< HHHI %%%% M!1110!C>*03X=N?DWE^(H?M&C20XSO>-<^6SX MRXYP[!XZYZ#OQFN=_P"$- Z? P#R# | 95K3DDM29)LY:BNI P"$- Z? P#R M# | 94?|(;_T_P#
)! ^RK3VD>Y/*SE]*ZG_A#?^G _,@ 94?\(;_-/_ M /Y! P#L]/:1[ARLY:BNI_X0W_I__P#(/ V5' "& P#3_P#^0?\ [*CVD>X< MK.6HKJ?^$- Z? | R#]E1_PAO_T | _D' .RH]I'N'*SE]*ZG_A#?^G__M
,@ 94?\(;_-/_/Y! P#L]/:1[ARLY:BNI_X0W_I__P#(/ V5' "& P#3 M_P#^0?\ [*CVD>XXXXV!+&>2Y7[<@\F7R_EC) A!YSC!YZ#/U[ ]I'N'*SE]*ZG_A#?^G _M ,@ 94?\(;_-/
/Y! P#L]/:1[ARLY:BNI_X0W_I__P#(/ V5' "& P#3 M_P#^0?\ [*CVD>XO!%5/'-U/9>#KZYMI)8YD.15H6VO_K%! M .1U'YXU:M/:^$CN3MY^R1\[7Y^=^_W/R^;UX([77]) MS19].\ R/-*'S-F
M[&UPW3(].4^H&+=>,Y-(6^76].CM9:.UCN46"Z$JR*[^6%+,J;3NP#VYSFFZ M;XW6_N[!&*"QN[Y;8W,.6F:BERLF"%*%B$V-EEZC&#G/!JIK/A2/6=0N+J6[M>(2V:6RB-1N1TE\U9
3Z.!OCM3+SP[IVK:7>V6J:Y'(EQ:^4BVUD(D#9SO<% MV+= " R@@D8Y!#T Y_7&D]OI?B#3$:RAOK;3);E)],U'S_+*MM^L=B%&!(J M#6]<'(QC'-S4?!TM](J)344C@OTMO,0VY#E:%@0 M0V\#!
(OCOG/:BZ 9=^,:S2S=1ZII$,4MM'!<2"&||O?(>38SY*+RF"2,8(MWJVI'5OMVLZG91P@16!CC:??G=(RIBN,<8!7G/?VIEJ^DVPOK_5KPS36TVF_M89;6"W:5V4LQ) 7).=^,8XZYIO@?
2+C1?"EI!>EC?2@SW):[WF-R0?<#"_A2 MTL!'XN.%KJ&ZQ_T^UOTL4M!+_K6@;_"_.\K:C9OX^]NQSM[5:N?"T5SXOM=>-PP6%!NM=N5DE4,J2 M$YZJLCCIW'I50^#YO(.EC4U_L$W7VDVGV?]
>XW^9Y?F[ON;^2N[L<;N\/0" MM#HO&OSJ[:;2YP;O5[^0)/|8CD* <|=@,C%3R^,K@#WT=E;Z4LT)FI3;>@ M:YV+F./?O)VG J1@X'//2G_\(C/!,EU9ZDD=Y%]%O>QO+;:TQ-D.C*'!_>H
M8=.E)IW@^6SOI6]GU/[1+#[$]^_[C;O.L1C*CYC@#.>_I[T: 4+ ,,3ZO$96FDG@U!$F.L?VI&7MRZ]?*$6P@,">,G.1] M*FL #^IZ; HECK2PZ6)S*D/V0-.BD[C&)"VW;DG&4) ,YYHT RF^)%@MTS9
MT\V2W/V? D0)]/S;-X@Q]W=_M;MO..U33>-;N&VU"\;28$LK2 ;P\Z6]*Y< M2! [?NR$CYR6R2,'@];OVOA_4].W6EAK2P:89VF6(V@>:,,VYD60MMV[B<90 MD XSP#4MMH-W86-[%8ZIY-
Q<7\EZLIMPZC>^XQLI/(QP2"I]"*-)M*U2^U. MQ6X%G9@&4!9(;X30RO=WC<+DD1UQS6O7+V&AW'ATW%S;&UDN;^[@\Z. MVLC%"J9"L50.=K8+.69CDCIT%=128!1112 **** "BBB@ HHHH
**** "BBB M@ HHHH **** "BBB@ HHHH HZLY2S5@^P^?$,^8R?QKQE03^'0]#Q5ZJ.K.4 MLU8/L/GQ#/F.G\;\94$_AT/0\5>H **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** _6AG3 MQ\F]]$2-C- &O.%.?QZ#]>*?3-;&=/'R; WT1\H.IXI] !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% %6T _X2.Y.WG[)'SM?GYW[_<_+YO7@ MBKNI:E::1I\MI?S"&UBQOD()"Y(Z>Y%4K0# _A([D[>?LD?.U^?G?O\ <_+Y
MO7@BHO%^GW.J^%[NRLXO-GD,>U-P&<2*3R>,@-,"6'01H\T=V_VLPBTC$TPN M87@*QG.'PZ@E3@\C(]73=>T_59T(+6643QJ'-&>"2!!IZ-MD4$KP>0,5SOBG MP[]6KZM=RVL:>6VGQ+&SN
KRQW EV'N,A<9QCFK]C:ZC]/BR/6;O3I=.AM[% M[98YI8W>5G=6)^1F&T;.YR2>@QR60%[4$VDZ72.UEDCA)Y =U4]O!!Y(X(-8WB/3 M-1DU2XN=)T_48;]XT\F_L;Z-8Y&
8!9XI#@@$]0CDCH1TK*\1Z+XGU:QU:RG MMKRZEDC*69MKR.WLPI12Q90RN[E@W#AER1]T$D-) ;G_ ERCQ3J5I-,EMIF MFP))+)+9RDN6#9(DR%4<+@8.[G!])-7\;6%AH>H7MLD\MS:(&-K-
;2PO\QP& M*L@8)G/S8QQC-9&H^%)5Q_[8<0;6E33Y85:?9YSP$LZ;D.4/0:O4Y!XINH^' M+G4=)U<6>AZA;W4MEY,3ZCJIGDD.\453)(JCY1\0&<8QS19 =6/$NDFPO; MUKAXX;
(@7(E@D1XR55@"C*&Y#+CCG.,M5_%VOR>'O#[WT$9>9I(XH\P22*"[MJN6"\\ DXR,G SDBN>UC3[F^\;:7%'$\%MJD:7.HVSLI9/LS;E+;21R713@X M^45T?
B[3[K5/#LEK9Q>;.;BW<+N"\+.C,TWZE]22R MFZ^R](=/FB;S?+5_+\LEF+8.?Q"XR.;]^)|(;3GOA(GO=WF+_ *DVH0-C/]X8QU]|)M!U;'Q' M=:S%9F=8=66ZBMQ*@,\1MA"Q7)P&!)(#$9QUY%.R
NV/C!+_ %6]A6XA@MHK MZ"UA,EK+YDA>/;&BZW>Z(/],NE-:)+K%I=!'FC9A%'$49FVL1G..!GKQG MK5BW\/ZG%X4TNR^R[;F'6UNY4$B\1?:VDW9S@_(0<=>W7BBE VYO&&A07(@D MO'!-
P+59!:RF)IB<;!(%V%L)0#O@YZ'$T'B?2+F^2SBN7.DDC11N8)!%(ZYW M*LA78O&UN 3T/!7"W)NK?PYHVC):K/ NMPI'I_=Q&\4P^T;OEPQ?>.0P*@#: M_/'.U:Z7]UKKD#:;8W^F1?:G-
VAOHYK&2(NS,R(275VR#A50 DY]RR [>BBB MI **** "BBB@"(S@$C9(<>B&C[0/^>#5W[0/^>*?0!'YP_N2?]\&CSA_JSXTRYWM_I!P S/M&U>,$?+]! MQSGO6A5*P8M-? ONQ8S;?D7CD?
+]!D=^YH L^\,745KK&H?9II4\Q%\F1\KDC.54C]#6_7F7BO^V?\ A;FD?V%]@^W? MV6^/MV_R]NYL_ MU7Q#H_@?5+GQ'?6-C5EW$ _+(R -UPQ:KK6GZ(';2:C<>2MS<+;1' M8S;I&SA?
E!QT/)XJ_7BVJ:;GS.+NU?19?$/A-+^ZDU*]O8?[0F>9BZQS'G:V<@)@CV)H]?HJ&SMS: M65O;&628Q1K'YDC%F? ODD\DGN:FM **** "BBB@ HHHH **** *.K.4LU8/
ML/GQ#/F.G\:\94$_AT/0\5>JCJSE+-6#[#Y\0SYC)_&O&5!/X=#T/%7J "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH ****
"BBB@#%\5WT6F>'IKX,O%#)$S*%),/7IR.?Q_/I7) M _7F7BO^V?\ A;FD?V%]@^W? MV6^/MV_R]NYL_ MU7Q#H_@?5+GQ'?6-C5EW$ _+(R -UPQ:KK6GZ(';2:C<>2MS<+;1' M8S;I&SA?
E!QT/)XJ_7BVJ:;GS.+NU?19?$/A-+^ZDU*]O8?[0F>9BZQS'G:V<@)@CV)H]?HJ&SMS: M65O;&628Q1K'YDC%F? ODD\DGN:FM **** "BBB@ HHHH **** *.K.4LU8/
ML/GQ#/F.G\:\94$_AT/0\5>JCJSE+-6#[#Y\0SYC)_&O&5!/X=#T/%7J "BB M

Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Other Income, Net link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Significant Agreements link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Corporate Restructuring link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Immaterial Error Correction (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Other Income, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Corporate Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Immaterial Error Correction (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Description of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Fair Value - Schedule of Fair Value of Cash Equivalents and Short-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Fair Value - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Other Income, Net - Schedule of Other Income, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Significant Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Commitments and Contingencies - Operating Lease Expense and Variable Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Stock-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Stock-based Compensation - Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement Plan (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Corporate Restructuring - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Corporate Restructuring - Summary of Cost Associated With Termination Benefit Payment of Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Immaterial Error Correction (Unaudited) - Summary of Immaterial Errors Correction in the Weighted-Average Number of Common Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items]Statement [Line Items]Plan NamePlan Name [Domain]Entity Address, Postal Zip CodeEntity Address, Postal Zip CodeBasis Of Presentation And Significant Accounting Policies [Table]Basis Of Presentation And Significant Accounting Policies [Table]Basis of presentation and significant accounting policies.Entity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeNumber of operating segmentsNumber of Operating SegmentsStock Issued During Period, Shares, Employee Stock Ownership PlanIssuance of common stock under employee stock purchase plan, sharesWeighted-Average Exercise price per Share, Options exercisableShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise PriceBeginning balance, sharesEnding balance, sharesShares, OutstandingFair Value Hierarchy and NAVFair Value Hierarchy and NAV [Axis]Level 2Fair Value, Inputs, Level 2 [Member]Share Based Compensation Arrangement By Share Based Payment Award [Line Items]Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Error Corrections and Prior Period Adjustments Restatement [Line Items]Remaining 2024Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal YearCommitments and ContingenciesCommitments and Contingencies Disclosure [Text Block]Restructuring Cost [Table]Schedule Of Stock By Class [Table]Stock, Class of Stock [Table]Product and ServiceProduct and Service [Axis]Collaborative Arrangement and Arrangement Other than CollaborativeCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Short-term InvestmentsShort-Term Investment [Member]Short-Term Investment [Member]Name of plaintiffLoss Contingency, Name of PlaintiffCommon StockEquity [Text Block]Sale of StockSale of Stock [Domain]Cash and Cash Equivalents [Domain]Exercise Price $20.55 to 29.41Exercise Price Three [Member]Exercise price three.Entity Central Index KeyEntity Central Index KeyChanges in operating assets and liabilities:Increase (Decrease) in Operating Capital [Abstract]Entity reincorporation, date of reincorporationEntity Reincorporation Date Of ReincorporationEntity reincorporation, date of reincorporation.Common Stock, Shares, Issued, TotalCommon stock, shares issuedCommon Stock, Shares, IssuedSchedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]Prepaid expenses and other current and long-term assets, netIncrease (Decrease) in Prepaid Expense and Other Assets, TotalIncrease (Decrease) in Prepaid Expense and Other AssetsEntity Address, State or ProvinceEntity Address, State or ProvinceRevision of Prior Period [Axis]Investments and Cash, TotalInvestments and CashCash, cash equivalents, and investmentsAccounting Standards Update [Extensible Enumeration]Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]Aggregate Intrinsic Value, Options exercisableShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic ValueCover [Abstract]Net loss per share attributable to common stockholders, basicNet loss per share, basicEarnings Per Share, Basic, TotalEarnings Per Share, BasicSchedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]Share-Based Payment Arrangement, Option, Exercise Price Range [Table]Prior Period Adjustment [Abstract]Investments, Unrealized GainsDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before TaxOptions and restricted stock units grantedShare Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Unit GrantedShare based compensation arrangement by share based payment award options and restricted stock unit granted.Operating expenses:Operating Expenses [Abstract]Bothell, WashingtonBothell Washington [Member]Bothell, Washington.Stock-based compensation expenseShare-Based Payment Arrangement, ExpenseRetained Earnings (Accumulated Deficit), Ending BalanceRetained Earnings (Accumulated Deficit), Beginning BalanceRetained Earnings (Accumulated Deficit), TotalAccumulated deficitRetained Earnings (Accumulated Deficit)Plan NamePlan Name [Axis]Shares OutstandingShares, Beginning BalanceShares, Ending BalanceShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, NumberCurrent assets:Assets, Current [Abstract]Reserved shares of common stock for future issuanceCommon Stock, Capital Shares Reserved for Future IssuanceWang V. Athira Pharma Inc.,Wang V Athira Pharma Inc [Member]Wang V. Athira Pharma, Inc.Net cash used in operating activitiesNet Cash Provided by (Used in) Operating ActivitiesWeighted-Average Grant Date Fair Value, Non-vested, CancelledShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair ValueProduct and ServiceProduct and Service [Domain]Accumulated other comprehensive income (loss)Accumulated Other Comprehensive Income (Loss), Net of Tax, TotalAccumulated Other Comprehensive Income (Loss), Net of TaxOperating lease initial termLessee, Operating Lease, Term of ContractProperty, Plant and Equipment, Net, Ending BalanceProperty, Plant and Equipment, Net, Beginning BalanceProperty and equipment, netProperty and equipment, netProperty, Plant and Equipment, NetOperating activitiesNet Cash Provided by (Used in) Operating Activities [Abstract]Recurring BasisFair Value, Recurring [Member]Other Income and Expenses [Abstract]Restructuring and Related Activities [Abstract]Common stock, par valueCommon Stock, Par or Stated Value Per ShareStatement of Cash Flows [Abstract]Antidilutive Securities, NameAntidilutive Securities, Name [Domain]Payments for Legal SettlementsLegal settlement amountRevision of Prior Period, Error Correction, Adjustment [Member]AdjustedRoyalty obligationRoyalty ObligationRoyalty obligation.Equity ComponentsEquity Components [Axis]Stock Options to Purchase Common StockStock Options To Purchase Common Stock [Member]Stock options to purchase common stock.Entity Address, Address Line OneEntity Address, Address Line OneEmployee-related Liabilities, Current, TotalEmployee compensation and benefitsEmployee-related Liabilities, CurrentIssuance of common stock upon exercise of common stock options and vesting of restricted stock units, SharesIssuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Unit SharesIssuance of common stock upon exercise of common stock options and vesting of restricted stock unit shares.Share Equivalent, GrantedGranted, sharesShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in PeriodProperty Plant And Equipment [Line Items]Property, Plant and Equipment [Line Items]Total other income, netNonoperating Income (Expense)Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common StockholdersSchedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Risk-free interest rateShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest RateUnbilled grant receivableIncrease Decrease In Unbilled Grant ReceivablesIncrease (decrease) in unbilled grant receivables.Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, NumberShare Equivalent, Non-vested, Beginning BalanceShare Equivalent, Non-vested, Ending BalancePhase 3 Clinical Trial InitiationPhase Three Clinical Trail Initiation Of License Agreement [Member]Phase three clinical trail initiation of license agreement.Amendment FlagAmendment FlagOperating lease liabilityIncrease (Decrease) in Operating Lease LiabilityOperating lease liability, less current portionOperating Lease, Liability, NoncurrentAdditional Paid in Capital, Common Stock, Ending BalanceAdditional Paid in Capital, Common Stock, Beginning BalanceAdditional paid-in capitalAdditional Paid in Capital, Common StockInvestments, Fair ValueDebt Securities, Available-for-Sale, NoncurrentNet lossNet lossShares, ExercisedIssuance of common stock upon exercise of common stock options, sharesShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in PeriodShares ExercisableShares, Options exercisableShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, NumberResearch and Development ExpenseResearch and DevelopmentResearch and Development Expense [Member]Equity ComponentEquity Component [Domain]Statistical MeasurementStatistical Measurement [Domain]General and Administrative Expense, TotalGeneral and administrativeGeneral and Administrative ExpenseUnrealized gain on available-for-sale securitiesUnrealized (loss) gain on available-for-sale securitiesOther Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, TotalOther Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to ParentOther income, netOther Nonoperating Income (Expense), TotalOther Nonoperating Income (Expense)Athira Pharma Inc V Dr. Kawas.Athira Pharma Inc V Dr. Kawas [Member]Athira Pharma Inc V Dr. KawasNet Income (Loss), Including Portion Attributable to Noncontrolling Interest, TotalNet lossNet Income (Loss), Including Portion Attributable to Noncontrolling InterestProceeds from Stock Options ExercisedProceeds from exercise of common stock optionsPayables and Accruals [Abstract]Restricted Cash, CurrentRestricted cash, current Employee Stock Purchase Plan MemberEmployee Stock Purchase PlanEmployee Stock Purchase Plan [Member]Short-term Investments, TotalShort-term investmentsShort-Term InvestmentsShare-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement PlanOperating lease expenseOperating Lease, ExpensePrepaid expenses and other current assetsPrepaid Expense and Other Assets, CurrentRestricted Cash, NoncurrentRestricted cash, non-currentCollaborative Arrangement and Arrangement Other than CollaborativeCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Total severance expenseTotal severance expenseSeverance CostsSignificant AgreementsCollaborative Arrangement Disclosure [Text Block]Comprehensive loss attributable to common stockholdersComprehensive Income (Loss), Net of Tax, Attributable to ParentCommon Stock, Shares, Outstanding, Ending BalanceCommon Stock, Shares, Outstanding, Beginning BalanceCommon stock, shares outstandingCommon Stock, Shares, OutstandingFair Value MeasurementsFair Value Measurement, Policy [Policy Text Block]Purchases of available-for-sale securitiesPayments to Acquire Debt Securities, Available-for-SaleMaturities of available-for-sale securitiesProceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-SaleAntidilutive SecuritiesAntidilutive Securities [Axis]Corporate BondsCorporate Bond Securities [Member]Fair value of options grantedShare Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair ValueShare Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair ValueEntity Interactive Data CurrentEntity Interactive Data CurrentDocument Quarterly ReportDocument Quarterly ReportWeighted-Average Grant Date Fair Value, Non-vested, VestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair ValueStatistical MeasurementStatistical Measurement [Axis]Proceeds from follow-on public offering, net of underwriters' discounts and commissions and issuance costsIssuance of Common Stock Value During Period Follow-on Public Offering Net of Underwriters Discounts and CommissionsIssuance of common stock value during period follow-on public offering, net of underwriters' discounts and commissions.Operating lease expenseOperating Lease, CostProfessional services and otherAccrued Professional Services And Other CurrentAccrued professional services and other, current.Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability PaymentsLessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]Commercial PaperCommercial Paper [Member]Summary of Restricted Stock ActivityShare-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]Shares Available for Grant, Ending BalanceShares Available for Grant, Beginning BalanceShares available for grantShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for GrantWeighted-Average Grant Date Fair Value, Non-vested, GrantedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValueRemaining weighted-average period expected to recognize unrecognized compensation costShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for RecognitionInterest and Other Income, TotalInterest and other incomeInterest and Other IncomeResearch and Development ExpensesResearch and Development Expense, Policy [Policy Text Block]Income Statement LocationStatement of Income Location, Balance [Axis]Cash and Cash Equivalents [Axis]Total assetsAssetsExpected term (in years)Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected TermShare Equivalent, VestedShare vestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in PeriodRSUs vestedAnnual minimum royalty paymentsAnnual Minimum Royalty Payments After First Commercial SaleAnnual minimum royalty payments after first

commercial sale.Accrued liability associated with restructuringRestructuring Reserve, CurrentNew Accounting Pronouncements, Policy [Policy Text Block]Recently Adopted Accounting PronouncementsEntity Address, City or TownEntity Address, City or TownAccumulated Other Comprehensive Income (Loss)AOCI Attributable to Parent [Member]Equity [Abstract]Share Equivalent, CancelledCancelledShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodGrant incomeGrant IncomeGrant income.Cash used in operationsNet Cash Provided by (Used in) Continuing OperationsNet Cash Provided by (Used in) Continuing Operations, TotalShort-term investments effective maturity dateShort Term Investments Maturity TermShort-term investments maturity term.Restructuring Cost and Reserve [Line Items]Depreciation, TotalDepreciation expenseDepreciationAggregate offering priceAggregate Offering PriceAggregate offering price.Revision of Prior Period [Domain]National Institutes of Health GrantNational Institutes Of Health Grant [Member]National institutes of health grant member.Issuance of common stock upon exercise of common stock options and vesting of restricted stock unitsIssuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock UnitsIssuance of common stock upon exercise of common stock options and vesting of restricted stock units.Stock-based CompensationShare-Based Payment Arrangement [Text Block]Construction in ProgressConstruction in Progress [Member]Weighted average discount rateOperating Lease, Weighted Average Discount Rate, PercentFair Value Disclosures [Abstract]Weighted-Average Exercise price per Share, Forfeited/expiredShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise PriceResearch and developmentAccrued Research And Development Expenses CurrentAccrued research and development expenses, current.Issuance of common stock upon exercise of common stock optionsStock Issued During Period, Value, Stock Options ExercisedCurrent liabilities:Liabilities, Current [Abstract]Issuance of common stock upon vesting of restricted stock units, sharesIssuance of Common Stock Upon Vesting of Restricted Stock Units, SharesIssuance of common stock upon vesting of restricted stock units, shares.Description Of Business [Line Items]Description Of Business [Line Items]Description of business.Document TypeDocument TypeU.S. Government Debt and Agency SecuritiesUS Government Agencies Debt Securities [Member]Security12b TitleTitle of 12(b) SecurityCash and Cash Equivalents, at Carrying Value, Ending BalanceCash and Cash Equivalents, at Carrying Value, Beginning BalanceCash equivalents, Amortized CostCash and cash equivalentsCash and Cash Equivalents, at Carrying ValueLease, Cost [Table Text Block]Weighted Average Remaining Lease Term and Weighted Average Discount Rate and Operating Lease Expense and Variable Lease ExpenseStatement of Stockholders' Equity [Abstract]Document Fiscal Period FocusDocument Fiscal Period FocusAggregate intrinsic value of options exercisedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic ValueResearch and Development Expense, TotalResearch and developmentResearch and Development ExpenseOptions, grantedShares, GrantedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, GrossAsset ClassAsset Class [Domain]Property, Plant and Equipment, Gross, Ending BalanceProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, TotalProperty and equipment, at costProperty, Plant and Equipment, GrossInsurance recovery in operating expensesInsurance RecoveriesLeasesLessee, Leases [Policy Text Block]Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing ModelSchedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]Shares Available for Future Grant under 2024 Inducement Equity Incentive PlanShares Available For Future Grant Under Two Thousand Twenty Four Inducement Equity Incentive Plan [Member]Shares available for future grant under two thousand twenty four inducement equity incentive plan.Milestone payments on development milestone achievedPayment On Achievement Of Development MilestonePayment on achievement of development milestone.Lab EquipmentLaboratory Equipment [Member]Laboratory equipment.Summary of Cost Associated With Termination Benefit Payment of RestructuringSchedule of Restructuring Reserve by Type of Cost [Table Text Block]Error Correction [Table]Office Furniture, Fixtures, and Computer EquipmentFurniture Fixtures And Computer Equipment [Member]Furniture, fixtures and computer equipment.Financial Instruments [Domain]Description Of Business [Table]Description Of Business [Table]Description of business.Deposit of final settlement payment to settlement fund account.Deposit of Final Settlement Payment To Settlement Fund AccountDeposit of final settlement payment to settlement fund accountShare based compensation percentage of number shares of common stock issued and outstanding on immediate proceedingShare Based Compensation Percentage Of Number Shares Of Common Stock Issued And Outstanding On Immediate ProceedingShare based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding.Sale of StockSale of Stock [Axis]Investing activitiesNet Cash Provided by (Used in) Investing Activities [Abstract]Statement of Comprehensive Income [Abstract]Milestone payments payable upon marketing approvalMilestone Payments Amount Payable Upon Marketing ApprovalMilestone payments amount payable upon marketing approval.Options and restricted stock units forfeited, cancelled, or expiredShare-based Compensation Arrangement by Share-based Payment Award, Options and Restricted Stock Units, Forfeited, Cancelled or ExpiredShare-based compensation arrangement by share-based payment award, options and restricted stock units, forfeited, cancelled or expired.Corporate RestructuringCosts Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), TotalShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)Shares reservedThereafterLessee Operating Lease Liability Payments Due After Year TwoLessee operating lease liability payments due after year two.Entity Address, Address Line TwoEntity Address, Address Line TwoLitigation CaseLitigation Case [Domain]Liabilities and stockholders' equityLiabilities and Equity [Abstract]Document Period End DateDocument Period End DateNet cash provided by financing activitiesNet Cash Provided by (Used in) Financing ActivitiesOutstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per shareAntidilutive Securities Excluded from Computation of Earnings Per Share, AmountAPIC, Share-based Payment Arrangement, Increase for Cost Recognition, TotalStock-based compensationAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionTotal accrued LiabilitiesAccrued liabilitiesAccrued Liabilities, CurrentOther Nonoperating Expense, TotalOther Nonoperating ExpenseOther expenseEmerging Growth Company StatusEmerging Growth Company Status Policy [Text Block]Emerging growth company status.Loss on disposal of equipmentLoss on disposal of equipmentGain (Loss) on Disposition of Property Plant EquipmentGain (Loss) on Disposition of Property Plant Equipment, TotalTrading SymbolTrading SymbolTotal stockholders' equityBeginning balanceEnding balanceEquity, Attributable to ParentExercise Price Two [Member]Exercise price two.Exercise Price $8.93 to 19.942020 Employee Stock Purchase PlanTow Thousand And Twenty Employee Stock Purchase Plan [Member]Tow thousand and twenty employee stock purchase plan.Long-Lived Tangible AssetLong-Lived Tangible Asset [Axis]Stock-based CompensationShare-Based Payment Arrangement [Policy Text Block]Restricted Stock Units (RSUs)Restricted Stock Units (RSUs) [Member]Variable lease expenseVariable Lease, CostSchedule Of Property Plant And Equipment [Table]Property, Plant and Equipment [Table]Change in Accounting Principle, Accounting Standards Update, Adopted [true false]Change in accounting principle, accounting standards update, adoptedSelling, General and Administrative Expenses, Policy [Policy Text Block]General and Administrative ExpensesStock-based Compensation Expense RecognizedShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]Description of BusinessNature of Operations [Text Block]Insurance recovery receivable related to legal settlement (Note 7)Insurance recovery receivableInsurance Settlements Receivable, CurrentGeographicalGeographical [Axis]Investments, Unrealized LossesDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before TaxUnrecognized compensation costShare-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount2020 Equity Incentive PlanTwo Thousand And Twenty Equity Incentive Plan [Member]Two thousand and twenty equity incentive plan.Use of EstimatesUse of Estimates, Policy [Policy Text Block]Phase 2 Clinical Trial InitiationPhase Two Clinical Trail Initiation Of License Agreement [Member]Phase two clinical trail initiation of license agreement.Exercise Price RangeExercise Price Range [Domain]Class Of Stock [Line Items]Class of Stock [Line Items]Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]Scenario [Axis]Expected dividend yieldShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend RateSecurity Exchange NameSecurity Exchange NameLong-Lived Tangible AssetLong-Lived Tangible Asset [Domain]Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalLess: accumulated depreciationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentLegal expenseSettlement Liabilities, CurrentFair ValueFair Value Disclosures [Text Block]Research and Development Arrangement, Contract to Perform for Others, TypeResearch and Development Arrangement, Contract to Perform for Others, Type [Domain]Shares Issuable Upon the Exercise of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units GrantedShares Issuable Upon The Exercise Of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted MemberShares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted.Error Correction [Text Block]Immaterial Error Correction (Unaudited)MaximumMaximum [Member]Maximum [Member]Corporate RestructuringRestructuring and Related Activities Disclosure [Text Block]Total liabilities and stockholders' equityLiabilities and EquityPercentage of termination in workforceRestructuring and Related Cost, Number of Positions Eliminated, Period PercentOperating lease right-of-use assetOperating Lease, Right-of-Use AssetSupplemental disclosures of cash flow information:Supplemental Cash Flow Information [Abstract]Net loss per share, dilutedNet loss per share attributable to common stockholders, dilutedEarnings Per Share, Diluted, TotalEarnings Per Share, DilutedLeasehold ImprovementLeasehold Improvements [Member]Entity Ex Transition PeriodEntity Ex Transition PeriodTotal liabilitiesLiabilitiesRestructuring and related cost, estimated to incurRestructuring and Related Cost, Expected CostRestructuring and Related Cost, Expected Cost, TotalFair Value Hierarchy and NAVFair Value Hierarchy and NAV [Domain]Total current assetsAssets, CurrentNet Cash Provided by (Used in) Investing ActivitiesNet cash provided by investing activitiesAgency Securities [Member]Agency SecuritiesCommitment And Contingencies [Table]Commitment And Contingencies [Table]Commitment and contingencies.ForecastForecast [Member]Number of shares issued and soldStock Issued During Period, Shares, New IssuesOperating lease existence of option to extendLessee, Operating Lease, Existence of Option to Extend [true false]Entity Filer CategoryEntity Filer CategoryProperty, Plant and Equipment [Abstract]Current Fiscal Year End DateCurrent Fiscal Year End DateFair value of options vestedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair ValuePresent value adjustment for minimum lease commitmentsLessee, Operating Lease, Liability, Undiscounted Excess AmountShare-based Payment Arrangement, Noncash Expense, TotalStock-based compensationShare-Based Payment Arrangement, Noncash ExpenseAggregate Intrinsic Value, Outstanding BalanceShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic ValueEntity Registrant NameEntity Registrant NameSchedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Net Loss Per Share Attributable to Common StockholdersEarnings Per Share [Text Block]Entity Emerging Growth CompanyEntity Emerging Growth CompanyMoney Market FundMoney Market Funds [Member]Weighted-average shares used in computing net loss per share attributable to common stockholders, basicWeighted average shares outstanding,basicWeighted Average Number of Shares Outstanding, Basic, TotalWeighted Average Number of Shares Outstanding, BasicLitigation CaseLitigation Case [Axis]Common stock, shares authorizedCommon Stock, Shares AuthorizedLaboratory and Office FacilitiesLaboratory And Office Facilities [Member]Laboratory and office facilities.Level 1Fair Value, Inputs, Level 1 [Member]Accounts payable and accrued liabilitiesIncrease (Decrease) in Accounts Payable and Accrued Liabilities, TotalIncrease (Decrease) in Accounts Payable and Accrued LiabilitiesWeighted-Average Exercise price per Share, Expected to vestShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise PriceWeighted-Average Exercise price per Share, GrantedShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise PriceExercise Price RangeExercise Price Range [Axis]Licensed ProductsLicensed Products [Member]Licensed Products.Financial Instrument [Axis]Weighted-Average Remaining Contractual Term (in years)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermNet Loss Per Share Attributable to Common StockholdersEarnings Per Share, Policy [Policy Text Block]General and Administrative ExpenseGeneral and AdministrativeGeneral and Administrative Expense [Member]Share-Based Payment Arrangement [Abstract]Basis Of Presentation And Significant Accounting Policies [Line Items]Basis Of Presentation And Significant Accounting Policies [Line Items]Basis of presentation and significant accounting policies.Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]Collaborative Arrangement and Arrangement Other than Collaborative [Table]Unaudited Interim Condensed Financial StatementsUnaudited Interim Condensed Financial Statements Policy [Text Block]Unaudited interim condensed financial statements.Accounting Policies [Abstract]Share-Based Payment Arrangement, Option, Activity [Table Text Block]Summary of Option Activity under the 2020 Plan and the 2024 Inducement PlanNet cash proceeds from issuance of convertible preferred stock, common stock warrants, and convertible notesProceeds From Issuance Of Convertible Preferred Stock And Common Stock WarrantsProceeds from issuance of convertible preferred stock and common stock warrants.Fair value of restricted stock units grantedShare-based Compensation Arrangement by Share-based Payment Award, Other Than Options Grant Date Fair ValueShare-based compensation arrangement by share-based payment award, other than options grant date fair valueStockholders' equity:Equity, Attributable to Parent [Abstract]Legal settlement expenseLegal expenseLitigation Settlement, Fee ExpenseSlyne V. Athira Pharma Inc.,Slyne V Athira Pharma Inc [Member]Slyne V. Athira Pharma Inc.Restricted CashCash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]Statement [Table]Statement [Table]SegmentsSegment Reporting, Policy [Policy Text Block]Schedule of Property and EquipmentProperty, Plant and Equipment [Table Text Block]Cash equivalents, Unrealized GainsCash And Cash Equivalents Accumulated Gross Unrealized Gain Before TaxCash and cash equivalents accumulated gross unrealized gain before tax.Weighted-Average Remaining Contractual Term, Expected to vest (in years)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual TermEntity File NumberEntity File NumberNet (decrease) increase in cash, cash equivalents and restricted cashCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectEarnings Per Share [Abstract]Cash EquivalentsCash Equivalents [Member]Statement of Financial Position [Abstract]Entity incorporation, date of IncorporationEntity Incorporation, Date of IncorporationLoss from operationsLoss from operationsOperating Income (Loss)Expected volatilityShare-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility RateEntity Shell CompanyEntity Shell CompanyStock Issued During Period, Value, Employee Stock Ownership PlanIssuance of common stock under employee stock purchase planEntity Tax Identification NumberEntity Tax Identification NumberAssetsAssets [Abstract]Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]Summary of Immaterial Error CorrectionEntity Current Reporting StatusEntity Current Reporting StatusWeighted-Average Remaining Contractual Term, Options exercisable (in years)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual TermExercise Price ($)Share Based Compensation Shares Authorized Under Stock Option Plans Exercise PriceShare based compensation shares authorized under stock option plans exercise price.Property and Equipment, NetProperty, Plant and Equipment Disclosure [Text Block]Non-vested Restricted Stock AwardsUnvested restricted stock awards.Unvested Restricted Stock Awards [Member]Unvested RSAsPreviously Reported [Member]As ReportedGeographicalGeographical [Domain]Document Fiscal Year FocusDocument Fiscal Year FocusUnbilled grant receivableUnbilled Grant Receivable CurrentUnbilled grant receivable current.Change in Accounting Principle, Accounting Standards Update, Adoption DateChange in accounting principle, accounting standards update, adoption dateShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, TotalShares, Forfeited/expiredOptions forfeited, cancelled, or expiredShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in PeriodCash equivalents, Unrealized LossesCash And Cash Equivalents Accumulated Gross Unrealized Loss Before TaxCash and cash equivalents accumulated gross unrealized loss before tax.Purchases of property and equipment included in accounts payable and accrued liabilitiesCapital Expenditures Incurred but Not yet PaidMilestone payments, amount payableMilestone Payments Amount Payable Upon Trial InitiationMilestone payments amount payable upon trial initiation.Cash, cash equivalents and restricted cashCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued OperationsCash, cash equivalents and restricted cash, beginning of periodCash, cash equivalents and restricted cash, end of periodLong-term Investments, TotalLong-term investmentsLong-Term InvestmentsCity Area CodeCity Area CodeTotal current liabilitiesLiabilities, CurrentWashington State University License AgreementWashington State University License Agreement [Member]Washington state university license agreement.Non-vested Restricted Stock UnitsNon Vested Restricted Stock Units [Member]Non-vested restricted stock units member.Organization, Consolidation and Presentation of Financial Statements [Abstract]Local Phone NumberLocal Phone NumberAntidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]Loss Contingency, Lawsuit Filing DateLawsuit filing dateSchedule Of Share Based Compensation Arrangement Shares Available For Grant Table [Text Block]Schedule of share based compensation arrangement shares

available for grant.Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement PlanCommitments and Contingencies Disclosure [Abstract]Fair Value By Balance Sheet Grouping [Table]Fair Value, by Balance Sheet Grouping [Table]Investments, Amortized CostDebt Securities, Available-for-Sale, Amortized CostCurrent operating lease liabilityOperating Lease, Liability, CurrentNet sales exempt from royalty paymentNet Sales Exempt From Royalty PaymentNet sales exempt from royalty payment.Operating lease expiration month and yearOperating Lease Expiration Month And YearOperating lease expiration month and year.Accumulated DeficitRetained Earnings [Member]Payments to Acquire Property, Plant, and Equipment, TotalPurchases of property and equipmentPayments to Acquire Property, Plant, and EquipmentSchedule of Other Income, NetSchedule of Other Nonoperating Income (Expense) [Table Text Block]Document Transition ReportDocument Transition Report2026Lessee, Operating Lease, Liability, to be Paid, Year TwoSchedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]Antidilutive Security, Excluded EPS Calculation [Table]Weighted-Average Exercise price per Share, ExercisedShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise PriceMinimumMinimum [Member]Minimum [Member]Common StockCommon Stock [Member]Shares Available for Future Grant under Employee Stock Purchase PlanShares Available For Future Grant Under Employee Stock Purchase Plan [Member]Shares available for future grant under the employee stock purchase plan.Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]Aggregate Intrinsic Value, Expected to vestShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic ValueLoss Contingency, Accrual, CurrentAccrued legal settlementWeighted-Average Grant Date Fair Value, Non-vested, Beginning BalanceWeighted-Average Grant Date Fair Value, Non-vested, Ending BalanceShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueNon-cash lease expenseOperating Lease, Right-of-Use Asset, Periodic ReductionAdditional Paid-In CapitalAdditional Paid-in Capital [Member]Debt Securities, Available-for-sale, Current, TotalInvestments, Fair ValueDebt Securities, Available-for-Sale, Current2024 Inducement Equity Incentive PlanTwo Thousand And Twenty Four Inducement Equity Incentive Plan [Member]Two thousand and twenty four inducement equity incentive plan.Adjustments to reconcile net loss to net cash used in operating activities:Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Income Statement LocationStatement of Income Location, Balance [Domain]2025Lessee, Operating Lease, Liability, to be Paid, Year OneOther Assets, Noncurrent, TotalOther long-term assetsOther Assets, NoncurrentProceeds from Sale of Debt Securities, Available-for-SaleProceeds from sales of available-for-sale securitiesEntity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingSchedule of Reserved Shares of Common Stock for Future IssuanceSchedule Of Reserved Shares Of Common Stock For Future Issuance Table [Text Block]Schedule of reserved shares of common stock for future issuance.Basis of PresentationBasis of Accounting, Policy [Policy Text Block]Scenario [Domain]Common stock, $0.0001 par value; 900,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 38,669,073 and 38,172,603 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectivelyCommon Stock, Value, Issued, Ending BalanceCommon Stock, Value, Issued, Beginning BalanceCommon Stock, Value, Issued, TotalCommon Stock, Value, IssuedCollaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]Cash equivalents, Fair ValueCash and Cash Equivalents, Fair Value DisclosureSchedule of Fair Value of Cash Equivalents and Short-term InvestmentsFair Value, Assets Measured on Recurring Basis [Table Text Block]Net lease liabilityOperating Lease, Liability, TotalOperating lease liabilitiesOperating Lease, LiabilityShare based compensation maximum annual increase in number of shares that may be issued under the planShare Based Compensation Maximum Annual Increase In Number Of Shares That May Be Issued Under PlanShare based compensation maximum annual increase in number of shares that may be issued under the plan.Measurement FrequencyMeasurement Frequency [Axis]Schedule of Accrued LiabilitiesSchedule of Accrued Liabilities [Table Text Block]Weighted-average shares used in computing net loss per share attributable to common stockholders, dilutedWeighted average shares outstanding, dilutedWeighted Average Number of Shares Outstanding, Diluted, TotalWeighted Average Number of Shares Outstanding, DilutedSignificant Accounting PoliciesSignificant Accounting Policies [Text Block]Research and Development Arrangement, Contract to Perform for Others, TypeResearch and Development Arrangement, Contract to Perform for Others, Type [Axis]Operating lease, additional term of contractLessee, Operating Lease, Renewal TermShares, Expected to vestShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, NumberTotal undiscounted lease paymentsLessee, Operating Lease, Liability, to be PaidEntity Small BusinessEntity Small BusinessAt The Market Offering.At The Market Offering [Member]At The Market Common Stock OfferingSalesRevenuesRevenues, TotalProceeds from follow-on public offering, net of underwriters' discounts and commissions and issuance costs, SharesIssuance of Common Stock Shares During Period Follow-on Public Offering Net of Underwriters Discounts and CommissionsIssuance of common stock shares during period follow-on public offering, net of underwriters' discounts and commissions.Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase planProceeds from Exercise of Common Stock Options and Issuance of Common Stock Under Employee Stock Purchase PlanProceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan.Short-term InvestmentsShort-term Investments, Policy [Policy Text Block]Short-term investments.Other Income, NetOther Nonoperating Income and Expense [Text Block]Amortization of premiums and accretion of discounts on available-for-sale securities, netAccretion (Amortization) of Discounts and Premiums, InvestmentsCommitments And Contingencies [Line Items]Commitments And Contingencies [Line Items]Commitments and contingencies line items.Financing activitiesNet Cash Provided by (Used in) Financing Activities [Abstract]Weighted-Average Exercise price per Share, Beginning BalanceWeighted-Average Exercise price per Share, Ending BalanceShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise PriceAccrued LiabilitiesAccounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]Loss Contingency, Name of DefendantName of defendantAsset ClassAsset Class [Axis]Right-of-use asset obtained in exchange for new operating lease liabilityRight-of-Use Asset Obtained in Exchange for Operating Lease LiabilityMeasurement FrequencyMeasurement Frequency [Domain]Schedule of Cash, Cash Equivalents and Restricted CashSchedule Of Cash, Cash Equivalents and Restricted Cash [Table Text Block]Schedule of cash, cash equivalents and restricted cash.Weighted average remaining lease term (years)Operating Lease, Weighted Average Remaining Lease TermExercise Price $0.16 to 4.22Exercise Price One [Member]Exercise price one.Accounts Payable, Current, TotalAccounts payableAccounts Payable, CurrentChange in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]Total operating expensesCosts and ExpensesShares Available for Future Grant under 2020 Equity Incentive PlanShares Available For Future Grant Under Two Thousand Twenty Equity Incentive Plan [Member]Shares available for future grant under the 2020 equity incentive plan.Jawandha V. Athira Pharma Inc.,Jawandha V Athira Pharma Inc [Member]Jawandha V. Athira Pharma Inc. XML 9 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	**9 Months Ended Sep. 30, 2024**	**Nov. 04, 2024**
Cover [Abstract]		
Document Type	10-Q	
Amendment Flag	false	
Document Period End Date	Sep. 30, 2024	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q3	
Entity Registrant Name	Athira Pharma, Inc.	
Entity Central Index Key	0001620463	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Current Fiscal Year End Date	--12-31	
Entity Filer Category	Non-accelerated Filer	
Entity Common Stock, Shares Outstanding		38,669,073
Entity Shell Company	false	
Entity Small Business	true	
Entity Emerging Growth Company	true	
Entity Ex Transition Period	false	
Entity File Number	001-39503	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	45-3368487	
Entity Address, Address Line One	18706 North Creek Parkway	
Entity Address, Address Line Two	Suite 104	
Entity Address, City or Town	Bothell	
Entity Address, State or Province	WA	
Entity Address, Postal Zip Code	98011	
City Area Code	425	
Local Phone Number	620-8501	
Document Quarterly Report	true	
Document Transition Report	false	
Security12b Title	Common Stock, $0.0001 par value per share	
Trading Symbol	ATHA	
Security Exchange Name	NASDAQ	

XML 10 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Current assets:		
Cash and cash equivalents	$ 68,856	$ 90,584
Restricted Cash, Current	8,373	
Short-term investments		56,835
Prepaid expenses and other current assets	3,145	5,682
Insurance recovery receivable related to legal settlement (Note 7)	1,628	1,628
Total current assets	82,002	154,729
Restricted cash, non-current	631	631
Property and equipment, net	2,687	3,388
Operating lease right-of-use asset	871	1,049
Other long-term assets	55	448
Total assets	86,246	160,245
Current liabilities:		
Accounts payable	388	129
Accrued liabilities	16,961	18,343
Accrued legal settlement	10,000	10,000
Current operating lease liability	402	368
Total current liabilities	27,751	28,840
Operating lease liability, less current portion	912	1,217

Total liabilities	28,663	30,057
Stockholders' equity:		
Common stock, $0.0001 par value; 900,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 38,669,073 and 38,172,603 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	448,719	439,739
Accumulated other comprehensive income (loss)	3	(349)
Accumulated deficit	(391,143)	(309,206)
Total stockholders' equity	57,583	130,188
Total liabilities and stockholders' equity	$ 86,246	$ 160,245

XML 11 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	38,669,073	38,172,603
Common stock, shares outstanding	38,669,073	38,172,603

XML 12 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:				
Research and development	$ 17,922	$ 27,202	$ 61,312	$ 70,110
General and administrative	7,572	7,840	19,897	26,342
Legal expense	4,127		4,127	
Total operating expenses	29,621	35,042	85,336	96,452
Loss from operations	(29,621)	(35,042)	(85,336)	(96,452)
Grant income				157
Other income, net	880	2,072	3,399	5,908
Net loss	(28,741)	(32,970)	(81,937)	(90,387)
Unrealized gain on available-for-sale securities	41	261	352	1,278
Comprehensive loss attributable to common stockholders	$ (28,700)	$ (32,709)	$ (81,585)	$ (89,109)
Net loss per share attributable to common stockholders, basic	$ (0.75)	$ (0.87)	$ (2.13)	$ (2.38)
Net loss per share attributable to common stockholders, diluted	$ (0.75)	$ (0.87)	$ (2.13)	$ (2.38)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	38,517,602	38,054,583	38,406,709	37,993,002
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	38,517,602	38,054,583	38,406,709	37,993,002

XML 13 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2022	$ 235,137	$ 4	$ 428,623	$ (1,956)	$ (191,534)
Beginning balance, shares at Dec. 31, 2022		37,877,387			
Issuance of common stock upon exercise of common stock options	99		99		
Issuance of common stock upon exercise of common stock options, shares		73,213			
Stock-based compensation	2,782		2,782		
Unrealized gain on available-for-sale securities	927			927	
Net loss	(27,820)				(27,820)
Ending balance at Mar. 31, 2023	211,125	$ 4	431,504	(1,029)	(219,354)
Ending balance, shares at Mar. 31, 2023		37,950,600			
Beginning balance at Dec. 31, 2022	235,137	$ 4	428,623	(1,956)	(191,534)
Beginning balance, shares at Dec. 31, 2022		37,877,387			
Unrealized gain on available-for-sale securities	1,278				
Net loss	(90,387)				
Ending balance at Sep. 30, 2023	154,764	$ 4	437,359	(678)	(281,921)
Ending balance, shares at Sep. 30, 2023		38,054,583			
Beginning balance at Mar. 31, 2023	211,125	$ 4	431,504	(1,029)	(219,354)
Beginning balance, shares at Mar. 31, 2023		37,950,600			
Issuance of common stock upon exercise of common stock options	11		11		
Issuance of common stock upon exercise of common stock options, shares		7,882			
Issuance of common stock under employee stock purchase plan	231		231		
Issuance of common stock under employee stock purchase plan, shares		96,101			
Stock-based compensation	3,119		3,119		
Unrealized gain on available-for-sale securities	90			90	
Net loss	(29,597)				(29,597)
Ending balance at Jun. 30, 2023	184,979	$ 4	434,865	(939)	(248,951)
Ending balance, shares at Jun. 30, 2023		38,054,583			
Stock-based compensation	2,494		2,494		
Unrealized gain on available-for-sale securities	261			261	
Net loss	(32,970)				(32,970)
Ending balance at Sep. 30, 2023	154,764	$ 4	437,359	(678)	(281,921)
Ending balance, shares at Sep. 30, 2023		38,054,583			
Beginning balance at Dec. 31, 2023	130,188	$ 4	439,739	(349)	(309,206)
Beginning balance, shares at Dec. 31, 2023		38,172,603			
Issuance of common stock upon vesting of restricted stock units, shares		154,049			
Stock-based compensation	2,679		2,679		
Unrealized gain on available-for-sale securities	212			212	
Net loss	(26,337)				(26,337)
Ending balance at Mar. 31, 2024	106,742	$ 4	442,418	(137)	(335,543)
Ending balance, shares at Mar. 31, 2024		38,326,652			
Beginning balance at Dec. 31, 2023	$ 130,188	$ 4	439,739	(349)	(309,206)
Beginning balance, shares at Dec. 31, 2023		38,172,603			
Issuance of common stock upon exercise of common stock options, shares		75,660			
Unrealized gain on available-for-sale securities	$ 352				
Net loss	(81,937)				

Ending balance at Sep. 30, 2024	57,583	$ 4	448,719	3	(391,143)
Ending balance, shares at Sep. 30, 2024		38,669,073			
Beginning balance at Mar. 31, 2024	106,742	$ 4	442,418	(137)	(335,543)
Beginning balance, shares at Mar. 31, 2024		38,326,652			
Issuance of common stock upon vesting of restricted stock units, shares		2,000			
Issuance of common stock under employee stock purchase plan	148		148		
Issuance of common stock under employee stock purchase plan, shares		110,723			
Stock-based compensation	3,205		3,205		
Unrealized gain on available-for-sale securities	99			99	
Net loss	(26,859)				(26,859)
Ending balance at Jun. 30, 2024	83,335	$ 4	445,771	(38)	(362,402)
Ending balance, shares at Jun. 30, 2024		38,439,375			
Issuance of common stock upon exercise of common stock options	12		12		
Issuance of common stock upon exercise of common stock options, shares		75,660			
Issuance of common stock upon vesting of restricted stock units, shares		154,038			
Stock-based compensation	2,936		2,936		
Unrealized gain on available-for-sale securities	41			41	
Net loss	(28,741)				(28,741)
Ending balance at Sep. 30, 2024	$ 57,583	$ 4	$ 448,719	$ 3	$ (391,143)
Ending balance, shares at Sep. 30, 2024		38,669,073			

XML 14 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Operating activities		
Net loss	$ (81,937,000)	$ (90,387,000)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation	8,820,000	8,395,000
Depreciation expense	727,000	724,000
Non-cash lease expense	178,000	158,000
Amortization of premiums and accretion of discounts on available-for-sale securities, net	(488,000)	(1,131,000)
Loss on disposal of equipment	7,000	
Changes in operating assets and liabilities:		
Unbilled grant receivable		1,227,000
Prepaid expenses and other current and long-term assets, net	2,930,000	(366,000)
Accounts payable and accrued liabilities	(1,123,000)	7,159,000
Operating lease liability	(271,000)	(239,000)
Net cash used in operating activities	(71,157,000)	(74,460,000)
Investing activities		
Purchases of available-for-sale securities	(11,322,000)	(27,671,000)
Maturities of available-for-sale securities	68,997,000	116,673,000
Purchases of property and equipment	(33,000)	(304,000)
Net cash provided by investing activities	57,642,000	88,698,000
Financing activities		
Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan	160,000	341,000
Net cash provided by financing activities	160,000	341,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(13,355,000)	14,579,000
Cash, cash equivalents and restricted cash, beginning of period	91,215,000	96,386,000
Cash, cash equivalents and restricted cash, end of period	$ 77,860,000	$ 110,965,000

XML 15 R7.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure								
Net Income (Loss)	$ (28,741)	$ (26,859)	$ (26,337)	$ (32,970)	$ (29,597)	$ (27,820)	$ (81,937)	$ (90,387)

XML 16 R8.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 17 R9.htm IDEA: XBRL DOCUMENT

Description of Business	9 Months Ended Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Description of Business	

1. Description of Business

Organization

Athira Pharma, Inc., or the Company, was incorporated as M3 Biotechnology, Inc. in the state of Washington on March 31, 2011 and reincorporated in the state of Delaware on October 27, 2015. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Bothell, Washington. The Company is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.

Liquidity and Capital Resources

Since the Company's inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company's inception through September 30, 2024, it has raised aggregate net cash proceeds of $407.4 million primarily from the issuance of its common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes.

As of September 30, 2024, the Company had cash, cash equivalents and investments of $68.9 million. The Company's net loss for the nine months ended September 30, 2024 was $81.9 million and cash used in operations for the nine months ended September 30, 2024 was $71.2 million. Since the Company's inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company's intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.

Based upon the Company's current operating plan, it estimates that its $68.9 million of cash, cash equivalents and investments at September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date of this report. Historically, the Company has incurred net losses from continuing operations and negative operating cash flows. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs; therefore, the Company will need to continue to raise additional capital to accomplish its operating plan. The Company has a sales agreement in place with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and BTIG, LLC, or BTIG, for an "at the market" equity offering facility through which it may offer and sell shares of its common stock equaling an aggregate amount up to $75.0 million. The Company has not sold any securities pursuant to this ATM offering. Should it be determined to be strategically advantageous, the Company could pursue public and private offerings of its equity securities similar to those the Company has previously completed, debt financings, or other strategic transactions, which could include income from collaboration, licensing or similar arrangements with third parties, or receiving research contributions, or grants.

XML 18 R10.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies	9 Months Ended Sep. 30, 2024

Accounting Policies [Abstract]
Significant Accounting Policies

2. Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP. The unaudited condensed consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying condensed consolidated balance sheet as of September 30, 2024, and condensed consolidated statements of operations and comprehensive loss, cash flows, and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, are unaudited. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of September 30, 2024, and the unaudited condensed consolidated results of its operations and its cash flows for the three

and nine months ended September 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year ending December 31, 2024 or any other period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 22, 2024.

Fair Value Measurements

The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts.

Restricted Cash

Restricted cash consists of $8.4 million paid into a settlement fund account pending resolution of the securities class action settlement discussed in Note 7, as well as collateral pledged in connection with the Company's corporate credit cards. The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows.

	September 30, 2024	December 31, 2023
Cash and cash equivalents	$ 68,856	$ 90,584
Restricted cash, current	8,373	—
Restricted cash, non-current	631	631
Cash, cash equivalents and restricted cash	$ 77,860	$ 91,215

Short-term Investments

The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, and short-term investments on the unaudited condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net.

The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.

Research and Development Expenses

Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company's drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company's research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.

Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred.

Leases

The Company adopted Accounting Standards Codification, or ASC, *Topic 842 – Leases* effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use, or ROU, assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company's use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company's leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company's incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.

The Company's leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company's lease agreements do not contain residual value guarantees or covenants.

The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company's leases include variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.

Lease expense is recognized within operating expenses on a straight-line basis over the terms of the leases. Incentives granted under the Company's facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.

Stock-based Compensation

The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company's common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.

The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.

Net Loss Per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.

Segments

The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company's chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.

Corporate Restructuring

On September 15, 2024, the Company committed to a workforce reduction that is expected to result in the termination of approximately 70% of the Company's workforce, or the Restructuring. In connection with the Restructuring, the Company currently estimates it will incur costs of approximately $2.8 million, consisting primarily of cash severance costs and termination benefits, which the Company expects to recognize in the third and fourth quarters of 2024. The Company expects to substantially complete the Restructuring by December 31, 2024.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting

new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures.

XML 19 R11.htm IDEA: XBRL DOCUMENT

Fair Value

9 Months Ended
Sep. 30, 2024

Fair Value Disclosures [Abstract]
Fair Value

3. Fair Value

The Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are:

Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2—Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3—Inputs are generally unobservable and reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies.

The determination of a financial instrument's level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

The following tables reflect the Company's financial asset balances measured at fair value on a recurring basis (in thousands):

		September 30, 2024			
	Level	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:					
Money market fund	1	$ 33	$ —	$ —	$ 33
U.S. government debt and agency securities	2	18,120	5	—	18,125
Commercial paper	2	23,983	1	(3)	23,981
Total cash equivalents		$ 42,136	$ 6	$ (3)	$ 42,139

		December 31, 2023			
	Level	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:					
Money market fund	1	$ 63	$ —	$ —	$ 63
Commercial paper	2	59,227	—	(30)	59,197
Total cash equivalents		$ 59,290	$ —	$ (30)	$ 59,260
Short-term investments:					
Commercial paper	2	6,431	—	(4)	6,427
U.S. government debt and agency securities	2	50,723	—	(315)	50,408
Total short-term investments		$ 57,154	$ —	$ (319)	$ 56,835

All the commercial paper, U.S. government debt and agency securities, U.S. treasury bills, and corporate bonds designated as short-term investments have an effective maturity date that is equal to or less than one year from the respective balance sheet date.

As of September 30, 2024, the Company does not intend to sell any securities in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell such securities prior to the recovery of the amortized cost basis. Based on the Company's assessment, the Company concluded all impairments as of September 30, 2024 to be due to factors other than credit loss, such as changes in interest rates. A credit loss allowance was not recognized and the unrealized losses for available-for-sale securities were recorded in other comprehensive loss.

XML 20 R12.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net

9 Months Ended
Sep. 30, 2024

Property, Plant and Equipment [Abstract]
Property and Equipment, Net

4. Property and Equipment, Net

Property and equipment consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Lab equipment	$ 705	$ 688
Office furniture, fixtures, and computer equipment	712	712
Leasehold improvement	4,322	4,322
Property and equipment, at cost	5,739	5,722
Less: accumulated depreciation	(3,052)	(2,334)
Property and equipment, net	$ 2,687	$ 3,388

Depreciation expense was $243,000 and $727,000 for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $244,000 and $724,000 for the three and nine months ended September 30, 2023, respectively.

XML 21 R13.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

9 Months Ended
Sep. 30, 2024

Payables and Accruals [Abstract]
Accrued Liabilities

5. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Research and development	$ 7,644	$ 11,916
Employee compensation and benefits	4,440	4,545
Legal expense	4,127	—
Professional services and other	750	1,882
Total accrued liabilities	$ 16,961	$ 18,343

XML 22 R14.htm IDEA: XBRL DOCUMENT

Significant Agreements

9 Months Ended
Sep. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]
Significant Agreements

6. Significant Agreements

WSU License Agreement

The Company is party to an amended and restated exclusive license agreement with sublicensing terms with WSU that the Company entered into in 2015. Under this agreement, the Company has an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration. ATH-1105, the Company's small molecule drug candidate currently in development for the potential treatment of ALS, is not covered by the WSU license agreement.

To keep in good standing, the agreement requires the Company to meet certain development milestones and pay annual maintenance fees. All contractual requirements have been met as of September 30, 2024.

During the year ended December 31, 2020, the Phase 2 clinical trial milestone was reached and a payment of $50,000 to WSU was recorded.

The Company may also be obligated to pay the following if the related milestones are reached:

- $300,000 – At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product; and
- $600,000 – Upon receipt of marketing approval in the United States, European Union or Japan for the first licensed product.

Under the terms of the agreement, the Company will pay a royalty in the mid-single digits of net sales, with the first $100,000 of net sales being exempt from royalty payment, and annual minimum royalty payments of $25,000 beginning after the first commercial sale of a licensed product. As of September 30, 2024, no sales of any licensed products had occurred and the Company had not incurred a royalty obligation under this agreement.

Additionally, the agreement allows the Company to sublicense the rights conveyed by the agreement, subject to additional payments to WSU based upon the sublicense consideration received in such event. Such amounts are dependent on the terms of the underlying sublicense and range from the mid-single digits to mid-teens of any non-sales based

payments received, and low twenties of net sales based sublicense royalties. As of September 30, 2024, the Company has not entered into or incurred any liability from a sublicense agreement.

XML 23 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]	
Commitments and Contingencies	

7. Commitments and Contingencies

Legal Proceedings

From time to time, the Company is subject to various legal proceedings or claims that arise in the ordinary course of business. The Company accrues a liability when the Company's management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. The following is a brief description of the more significant legal proceedings.

Securities Class Actions

On June 25, 2021, plaintiffs Fan Wang and Hang Gao filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company and the Company's former chief executive officer Dr. Leen Kawas, captioned *Wang v. Athira Pharma, Inc., et al.*, No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, or Exchange Act, and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding the Company's business. Specifically, the *Wang* plaintiffs allege that the Company failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU, including the manipulation of data, and that as a result, the defendants' positive statements about the Company's business, operations, and prospects were materially misleading. The *Wang* plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys' fees.

That same day, on June 25, 2021, plaintiff Harshdeep Jawandha filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company's then chief financial officer, certain members of the Company's board of directors at the time of the Company's initial public offering, or IPO, as well as the IPO underwriters, captioned *Jawandha v. Athira Pharma, Inc., et al.*, No. 2:21-cv-00862. The *Jawandha* complaint asserts violations of Sections 11 and 15 of the Securities Act of 1933, or Securities Act, alleging that that the Company's IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawas's published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to the Company's efforts to develop treatments for Alzheimer's disease, and that the defendants' positive statements about the Company's business, operations, and prospects were materially misleading. The *Jawandha* plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneys' fees.

Also on June 25, 2021, plaintiffs Timothy Slyne and Tai Slyne filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company's then chief financial officer, and the same members of the Company's board of directors and underwriters as in the *Jawandha* complaint, captioned *Slyne v. Athira Pharma, Inc. et al.*, No. 2:21-cv-00864. The *Slyne* complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawas's doctoral research at WSU should have been disclosed in the Company's IPO registration statement. The *Slyne* plaintiffs seek unspecified compensatory damages, reasonable costs and expenses, including attorneys' fees, and injunctive and other equitable relief.

On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel.

On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against the Company, Dr. Kawas, the Company's then chief financial officer, certain members of the Company's board of directors at the time of the Company's IPO and secondary public offering, or SPO, and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawas's published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffs' consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed

the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint.

On August 12, 2022, defendant Dr. Kawas filed a motion for partial reconsideration of the court's July 29, 2022 order. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, the Company and Dr. Kawas filed their individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery.

On March 10, 2023, following a mediation and the parties' agreement in principle to settle the securities class action, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffs' motion for preliminary approval without prejudice, citing the motion's failure to satisfy the court's questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023.

On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffs' renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024. In its order, the court preliminarily approved the proposed settlement and certified a class with two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement. On March 29, 2024, the court issued a minute order (i) granting the portion of plaintiffs' renewed motion for preliminary approval that the court had previously deferred ruling on, (ii) setting a final approval hearing, and (iii) ordering plaintiffs' motion for final approval of the proposed settlement to be filed on or before September 26, 2024. On September 26, 2024, plaintiffs filed a motion for final approval of class action settlement and plan of allocation. On September 30, 2024, the court issued a minute order requiring additional information related to the claims administration process, to which plaintiffs responded. On October 25, 2024, the court held a settlement final approval hearing and ruled that the terms of the settlement are fair, reasonable and adequate and that notice was reasonable. On November 1, 2024, the court entered a final written judgment and order granting final approval of the settlement and closed the case.

As a result of the foregoing, the Company recorded a legal settlement expense of $10.0 million in operating expenses in the fourth quarter of 2022 and an accrued liability of $10.0 million on the accompanying condensed consolidated balance sheets. Additionally, the Company recorded an insurance recovery of $1.6 million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $1.6 million on the accompanying condensed consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by the Company's insurers. The Company has deposited $8.4 million into a settlement fund account pending final payment of the settlement amount, and such funds are legally restricted for use and are included within restricted cash, current on the condensed consolidated balance sheets.

Shareholder Derivative Actions

On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of the Company's board of directors, captioned Bushansky v. Kawas et al., No. 2:22-cv-497. Plaintiff purported to bring the action derivatively on behalf of the Company, which was a nominal defendant to the action. The derivative complaint alleged that the Company's board of directors breached its fiduciary duties by failing to prevent alleged misstatements in the Company's public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint sought unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys' fees.

On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain current and former directors and officers of the Company, captioned Houlihan v. Kawas et al., No. 2:22-cv-620. Plaintiff purported to bring the action derivatively on behalf of the Company, which was a nominal defendant to the action. The derivative complaint alleged that certain of the Company's current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in the Company's public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint sought unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneys' fees.

On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. On March 18, 2024, following a mediation and the parties entering into a stipulation of settlement to settle the consolidated derivative action for certain corporate governance reforms and the Company's payment of a fee and expense award to plaintiffs' counsel, plaintiffs filed an unopposed motion for preliminary approval of a settlement of the derivative action. On May 3, 2024, the court entered an order preliminarily approving the settlement. On May 17, 2024, plaintiffs filed an unopposed motion for approval of attorneys' fees and expenses and service awards to plaintiffs. On July 3, 2024, plaintiffs filed an unopposed motion for final approval of derivative settlement. The settlement final approval hearing took place on July 18, 2024, and no Company shareholders objected to the proposed settlement or attorneys' fees or service awards sought by plaintiffs. After the hearing, on July 18, 2024, the court entered an order and judgment granting plaintiffs' motion for final approval of derivative settlement, finding the settlement to be fair, reasonable, and adequate to the settling parties and the Company's shareholders, and dismissing the derivative action with prejudice.

The Company paid the fee and expense award related to this shareholder derivative action settlement during the third quarter of 2024.

Government Investigation

In November 2022, the Company received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand sought documents and information relating

to the Company's relationship with WSU, certain of its grant applications in 2016 and 2019 with the NIH, and the Company's receipt of an NIH grant in 2020. The Company has been cooperating with the Department of Justice with respect to the Demand.

The Company recorded a legal expense of $4.1 million based on developments in the third quarter of 2024 and a corresponding accrued liability on the accompanying condensed consolidated balance sheets. Failure by the Company to obtain a favorable resolution could have a material adverse effect on its business, results of operations and financial condition.

Operating Leases

The Company has operating leases for laboratory and office facilities in Bothell, Washington that expire in August 2027. The initial terms of the leases range from 6.3 to 7 years and the Company has options to extend the leases for an additional five years that it is not reasonably certain to exercise. As of September 30, 2024, the Company was not party to any finance leases.

The following table reconciles the Company's undiscounted operating lease cash flows to its operating lease liability (in thousands):

	September 30, 2024
Remaining 2024	123
2025	494
2026	509
Thereafter	346
Total undiscounted lease payments	1,472
Present value adjustment for minimum lease commitments	(158)
Net lease liability	$ 1,314

The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:

	September 30, 2024
Weighted average remaining lease term (years)	3.2
Weighted average discount rate	8.1%

Operating lease expense and variable lease expense consisted of the following (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Operating lease expense	$ 89	$ 89	$ 265	$ 265
Variable lease expense	41	42	108	144

XML 24 R16.htm IDEA: XBRL DOCUMENT

Common Stock

9 Months Ended
Sep. 30, 2024

Equity [Abstract]
Common Stock

8. Common Stock

Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and if declared by the Company's board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception.

The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:

	September 30, 2024	December 31, 2023
Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted	10,785,447	7,130,956
Shares available for future grant under the 2020 Equity Incentive Plan	1,426,486	3,158,094
Shares available for future grant under the Employee Stock Purchase Plan	1,399,735	1,128,732
Shares available for future grant under the 2024 Inducement Equity Incentive Plan	350,000	—
Total	13,961,668	11,417,782

The Company's 2020 Equity Incentive Plan, or the 2020 Plan, provides for annual increases in the number of shares that may be issued under the 2020 Plan on January 1, 2021 and each subsequent January 1, thereafter, by a number of
shares equal to the least of (1) 3,230,000 shares, (2) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company's board of directors.

The Company's 2020 Employee Stock Purchase Plan, or the ESPP, provides for annual increases in the number of shares that may be issued under the ESPP on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) 646,000 shares, (2) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company's board of directors.

Effective January 1, 2024, the Company's 2020 Plan and ESPP reserves increased by 1,908,630 shares and 381,726 shares, respectively.

In February 2024, the board of directors adopted the Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan, or the 2024 Inducement Plan, and, subject to the adjustment provisions of the 2024 Inducement Plan, reserved 750,000 shares of the Company's common stock for issuance pursuant to equity awards granted under the 2024 Inducement Plan.

XML 25 R17.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

9 Months Ended
Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]
Stock-based Compensation

9. Stock-based Compensation

Stock-based compensation expense recognized was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Research and development	$ 1,124	$ 944	$ 3,263	$ 3,228
General and administrative	1,812	1,550	5,557	5,167
Total stock-based compensation expense	$ 2,936	$ 2,494	$ 8,820	$ 8,395

Valuation Assumptions

The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally required significant judgment.

- *Fair Value of Common Stock*—The fair value of each share of common stock is based on the closing price of the Company's common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.
- *Risk-Free Interest Rate*—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.
- *Expected Volatility*—Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.
- *Expected Term*—The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity.
- *Expected Dividend Yield*—The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of zero.

The fair value of each stock option was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

	Nine Months Ended September 30,	
	2024	2023
Risk-free interest rate	4.26%	3.54%
Expected volatility	96.93%	99.18%
Expected term (in years)	6.00	5.48
Expected dividend yield	—	—

The grant date fair value of restricted stock units is based upon the fair market value of the Company's common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market.

The fair value of options granted during the nine months ended September 30, 2024 and 2023 was $10.2 million and $9.8 million, respectively. The fair value of restricted stock units granted during the nine months ended September 30, 2024 and 2023 was less than $0.1 million and $0.4 million, respectively.

Stock Option Activity

Changes in shares available for grant under the 2020 Plan and the 2024 Inducement Plan during the nine months ended September 30, 2024 were as follows:

	Shares Available for Grant
Shares available for grant at December 31, 2023	3,158,094
2020 Plan reserve increase on January 1, 2024	1,908,630
Shares reserved upon adoption of the 2024 Inducement Plan	750,000
Options and restricted stock units granted	(4,090,804)
Options and restricted stock units forfeited, cancelled, or expired	50,566
Shares available for grant at September 30, 2024	1,776,486

A summary of stock option activity under the 2020 Plan and the 2024 Inducement Plan for the nine months ended September 30, 2024 was as follows:

	Shares	Weighted-Average Exercise price per Share	Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2023	6,820,869	$ 7.97	8.24	$ 387
Granted	4,088,804	3.16		
Exercised	(75,660)	0.16		
Forfeited/expired	(50,566)	11.48		
Balance at September 30, 2024	10,783,447	$ 6.18	8.27	$ —
Expected to vest	5,905,187	$ 4.27	8.86	$ —
Options exercisable	4,878,260	$ 8.49	7.56	$ —

The total fair value of options granted that vested during the nine months ended September 30, 2024 and 2023 was $9.2 million and $8.3 million, respectively.

The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company's common stock underlying all options that were in-the-money at September 30, 2024. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2024 and 2023 was $0.2 million and $0.2 million, respectively, determined as of the date of option exercise. As of September 30, 2024, there was $17.7 million of total unrecognized compensation cost related to non-vested stock options. The Company expects to recognize this cost over a remaining weighted-average period of 2.2 years. The Company utilizes newly issued shares to satisfy option exercises.

Stock options outstanding and exercisable under the 2020 Plan and the 2024 Inducement Plan consisted of the following at September 30, 2024:

Exercise Price ($)	Shares Outstanding	Shares Exercisable
0.16 to 4.22	7,703,393	2,515,358
8.93 to 19.94	2,727,806	2,084,154
20.55 to 29.41	352,248	278,748
Total	10,783,447	4,878,260

Restricted Stock Unit Activity

A summary of restricted stock unit, or RSU, activity for the nine months ended September 30, 2024 is as follows:

	Share Equivalent	Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2023	310,087	$ 11.44
Granted	2,000	2.51
Cancelled	—	—
Vested	(310,087)	11.44
Non-vested at September 30, 2024	2,000	$ 2.51

XML 26 R18.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders

9 Months Ended

Sep. 30, 2024

10. Net Loss Per Share Attributable to Common Stockholders

The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:

	Nine Months Ended September 30,	
	2024	2023
Stock options to purchase common stock	10,783,447	7,019,311
Non-vested Restricted Stock Units	2,000	313,337
Employee stock purchase plan	8,709	11,373
Total	10,794,156	7,344,021

XML 27 R19.htm IDEA: XBRL DOCUMENT

Corporate Restructuring

Restructuring and Related Activities [Abstract]

Corporate Restructuring

9 Months Ended

Sep. 30, 2024

11. Corporate Restructuring

The Company currently estimates that it will incur costs of approximately $2.8 million for termination benefits relating to the Restructuring, substantially all of which the Company expects to recognize in the third and fourth quarters of 2024 and pay out in cash during the fourth quarter of 2024 and first quarter of 2025.

The Company expensed the following costs associated with the termination benefit payments resulting from the Restructuring (in thousands):

	Nine Months Ended September 30, 2024
Research and development expense	1,007
General and administrative expense	1,309
Total severance expense	2,316

As of September 30, 2024, the accrued liability balance associated with the Restructuring is $2.3 million and is included in the accrued expenses line of the accompanying unaudited condensed consolidated balance sheet.

XML 28 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

Accounting Policies [Abstract]

Basis of Presentation

9 Months Ended

Sep. 30, 2024

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP. The unaudited condensed consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation.

Unaudited Interim Condensed Financial Statements

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying condensed consolidated balance sheet as of September 30, 2024, and condensed consolidated statements of operations and comprehensive loss, cash flows, and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, are unaudited. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of September 30, 2024, and the unaudited condensed consolidated results of its operations and its cash flows for the three

and nine months ended September 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year ending December 31, 2024 or any other period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 22, 2024.

Fair Value Measurements

Fair Value Measurements

The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts.

Restricted Cash

Restricted Cash

Restricted cash consists of $8.4 million paid into a settlement fund account pending resolution of the securities class action settlement discussed in Note 7, as well as collateral pledged in connection with the Company's corporate credit cards. The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows.

	September 30, 2024	December 31, 2023
Cash and cash equivalents	$ 68,856	$ 90,584
Restricted cash, current	8,373	—
Restricted cash, non-current	631	631
Cash, cash equivalents and restricted cash	$ 77,860	$ 91,215

Short-term Investments

Short-term Investments

The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, and short-term investments on the unaudited condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net.

The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.

Research and Development Expenses

Research and Development Expenses

Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company's drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company's research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables.

Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.

General and Administrative Expenses

General and Administrative Expenses

General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred.

Leases

Leases

The Company adopted Accounting Standards Codification, or ASC, *Topic 842 – Leases* effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use, or ROU, assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company's use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company's leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company's incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date.

The Company's leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company's lease agreements do not contain residual value guarantees or covenants.

The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company's leases include variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term.

Lease expense is recognized within operating expenses on a straight-line basis over the terms of the leases. Incentives granted under the Company's facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease.

Stock-based Compensation

Stock-based Compensation

The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company's common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur.

The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.

Net Loss Per Share Attributable to Common Stockholders

Net Loss Per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company.

Segments

Segments

The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company's chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.

Corporate Restructuring

Corporate Restructuring

On September 15, 2024, the Company committed to a workforce reduction that is expected to result in the termination of approximately 70% of the Company's workforce, or the Restructuring. In connection with the Restructuring, the Company currently estimates it will incur costs of approximately $2.8 million, consisting primarily of cash severance costs and termination benefits, which the Company expects to recognize in the third and fourth quarters of 2024. The Company expects to substantially complete the Restructuring by December 31, 2024.

Emerging Growth Company Status

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable

Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures.

XML 29 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables) — **9 Months Ended Sep. 30, 2024**

Accounting Policies [Abstract]

Schedule of Cash, Cash Equivalents and Restricted Cash

The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows.

	September 30, 2024	December 31, 2023
Cash and cash equivalents	$ 68,856	$ 90,584
Restricted cash, current	8,373	—
Restricted cash, non-current	631	631
Cash, cash equivalents and restricted cash	$ 77,860	$ 91,215

XML 30 R22.htm IDEA: XBRL DOCUMENT

Fair Value (Tables) — **9 Months Ended Sep. 30, 2024**

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Cash Equivalents and Short-term Investments

The following tables reflect the Company's financial asset balances measured at fair value on a recurring basis (in thousands):

		September 30, 2024			
	Level	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:					
Money market fund	1	$ 33	$ —	$ —	$ 33
U.S. government debt and agency securities	2	18,120	5	—	18,125
Commercial paper	2	23,983	1	(3)	23,981
Total cash equivalents		$ 42,136	$ 6	$ (3)	$ 42,139

		December 31, 2023			
	Level	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Cash equivalents:					
Money market fund	1	$ 63	$ —	$ —	$ 63
Commercial paper	2	59,227	—	(30)	59,197
Total cash equivalents		$ 59,290	$ —	$ (30)	$ 59,260
Short-term investments:					
Commercial paper	2	6,431	—	(4)	6,427
U.S. government debt and agency securities	2	50,723	—	(315)	50,408
Total short-term investments		$ 57,154	$ —	$ (319)	$ 56,835

XML 31 R23.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net (Tables) — **9 Months Ended Sep. 30, 2024**

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Lab equipment	$ 705	$ 688
Office furniture, fixtures, and computer equipment	712	712
Leasehold improvement	4,322	4,322
Property and equipment, at cost	5,739	5,722
Less: accumulated depreciation	(3,052)	(2,334)
Property and equipment, net	$ 2,687	$ 3,388

XML 32 R24.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables) — **9 Months Ended Sep. 30, 2024**

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Research and development	$ 7,644	$ 11,916
Employee compensation and benefits	4,440	4,545
Legal expense	4,127	—
Professional services and other	750	1,882
Total accrued liabilities	$ 16,961	$ 18,343

XML 33 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables) — **9 Months Ended Sep. 30, 2024**

Commitments and Contingencies Disclosure [Abstract]

Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments

The following table reconciles the Company's undiscounted operating lease cash flows to its operating lease liability (in thousands):

	September 30, 2024
Remaining 2024	123
2025	494
2026	509
Thereafter	346
Total undiscounted lease payments	1,472
Present value adjustment for minimum lease commitments	(158)
Net lease liability	$ 1,314

Weighted Average Remaining Lease Term and Weighted Average Discount Rate and Operating Lease Expense and Variable Lease Expense

The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:

	September 30, 2024
Weighted average remaining lease term (years)	3.2
Weighted average discount rate	8.1%

Operating lease expense and variable lease expense consisted of the following (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Operating lease expense	$ 89	$ 89	$ 265	$ 265
Variable lease expense	41	42	108	144

XML 34 R26.htm IDEA: XBRL DOCUMENT

Common Stock (Tables)

9 Months Ended
Sep. 30, 2024

Equity [Abstract]

Schedule of Reserved Shares of Common Stock for Future Issuance

The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows:

	September 30, 2024	December 31, 2023
Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted	10,785,447	7,130,956
Shares available for future grant under the 2020 Equity Incentive Plan	1,426,486	3,158,094
Shares available for future grant under the Employee Stock Purchase Plan	1,399,735	1,128,732
Shares available for future grant under the 2024 Inducement Equity Incentive Plan	350,000	—
Total	13,961,668	11,417,782

XML 35 R27.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

9 Months Ended
Sep. 30, 2024

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock-based Compensation Expense Recognized

Stock-based compensation expense recognized was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Research and development	$ 1,124	$ 944	$ 3,263	$ 3,228
General and administrative	1,812	1,550	5,557	5,167
Total stock-based compensation expense	$ 2,936	$ 2,494	$ 8,820	$ 8,395

Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model

The fair value of each stock option was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

	Nine Months Ended September 30,	
	2024	2023
Risk-free interest rate	4.26%	3.54%
Expected volatility	96.93%	99.18%
Expected term (in years)	6.00	5.48
Expected dividend yield	—	—

Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan

Changes in shares available for grant under the 2020 Plan and the 2024 Inducement Plan during the nine months ended September 30, 2024 were as follows:

	Shares Available for Grant
Shares available for grant at December 31, 2023	3,158,094
2020 Plan reserve increase on January 1, 2024	1,908,630
Shares reserved upon adoption of the 2024 Inducement Plan	750,000
Options and restricted stock units granted	(4,090,804)
Options and restricted stock units forfeited, cancelled, or expired	50,566
Shares available for grant at September 30, 2024	1,776,486

Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan

A summary of stock option activity under the 2020 Plan and the 2024 Inducement Plan for the nine months ended September 30, 2024 was as follows:

	Shares	Weighted-Average Exercise price per Share	Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2023	6,820,869	$ 7.97	8.24	$ 387
Granted	4,088,804	3.16		
Exercised	(75,660)	0.16		
Forfeited/expired	(50,566)	11.48		
Balance at September 30, 2024	10,783,447	$ 6.18	8.27	$ —
Expected to vest	5,905,187	$ 4.27	8.86	$ —
Options exercisable	4,878,260	$ 8.49	7.56	$ —

Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement Plan

Stock options outstanding and exercisable under the 2020 Plan and the 2024 Inducement Plan consisted of the following at September 30, 2024:

Exercise Price ($)	Shares Outstanding	Shares Exercisable
0.16 to 4.22	7,703,393	2,515,358
8.93 to 19.94	2,727,806	2,084,154
20.55 to 29.41	352,248	278,748
Total	10,783,447	4,878,260

Restricted Stock Units (RSUs)

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Summary of Restricted Stock Activity

A summary of restricted stock unit, or RSU, activity for the nine months ended September 30, 2024 is as follows:

	Share Equivalent	Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2023	310,087	$ 11.44
Granted	2,000	2.51
Cancelled	—	—
Vested	(310,087)	11.44
Non-vested at September 30, 2024	2,000	$ 2.51

XML 36 R28.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended
Sep. 30, 2024

Earnings Per Share [Abstract]

Summary of Dilutive Securities Excluded from Computation of

The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:

Diluted Net Loss Per Share Attributable to Common Stockholders

	Nine Months Ended September 30,	
	2024	2023
Stock options to purchase common stock	10,783,447	7,019,311
Non-vested Restricted Stock Units	2,000	313,337
Employee stock purchase plan	8,709	11,373
Total	10,794,156	7,344,021

XML 37 R29.htm IDEA: XBRL DOCUMENT

Corporate Restructuring (Tables)

9 Months Ended

Sep. 30, 2024

Restructuring and Related Activities [Abstract]

Summary of Cost Associated With Termination Benefit Payment of Restructuring

The Company expensed the following costs associated with the termination benefit payments resulting from the Restructuring (in thousands):

	Nine Months Ended
	September 30, 2024
Research and development expense	1,007
General and administrative expense	1,309
Total severance expense	2,316

XML 38 R30.htm IDEA: XBRL DOCUMENT

Description of Business - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended						9 Months Ended	
	Jan. 31, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Description Of Business [Line Items]									
Entity incorporation, date of Incorporation								Mar. 31, 2011	
Entity reincorporation, date of reincorporation								Oct. 27, 2015	
Net cash proceeds from issuance of convertible preferred stock, common stock warrants, and convertible notes								$ 407,400	
Cash, cash equivalents, and investments		$ 68,900						68,900	
Net loss		$ (28,741)	$ (26,859)	$ (26,337)	$ (32,970)	$ (29,597)	$ (27,820)	(81,937)	$ (90,387)
Cash used in operations								$ (71,200)	
At The Market Common Stock Offering									
Description Of Business [Line Items]									
Number of shares issued and sold	0								
At The Market Common Stock Offering | Maximum									
Description Of Business [Line Items]									
Aggregate offering price	$ 75,000								

XML 39 R31.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Additional Information (Details) $ in Millions	9 Months Ended		
	Sep. 15, 2024	Sep. 30, 2024 USD ($) Segment	Dec. 31, 2024 USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]			
Legal settlement amount		$ 8.4	
Number of operating segments | Segment		1	
Percentage of termination in workforce	70.00%		
Restructuring and related cost, estimated to incur		$ 2.8	
Forecast			
Basis Of Presentation And Significant Accounting Policies [Line Items]			
Restructuring and related cost, estimated to incur			$ 2.8

XML 40 R32.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]				
Cash and cash equivalents	$ 68,856	$ 90,584		
Restricted cash, current	8,373			
Restricted cash, non-current	631	631		
Cash, cash equivalents and restricted cash	$ 77,860	$ 91,215	$ 110,965	$ 96,386

XML 41 R33.htm IDEA: XBRL DOCUMENT

Fair Value - Schedule of Fair Value of Cash Equivalents and Short-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		
Cash equivalents, Amortized Cost	$ 68,856	$ 90,584
Recurring Basis | Short-term Investments		
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		
Investments, Amortized Cost		57,154
Investments, Unrealized Losses		(319)
Investments, Fair Value		56,835
Recurring Basis | Short-term Investments | Commercial Paper | Level 2		
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		
Investments, Amortized Cost		6,431
Investments, Unrealized Losses		(4)
Investments, Fair Value		6,427
Recurring Basis | Short-term Investments | U.S. Government Debt and Agency Securities | Level 2		
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		
Investments, Amortized Cost		50,723
Investments, Unrealized Losses		(315)
Investments, Fair Value		50,408
Recurring Basis | Cash Equivalents		
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		
Cash equivalents, Amortized Cost	42,136	59,290
Cash equivalents, Unrealized Gains	6	
Cash equivalents, Unrealized Losses	(3)	(30)
Cash equivalents, Fair Value	42,139	59,260
Recurring Basis | Cash Equivalents | Money Market Fund | Level 1		
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		

Cash equivalents, Amortized Cost	33	63
Cash equivalents, Fair Value	33	63
Recurring Basis | Cash Equivalents | Commercial Paper | Level 2		
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		
Cash equivalents, Amortized Cost	23,983	59,227
Cash equivalents, Unrealized Gains	1	
Cash equivalents, Unrealized Losses	(3)	(30)
Cash equivalents, Fair Value	23,981	$ 59,197
Recurring Basis | Cash Equivalents | U.S. Government Debt and Agency Securities | Level 2		
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]		
Cash equivalents, Amortized Cost	18,120	
Cash equivalents, Unrealized Gains	5	
Cash equivalents, Fair Value	$ 18,125	

XML 42 R34.htm IDEA: XBRL DOCUMENT

Fair Value - Additional Information (Details)	**9 Months Ended**
	Sep. 30, 2024
Recurring Basis | Maximum	
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]	
Short-term investments effective maturity date	1 year

XML 43 R35.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Property Plant And Equipment [Line Items]		
Property and equipment, at cost	$ 5,739	$ 5,722
Less: accumulated depreciation	(3,052)	(2,334)
Property and equipment, net	2,687	3,388
Lab Equipment		
Property Plant And Equipment [Line Items]		
Property and equipment, at cost	705	688
Office Furniture, Fixtures, and Computer Equipment		
Property Plant And Equipment [Line Items]		
Property and equipment, at cost	712	712
Leasehold Improvement		
Property Plant And Equipment [Line Items]		
Property and equipment, at cost	$ 4,322	$ 4,322

XML 44 R36.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net - Additional Information (Details) - USD ($)	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Property, Plant and Equipment [Abstract]				
Depreciation expense	$ 243,000	$ 244,000	$ 727,000	$ 724,000

XML 45 R37.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Payables and Accruals [Abstract]		
Research and development	$ 7,644	$ 11,916
Employee compensation and benefits	4,440	4,545
Legal expense	4,127	
Professional services and other	750	1,882
Total accrued Liabilities	$ 16,961	$ 18,343

XML 46 R38.htm IDEA: XBRL DOCUMENT

Significant Agreements - Additional Information (Details) - Washington State University License Agreement - USD ($)	**9 Months Ended**	**12 Months Ended**	
	Sep. 30, 2024	**Dec. 31, 2020**	**Dec. 31, 2015**
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]			
Milestone payments payable upon marketing approval			$ 600,000
Annual minimum royalty payments			25,000
Net sales exempt from royalty payment			100,000
Royalty obligation	$ 0		
Licensed Products			
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]			
Sales	$ 0		
Phase 2 Clinical Trial Initiation			
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]			
Milestone payments on development milestone achieved		$ 50,000	
Phase 3 Clinical Trial Initiation			
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]			
Milestone payments, amount payable			$ 300,000

XML 47 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	**3 Months Ended**			**9 Months Ended**
	Sep. 30, 2024	**Dec. 31, 2023**	**Dec. 31, 2022**	**Sep. 30, 2024**
Commitments And Contingencies [Line Items]				
Legal settlement expense	$ 4,127		$ 10,000	$ 4,127
Insurance recovery in operating expenses		$ 1,600		
Insurance recovery receivable	1,628	1,628		1,628
Accrued legal settlement	$ 10,000	$ 10,000	$ 10,000	10,000
Deposit of final settlement payment to settlement fund account				$ 8,400
Wang V. Athira Pharma Inc.,				
Commitments And Contingencies [Line Items]				
Lawsuit filing date				Jun. 25, 2021
Name of plaintiff				Fan Wang and Hang Gao
Jawandha V. Athira Pharma Inc.,				
Commitments And Contingencies [Line Items]				

Lawsuit filing date		Jun. 25, 2021
Name of plaintiff		Harshdeep Jawandha
Slyne V. Athira Pharma Inc.,		
Commitments And Contingencies [Line Items]		
Lawsuit filing date		Jun. 25, 2021
Name of plaintiff		Timothy Slyne and Tai Slyne
Athira Pharma Inc V Dr. Kawas		
Commitments And Contingencies [Line Items]		
Lawsuit filing date		Aug. 12, 2022
Name of defendant		Dr. Kawas
Laboratory and Office Facilities | Bothell, Washington		
Commitments And Contingencies [Line Items]		
Operating lease expiration month and year		2027-08
Operating lease existence of option to extend		true
Operating lease, additional term of contract	5 years	5 years
Laboratory and Office Facilities | Bothell, Washington | Minimum		
Commitments And Contingencies [Line Items]		
Operating lease initial term	6 years 3 months 18 days	6 years 3 months 18 days
Laboratory and Office Facilities | Bothell, Washington | Maximum		
Commitments And Contingencies [Line Items]		
Operating lease initial term	7 years	7 years

XML 48 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details) $ in Thousands	**Sep. 30, 2024 USD ($)**
Commitments and Contingencies Disclosure [Abstract]	
Remaining 2024	$ 123
2025	494
2026	509
Thereafter	346
Total undiscounted lease payments	1,472
Present value adjustment for minimum lease commitments	(158)
Net lease liability	$ 1,314

XML 49 R41.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)	**Sep. 30, 2024**
Commitments and Contingencies Disclosure [Abstract]	
Weighted average remaining lease term (years)	3 years 2 months 12 days
Weighted average discount rate	8.10%

XML 50 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Operating Lease Expense and Variable Lease Expense (Details) - USD ($) $ in Thousands	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Commitments and Contingencies Disclosure [Abstract]				
Operating lease expense	$ 89	$ 89	$ 265	$ 265
Variable lease expense	$ 41	$ 42	$ 108	$ 144

XML 51 R43.htm IDEA: XBRL DOCUMENT

Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details) - shares	**Sep. 30, 2024**	**Dec. 31, 2023**
Class Of Stock [Line Items]		
Reserved shares of common stock for future issuance	13,961,668	11,417,782
Shares Issuable Upon the Exercise of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted		
Class Of Stock [Line Items]		
Reserved shares of common stock for future issuance	10,785,447	7,130,956
Shares Available for Future Grant under 2020 Equity Incentive Plan		
Class Of Stock [Line Items]		
Reserved shares of common stock for future issuance	1,426,486	3,158,094
Shares Available for Future Grant under Employee Stock Purchase Plan		
Class Of Stock [Line Items]		
Reserved shares of common stock for future issuance	1,399,735	1,128,732
Shares Available for Future Grant under 2024 Inducement Equity Incentive Plan		
Class Of Stock [Line Items]		
Reserved shares of common stock for future issuance	350,000	

XML 52 R44.htm IDEA: XBRL DOCUMENT

Common Stock - Additional Information (Details) - shares	**9 Months Ended**			
	Sep. 30, 2024	**Feb. 29, 2024**	**Jan. 01, 2024**	**Dec. 31, 2023**
Class Of Stock [Line Items]				
Reserved shares of common stock for future issuance	13,961,668			11,417,782
2020 Equity Incentive Plan				
Class Of Stock [Line Items]				
Share based compensation maximum annual increase in number of shares that may be issued under the plan	3,230,000			
Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding	5.00%			
Reserved shares of common stock for future issuance			1,908,630	
2020 Employee Stock Purchase Plan				
Class Of Stock [Line Items]				
Share based compensation maximum annual increase in number of shares that may be issued under the plan	646,000			
Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding	1.00%			
Reserved shares of common stock for future issuance			381,726	
2024 Inducement Equity Incentive Plan				

Class Of Stock [Line Items]	
Reserved shares of common stock for future issuance	750,000

XML 53 R45.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock-based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]				
Stock-based compensation expense	$ 2,936	$ 2,494	$ 8,820	$ 8,395
Research and Development				
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]				
Stock-based compensation expense	1,124	944	3,263	3,228
General and Administrative				
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]				
Stock-based compensation expense	$ 1,812	$ 1,550	$ 5,557	$ 5,167

XML 54 R46.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]		
Expected dividend yield	0.00%	
Fair value of options granted	$ 10.2	$ 9.8
Fair value of restricted stock units granted	0.1	0.4
Fair value of options vested	9.2	8.3
Aggregate intrinsic value of options exercised	0.2	$ 0.2
Unrecognized compensation cost	$ 17.7	
Remaining weighted-average period expected to recognize unrecognized compensation cost	2 years 2 months 12 days	

XML 55 R47.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]		
Risk-free interest rate	4.26%	3.54%
Expected volatility	96.93%	99.18%
Expected term (in years)	6 years	5 years 5 months 23 days
Expected dividend yield	0.00%	

XML 56 R48.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan (Details)	9 Months Ended
	Sep. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Shares Available for Grant, Beginning Balance	3,158,094
Options and restricted stock units granted	(4,090,804)
Options and restricted stock units forfeited, cancelled, or expired	50,566
Shares Available for Grant, Ending Balance	1,776,486
2020 Equity Incentive Plan	
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Shares reserved	1,908,630
2024 Inducement Equity Incentive Plan	
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Shares reserved	750,000

XML 57 R49.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]		
Shares, Beginning Balance | shares	6,820,869	
Shares, Granted | shares	4,088,804	
Shares, Exercised | shares	(75,660)	
Shares, Forfeited/expired | shares	(50,566)	
Shares, Ending Balance | shares	10,783,447	6,820,869
Shares, Expected to vest | shares	5,905,187	
Shares, Options exercisable | shares	4,878,260	
Weighted-Average Exercise price per Share, Beginning Balance | $ / shares	$ 7.97	
Weighted-Average Exercise price per Share, Granted | $ / shares	3.16	
Weighted-Average Exercise price per Share, Exercised | $ / shares	0.16	
Weighted-Average Exercise price per Share, Forfeited/expired | $ / shares	11.48	
Weighted-Average Exercise price per Share, Ending Balance | $ / shares	6.18	$ 7.97
Weighted-Average Exercise price per Share, Expected to vest | $ / shares	4.27	
Weighted-Average Exercise price per Share, Options exercisable | $ / shares	$ 8.49	
Weighted-Average Remaining Contractual Term (in years)	8 years 3 months 7 days	8 years 2 months 26 days
Weighted-Average Remaining Contractual Term, Expected to vest (in years)	8 years 10 months 9 days	
Weighted-Average Remaining Contractual Term, Options exercisable (in years)	7 years 6 months 21 days	
Aggregate Intrinsic Value, Outstanding Balance | $		$ 387

XML 58 R50.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Stock Options Outstanding	9 Months Ended

and Exercisable under the 2020 Plan and the 2024 Inducement Plan (Details) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Shares Outstanding	10,783,447	6,820,869
Shares Exercisable	4,878,260	
Exercise Price $0.16 to 4.22		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Shares Outstanding	7,703,393	
Shares Exercisable	2,515,358	
Exercise Price $0.16 to 4.22 | Minimum		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Exercise Price ($)	$ 0.16	
Exercise Price $0.16 to 4.22 | Maximum		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Exercise Price ($)	$ 4.22	
Exercise Price $8.93 to 19.94		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Shares Outstanding	2,727,806	
Shares Exercisable	2,084,154	
Exercise Price $8.93 to 19.94 | Minimum		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Exercise Price ($)	$ 8.93	
Exercise Price $8.93 to 19.94 | Maximum		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Exercise Price ($)	$ 19.94	
Exercise Price $20.55 to 29.41		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Shares Outstanding	352,248	
Shares Exercisable	278,748	
Exercise Price $20.55 to 29.41 | Minimum		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Exercise Price ($)	$ 20.55	
Exercise Price $20.55 to 29.41 | Maximum		
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]		
Exercise Price ($)	$ 29.41	

XML 59 R51.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs)	9 Months Ended Sep. 30, 2024 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	
Share Equivalent, Non-vested, Beginning Balance | shares	310,087
Share Equivalent, Granted | shares	2,000
Share Equivalent, Vested | shares	(310,087)
Share Equivalent, Non-vested, Ending Balance | shares	2,000
Weighted-Average Grant Date Fair Value, Non-vested, Beginning Balance | $ / shares	$ 11.44
Weighted-Average Grant Date Fair Value, Non-vested, Granted | $ / shares	2.51
Weighted-Average Grant Date Fair Value, Non-vested, Vested | $ / shares	11.44
Weighted-Average Grant Date Fair Value, Non-vested, Ending Balance | $ / shares	$ 2.51

XML 60 R52.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]		
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share	10,794,156	7,344,021
Stock Options to Purchase Common Stock		
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]		
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share	10,783,447	7,019,311
Non-vested Restricted Stock Units		
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]		
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share	2,000	313,337
Employee Stock Purchase Plan		
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]		
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share	8,709	11,373

XML 61 R53.htm IDEA: XBRL DOCUMENT

Corporate Restructuring - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2024	Sep. 30, 2024
Restructuring Cost and Reserve [Line Items]		
Restructuring and related cost, estimated to incur		$ 2.8
Accrued liability associated with restructuring		$ 2.3
Forecast		
Restructuring Cost and Reserve [Line Items]		
Restructuring and related cost, estimated to incur	$ 2.8	

XML 62 R54.htm IDEA: XBRL DOCUMENT

Corporate Restructuring - Summary of Cost Associated With Termination Benefit Payment of Restructuring (Details) $ in Thousands	9 Months Ended Sep. 30, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]	

Total severance expense	$ 2,316
Research and Development Expense	
Restructuring Cost and Reserve [Line Items]	
Total severance expense	1,007
General and Administrative Expense	
Restructuring Cost and Reserve [Line Items]	
Total severance expense	$ 1,309

XML 63 R55.htm IDEA: XBRL DOCUMENT

Immaterial Error Correction (Unaudited) - Summary of Immaterial Errors Correction in the Weighted-Average Number of Common Shares Outstanding (Details) - $ / shares	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Error Corrections and Prior Period Adjustments Restatement [Line Items]				
Weighted average shares outstanding,basic	38,517,602	38,054,583	38,406,709	37,993,002
Weighted average shares outstanding, diluted	38,517,602	38,054,583	38,406,709	37,993,002
Net loss per share, basic	$ (0.75)	$ (0.87)	$ (2.13)	$ (2.38)
Net loss per share, diluted	$ (0.75)	$ (0.87)	$ (2.13)	$ (2.38)

EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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fKFC9AY3\V+BU[O) !WB1-X.O$/,+B.4JF9KQSV(!=Z8^-&TN!=Q=R MN=8SR&^0H#9H.^*!M9SGL""[TB#{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l6VB@\>S^&K+;ZYKF.//P@].@MN!E M'l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

M_<.55#Z6G*HP;+%SK+EXEF%=]1.U,ELK!:SQ>DS^DX&3T]$W\EW]/T2*NW, M'YI=':L;[Z*WIM09&ZY4MX$BN:1WH7AOG':%T5;=89$ Q!35OZ]7,05 Z3_' M(I0-.#UN)?
7V]CJ@BY'+9\5[FET]>*^:O9^3/NG0[NG3ZG_:\D\GE%\XGZ MCBYU&$)UG6H3M+JM-8ICK#ZX8C)6/JA4$Z+;M-IMQVJCHS*N*'U 4$L%9X_
MG:BE\8F*VGGKJVV6Q381C1QL/O4W'6OCJL0V./5)AZ)6)W.&PWPN"0OT2/-3 M^7=D]48'8NE?BN17%-3B3.1?J@G.5-=M,):?WXP/K59%K5W%&I%PIQM2R1_S M5GTYE.E"
$+L5M5PT;_7IB"CTN+5&5DGRV5T6_>^U!"+ 7CI9T#YMW5%1ENK&@_^ZRQ%=@*H M@R&D^!7!.VBH2=M4BYT1])Q?E%21HR!9GJB/YO?,E"9M9=>-;DV"X*%*O@L% MU-
XA"708OA<_O%[,S\XE[]3F:C-)PK+NF!LDKN@]^82HD 7T X/0;0R,:8,O MB$KL#K[)*=4VQ]+$V&D^^NF%\PTW#V%9%;8B>);$[)1[E_NMP*1 M(6B4\E@'T'LHY8+)?1]RT0M!0I(H>$A*;K:E85
#=9(NR3I]+A1XH%"92G*CW M.]N_&Q2\#;ZK:@6> [LP.G=D-\0K:.-YU545J&)8.W3I IC9!PF1^%&=SLXF MI^@.UK+B?3R'"!X&CJ/_*") _HX?"=B5CYJDC?__1G;BKL7<8_X>5E^M2_%Q
MG#TEP.\> &#V%0Q .4R9C<7Y5Z\G;W:^/ZJB(>8<>O!7^N>GASH#)4A[8H$ MDM\:)=3UHWH]WVO/?K%14FXHY ,4_P^ZS^:3O=[ROU)(*'//G!<[M"|$"%T* MZ>9ZIQ,B=(_L%Q(O%9F^,D(A
M>F\$]IGOK*SJ$E.6X2;/XR+"TK+F77HC'>1\HI:;@=*"UWAVUM&*.O&VR>]< M17B-*DVQ25_:]&,V3(>$RQ/&147OJF%.Y;'5 FKGL:0:F")R$L?$SQG'T!0Z+#/G9+,N%
MUUEFS>D[,80M\ZI:5+XA.M0C+%)(2M\$2Z MZ@U8 A!^;](?%6.]5"]TTYY#1Y[:OGF?:V3YY<,_Q^KCQQO9E)^X%! 1OEB M=]XS M!QOE*2M?FYH!4UB3&
(!!11^<;RR@X]F!H4![!CD^FVYG3);1$PY%(^V M*NC5-O/$)6#1@]H0PY;]#5EY/9T8;09U\EY-ARSC&2@>6"$)%]N\!-4G(L M>+W^!EQF /1<^\YRZ7!-E90H@"=R2KG(F"^HRJ!&1N^A"$.:
[^*3T5*4R%%H MIQW@5_1[WD3RP,QKXID,VTT?ZIH+0I>\-3K9;86\+6Y'-DE9@ ML7RG@7[))X^A86\[>%N[J.6ZC TY1]EB5"5&!-J-/GU!VGZXE=8$5_BNSN49 M!B-E)*AZZA @\AP-?W7((^]@0I"-
X#@T*2X2)0=;TEV"235YP%GA.M\>]YOS[!]X)91&;"!35$9Y.SER,5\KT^/R3? MREUZY1-NYO(5)W!@3?@_=]C+_&ULW5Q+1FYV%O+VSB\3]'ERT[F;_=:87KVQ]\8_/=CV???M@P>^VI:
M^V7;F89^6:>NUCW]Z38/?.>,+GE173TX.3IZ]*#6MCEX]H2_>^/6F'OK*- M>>,4'^I:N]OGIFIOGAX<'\0OWMK-ML<7#YX]Z?3&7)G^7??&T5\/$I72UJ;Q
MMFV4,^NG!O?'WSX_P_AP#^MN?'99P5)5FWI,_YX73X].)#IC)%#PJ:_G-M M+DU5@1"Q\4>@>9"VQ.+\GARH8O!6X?%O$%M&_FO?A_TD"TX/[JSX"0L,&&^_M92/F\H7N]:,GKKU1#D\3-
7Q@47DU,6<;&.6]=_2KI77]LRN[:>S:%KKIU451_MM$/3VVC:W CW+25+:SO3OITM D>?5 $@L^%X,D>@M^HG]FWWKULBE-,5W_@)A+ M')Y$#I^?W$OPRG1+=7]T4"=')V?WT#M-$\]RO=.]l'9(J?
[G8N5[1Q[RO[L$ M%GIGN^DA:K[UG2[,TP,*"V__'3\Z^NX>;L\2MV?W4?\4^]Q\$0M MU0>(JN?:6Z_:M7H#@9I>Z^V^MJHE3&-(@UUVM%SML$Z)!7;WY/+]UOU;GFU5!O3&*>KZI;B MM3
=2,J1P\Y9(MY5QB]4ZV3%]Q<7;Y;?P1Q1K(;2J)XH4*YS+"Q+?]%OK=/[MS593^" 4ZZ98+I1NB'E:=K-MP65[TQ#ABP'N4UG=4'9;>5M;2G!+=5%51+XW MKFCK3C>WE#\]8H
T#"]THO&ZD.U&%9G*4IPSOT/7-ID$].!2O4M"O@9E6ZO+ M).QE+NRK).S5*'S4!'TR.]#H'DT%1I44!LWJN((YZI5Q*1I%&WM(9"]FQ9EF_M94U-KK!)YJ;300OMMVI-5<(+7^DY=
(X__>_G9\WI2 M8C"71C?-0+3^!7*P/1>(>0DRVR"?$(%:-U3Y07*!"H]2K2CXE2Y_HXCBK1:1 M1W@KR6H0=&O5H"17M*@8G,-/DR4-<>]Q6!B;ZVM4UV>SH@(?KB46 @.YC-Q
MN]9;00[WNG__9F'-B:8P'20/&;1@*]&[_]<[Q:O&>4@#C3_V!)11U80* ?) M2NL+"C[)Q_2K-Z38GO*3,Q7SW;>?PPF'F:Y\,X^UOZ*O3%>?JAC'8B6OL.1" MMBFI_@$11D>(6Y+
(*Z/,^XZ]!%O W:%V_C8T FQ3X,Y=^=^5EF+)9$[@NQ>2*=Z:KG4]T@L LSH^ M.OPOVJZBYQ*+5XA7BJI0 E^^+[:ZV3#KM?5 ^ES8KUY>+IB.6;D!87QR(CI>
MJE<(Y'_J:C#]DZ/]X++*5FCGN*KI&HB!A2J,ZZDWR>2V#17K(60*$84K(05@ M*$*H,M>ZDB?(+WIGV1?D$=ME6)5]*7;]#GX41D8I*UZUS[MW6+4,R78):>$?
#+XD$]^IDRB'B_@7#<&21WEID)><;! 0;L]N7_X$U MCMP*FBNH>-D>5BZ]Y)&>5;Y":XE2T)*!"1LR@02UX -0"\,.F77YRYF!Z6^X ML=3)CTKN$^3@HRGG#-SUK7_-[E.<-9:1Y1?
35)B'\1>F4K]$,'!N&[D0& M?1(_F+DTFF8B@)INR/,$5Q7MM:&"VI+I'/GNRYW;)Y6Y,GA1 US>WK"C$?QJ MA\UVEQ;?>3;!2X+K->L,:I7&(Z'N/5WX[GD
NGOBA$*&LD+6+T#F6O].0"UM M01[E_5!W@A;[+;FV7J_15 C BQX_H@-ZWH2L0]T[:S9B$RP)^#C486(07OVCB MW[=.=D)SU^T QZ]0/,1R5SI[X#].*GT:#C7$4FXO<6)P1 MZ-[-
"RFE.1T\FV)R[0.P!/NAMONO)#>\,$PC MK*-$1O;A>DV!#TM1OBKZ@7M,:0P*!N&E)8]RL?>?;L/8C(!S(=G^A;FF\.]8 M^I?1JI,GRNR)9/> WS#LJ]59(0.6Y/]HCCGHPQ]%ZV5^-
;!58"*7J&/:'>PY M8MQ\O^"?G>T,LMDXS9BW$:4;-AP)DCG,FC;*?'A&$QF05Q3T %I1-/KJ/#C&*N [?/:H3K"3G42\(A'_>>##80]W57M;>&ZQB9W7#K(4M6A&76]D/1%BFS(T1J;
(LW.@#MO5+D MWL)=H"]R5#A3VI3OS#.1+HJ)D,$IFSYL2:6 ':.!5E M*9#FLA3-!_4?5K8 [@CFSAB7M>AZ"JXCJC?%MFFK=@,!! \!Y7 =X3$:A@BW MID=E-#P!=&8#^
,7YA:/4ER("Y2>,'9(%1YE&F2XF)+#-S)_6 _3.7C M)#5*^#.!:&?0]TF?65YS8J:^4VH*-+UIVS+$D"7MC"A"MY0 XCQ OH2B2/MA-V 92B%$%<1=1"S1>1,G>)#" 34^SH$B
MX!I3**"#L1BM(D8BD75>"?@XF35#;+:0*P-)HHQ2+Z>@W/ M1X[O,7-G=PY$6;=A%C*G>LWA.2;,R/TB3QU9+4J]>P:I"GR@+:O;J2:VI+WH M-
%+J2AXJQ0P9ZH_A2K4R_0TFN[&*MTZPEBUCO##(9@GE"PJ/@I&VZ:1 ?R]M M$CJY49(2+$XRV"]3R@(U"SKCPD1$Q -U@%]DV& M9_:BCJC)&1RS&;
[(.>66D"==C<"QJ#"I=+/2]Q$Y'3[']U8G[5B^I2%]?> MJX(/Y>T?C?9FVKGKLN5SO^QD\HJ@68FQ#SU4\LEE'T>%%U>7"_5KV]E"G9^= MR SB^+M(US#\!R,_$&3)%%FF$?3J"L-
NF_IZ=:XSG#8K@^I9K"BW_[R M;I'W$7-V)GW0M./,VR(9:93&53*!!4$*<_20V; BB30'8L3-75[G6TN&"&,! M<.@S]D(RS>>;"U>MASJ02:54*B1G?GP/6RPA?Q(?
2V7XG(23%|_I3_FZ781] M$% Z-$\[]Y+/=V%YCB]Z:L98C1D5;4@T5@9M?;89;;!&69!!+)>C"K,N^14. MVR 0?$(OU.#XG3]N)';&"5K9*B:N[5?]5'DCZ"&\ M5.7(PSI[9)Z?+)T%QPXT>
MVP).A(XFL+_+3S05U9]\UK&?2(?FIRZ8'[F-+A[FQ"GM]?<9.B[S)G%@R,E$8 !F5 M65>@>$Q(W)#]7A M(@NARGCUBV"Z9K3%ML1L$]XL!5PC<%8F]T@#*G,CRP3H;HVD8 -O#>_-
M%-"_K MG$UXR|KE:.&@|CN4)NV!C)7W54A\!MYDCQ%"X;%[/2)BC;1TET2+!#S@;O0 M.:$5;O+UIAF1QUTULV*)MZ V0:71V6?W**+;21,U%E$.%@K-XY-X?DNFY83%
M.*,-5HD>408E3+:,5R;/NUK(]?MHFSYP*DD[NUKPQIX+<2AB@RR=M:3'W-C"O.I8((/VWS:'HGM,?:1'J?TO^%*0$I4([[X" M,0(&7I]/D+B7W_+9PZU?W"GT/K^'
=U/7/8CN9\6T26AOQ'V7^:P/S=GJ,=^ M?V. BR5Y!Y'2.%PD-@V+@)K"0%&J,\:+DX0>:TLY&[,R$+BA7!.S.2LI)/!7 MQ /O'W/CM%^<]L#CPMD6W,"&$)"MQG+YO-
(DW55!]H&K\$.'U)$5>*!NJ4N7 M$-A+/#MY$TZ'ODIY%O'Y0EJZ3D.-WN]F5N?GOB29)5!+.N0++U7KPYT^M&+^ MSLEGX*
(+M^'+G[4O]1_J^ZI=X68;9R+U$S.RG#K'[LA*CL9G"M[V)LX5TMAA MCX^R =?&]NQE=QV?,S\?]TSSC&3'>_PR]XGY^>=H!5$#>L75;WRBT>:CBN#2 M-8Z_>\KN"H=
W%Z/\B*Q]R,M$$Q< MH=:LF?HS>0Z0*1U]KQP9W6D(MP%K$,M;,A#DY-;AKE?+B>* B ML?DS^?&/+67V-Z2NJRVL>]&3$59#'[':I7CR578KD2_*%CCYXG,S;$MECI'5
M;'$>!G$QKM_IJ@CGIRN"V9;@=8SE1/1C2-%BK+GA.^BF/-1D=;* :@8^\2>A MF2VY(9!'9#OT./;@76/+)>ZPX")$O\NPIC3C 5[7 NI8:0UL-8@9L@/Q%_@2
M^."3%2/GN37GA=7G*%D&7IRSY23PP_Q+_]#;P_3;AOYIIE:9ICL4*;.Y>PEA MULMS&%'@25T/@QB).%1VDQ5\+^0680 :5+)"KC>R?1C%Q"$0=PP.!XWVS^!#
M3G>&!"CV@'"$X3K;LC0$DF!BG*NZA21I?B9-T&)QQ(#N&B](3*Y5C4V.G.;1 MS0;(NX]%/CG8X+I6#HK#B4&\<,1C-X5$'N_\\%V2(9ST]%^:['I?\<-X#3.W M!/1@^S!NU_Q.";U;
(,3+H1B1H_63P;P<\L61H5@L.7QV?8M(&,DR"]CQ4P)XQQ6_'$"7%B-/G8"7!&3(C'K#!<+!T?"_D&M7(_)WE M0M^ONTGA'GVO8YBB>%8F],E3GZ#<=^,.N L_3(,T MC0@HTL"'?
D^2)&2;(WZ9*L^F&H.^+-I>H7TO[S&)-7^&KH/,Z-1;SC$W:# M'WYY?H4O<7D_8N[XW6+/QGS+CM@BS*;#2!3/-.9&\:'-M?5F\FJ$3R-2ZST. M Z!
PCCAK@1GP(;J9%Z^(Q/AI@AW@WPPI.,1^DB5?(OL -3A[#7?QHM\[N\/ MZ>F!>S\.MEX.8?BU![E8'8#'NI6+0S(1)CX&#G'<[EX)M)G\UX^>6;2W; B MO,-.>(?
W(#EK1[O*2K',AI62L{G_KXZ_IH:4DG^SP=!GK\/P/E^=?(V;)Y;S MX36"D<=",C7E.[0GI(]:IOW.X>]82QV^A^R76&AKM1-%+/;AQC,6?25'$"?G1U\OU.L:-C.INY3'6*%QY8MT
MLXB?L+(BX%)^,B" _Y2N <5Z(9;6*;9:CXF+#.2>@7?\ME[7I'<9)+0I.OH M,G#F:]RAV\'+2_OVQLM15^^B/D(SQ+]+- ->,91B-\&$M-E4NZ1;3NC8_,"&
M+S'1_EJNW>.TD*-.QB])J:'K!^ P.DBW8F#1!(I(^KX2[3.TLW,\Y64 MT!TZT[O6=X%1 3= &Z2QN&L8@B,"7]X7GI-3]#CTDC(HS5)-H.5 MPZ-THV \'R9/TD6?
FNP/7_V7>76&,L*Q5>A#1MBGQU]K0[O!-'X:!X\HD'03)<$I5EMQ EO MTSLN"@9#-"A<4=FT?(8?CXB3U_%9*E)_O$X>;ZN,US'3,4@I?>4, ^\JEBK"8 M1\ZF#DS5,A$E#
36I'W%NRP>WXFC]>(9-R,T3I%F; MD@]APZ5;"!*G#.&0V'A^ T!41LU54Z:[E^Q:V'(2RG)](I[' N6 /+O7]].E MC8R3/?'6S:/M_UW<[!3^$'V5C>P!K^[SM<0FUY>\$[?IM?
C+^2M\/%Q>;?^ M)PDH@G'NFI8>+1_/) #WOA'WW;\COB[]?NVYH];H\FA#]OFZI9PY_8/(7T M?QKP[(\ 4$L#!!0 (.F!9UE%96VV 8 & 0 9 >&PO=V]R:W-H M965T?%G
MI6MW/2Z];RZG4Y>75$DW.0W5^+(VMI(>KW8S=8TE602A2D_3V>QT6DE5CV^N MPMH[>W-E6J]53>^L<&U52;N_(VUVU^/YN%_X26U*SPO3FZM&;NB>_/OFG<7;
M]*"E4!753IE:6%I?CV_GEW<+WA\V_*)HYP;/@CU9&?.!7[XKKLBH+5LM?_) M[+ZESI\EZ\N-=N&OV.6]V6(L\M9Y4W7"0%"LOI*/SL>!@+GLV<$TDX@#;BC MH8#RC?
3RYLJ:G;"\&]KX(;@:I %.U1R4>V_Q54'.W[R5RHI?I&[I:NJACU>G M>2=[%V739V0OQ ^F]J43W]0%%0_EI\Q)/V8.[2%Q7>4S,1V2P1Z2Q=O* O
M.SB7!7W9)YT3;Y3+M7&M)2=^NUTY;Y$/OS_E%HEU\BE:V1.UV,4@2.[MI?'-%Y_-3V>O7@"\. !>O*3]$]%X6383$S%P^.>2Q&M3-;+>BU(ZD9/U]%$A MG2/OA*P+H95<*:V\
B>^E%Y(2Z(BR2P5 N]K5K<-ZKB 4(1Y;ZV]-UP("DKR MW-B"W[W!Y\'V4I&5-B_W47%CE;$P]%>P1$+53>M=PF#;]N'RC(A86(9J]927 MM?K80]!U0
,#';*!F4GPTI>62&C:DG;"K(.!)Z' O4OQ/>\3<_'%9^?I/'WU MOI;%'R@SF/C8&OX!UAQ65=\Q4&WV U-VH ANDW-JI8E)8G,=-#0K+PKI8=]8 MH0J\JESJ1+0UI!9#_*[HY(-
U>!90Z2MCPI#5-%GN0G#@QI]GH$%\;-73H 5A=9*(7## ;A> M1I=%(RUX5$AEV-J95A><$\P)LQ/2#$S(M Y9W-%H2C M^A>=<*:U.3TH6:X3S;NV1F\AT3$->[1E.]/(74([%5D R.-
;.!"%M(LN3C/8/,K M(ZOX^M\|+/QV),_@OSBS299Z=XX']1I%N\&+VAO"-F'HC)_@]B3I\CYC1[MRKWE19*F9X=M0#P#9*S.+\Z>]Y*E+F8/U'>2\=OI;'1?PJD3;B:O8O(KF<)6=I-
L0_7[(#LV0Q.^\<<$|"8:AGR7RY>.S& M_"+Z<9J<9TMQB^'#M9,_PIV(3X%S7"AA0G9[O0UEM1?HQ]K%-H!32&,LS]V5 M0?U "34N(VB]IG[0>[:UCR.\[YD(&N"BT?%H0(&HT,K
M/U+!$:LJIC:.M4XTQJDP.B,E*F!G3:@+.M'] [K?"4,_X<7@W-#P#FOR*[>< MHY:.EVI+:CXP'8YR_?! &^/0[?L))]%F!OG8V^;B+M^:@T,?ND& ^PA!Y@V M/'@Y>+"OL*AL#)E\AL-
N#!7HKGA:H]D;GE7A)!.BE<,C,,)$)=$C/A'CRR:2 MR6SS"4UP$@'QI5""89A=".A.1D[9;TQ2=I3)9O2/XD'Q['68?2=X.W&H_2&7 M.Q@-
NFP1)U*$C"K!W:+DF^^6@K;)4W>+Z>#6AZK:A+LMW#)M[>,%\+!ZN#[? MQEOC<7N\>_\@[0;G$N3W&J*SR=ER+&R\S\87;YIPAUP9CQMI>"PQWLGR!GQ? M&YQ6NQ!
(%."ZR8[LL:!=WD4E7,D*A6@:X5LLP95640A>%)4#$NO/G4 MG2W42"H;4W*!"P6ZJ2]FGL^QE.N9-_!>#F[YJC#V(O/A:/[;".S1?ZX4B*>A0
M,EZAT%P*4)C/O+/!Y#RQ^D[A&\>UWMJ#S60IY;T5/F4S+[0!88FIL0B,/H]X M@65I@2B,APVFU[FTAMOI%_0/+G?
*9*DOM5EBWN@EY3!MM9+4Q)KGBHOVRITT=M@S&X2L&T<8@8KH1!GI/=M>V..Y=L^46^EL8 MA4-;3\;CWI<\YRGA-TIPTRCT(>=/=J-]%]-H$-E?[QII1@M99L"K6LE'=$B)
M'T=1N_;VIT(H-AUM8.B/XE.[1A9-ZPE11]I43R'PPB. M:1?Y<9S \;OP FU"D7\R'M$W]N/QF*JP!89/Q+0:8J!>56 M,+)V5+B4AHC5;0MZR5!9!;K/I30O@G7O08WS7U!+ P04 "
#I@6=9CW:W MP[T" #P!0 &0 'AL+W=OV+8RUA$L MYPW=PB.8;\U&H17T+ 6K06@F!5%0+KQ5-%NG-MX%?&>PUT=[8C/)!RRQI=B MX856$'#(C66@N#S##7!NB5#&
[X[3ZZ^TP./]@?V3RQUSR:B&&\E_L,)4"V_] MD0)*NN/F0>X_0Y?/R/+EDFOW)?LV-DD\DN^TD74'1@4U$^U*7]IW.),PS< M<0>(G>[V(]?REAJZG"NY)\I&
(YO=N%0=&LQ88OR:!2>,L29Y2K/U0X*U6\@I(_('MH2V MCLG@ 450E5>N"@4\XT1HL+\->4O "BAQO&C:=O! M",M 0,F,)JF?IB%^1^EH< =;R@F\V%! 7Q1/R.7%-
([BZ\%&R1*TG2$88A^! MY=U_(#$E12:CD$3^=!H/OD]#(?3$0Z"NL7\UCNQFZB=I0D[5.#CJPAK4ULT: M^XH[8=]&[+W).%NU?
PWO)V%]U1MF="$0XG0<#@9>42U\Z4UC&Q<3V?2X(1P MVPI',B@;@.>EE.9@V OZ(;_\ U!+ P04 " #I@6=9*:LM+\@% #3#0 M&0 'AL+W=OIVO[QE2ENV]H07ZX@O%F3DS<^:0
M.EM9=^,KHB#N:FW\^: *H3D9CWU>42W]R#9D\&1I72T#_KIR[!M'LHA&M1Y/ ML^QX7$ME!A=G<>W*79S9-FAEZ,H)W]:U=.M+TG9U/I@,-@M?55D%7AA?G#6R
MI#F%Z^;*X=^X]U*HFHQ7U@A'R_/!;')R>$_OQ;G M@XP!D:8\L>)KUMZ1US(\#XT?D<|"9 M#D1!2]GJ\-6N/E&7SQ'[RZWV\5.LNKW90.2M#[;NC(&@5B9]R[NN#O_&8-H9
M3"/N%"BB?"^#O@AS=B4<[X8W_A%3C=8 IPPW91X.\\W.9_$R?\/.+^&)-J+SX8 HJ]NW'P-0#FVZ 74Z?=3BG M9B0.LJ&89M/#9_P=](D>1"\'3_C[W972])^2N3
4[ZSQ5JM")FJ80EPY\D@] M+=BE^*B,-+F26LRQF,HB_IPM?'!@TE^/52@!.'P< $_7B6]D3N>#AF.Y6QI< MO'HQ.UM!+!8BYQ<@ IN7!6H1>#"#0$, M80K.IU 5WV-
5T6]TKE%2+Y4TAB^ ! MY=U_(#$E12:CD$3^=!H/OD]#(?3$0Z"NL7\UCNQFZB=I0D[5.#CJPAK4ULT: M^XH[8=]&[+W).%NU?PQPT#AFWYBR8_/6T@(Y7
3,X8S[!8YW8"\D\"BR+@WI)?2V=2X\ MIGH#O/0K-G!F,,-YYS&?:2H-:16E*U#*S:Z1>64,XS4TY/2&R,)#BEO@"8!4 MNG5]S%;] *OFZ5K_2:!ITKK:9-1B%>TZ E K[%W8/.%'1'J
FC1=OS&:)& O(M,#![@9!C_]*E23@(?,SP?KMGEB6KT?90+S-X.18UY-R,*V_?_S@A][Q!.DP_ M:3Z>"7+=0(W@)@:,1NT/!LVY>%U#@+R+[>HQTZEK6T@$L?PM:L[8HV:G(WC9
MPN0)B#]/:@B*>CR<2&+@&5E;0K@)0L:-NX!S:1)=4W92-:)H&(:79 "JX\ M-(NS69"XIRW2-&"VU5LC1@;H&+01&7+W!GL!A&/0?BH,[*)+ZT/SD;9OI>&WA?
V)6?'/J@]T'O=E=RIRVR7BY]lT-;_]O\" MZ4(*QX#_]7"'Z3V69Y,8?($@.7J' \6.!D)P=-E/RV"|'O ML/DO=;@O+Q; BF.GDM. < M7Y?%M6%_MZ5J.U!4#]\)X0HRTD)EM
)TE#$O/^B\INKVG'F93P;4 Q*T8M&O M,%_J+>/=_V9MR4ON\-;QJJ13B@P+#GG4>OQ$S>:36]U>/.MVEKG:+HOZ:EW] MX5G6UP_,K[Z6,"*1
<2H&\AD8SG6)>=8'O?"E,M>D@5@\H%/H[:EN>:`^2*,9 MBAY1CZ:X)FPF$/'V;'+9F/QX@+-O'H$M"2S/4!C=V?*.FA.K\; M*O<$KB@%;]&FAT:"/*3ZI5GK;.7]88.PI891L'
+Y[PIX#=+V$C46PKQ)V!]_ZV5.-G%G;EF7<>H<' XH M,'F']PY#.+6IRHOJ@53:_(\)N9DTHH9=89ZT4?!0TYK&9)H%9OZ>B-L !P) M#91U0D5TU,DHYHLXBIBT:5=]-'NL?
J$L@L.TIKX:H41^6C,>H-(*F9S5-[;=.,:FIRYNZ'=QP?>75[V%MF$3;]I M!1D8>HE-.@]=2>*_[IH>YC)Z=;))#H'@%N:U+;VCBB'S4!?(9/E7@7!+;*_ MQ&XS 7YHC
\LI:*HPIO'(SRC(IJ=:-O\H&76"Q3<\G53IJ2,@@>Q7W5:8X* M6\PQB43S^DC2SHVCDC;@C1S\2&[-R9V7+] ,6>\PV&CWH<2$C"F %G'2/9;] M+$4\6NJ1-(LN=
[^QL/96WZF36;#Y<(NE8]ZC"K!;4EY2AF@<*GD,1<2?)3QP M1>=%W'7P)Z@G2](!P"GO([;LH7J4-5L2Z;3&I,E3G+1I"$BB-T&:N MFB:%N%M(N;NG!@^W&M1V:;;5#
[;S_F$24/L*^81M\9U9EERJ^]>++T@5 M42F5\=.AI>[)OK0+:"F3]H,$L0T%[0D3A+-'8"\%X][E4)"MM)6I7==FNTZ% M/Q8O8F<844H/[8-!RKP;YHJ?F(XQ12487\I^WJBKV96:I4+
\3]<]=%1*%4] MOM-1],(LVFY\RC)]LB[T/+*/6^/Q^M":#_TOMU93L\2:H!?-D+U?:50'O5 M(PM&VKVH\!IK5(]<9&DLLW]G]?H[(< _4N?2M#'18FN$26?!A;I0=1:4
M/=+&N9673F>WYUJ<%F(,.O@BX?VUMVRX,/0[04[@_6' C:7VUYR\4HR@I 8 M^1HL!96VR\ W$*A'CU$#+,%^LRTH@>JFQR/(L389YR&MM..VEJY\+8E9LR'2;/PFSU-BI3*ZP
M>5PU%NLAX;CK]0%$6KF\$G)>[A2%X^0PA;SPJF#WCU->*F#*E)F2*R(1:=^6 M)0I?(?><'L,ALHRL2$T;.6,!BZ%[&UK)*Q)VC;T,D 11,)OK'M9D[B_8_@%4^2RP[=
M]B53YM[CATB3=)TI-5RW8=)7ZF*ZB+1&'9%.8-:DE"1A#J#%M'7KK=[QD!&O M9H8%J5T-E" JCD.4W30C$25O-E(@U+X%24,D!\47M(_*U8\P%/&Q1II&M[#R
M*FC^GLJ^7(/XNL@H0-]@\[B6_#6Z-B4%SZPI+J&(:$[:SO%HW9:9RUUTY\A9 MF2WUJ5_5F)ZJ[3[O?\:"N*8Z]"GR!1;>C'GS8%A^?M;Q>AP):#LV:,[YG9DM
MGIQ'=Z.B5BAY8E.\>/6T"H.]^UW5MN4O^P@?70.9-^Q:;1_';T=4APY,D1T M9"?-X_UW $9Z_TN@/[55.!5<613PEC*8M);"7FXH^32+4A<3K4.=N::GON<8 MSC??
5TP%^H[HA09!K\%-E 97GJ1A+N$4D:CT)R-[" R6-[@[E<0G128-NSLY MW^BI$8)@[U%1VTF/J(@]N7,4ZQ'FI?Y^:9=UT^*PB-:-W&R4%H6V:=CK]5*R M/Y$5/E$QX
+ZX68<09(CPO\68Z.&4MM9G3!2V:H6L5(#_91R#B%"'Y-F%[WQOC@\1 T. M'PG7(,L]KB#XML-9!&'23OTB)/NP+C;XYOL".?J:=\8_,>ZEP'\X5X?UF+L M:MB[%,KYL?_%Z
K.E4;0Y3[ZZL!-VF!_N_#VSWA*G['W!OZ_DR09@E)8E"; MC*:;%R)4]R S@-X5;12Y3Q'ZGVH^:-@97YV]X'A\"H&7*07+#2._]TXT^3 M5I2)4P[.D^,#F+AS?A'*L7MUSJ54D]:*Y+-
[&]3=+GHG?QRB)'E% URW6&?O M/?8H8]:DV=A$WGH4BR/GP7QY9*RYD$./Q58Z&??HI7=R>Z_M@:!M]_J6*CC8 M>ZQC-NS_-B1GY_L;)7MDZ? _YI]=3Y<+&^4UE?
BL4]=5:GO^??)@5H;U?*2\ M6-K>Z<.>]D95%)]H<7!:>)Y:5RV*H;U>^$'HZ<,H0&7J\--.GV M@>*F*7/D46-?U,::[YS,!P9&\BG+;Q3Y@X5N_;U%ONOO9XP!0*V/;XB)Z^,;3F #L_U*

[B$Q>?-0H-T9.GYWTR+9*Z?6=E MT+",FN!]L\GW0/2UW8I!^,6.*,&BLH_]DCPN\SLWYR'SX]F9OS(W>])>VWKW M]OO)7C=A-6T%W',:ZFDS.4H^^TT8OLJ9%&V;JEEG5%GR-359_2%FJSC5)3[H M"G9:@8OIK.GW-)?-_.7O3KHWZD422K3]^78O[\7#KN"7-\6^\T=MW786"5PL MV7+8.O4U]EZY+0I"4ELF[259/7RIR:Q6I+9"SGW:R^;29N5$L:UWWIP)RP5# M8IS;DM#SCXVU_F$XK^E;M35G)@/X_%LOB[)]T4:2=+HI0-JRDON^HKHSPR8? ME4M<$L!ZEMMBX<(+['#N31[>_>ATQ?W")2>X')=GTQ-2X+G: \>3V-J?EXX<8@2>]

MJH@<10);GU\9LY)H"5O|ERK#!6(Z><4V[D;#M,ZY[5+$^S]8W%,4:U CO7 M)X2]$:V+/^(P*6H';;K'3P\Z AW\9.A->9K'43.;GQS@PZE:/%G0AS-U>OSD MX -

=X=&\S9XLS@X^%!4TVV%0%O5YHU.SR>)\?O!>FL,*6V0-9T]_@5-(FD%W M?;#JIM[XF8_4[/1^/3YX9ZJ! %^!W,ELP4]\X;?:"3+HKL 5:3'P+]/(P1J_

M&8P.'"O.B&LG^U=]:!;=)]%)^S7)-U*I \&6='U5?KP7;X_8&1^KD^E\.*/+ MWP40\#^B2!8]S38,(>FU97:F[E=\6\RQXX1CF>![?6_XP/?/XY?D>Q[_CO2R

M__L#=AL^EF@^'>QC^2MU\23\-S\[E?\/_C4NQ&*F%G,U.[Y 1;008^^!T5_ M9F!CRBO^8PJ.JY!*_N) \[3Y>PTOY<\4M,/ECSV@?KNR.5UT76']\?3\]%"5 M\@<4Y)>JV/(?+5@6R%4W_!'9)A(=&H#O5T51A5]H@>:O6+SX'U!+ P04 M" #I@6=9JS^WW1,% !V#0 &0 'AL+W=OJB\' ICF6 MPO9UA8IV5MJ4PM'4K >V,B@RKU06@S@,QX-22-6;7_JUA9E?

ZMH54N'"@*W+ M4IC=#19Z>]6+>ON%#W*=.UX8S"\KL<8[=+]7"T.SP0$EDR4J*[4"@ZNKWG5T M<3-D>2_PA\2M[8R!/5E]_9DG[I*K7LB$L,#4,8*@GPV^PJ)@(*+OI<7L'4RR M8G>\1W_C?2=?EL+B*UW*3.77_6F/K"?=#;M]CZ,V*\5!?6_X=M(QN1 M<%I;I\M6F1B44C6_XFL;AX["-'Q$(6X58L^[,>19OA9.S"^-WH)A:4+C@7?5 M:Q,YJ3@I=\[0KB0]-W^ERY*"

<^=T^OERX B1UP=]JWW3:,>/:,_@O58NMW"K M,LR^UO?UD#.=>$_G)GX2\ ZK/B1A '$8#Y_ 2P[N)1XO>03O]DLMW0[^NEY: M9Z@"_C[E8P,Q/ W!I^+"5B+%JQZ5O46SP=[\^;-

H'+Y\@N#P0'#X%/IWX_^T M]K0/70"X%6D.-A<&0:\@;;;LW\]%!9_YL&D>3EQ:66IB,B622##EM;$]8_F)QFR< M52HCM6E<\90[[.DF$+ZUZ*>-%]2-K"/S4JTI$!O^\1!<&RT*AT??

>]2'WS2D MPN8=)TD388FHCEPXI@PKHTN0*L6*NT\3Y-93GXNVE#*OO](%=4>FY9-WG ;J MOA1:5U-C M\1[E/N,=VFLCE .J#K+-P&0VA"@8QN-

@.!U#$D2C:1#.AC\$$@7);!9,DA&- MHGA*H.A'20PA&85!&(;@"S[^>?91.U% E 2S<12,QU.(B&8T(7_C;A8/]>H] M:1O-.TJ,XGL&%H50E.L\U*9337D_6TA%(UV:**

(RH0N5*U8V45>USQ'7;^.- MRX6CMK^C\O-)HE0_""6C^+=1+BU]JHM>5(7TRO7)H M BYF<6R:=(AB>_ *HNEX\T5T3CF+DR9TC6@ +^)S&,%/+'#2C8=EW;K"'+O%

MU=:>+$O,I'!(7:3BGN,WNQ7L-5\DY_X4WJY6Z)I\#Z(W#$Y"W!\B M)N #W[9H>\BBMQ\%LW :C)-]B+Q\,HV"23P^1(W^58WU8M>GK@!O<&D\B7L& M)RX-D>G*M7?"MIR#[1 M4],+^2KF)I?=I_PTS.'^FHRZ/6"OU(;W9WM\C^TO,*AJPR// AM/Q)9B8IL^ M_;#'9'HGWI_#3IOX1+-VK_XF0554O,L/JP>/BJNF[?TO7CS1?>F+6D.!2X M(M6P/QGUFM?"?

N)TY5_62^WHG>Z'.7T8H6$!VE]I>E^U$S9P^-2:_P-02P,$ M% @ Z8%G6?$>MU'\"0 NAH !D !X;"]W;W)K&ULK5EK;!%OWN7T%X.H,$4&19EFTY30(D?4T7F$Z0M!TL%ON!EFB;

M4UE413JN^^OW7%*2I<1)&\P"022+O*]SGY3.MJK\HE="&/9MG>7ZO+\RIC@= M#'2R$FNN?56(""L+5:ZYP<]R.=!%*7AJB=;9(R"R6#-9=Z_.+//KLN+,[4Q

MFY*9&I[WA_VZP+7H.&2RK7(MM50Y*\7BO'\Y/+V*:+_=\%E=[.])DKM07^O$^/>\'I)#(1&*(\?E3KP2 M64:.H,;7BF>_$4F$[?N:^UMK.VR9J>POF9K5>3_NLU0L^"8S-VK[NZCL

M&1._1&7;_F=;MS<:]5FRT4:M*V)HL):YN_)O%0XM@CAXA"'L"$*KMQ-DM7S- M#;\X*]66E;0:W.C&FFJIH9S,R2FWIL2I)VYN#4J^7)"=J7LE5K#UYH37&<# M

^ZT9Y!4G*X2K2+OT 6C6JA;5J5^&3#&I%X;-1X+$P M"*,G^(T:4T>6W^@Q?BM>BI,K:^HUWR&R#+LL2YXOA;W_S^5 MT6'>E#JGNN"),.\C-[0H[T3_XK=?AI/@Y1.:1XWFT5/I_KX

MM/=Q50K1"14&1QNQGHO2>OL#5'YBO4?10"$Q8LU=[P:F\#)9,0A!3MZAUA36 MIR_8T!MBUPLVB^C_R LG(W<-X]XD8N29Y*I\@N20% 90)D\3#$__$X8&/\ MG^+_<#+M?

50&!+H%UT$\7K#0FXTF]AK-2'+L 4-[*%G2K MV<>58 LN2W:'9<'4P@EBJEHG:%-A1 E5(7FC9;X$N()=91SZW"8KE0E=;3\I M2IG0AK5*A;.1MO*6O#G59)^]X4 .PK ,U65>;(QF4J-

0S_\6MFI:ZJ5#*IO! MVU\WLH0&6L+I"YEP0/WW)ET2YCZC< DG+]E;.N5S;0K":ET'E-TR#%\^-%B0 M+IHRE7XECL:A (T6__2E[G*H"%-NI/XEFZTVOJ_#=7A<2"! E>C86

M.A!"0(E9H[V;>%,.\Y+/,\&*S3R32>9T &$F%X+I1(H\$=IMS"4E&3@Q7N') MD! (,>]![&=R[BM'M!#\LSLG*3&(3++("LW,D?206E>%&0PT(9W%.S4;(-5% W4 M@

7R6U(MY6N%I\37N05IGT&V&PS=C+;D95K7!;&("'OJ6V=B"YEYV@::QC+ M[SAL @ \0NPC0=C*E2ZVR$CJ8L#2BJR<8595^<?+--]"-TW0M'@HZ, PJ@)' MEP@4C?*1(@OH"^ L\7

MT-)2=M1QS5]FA4(&@Z?9"N$>WE$@@H&M.74-%KA6 M84%NH)G#A@]D'E.A:6?/"K\S.)WTK=,!M$VMZL25^";*1"+_[+ KR?$/$'V- MA90T^+>D &MAVQ:9"XKO@DO*3D>@R=#

[66AML@2*%1E'4P&H!=^U]):* $"8 MD =L)&+P5B7"5QK 2[[)SZIZ=C.J@=3;:'S#S1'URO:]G>]GYZ3NG=/%+?(S^FP.5;#;Q9R-LF8Z.?1JL=YAY]S"9^@#G%C^+]EGM

5GYNK@2G:PLV-+O(DHY A@X?#>Y M=#.!BWC;=$SMD+5M>7OJ' ;A)FUL-'7;^+TV^Z!=UP^?[+T/0Z6>H"P/ F=3 MUK&1DQ_7SH_BP#Q4A1;F=.BC ,E8$?

(M^SS!XLL8;YTH_K)O[A5[C)*=L= M4N<1?\OVF54OE$"64#U4JK,/0(V#4J05/MK(KO\W23N'.677RNB;8A[H\5ISUFM/5Y:!. M: *O15+Q&7H.H9$W',=>.

(MZ>T6K@Q!,3&BX$A1C_^+YAJ/4#BOY0V\6Q-YD M%-02*Z(J%WA:5: J_*?CP N"H/=G%7>$Q0^=#KQHGC"+NO7,O=/'4TK>;Z/2?K/.[AS;*S]R_ZJ:W#K M[G*YI%'#B-

X5AQRJ&H=N'#:[%$P?FA]]%U58RF9^ R0DHQ.Z1@/D1&"VOB29L_Z&O'K:UUI.N MK]SVD SB"I:Z6=\;2'UV:;<<4,&>XP!)U5FG_K11@7C:8-WDK1=,G1G71/0&[:M+-JP]B=?

RR_ZFQ7"GJK?7 2K$X:4# $0'8(MZTK8T 3W7= @O<79RA[0T[J#0BRIKQ>[^SCIN@W7KKU_.&DG^[,+,@X;6EIL M*F_M9IV#,7C:%$1V:5/FZ,4QJPISU7^I,)(]*% AFWK38.2-

,+*&WG@X]D;C MN!?3!(L-PYD_PSSL3<,IZNT$=T$\5M90L$P\&^-YGO_BHX7)<<>E*/;"U M8__""F"'7D\/6M\3U]L=_NONI@)%^B:F$] M78 T*?C/BO=EQ+WPZC"?

IV8*V/4VMZN!$=@TP:L+Y0R]0\2T'RNNO@?4$L# M!!0 (.F!9UD24A(H* , /T& 9 >&PO=V]R:W-H965TCX)1"V674.=>?)XFM.Y3, M'ND>%9VTVDCF:&DVB>T-

LB8X29'D:7J22,95M%J$O5NS6NC!":[PUH =I&3F MZ1*%WBZC+'K>N..;SOF-9+7WD%7Z+[VMX96R832<(G*[_XV"RCU!-"@;?S"(R&![Q"(3P0T?AOAQE-(;WC_OP9

M_4/(G7*IF,4K+;[SQG7+Z#2"!ELV"'>GMW_C+I]CCU=K8<,7MJ/M\7$$]6"= MECMG8B"Y&D?VN*O#GL-I^H9#OG/(^\Q4&#Y%W-LM3!Z"\9;$Y]?A%2#-Y'C MRO^4M3-

TRLG/K6[HOW_2UL(M&EAWS"!<.&=X-3A6"02GX4I+2?5;.UW?=UHT M:.PB<13;(R3U+L[E&"=_(\X9?-;*=1;N58/-2_^$.$_$\V?BE_E!P#7V1U"D M,>1I7A[*Z9"% &O>

/OFAG%U6:_$/I<5-89ZIM_7\MWA"M?A_-WZ=SVK,9E M1)?%HGG :/'N^PD_?, V7(B6QY"_Q__VL$XKV>1I4?P>P3@2X?0:D%*0*4& MT@CKF&K\W'H,"

[J%7CM4CC,AGJ#A8O"W%BS6@^&.D\D6*1@^UF*@1H+6: F. M8&LM>PH>KCJA^*W@33:*R I/MB>R(1"P7\C6(UF[3Y84+\"0%]<->?I]8 M8VG M^?@P?&9FPZD2**

EMR38_F)*5F%-MQX70?!*[2CN0R3#MZG]!X SIO-;74;N$# M3"_>Z@=02P,$% @ Z8%G6:R)+LV, P !@@ !D !X;"]W;W)K&ULE551;^,V#'[/KQ"\8=B (':@U/0'^T#\B[](!2F@9<,-XI

MA&J>+,>W=U/1CPI_&MB$H[622%;>?Y3-;^4\R8006"A(S#3_GN$>K!4@IO%I MAYD<7(KA\7J/_B[&SK&L=(!I;_\R)=7SY"91)52ZL,3H-[_"+IXKP2N\#?&K M-

KWNE)6++I!O=L:,H#&N_^N771Z.#&ZR5PSRG4$>>?>.(LN?-.G%#/U&H6@S MFBQBJ-&:R1DGE,)$R%+#=K2X]]AZU 3J$0)A5U"'QJUG^3&XJ*3%#NBN!\I? M 7JKWGM'=5

_NQ+*4_N421V8Y7MF=_E%P"=H1VJ2#56>Y=,+>)-#I).(-WD% M[R0^I5W)$5L.O%1+J0Q#!H+Z>]EB+2Z5?\YEH'"

l VN

<+]$0"? M(5E\]\WX.OOQ OWI@?[T$OK_N:C+0./Q2+T"IC[4P+*FU6[+Q8<(CNQ6L8KA M^N?T4*U)&>(:M589QRJ]\(&"\I72;8O^)2JRS;%7P=VI'1EC'Y(XXVM2GJJ+VG"B\M-

WD0$(3" MKYWY%YA>U*':8!FON_(=4]T^=1]92^0LI15EK=XJ'EEB5.A0J[+/AP"@@+<9TV'X L3:W!CJ(_I3)]$'<_!F*[TT8 M*O3-UQE3W\>H?!>87OCA=O [7_Y)8PZXK0B:%?/=]]: (4

CYU1B*N&9)W4K M_O:DU7B896\&OS ;U#9JZ9))&FD5&:I'BI/LI>"#)U8+#(3:%9^E^7 ROE;+ MF/FO:0QC.+HHL.-\6*-7QAK:\LRU$>510=L*4#[E0;<>Q[TMB

M[V/'%RAI$2&U$_97)XB=TUIQ&7A.7OQ(GD5O#5E9+(G%P?PZ%R;IT>SN0%< MQQ/H7_P%02P,$% @ Z8%G6?W;L]<9%@ M(D@ !D

!X;"]W;W)K&ULW5Q;C(YMM5"GMM&Y4!;]9 MU::4#GXTZR/;&"5S6E061_/CXR='I=35P8MG]-T'\^)9W;I"5^]#$;8M2VGN MKE11;Y\?S ["%Q_U>N/PBZ,7SQJY5@OE/C4?

#/QT%%GENZ5U74EC%H]/[B< M_7 UN\ %],2_M=K:Y+/ HRSK^C/\'9_?G\',*E"90"Y2/C?C;I618&4@(_? M/=&#N"Z

MT)E65CP*GQX_.W*P'ZXZRCSM*Z8]WT/[J7A;5VYCQ:LJ5WE__1'P&9F=!V:O MYJ,$%ZJ9BI/CB9@?ST]'Z)W$Y%0O9,]]'8=^'\NE]894);_W75@IG>ZFQY: MT ^VD9EZ?@

F8I6Y40X/8W@#^,;V MD$C4 !8GM\]K2E#7#887N)NBMJ!TF;0;L8(X99DN.-_L,VA"KHS]YS\NYK/S M'X7ZO46=!MTFG7(;HQ0]7(&81,G^3J&_V\$N/0@?3H"^252:-7S7D5^JS).8

M$8D3L85? $/ -:B\J4MB(S&-+Q@$DT4^PA'NE#2>XWN[#4U/^QO_1O^ T1AC M*?@A7*^M@R?93Z2GD575 JV_X!QTGQ/T2^P(=(4^#PB4L@+L@20GB#$0*PAP

M4$+FOX'5TU:3P"-J*YQ5H6-8B0HQ00&+LM88_%5O2O04<6 M^(K*WDMJ()G6Y M0 1_<SX\/_@NT*>"ZRNS![!:OR8?K5;;:1U9I8+[7%7(Q^+5 M]83HJ*5IT8SG1'=6C

MHM/S6,Z*1M[)9<$& E^:%IY'?09M [$WC:EO-3@ @F5P G*--W@,"&UP%F_S MH'3&'8*RE@(0$QR.#06\13C3V&6W$Q/871N0"7:_! 2FLXYXOE*[S?U? MN,: Y>&-9A#?

M4/MRRV[6D>JL,3\'Z-E#8H'$)\(1,2,NHEB(60VT#KZ'X=$G)S/\ MC_;]2I%\+\[/)Q=/CI&1V60^.Q,CMGD1;?-BU#87G0=XTSF:72;Z$#JDG5Z'

MD]2479JEN*)N,6#S"3'4Q,5B;60>7!1]$T75$G0?+IIW6NE;AW(-%*IG(I% MFVU2QTGP((UH>TW!IR7=:5(J#L.$"?L)O=((N(&7&ZD+M-A#",2'%O:=^/OV M*B]=XJ_9%

[05H()"_P& 74-X807!E$K9WKG ?;5ER[B.,4H_",_R>H1+'T." M7<*.^@\&BB&4*YI(+$ +'$](@F\W!8^[CR4O*#R;=YNVYSB1,#J[=47K=Y-/ M=8>1%J Y5!^%@I$(8;

<;1>MRE:%"HBQZH1F=QK48595+TE10.P7+?KS0XICKB(I%%/!VO1EBZQ%>0GB&B MV.D<_AP%NEI.56.>MJ>VM+O*A34KD :8+3C)),-$N9?R,T#[N!5IM;5MV7!^

MX39@7G*UPC244X)@=1V(@^>5=*%YML-:!:7^(S*PR5@$/-6W'W?.MX)?4, M$;L1NJ>_BZ6([?*64N'N.:KK^42DDW!7E4,PUUJ?Y21^9>)YQ%0]KYDHR/7

M$/4.2>9JI0R6')R\!123VLXAUO.Y%@3\"?Y=UWA* M+F>T%C]O -K5!AT"B<9HA?QT&? *4%EM_/53VQ7#? F%2WT!2MMP)G" M_1!\ >>#-P4^,W,M524XE MJAMP8PU\)\77C)W-

@V^D*7I/Y,D341\]S,;2L@24Z3:0O4,F:4N>B"T/M^)9J(;RWJ'!$I9.;\EA"CP MT1$<@0KP-96(WNQTOW6P5#%D>](4LL/UH?@/"YTA)O/7G3#.:S$YS2B^":>R M3547]1H/V-HO"(?

B&Q6$L1QVIQRB!D6U;*/6" U1A:E" *[7VP6&1%] B^@' M(0R2(:]"E]Q)6W54IV@M:I_/G*>W0G?0:YC%*;47*:(;RA@-/*.8QU*>EW7

MN;CH4P.BN:L0!7J@8>8Z@3!NLQC78>DC*@C@@3I.]W0YP' M+@2H(G$3T%Q0WL@)/@CF@-@C5#0#&.U<.[DDBKW,YW:C@3>+V4*,G65_6&5&_(/#N'&;B? MI*XCB9&Q])/

S0P_P);%75\2&Y!>4!H.P3F51X.'I'%1401=*K?%'D5 %[5A M#*CS8"^4@-)^0LPCXRR$-5\]7DW2[KQL]&@]Q.GH;3;90Z"U-A)-T>#;?? M3%6DS\C^,^/A]+Y;3H+&W^^3?911MY#

(;<3T+&U+"8>Q<8BI,\R3\0&/"2Y MJ+HU63^6#T%&D)]VAMCT M7Z2<4B))=R* 6P0&,?@05#*BFB#UD!]?;;5-$F@Y$I3#VE$1?"&BC%G&O+,.

M^:@._Z+D/N7_FH4]SR#SFH8/DOF/!2#I'(N6\%!. S$N] (N%[<3\6O=Z$Q< MG,ZY@C;[47BZBK(UE,+/@*2P5 52;,H,X5#$/=VE$1?&QMJ(7M^L/E'WV N

MPYTN$(=G8VV4+S\'_IT!3=*O%4A*I5I',3+UW5@Y;*CN]7Y W># U&&].H10 M2H+^^/[3)$W[ANSTTM9^D2;-8KD*EBM3G)1(3!P($"(GZ/=S'%\)?CXU)NZ<3#<>0+

M]/M\W4U\D/3)"TH>=G891_BPI;H2'8".H@'[4[95RP[71%U[PFYX2X3^<$ZS1X>)UIQY55P 7" M1%SP (\KGLISFKZ+,S@%=]% <*#JX*:HT4+)]:^0U]-'I(;FY\%*X*#KG)!. M]I?

WC&)+>3G=!2H1)GJ>_5UZ(@%KE*"UAO2$$U?;&5&TIIZIN.]R1+?GQBZS MYV>&-^4]%)BD+U1A)=*IB!7QH1\3968-[DDUUGK6#R!6V=8[O T!I;6%7!] M%

[N4/8$A3H48;S*,7#U2(WQW#LP@'L' 0W2.8(YU]$\>&X)BH9E6!TA7 "8D *'A9VJ.MAS7\PD6.#-BXW!?E#VP:!44#O.+;L@2L8" MICF;AP$-N%IR6 1R:G\K02/@4@$0;F34K/NQ;

(^>UE$S^P>)_? 5;4QBHV < M/#-;RFX6;1+^(H"CP2F$710ZJ=;$=<>=\>27]#*9^1@PD0]=/6R/R'9G^U@U MB.Y_3::4/>/4 09:GQ;6J,2QH7;5G9W<"_0V';1"V?=4]BNY[P?148#:

MS1+/1H=_7RR2O.4ZR5MV0M:'D>IIEX<'=G^2A(-L385HPIJ;$B@)A]$^7(T M@P4L3O?B2PAU^:!(3]AD"ZXO!!>Z>Q]/7@,/M']PU?VLOE^IZ!8.MJ R@[=(MWJJ+WE>%A-,M,E

7U%QZZ!"RTPP?*.M<%6R1>XDG;6SFM*TTHP4^/@WIQO$] M2'H_JP'L&*HV.SI/+7OXJ>B7N(D M+3E&\988F?:58[>A1[VGCI353H7J3RP.[3$9NL"5THZT[+X=4B"BQF#?[;&S

M'M'+5">&PP3=+; 8,&|>_D;]L#HM*'F5+G&6Q$&P$=C&I%)#=UZ,.Q22 Y0< M')S@1]*?2W(TCI_91D,JG);XN_U RH!6EQCZ]O2,B#P92)^.'#U'0K=O@I3

M8YZ)$K4K/]@36@]]0W[_MK/=D8WW;?CR#;'%[W/L]L_$V"=V +0]00K#Z MR!<;U)!+!Q>Y;%V G]=L#8MDDGJG/_P[-A+XID.&C69J4Z,.#0+ATL3FTV M+,;99%ED?

EQA"2F*AM0D.)Y(]&M(P6)ZZRY:KK53SE|&'^WAG^]_JWT?7-X@.,>K)B-O_BP M4.N|\T=?N?0>SDUR4G(YX*08DOD"GLG!&4JP6J6R4U\2=_?R!+CHN+3^Q)>

M*!Y2LF>PI:_\"IL9*- ?MF>_ E=UBK9,E> ;U'#<(+!3#B@T3.Q\A] !!9V M;_#MN=Z<:9>?8-+F SZ)^MZ:I>23#]\#"I".5:\?OLIO G8U/SE['

M@44:A&M]_W/GU3Z(DGA?)9/@L[PL)^])=Z*=KZ=)>GU19!"ALXZ;[,N!=&V MU_CBYGXH?+/^1.M/IFO!?LZ/O7_I RQINTEHSO0.@(A^Y]1G[ZG!@7A^L$BQ_MG?

8M,RYVXSYHY<'$^$T'43V#IZD)/$ M:$-*25@F"A(K]GX$O35PV-]:">C,$+LT^MWOLW6D*TP)X//0MA3*%_PZ>L$ M!()[0_NC^MP-,<_&IYA?@7FO<8N?8"GP'KC$-

Z_:W1[K6PCV).&+86'!FA?X M5[QH,BV'"ZGB.Q[BY[9L0&#&B?>@$E?!;2WP][:Q.,3",I_-23=_?G^UP"^G MXE/,*,-WDST;TP0TL 4I@/0%?WRF4EM!G=H;;57O[4,;&P#:6NP XJT"9/:#

M6Q2C*@!=*1H,3/C1.:IU4#=8AGF>CBHH/"@'@EBC;VA2.O"YO_H!3[=4V2 / MX+CS2F\6\GM!'L>N:IZDY'HW&>K7G+-KQH=&]$NZ&31N0]2;=@GPF2SC'N_^ MY"0=:0K-<"8IQ7-,

_X?S1Z+"K+UNEICT2.OPM ^C^:/<0Q.4\BX00]!14_P M+C<0$;#X O=I$1^%[4;$XXO*G?I%U6DKJK4@YT%',%F2K8TKO[QLB)I\$5UG3_30'?%7S.>J_(^,L(PAK>UZ@WZ<:N

M9^/STA]5QFI\\GZCI$./JYV>Y:\BCA'H'>1SY"_Y-3Z46/=>Z<[^W54-_R,_M\?IR<34)YKSSV4\-MS&HR_>)7RXZ/#Z?"_8_!M%N.@1=P#G%\>/)^)-B4JE M8C6%'Z,;#RM?

QCE,>D+S"1'T9,>Q:43FWYJU-/U<[.JVD@:7L@3D*)RF^3 MM_<#N5XAKXJO>W&_AUZ3\MD]OL"\;V]\07KQ*W8WB-)C9,>8X.B M6A>[3C?MT=%IOY1&/F%_R:^UX0P&^

/*V.4*F.YBI8=/)Y,XQ8PG8O/ND..? MHG4:9^G]BVV2!N5\-<0H9VK;>$89H^)& XF%77T/"EWS$'_T6L"AYHS@P\:^U2VRIQBE,2O M\=K\'HG>$2]LDQL$DPM6E]*?T7CW.]\J;_&/2;

-G9\>/O:'\XRH>S0U M!I8@THPCU5R%K6.YB@P-H5WD<(,73= M'[N0.==1!OD+CWKYQ=3Q4:5GJN2&!"!'9(W+-?BNJ,6$=RI>(Z[$!,D-CQ1Z M":F)8UV 6DB

=RU@KI7*:0##OR:!!PE5-3\@HBR]/L8B@_R\RN.D,JD6:MDS M91[J"N,0?]H@3T=U/XZ2)9SLL;=F:&W_[^QF5UP^2OYL"X(A^N,T-+1=.?X+ M+O';^

=P+OG/OG2/\U_/>2L12V$W905+CZ?G9P<\7Q%^<'5#?P1F63M7E_1Q MHR0H%#X OU_5M0L_X ;QSP*]^#02P,$% @ Z8%G6:D%'(+D @ VP8 M !D

!X;"]W;W)K&ULM57?;]HP$'[GKI#2]MJD MC(2$'VD+D8!UVAX](>BVAVD)/CF(5<=.;:=T__W.#E"Z =K+'DCN?'???6?N M+L.-5(^Z

##DI>1"C[S"F.HF"'160$EU6U8@T+*2]J0&5;4.=*6 YBZHY$$4 MAOV@I$QXZ="=S50ZE+7A3,!,$5V7)56_)L#E9N1UO-W!G*T+8P^"=%C1-2S M?*UF"K5@CY*S$H1F4A

%]JY$W[MQ,NM;?.7QCL-$',K&5+*5\M,J7?.2%EA!P MR(Q%H/AZABEP;H&0QM,6T]NGM(&'\@[]DZL=:UE2#5/)O[/<%",O\4@.*UIS M,Y>;$[*MIV?Q,LFU>Y)-X]OK>22KM9'E-

A@9E$PT;_JRO8>#@"0\$1!M R+' MNTGD6'ZDAJ9#)3=$66]$XU44C.2;LG[(P"]TXRZ8&O\5BRCP!QELE: M&";69"8YRQAH\NZ!+CGH|V 8#8;$V1;Y$F#')U

OB;W4IA"DSN10_XV/D"6 M>ZK1CNHD.@NX@*I-XM G41AUS^#%^]CAQ>?P#M6[H_Q4AN%K?+S6,$-7OSH<&]0Q>>G71Z8>W9]AV]VR[Y]#3!8YC7G,@^>Y*[

MIYH]4P[":$)%3N: .%EF('?V8U6CV;S=:S_N MV%]K^N]7&ULM5;;;N,V$'WW5PRTQ2{!U.C]:VP#N>5B"W2!8)UL M'XH^T-+((D*16I*R-_WZ#B5'<0+'[4L?+'&&G,-

S1AR.YSNE'TV):.%G):19 M>*6U]2P(3%9BQA.86B/+VZ!*!'$8CH<>DMZYWO3B_G MJK&"2[S38)]J8OKI&H7:+;S(>W9\XYO2.D>PG-=L@NNT#_6=)BOH47)>H31<**

M2=!8++RK:'=NO7M@N\<=^9@#$[)6]E'9WS)%U[H"*' S#H$1]\MW] 0#HAH M_-AC>OV6+O!P_(S^N=5.6M;,X(T2?_#S]#A94]8 M]@F[;NTX]"!KC%75/I@85%QV;_9SGX>#@,E[

?$^(&YY=QNU+&^99B03B[9VN!YGP>6)VTT&V![GN_M0.)W0*;P54E;&O@D<\Q?QP=$J&<5/[.ZCD\"KK"^@"3T(0[C] 1>TJM,6KSD MWU7>AW3%,C,URW#A4348U%OTEA_1*/P

M\@3AM">J M)(#(N&DAC!+Y D]&B%Q)>O1DDR>+A87((9H MXD=Q",,^KG4,!Y2@"G6;D9K5)"&&./&GDX3V/(,$SCLS&MPK2VNR-V1I^S3V MHV1$ _?K0O;.Z>

6LWUBHC8QR?^1F-%[B1DEQ^0-IWX'_*.A M$Q#Z:3C9"S!']3B]8S\:IF]E1--.Q\B?)$,X=D<$!]D-EP8$%A0:7HR"NBN076&577;%-;*4HMIAR7U=-1N M

&ULA55M;]HP$/[.K]"R:2I2U(0D0)1! MI-)VVJ1V0V4O'Z9],,F%6'7LU'9*^:]W=B"C$F4?<'SVW>/G\?F.V5:]UT" M&/)<<:'GF7DF/,0T"G95047TN:O"X4TA548.FV@2Z5D!S%U3Q(

K#45!1)KQT MYM:6*IW)QG F8*F(;JJ*JI<%<+F=>P-OOW#/-J6Q"T$ZJ^D&5F!^U$N%5M"A MY*P"H9D41$$QJRX'TT5B_9W#3P9;?3 G5LE:R@=K?,GG7F@) 8?,6 2*GR>X M LXM$-)XW&%ZW9$V\'"^1__DM*.6-=5P)?DOEIMR[DT\DD-!&V[NY?8SI/0, M+5XFN78CV;:^"9Z8-=K(:A>,=L5$^Z7/NWLX")B$;P1$NX#

(\6X/S$27712(X)FY254;C+,,ZD2X7Y5>:%4)&3F\>&U7CCQB=?\3V< M?:=K#KH_"PR>9/V#;(>Z:%&C-U OR)T4IM3D1N20OXX/D&%',]K37$0G 5=0

MGY,X]$D41LD)O+B3'3N\^#^R?;+D5)C7ZLGOR[4V"A_,GV/26^3D:+(MHJFN M:09$#ZM$@WH"+_WP;C *JY[@G27OUD/HU2OJ+,FJX$%OXZD[QO@DYG'&K\"A MNYE,8CEJ

[DE8$H@A>18UTQLR!D3N"(;C1&Z/^UAR@Q4:U N;]>0[8R!W[-) MM)F,>[=T?8#^GHS#(8ZCR:3WK2A8AOB-$LPT"GQ2L&<[T;[C-!Y$]M>[!:S) M4O*-2$,7*T88,_7%\8"M3&M2B-

MU!IAVCKN5KLN>-D6_S_WMH7>4;5A0A,.!8:&Y^.A1U3;EEK#R-JU@K4TV%C< MM,1.#LHZX'XAI=D;]H#NOR']"U!+ P04 " #I@6=9442HEL@ #M!0 M&0

'AL+W=ORDJHJ+H4#=3X4@A948VBW'JJD4!SZU1Q+_3JB5=1 M5CO)PNK6,EF(5G-6PUH2U585E>\WP,5NZ03.TO'$MJ4V"B]9-'0+&!9Z?F[5$

MR1M020K%5:5+TS,JA8W9WTK;_#@ M44V3A10J(HTUHIF+3=5Z(SE6FZ9LM,17AGXZ6669;"$G#XRFC#/-0)'/SS3E MH"X6GL8(QL[+>K2;#BW

.V*/(I:EXKDL^LQHUHE581'4Q'V&3-%0I2-NI.\AZ(7!' MIFVF=]'H"8-1F96V\CF\XCIH<+@U^42F[B2.\0P"]RJ8C.ZKAHMW *10X>Y1 MM!M?=$NAAH)I16(WCGW\CN/QZ &VE!-X,Z:

NB"#.9N'H66@TH4<*@;PF[M4D,)>9&\41.=97[V $*Y!; MNVA,%=M:=],X:(==MNI&^)]YMP@?]=RR6A$.!;KZE].Q0V2W7#I!B\8.="HT MK@=[+7$?@S0&^%X(H?
>""3!L^.0O4$L#!!0 (.F!9UD'HRT9M@, &8) M 9 >&PO=V]R:W-H965T<;/V!EMA/RI$D0-+UF;J[&;:%W<>)Z*$LR8ZH@"<[(LA;J0R&+K ME*5>T.T.O(SQW)V.
[+>IG(Q$J5.>XU2"*K.,R>T=IF(S=GVW^3#CJT2;#]YD M5+ 5/]+^44PES;PV2LPSS!47.4A8IB80P?BWCNFV*8WC[KB)_L5R)RX+IO!>I,\\ULG8 M';H0XY*5J9Z)S>]8\[$ (Y$J^X1-
O;;K0E0J+;+:F1!D/*_>[*6NPZ\X!+5# M8'%7B2S*!Z;99"3%!]193=', P%*UW@2.YV93'K4D*R<_/;D76<8U55DK8'D, M]R+7/%]A'G%4<#%GBQ35Y%$=]ZZ$*KY(>PW?
*%*BX',>8[SO[Q'& M%FC0 +T+S@9\Q*(#O>Y'"+I!>"9>KR7>L_%Z_XOX U=1*E0I$?ZZ72@M23U_ M'ZM"E20\GL1TU(TJ6(1CEUI&H5RC._GPSA]T/YVA$+84PG/1)S.,!,%-.;,"
M%TOXD<<$7)2YQAC^+% RPPF^(ND6[IE*X MUH0(MWEB_6\3.: C_H.33H M0W@=FL$ ^MUKA^#38;?4QB<<.'.A6;H/L$I:U%4#_V-X%3A3PS_7L&9IB<#B M?ZB5C9U*(4T?
\ZS,:L\+\/M#N'2^TQ%\2.]A>OY(9Q12[]52_^L6I[M 45X M;]=4KA7"*_U* 7.4F6V%-RL?:K(P8QKMDD/U?'ZA6T)5MB513ZJ?>^B3I,<64[:&DYO3:A
M85O,$XFX=V##'BOX;NIRVN[8_J%'#]J1QA>-X]@T*^>SM-QJ/80!^ M=PA^>+P+O)V[+T.YLC>\ EO!ZALO[8_$;?5W?FZO/H#^<;DBN>*("S)M=NY
M(GW*ZE:O)EH4]B9="$WWLATF]".$TBP@^U((W4Q,@O;7:O(?4$L#!!0 (M .F!9UF!.MZK^0((X& 9 >&PO=V]R:W-H965T(N96[M3BYEL3<4%WBG0;5TS]7])E=S. MOF\,-
I.5E(]VT6]<[I3+ MBFF\DM4O7IAR[DT*'#-VLK:N-K'MG4E!S MT3W92[\/>PZ3\ V'N'>(G>XND%-YS0Q;S)3<@K+61+,#EZKS)G%%^?6FY>X??%2AM%I?#G M4(X=(CV,L-?
C7#&7(P+306!ZC+Y8TG4KV@I!KN&^ MHQ>P+!E%LDO_G1/=1;AI3:L0;K5NF M!NL5*G?HUYCWD\@_L15@RR YZ;?#L:E0H6T(;I7A"ZJ<:[=YU'FT8:*P.J/0 M'T]&?
IJ.8>Q'1)Z.LAV%/3->.[(UBPD!+1:P4;PZ%R#/9Z1(UJXSJAIO-KA>G;Q; Z--N+KL?\.^\Z]7>F-EQH MJ'!-KN'9>.2!ZKI?-S&R<1UG)0WU+SQ 89/T.(O4$L# M!!0 (.F!9UE&4]U)E 8 ,,3 9
>&PO=V]R:W-H965T&A M[JZDN+^^,TN*HA*&==, !03QVIGY9O;;;Y8\W];BDUQRKN!S653R8K)4:G4V MG9-BJ+J6O;X;1D>36Y/-?W;L3E>;U6 M15[Q&P%R799,/%SQHMY>3)S)
[L9MOE@JNC&]/%^Q!; CZOW]1N#5M/.2Y26O M9%Y7(/C\8C)SSJX<;;!'?,CY5O;.@5*YK^M=/=$]NYCB&A@7/%7D@N%APZ]Y M49
GO/%GZW32Q23#_OG.^PN=/"9SSR2_KHN/>::6%Y-X AF?LW6A;NOM+[Q- M*"]_:5U(_0_;=JP]@70M55VVQHB@S*OFR#ZWA7B,@=L:N!IW$TBC?,84NSP7
M]18$C49O=*)3U=8(+J]H5NZ4P*'\9$*Q:<"2=@OL'Z(^[80_Z]FS+1 ;_ M_X8NX97BI?QC]$!-?'\X/BVT,]EB*;^8X$J27&SXY/+G)TYH(QW)SN^R\\>\ M?
WM&GW^FS:R=,F;MJ/R]NXHHL+6R8! M?_.Z0%60<)Q7H);U6K(JDR=GQKNEX/R 18 +3OV>ZH=<%1BLQQ&X9N*%^N@G%#DVL8;Z MZ"4!C' AZ+@0C'+AHQ8EGIVW.-IC$@L-
,HORN";(:$-2'#RC^7*D=YRZL%O&"Y M@ ^L6'.HY\ 95DM/+KSM;&C85<$PM;MT6:-"M,],:T2>TL/7=<:+(6:-0AUF MUKLEASEAVAQ@TJ6%6L?57.)~"IA/
U"AW2'(9O#I]@59$DB46K748QLBTH/M MKF*LK1C;5^S,>#3OC-M0&C9R#O+C_=#LGR39QR9^I#S M(@-:DX[[M#N.,"KL&!6.JTO3O6DJFGF'&?55 GZ])/&41"FMG!)F&Y87U$:P
MP)>HK@J6&/9A"XZULF&FX)5>FVU=WQX567KM-%@>CC$I%&(PTS]@9,-.'8 M;O%=X"!;BQW2*N)&V7"##VB6MM\B%7K*=V8TE6H/@YB8@F<\;?TX9B-KGND$
ML6DGOK$'VN:**:X/T.!P^8B1V;H6?O(K9&N'!6M$?*VD6% MTTLY18%MVK9M]8_U8*XC*N(Z-:LPW65*]F Q7O'X",NVXQM'TX>8XB9SGF. M=TW :$$8_D.Q!JKJF%$4FGX?2_#?
P1W1X,/VVS,3I@/M8]^+ M3)?T\:P]:-<[TD+777IGL\5"\ 4JG7'%,$[*A_D;4J,BS:6F6!2886C#"=CTY,6.05-LK;G0(QHJX0C' M(87L@1GBCVU&L6?Z?H000I)=A$/GK7#V-
+BEY@.L(FWU,@WP:&UMQV#/8 M\9XWH#6+?3..8MQ;Z YO^0DF'01LQK@;=|R-\'O=P[!|=JVD0D*06!$OGO=P M_0A6C\(:V36V1,;^_ 5 _A\ XG8+WQHES5>K8_O^/DB
LXY<0+L8#L='>][L> MU@HT$8UF'R?;A_%M"O]> MB^_Q[=W[X7>\47??^0KCV/NW4OM_?D5K ?S@!'NOWX)ODN"O[5IM;XT#@^[KRZ:\T M][52=:E/EYRA\-$?#ZO:[6[H #==
[O+OP%02P,$% @ Z8%G65#/0!H\ M P #P< !D !X;"]W;W)K&ULG57;;N,V$'WW M5PRT0-$"VNB:.$EM TDV10OL!D&<;1^*/E#2R")"D2I)Q1*;3 MR"H?U(HHC>.+]&5 2'S68OFV9?
K]%H;;+(EV"T]\TUBW M$*T6'=O@&NW7[E'3+)I0*MZB-%Q)T%@O@YOD^C9WY_V!WSENS=X8G))"J19%;UDA$*R".]6V5+^U5>5+HT2%VL"/SV[7_+2(+)%P4%$Y)KP= M$J;?
27@%7Y2TC8%[66%U&!\1^4E!NE-PFYX$7&-W!ED<0AJG^0F\;*I{YO&R M[^#=,RVYW.Q7Y,^;PEA-#?37,;T#7'X$](@:/G'1NPZ'-9:]YI8CU?BM%#V5&6]M6G>1'5VK?PV[M -K[?
RUPK!(GN1ZOO'.#4"M!WD U!W(-8YFLW-@X)L81[91%:3D3XAVJG4KS M3>46B3(>2+4$6O[*=4O5*%F29.$D=R39)P+V+\GE(-GL=SUYH(>A*XJBG8R MI ,LL&2]0;?
+-6!=D^F0' 6B@H81VP*1'(A$?-P)N)X]4'T.'@/=7&>Q+8@3 M]?/,];-KZFSFZPZJ>"LVI*"7=O"K:75R^YO! MY+X='SX57YC><*J$P)I"X[/Y>0!ZL-
!A8E7G+:I0E@S4#QOZ8]%V!VB_5M12 MX\0EF+Z!]W\ 4$L#!!0 (.F!9UE!)]9QP(!P& 9 >&PO=V]R M:W-H965T3'(A5AT[R~E_>]W=D(*$^6%V.?OOOO.OCLF6VT>;0&
[+F4RDZ# M_K$:AZ%-"RBYO= 5*#K)M2DYTM9L0EL9X)EW*F481|%56'*A@F3B;0N33'2- M4BA8&&;KLN3F90Y2;Z=!/]@9[L6F0&<(DTG%-[$_%DM#.W"CB43)2@KM&(&
M\FDPZX_G0X?W@%\"MG9OS5PF:ZT?W>9[-@TB)P@DI.@8.'V>X!:D=$0DXV_+ M&70AG>/^>L?^Q>=,N:RYA5LM'T2&Q32X#E@&.:\EWNOM-VCSN71\]9;6_])M M@QV-
I;6%G79.I."4JCFRY_;>]ASN(|><(A;A]CK;@)YE9\X\F1B])89AR8V MM_"I>F\2)Y1[E"4:.A7DA\FM-I4V'('=@T53IU@;H3;LPX]O=BS28@4Q6'# MM&6<-XSQ&XPW[$XK+"S[K#+
(#OU#4M=)C'<2Y%)PB54%VP0G;,XBH]LVH?IG-UJXSDQFK4Z%U_\@L& K,%0G MW-?\'!3D MF"OU CH?,YR/Y8;B>C\]M50!I^2NN7A@\T[RP) ;)F&M)7>^N
M.26IEO%7K5NGU6%P3^^ZU5LU>BVUO:7V<@2YT:7'_U>G0I%5UY;>T9Z->S](M[T$!]JA\$,HUF*Z&>D0!W*2%?_P,GF@T5?Y^6O&L?QY%H]Y74F.X]"B>D4CA M2L)-
D3W@(+KIK302S!*1X2I]/8W/|_TK=NS-P[V.+<%L_%RR=$NUPJ9Y.VLW M^F9-Q[_"F]EYQ\U&*,LDY.0:78PN V::6=1L4%>^_]<::9KX94'C&XP#'T'FN M->XV+D#WAY#\ U!+ P04 "
#I@6=9!"Q6E<4% !S+@ &0 'AL+W=O M2*6)&F ?UVBQ.ROQZIHZ>"C_%VQ\N"\7*1!UM\ MA_GG_ ,51^.6$L4ISEA,,D3QYGITHUZMU5DIZ&\&>,].]-RDNY)^2A//"C
MZY%21H03'/(2$8A_CWB%DZ0DB3B^~-!1VV8I//[]1'>]BQ<7P\W%U0%&)*$57_1OJFKC%!8,$[21BPB2..L_A]\;6[$ MD4!PY *M$6A#!9-&,#D53'\@F#:"Z5#!K!',A@KFC6 ^5* W
GVHP&@$QM"[M9#8"HMNHB@NBX,$^5EMQ++2:POS($[8&U'E\YV% M7K]Z@UZA.$.?=]1@01:QQ9B+P$K\.&R"N*V#'T'X0A(K>D8SO&+*S"$<2 ,I? M/WE)[_?KS1[]6-
S0]JYJ3W?U5NL%KH/L$DW4"Z0IVD1V/?WR.YP+N5+)IQ*Y M]4+K1=8KM_OE[P+:!B^3.\.#EUV[.SQXF=P;'KQ,IO^_.[_^S]?>R:-)Z\Y) MQ9L,<.?[(W?
^_;OXCWR.4_:/S&XU=2]GED/N%N-:1]]:6<\YM_$R!,2FA-; MC4X7* HX+@^+D6@819D# ;$N9 PEQ(F <)_OSKAUAQ$->566N M JFXXI9ZXK9$%=0_ -?G)R0.:.W@7.=
0FS(&$V),R!A+F0, \2YO?GWON0 M7R)-KYTQDSD#*)B.,^:M,^:]T?V!.0H#MD,Y)2'&$4,;2E(4,U8$65B9(R39 M(Z8\OD^PJ(4WF%(<(?$6%CYEU-%GRK*8OQX[!Z@-CONT5OW
MZ+WN60GG7-3^5P*^#%(<)O^L!S$U]_=JOFAGEZIRS()FU(MF ,)$@(4R:L;W*):Q;S5#GZHG #2NK-C=F9K>;+:TVF>C=:HZDV0S!9,,<&4TI#Q9-=W03FB\:\S3WQJJ
M>1K;6D(SE8EQJ-;I3[/M3_/%!Q0J&"X?1XCDN)[?2KNW%W1N]T+"+$B8#0ES M(&$N),R#A/GF\S45>W9@PNHS4ZBJ\KAD[W2F^HW"'W:821>1'_$0VQ5STOO
MJGGI^XV8M,;95OH-OI=Z;MZ#TBQ0F@U*0])LT%I#BC-!;5YH#0?E+:& MHG7S_K"RJO8N3@V91*'OXO37."U2J0E %UE!:18HS0:E.: T%Y3F@=)\4-H:
MBM;URV&U59W^G.D4Z$(K*,T"I=F@- >4YH+2/%":#TI;0|&Z-CDLOZK|:V M MVRW%VWJQM1E%R>:]DW"]W5%>[M5P_X>CNVF(UMXMAX&!$4\]E+4J\]E+BZ,UCN&PO M=V]R:W-
H965TUBV 4C'M_#_![<93] ML]X#&/*EX$(OO;TQAQO?U^D>"JI'\@ "W^RD*JC!HLI]?5! ,R.']-BI>R-)P)F"CB"Z+@JH_U\#E<>F%WG/% \OWQE;X\>) <]B"^738
M*"SYC4O&"A":24$4[):>*KQ)PL *W!> _,#CJDV=B4WF4\K,MW&5++[M @ZI ML184_Y[@%CBW3MB./VI3KXEIA:?/S^X_NN0QF4>JX5;R7UEF]DMOYI$,=K3D MYD$>?
X(ZH:GU2R77[I<" M\;D(XUHP?B6(HC."22V8.#)5*HY#0@V-%TH>B;)?HYM|<#"=&M-GPO:[UBA\ MRU!GXBW+!=NQE I#5FDJ2V6&8R,E&PD=43>/&WWX17P?==K(-+PG?>
[Q!\AQ M!F@PAH,="806EFP7P%ZC2P%69G-G9A?QIW@VPE'I=,IEH(M+M.&R[27R\>R M> 1%Y[(@7J2H&VJZFBR;.-4S;]:IOI=BJLRF)YC"5Y &"M>"=-5 NNJ%M &5
MVCF:@P5E0.%*7DU87#KMQHCK:@I=D"I?W%=?$@M&U^W4;GN#7SK)!C)K<;IN M.%WWI67@AC2+!G(K$5LWA";_T\[YWQ(MWD.:)0.9M7B'PZZHXD;9]6)
MO:EMKE0K=Y'P7SZO[F/W5.5,;,)QA0!+<$?!W4]45IRH8>7"'_D=I\ KA'O=X M+01E/\#W.RG-<\$&:"Z:\5=02P,$% @ Z8%G63X=(2+| @ #0L !D M !X;"]W;W)K&ULK99=;]L@%
(;_"O*JJ9/:^MM) MN\12VV3:+B9%S;I=3+L@]DF,:H,+..G^_0"[:C[<+)%R8X,Y[\OAP: S6#'^ M)#(B5Z*G(JAE4E9WMBV2#(HL+AB)5 U,F>\P\)%)U^<(6)0><&E&1VY[C1':! M";7B@?
DVX?& 53(G%"8OWP0!:9U!_L>%#B!4Q!/I83 MKGIVZY*2]@@C"(.\Z%UZ]Z,(QUO GX26(FU-M(KF3'VI#O?TJ'EZ(0@AT1] M!ZQ>2[B'/-=&*HWGQM-
JI]3"|?:K^Q>S=K66&19PS_)?))79T.I;*(4YKG+Y MP%9?H5E/I/T2E@OS1*LFUK%04@G)BD:L,B@(K=_XI>&P)G"#=P1>(_.%?B- MP M#]4$#2"X%!!V C,TNUZ[0;<"$L<#SA;
(:ZCE9MN&/I&K7@1JO^3J>1JE"B= MC*=D0?E,7C=(3.SSZA,T0H^I&Q2BB%&-A2+4"G M82=-LG=ULMY[R4)YA7SG GF.%W3([_?+1Y HN6OD?H=\=/CL7?+QX;-[FW);
M;5J[#LC7?M16T7&2M_G MRSCJ[\-H8"_70>]&73MA/]B,&NU-ZUB")S+;(]BT!(.]!-?ND<3<-DG%N2+8 M!;!V"M?0]/V>O\5O[W3'_]BG-!N?R&P#<]AB#H_#3!F]W(ZW$$=^>X6Z0-
B M1GNS.A;@B&PO=V]R:W-H965TC7!? M3\A'?(WI2FQ[!MK*$V/?!,'M]+P1Z8AH0B=22Q#U:TE'-$FTDHKC^T:T4=Q3 M3]S^_*9^G9M79IZ(H".6_!%/Y>R\T6N *7TFBT0^L-
5O=&.HK?4F+!'Y3[#: MC(T:8+(0DJ6;R2[^-,[6O\F/32*V)L!6Q02TF8#VG8 W$W!N=!U9;NN*2#(<
M<+8"7(]6:OI#GIM\MG(39_HQCB575V,U3PZO2DH1F4@"23<%XQK@\D92GX#9;4B'3_-+'*RI)G(A/2O%Q M? 4^?O@$/H X [_/V$*HB6+0E"IT'4!SL@GSG $>? 8I0RS%]
MY)]^12=J.LRGX_+TIDI8D3549 WE>OB_LW9)$I)-J$]&7G0WG"WF?8"?ZQ9690&*E/.$B3]BG/LS+AIJR^0PN4E4S\=]T"D9,2)?YM6(G M5]1-
:#GL|'KMS]"YW'9EC^'I5ZKK%4*MU6$V_*&^T G"\[UX[LD(A;@GXH2 M=X7M5:[[S *)E9+0+I+0/F9MMT/F*9!8*4^=(D\=:,[%LU<,^9>T5]^M[+=;> MJOYV%
[8KJK]:&.KN;^@Q4U"0Y([NF!#46?->O;]>NI:G$PS[;DN]PE)O?TNF ML%U>O$)UO?3LY]/IX;;;3+\PTP_2G=2%$4M3RO,E>D_FE*M3=W1)$X!G'F'3W,+UC;%K*
[6$5;A@:BH)^B:G0QOU)M-]CQD%"WPH^A+!@&L]2%Q]/Q M*;AA2\JS?*5>T2>9?_>X>*'9Y!6,M50L8RK\+V\'(+/H $T>%1"@T$1 M+91:.5<&TF!02O.KU?;NX+2HJ[^!.A>0
348FM3\@K5].5FM F^@@348C-;\ M2K7!.\@M:D6]"D,&V&!=8MO=1W%Z"\ICH=3*^R0&R-!1@0P%!;)0:N5<&2!# M?B![SVX)LCFJA2#>W2YQ#&OW43]R5SC:V@?
S\Y8=\E8[NB%QYJQP9%.2%? A MMJV002Y4=^-JKS:+;& ZP;O.7&,]'H1A*N1G*CM@?P/=R.W637\W6'N8JIM. M5;@&89#WS_X>G5&=^L(R^@J^$/Y-]8OKA:*^-
\:#3DM!N2646CE!AEM0YZA] M,RCGA%(KY\K@$/+CT+OZIHTPV%JI]IA.!;LA SG(#SFU%ZK-)G:@!IC*0 V\ MH\++[4WFOQWK%UUAR ;;,@&'Y5L<%"R";56SI4A&QR>;+"-+ CW>
[NU[QBF M_D)5;5)@0S;X$&2#;+!NP$?Y!]R6_^1.PC9X#W(QCFF A6P(1LX+A_MU7<=.SB[O@)M&95]&9S"?IRJW<;Z M5G_23/MR%12"FELO$NFWN-1WKQ>5<9#09R4?
G795@OGZO:CU@63S_^6N)R8E M2_,/,TJFE.L!ZOHS8_+M0+^N5+R>-OP74$L#!!0 (.F!9UD-RR\P9P(M *,% 9 >&PO=V]R:W-H965TK*)[XT]OG>
M\WN^WDU7UMW[!I'@42OC9TE#U)ZFJ2\;U,(?VA8-G]36:4&\=^UXEPXLE=1HO+0&'-:SY&QT.C*^3'A5N+*;ZTA.+FS]CYL+]M9D@5! MJ+"DP"#X\X#G]%0@8AD_UYS)<&4
;]\WI!?1.WNY$QI/K?HF"_VIFR=L$*]Q% MI^C&KC[CVD\46%KEXR^L^MR3XP3*SI/5:S KT-+T7_&X?H!6] IA ,Z]2H:W M$@HN35_P*O/B)I?
SK:4I\90"FY9I^WM/GS]"_@RMKJ/'PT518_8U/6>]@ M-]_HG>=["1?8'L(X>P-YED_V\(T'_^/(-WF&[P:+SCEIEC 77GKX!5?B4>I. M[_*ZERJTSZEO18FSA/O#HWO
I'CY8G2E6XVATRS@> M/)2V,]3WT! =)M!9WWA_TOOQ=27<4O)#*ZP9FAV>L";7CX1^0[:-;7AGB9LZ M+AN>HNA" I_7UM)F$RX8YG+Q&U!+ P04 " #I@6=9\WA/#5T# "I#@ M&0
'AL+W=O=A+1I0Q@HO+1VF7,14H53L3!E+(#Z:5(8F(YE M=SR'@ZZ%&A&T\?;MAB]?0%/Z%?IL5C,3,J84$?C>3R0Z2]9Y[&60;Q$*A[FR<@@9%'V3Q]R(;82L-#]!"=/ M2PPM0E
7R$X;?3B_(X<$G M2(Q5@Y,A43UXTPO)W6>D7*>(36%^)BX5HLXEM.N2! 7IU^ A^EV MFNZ6TTV4I]#(*31R4CSW)8TF <6*STKU_[G&:'*E()1 JRK-H-O5T'J[I48 M>C
T[(:=7KNR0X15"):[O@V]E>@U2GN(GPDO")* *?%S9*(G'J/YV M5%'-\#I;+(YQQ<+K]W@[1_2#7[?>K
M>78+GMUZ4>ELX_LJ9K7IK[5Z0V"E2GM%I;WW6_"])E5H"*RD0K]0H=_T@N_O MV:YG=7:LN1_3?^N(; 2G+8UF93M]
[/P#EV0T(TA5968]N|L9LV<8Y88M;VWO]4]MU]NSZ0E3&U]PZ1^A#W#&UL MK55M;],P$/XK5D!H2&-)DVR%DD9JFR+V8:A:-?B ^. FU\::8V>VVV[_'K^D MH=VR,L&^)/;YGN=\+
[Y+MES_+O(0*RS->],G2RX] MK/16K'Q9"\"%!574#X@PJ\P85Z:6-E,I E?*TH8S 22ZZK"XF$,E&^'7L_; M*:[)]E1&X*=)C5^2U+02I@DG"&!"R'WJ@WF,9&WRI\)["5>VMD M/%EP?
FLVE\70"\R%@$*N# /6OPU,@%)#I*]QUW!ZK4D#W%_OV+]8W[4O"RQA MPND/4JARZ'WT4 %+O*;JFF^_0N//N>'+.97VB[9.MQ]Y*%]+Q:L&K&]0$>;^ M^+Z)PQY
\W0#P@80/@;$SP"B!A"]U$+< .*76CAO -9UW_EN Y=AA=-$\"T2 M1ENSF86-OD7K>]%FZF2NA#XE&]?2F= E)]0#PJQ TILUJ741]%/T39?H!S0]
M"F+RB2FZ9*XH379/,E"84/E>]IS,,W3R]GWB*WT;P^GGC>6QLQP^8SE"5YRI M4J(I*Z#HP&?"\9^.X'T=A384X2X4X_ HX1SJ,Q0%IR@,PKCC/L7PZ,N=_[/ M^O2?
K1\$(VKK(K)\T5_JXA3-*&;JL#S0S|%"*J$?^:^NO#OFN)O9-+Z!K'$. M0T]W-@EB U[Z[DWO(OC<%?37),M>DVSZ2F0'Z8G;],3'V-,,-&E.W'.$>STU M)'2EPK%
<6!8S,C9I&$=!$"3^9C_(76KQ$[7LJ$H_[#]1FW:I'; YE_V]KE6! M6-EQ(5'.UTRY0FVE[40:V4;\2#[N#2:]#(GFF)Y@;,' HW>B[PF)%F$04EMI4 M<-;7356XD>
(VBM>9VRZXT4B+DL]A4$8!7V^Y%SM-L9 .]?3WU!+ P04 M" #I@6=9R96JV!(" #L!P &0 'AL+W=OKP5\E$5)H\E;Q2$ZO0NKZT;9464%)U+FJH\$LN
M9$DU3N7*5K4$FC6DDMN>XT1V25EE)>/FW5PF8['6G%4PET2MRY+*YVO@8CNQ M7.OEQ1U;%=J\L)-Q35>P /U0SR7.[%XE8R54BHF*2,@GUI5[.8T-O@%\9[!5 M.V-
BDBR%>#23K]G$X+L5:TRM38UNC.K&&GG9\KUHGWAI,%U.?$=SX0S_&" ?KT.'T& M*=+=ANZ_IMM8D[XP7E\8K]'SW]";TV>ZY)@5T[0UH%R1GU=+I27NO5]# 5O%
M8%C1G,=+5=,4)A8>. 5R U;R_IT;.9^&XOXGL5?A_3Z\?TP]N4-%*M.B"9_! M!@][C4=7#X5NE:)&R?2,31)' ?Z!F]TPAR#7O7"C'O7*9="[#(ZZ_%S67#P# MD%24V-
44;1L#6EY"!3G3@[NPU0QWK 1!X,SY'0"%03AL-^SMAD?MWL**<@)/ MQBH,.0L/%W6]>,_9T37^<5M$?8+H:(*Y%#DHT\ QB!%G:7= A"Y #F6*#C+% MX7ZQ#S'N:.0-
%SONK<9'K=X+C1(I8>\.\@H&F,
,<0<'*^I<^-2#V#%"GVR\I#)+7!L,C!KW& MH/?:H'_$H-\8|"V9>BJ60THUG8RDV!)I6J.:*5B8UAJGSTJS[C,M\2U#.5V9 ML67)%BRCI2;3I03 -=6*_$RF><[,RE!.,LO:\PZ?
4A!4\;51VSRC:H5*Y<: MJV>::B"/):ZA5$P_DR\L0^> G2:V?YREY,,'T>AQH&;[L.L&>1U/L%TG3L495&>D%WTB293TNP;D-D\A M0_/8FD<=YNE_-H\'CMGT6B?H6;W>$3W<-
)S.A:1F#Y*IE+1<-HXP+7/R5939 ML1;D=RPJ:C>Q(G]^065RJZ%0?W4MN'2/%,.0:>%X1=B)R"IR+R*9;68H,]1,G@**%A2VCH)/05CPV*HF\1>(*B
MTF0AQ1M079R">FB0B#EG2_N=ZZ)R_L:-=]W6 M4W7VQ [07;;H+M_'MM_32)WZ?8]DGL0\<;0[T$9.WYV9B-=YQHS^=0.[I4_EX$OM$,3>R3YV@KA? M83Y$$G*#+_" S]&IF#W-
X[G^:)!S:Y[]5E[54E]JASR3'<_D?>SL9AR^UL"G M6NI+[7 -=HE*[#R(=QV5\8"S\[M;>2K^IOS+VMO4O&ULM9M= M;]LV%(;_"N$50P>DMB7YJYECP#'9-
5V[!DT_+H9=,!)M$Y5$CZ3C&-B/'RDY MEN7(M!4<]Z*19)U'Y'DE'KT2-5P)^5/-&=/H,8E3==68:[VX;+54.&<)54VQ
M8*GY92ID0K5$9E;.66DA&HRPHB5M^N]UK)92GC=$PVW8K1T.QU#%/V:U$:IDD M5*ZO62Q65PVO\;3A"Y_-M=W0&@T7=,;NF/ZVN)5FK;6E1#QAJ>(B19)-KQIC M[Y($71N0[?
&=LY7:64:V*_="_+0K-]%5HVU;Q&(6:HN@YL\#F[XMB33CG\W MT,;VF#9P=_F)_B[KO.G,/55L(N(?/-+S]\:@2(VI_H5>(I^CK7"R5 ;EA2YOFV8.TPDU3KO.F^ >:$J!/YN!SA4@:
ML:@BGKCCWSKB6R8MV[SX3[FY[IW .[9HHJ!]@?RVWZEHS\0=CEEHPKTL/*@(MQZ>'^U79>"C2\D(MB=*D/&"$TZ4\;,3Y>^/9G=THUFB_JE2/F=WJMEV,+Q4
M"QJRJX89[123#ZPQ^O47K]2^2OKMD# ,"2- L)) G:U '1=]])'-$S6JF-8Q MLS(A]FBJB6)51AU/_K#UL)MFY^'JIOGY$;VV^5<+)#G2KE)>
MNMN\=)UYN4G54M(T9*:NA>*!R;4=ITREE=2>P$[IJARPG.2ZIVWW>0IZ^QG MD$1&,]YY*BVSDU!W7F_BYL7E1EV@FKFVE(&(;$$2!821&O M7=R'M\]X?[6! VD$2L.@-
)%*\NT8Y<\]UT67:FE&<>F/+8W#Q'5E<7,3:FM M!R0-@]+(D7Q]6*9-Y'FT4@ GH[8 MD#0,2B-'LO6.IB@;[ZV[?V\7_J#"I4-A"#VGG1E]H"O#G-,:E<1-K*T*]!$$ MI1$H6EF;P@MZG7-
6$TCK-P&E85 :@:*592]LJ>?VIJ=6$U ?"DK#H#1R)%^G M5Y/"IGINGWI:-8&TE!-0&@:ED2/9>D^EFD>,+=#3Z,\2H?##GML0W\5K,R#5 MJ"--7&T](&D8E$:@:&5A"M?
N#A/[6.@#IY M4!H&I9$C^3JYCOB%?_>=QO.T.N)FU!4 E(9!:>1(MK[R1.CY&N4#O[4F7RG/ MUUQJ%#:==]0.9W4$?4=8-M&?IFI5/NEW\VHK VK806D$BE96IG#OOG_&BN*#
MVGI0&@:E$2A:6:;"W/MN1(OL;+61-Y?EY1?)<$A8?W MW2]TGRI*Q*8LC6CU6Q WHJ8 H%8=E$:.9.O Z%[.?6',_6/&_%Y(JH5<9\7I M\W3*0X;>T=[<#MH.5/^A:U/ 6!Q?H!]4SE85
:@:*5)2N, MO-\[9V$!=?B@- Q*(U"TLDR%U??=5O_S=N)%S*AB=OH%E_FDLL1.W\JNMS6C MLE(E4-\/2L.@-'(DBZ;(]-^T!RY%"H_ONU_-/U>$*\WLS U3?,0BDT8+L]EL
MK)J6=^WFUU8%U.:#TLB13&JY=-]7PL_[;G^Z)\D%HL4T3,UD8I4)S=4B:5A] M5^#&=[,+K,H'3=R1M;,/:NI?TJOR7,?"S0=N?_JR^F^V?N(I3Y9)Y1Q(4/,/ M2L.@-)%*XM7F/_ .^.=0
#Z) "4AD%I!(I6EJEX$A"XWTSOUQUSY6B^&> J MA7'C>OGECX+\/D(A;V!IZ[IRE'.C;JL":OQ!NEF69&>.]S'7_])ACSX>'/9@ MYWI#3OZ&G?U]CG?^0?&\(#CG,_\ ]$$"*
V#T@@4K2Q3\6@A<#[;]#WLN7'] MP_=R[LC:(H ^+'A)K_*$MW8^=DJ8G&5?F2F4S1/,O^W9;MU^R3;.OM_;VW[M 7>+\>[0"DW\>]XG*&4^5$6AJD.UFWS16YE^,1DS:
M'&PO=V]R:W-H965TH, MP)"GG L[<3)CBBO7U4D&.=67L@"!*VNIM[7N3FE DG M'E??YBH>R])P)F"NB"[SG*KG&^`IR-W%ZSO[#@FTR8S^X\;B@&UB">2CF"F=N MZR5E.0C-I"
*UA/GNG=U,[+[JPU?&.STP9C82%92/MK)AW3B>%80<$B,]4#Q MM84I<&X=H8R?C4^G15K#P_'>^VT5.\:RHAJFDG]EJSR%)]8W,&V-4D#-1O^E3DX<#]|_P:>3X#0QG7;@988+
<9[+4J$./78/168UNTD1R4T?BOQ#)$HI+ MTO?>$M_S_*PG)'SLS=_NG$Q.6V&_#9#?N6W_U\9FF$NN-2E O+M>]6-PF/V MO4M\#0FZ(;TKG1!$Y@X6%L:U!:
<^/6K7N2l.Q%"OPVA?\[IO !;GO8_V-GT MJ:OMH\K>UO$V[OG]L;OM@ 8M-#@)1538A;JMP@-4, JZ46&+"O^%BKI0X1$] M]$:=]*A%12=1]QE@[UL;4%W Z C8#Z)NX*
%#DX#I:&^2Z5(W M%)WT0N'W>I&K;K1276?\/ZJX7S?9+K0H^-SWN_]??K<@W9J;Z:/5&V8T.A_ MC6;>Y0"EJ[K;QU,CBZK#KJ3!?ET-,[P@0=D-N+Z6TNPGMFFW5V[\"U!+ P04 M

" #I@6=9'7\'D6 " !?!0 &0 'AL+W=O>W[OS.=L:^^@J1((GK6HWB2JBYBJ.75&A%FY@&JQY M9VFL%L13NXI=8U&4 :15G";)1:R%K*,\"VLSFV=F34K6.+/@UEH+N[M!9;:3 M:!CM%^9R59%?B/.L$2N\1_K:S"S/XIZEE!IK)TT-%I>3Z'IX=3/\'2'@F\2M M.QB#=[(PYM%//I:3*/&"4&%!GD'P;X-35.H3L8R?'6?4'^F!A^.]^_O@G;TL MA,.140^RI&H27490XE*L%NCF85U(=/ &'H(M+.%Z@Y:K!'/TI>80N$/.!GO!JP/R MK\A;Z0JSK@GF@A#(P"T2![, H KA<\-A])OH3HJ%5))V<.;!0BKW*HN)+7JA M<=`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

MOR^IE1;;53Y!4[AH;R05;%RHOWI7P)F>?O ?MM4U264 M_6ZNK2R/G^LZ)0A&.14&#YE36V/+UW_B397O^DG9MV7:'O-GV>7+< M[PYYT6Q*Z1]"R,M-VK?
YINO3X7QDU0W[MIR7PSKT[?*]7:>@T^DL##]G-(_S MGS,GKZ<^_65BMUIME^FI6W[LTZ'\,CA\=L-[WJ14FLEK.ZQ3633AN+ONSN&R MD9OSY&;R_+9HAN"X(M!&
(+DBT$9@NB+01J"[(M M!&X+PBT$<@O2+01V"^(M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&|%O95 ;T6] ME4!O1;V50&|%O95 ;T6]E4!O1;V50&]#O8U ;T.]C4!O0IV-0&\;O2PAT-M0
M;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#;4&\GT-M1 M;R?0VTD4#O MB'I' KTCZAT)](ZH=R30.XX^5OZGWKF<=BE?>
[I[7>/W_I+]YNZ:OPX681@'QCS^8)]J[5-C MJ8DC,^-J'>)?-V=6YTL])R8&@R'+31.H"?W0UD@FHR>:Z545>L^;>-N7IADG MCBJ?]!YW$]NL<:*MKE/MPHNNXRRVJ9@/VXI\>K[$B1[-
;%;F5)A\5<.=.$71*&N MTEW1F_/)(>XP[7]YU?E=F7.!<>;4&>OCB3FZ/.YP).W]OHV%R(7R_",>$V/I MJY^/VM,NJ/AE=MS>#^.6W7EXUEVNW^.O9WRL?V$?]0/"=*' NDC ^EC"-+'
M+4@?=R!]W((TP0&UL M4$L! A0#% @ Z8%G65+#ZA_O *P(!$ (!KP M &1O8U!R;W!S+V-O&UL4$L! A0#% @ Z8%G69E&PO=V]R M;W-H965T&UL4$L! A0#% @ Z8%G621!/1?
N!0 IQ< M !@ ("!3@X 'AL+W=OCS$% M _%@ & @(%%P >&PO=V]R:W-H965T&UL4$L! A0#% @ Z8%G65&,[*B&"P CFL !@ ("! MKAP 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ MZ8%G60!ZCZM# @ B@8 !@ ("!L#$ 'AL+W=O&PO=V]R:W-H965T !X;"]W;W)K&UL4$L! A0#% @ MZ8%G63O%")I9$P T4(!D ("!2F0 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ Z8%G61)2$B@H P M_08 !D ("!5X< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Z8%G6:D%'(+D @ VP8 !D M ("!R:0 'AL+W=O&PO=V]R:W-H
M965T&UL4$L! M A0#% @ Z8%G65%$]);(@ [04 !D ("!H*X 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Z8%G M6493W4F4!@ PQ, !D ("!O+@ 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ Z8%G600L5I7%!0 &PO=V]R:W-H965T&UL4$L! A0#% @ Z8%G614@?R*3!0 JB8 !D M ("!WM('AL+W=O&PO=V]R:W-H965T M$\-70, *D. 9 M " @4;;
!X;"]W;W)K&UL4$L! A0# M% @ Z8%G66H,')"; @ XP< !D ("!VMX 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ Z8%G65*U M2:+M!@ S@ !D ("!-ND 'AL+W=O&PO=V]R:W-
H965T18 (%\% 9 " @7#S !X;"]W;W)K&UL4$L! A0#% @ Z8%G62]K10O+ @]P@ !D M ("!! 8 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ Z8%G6>&G:GN5 P]A !D ("!
MSP$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ Z8%G68AI?E1B P 3@L !D ("!] P! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Z8%G6>!AQ$K< @ Y @ !D M ("!ZB0!
'AL+W=O&PO=V]R M;W-H965T7!E&UL4$L%!@ _ #\ ,!$ *8X 0 $! end XML 65 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /*
v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a
{ display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px;
text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }
.report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white;
border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report
th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica,
Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report
td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header
rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re,
.report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td
{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space:
nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding:
0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more
{ display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-
size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html1492391false450false5 falsefalseR1.htm100000 - Document - Document and Entity
InformationSheethttp://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm100010 -
Statement - Condensed Consolidated Balance Sheets
(Unaudited)Sheethttp://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedCondensed Consolidated Balance Sheets
(Unaudited)Statements2 falsefalseR3.htm100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)
(Unaudited)Sheethttp://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnauditedCondensed Consolidated Balance Sheets
(Parenthetical) (Unaudited)Statements3 falsefalseR4.htm100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)Sheethttp://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedCondensed
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Statements4 falsefalseR5.htm100050 - Statement - Condensed Consolidated Statements of
Stockholders' Equity (Unaudited)Sheethttp://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedCondensed
Consolidated Statements of Stockholders' Equity (Unaudited)Statements5 falsefalseR6.htm100060 - Statement - Condensed Consolidated Statements of Cash Flows
(Unaudited)Sheethttp://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedCondensed Consolidated Statements of
Cash Flows (Unaudited)Statements6 falsefalseR7.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance
DisclosureNotes7 falsefalseR8.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading
ArrangementsNotes8 falsefalseR9.htm995455 - Disclosure - Description of
BusinessSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessDescription of BusinessNotes9 falsefalseR10.htm995465 - Disclosure -
Significant Accounting PoliciesSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSignificant Accounting PoliciesNotes10
falsefalseR11.htm995475 - Disclosure - Fair ValueSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueFair ValueNotes11 falsefalseR12.htm995485 -
Disclosure - Property and Equipment, NetSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetProperty and Equipment, NetNotes12
falsefalseR13.htm995495 - Disclosure - Accrued LiabilitiesSheethttp://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesAccrued LiabilitiesNotes13
falsefalseR14.htm995515 - Disclosure - Significant AgreementsSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsSignificant
AgreementsNotes14 falsefalseR15.htm995525 - Disclosure - Commitments and
ContingenciesSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes15
falsefalseR16.htm995535 - Disclosure - Common StockSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockCommon StockNotes16
falsefalseR17.htm995545 - Disclosure - Stock-based CompensationSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStock-based
CompensationNotes17 falsefalseR18.htm995555 - Disclosure - Net Loss Per Share Attributable to Common
StockholdersSheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersNet Loss Per Share Attributable to Common
StockholdersNotes18 falsefalseR19.htm995565 - Disclosure - Corporate
RestructuringSheethttp://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringCorporate RestructuringNotes19 falsefalseR20.htm995585 - Disclosure -
Significant Accounting Policies (Policies)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPoliciesSignificant Accounting Policies
(Policies)Policieshttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies20 falsefalseR21.htm995595 - Disclosure - Significant Accounting
Policies (Tables)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTablesSignificant Accounting Policies
(Tables)Tableshttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies21 falsefalseR22.htm995605 - Disclosure - Fair Value
(Tables)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueTablesFair Value
(Tables)Tableshttp://athira.com/20240930/taxonomy/role/Role_DisclosureFairValue22 falsefalseR23.htm995615 - Disclosure - Property and Equipment, Net
(Tables)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTablesProperty and Equipment, Net
(Tables)Tableshttp://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet23 falsefalseR24.htm995625 - Disclosure - Accrued Liabilities
(Tables)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesTablesAccrued Liabilities
(Tables)Tableshttp://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilities24 falsefalseR25.htm995645 - Disclosure - Commitments and Contingencies
(Tables)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTablesCommitments and Contingencies
(Tables)Tableshttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies25 falsefalseR26.htm995655 - Disclosure - Common Stock
(Tables)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockTablesCommon Stock
(Tables)Tableshttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStock26 falsefalseR27.htm995665 - Disclosure - Stock-based Compensation
(Tables)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTablesStock-based Compensation
(Tables)Tableshttp://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation27 falsefalseR28.htm995675 - Disclosure - Net Loss Per Share Attributable
to Common Stockholders (Tables)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTablesNet Loss Per
Share Attributable to Common Stockholders (Tables)Tableshttp://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders28
falsefalseR29.htm995685 - Disclosure - Corporate Restructuring (Tables)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringTablesCorporate
Restructuring (Tables)Tableshttp://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuring29 falsefalseR30.htm995705 - Disclosure - Description of Business -
Additional Information (Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetailsDescription of Business -
Additional Information (Details)Details30 falsefalseR31.htm995715 - Disclosure - Significant Accounting Policies - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetailsSignificant Accounting Policies -
Additional Information (Details)Details31 falsefalseR32.htm995725 - Disclosure - Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetailsSignificant
Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)Details32 falsefalseR33.htm995735 - Disclosure - Fair Value - Schedule of Fair Value of
Cash Equivalents and Short-term Investments
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetailsFair Value - Schedule of
Fair Value of Cash Equivalents and Short-term Investments (Details)Details33 falsefalseR34.htm995745 - Disclosure - Fair Value - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetailsFair Value - Additional Information (Details)Details34
falsefalseR35.htm995755 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsProperty and Equipment, Net -
Schedule of Property and Equipment (Details)Details35 falsefalseR36.htm995765 - Disclosure - Property and Equipment, Net - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetailsProperty and Equipment, Net - Additional
Information (Details)Details36 falsefalseR37.htm995775 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetailsAccrued Liabilities - Schedule of Accrued Liabilities
(Details)Details37 falsefalseR38.htm995795 - Disclosure - Significant Agreements - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetailsSignificant Agreements - Additional Information
(Details)Details38 falsefalseR39.htm995805 - Disclosure - Commitments and Contingencies - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetailsCommitments and Contingencies -
Additional Information (Details)Details39 falsefalseR40.htm995815 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash
Flows to Operating Lease Liability Payments
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLe
and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)Details40 falsefalseR41.htm995825 -
Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountR
and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)Details41
falsefalseR42.htm995835 - Disclosure - Commitments and Contingencies - Operating Lease Expense and Variable Lease Expense

(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseExpenseAndVariableLeaseExpenseDetailsCommitments and Contingencies - Operating Lease Expense and Variable Lease Expense (Details)Details42 falsefalseR43.htm995845 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetailsCommon Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)Details43 falsefalseR44.htm995855 - Disclosure - Common Stock - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetailsCommon Stock - Additional Information
(Details)Details44 falsefalseR45.htm995865 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense Recognized
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetailsStock-based Compensation - Stock-based Compensation Expense Recognized (Details)Details45 falsefalseR46.htm995875 - Disclosure - Stock-based Compensation - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetailsStock-based Compensation - Additional Information (Details)Details46 falsefalseR47.htm995885 - Disclosure - Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOption based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)Details47 falsefalseR48.htm995895 - Disclosure - Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAn based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan (Details)Details48 falsefalseR49.htm995905 - Disclosure - Stock-based Compensation - Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetailsSt based Compensation - Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan (Details)Details49 falsefalseR50.htm995915 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement Plan
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe202 based Compensation - Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement Plan (Details)Details50 falsefalseR51.htm995925 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Activity
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetailsStock-based Compensation - Summary of Restricted Stock Activity (Details)Details51 falsefalseR52.htm995935 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders
(Details)Sheethttp://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComp Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)Details52 falsefalseR53.htm995945 - Disclosure - Corporate Restructuring - Additional Information
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetailsCorporate Restructuring - Additional Information (Details)Details53 falsefalseR54.htm995955 - Disclosure - Corporate Restructuring - Summary of Cost Associated With Termination Benefit Payment of Restructuring
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetailsC Restructuring - Summary of Cost Associated With Termination Benefit Payment of Restructuring (Details)Details54 falsefalseR55.htm995965 - Disclosure - Immaterial Error Correction (Unaudited) - Summary of Immaterial Errors Correction in the Weighted-Average Number of Common Shares Outstanding
(Details)Sheethttp://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumber Error Correction (Unaudited) - Summary of Immaterial Errors Correction in the Weighted-Average Number of Common Shares Outstanding (Details)Details55 falsefalseAll ReportsBookAll Reports atha-20240930.htmatha-20240930.xsd img106170215_0.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "atha-20240930.htm": { "nsprefix": "atha", "nsuri": "http://athira.com/20240930", "dts": { "inline": { "local": ["atha-20240930.htm"] }, "schema": { "local": ["atha-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 205, "keyCustom": 34, "axisStandard": 20, "axisCustom": 0, "memberStandard": 18, "memberCustom": 27, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 149, "entityCount": 1, "segmentCount": 45, "elementCount": 519, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 458, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_905416e1-5d99-4340-b995-6c51abd9b923", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R3": { "role": "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_1051e2a4-eb3f-4d4f-a0a1-0b6cb8032b2c", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bc4d53ca-fa53-4137-982d-a1a0791837bc", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R6": { "role": "http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness", "longName": "995455 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies", "longName": "995465 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValue", "longName": "995475 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef":

"atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "longName": "995485 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilities", "longName": "995495 - Disclosure - Accrued Liabilities", "shortName": "Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreements", "longName": "995515 - Disclosure - Significant Agreements", "shortName": "Significant Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995525 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStock", "longName": "995535 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation", "longName": "995545 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders", "longName": "995555 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuring", "longName": "995565 - Disclosure - Corporate Restructuring", "shortName": "Corporate Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies", "longName": "995585 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables", "longName": "995595 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "atha:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "atha:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueTables", "longName": "995605 - Disclosure - Fair Value (Tables)", "shortName": "Fair Value (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "longName": "995615 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesTables", "longName": "995625 - Disclosure - Accrued Liabilities (Tables)", "shortName": "Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995645 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockTables", "longName": "995655 - Disclosure - Common Stock (Tables)", "shortName": "Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "longName": "995665 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "longName": "995675 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true },

"uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringTables", "longName": "995685 - Disclosure - Corporate Restructuring (Tables)", "shortName": "Corporate Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails", "longName": "995705 - Disclosure - Description of Business - Additional Information (Details)", "shortName": "Description of Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:NatureOfOperations", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:NatureOfOperations", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995715 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "shortName": "Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:PaymentsForLegalSettlements", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:PaymentsForLegalSettlements", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "longName": "995725 - Disclosure - Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails", "longName": "995735 - Disclosure - Fair Value - Schedule of Fair Value of Cash Equivalents and Short-term Investments (Details)", "shortName": "Fair Value - Schedule of Fair Value of Cash Equivalents and Short-term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_11477371-8fcd-413c-95c6-6537d7203fe4", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R34": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails", "longName": "995745 - Disclosure - Fair Value - Additional Information (Details)", "shortName": "Fair Value - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_f3333f2e-1a36-4673-877f-1fe2d8d39276", "name": "atha:ShortTermInvestmentsMaturityTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f3333f2e-1a36-4673-877f-1fe2d8d39276", "name": "atha:ShortTermInvestmentsMaturityTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "longName": "995755 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "longName": "995765 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "shortName": "Property and Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails", "longName": "995775 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "atha:AccruedResearchAndDevelopmentExpensesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "atha:AccruedResearchAndDevelopmentExpensesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails", "longName": "995795 - Disclosure - Significant Agreements - Additional Information (Details)", "shortName": "Significant Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_e84a395d-1ac5-4193-9a64-ebfd9bb1466b", "name": "atha:MilestonePaymentsAmountPayableUponMarketingApproval", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e84a395d-1ac5-4193-9a64-ebfd9bb1466b", "name": "atha:MilestonePaymentsAmountPayableUponMarketingApproval", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995805 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_27c64596-4b6b-4cbc-a503-6a5808bd20ca", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R40": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP "longName": "995815 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)", "shortName": "Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermi "longName": "995825 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)", "shortName": "Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseExpenseAndVariableLeaseExpenseDetails", "longName": "995835 - Disclosure - Commitments and Contingencies - Operating Lease Expense and Variable Lease Expense (Details)", "shortName": "Commitments and Contingencies - Operating Lease Expense and Variable Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails", "longName": "995845

- Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)", "shortName": "Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c3555810-979f-4e0d-a341-3008bd8381a9", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R44": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "longName": "995855 - Disclosure - Common Stock - Additional Information (Details)", "shortName": "Common Stock - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "atha:ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d2c70d8c-159b-4895-9853-2034917e6668", "name": "atha:ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R45": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails", "longName": "995865 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense Recognized (Details)", "shortName": "Stock-based Compensation - Stock-based Compensation Expense Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "995875 - Disclosure - Stock-based Compensation - Additional Information (Details)", "shortName": "Stock-based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "div", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "atha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R47": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackS "longName": "995885 - Disclosure - Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)", "shortName": "Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc "longName": "995895 - Disclosure - Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan (Details)", "shortName": "Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_905416e1-5d99-4340-b995-6c51abd9b923", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "atha:ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_905416e1-5d99-4340-b995-6c51abd9b923", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "atha:ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails", "longName": "995905 - Disclosure - Stock-based Compensation - Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan (Details)", "shortName": "Stock-based Compensation - Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_905416e1-5d99-4340-b995-6c51abd9b923", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R50": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement "longName": "995915 - Disclosure - Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement Plan (Details)", "shortName": "Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9eb8890c-25b5-4207-9a06-19a07aa1259c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R51": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails", "longName": "995925 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Activity (Details)", "shortName": "Stock-based Compensation - Summary of Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_ac4602b2-8cdc-4484-b273-055601d8a012", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ac4602b2-8cdc-4484-b273-055601d8a012", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu "longName": "995935 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails", "longName": "995945 - Disclosure - Corporate Restructuring - Additional Information (Details)", "shortName": "Corporate Restructuring - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b5077a20-6441-4168-ad8f-c76174950d1b", "name": "us-gaap:RestructuringReserveCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "unique": true } }, "R54": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails", "longName": "995955 - Disclosure - Corporate Restructuring - Summary of Cost Associated With Termination Benefit Payment of Restructuring (Details)", "shortName": "Corporate Restructuring - Summary of Cost Associated With Termination Benefit Payment of Restructuring (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:SeveranceCosts1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-

gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_642c2e55-1a6c-43c4-8503-a6065026b76c", "name": "us-gaap:SeveranceCosts1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh "longName": "995965 - Disclosure - Immaterial Error Correction (Unaudited) - Summary of Immaterial Errors Correction in the Weighted-Average Number of Common Shares Outstanding (Details)", "shortName": "Immaterial Error Correction (Unaudited) - Summary of Immaterial Errors Correction in the Weighted-Average Number of Common Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_9dffce63-21d7-436c-b441-18d67dc25a82", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "atha-20240930.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth_ref": ["r123", "r124", "r125", "r126", "r127", "r128", "r167", "r168", "r169", "r217", "r218", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r275", "r276", "r279", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r416", "r417", "r418", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r461", "r462", "r471", "r485", "r486", "r487", "r488", "r489", "r490", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r875"] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilities"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r381"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r53", "r727"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of premiums and accretion of discounts on available-for-sale securities, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r78"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails", "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total accrued Liabilities", "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r55"] }, "atha_AccruedProfessionalServicesAndOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "AccruedProfessionalServicesAndOtherCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Professional services and other", "label": "Accrued Professional Services And Other Current", "documentation": "Accrued professional services and other, current." } } }, "auth_ref": [] }, "atha_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Accrued Research And Development Expenses Current", "documentation": "Accrued research and development expenses, current." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r34", "r135", "r567"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r15", "r16", "r68", "r141", "r564", "r594", "r598"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r8", "r16", "r420", "r423", "r490", "r589", "r590", "r863", "r864", "r865", "r872", "r873", "r874", "r878"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r790"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r63"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r608", "r872", "r873", "r874", "r878", "r940", "r1000"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r803"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r803"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r803"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r803"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r48", "r49", "r338"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AgencySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AgencySecuritiesMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Agency Securities [Member]", "terseLabel": "Agency Securities", "documentation": "Securities issued by government sponsored entities." } } }, "auth_ref": ["r887", "r888"] }, "atha_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "AggregateOfferingPrice", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price", "label": "Aggregate Offering Price", "documentation": "Aggregate offering price." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r836"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r762", "r772",

"r782", "r814"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r765", "r775", "r785", "r817"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r837"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r803"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r810"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r766", "r776", "r786", "r810", "r818", "r822", "r830"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r828"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r370", "r379"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "verboseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "atha_AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "AnnualMinimumRoyaltyPaymentsAfterFirstCommercialSale", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual minimum royalty payments", "label": "Annual Minimum Royalty Payments After First Commercial Sale", "documentation": "Annual minimum royalty payments after first commercial sale." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu], "lang": { "en-us": { "role": { "terseLabel": "Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r191"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r28"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r28"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r407"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r99", "r107", "r137", "r162", "r196", "r199", "r210", "r211", "r253", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r409", "r413", "r463", "r562", "r634", "r699", "r700", "r727", "r753", "r906", "r907", "r957"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r130", "r142", "r162", "r253", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r409", "r413", "r463", "r727", "r906", "r907", "r957"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "atha_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "AtTheMarketOfferingMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "At The Market Offering.", "label": "At The Market Offering [Member]", "terseLabel": "At The Market Common Stock Offering" } } }, "auth_ref": [] }, "atha_AthiraPharmaIncVDrKawasMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "AthiraPharmaIncVDrKawasMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Athira Pharma Inc V Dr. Kawas.", "label": "Athira Pharma Inc V Dr. Kawas [Member]", "terseLabel": "Athira Pharma Inc V Dr. Kawas" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments, Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r226"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Investments, Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r227"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Investments, Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r223", "r271", "r561"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-sale, Current, Total", "terseLabel": "Investments, Fair Value", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r221", "r271"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments, Fair Value", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": ["r133", "r221", "r271"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r825"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r826"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r821"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r821"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r821"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r821"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r821"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r821"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r366", "r367", "r368", "r369"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r824"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r823"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r822"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r822"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "atha_BasisOfPresentationAndSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://athira.com/20240930", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesLineItems", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Line Items]", "label": "Basis Of Presentation And Significant Accounting Policies [Line Items]", "documentation": "Basis of presentation and significant accounting policies." } } }, "auth_ref": [] }, "atha_BasisOfPresentationAndSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://athira.com/20240930", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTable", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basis Of Presentation And Significant Accounting Policies [Table]", "label": "Basis Of Presentation And Significant Accounting Policies [Table]", "documentation": "Basis of presentation and significant accounting policies." } } }, "auth_ref": [] }, "atha_BothellWashingtonMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "BothellWashingtonMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bothell, Washington", "label": "Bothell Washington [Member]", "documentation": "Bothell, Washington." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r22", "r23", "r24"] },
"atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents, Unrealized Gains", "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax", "documentation": "Cash and cash equivalents accumulated gross unrealized gain before tax." } } }, "auth_ref": [] }, "atha_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Cash equivalents, Unrealized Losses", "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax", "documentation": "Cash and cash equivalents accumulated gross unrealized loss before tax." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
"http://athira.com/20240930/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash equivalents, Amortized Cost", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r20", "r132", "r692"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r132"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents, Fair Value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r943", "r944"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r21", "r98"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r20", "r76", "r159"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r76"] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r132"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": ["r119", "r120", "r128", "r166", "r217", "r254", "r255", "r256", "r262", "r263", "r275", "r279", "r387", "r390", "r391", "r399", "r400", "r402", "r416", "r417", "r427", "r428", "r461", "r462", "r471", "r485", "r486", "r524", "r525", "r587", "r588"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": ["r119", "r120", "r128", "r217", "r254", "r255", "r256", "r262", "r263", "r264", "r275", "r279", "r387", "r390", "r391", "r399", "r400", "r401", "r402", "r403", "r415", "r416", "r417", "r418", "r427", "r428", "r429", "r432", "r461", "r462", "r471", "r485", "r486", "r524", "r525", "r587", "r588", "r844"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": ["r167", "r181", "r259"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {

"label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r801"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r798"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r796"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r138", "r139", "r140", "r198", "r311", "r312", "r313", "r315", "r318", "r323", "r325", "r602", "r603", "r604", "r605", "r706", "r841", "r870"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r802"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r802"] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreements"], "lang": { "en-us": { "role": { "terseLabel": "Significant Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r110", "r112", "r122"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r407"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r88", "r298", "r747", "r748", "r749", "r750"] }, "atha_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://athira.com/20240930", "localname": "CommitmentAndContingenciesTable", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commitment And Contingencies [Table]", "label": "Commitment And Contingencies [Table]", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r86", "r291", "r292", "r677", "r896", "r900"] }, "atha_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://athira.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Commitments and contingencies line items." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reserved shares of common stock for future issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r62"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r743", "r744", "r745", "r747", "r748", "r749", "r750", "r872", "r873", "r878", "r940", "r999", "r1000"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r62"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r62", "r622"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Common Stock, Shares, Issued, Total", "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r62"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r62", "r622", "r640", "r1000", "r1001"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value; 900,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 38,669,073 and 38,172,603 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r62", "r563", "r727"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r807"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r806"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r808"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r805"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r17", "r144", "r146", "r151", "r557", "r573", "r574"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Construction in Progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate Bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r74"] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [

"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Corporate Restructuring", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": ["r13", "r83", "r84"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "atha_DepositOfFinalSettlementPaymentToSettlementFundAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "DepositOfFinalSettlementPaymentToSettlementFundAccount", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Deposit of final settlement payment to settlement fund account.", "label": "Deposit of Final Settlement Payment To Settlement Fund Account", "terseLabel": "Deposit of final settlement payment to settlement fund account" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r33"] }, "atha_DescriptionOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri": "http://athira.com/20240930", "localname": "DescriptionOfBusinessLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Description Of Business [Line Items]", "label": "Description Of Business [Line Items]", "documentation": "Description of business." } } }, "auth_ref": [] }, "atha_DescriptionOfBusinessTable": { "xbrltype": "stringItemType", "nsuri": "http://athira.com/20240930", "localname": "DescriptionOfBusinessTable", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Description Of Business [Table]", "label": "Description Of Business [Table]", "documentation": "Description of business." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r336", "r340", "r371", "r372", "r374", "r713"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r757"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r789"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r800"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share attributable to common stockholders, basic", "terseLabel": "Net loss per share, basic", "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r152", "r170", "r171", "r173", "r174", "r175", "r177", "r184", "r186", "r188", "r189", "r190", "r195", "r397", "r406", "r436", "r437", "r558", "r575", "r694"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "verboseLabel": "Net loss per share attributable to common stockholders, diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r152", "r170", "r171", "r173", "r174", "r175", "r177", "r186", "r188", "r189", "r190", "r195", "r397", "r406", "r436", "r437", "r558", "r575", "r694"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share Attributable to Common Stockholders", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r28", "r29", "r192"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share Attributable to Common Stockholders", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r183", "r191", "r193", "r194"] }, "atha_EmergingGrowthCompanyStatusPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://athira.com/20240930", "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Emerging Growth Company Status", "label": "Emerging Growth Company Status Policy [Text Block]", "documentation": "Emerging growth company status." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Employee compensation and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r55"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining weighted-average period expected to recognize unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r373"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r937"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "atha_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan Member", "terseLabel": "Employee Stock Purchase Plan", "label": "Employee Stock Purchase

Plan [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r755"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r755"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r840"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r755"] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity incorporation, date of Incorporation", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r839"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r755"] }, "atha_EntityReincorporationDateOfReincorporation": { "xbrltype": "dateItemType", "nsuri": "http://athira.com/20240930", "localname": "EntityReincorporationDateOfReincorporation", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity reincorporation, date of reincorporation", "label": "Entity Reincorporation Date Of Reincorporation", "documentation": "Entity reincorporation, date of reincorporation." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r755"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r755"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r755"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r794"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r835"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r835"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r835"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r125", "r147", "r148", "r149", "r163", "r164", "r165", "r168", "r175", "r178", "r180", "r197", "r258", "r265", "r276", "r326", "r385", "r386", "r393", "r394", "r395", "r398", "r405", "r406", "r419", "r420", "r421", "r422", "r423", "r424", "r435", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r490", "r571", "r589", "r590", "r591", "r608", "r660"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r804"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r762", "r772", "r782", "r814"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r759", "r769", "r779", "r811"] }, "us-gaap_ErrorCorrectionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ErrorCorrectionTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnaudited1"], "lang": { "en-us": { "role": { "label": "Error Correction [Text Block]", "terseLabel": "Immaterial Error Correction (Unaudited)", "documentation": "The entire disclosure for reporting error correction." } } }, "auth_ref": ["r176"] }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh], "lang": { "en-us": { "role": { "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r170", "r171", "r172", "r177", "r178", "r179", "r180", "r195"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r810"] }, "atha_ExercisePriceOneMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "ExercisePriceOneMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price $0.16 to 4.22", "label": "Exercise Price One [Member]", "documentation": "Exercise price one." } } }, "auth_ref": [] }, "atha_ExercisePriceThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "ExercisePriceThreeMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price $20.55 to 29.41", "label": "Exercise Price Three [Member]", "documentation": "Exercise price three." } } },

"auth_ref": [] }, "atha_ExercisePriceTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "ExercisePriceTwoMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement
], "lang": { "en-us": { "role": { "label": "Exercise Price Two [Member]", "documentation": "Exercise price two.", "terseLabel": "Exercise Price $8.93 to 19.94" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Cash Equivalents and Short-term Investments", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r943", "r944"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r444", "r445", "r446", "r447", "r448", "r449", "r454", "r717"
] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByAssetClassAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r444", "r445", "r446", "r447", "r448", "r449",
"r454", "r717"] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByBalanceSheetGroupingTable", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value By Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r51", "r52"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r308", "r328", "r329", "r330", "r331", "r332", "r333", "r438", "r440", "r441", "r442", "r443",
"r452", "r453", "r455", "r494", "r495", "r496", "r704", "r705", "r709", "r710", "r711", "r716", "r719"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency",
"label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r439", "r440", "r441", "r443", "r716", "r946", "r949"
] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": {
"en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValue"],
"lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [
"r448", "r450", "r451", "r452", "r455", "r456", "r457", "r458", "r459", "r556", "r716", "r720"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r308", "r328", "r333", "r440", "r453", "r494", "r709", "r710", "r711", "r716"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r308", "r328", "r333", "r440", "r441", "r453", "r495", "r704", "r705", "r709", "r710", "r711", "r716"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementFrequencyDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency",
"label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r439", "r440", "r441", "r443", "r716", "r946", "r949"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang":
{ "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } },
"auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r308", "r328", "r329", "r330", "r331", "r332", "r333", "r438", "r440", "r441", "r442", "r443", "r452", "r453", "r455",
"r494", "r495", "r496", "r704", "r705", "r709", "r710", "r711", "r716", "r719"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Recurring Basis", "label":
"Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r716", "r943", "r944", "r945", "r946", "r947", "r949"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": {
"label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r226", "r227",
"r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249",
"r250", "r251", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r309", "r323", "r425", "r460", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498",
"r499", "r500", "r501", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521",
"r572", "r703", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r728", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r889", "r890", "r891",
"r892", "r942", "r945", "r946", "r947", "r948", "r949"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],
"lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r766", "r776", "r786", "r818"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang":
{ "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } },
"auth_ref": ["r766", "r776", "r786", "r818"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],
"lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r766", "r776", "r786", "r818"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],
"lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } },
"auth_ref": ["r766", "r776", "r786", "r818"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name",
"terseLabel": "Name" } } }, "auth_ref": ["r766", "r776", "r786", "r818"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r799"] }, "atha_FurnitureFixturesAndComputerEquipmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://athira.com/20240930", "localname": "FurnitureFixturesAndComputerEquipmentMember", "presentation": [

"http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Office Furniture, Fixtures, and Computer Equipment", "label": "Furniture Fixtures And Computer Equipment [Member]", "documentation": "Furniture, fixtures and computer equipment." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of equipment", "terseLabel": "Loss on disposal of equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r6"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r71", "r644"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative Expense", "verboseLabel": "General and Administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r71"] }, "atha_GrantIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "GrantIncome", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Grant income", "label": "Grant Income", "documentation": "Grant income." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r277", "r278", "r284", "r445", "r449", "r454", "r584", "r586", "r645", "r689", "r718", "r970"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r278", "r284", "r445", "r449", "r454", "r584", "r586", "r645", "r689", "r718", "r970"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r845", "r867"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current and long-term assets, net", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] },
"atha_IncreaseDecreaseInUnbilledGrantReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname":
"IncreaseDecreaseInUnbilledGrantReceivables", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Unbilled grant receivable", "label": "Increase Decrease In Unbilled Grant Receivables", "documentation": "Increase (decrease) in unbilled grant receivables." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r766", "r776", "r786", "r810", "r818", "r822", "r830"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r828"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r758", "r834"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r758", "r834"] },
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r758", "r834"] }, "us-gaap_InsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceRecoveries", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Insurance recovery in operating expenses", "label": "Insurance Recoveries", "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses." } } }, "auth_ref": ["r70"] }, "us-gaap_InsuranceSettlementsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceSettlementsReceivableCurrent", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Insurance recovery receivable related to legal settlement (Note 7)", "terseLabel": "Insurance recovery receivable", "label": "Insurance Settlements Receivable, Current", "documentation":
"Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r860"] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureOtherIncomeNetScheduleOfOtherIncomeNetDetails"], "lang": { "en-us": { "role": { "totalLabel": "Interest and Other Income, Total", "terseLabel": "Interest and other income", "label": "Interest and Other Income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Investments and Cash, Total", "label": "Investments and Cash", "terseLabel": "Cash, cash equivalents, and investments", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": ["r967", "r968"] },
"atha_IssuanceOfCommonStockSharesDuringPeriodFollowOnPublicOfferingNetOfUnderwritersDiscountsAndCommissions": { "xbrltype": "sharesItemType", "nsuri":
"http://athira.com/20240930", "localname": "IssuanceOfCommonStockSharesDuringPeriodFollowOnPublicOfferingNetOfUnderwritersDiscountsAndCommissions",
"presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Proceeds from follow-on public offering, net of underwriters' discounts and commissions and issuance costs, Shares", "label": "Issuance of Common Stock Shares During Period Follow-on Public Offering Net of Underwriters Discounts and Commissions", "documentation": "Issuance of common stock shares during period follow-on public offering, net of underwriters' discounts and commissions." } } }, "auth_ref": [] },
"atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares": { "xbrltype": "sharesItemType", "nsuri":
"http://athira.com/20240930", "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnitShares", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Issuance of common stock upon exercise of common stock options and vesting of restricted stock units, Shares", "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Unit Shares", "documentation": "Issuance of common stock upon exercise of common stock options and vesting of restricted stock unit shares." } } }, "auth_ref": [] }, "atha_IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits": { "xbrltype":
"monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits",
"crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of common stock options and vesting of restricted stock units", "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Units", "documentation": "Issuance of common stock upon exercise of common stock options and vesting of restricted stock units." } } }, "auth_ref": [] }, "atha_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares": { "xbrltype": "sharesItemType", "nsuri":
"http://athira.com/20240930", "localname": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Issuance of common stock upon vesting of restricted stock units, shares", "label": "Issuance of Common Stock Upon Vesting of Restricted Stock Units, Shares",
"documentation": "Issuance of common stock upon vesting of restricted stock units, shares." } } }, "auth_ref": [] },
"atha_IssuanceOfCommonStockValueDuringPeriodFollowOnPublicOfferingNetOfUnderwritersDiscountsAndCommissions": { "xbrltype": "monetaryItemType", "nsuri":
"http://athira.com/20240930", "localname": "IssuanceOfCommonStockValueDuringPeriodFollowOnPublicOfferingNetOfUnderwritersDiscountsAndCommissions", "crdr":
"credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": {
"role": { "terseLabel": "Proceeds from follow-on public offering, net of underwriters' discounts and commissions and issuance costs", "label": "Issuance of Common Stock Value During Period Follow-on Public Offering Net of Underwriters Discounts and Commissions", "documentation": "Issuance of common stock value during period follow-on public offering, net of underwriters' discounts and commissions." } } }, "auth_ref": [] }, "atha_JawandhaVAthiraPharmaIncMember": { "xbrltype": "domainItemType", "nsuri":
"http://athira.com/20240930", "localname": "JawandhaVAthiraPharmaIncMember", "presentation": [

"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Jawandha V. Athira Pharma Inc.,", "label": "Jawandha V Athira Pharma Inc [Member]", "documentation": "Jawandha V. Athira Pharma Inc." } } }, "auth_ref": [] }, "atha_LaboratoryAndOfficeFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "LaboratoryAndOfficeFacilitiesMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Laboratory and Office Facilities", "label": "Laboratory And Office Facilities [Member]", "documentation": "Laboratory and office facilities." } } }, "auth_ref": [] }, "atha_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lab Equipment", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory equipment." } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Weighted Average Remaining Lease Term and Weighted Average Discount Rate and Operating Lease Expense and Variable Lease Expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r953"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvement", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r82", "r484"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r476"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease existence of option to extend", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r477"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r954"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r483"] }, "atha_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Two", "documentation": "Lessee operating lease liability payments due after year two." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r483"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r483"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP], "lang": { "en-us": { "role": { "terseLabel": "Remaining 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r954"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP], "lang": { "en-us": { "role": { "negatedLabel": "Present value adjustment for minimum lease commitments", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r483"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, additional term of contract", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r952"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease initial term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r952"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r14", "r54", "r55", "r56", "r57", "r58", "r59", "r60", "r162", "r253", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r410", "r413", "r414", "r463", "r621", "r695", "r753", "r906", "r957", "r958"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r67", "r100", "r566", "r727", "r871", "r893", "r950"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders' equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r56", "r131", "r162", "r253", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r410", "r413", "r414", "r463", "r727", "r906", "r957", "r958"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "atha_LicensedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "LicensedProductsMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Licensed Products", "label": "Licensed Products [Member]", "documentation": "Licensed Products." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Legal settlement expense", "terseLabel": "Legal expense", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": ["r849"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Long-term Investments, Total", "terseLabel": "Long-term investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r133"] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Accrual, Current", "terseLabel": "Accrued legal settlement", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r293"] }, "us-gaap_LossContingencyLawsuitFilingDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyLawsuitFilingDate1", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Lawsuit Filing Date", "terseLabel": "Lawsuit filing date", "documentation": "Date complaint was formally filed in court of law, arbitration, or mediation, in YYYY-

MM-DD format." } } }, "auth_ref": ["r901", "r902", "r903"] }, "us-gaap_LossContingencyNameOfDefendant": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNameOfDefendant", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Name of Defendant", "terseLabel": "Name of defendant", "documentation": "Identifies the named defendant in a lawsuit." } } }, "auth_ref": ["r36", "r37", "r87"] }, "us-gaap_LossContingencyNameOfPlaintiff": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNameOfPlaintiff", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Name of plaintiff", "label": "Loss Contingency, Name of Plaintiff", "documentation": "Identifies the plaintiff in the lawsuit." } } }, "auth_ref": ["r36", "r37", "r87"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Maximum", "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r334", "r380", "r443", "r522", "r583", "r585", "r599", "r613", "r614", "r665", "r667", "r669", "r670", "r672", "r687", "r688", "r702", "r706", "r712", "r719", "r720", "r724", "r725", "r738", "r908", "r959", "r960", "r961", "r962", "r963", "r964"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r802"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r802"] }, "atha_MilestonePaymentsAmountPayableUponMarketingApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "MilestonePaymentsAmountPayableUponMarketingApproval", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments payable upon marketing approval", "label": "Milestone Payments Amount Payable Upon Marketing Approval", "documentation": "Milestone payments amount payable upon marketing approval." } } }, "auth_ref": [] }, "atha_MilestonePaymentsAmountPayableUponTrialInitiation": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "MilestonePaymentsAmountPayableUponTrialInitiation", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments, amount payable", "label": "Milestone Payments Amount Payable Upon Trial Initiation", "documentation": "Milestone payments amount payable upon trial initiation." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Minimum", "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r334", "r380", "r443", "r522", "r583", "r585", "r599", "r613", "r614", "r665", "r667", "r669", "r670", "r672", "r687", "r688", "r702", "r706", "r712", "r719", "r720", "r724", "r738", "r908", "r959", "r960", "r961", "r962", "r963", "r964"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r821"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money Market Fund", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r910"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r829"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r803"] }, "atha_NationalInstitutesOfHealthGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "NationalInstitutesOfHealthGrantMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "National Institutes of Health Grant", "label": "National Institutes Of Health Grant [Member]", "documentation": "National institutes of health grant member." } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness"], "lang": { "en-us": { "role": { "terseLabel": "Description of Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r109", "r121"] }, "us-gaap_NetCashProvidedByUsedInContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInContinuingOperations", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash used in operations", "label": "Net Cash Provided by (Used in) Continuing Operations", "totalLabel": "Net Cash Provided by (Used in) Continuing Operations, Total", "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label." } } }, "auth_ref": ["r866"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r158"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r158"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r76", "r77", "r78"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r69", "r78", "r103", "r129", "r143", "r145", "r149", "r162", "r167", "r170", "r171", "r173", "r174", "r175", "r179", "r180", "r187", "r253", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r397", "r406", "r437", "r463", "r570", "r642", "r658", "r659", "r751", "r906"] }, "atha_NetSalesExemptFromRoyaltyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "NetSalesExemptFromRoyaltyPayment", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net sales exempt from royalty payment", "label": "Net Sales Exempt From Royalty Payment", "documentation": "Net sales exempt from royalty payment." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r802"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r766", "r776", "r786", "r810", "r818"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r793"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r792"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r810"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule

10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r829"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r829"] }, "atha_NonVestedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "NonVestedRestrictedStockUnitsMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu], "lang": { "en-us": { "role": { "terseLabel": "Non-vested Restricted Stock Units", "label": "Non Vested Restricted Stock Units [Member]", "documentation": "Non-vested restricted stock units member." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureOtherIncomeNetScheduleOfOtherIncomeNetDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r72"] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r700", "r880"] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "terseLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r106", "r696", "r879", "r881", "r882", "r883", "r884"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseExpenseAndVariableLeaseExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r478", "r726"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseExpenseAndVariableLeaseExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r951"] }, "atha_OperatingLeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://athira.com/20240930", "localname": "OperatingLeaseExpirationMonthAndYear", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expiration month and year", "label": "Operating Lease Expiration Month And Year", "documentation": "Operating lease expiration month and year." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedOperatingLeaseCashFlowsToOperatingLeaseLiabilityP], "lang": { "en-us": { "role": { "verboseLabel": "Net lease liability", "totalLabel": "Operating Lease, Liability, Total", "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r475"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r475"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, less current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r475"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r474"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r868"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermi], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r482", "r726"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateToDetermi], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r481", "r726"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Noncurrent, Total", "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r136"] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-sale securities", "verboseLabel": "Unrealized (loss) gain on available-for-sale securities", "totalLabel": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r3", "r8", "r97"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureOtherIncomeNetScheduleOfOtherIncomeNetDetails"], "lang": { "en-us": { "role": { "totalLabel": "Other Nonoperating Expense, Total", "label": "Other Nonoperating Expense", "negatedLabel": "Other expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": ["r73"] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureOtherIncomeNet"], "lang": { "en-us": { "role": { "terseLabel": "Other Income, Net", "label": "Other Nonoperating Income and Expense [Text Block]", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": ["r153", "r154"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r73"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r802"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r764", "r774", "r784", "r816"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r767", "r777", "r787", "r819"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r767", "r777", "r787", "r819"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r791"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "atha_PaymentOnAchievementOfDevelopmentMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "PaymentOnAchievementOfDevelopmentMilestone", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments on development milestone achieved", "label": "Payment On Achievement Of Development Milestone", "documentation": "Payment on achievement of development milestone." } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"PaymentsForLegalSettlements", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Payments for Legal Settlements", "terseLabel": "Legal settlement amount", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": ["r4"] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of available-for-sale securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r19", "r155", "r220"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r75"] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r801"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r801"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r793"] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r810"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r803"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r792"] },
"atha_PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "PhaseThreeClinicalTrailInitiationOfLicenseAgreementMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Phase 3 Clinical Trial Initiation", "label": "Phase Three Clinical Trail Initiation Of License Agreement [Member]", "documentation": "Phase three clinical trail initiation of license agreement." } } }, "auth_ref": [] }, "atha_PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "PhaseTwoClinicalTrailInitiationOfLicenseAgreementMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Phase 2 Clinical Trial Initiation", "label": "Phase Two Clinical Trail Initiation Of License Agreement [Member]", "documentation": "Phase two clinical trail initiation of license agreement." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936"] },
"ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r794"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r838"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r793"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r862"] }, "us-gaap_PriorPeriodAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodAdjustmentAbstract", "lang": { "en-us": { "role": { "label": "Prior Period Adjustment [Abstract]" } } }, "auth_ref": [] },
"atha_ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "ProceedsFromExerciseOfCommonStockOptionsAndIssuanceOfCommonStockUnderEmployeeStockPurchasePlan", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan", "label": "Proceeds from Exercise of Common Stock Options and Issuance of Common Stock Under Employee Stock Purchase Plan", "documentation": "Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan." } } }, "auth_ref": [] }, "atha_ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net cash proceeds from issuance of convertible preferred stock, common stock warrants, and convertible notes", "label": "Proceeds From Issuance Of Convertible Preferred Stock And Common Stock Warrants", "documentation": "Proceeds from issuance of convertible preferred stock and common stock warrants." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Maturities of available-for-sale securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r155", "r156", "r886"] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales of available-for-sale securities", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r18", "r155", "r220", "r252"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r2", "r12"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r213", "r523", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r690", "r707", "r737", "r738", "r739", "r741", "r742", "r904", "r905", "r909", "r969", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r213", "r523", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r690", "r707", "r737", "r738", "r739", "r741", "r742", "r904", "r905", "r909", "r969", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r129", "r143", "r145", "r157", "r162", "r167", "r175", "r179", "r180", "r253", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r397", "r406", "r408", "r411", "r412", "r437", "r463", "r559", "r569", "r607", "r642", "r658", "r659", "r714", "r715", "r752", "r865", "r906"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r7", "r484"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r81", "r114", "r117", "r118"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "terseLabel": "Property and equipment, at cost", "label": "Property, Plant and Equipment, Gross",

"documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r82", "r134", "r568"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r484"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r484", "r560", "r568", "r727"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r82", "r484"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r791"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r791"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r327", "r334", "r366", "r367", "r368", "r380", "r443", "r497", "r506", "r522", "r583", "r585", "r599", "r613", "r614", "r665", "r667", "r669", "r670", "r672", "r687", "r688", "r702", "r706", "r712", "r719", "r720", "r724", "r725", "r738", "r745", "r897", "r908", "r946", "r960", "r961", "r962", "r963", "r964"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r327", "r334", "r366", "r367", "r368", "r380", "r443", "r497", "r506", "r522", "r583", "r585", "r599", "r613", "r614", "r665", "r667", "r669", "r670", "r672", "r687", "r688", "r702", "r706", "r712", "r719", "r720", "r724", "r725", "r738", "r745", "r897", "r908", "r946", "r960", "r961", "r962", "r963", "r964"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r759", "r769", "r779", "r811"] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": ["r384", "r939"] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": ["r384", "r939"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r383", "r689", "r699", "r965"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "verboseLabel": "Research and Development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r382"] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh
], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": ["r126", "r163", "r164", "r165", "r167", "r168", "r170", "r171", "r172", "r173", "r176", "r177", "r178", "r179", "r180", "r182", "r195", "r260", "r261", "r394", "r395", "r397", "r398", "r405", "r406", "r431", "r435", "r436", "r437", "r470", "r472", "r489", "r490", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r600", "r885"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r760", "r770", "r780", "r812"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r761", "r771", "r781", "r813"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r768", "r778", "r788", "r820"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh
], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": ["r126", "r163", "r164", "r165", "r167", "r168", "r170", "r171", "r172", "r173", "r176", "r177", "r178", "r179", "r180", "r182", "r195", "r260", "r261", "r394", "r395", "r397", "r398", "r405", "r406", "r431", "r435", "r436", "r437", "r470", "r472", "r489", "r490", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r600", "r885"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r132"] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Current", "terseLabel": "Restricted cash, current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r857", "r869"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash, non-current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r108", "r858", "r869"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)",

```
"label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r280", "r281", "r283", "r286", "r290" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related cost, estimated to incur", "label": "Restructuring and Related Cost, Expected Cost", "totalLabel": "Restructuring and Related Cost, Expected Cost, Total", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r282", "r285", "r287", "r289" ] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of termination in workforce", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r287", "r288", "r289" ] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "presentation": [ "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liability associated with restructuring", "label": "Restructuring Reserve, Current", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r859", "r898", "r899" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r64", "r93", "r565", "r593", "r598", "r606", "r623", "r727" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r125", "r163", "r164", "r165", "r168", "r175", "r178", "r180", "r258", "r265", "r276", "r385", "r386", "r393", "r394", "r395", "r398", "r405", "r406", "r419", "r421", "r422", "r424", "r435", "r471", "r473", "r589", "r591", "r608", "r1000" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Revenues", "totalLabel": "Revenues, Total", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r104", "r105", "r150", "r162", "r196", "r200", "r201", "r209", "r211", "r213", "r214", "r216", "r253", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r463", "r559", "r699", "r906" ] },
"srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh
], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Error Correction, Adjustment [Member]", "terseLabel": "Adjusted" } } }, "auth_ref": [ "r170", "r171", "r172", "r177", "r178", "r179", "r180" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset obtained in exchange for new operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r480", "r726" ] }, "atha_RoyaltyObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "RoyaltyObligation", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty obligation", "label": "Royalty Obligation", "documentation": "Royalty obligation." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r829" ] },
"ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r829" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r335", "r877" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh
], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "terseLabel": "As Reported" } } }, "auth_ref": [ "r126", "r163", "r165", "r167", "r168", "r170", "r171", "r180", "r195", "r394", "r397", "r398", "r405", "r406", "r431", "r435", "r436", "r470", "r472", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r600", "r844", "r846", "r847", "r848", "r876", "r885", "r894", "r895", "r941", "r955", "r956" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r182", "r335", "r842", "r877" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu
], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r28" ] },
"atha_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://athira.com/20240930", "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash", "label": "Schedule Of Cash, Cash Equivalents and Restricted Cash [Table Text Block]", "documentation": "Schedule of cash, cash equivalents and restricted cash." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
```

"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation Expense Recognized", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r47"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh], "lang": { "en-us": { "role": { "label": "Error Correction [Table]", "documentation": "Disclosure of information about prior period adjustment to correct error in previously issued financial statement. Includes, but is not limited to, effect of correction on financial statement line item, affected per-share amount, cumulative effect of change on retained earnings and other appropriate component of equity or net assets in statement of financial position, and effect of prior period adjustment on net income of each prior period presented." } } }, "auth_ref": ["r170", "r171", "r172", "r177", "r178", "r179", "r180", "r195"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedTables"], "lang": { "en-us": { "role": { "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Summary of Immaterial Error Correction", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": ["r25", "r26", "r27"] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureOtherIncomeNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Income, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7", "r484"] }, "atha_ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://athira.com/20240930", "localname": "ScheduleOfReservedSharesOfCommonStockForFutureIssuanceTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reserved Shares of Common Stock for Future Issuance", "label": "Schedule Of Reserved Shares Of Common Stock For Future Issuance Table [Text Block]", "documentation": "Schedule of reserved shares of common stock for future issuance." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r282", "r283", "r284", "r285", "r287", "r288", "r289"] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cost Associated With Termination Benefit Payment of Restructuring", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": ["r35", "r85"] }, "atha_ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://athira.com/20240930", "localname": "ScheduleOfShareBasedCompensationArrangementSharesAvailableForGrantTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Arrangement Shares Available For Grant Table [Text Block]", "documentation": "Schedule of share based compensation arrangement shares available for grant.", "terseLabel": "Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan and the 2024 Inducement Plan" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r337", "r339", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r366", "r367", "r368", "r369"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": ["r44"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Summary of Stock Options Outstanding and Exercisable under the 2020 Plan and the 2024 Inducement Plan", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r44"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Option Activity under the 2020 Plan and the 2024 Inducement Plan", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r10", "r11", "r94"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r96"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r38", "r39", "r40", "r41", "r42", "r43", "r89", "r91", "r92", "r93", "r138", "r139", "r140", "r198", "r311", "r312", "r313", "r315", "r318", "r323", "r325", "r602", "r603", "r604", "r605", "r706", "r841", "r870"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "verboseLabel": "Security12b Title", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r754"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r756"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r214", "r215", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r610", "r611", "r612", "r666", "r668", "r671", "r673", "r676", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r691", "r708", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r740", "r745", "r909", "r969", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r202", "r203", "r204", "r205", "r206", "r207", "r208", "r212", "r214", "r697", "r698", "r701"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": ["r938"] }, "us-gaap_SettlementLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettlementLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal expense", "label": "Settlement Liabilities, Current", "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers." } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringSummaryOfCostAssociatedWithTerminationBenefitPaymentOfRestructuringDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total severance expense", "totalLabel": "Total severance expense", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Share Equivalent, Cancelled", "terseLabel": "Cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r358"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r358"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share Equivalent, Granted", "verboseLabel": "Granted, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r356"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r356"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodStartLabel": "Share Equivalent, Non-vested, Beginning Balance", "periodEndLabel": "Share Equivalent, Non-vested, Ending Balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r353", "r354"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Beginning Balance", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r353", "r354"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Share Equivalent, Vested", "verboseLabel": "Share vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "RSUs vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r357"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value, Non-vested, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r357"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackS
], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r367"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackS
], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r366"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackS
], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r368"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r337", "r339", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r366", "r367", "r368", "r369"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc
], "lang": { "en-us": { "role": { "periodEndLabel": "Shares Available for Grant, Ending Balance", "periodStartLabel": "Shares Available for Grant, Beginning Balance", "terseLabel": "Shares available for grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r44"] }, "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted": { "xbrltype": "sharesItemType", "nsuri": "http://athira.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted", "presentation": [

```
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc
], "lang": { "en-us": { "role": { "negatedLabel": "Options and restricted stock units granted", "label": "Share Based Compensation Arrangement By Share Based Payment Award
Options And Restricted Stock Unit Granted", "documentation": "Share based compensation arrangement by share based payment award options and restricted stock unit
granted." } } }, "auth_ref": [] }, "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired": {
"xbrltype": "sharesItemType", "nsuri": "http://athira.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc
], "lang": { "en-us": { "role": { "terseLabel": "Options and restricted stock units forfeited, cancelled, or expired", "label": "Share-based Compensation Arrangement by Share-
based Payment Award, Options and Restricted Stock Units, Forfeited, Cancelled or Expired", "documentation": "Share-based compensation arrangement by share-based
payment award, options and restricted stock units, forfeited, cancelled or expired." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails",
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement
], "lang": { "en-us": { "role": { "verboseLabel": "Shares Exercisable", "terseLabel": "Shares, Options exercisable", "label": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance
sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r347" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-Average Exercise price per Share, Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the
shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r347" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr":
"debit", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Aggregate intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period,
Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or
share units converted) into shares." } } }, "auth_ref": [ "r360" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation":
[ "http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total",
"negatedLabel": "Shares, Forfeited/expired", "terseLabel": "Options forfeited, cancelled, or expired", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that
were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that
expired." } } }, "auth_ref": [ "r917" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-Average Exercise price per Share, Forfeited/expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or
expired." } } }, "auth_ref": [ "r917" ] }, "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://athira.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of
options granted", "label": "Share Based Compensation Arrangement By Share based Payment Award Options Grants In Period Fair Value", "documentation": "Share Based
Compensation Arrangement By Share based Payment Award Options Grants In Period Fair Value" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "verboseLabel": "Options, granted", "terseLabel": "Shares, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r349" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." }
} }, "auth_ref": [ "r44" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails",
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement
], "lang": { "en-us": { "role": { "verboseLabel": "Shares Outstanding", "periodStartLabel": "Shares, Beginning Balance", "periodEndLabel": "Shares, Ending Balance", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both
vested and non-vested options." } } }, "auth_ref": [ "r345", "r346" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
"presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc
], "lang": { "en-us": { "role": { "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease),
Total", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)", "terseLabel": "Shares reserved",
"documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are
outstanding, including vested options." } } }, "auth_ref": [ "r917" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "periodStartLabel": "Weighted-Average Exercise price per Share, Beginning Balance", "periodEndLabel": "Weighted-Average Exercise price per Share,
Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r345", "r346" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of
fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are
expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r361" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
"presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Shares, Expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected
to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan.
Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance
condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r361" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-Average Exercise price per Share, Expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can
acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service
period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [
"r361" ] }, "atha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://athira.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue", "crdr": "debit",
"presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair value of restricted stock units granted", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options Grant Date
Fair Value", "documentation": "Share-based compensation arrangement by share-based payment award, other than options grant date fair value" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails",
```

"http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r366", "r367", "r368", "r369"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise price per Share, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r350"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise price per Share, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r349"] }, "atha_ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan": { "xbrltype": "sharesItemType", "nsuri": "http://athira.com/20240930", "localname": "ShareBasedCompensationMaximumAnnualIncreaseInNumberOfSharesThatMayBeIssuedUnderPlan", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation maximum annual increase in number of shares that may be issued under the plan", "label": "Share Based Compensation Maximum Annual Increase In Number Of Shares That May Be Issued Under Plan", "documentation": "Share based compensation maximum annual increase in number of shares that may be issued under the plan." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r336", "r344", "r363", "r364", "r365", "r366", "r369", "r375", "r376", "r377", "r378"] }, "atha_ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding": { "xbrltype": "percentItemType", "nsuri": "http://athira.com/20240930", "localname": "ShareBasedCompensationPercentageOfNumberSharesOfCommonStockIssuedAndOutstandingOnImmediateProceeding", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding", "label": "Share Based Compensation Percentage Of Number Shares Of Common Stock Issued And Outstanding On Immediate Proceeding", "documentation": "Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range", "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r45"] }, "atha_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://athira.com/20240930", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price ($)", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price", "documentation": "Share based compensation shares authorized under stock option plans exercise price." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range", "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r46"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsOutstandingAndExercisableUnderThe2020PlanAndThe2024Inducement], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedInEstimatingFairValueOfEachStockOptionsUsingBlackS], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r365"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r44"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term, Options exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r44"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r95"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term, Expected to vest (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r361"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of options vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r360"] }, "atha_SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "SharesAvailableForFutureGrantUnderEmployeeStockPurchasePlanMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares Available for Future Grant under Employee Stock Purchase Plan", "label": "Shares Available For Future Grant Under Employee Stock Purchase Plan [Member]", "documentation": "Shares available for future grant under the employee stock purchase plan." } } }, "auth_ref": [] }, "atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares Available for Future Grant under 2020 Equity Incentive Plan", "label": "Shares Available For Future Grant Under Two Thousand Twenty Equity Incentive Plan [Member]", "documentation": "Shares available for future grant under the 2020 equity incentive plan." } } }, "auth_ref": [] }, "atha_SharesAvailableForFutureGrantUnderTwoThousandTwentyFourInducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "SharesAvailableForFutureGrantUnderTwoThousandTwentyFourInducementEquityIncentivePlanMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares Available for Future Grant under 2024 Inducement Equity Incentive Plan", "label": "Shares Available For Future Grant Under Two Thousand Twenty Four Inducement Equity Incentive Plan [Member]", "documentation": "Shares available for future grant under two thousand twenty four inducement equity incentive plan." } } }, "auth_ref": [] }, "atha_SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember", "presentation": [

```
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Issuable Upon the Exercise of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted", "label": "Shares Issuable Upon The Exercise Of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted Member", "documentation": "Shares issuable upon the exercise of outstanding common stock options and the vesting of outstanding common restricted stock units granted." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "atha_ShortTermInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "ShortTermInvestmentMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Short-Term Investment [Member]", "documentation": "Short-Term Investment [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": [ "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Short-term Investments, Total", "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r101", "r102", "r861" ] },
"atha_ShortTermInvestmentsMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://athira.com/20240930", "localname": "ShortTermInvestmentsMaturityTerm", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments effective maturity date", "label": "Short Term Investments Maturity Term", "documentation": "Short-term investments maturity term." } } }, "auth_ref": [] },
"atha_ShortTermInvestmentsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://athira.com/20240930", "localname": "ShortTermInvestmentsPolicyPolicyTextBlock", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Short-term Investments, Policy [Policy Text Block]", "documentation": "Short-term investments." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r79", "r160" ] }, "atha_SlyneVAthiraPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "SlyneVAthiraPharmaIncMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Slyne V. Athira Pharma Inc.,", "label": "Slyne V Athira Pharma Inc [Member]", "documentation": "Slyne V. Athira Pharma Inc." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r62", "r65", "r66", "r125", "r147", "r148", "r149", "r163", "r164", "r165", "r168", "r175", "r178", "r180", "r197", "r258", "r265", "r276", "r326", "r385", "r386", "r393", "r394", "r395", "r398", "r405", "r406", "r419", "r420", "r421", "r422", "r423", "r424", "r435", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r490", "r571", "r589", "r590", "r591", "r608", "r660" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r214", "r215", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r610", "r611", "r612", "r666", "r668", "r671", "r673", "r676", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r691", "r708", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r740", "r745", "r909", "r969", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r163", "r164", "r165", "r197", "r473", "r523", "r601", "r609", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r635", "r636", "r637", "r638", "r639", "r641", "r643", "r644", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r660", "r746" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] },
"srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureCorporateRestructuringAdditionalInformationDetails",
"http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r182", "r335", "r842", "r843", "r877" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r163", "r164", "r165", "r197", "r219", "r473", "r523", "r601", "r609", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r635", "r636", "r637", "r638", "r639", "r641", "r643", "r644", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r660", "r746" ] },
"ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r763", "r773", "r783", "r815" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan, shares", "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan." } } }, "auth_ref": [ "r9", "r50", "r61", "r62", "r93" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued and sold", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r61", "r62", "r93", "r602", "r660", "r674" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityUnderThe2020PlanAndThe2024InducementPlanDetails",
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares, Exercised", "terseLabel": "Issuance of common stock upon exercise of common stock options, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r61", "r62", "r93", "r350" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan", "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r9", "r50", "r61", "r62", "r93" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of common stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r62", "r65", "r66", "r93" ] }, "atha_StockOptionsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "StockOptionsToPurchaseCommonStockMember", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu
], "lang": { "en-us": { "role": { "terseLabel": "Stock Options to Purchase Common Stock", "label": "Stock Options To Purchase Common Stock [Member]", "documentation": "Stock options to purchase common stock." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r62", "r65", "r66", "r80", "r624", "r640", "r661", "r662", "r727", "r753", "r871", "r893", "r950", "r1000" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStock" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r90", "r161", "r310", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r324", "r326", "r426", "r663", "r664", "r675" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://athira.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://athira.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
```

"Supplemental disclosures of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r809"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r801"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r808"] }, "atha_TowThousandAndTwentyEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "TowThousandAndTwentyEmployeeStockPurchasePlanMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2020 Employee Stock Purchase Plan", "label": "Tow Thousand And Twenty Employee Stock Purchase Plan [Member]", "documentation": "Tow thousand and twenty employee stock purchase plan." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r828"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r830"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r309", "r323", "r425", "r460", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r572", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r728", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r889", "r890", "r891", "r892", "r942", "r945", "r946", "r947", "r948", "r949"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r831"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r832"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r832"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r830"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r830"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r833"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r831"] }, "atha_TwoThousandAndTwentyEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "TwoThousandAndTwentyEquityIncentivePlanMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2020 Equity Incentive Plan", "label": "Two Thousand And Twenty Equity Incentive Plan [Member]", "documentation": "Two thousand and twenty equity incentive plan." } } }, "auth_ref": [] }, "atha_TwoThousandAndTwentyFourInducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "TwoThousandAndTwentyFourInducementEquityIncentivePlanMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityChangesInSharesAvailableForGrantUnderThe2020PlanAndThe2024Inc "http://athira.com/20240930/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Inducement Equity Incentive Plan", "label": "Two Thousand And Twenty Four Inducement Equity Incentive Plan [Member]", "documentation": "Two thousand and twenty four inducement equity incentive plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r407"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureFairValueScheduleOfFairValueOfCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Debt and Agency Securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r693", "r709", "r966"] }, "atha_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://athira.com/20240930", "localname": "UnauditedInterimCondensedFinancialStatementsPolicyTextBlock", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Interim Condensed Financial Statements", "label": "Unaudited Interim Condensed Financial Statements Policy [Text Block]", "documentation": "Unaudited interim condensed financial statements." } } }, "auth_ref": [] }, "atha_UnbilledGrantReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://athira.com/20240930", "localname": "UnbilledGrantReceivableCurrent", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Unbilled grant receivable", "label": "Unbilled Grant Receivable Current", "documentation": "Unbilled grant receivable current." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r827"] }, "atha_UnvestedRestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "UnvestedRestrictedStockAwardsMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilu], "lang": { "en-us": { "role": { "verboseLabel": "Non-vested Restricted Stock Awards", "documentation": "Unvested restricted stock awards.", "label": "Unvested Restricted Stock Awards [Member]", "terseLabel": "Unvested RSAs" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r30", "r31", "r32", "r111", "r113", "r115", "r116"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeaseExpenseAndVariableLeaseExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable lease expense", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r479", "r726"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r797"] }, "atha_WangVAthiraPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "WangVAthiraPharmaIncMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Wang V. Athira Pharma Inc.,", "label": "Wang V Athira Pharma Inc [Member]", "documentation": "Wang V. Athira Pharma, Inc." } } }, "auth_ref": [] }, "atha_WashingtonStateUniversityLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://athira.com/20240930", "localname": "WashingtonStateUniversityLicenseAgreementMember", "presentation": ["http://athira.com/20240930/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Washington State University License Agreement", "label": "Washington State University License Agreement [Member]", "documentation": "Washington state university license agreement." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted", "terseLabel": "Weighted average shares outstanding, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r185", "r190"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://athira.com/20240930/taxonomy/role/DisclosureImmaterialErrorCorrectionUnauditedSummaryOfImmaterialErrorsCorrectionInTheWeightedaverageNumberOfCommonSh "http://athira.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic", "terseLabel": "Weighted average shares outstanding,basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r184", "r190"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r795"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480637/718-40-25-10" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" },

"r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",

"Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section":

"19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r841": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r843": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",

"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 71 0000950170-24-123372-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-123372-xbrl.zip M4$L#!!0 (.F!9UD?YF2YNS0# -<)) 1 871H82TR,#(T,#DS,"YH M=&WLO7EWVTB2+_K_?
IO7G__/KO_W\OPA)GK]\]3IYI3\G^[8M/_GG M96,G53.K??+XX/>?DE?323GUR?_]RIO?DN>5G1W[:9N0Y*AM3_:>//G\^?.N M"^6TJ2:S%M[5I-
KJ^$E"R/SASVJO\?/DN6Y]LLZA1RVL!ZS)M/GET[57WXA"FEGISB-8^Z MB_9.33UQY?):_#->R2G-GW1?7KBTO?;2K+NT7;VTO#" U:O3)["-+4S-+ZZ' ME?_C"Y?
CUT8WR\M/KUQ_87[X[>+2\O2FYS('BL]D$9\67MJ"[8G&#M^[Z8< 7%Y[L M8=;\.B+@](D_;?VT*$M@\!?N6TSF?,.?M+6>-J&JC^,8D1XR0N7*)$4VOK&G55/X-M'O_Y;
M\O.1UP[^37YNRW;B?V64_/WG)]WO^.FQ;W5$-^+ .2L _?+H636%[6O)>UC7 M1XGM_OKE40N[^B1"QA-\ZI/Y8W\VE3M+FO9LXG]Y=*SKPW*ZE^A96_VO\ODD
MJH'&VZPE[^B@.PI6?%L]P97,RT6?(@AZ^_;D\ MW<-7^;K[M73.3^.OYSR:E$"T+S^F)N1";T,R[3D1MC!$"Z=)X;-@O V!9;!T
M4WV.;_'EW@+=7X($T).W*3*O83/FOFL3]MW/L!Z?,P%M]QG&6$ZMT2D5A"9 M ;'IG.89Y;DI*.\X M71WEBRGLU=DS&&>M)Z^FSI_^IS^[VP@I0%#.JPX/2@A%19 41$N28
MHBH0E7J2) -ZGJYG/_M=?UBZE ,WFVPA# .;'BKD4K!1&%T(#P4 M 88;-&2PL(JF2N76BW28G6D^[#M+F[!1! _>;7A!3QI_97!/+I)HI8.');&^ M^?5GE$9[301 _>%$2I=,>8M+6WTD
MM<5?I<._0^GK) [:7PNESU[)YT7"NGSSXG&-/\05[_YT\++3DTEIR_9W?VS@ M%;X\1ID!VMNCN2#;V_^L;XVO *CM!^".^OWGZOU1-6OTU+W_#"\\>PGK WPSLQ[?_P) KCT#
[0G'I\F_ MG>AI-X*?GUP[L%\7,UJ. \EUBW42T6.Y=%&XM[)&|8\]DM+ENLR_6?R]N,) MA8C*[MT=EO_I.?7!S&\J)7TY-9 MV\0K^!H&L]\TOGTVTXV6:A1=->AK(?.;EB# ME4N;=]Z";
85;*U0ERXD=@]0E^F4%Z ;26DTB*T\)\87&>&&.Y-)6C [6+%U MT),G(L:((H34&6O\,P^Z,2(B4@LI7L%V'A2MGJR;F&4]K5#.0LRE9: 0@0[M%*@G1AG4NX)DH"JFA@]WAU")^
O((H>;]]&X317+6;M4567__(N:A,';67_ M>'.'WZ.JT/SE[,4LGCCWX+"Y]^!!%N5:!>^!$WDQA" XG/E'?CG[_JT/)X= M?Y]R4MJDPZJ:"98#]H+
M*#*HR0@*;*\RDMN,:>,4J#/ING=H8U))<18,S2G)<[0,E==$>U@!X;22UE,& MIM90R?-NQM0+,$RK,^\C#+X%._,(4'/M-E.O6\9#%@Q(/;4X$=3G1*(B(0L'
MMA156ED[U"V(+:)8.SN>3>!:IZ8]\C5>5_LC?-HGT(1M=>RWQ<)5*?,.L M$@+0)3BBI("G2XU6DL]H*(:Z6\.PDP9M((1**<*X8#EQ.4N)D#E <2I $*7]I?XJ0Q4O\)QP@/H?"(K4B*Y-
$1F(I7, M93XS;LNW$YT#8&2@(%V_[BYNK[OG?6UA#D:Y]!D!)2@#CBPH~F0D<((H:RW M#],OV[V%&]+=>\-,#(1IG9%@ NA"H,H3S5+0XGU62##8G95LVW=HP[I0G[NE M:,%%
;H00P>+X!BYR5$A2ID!*\P7=.VV\.8FKU,.DGHB"@, N+5$!T9!BI?'Q.]^T=6D!:*)(_S M08L^^+ U^K,+P?H\)9RY BPMV!N0TXPPZ7(P MC7FFY1#090BTZXV4BEK",P-
Z#89M2&&%B2S(E !Z>E?C&& O_JSWKJCO0/$4?7&34Y;$4D MXV!H"!ON!@DZZD%[*(TEFT@"&JW;$>(>X MX#,+K_7Q*C6\KSXO\I_V%RE0#^C&\'*&2BU3'C#K'NPE47!/ MC
TYT9Y29TQAI1FLMHF*YINP7]?(?WCOA72IYJB<'K;H18*U 94S%CRT9[\! MWT]!*AS6/M[3EU\9:PHPUP;HZ#GFTE0G<43G@\-4X5K;]GWUUM>8SORRJ]/= M#9!U*=;T%DGN_1&,\-
FDG)963||7NIR\ KVYC$CX)GSC-.ZE4["LOQB3-JZP M.9J_&3HOG6(8M0"%D2O*"EZ$$ 8;M>Y\(DN3];?*QLVX:.O\U4||K2= !OON M/+!^-
R9,O3E&.K4'WN^R1OBV(].B1UE;DE!M.I'66""$%,;S /34L *(M$*C2 ,8P4%)>RV8)+!OB@C*&+I< I': M@H:)"<)NN!ESM]O"=[[5Y=2[%
[]>@J;RM0#W=@:Z3)%CNCWL'DU1,BC,P#>, MV"!59KWT6@_6"'U;5S#5]@QU_Q;D.6YG5.I6];7%Q;]Y4-F.JHE[=7Q25Y^Z M3(%M0PE5W]+B8H5!G#3@-()
"0R4)A,RC/"P(Z5ROO4^6QH1/5-2'&|C^]I MQHF465Y03ZR$QV+"(P%YF1%KLM04FK+'\|>?7_D%U3R)KR9M:BI M8E^*%<=#1V\-!DZ. ,#]\|\T\+7UUQ[G2;8NR#>]B$4%
(8AV&4@O&P8I5 MDK!,4&YS:G,W6,&P;(CT"A:@GET*DQP BK3O?7W\:OH)]JG/@,A8D+Q5]08] M.I^M"CS-1$ZHL078IC(CQL,/FP<;P'!-,S7Z7V^=)MI7$;(UN1%>6<(8Q;(!
M71#I@B"2&@Z(QIC3V[XK \AH[JMVU/K),\M<19C&,P7Q(@":T>]*M)0:#M< M#6/02;WI[?W@:7]^UE7Q[C#LW:>F;"(9[P%LR1:,&?7/V#5'ME0RLUF MHN5 "V
?!$\415I0(2,J4X(4.@2KC:.<#Y86!B<>>U-:'/"@38$O%>6@XRN3 M@HY/*?&V,(6UNA!J<,FNPXXX;@9I'!LBPS/-C! ME45_-Y[AM22W#\#?XZAGPCA&;%8
917>$I5[L&@LQ3:;5FH[V##V^L7WJC?H M?;60WP^:HK()FN"P5\H;DE'NB;!2$<,Q'QI4=R6UEUP.MD_=\%*A+SKN5K?S M7D*=VX(Z"39OIL"*D@I4+9FEA--4*%;X/,_E-
NW1>;O.\SUZB!Z=0V"WW!:Y M#I; ,F/;6H$%DH4B3BN?%9ER-!ULCNF0W1<#:&CA"L\UZMK*2>!2=!6]S#CL MVLJ,-C:GP^V&<*LDL,8(5.+:$V8%LDK3!(QTDAN'*:9E0,..([
M,PVH6KH^.] 3_R9$N;NR@_OM^R/_NZ[_\"T0D%|/3. >'A+64\]6"UHH"5A0 M@* &U,T[!VU6H[?$F>%]R$W)" 5=27TMB? /YR!N)G$ M4Y^I+!>Y-
>QZ@'1.8|\%!W(6BH,1:#/<'YH&#F"5"&\.]275PVVZY/U2&%N]Q M5T [M%QIDN5HATN6$N.])04-KI VDR8?K&?_]G;XRQGHA5BL_K(\Q7^POJ9+ MT/#U\]ZM8:20<>ET2H)!WZ40H
>"L4RL,""&C"P8W?:<\X=BI![-8< S; NM M"2\TEC,Y@^W>#)A:GG)/:;'RM9^-N1UV#-:Q@,4B24ZCXP K@FDH2*Y"8&#Z MYBD;K.([^(K@S43, B\$345.BH &C87-E07\8$)*
[0OQ=87)VW:ENE1@(04 M_@O<$Z93T,1R/.ND*)AP7,G7:IX,5@&?#C%^:M#^L&ZU(:L4"G68ZL,3T2P M(."48(;87&>:<\4>H&'[-
JL=0Y"\.;O:@(D(R(Z@3\8",^4D]5F:$@]&>^4*D63:X@H\A,?MZG) A2.=RAH_# MTPDS42 $*Z*H*S3LBE,#SKP>=N, 'GF'4BFY]%$9QE)$0'I=*. =;9G23 KO MAJL,#Z<]SF
L>PH;)WR*5/MB* @CJ55$M@Z9R;EH"\/]TSHP=NKF^F$2YG@ M,F@P>:0&7=84BLB<4I()&20-6@D]V.3XP8;$-[*/-K/::F*D!*CE.2BT@7]B
M!05=UF=:JL'&%+:@#>5F4@.IU'E:2$,T]9CZE7,B0>\A(^*+ M)R0=3,ZF_HA#%MB1,0E[.]C<^8&F^ZWN*LMNS;"784(NUN4X$$(@::,3D MUDB:-7?ULC"Y8:"X"5!NS.!LJ(
MY!ATE)D3&<^=V/IXT28J./K<(>T+IHM I.'8_<&#H07\0I0M-).YAW5=N[9^ M!Y-T _VOF Y92E-&@HI9EAU$WT9I2%3 M!LIOK@6V'$)=N+":<"6D7]N% [F1UX4'&N"0-?
56A&CJ0%\LE86H6 BK-U<_38R$3V2B:9X;)HF MJ866=)=Q*3D0 -I3:**($]9SGPMHPV&#IMG M(LV(TR[#,)LGVC))+%BS'FQ:)=1PH71;;)[-Y&%ST(HR8$VB:*; YI%XE',! M
_%!*;!K,YH/%C3O=C3P2@^Z!^RPNYY\0!ZR5!9,$_A'$^%408S'1M4NM:D+ M+F@U6(MU2W>O1Z=104A!0>!!8N;O25%NI=" IQS8F0@0B=&5R4/EC&56\'M8&-_WW&;T5N]=
..L1ZMA#2C(C!06W6.7O%, M"B*-I,3!%U8K0Y5:N_;T[7KFK8,G:7_!$UB00BCM2.X* ?94P#5SC#@J,LNH MS>CZ6ZM],T#U5=*9%EH)8SUAB@DL+I/$%)QA+P:K"Y,J:[;=R_.
A;:]B8TB M2,LL)[YP8"1ZD!U:>*SC|%Q;'V3(AM#,9SU5QJEB&UU-_^$;4(VN\T4/RG#LRP^0*B]4GF?8R@J,$72;F!R0 M.C,LETQHZ_Q@>P$,OOYU,ZZ=5'-):0BD2%G
XR^PXL,'PID(+E69*O+!&C'7 M[!9*<<\SF&JM;?N^ K8.57W\LJC'=-<49S?8C#^_>?JV:2$[7 MGDVR.7/59$414-9*78"YRO" &N&)Q@8|'=<%8,-V0ZC0<]6]!E&C1B[8:#; M&B@STX
M9TLB"#UFT8FV4)EUAF>#==6-+H'QZ*%!H(W)',>,79EI M!@:686!@44UR:U)&::XT'ZSM^WU'M#:DOWEO5>8D<:F@1&2:$Z5%2K+42*Z4 M,MEP<[@>(G+PU<%@/@[H*6YFVS?
U@:_P?-7%9/N=6Y^R?<9%LT8 Z),P6[/ M'";X*% O5< B>A.\]4)E=-LS-S;3WZ:W:$K&1$IE80EWPF(H*1"=,]"D5"' M7Y)I"XI&9L(/3U:? MJVW1#;-,Y3[+,R(=PKA6AB@\ -'0W$IC?
2I\&.QN#BL!K\?FEYESS&G!B3,4 M>,QR2E2]X8<+B@G-C/&#U="&[". #)\;Z-F>^52RHA D]8"<0IF"&(:UZ9G4 MF'C$F!QLCL,VG3C:)T8&JA4&V L9,&)E%5'>X%&+K98+T=
\V+6P];Y5QR(1BV8L#/% MB#2L(K6UN09RT4QJAX/7I&1)Q>4H3S3+!.3!2R@>;C3&6 MC%VT0LOI-I6,Y8);[K..,(W-^%,K0"D"L8!EVQGEN2GR(71\'X)GL/H\QQ$ MG/4&>-1ID&
[,!Y!S.:.*VN#6?\[('59*$9;=>]7.+[W?2AFA"BF(RI7$*$C MV@L MQPL79,+J]*!I5,+ A*1BEX8*GO\N5LZ@:5 M6L%^M&R&'I/;+,<,)I-_ ,A7T#1(M*8$R4++#1 M=2&Y5E:8?
+#ZXX!WJ,?L_((Z">P3,\'JT4U)[H D!Q5SCE4U /![M#H_8P M:@\/[V0JN.5I 1#)4PXV<5$HL(F](<9)F7-M@DLQ=*2H>[.D'-M0U#W,,I=Y(QHK1@>J1*(MY-
9B[V":ZDP&^'9H6WO!D7\ _*1AON?^]<4G+ZO:6]VL. #6G];@6.:-0U3% MTT5YFA/I8*_SG$H9W+AX\GH/ LU_VX4X!^G3\#?ET\8/'-XF]\PC5/
M;V+"X0W/Z[\QB<>=,MSY9%=E6KWY3<^$NL?L!0"-K5Y$_:/8:FL?EY-)KIN M8L;D\F6N_ 3TL_J(US,X',.KE\=3-I7@K-C[MUC M;[MR%QIQY,+HQI(:!\^O+,XM)P-_E*=[,+)J5EO?
=\>>>TB>%1NT=WLW+ZI*1JHL$*SYO$6,?31RL/ M.5D\PE0U/)ZTUV\U.VL15,S/Q3T^TPV8"W1G M 9B -.6_]ZC<,6QK@]A$'@#[;X+^KB+L;X^0@(C.
GUN^!"D0^U_IDY>TYO'SU??MU MJ2=Q03Z7KCW:"V5+(L-.6WCR__YWEM.G/S_!%\""G%Q;DZTF5;WW[S3^ M]_3F&7[N]M14$[>ZX-\VJP^O7[U_\3PY>+___L7!CS7U@Q?//KQ[!?
[5BX-D M__7SY,7_??:W_==_?9$\>_/[[Z\.#EZ]>;WMZT&_:3W.\TAVDN?/$DXSH1YP M!28^M"-[]TSC+]^\^SU93'EU%%%][(HP:1,RTFD8Y6MHHPUY^+#Q73N0:K.L, MTT8*1TR:B=#
[=.RDFF&M5-Y\N]YQ68MS!^S+?:Y.(Q M2OZ^))<+B_'K=4OZH&-+OGO.;+'ST>)U\|'A2$")83+[T].Y>H)# -3"$>,- M9*+/JED++SCU[FGW,J5VZ?)ZB]KG2>/!&CC1H!^B\@.O@_?
5BY=]*IO28!(? MV=[BZOE%<)5;KD!\=HH//L5)XR#F4X)5/'WZZ,D-MZCB:_?_*2M+P]JKL$Q MU+BN7?S/,#]B:J__V(L_"7YPS;A7U3>Z"^8-:H3SS^;K2UD!'W[R=8L9AW_J
M@,N7URVHY-+M]5S)[.X'BGDHJKP>]U*9I1G/&PG9^_\256WCQ+LFJK:7QZ5IW-B)&T]NP./?;?R?O7KQ|\^Y|\O;#NX,/^Z_?)^_? M)*!2O@>]6,%I\N9=PK+'[]?
DS)"O:YE+3W'_V'K]F*A77;=@"!N!? MA+;O%.>W3@/[-JWZ954G[9%/_KD B*1S&"4>+&;W-=WL^G?=H)M)J@'1I"%> M9!YT,Y$1DP'PY($;K5Q(M4C[PKNW<1(O.F?^1;1S\
DYAK<G.1U'K:.?-OMCN"GC1]&QYB-#P>VO!X_V[_ M]<&K:%Z,EL;1+C%B8']&NCI./\% 25O'?;U^8]-)0MFMIL*:Z;##U M('E9@K@'] ++8*]7LX 7FMDBYX2)%'L<@36F,S
+.*G68,B(3VU69+GE MKM#]L-L[?QBK1*Q1] W^- +4@#2X M@:D?]*RMOL'YP"C]HO?APF[&9]_+'Y'1;W=(?/V>+SDDZ+(LU!JT_J:M/^)Q>8@DW,>9S/]&?-6;D;J6+8RB$E*92938C
M128Q&I52(HW'P[F8YWF1["[;O#@^F51GOHX;&"/B_'S&Q[USMFV;^SV_E M-+:NWYB)R&1!_Y&\U?4?G_794/UG_69-.,W2@H.>]3$E#_:=
M$*69PJ*UX*GUMK#WCI+=M.]\HXDH,WA\PNA7DR>VC9/S7'.I@9-!\P.%3U-* MM#24I+G71O&B<+3?'7T&O[ZIWU>?-YI8-._"^6-P;98];W+*"'!GP".0 ;=E MX6#
[0AXX.>E/B^@&2HQ|$H+GNK%M!9L]^?_*D^@@V. R*DD9&RI\WV\E MY++YN><[@S[NDQH8M#S1D\2?>AO/2H./L2MRTL6Y5N=_]WJ24HZX"4\ M((?3[F1SF;%
M#>%9VEF>TCJ14&Z7WN|:;X2/!LJYSHD4*6RJ ML0"=(6@BO3=*+TTWE,V]?>)2>SNIEA<+NM$K@B^M\8?VQ^0KT 4]#V:;LWAFZ'&;H5=PC= M\CO<_7WC &2
\UE$4'YP=PYV/FS' MM-;E?CW/VXKD[4_M$1Z*DX!4@Q?!)^>B[QOCO,/)6CDNG5OIY?0=Y!L(S;5B M&2,I6%%$9%X3#38S84((;T5(6TT(2PG5O"!"%08/)[-$IR%S+# K
MV;T#CG.X[M"Z/R+9?_^W_7'_[[G_)DT=-9:3X')*|"LD45X4Q'HA>9I;;FS1 M%TZ\F(N.F"A^)72!@N6N48L;%06PME[QNE_=EB2=/W'D]|^>]9/JM*WBK"O MBBQV;]6$#:
(8].N&YMU,R|NP\[B&]U_#M4+B-?,=KH_Q=D[$%:3YZZ0R>I(< M^(FW[1QQQN2K7QZM=D85NYE<3V?4^Y0BW\4'^&KJ,.G,)^8LL4<>9 P,[@\P
MC7Q,ED1_WT]]RV/V4W*DFR24$^\2/9G EUBIC@[$?]\Y*=!^V56+_)XYM*# MF&):95?*//UD>;F?$D=]-IDL?P/!# M23,#
(ZXYJK#H9E$3VQ[I]O+8/^N+H\0A=C?/Y_#33]*G+GG,NSD:$.7PO?D? M9 .X/EX*-^$HYL^))U[$0<1!ZJ9-%$VXTP*9,*]TP@F:%@#:4Z)UHJ M1CP7@A8%*[BZ=U.:+CC_;%;7,*FN_P
JO:UN[|R9YB|T^-^^64-L^@'?,\1A!DV_"(L 2(=EVT+&!8%=%U-49N9 MG"4>-)NSY!7]"MK&A(WGNM5=2?PE=#Y_QFJPY]T,KA0T0P!^YP_Q2!)$[@/R M?MU0W(UGB;"^^:E?_,R-
S&0F%%&* 18JRHGF1I%4!&F,H130L*\RJ.7RX^K/ MX73SQ_1_S)|I:P$\,P;H(.34J?l=^F@ /D6N_:(X!>.$M M|4); @@YAHF?H:H+3P/|$!?J,#FLJ_MT>+;7=!\?
1R:\Z&D.\S<./P%M>AMCN_]H:A+JXLIYUT8-P0OM#?5Y7V,2%@J D! MV1UJN>^0#[".USRDXW(#,=5!^ QNQ1"_78](PP|:,W}R<MQP6)\XN4R6FYIDU>GYJ1_=,5Q7;6Y351,#6FK5FNKT
M/E355W#Q=DTRQICC,N;88%.A973P,7!9#/UU3:._'%G[:3?Y;UB)H026-QU, MOS=K9YD F>XHH;GA1#@*EB65'H|SR+4PA:.N+\L2-_T+&N@=C_+I/3_B>V/G

MR\ORE;A!#+V_KCYUYPF*G03/PMM!/JQ]\AE_?!L==]^[ARTQ)IN7,8\(A-_< M(T)3876PA%K-B"B$)28O#)% SEPHGN;27J5;(U0A!5&YDF!V =%I+Q01N5;& MY,*J-
+TF!S16K\6"DP,L4FO>S-HHIT%@/TIFT)[_(>/L82M>0189LMC(.9? M'KUZ_?(BI4]GQ\15+9E?\NC75.[DN=JA1;]@N\4\[Y^@]&T;WU7@-1<[^B]; M:-BNA*_Y:@G?
3E*=+_N34:#=R5G[K: MV!<^/5\6/^**'.Z1]*G8>)/B2OK3@W$;(?9\?2I*YN3B3[; MPV_C(.:N,+J;@7'V/[.F+WKR69\U\UR&U?E= MM%1QR"LSOC*=JZ-
>29I8[OWIL&S2NTC\:TS4O:X,M[JFEX9%[V-J$>#0L^ZC M9MC)5(S_L-E4:EMM7&JT8;?\XK,'>=F1.U"'^ MUV_9YR*Z--I@ :;?7A=(46^^I+,1BWY5LNFP8B]4/0CG[!WW
M8/_=^^35[B:PH/=5T\E1C>;?OX.$;3^62Z_NQW+:&7Z@]JZ\N#?)G?@B,!+G M1W#L@;CR-2K8W[#*+U^]WG_][-7^;PF8H6_> ,;Z/9^@NUUS?9]TO!8EN@I!A MY_;=?B6S$3 >5
Z^:OUQPKXS?(5.?[(/IX#1&SN'DNF/\ZF>N;@ K?U@,Z]<1-+85-#9BA&P/T/2G< \"8F!BL!F-=Q_AMZCM8]+P1Z,G MP-[^8W/D??N%Y@7KA)AGBZ&A4V1,'&"N-
L>P7P[*U/\:L%'$;U4S8M%=Z#P?L6CTO X$@K"?.M2GLV8 B*&05'U00>W\SCI,F+..@1>^Y V<6(/:,>-#00LKHY^A@&&#$+/8(#)
MRTGU>51X[D+0:@2=$70>%G2F5>N;CVUU[C3^>"T.;09T7N/HL%1AZ3U.;L"A MZYS.(P;=@;X9'0((#8[CUAN>XM]C>(I_A-OTX5QY<65C9TT#4/ 1/IV<-66S
M*5WF]^6PEAG)SY>CBQZ<_?D(4:DYAQ;$GJXV"Z]YYYO9Y++_9\2<.[3T?, M>7C,2;]'S$D_A/+&\LV9G/C'Y/%[PA DVI#$:N_KXPJHL??ST<6P0=&-L." MB7U3S18'
R3ORN:/$5'N0.#I(/PWPV.6]2**Z %1X)L!P8E &ZBMJTGS\:2N MK'?(HQMSP,2!1/1XNQS," \C/&QMTN[WF;5;5O7F[W7?O/ ;BW=CKNY[@4*. M0#$FZ_:4K#OQAWK2Z1'QC(\-*1*_X3
Z#:(;QH@,(S)L"S+L?Y?0H#_68.E_ M#-JV5;TA6$!?0_*R&\&("'<@4#%&3L;(25^1D]FT:QOB#:"LYP&%A^*/+,UH]E2:U36>F?^;_+V2(.B&9V09+SZ;5(?
53GQ8U1U7$//OS^^_Z[_T[>O3KXS^3E_K/W:IX=;%XLKGE[OW3@3)I^Z< 9<7>T M6:,&<*,?"$2[F9\YBR=$-3/S/P#L*!,G> Q/-0-Q639S[3^;6M!]=3G%<-.J
MM&^/JL8G1T!M$Z2X[C@IE/7-_-RT>)[4N>BU^@0_ANNPJI#3IZL9-;OQ,_8T M>0\"-5D4GV.TCN>7S4[A@4\6YQ/=0)RW98G>C(?Y&>X 1?FP0^)NEFPHG5/ M)J
L$3^)=93Q52>^?G0)S&\/M/Y 7EW^Z=+#(.7'A:4;7BLTH IY&,B+XQF;/ MZ,9'R^@RP9W/ 6FY^-/:*?[VF%47L%AEGA>^I!<]U\^T37\#$123],I"0,](DI MJY.H*%L_BR;F\]2V[BS#9%
(>Q\K^KLL;<@4P%?#,V?GQ@Y=TAI$21TK\"OX[M_PDLH1.DB&AHO?\;88QF8#WAT9F?P-":>.U0).AH4?GNS)23NG(SV^Z.A#<2 MWMT(3W>GW2!E'?
HI(AH>6/G)3V==W2]8^B7\B90&-R^N=OX$[!I056"WR@ H M.6TGH!!,HYMBY9&+NS5J,GBB'M!V%;4;L%.:D6Q'LKTKV9X 0:(7"H@,1GWH MHR">^EE=M34(\-
(F\^QTT%%!@SX\BKKJK,OQ:(YA79+C:N+M#'-"0:W%#7=(MP4"]%6!Q//)1GT0=8/FVG01F B_UIV!TPWVSZ+8:8037-]Y/.PUX-P'=XD@# MV2]4!:=;G82Z.@8V\@M]
Y8*%/=Y\NGRPQ:G'A^+C8)6]7L\6'DA%SJ?'6C: MP'EX-+.!WSJK .;MVR3,T+F^>-CG$F9[5OK)?"1P53,[B4; 7(?O\F5V$A^0 MF>U9?'P+ZU,OF!D9%^54/3O$E[K8QVCDX)&#
[ZA[1\6FH]QF9BV8OF$V0N;XB@*"ET#4($*795[0?L!41N M4 8A3;:P/NW"'N@>,8GW %V5)RB<)B#OZD_H'6K.&DS*<'ZNPF&3%IAZ]/TV M("N2$,$,L&1ANM15H%1<;:44'-
Z1X:8VQ2K8QMY8.2!._# LX52LTKFY?13 M-?F$:@^8M-/#]JA3-D"EFO>?CP7'33-WMTS/'9YXMK*MCOW.//JY;&<&_#0! MY25J=7A2*+S2WUK3FGMU&A ODQBX#+"#%R^"+
[&OXXIX@(>[,AHQ\?U@+K4S MO*[+](6' #-W1LYTSE435%(70ZMP@>#!8#.=E)^]%IU,EX:E;5W!G<WSYI8?OX A79A-=":!Q8B=-Y'SX M%GU>$]]>?N\2G7"[+)'"U2/=(6NZ)
OL"L1K@8X>+N6F%$@DY6+J03\#K\ M:;O>JB>SND'G!)Z_#L;9##CKDEF'!%S"[U8O5<.@RTDD<7T2LR_^Y9&2+UDS M%^^;*XTX),"18S#QEDZ0.5#
YT]B+:B[X(CARBVT5U7@&$=E15+AJ_D*V:MANET\=P M#\C9F)+5O39J]>B$!R['H6L']S5^+O$?/M!%/'=G)4RTT%CB_)=-6NVB2>L(M#B,XW $<]J,H)/@7[&3/.8_+?U7-
NI#]@@MG>EAIQI=& /NP=Q>0%&?9*E&7.51A$03=#O+MCQ>XFM&YCB G_C;[C(PULE^AF M;A *R$OQ[<8C]Z)1\"6R/:")'CZ@OZ63P6(GX!8!*6>R/VHVI4S4Z
MA0%9>JEM=.]OECH@S'(2WS[RULA;=XRE=OF J*$B;G<<%NW:)7%%4_1)IVJ G@(*,3-HEM,3X#@9:/^&3 M.PY8>7;'V.AI\VXDI['8[T#LKP*"?:?
U(H+.+6AM_SDKNOSZKNQE&4)$#],4 MM*JC\J39Z9)G.P/*X$@>]6UQ2#3@GL_'_DI2"0/5N3.(D_ 8.9[;3M;)XHA]*YF?51S9PKF7,N MCV.Y)G2*GX'I=]RMT:5E6(9%Z_D\SY=T3"8>6?
JN"MTBF+_(TKR:EPE$V49O MY:R.-M1D G]A!!.^ /J9^V'Q6_R@+GV+>AK<H0G2HZJ'(U MH"MAH![?%Q,\;2=LHKJT$H'_O##[YV$U&*F.@;71Z!^9Y:XV3@PVKY2]+,GU M/% Z0C\
[D*KXGN7+1(XC7+M+"= MF"M61P:;#GAHZ@^C M!(5!E<>PG",3C4QT-R;"0.P$\Q'GTF8N)/[P9YB.W@=S)WV5XL"<-*VDL) M$2N)F^?F[L+R[]@2$T;F:N!(L"/!WB/|/KI8,0*["O]
(R1Z+%Q>>+/SE9^6, M!-23$A6@98 P(FKGF9WY<]?M-0\-$?.CYPA+PJ(7JO,SCY0\4O(=H7 M(5NDR78L(I$O%S5![V5Y+PH@9?)R^?[Z\V_(]#>]J.2H%B M85\OO"PFLM=U?
\W<6#FIWW4HTR^CD)85I9\FY5_+<5SS,<00+C6D1 M:)QGSZQ8,@EP=P_F,7MX1%.XHWFK?5=QC2S[Y7<)W M^?'+*@X@RVDUO4T13.31+F/KXN/
AD'>Z;S"DI-Y$')1&@D?6%UC)Z!9B[>7 M=921M>Y\R6[6S@VE8P_6T[)DO'GMYB4CG_UU=2ASM\5UJ(=*8WTY1#36)8]L MU0M;O0# CF5,D=PP%'@-
;2TI=MG=AC/3YYA"D\9Q=:I\7!YT_5-*LIKBLN^R6/C/;32+QWK=&?7JB MC-K'LM:VJVN_5(3:=#87TO/.C>7]. %(#8>:H0,U;NHTJGFQI4Q7XW]]R=@J MH:]4M%\NFE_6?"Y+YT?
T'AG@+E6:\TY[YBQVB_@$U'&A]&41C^U4!ZRA_AK9 MPUS]V4GDETXK00*?U\\LF^##V\S< ;.Q2N+/,)5Y6O_3#VXB[KN=,\"V[Z"! MU2;_RYC*) C X_1C M?
2X,O.WP"Z8)!E?9C[O\A/L%#XD&(9 ITTOWMTYIJIV&4%#IQ36 M_(*,KR;S=C\Q9K'];EOZ^SHDMZ"\I'6Y-W7XL ME[UX;GO]U_>W4?8.ME4/N_):]>OWSS[O?]
M]Z_>O/[VPX>8O#MH=-08MPP5P8_LX_F>+85(\W$VC>T5O-ODYKW"3JQL-WFY M[/!TT,J-[]Y\B9+''Q9KI-/#;N'l<+\?"KYX#.*KJ7W(@P8O \J-[&-SD?T MM563&%5S'XV>H$?
Q8W/D_9<.(5[_6CU;##!YMAC@ &C8)7_I5B@YB"NT@>W; MX/P?1Q.IFC6@9S>Q*Y, .3M?[](Q|.*O8VP'V|R!O;=)8< I=4'?:YP.44F; MZTLX E2?
8,!X.0&M&DQ&>/RI=T^7QO,NF, S&V(0^:3Q>XW'[,AVZ7#H#A:. MSWYT^5AIL'C++D2UM[C_Z=6SX[O7Y6PW%W]:5>WF\^QTNR%\<1261ML_#FM@1D?F4!'B?W<\=WQ!:=<>?
CTHBV#^ M_#__S4\^>1QI\MO[Y&U=_7D'T*LA#3:_^A;3X)I3P7_P5;CF#/KK5V1I-"X\ M!R@T4*(G"[EUS?RN64,Y3$EZKS4^ GJX\%4*=VY&\%]87D[7]?I(!9X:WBU MKV486?
6[8M7GWLXYE8VRZ6-H/30T_ MV'0'3?SC3]I=>D:W\E7Q:4&%"+97'S\V_9_M3@P(8K8O1%G1IP9 M<6:D_9'V1]J_NSU[2W&Z6D(7*^2NG0I;/7U9SP^?
Q[J)EQ^9D"HHEI+"&T:$UX88(W+B'55I88,*7CZ*32%@ MK.]\^.71LX\FHT6A.26Y$' /RR713@9BBYP50F74,?,H5MG_\FC6D$.M3_:0 M6?>G#O]Y<DCY*G+?E
ML9XTOSPB\%=75_;+H_*TW9O.CHFK6C*_XM&ON=R16?[SDXL3_G6;>6*=_#]" MX."V>X3 !X1 G7%'OH+E7,KTJOBZ2X:^CF+HH2: M.[Q[$D=R)RW241]-
0#=N]Y8":_;P+P5RX].$*/G>$/:Z,%15;<$6.EXWJCT M>'0;CQ 1O0O(T2/_C]N]K?S_ +:H3V5A,V]4\81$=("S%#!2:"&:2XSEJJL M#U=I%-
#003Z_.A?//9FB6;XCTVRT14?/Z#!TT;>U/|&EFQ[8[IO5PT0O)!V. MXFD43Z-X^)X"H5R7.>X2|&V%/*B:-TCFQ.2V(<)DB4CE-M"^T$8|; M,.7[T,H?#O:RG5SR$?9&?
_$P=/17TV96QS[)M8]G5I[A+I[\%+OEQI,%\.#* M*IGX0SWYV=1/YKNX^A.XI.U.ITD>OZY:GQ1?;7,PRK;;_1=>_8,GNOO2!#?.MU/OP^Y:/F?4^!2 D(7A#A P!Y&/.B!-
:!BF94SKT818L8>)@R>K-NR5.]"LA MV4[.Y?HDY-U[.GVO_#0"[BP(\!>#[#6RD+ZS)$@,2S %272,M!"0S#,!AVT M%7T8("/ ;@,_/6@H@S)3XD.TW4]Y7+1Y..D8-1O?9Z#
[[A@1K+51*K26* M.D&$=YS(M-!$9(PS)W.?VEX2K-?A*)-\A]+14S8BW+C=(\+=B'!% +1"A=RD MJ@"$RPNB% !>,*"@*Y4JUX]^O@Z$8YG8*;@:(>ZA@P%W4:JW8HN^4IH(5$;&
M\L11MHRRY5;:LW1I+HTFC&I+A"@*HG,GB1,ID]SXU-A>G.L7RQ-?5U;JYC) M4S:*F!'IQNT>D>XFI.. 9G[G+K<]Y+/\B+=%BC3 MW^BR_E&4Z;=U=0*S.HM9[-B2[P2#-
!3^U&7'B7,&&^DK\>F+3"6N)4X3NY+$8Y,^+=N-TC MWMV8F*=54")/B=(\0^RB1%*?$]J"EMZ9E'/=3^+ZVO$NW4GE&M-%MI0!1B=U M3WKU&Z!?
W9;3PV3B=>.3R+&D"FO&?\1,CU'7-5+9OT->?4=SO9-^-#X&!M*_&C&+TX(]R-VSW" MWYS96C?6C7#P%W;(>*,0=D=N9O.L M_58FU?2PZPHXYD2/U4-C]=!#92?
ZS$GC.'%!IZ"69X'(@@:2!R$E%\Z*8'I1 MR\^[%?0>5,W6V*3E.RX5&M%T1-,137M%4V-$4%IHDC$+&KRWEA@C);&*2DN9 M4))>B2'>2>M?(YH*,59>#M+=/E9>?JGR%X
MMMLLS8\C]*12C-.49-)I(ESAB!0I&!-9,#04RAN;]E?"V9<+/]_A8HW'5'Z1 M0K9=U(V(.B+JB*CK0U3!*+=<24)IBF4]7!%M 1TU3T6JG0D%[279O5=$!4X!
M2'TP5\QW!JEWCR9<1VZW-2FV*KPN5L/4TW<-Z#4;Z4VY:1LRWE]IZ:M[!' M\ Q?-W^.:?+MV==H] >19[1^,TOC_BC+\]\&$C\(,)]7"1]L>M_X$6X.Y^
MO]!'$M]JB>>M2)+)N0#>&\%F!)L1;$;;'VE_I/WQU+,-">9]:V%5VR8YT6?8 MNW=T\6YU.O<0W+?#@*H'<,T&D87<<$&L8H((ZQDQ:28)U7G&\BP5JI^.2PL> M?
=NQ:,\'FXW5DB/@;>]VCX#W@(#'A/?>L8SX0 'P"%;PY<80%IAVF<'RO7YB M4>L$/#;V,-ULOMJH?E]0O^N9=ZM^L5$@;;5 VJ#^\09/*:>'?FK/(NO] MR3-=UV?PT3_T9-;WEXCNP!*-
PFJ$OW&[1_B]T2'N4LXT%23DA<0:;T.D%I+P MX!UEBA:Y97VHYB/\#8,?1C_YAO-'JTOM5Q=^\Z]6;8S":FQJ,C8UN;^^GQ?4 MI*DD-
&6@NQ=2@^X.JCP5RGKOE>;N2@3X_IU;%RZILWZ%G%CG@;W?<7>3$5=' M7!UQM=_#&YG,7,%SM (R(ARCV#>#DXRF65 TZ$)>.?K_BUBUX2K:3YVC1I\
M)&#L&G6Y:Y2]6J,V2K_1!3:ZP+X2 9!.YH4B6F;%_#!.G3L"AD#@AGF9J2N2 MZTX1@'6%I7FQ4V1C$LX(<^-VCS!W(\SE+#=>IXY(BI"5\HR8(F6$.F=3ZPMK M]97>V'?R]*\-YN2.%*-
'?SP8[8$.1EMZYG?@@Z99:MN""%$5<"U#WZZWMO2*[8Z+(?M?D16D=H MW3BT8HE_,(&3(G,9$5YF1&MNBS-1X4_QV#Z^ZW MWZC??
O37CZ)O%'T/>GZSYXHZ+HF3%BR$S#HB96Y)KFT1O*(Y%T7//O_^O&!Y MOL8:M.]8RHTX.N+HB*.]XJ@UP3E- Z%""L!$^&%488E07.8A*[S7O53V]H^C M*=VAV6@MC#VE-
ZC[!UQS>,/85'ILK#LVUAUI?Z3]D?;'SAJ;DLS/JN/C"A\- M GHG6;::?&#M6@EL2ZERXK@ [5J!@JC"*4)9#AJ59-[EO70)ZV8;M9&WNGY3 M'[2Z]2X6Y;[U]
<&1KOU%K1M^]2Y>U;P)^\>^!NIX7DTFNF[F5Y]KXJ]>O_R* M*GY#;V)I32J4)CG-,R(L_)":>L+2+*=.>VWS7@H*-CQYN@O$",T&T2CG)4Z:9%IFEZ95< MSEYXY%73S-
;&'\H4N<\YZ#(<2\@DPS9Q3)*LR(TM?"$E[^7HY2NS>C-KFQ;(MH)P>WGMJ*?KGU0XMKO/1;X8_D, W1*BZ /#B'I27W !\&;](#E:1@EMAL]RY MW*JU0-Y:"17U$F=E1E(F0$0YQT O
UQ7@6>V*(21J5O+K'HF5%;PG9P.AU#G M0%[&O;L)SH&8]_-EN"6FW_"P#NE7(7V,&XV%)&,AR1JG2(=<6],;AF*6F[MI'@VP32'I&]/? W<= S/.?+3IOSDDW(* M?
_OD\:1JFO$(F5%BC1+K*VB:Y MMWU8+N]\J\NI=R]T/2VGA\T*ICSO(*5W6:K8#EOG6_N5>:.F#YB^HCI M6X;I8.6 E90)HJSR!(N*B,:\>V:UE*:0DLI>C*4-8#I5.YSF(Z8_K!TUMOKK
M!0^Z5G_--2T_1M$]BMX??20^@&#,L^!3%(R1ZP15AJBTCPG++?8"C!+O;Y2 MM7478V>U]\^+R.]16*R8B>3/YY),X9L1C@=\"D&,<]>GZJ8,907!""5I'
M3W3A/'&!\C17&0]7^S3S-IVB7:V742.6#MB[8BUZ\-ZUWA"R\(]7D@ M0MB#]U(@^$M:5BT:.35\ M#)P(RFWL9R\;L,J).V1;SPPH)XY[,D)[[&7=[/!%FWMF+<6RJF>VC+&7^"#
M8WA7LWMI;5WY*;$3W0"SGNA#3Z:5\XN!P9+@U_.5^5[6?:.Q1!8Q\BHL-S]Q;\O3I+1F7#9(\;B*&[*KPP[.?^)V M'2W!#O,AE]-).85WMT :>WK65D\O?@&+V7T<=[=S/N@
,]K3D_ZK'GZZ,F2 M#N9/7FQ=A(JX32M;?V4+^]V!;8*F\UU9Y\3N1W^?NZTR(+KO/O/[]JBL=?+V M2(.DWTE>3>UE%'F(!8@*T!+I/JXBW<=S?/M8Q6,7-[EO@
M^E0S4&'*4^^>=]JBE.[2/RUNL-@M_:3Q>XT'10[8#'S:$MVSWYT.;SPJ6S* M[N#8O<7]U\0-NM=E=#>5?UJ5O_-Y=@+XR0VWL5W.[W#7M]B=ID4#_*F<4KC
ME!Y@2E^(!\HO)A7>_D2PJV!XG].!Y%H%TN .0]KFZ2Y/0\]_BT*W^NB (11\#@.RKLZ]_V).KEF6&DVDL!D1AG,BK37$ M"9UF-
.^8SMB58DX7@O5Y2CAS1;HG!$GHF75XXRS,M^=6FE1VOID_=\W-. M?='Y/QJJY"QV%.??52?_=?+!"V#V^X1^AX0^J2T*K59(67D@AE%#'!,U+H MU"B:>IYFQ67HX\'ESEA-
4IMK(C*/IR6FCH3<%/_>U_>W$9R[/E5#//L%W8$ M4E/W07DW@J.1O7HQ'BI&&N^?$W62[04!#AK02/[T6]4@*8H@)1+$R4X?$ B@ M@:[*S%^>E2FUI8DPN0OH8WK"($(?
0M_!DANA;XO01WSD1HEBP=F"9<)D!S9X M"=EFH373GJ:E$==*L,"2E$!=,?@$#P*,) 7_5#$3"2L J,(NH$_1(:<(?0A] M!TMNA+XM0A]CWEJ6+10P*S"FN
5#MH79HD/1',=$4C*04Y676IBN$HF]%-*BEXZ_ M$-$UJZ:AU&B4(^0AN1'R[H4\G6QF1$80TB>H&2=PCGL@)C$1A3/&+'42724" MNRW(,P*-
<80\)#="WOV0QW@PVC)0*A2+C3$"SA %QF524)"1;)>LO%4BK]N! M/&]'QFK$/,0\)#=BWGV8)WQ.G-9!&SH7S$M4@!4N%Q@A01&;!!=+-4:KA%RW M@WE,#;E UQ:K8/B:*= M
@&F"]D1%:REL* .FI D.CK02L#(<*P13!%,$4P7378)I$TMYP6B!4\V)EZ@2>T4-@2F M5@V%1,MT+PM^5XEC'V*@^J=)VP[R=')^%:R>C#%(C:=*#OI4R5H%Y"]7V[/M
M$';11EX'#\H&"B*&!$Z2 F>1!IV8BEPO-8A<)81]/0OHS3A,SE/%@X>KM[;0 MH#S;<3A[YQC\<&[Z*V(K8BMBZXZQ51.M"U!FH-P7G/26@6/.0'(V1I&=SWKI
M'/0J$>TM8.NFH]N(K8BMB*V(K0_&UJB4=IHYH*2>MR:4%AM49@@D^2P3-9HM MG4Y;)<"]!6S=+ ;L16Q%;$5L?7!V*JX8D)(HPH 4(;!3X0"](%65"+&Z>7 MRMI6B7=O 5LW'?
L^=&S=>.5V7P+<_YBZ\6S0=(R,2@R5&"JQ#1VCZ1=#H/SW MBMPH_\@0NUXMRC_*/\K_GC $RG^OR+T?\K^%$)//@>K%=!H% CB(K@8)40K M3=(T6V.?U"
[5S<[<4>>3+V)+Z^H%+;$1--9(;DA3GLS.TO0RA#08R+,NK64/VX# M5]F0;'+6'R(K(BLB*R+KPY U4)M]8APT,0%$Y@*LEZG@I;&>I>"U8&LI?MP& MLO(AMQ:1%9$5D161==?
(;B+7+&D/3%?#E6@)GN8$Q.I$%QH6U?8MH_I]E@-&GQK/_&U!=[P:K@QI*/&0%H(Y@CF"^56X7LHH)<\@E8\@7*;@K6.0K#99&^F<6DJ#KA*N_MWRB8FL94 1S!',$-&)5[CH-
3UXP'1=[< M!]>,7&$9*+P,;>'W09O"?-K,&ARJAREX3,%OI;@IA42$!2=C+FY(&*#*L\\ M35'RHL#H>CH2UQ3\]\EYN3]ZZ:?G(NH9?XWP^+(U"7$9^!:INI MLUP'L9:S"W?
HY2N=NXF3# 2+7[%>"]$=H;W'T*Z M6 &:9*)U4-X2M8YU2I[DM9N.F_%I^S9-WU5H^J'"RY<*N3Q-\=W,S5)[DH_/ MT[0PQX^3TRK"E3*1$T<*=NL*0@;"3CN:N6$TEI%90U;,@'6L?
[=], [MFQ2@"D05B"H056!?52#+2D:K+41+1?&"<@;GF 0NJ;%*<:(564?>;5]5H)?6 M4&KY"?W5062XNL1FPQX4@W"8A"41%B@/N MJ)?'((.65G4M::;'*EET;(TH*?
N%9NAI+JH2)W]2SI MG;6Q0U1!18.*!A7-5YQ?QJC)WH(-I#A_NJ;SLF3 LTJ!IUH*%->1 MPN_-IG MZ$I.8E$;,MH$PN2B-@PS(-1J)'8DXT)0ATP M+@SE8+6K#AS-VAGN(]GD2C?
GT0BB[CFLCHH&%0T]&E0T^Z!HF$M"^Z @4:*+ MHI$4G @,*%-"B6 R37D=Z;S=*QI)C4]&*+"D*@V5"/CJV11%HZ+CU@JREL3= MEA6-
'EK+AP1#9^M"E:O\7/FWIH&ZI_NC0C[_]A/6^L EL5N_\HA%?0;-5=)_ M7UODX@/U^XZ:6?FQ<.^RWY^E@0LU"^C&GXJD#<:36;G_+L]70*%\]'3]1H,+ M-YT-
)GDP.TMM*L+HYK%FU2L2Q#1N%\^Z%]JNOIR;L1N'6%VCRV7?%K M;V/S81!&KBWR>U$@ ,:3:M\N;]QL27WJC-RGH_KRNPL7*V37_O.5F/&K&Y;=GA36.W'PV>?
GE&V4S%R]WU%TDXUTN*SIRHS_*X2_NU&1\=__91C5+P>QNUO?P=;N<+/^/IE6=39X?S9-J;M)^;G UN"? MY0-G[>!UV<# >,,-&O/?I+,RY[-)FW97O:X2!]#*FV2E^4 M
9U/YH6E_MJS';FV?7; ,"T8P(LBKR\5?U5X"\"]63K'52=6VZYFX=;3+') MO)A4S<<47"XBA+R@OSYZH)0]R\OVG34IE)8%GW]Z6GOGX"^^^[O;Y7\?FK;Q MS:C@U-5!?]
5]74_Q\D+P^V?;GM$EPM=6 3?WW,=?4$(7>&RQU]B7BBF[W_M;.57Z0NZM?51H7%->[\F^T((C7R(;_IZT;7Y:N^LN_30W878RW3[7M]3(;" M[DB]KC$DWY?E%HZ!FRS.53Q^Z>:
EX[+?<[+1<;&Y3[+Y2)CXW*?Y7+WFK%7 M#F8]+)X>POQ\/G(/.'FW/UN"S-\7YD=*XW*1L9'2]TRWQ0C5'K#5(2_W&D#4 M-P!DU2GNAVPXOEJ,.NYJ!U9CF-
5G;A\H5O4,FO=?"6_8M8JQJT9SHZX3REO7 M1'@S1L;HY7)[+ /@8S%T5(,8:#21NE9P:;MSGR@]*#TH/2L$$1W%_4T M-
HH/B@~^S^/%9S%_??"7GR9M^\VY*2A$*$0H1,M[IV/36C0A$/Q0?%907R6 M&B6@]*P4Y+2]G^&RKA#?4T:XK,:$/[B1&XN\;L$RR*"4 MLB8%2?WMAH$PM":*TYUX9RMQ;<
MNY'^7QC/7PYG?/?C]?A%?A/_@'\#_@2B'J+>01(;46]WUEZ0!<,*ZFDK:)VC M8,%H5@"-,FUTB#+KI=%$U&C*?:! >"[79"; L'(--3(*R504RY/A-H=ZW XU
MOVM>PL&*PP'X/.M:_IU"@'"(FJ.0F1:$"P4ZU\&6!"F,\(=H(2[<)OP\;^LW%L\+@ MM<[N1D/TF5,=D??@D%<+3W,D#++EK#CY(H$A)((7D:14(%:X)7>?]BQ98JZ8
MN\85Y"W&LM.:USA!XEY'S8G: ?(2.V1$(?HB^B+Z/@_TW3H:VF)O%]<^ O%$ M%CO49' TU+AF\:TU"U9QM30@GDA!5:)UT]\%P04!;ZT$%21U/EIO&=]:&(!R M,J3&/"
<0W$G!P=6I]@<6"1+J -IQK.%2*P(L)=;TS72[[IGYA>3E[O_GR>B M\9NVG?7=0I9C""41#*"K"R&/I6TV*R.RE(7"IER%);
MS@4MG_2IV/C1@Q740U!.,N8L=9^#VVYVYHZN!/TD+UH"=2KNUR+D_UK(^$G^ MY5J6%^]527YW6=_PQ)('*L60/*_("V;^$!/W"1,WFNI8J\G1-1-@R XH^TAL ME'UDA\-B!X2#?
M,?X6!?V %-@1X1&V4?V0%EOY_$1ME_GNRPZ6.VF/6ZMYE< M#7"#=VVJQ^;/+]*X=34@C0C=SL[+K;3O)Y_G]-01/6_&ETTYNP]5SD]_=<.0_R7]/F_:LM!W:?]A M">>EMFC:3^5L*D]-
O]RW_T+.Z UU2-B MH^PC.Z#L]Y/8/?6D>$B,\TP@",]4)+ %&<(1.0TLN(2:9^62O]IDI9R!TR[M>@@N>]@MP<#;1%@B1%M%T)-Z/A*%A^-VE2\=5SV;51N.0Y.73,>%+%'UPS
MVHW<:,I)80A!V$'31M$&,. V-PAN*3$B6:LL G\C4D'.]N13'?J(Y3EA6=81UB_-R2A[6K(AHG>:S,^!#$B"DX>"58N"I3\%]:V*RMU4>U\Z*\GF@EI9K""E7:T:!YA2<]MP&
MOZ3R%F.?3^:S=N;&L1F?/GD")#=#7G2=DANLTOHJXV!("L%U7\!U'R;((\K> MB|+4<&F$XY!)+:RU7H*UP@#7/HJ@(,8BQB+&(L;N+\9F
MEQD+B@"S=>8YS0JLUP&BU8D2F[6N\?4O,=9(QYEF 8SQ#@H2*_])2RA&$>0N29*<5U M=$MA"YF)LSHJT"8;$"E8L"S6P+TN>D Y'?12 O8I8/^P<#W=7JQ^?Q ?D["(M\XCSB//?
Q'G#HY%>N!J9#B R3^ XB>5/ZJE+PC$OEP(GC%"]0X0L1ZQ'K#^ @(KQDL>L/#"32,'>:, 1KB%P
M]J,*48:\A+W,,*.T9F"YH""7%5G"OA'8"0D[(3VB$\(QUYUA%+2)ONBQ(,'8HM9,YI8;K863_+:N ML]*8H",#5NMIA-0U,D\LGV'#LE78WP@1$8E]@"FCO3[&V2MV0-GO$;%1
M]I$=]HT=$ [Z37^$@WUA!S0%>D1LE'UD!Y3]?A(;9?]YL@/.1=Z_G%=9U/2> M3%CZJF933X*#EE)"H+E)Z9 M)(8'PV)1$;RE'S7%[4>5=A3_'$^;
<:G;].TF<1%3NOUI3QW'SKY8YRF[5ES M\;9(\Y.S7922H68;K+]KE9 @(O:(V&CL(CN@[/>3V#VUAK**.5LM('!9JW^L M ALI!55LI!BMU5[1Y?:>3A.373UF0$!$2D'F@-_$1ME']D!9;^?
Q.ZK=0QIH5IS8"SS M.B5:@#/4 ")P5]G1CLO!NS;%FAV]2./658Y$Q=5SD42C%8U6E'TD-LH^RC[*/A(;'=[M'%:?]E1MXYTWG\]IR=G9=;;=]/CF-LZCVX MT5O7Q#?
C5^ZBF;E15^G46?*O;ACROZ3?YTU;%OHN33\T(2T\W5]2F)R.NV_I MG-XUN;9\R(A$Y_;Y:%-$U']3'ZVI?6$'M*9Z1&R4?60'E/U^$KNGGE0DRA>? M*8,
(3H&@3H,)O$%FP'[0IS*=%%!+V!$7EAX8O&KXH^TALE'UD!Y1])#;* M/K+#0;$#PL'>T_^9Q<"\DB*SK$%)0D%XX<%PJT$XPJBA)CD5;L? B(M!"A? M2FWK@6(-3KL$1
1GN<_$B:56*2>SLS2MH:UI.DOCMOF0WHS#Y#P=7[GTQ:.O M#OV[:W_^<]3LYS0[R>_=Q[>3:;WSX]ELVOCYK%[U?O+63G"7:4-"]"C)?26W9)*%>2:B4@RBQ 1";!2ZO
\"R3,MPHDV_G2;Q2 MR0EJRC76@B"4@A%:C+90ISZ1WFU*] M:.0&4QS[B>9*L+#&>^O".L(ZPCKSQK6L;_IT[$.PH>S0KR?Q?A'_8[$;?C**C]CL']RHFQ_JVCI"]_F MXS3@9#A@A
G4KAL24/:"50F-D[D?)=2O]VW(?FC8'=3)Q^R,=>"H-B \46"5 M)""SL-E0+T@4D#0M&L\2"2X8"21Y+I,67$]]U":^&P=Z,I^U M,S>.S?CTR<-"N1D*;H=<;["WPU<9!R-2"*[[

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|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l.^@M$*Q2X?*SD.KNNJ+N\Y68\:L;EMV>%[X_4;93,7+W?47=35N5Q6=.1&?IA/IC,,V(7(/-N#5M?)X M=5-YO+M6&5U!Y@U#L@:IU\.%@9AOS;K[Y-IU;Z#IV?35'5S'/Q<@&CPS_*[MLW;PNNQD7"Y>Y?W:H(\TX|)'DWE;MJ<=#M+'D&H=^%EGS9Q/YH6E_MJS';DV MU7:_\WKC;JHSBVYIC*3F8XHO%S]% M"7E!_GQU0:'8R%VTZ:A-Q0XNX'2ULXE7WSW=[=+\S\T;>.;4<&IHZOK[RJZ M[WZ.DQ>&VS_?5/&7"UWH^._ON8Z^((2N<-GC+S$O%%/VQG^V\]OT!=W:^]C0 MN*:]7Y-](81&/L0U??U E/G]@:B[|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|@_+%Q/AX1M<([=OF(^IF$1Z1'I$>F_C?2<2N.2!!-M .%E3:T*!SHIZC4+M.D1Y&^D9<8(S9B";:(I9GS689',Y)G"16;"6J>TC/:-VR&4/[7O$>L1ZO/H# M#*F(8A3'X!7$$"V(0 ,XEB@PG8Q320HIQ9*5[62F3 0PM2!2]*C*K!%E"I%I/ MLY9,$;ZUD JC=$B9[!_DK@-GL-G#!@IG'D23.DN]*Y29Y#I,^GQ2?Z:(R&!^ M49ZFRS'JY=V_^>GWEQ2\^?C%-9/%\74I3WOW8*MD!ZC^IPC@EOK(%M=:S:! M@HW,@[+.!,)4L%)]5'/G0J"U[1N<55BK,\(A>]^:.;$=6RI%+13?57>4_QQ M/FW&IXMI*(MRF>[-DX7\OKZ4^OCDPAD]-#@2!:$0B7V0R:*]/L#9*W9 V>\1 ML7MJ!NELB*9.0J)<%6^>1#"Z/'.<4"Y|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|PZ+UEF^P-^6^(C[F M8!'G$><1YQ_2REAJ;1W0'!P(HA,832,$'82DVAEF_6V(|),\L"%-C MSY%F8/6-PI[6AGP;>[DD6E@7044M0.3,P*E((1(A R5!$BJW%E"A1@RM[)%Y MO0Z1!-<(XTMC)Z=C'.O3YVU"MV0-GO$;%1]I$=4/;[2>R>NJV2 M6>EU<5L%4PY$-AH\-P0$]4()[KT4Z;;;:KGP,0<&<45>7-URH>.B7"T9+V]8 MXITZT.EG;"CL!JNW4*+Z72V |$=KJJ_L@-94CXB-LH_L@++?3V+WU),B*0AJ MK0+">7&GO#==@#8W J&-_H_MQB8X)9[J4&JVN@>PE620+>9REC1HM=3H5P6M7 X@%*\=(44 M2[6%Z&R26MI(^%)7@<,8B,C4!@\P|4JB*;4O|("RWR-B]]1N MRMRJ[%0")R4'824%$QP'+@,++!%O]-+![55RAV@W':@XX?G"724.<9(TSK,X ME'D6 ;6(]W/* EK-B#'[P0Z(,8@QB#&(,8@QB#$'Q51[P3((.WO,(0@["#MH MVB#&'`;&8(?;)R5*HI*,U)D3E$I5FU1(<%H(X#0EZ8A-B2Z-K4C22B5,AJA# M[7,1.5A)!7@1M(K6>L_Y5D>.L,XC%4(Q"R:[M NM:$7 N%<3V+OELD]"&K2/_C;"^W[".DZ2_)>+KF"3]+EW,TKE/4QPGO6D5 MNR_-X_=&R6+/^)MJCVFMDZC>3&VDQZP"Y4 '5567#HG'+FM]J2T*DDEP<18 MO!E7KBE>3P!/5# ^)"X2CI-^KK*$X+J/X{J3.?8:97WT-D8=P:@@0'@5ZU1H M#^4U*YADE)BEF-%**(OCI!%C$6,18_N(L;J8]T'4(=(F@I \@\W90(A6"24M MS7:YC;32-)@D(96+01A-P.@L07LA;$@A4BFV.$Y:#[G$Z4=8VX'@B^"+T?]O M@7V!9B\#I\!IL""H2 7L709-C#-*1\|\TBE_JY/,SDG(/C,0EDAPE>)KD]2& MK"E&O2'@N%% A*9&>UY_MYS;.DQPS\<0"SRK4D\S5$6"]/"A/O7-:&+.#<=*&#BW#<=*(]8CUB/6'$% 1 MC+!]J 863<'>H U8*QT5[WPL["DRBTLVMB6:"1TA%*0%(9@#KVJTVW#JB11) MDZ5.6IL;)RW%4"L,73^IW4/YM ;7Z)YNDN<_2];#8/3SKS]AM0]<%+OU*T]> MUJ/LMGL6N?A _;ZC.F^A"?/Y;[]2.O:.V.QW'K<57NY^G)NQFXS%RGX[JNR\O7*PU!#<*T9IQM_S+2JW%"[5M3), ,7?U@ M=RFD<7QY,6F[81-'TS1RL^9#*I+\L6YV^U988TC-Yl-7G[Y1MG,O#RFZ](UX%%1Z8;I%\BX7HIM24+;RW0|)DJVT?=E2L!5UGY\>RL MF;K!VS-75/EP\&8<;J/(-C:@LWFND>ZWFTCWVV=\^RVX]NRWO,OM>G6-Q)[N MHO&[N]SUK=[8]295'?*JI-/@[Z/)'^T.:+G#3?A+,R[Z@=5598;[L8,%0MJ,B^64/,QMQ9>+GZ*$O"!_OKJ@T&OD+MITU*9B#Q:1OEIYYY,NOON[V_7O'YJV\&Y' M5]??5?G>_9Q2+ZSE?[ZIQR\7NE#DW]]S'7VAV I7K7)>V',*C?8QS5]Y;2$M^>IIB;ODXZ%'*+Z9RK^2R'WR5]<8]GM,C'-'*+>.U1:.J>_\K^_4=U]?^:/. MT'V%-\Q^:L*']8@L[MC@G^7/LW;PNEB(\^;9W,/>?=V83UT>NO^ANEK-!_N/TF^ M4=VY698\N4A3-ZN)K)K0_?"@8;P#R2F]) \PWX/&: M]Y$]7+X852(>.*KDMBJ^&;+OON2^.25[H:D?%H3;U]"2 T:IQ]:8[=QZVTU= MYGY U%EX_Z*^LW6<6;2;.+6;?)@T]@U%.@*SO:C.FH6E.DXEZM O*8&Z M6D//@P C"0>GB)*$*;I5N%W'^78Z*;>SB;9FM72>ZVT/Y-I+&=M\53QBZS[2 M';%U+[%5T9"UU@9\;3.Z(#1YA@ 0#)!@@0=Y'WD?>WVIP ML%/%3PT./A-]WAWS!.\6!\G.+]*X==741(?VH!W:3:[U(/S8+7B9C 6IO//@ M/!/%8PP>C# 4E&&,RR0H#TNS":)X'5-FG^H$OKJAH"NZ32V&1JVP=$$_6)] M1+I>D;LW2<"YXKE##]2@EI1*;")\0)BQ) @+&6*KB.>MF&DXU38TJTMD(;&+Q-Q^&#]+%R>T)5A*H(5='7YSQR6]Q^I4%]&HM:D18\5T('#6U$-T2WM:(;42Y80AED1DDM!2KH)@0%:D5F M,E =]M'\=$-[(^BVP99N!\KN&-7>5))YC4J(%1 #U) H5C$ MB00.3%L&0A$*U@0/45OCK63!";$._KZL-A/54! J;L]R;^VZ;AMT^SX?%*(M\)]..[U>B.ZZ>H]NLJU_OT0"$;!7Y.X- @KA.1?%?I;66A#,F8)F2H+704LF M1(HLK\,$WQ4"2D1 C(`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|"1VDO1/=R$C51K\+FZ+SE\G^OGA\R#10\3"JX6>@ACUU64D1029? M%*FLR1[F+1 3HGO1UD@=?G52" M85 LFSSDLLEGX<7&8*)1G()U7H$PBD-741*,8X;8P*182l'Z6_>IZX'_?G(< M?I\WTW1\!0U_GTQK'^)WU|CP8_*/Z#[\2)U.N2,/:N2S'T(3B+<(MPBW*X" MM]QE$@OB@M>>%>C4%#RE!+BW*LGH<^!+<+M*T'W<.OT4&VR8N_0X7:KI?#H ME'RFQC_=[)+;T2M!-?FLU>16RLYS2HD[H()F$$)&*,Y" "65H,%1%=)22[F5 M?(;D*04V[|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|)TIN/ MMR\M-$O303]_&$T^I73YXL5E!$*0\'MKGHVZR@ZMRQ*+;Q1>Y!4"H>C_H!BC(GUZ(QT? M_)|URF0M>?[T)W9#X%"=P:9!E'XM&R@L"\P*ESP81WQQ3:0%0W("0;VDD@2>PUH.X&X=A=$[V"U0E'U0D9+ER1>K[V0V'N\6R1RYFF=C9MPJPX)_5]|$2P@<0A M-Y!X%B>HG(DZAZ0@&4E!&%_\%,8X:%>T)4V>6;>D(5?Q4ZIZK/|__1D3?KF& M@_K&\3A^<^<*-3[Y-TV82EZ10JD4-,_ 0M @I"HJ4C@",M.H8XR<*7Z,$NDH"I1D-':XG<(MY:":IXM*LY'ZRWC:U61U\KPQZ:]F+1N|(\"P!?EBO)WO:5F/$_Q9+RNV)ZE0T8W MZ&R@5&*2!9D&H7QMWHXNOHO*%(QE!99S\&*#%,!HTL7M,9P8?IQ0**9$T,2<@ M^:(#1!09'"&TEIT%;PAGGJTWA+0C*%=#;A1".69J#L$;2N5%|(,VKCS9"U;E M-$[F?I0.L>76GS:F1^_>FMYH4F)ULI08,#Q$$#0[\"%Z"%$K37,@/B^-_*2 M:.T8 24$+=ML:C/R+.*' :U12X^4_.OJ)F5'POW+OO|61JX$";GY0X^U8S4>#(K]^^FY>6" M(>5CIU,W&ERXZ:PZ;;.SU*8B?]Z(:^?!3>KII7;QK L!N/KRY0F@N-,$XTE,5S=6MJ2^?;DC_^G.2'T\OXRC|)'B,TT M=:)Z5/9J?CY^&0MLC-RGH_KNRPL7*Y3LL=]S&"_$/5"@410O5!*_WD3YP2?QFI+[=)6V8SC M]_GS2_'@[?_Y_B7?QX/!V]^?G4;,#9)[*L-Z*RF#@)_FTU^N\:YWZYQ[K<; M.+?+[?JY@^G99/#K-1;_NL;B5Y.[RCJW>G\WE,'?KY7!NVME<(G^/#|/Q9R\.G.1@Y5!!U"4*1#1Q-KT@P/EF2LB!+%DR=!=Z>1;'7263O)- MH]N;A1M;)-2-F_]T'+0^[,2L,_.FJD;0#USQ1?/:O?]%|@D_)38O% MM46R_M--P]F T^& $4JON?]+?S?3U%*]S498+I"TZZS2_%OOQC^K?K)M; M:$R,<@E1,E'+A#+80#D07S;(2"_4\J&_1[>>6K#++S=6>,TPMU[<0Y8Y";.) M3],!TQW3R#UAFA<%5P;%]-F5. .*#F\BTV1!C5RX:-9V=*@FUQV(-GA_\YKY M=%]^>O1I<.;J^,?3B^[70YIW@:?!I0=?B![FU00LS!W3AS2:7%2GOCUWH]'@ M?#)*83Y:V(TU#3LI4C!.\^ED7+[A++G1[*R|SW8T^6/Q1DRG:7QIZ+PX:-6U M(=7^4 /|O"GV]V*TYRMW43_^"6UD_DTI,.VAE81IG<%A-)-"?KO_S*,ZI>= M>D^=M3@LPM1)1JYM,Q>B-;FVI@=%$,N2RB\-_FAF76.9&\T[.R1WH_1%D\[; MG3R'%66[D&R-M)8UY50$,GY^\T;GS[O|JXX),/N&V]>UWFIBY>+N+A!D9NV M-OG\6%>ZN)O3>FEGMYPO|NAF(!K1J/MB\'?K^[]WDTI[TXG\].SP;OR=SJO M,.E)A4DFKO=KZIHJVN|T=)|JS8:W^B^L]BDLA-_6DFIK3WQ0#ES12,&H"H2 M$%EJ<"XJ(-)PYZSEY(^S]Z|-C1O7HNCW^RM0KY2X5HQ MRJ,Z,?9[=K6W^$MS^:9?%\ZC[OIY_!SPP8V\9&^8G/% MU5U%W9XFO'5G!!3T5P&DJ4BFR@_=MZ$*)85HYLPM@68+7T]+7GBB9Y2*7D,B7,Y()C)GF6'4XBG2::Q9G647; M5FF@I&!> \C;'1(;'HA$"3W;/JON^-SF/K8!&*\E>F_JI0"3%T %!BS86&#% M.N6E:DPLU,[=!]KXI!!9G>V+'-S3.0)?E O\5L/.EQ,/1 D7T*8 M]V:9:U[%O#_^._-X%C HAK6PM'[F_GKS>$4>0F@G'A7A7D)?%Z7LYF>3HQM M<!|):X%:[2*<3]=11E44$C_VP10+MXIRD<9X07^B42RD"%8]:T^["$+T-NRG.@ :K,O#H^_X$^_8$$CIZ(@M$7V"9MZ'SINUX E?7G.<;/':MSKBSSH2HPZ DLUDPAMX=K'!9PR*GF|<+0"PT:%0 X MU;3\U'XY9SOBZL".34RG#/O'P6Z(0&?3F]7C1,C$Y;&RFP44NU\0+*5G'TU M!/<\0[<(\K3N3.:.&QS$W,M%;V<9O8:)RQZ-GQ,'$)#X/N7 =] M]#R9["S_,C^R^4& O9(Z|_XY;# !V_KM>MF, H.T,=(+K/-+=&8H& +*;X28,]@.L2#P;/N9]91OH*U?]*@U#Z?V =4%$ M&'':\X?Q:Q#D"^#>"+<38;X\4?!_ 26)I] R,A83P3 V1#E[593]>-UD#;A.M=1YHL%LTF+EIP$F:Y8+X6@."# _0O0%9Z3]PWBLUZ08 NBG@S=;8X!,8;_M:946BZY]?FUX+<8']V[O8'KP66TO!7Y@^:?=<6'2Z'43D'#"BLVHW:3RVETZL&R&! 4YEDGZ-0._K;348-# @ZV=A7=5%6+I=@(_O&0 MH=&P%MM=RW \0#;?%KOA" GC)F=V8W8 2WDBI214^< ?8N /(I 1B?)89TD< M!C382WK:!9R_ "4%+N(<%(B$.E'A@P(<"Z!=DR"#(M7F5R(2]##ZI& 2$,=]+0&B.E&B2=]6O#],9N2.U/^TU6)NRP_ MHB!2$!59B9 M_1K76'>"U;R@C?)^NUC4R!FD ,773Q1A*LG!YDDR(O/0%YGT:9@\/DN@39'_ M<]=7+>)\FUF>I>8?C?[6164NVQ_*"B?"S$>B&MUU0KN+@95"]L7#3P_@#Z4 MNPV*\[;P$$?"7GVE]<+C6^/_+B-CTQ(]Y@,/K_C5< >5OD++ 3@"^N(HU$ZQ0OPA_"6;R0;LW$"5B!.0:H3$2. M*Z0-\Z)LT?K0)U]%$>Y-T-?PQ2-R&5EPV/]1V:P@[H&Z=1N+^=%A1!H%1M7 M>[H6C^F.V]0'?@'|%[O(9'CQH8HK/_X$0[,[:8PK8^@FA#QM5.98[7B%G.#@3$4TL5,K81M7FE=YACI-:WZ6LF\!(':.\H MR5?5!^:9J."M [/MZF>.6S]6.]M=U_@)GECKO[|.:-QF%8C6M41#]7O'5W6 M.Z^ .3DJ(>=6Y?O5A--13_P>,-]C/OD_<+PI_*X%R447F<#3-4,6$%3715Y; MT "<^.(#._"EI42]3'@L#>Z9]W^=-/2/_L;['/$%34).@CA+"C!\G2:Z MY%%ES'.;?V"8B-059OCU^$PQJP&'G,E3-!VOMJ023=;;I/82BR:-_['VYOP6 M&S#9Q#XI 4E5+X]G/J_*SR8K#=D W)@QK&[PVL PMKDGI]3]"C@(P7 I$(] M]3'2 .7]DR/FQW0D/M"MF[7V@6\,#DAPTNEETQPW0%M9U!S;4-O7CHY;)N.M?DRF_+9<+0(+/6KVS")'Z9_Z?FM\;PI_7^FV-80" 22,632-9 MNW1O$_V!!3=%70B39?NV667PTT$O4_/F.#[+LO!/_4Z'#C-MJ_W/DT/8N# M!S_[X>#LS1]^);'LZX^V(Z^6,,GYR|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|)_9P^?C3# M!3:>^ZBKZ|[LT$,V8GQQ[=DNNLY/|1"^RC:,S7BU;ER+;9E8VQEMG'KK?40 M8/_4%E@XM4PU+1#-,&F4T]=:%1PV:"!KNO0T8]6ZKEYGW@6.E!Y,?

*WTH$WK MUEY-;FA"=WO]51[6]FEBNXP5>8'C & O-[R8FF9#()X(3@6=.'^(Z\G$%[U^_MD+:3V')6:;C$/^#;2UZXAO=N^&K_7%S*Y?72-D>VC7Z',R()H4\DMD^:
M;6LJRO)WA\9XY:ZS:=N\VO7!LT@SZ*\W]S':=LL-\?9S-F 97"HB?EACV?@ M["=8 !4_#:1M>W7;Z?%>";11 7/X;N/K6YRLE"/3&0[1*#\92F[&XFY'TSO[MKSY6YONQTD(E$1%"Y(0%
(,YYS$)":>2SB,:!\->&U3ZDC>1OM?Z0?]<,3!][MKVXA' 38GX+]%?).>P@G'8*S)9Y:9LGM^$=V;7X-D?S\K,QVX|SLSJ]YUXV\QJC=I#IL]+VO7
MZK^G%VPI]Y1M.#WXT/)T(II;MH9+*IUK,\]IP3^[%7N3HXC@5KVYQOW;N7+> M3]V%=:*BF!@ 8"D) [T-_,IF#:.+1M^ MP)\C,GQG<7QCX^[51]^[['2T#W'-1?GQ :0$3U(-
+R6M<0 M'$>!7MNY*L T[9 LITNZ?\BRMM,]EX83YF:P=K.Z7!0WCH=VXP'Z[W,R85[, M-2K)W42[U8DGJEI>&NEC%5*=PXMZOUW9L!$2;I)X
M"6LBRT*HV57KY7P^-3M'L*&'TPZOZ> &U[I$EFFD$E]JQU6S"%!2-38 M7WM*&DG3O'LPW YE[?5\6MYJ8W_"M6LSM<$^(O1, Q9]0<(U*QM$:%;#"3Z7
MW'7ZWGJ*/K;8@3<5M6/%: -]lW#3!31H$^)&T&VU;Z$CVQ*)7-P!^PE)RH1PO6#7UK?6'HT,)6C-]B'9FI[_E M2S/V9UGKX?
F,K=.=\.=R!F(1YU_8J4/JQMAWO*$&K8J["\4ISH|(^8:,|"*8%5< MO&I\>XT\;G>"/P0)CZZ"9@I?XYKL##ZC91E3V>X3T OV5J.SOUVH.4V[6*M>
M37' 1C\P>E=ODM[,^;@UAY4:6_R''(4YFHH+'+)N)+1;U,#63:);7?7&:!R= M#MCL?M+7AGHF;3O)J>=\E/@7>.7T=@B)*X!>@S368E9FI%^C]#DS5AN#5^C% M)QQ8W#@#RLJZ;
K5T(OQ]YL3V@^ /*1Q^NOYQOGQ!QHNE[$P%C2+2>0G8(#& M(B>I"F*2)%F6\81&2O%]&*T7>@IR\O+O-@P%INNY@GL%]:LRI-;84>.DN=T,
M4@=':@T9#2+Y>D[0/SZR=U&Z;IQTS.]#F_9.%=^P]9RB;N= %N[Y-.)\W.V M8^R041D[\0KL#",5RV4EAQ;ARKES-P<4;-==H&/&L7;.SZ)29 [ZIFW#HI#7 M
Q"8(O*#%'B3,I7\6)XL!66:X)"T#SY%D0$LTH?)[Z";3\!FV"9LAJ_LEG9HRP'9CL#Y5, MI3'OQ0:[=C^@HB_,)QA2LLF@@ !N&Y>5=C, &[V\\XD:)IX# M;N@^:S>V3U\GQ_R N4D?
^K"RNDG>)65.P$0RJ/7KA|\F_>C;ZG8&T<-AKDL_ MF&B3B92NIG9,+2X(@AR3"WII0NV15EVIL)OUO:Z^VNH +B%GCB)JMN@BB'9T MN#$Q41A=+Z_=,JWE:
U"8^C@YW@79WC^]OCXJ)TTW![.6C3-^L-]W4Z<\>^\ M[AY>//"FB^;O/%&5L*O5C9VC=EA\$)80VC,]^B]#"]XC5:0G>5HK*\I9IG9 M;Q%A9T@=(6NLGWGG]488FR?
J7NZ:*HT&@/9\H8RY7H :5 M>P# BP'*VVCIIIW!*>QP9P \EF()&C3 M\\HV9@]8;MU+"[R]"AXM9W!+M^WP[&"H+\%#(=*HCH\6&H@#X;[[AAVW5!4
MOS8<,%+0\C]O;M1G3T_=X-D* M+"/C/#*TBEFC2/U(U@YA$-88HW/S*TV_GY;0YN7,^@O1?;7ZZ:0A4X-@AD1O M#3;9/%SKA%Q;:>#MM F[VVP<_#NZSPQ'L NYG]V!25V
L'UTTXDFK>F(! 1^ M)O@ $.33MC9CNO^-@-8V)L#FW72-O7EP9 M5#8"R5B*I;N5A@+@4L&JON(M):WK*EOHLP6<7B0=BQ|EYLP&:4K4;R6LZP
M>8MU3[UIK6#DWA[:KD8U,F%OF]ZS25\84WD/?>(?^]1BL:/5,/&BB]G#+K% MBTZ88#BEU9\N#6]65HO=]*;T-&[S?#^)PH2SKTS;_"VZ;58TY=])*2LF +D' M/&''W0\V?YJY7(^N"
IRD80B)E)01IB.?)*Q-"2,LS"(>1BG3.S%@7X%- 0- M*G/O>R[%#X9%G<]4BQ:_%.L-V:!/4-J/%1]4,]!VX?F]^-[LB;/V7?JHM2HQF71@B#0VD5I)JC4&["?0H1HKQ/ X:WAX MWY>5?
7^CXP[#>L-09??@RBM,G-&)=ON]SLS[9LKA=!<2V")R:/,C.@=BQQ!< METI/K6C?NGBOK8K=*1;+UIT=MIP0/)C' !E^UROVZ2H+MQJ36ZV%(2Z*:=0F M?[E"YXIQ@0_GRC:WX?
[R_3TO0G[P+HV%Y/YF-G V(88M :_F[MR2"O 1N;\&\;'=XB&LP%YKI8&"Q:ES=&HS5U[,;OK!:[AUTV*>!U68^'=;9 M:\>HC?BWR=\JK0-[J?IMF]#[!J7@$.@LVP):?=+&\8PG =?
NNL.64Z32>4A1.O< M%>HWZ:.]W *L*RRL.:X1>,&7ZGD^%W3T7[H;F X9O] M!&,%RX*0Y<372A'&,"5I2+$)+!,B ^Z1IW(?:OUWO$(>6_^B*Z/ACP'9W53X MGT%O^K&L:P\
YQG(>><+$()BN6A\VN^MYF24?2Q7!97TU2GX8# "2L^T+;1% M,>?5!EA\!5A]-=,|"T6IY%/I*MK%+2CS-X5]=.5VT5V6@H?O&8L,.P/M Q@ MH]YL:<;"@Y
UVZIM@+*G\9;+!1:1F;P]V9I M,@Y\)E)%$ATSPFB$VAW/B"]IGD:)SZ-HK?GE0XCY9R-R/N1M[D:#GX/.9N[# M?D^S'W[^?M#4C !'QL9FV&JXUK,W?
P/S%/I3W2OG[ZK[0Q@J@D4F)9$,W/G*E8N&JM+@'W/9WX (277)J*;L(?5$/ZKELBXDFN=X* MPM9 ,"5AGTVT %3LTY! ,&8VR&"?.)#F/"0.*!CTV9"0,>!@J/TC3<$,@,0[C
M6@5$:I$2IC@EG,J7M*4E,JFI,AX)^VQ5U:/)LTQ68#P&$@ M'B]CYC)_3$+'VJ]6,-E.G9CV0U6%*P&T27XV^7(-0?_K-###4#T24JEP2FH% M85'(":1<\(D&2^$^#XD.?
2%8RD(:KA7&)8+F(%"!"'D&AQ4@H-- 2B*RU]YE.;P M[1,?-CA+-]#<4RNM\)NIJ1SH55P-2K1,I\A:H]>H31>S144]QMY585F-=Q < M-K"LFRPR$W5LA0-6.MGB(U ?@8[_L^35
ITS\&842"LEL=U2]5*@=\]Y:C!@ M-]4NAW=PK^C_^E9+*^9"F_G/CJ,T)B(+$HH]ZU@0 AZ'DJ1AK$@L9:AC&K D M?I32:#K6?@=OO,3RSJK\M+AR@++I8\,5RU AWU
@;$'H6ABVV62B^.L6P3W N MC;X!T*4%D+3?FLZ5"NA^9LO(D?;^N:R>FSB>]P&$ZC>-Q7N!'RWG-78ALZ1- M R/=__GAFPO\\,S[K4VE:SZ;;'DQ^F$E;$L!OW;%4?B;&<#3U.[?
%+7NEVUZ M=5LL5=0UUH0C\!#_6;K.>\8#/ ,&W ^-7YMPK35-%]WI#\";AFS=]J R _" M*!5W*!ET>YS>UXM_'II2F;I^5(01@&O+9W=W(#'5Y-"QLLZ!7Q6+\6I/\K^K4W*[UI
M.;O$8HBM"&/>\U7P-?8Q+(RWX09U+%,N ?K932E-6B_<9XW1A^9U=X#'E:-T MZ->BSG)FLGAQYPV.H(0A8@36]#&U+]O9*Q.7PK^QP>$UH!DF*@L'G:H757"P M,M"P%]4II-
MO"O8|@[_+IH.BD7?N,AI@K=S7'3I6QM[U.VH"*?=#/V89D7F* M?_]^<4WDT8,;_SM;W-;N&@J MF7\S^GI(_&3BN;B U\8"O:]LC7&0^E]/O!^N41CH-BW6_LQPZN:);]L&N.87
MA7W")9B97SK';]5KFO7Z]9U_;#U[(];-C2]MR07*+1JN!A3D#U;M,L-*@[F MMF"RN'85GC,L^G)IFN?3Z=9W@X0 @#3P<%FG5?* MU8F[!(\N'Z'5;O%CO#;WCA[>]2-
E]IGQH!9W>CP(6$O+65H$SR98MX/#'S[R MSW FQS,2YG_MD36FT?VTSRPLQN";;>]NFV4[LT1WVUP'D!@@$5*_AUTL+TO3 M$ZOI,M-2F6G'@CHT^D-F6"?DZH*
[00!MG;6R";$K(3K;L.P|;&H>];7;U+4M MR?O/$ITC"YMW"VQ+UYCVOM9 M_F:]REQ?-)\;,Z5/-G ['S.EGFSF[9OB)R$]S2GV2)#HF3/.,B##C M< =Y]%@:)%S0?
1A^W_.B^A^L9>I)K1VLO)/4".YETVV[UO Q[I*|[!$+1:: MF5MY=1K;JM>ST2VV3!IIFR7T.^KTR_NL 8!RL!NHT;8+M=D)0]?%:"D5/+] MUBX\!^L TW?_C,T<$==KR;3"[?
XS[+IA(OC6>S.>]^Q^@&J M5JX;IOYNW$K<+RWC\>#^"318'?/RH^F;2P]MC/3Y!8$[WZ;M0U@_K,L\3^F M@M/UXS*JGRT,[:$DH)FNZ*T%[9JGT.%MB^/45H+O#\<(3
Q0^O:JD"'\=A5 MHD/XY]@9XF5@7O!$F/?_KJ+;&IZA;>%PT-A 768F1K.[=M8VP&X*PGN>)LO3 MS$*EP&)1=/A,/%V8)IY6![L%Q\#*0XE'*PB.0XH?NTKI&:\M9
M=X&NO#@WE>)=4E,IFI6,-I8:I&'?O(%K*8FY)DV]=L:;K!>4UYO;%E M31.^'IMR/:CI4PIM5_,5'FVF-M_5 G=RL|_NQ!8%FS7=[^K"#.LTZ2?Z_$R*M:V^S5=_H-
Z#C5O.JZWZ$>UI^PJ9];2-W MVY$0,+)-ZNPS&!AQ>XB>]#'FP316F'+7- M\29NDD!E2K%J6\]E&[HO38Q F2[014LH-V!XY85]U/4]! S78!O?3ER(VT6+ M!9Y4:=,!'IWT-G6]+_-
=:+]8W933FRZ^#._3-P@.>X:GE>/[*./*5) &44B4 M2AAADC"'-8M(E"4^2^,H"[)'#=5>LT_/C3KTDU/S/\Q^;91Z+)?'*9]) 1R_XW-IEJV83KH6K[LM7WLJ.^,KA=+FL@D?
KKS3;*BXGF_S^> M^=]?74!LX$Q#9Y/UE@D<2%&970"<<-]F;O64WY;+Q5O3S>^=?1WU_3/_3\T# MIK_HO-9OFRZ##0!,)UV[]IMF#[")UIUW4X"%823DVV:-
W@_AEZ]%CWDM8VXSSZ*3!2P>7OEU6YG"GBY%IN_K=9KF&UI8TAO+61!/Q@"YL"77Z-R;Y_:/574?WE;UB/.-'=(MFOMMAO,S6J+[.TZ^&JENI+]1ZHY(==AB4X]D-
Y+=2'8')3L,31J"6\O4'.EM MW\X9$[U;I\Y($XN]^Z= >#M@.%/D,&^*T+OUG82^[-@,#5 .%A]GR3;7$/TIV?UFVRMC<>:X.-U@=Y/X_7+-)? MU;\C3_QTK?N?RIF^;2HF+][S
MJL(VKR80L;7I>#AH.AY^H>EX&&YM,?Y*II,7(#D=V>#+L<*\:@RM'?^X8 M,C*&D3&,C&%D#"-C&!G#R!B>P("2,4T3GS+"$IH1QE(PAB@-29XS/V"!T(JM M#;S9GP&UH0?
B:$0=FB4^+N%K=! _6D3_=G9QYEV6)(-)/Z4RFZ80& MVP?'CB0QFTZA6?Z,*NNY*[+"F]1L-W$Y_Y)_WQ!ZCD3..G"DC"^$,XZ. M])-#C)$?O,IK/PU^< 1-
*FA*AI4\"E21^0G4:*'$XF_%P M_G-C-XI:T9AD?:(^]/?EI;6N3! M.9_K:LRQ'G.L1V_XT36;D^S5\,2ZS[TZ MM+QL[4B$4IPEA0<9()M.
(A$F4*#]GH:_UJG84BBA))1D),JHSG1(51SGC^&X)^.YIR,''CGPR(%/!#&>"P?>]JT7YU:91 M3SV/MTWCW^=6O9#<^"_ M'IG]R.Q'9G]45AQFF9^&:42
AP:$90(X:IKG)!,JBW6UDOBOQV=Q;;O?X19VY,: ZX*5+%EXNRN6W<13&[Q'WCS\F4WY;+!;SB MLU;OI.NH[Y_Y?VH>)*=\GFMW]9ZSBOO0QH &)*W:[_9%,&[*>I"%--B8[5=WX'8\&
(W'P>)?!.BW6NIK MH2LOI!,O\((P(+/%3PB<3SF)["EXVHN'^>OD_.W\N@30_*&5:6#]OJP7+YUF3Y>QC53Y?+#HU%39A=4,66(Z MQ4XYT,\9HB-=CG3YS.@28]Z[379XSB
="7,DS%,G3 Q]&I(T\<^1(I^L!&[/ M'B L5CK):M[]]D5<*7=[^P $_@*DGC* _E0"Y/55NKVB-*Z=Q>-D!\],0J, M0!CI8$2!$0@C'8PH,)AI(,1!5X-$,:I!T]LW?]4SO2M!SOX72^\'& \=K-Y
M@=UL]HHR="SO>A$#G4ZE2.LTQ-SZ^?=>@.4G(HE]KDB:L9@PG5'"%1<$)S3I M,.[I)&^K!5AQFB8QUEX%PD\)$X(1$8B+[7/C*&D3&,C&%D#"-C>&H#*HQD#L;2('Z@*6%1 M
K93P"A)8ZU5#-852]9ZH^_/@#I$16IC+"0 MYR2EH%=1Q46&W;U\Q9_2M1QEDR!(GFQBS$A6KS11>T2>5\"33]Z--2+7R)E& MY!DYT_/L I[$>9+XC!'.:4*8X"Q)8LD)2P(>4)^]@*\-
#;^//GHZ7<#]5ZB@ MGDH+\%$>)&LC#-6MFM2*A&12.*02,IC MG+&2DTRDBOB*AI1RD01!NJI)Y3&-TBC71.3:)RS7,>'XM.\G0L1)S+(H>.HX
M3'94, _=D:.RD3)03FCHS,NF123\'|^?A S,G@VDCJQI9UJI(39CS M/%4'T!9TSI*!]@7$ M$=BW\&4BN4(W ^.$::9(IFA$,D9%0&G*M%X+M. /X7#0T$T0OTZ.?1JE,V.O MY
<(@XNKLEH08#?77C&[T?7B^]$=D\<,ASN@\KKB-:\H-#/V!QS[XYT,-+! M2 1*NQC=DG F6LY1(I2/"$AH0 MD63? M\+]H]]7Y:P+G&IM_C3QQY(DOA">>?/[BZT.,D1^\RFM_@?
S@R9($DT!'?A"3 M6$A-6$!ID@62$I;F<:P#E41ZK:SE %K84?,%V8M3RTXE%7#DQR,_?LDVJU:A MCM,D)4F\+B2!'X5TS2/,@2G@G-\[4Y/_O@EAVG'/+-]\NJ@OWNSV0I=%?&
M9TP?8[_]W:,_W9V<>9=EG#P&2;? 6:+A<=GRN.7>B9O_RJJO[@KI/]9M\0R MRKK1D3\Z\D^B\N%$,H2?F'3&/E6M8I6EBDHA4I(`KLV`-?5#*$1CSP@RP(
M8KW6ITH+FD9^SL!6#3EA$E2L+&2,2)V$0>Z' :>G$@R(_$D2''@4R$AA8Y+] MB#ROD#V??%QB1*Z1,XW(,W*FYQDAB:2.)$]\PG6*>2IY3C*E%:$9CI@+52S\ MZ
BJZ7$[*M#H%2JKIQ)%&67#<\:B43:H''&?)SP2*0GB-$;EB!)!LXR$$8L"D<>Q2I)5Y8A2 MEB1A0DF:2T48#27)(AF3. H3E01^F&MV*A&79$*C R?ZG2BYG90!,K8#?'X(M-
/+K%QZ".1E,&UG5R*I&5O5\6=53Q62R1.NISIYF5&84%]\'DUZOL#@"*U=Y'E'.(5_:P#Z_):5X6$?ZOB MIG?$?K$+.XO"\$^']'CY[I)>%/GM[ORX>_UC@/.P4[*5MS[^G+MJD@\Y]?ET
MZBVN--#]L!G7Q/M"%9#7U?NXWRY *:N7U:TGBND4/L3?RK*:EQ4H;IXH9ZJ& M16HX*"IR']^WA*^*WZCX6E/YZ(]@+@KX!])ONO64[C4XHHOO*+&<:ZPW47I ME94WU76-
7\R\K9KR7>!IF:9#]"8EB>+<^"Y. !"G.(@RUJ4!,B.!AE+"(Q7&V M5H:8A_"_/-"$\A">B9.0I$F2$YKK0*4JS((D'DQV,1W//P(0?NA@\),I,'X\
MX'P$P/Y6+2L,@=9Z=D1,*6?:N]6\:].VRAG6P7[([7AY55X;U*UT/7=X(OB4 MSZ0&Q-)Z89#E[-41=.V5N7>AYPM]+73EA?[$"_R 30RLWI?7L ^@HQ*.,"N! MC/ YA414:V %^%U'V/
M2.?&UO*F8&QY|(NA+0Z B\,)>)*UV"$D6GQNY[> M$B1$@A\;4NV_^!/P!D_@I?UG652Z>W.IE%?]5\^K L@:OK57+)$1W>+1\-^\ MB68 [=4+N/:ZJ,^\;W@-GX#"
-#4P!R2K(0P 9G*Z5,B*X/T%?%A4 ME@'Q+3 \.H[#\0%6:JGQ;SGH-&4%6X-#5);728 @W !>S,1"$+8NX9M+>WEX MNT >"P]9,$#HO\$'KO\9.CE5[=WB'"^G!G
XN4BM%;N'|8%;N3Q1LDC\"]2 M@\+6O[M/\%*S5H70A7W8+8., 9AG,(U_O>; M.0@?0"RE&R@!9>'7[C+^,$3]^2T)W^53_9DH0#&C"+Z%:UI>S]ZIHIY/^>U; M_-:
W26@^&=1,7OGR+59V_R* 'F\:Y#^;:6G'#G-CGH>#1[..OY7@/D0=*-L M@/UHG .4?Z3N$H8ITXO')&(B =TEIR2CB2:A M3/V()HD?KNLXN,0MDH*,(=)=8PC.2D33R0\)C/\;F-
2*)Y:]]]TM5@KZXN/T% M1._B?*9PMM$<^6@WT.@CO.&;:2E_?^-IL.[F*(&KI=Z1AM(GD[^?+ ** M?LN/DAI[V<&9Q]R1X>KM!4T B(L^^NT!ZZ(@4F$W 5 "/=M-!W0&\HE*
7%9ZW> MV=A8'#WSR@8\%9VGZT,V.9UQWS6U(MGT[OS)X^P!BZDU*]W/I__H>>WFC_.W;[5T MU$9':CMHL=:):!O/F[9'9C8RLSLZX_6"#2,3.Q"5OOX0C'1W/[H+1[I['MU[
M7TNEIX]<=)[3_!KG81+'L2!2,T%8$E"2BC0@0:YB/!1< M,\U7PU(L"Z*8QCE1&,]BE&O"0YT2$=BI:2K0\=V1>%R4)I6G&2,P#C4G[,!.F!>-/?7W?2T \LXJFT<
M^_9B1Z*]AC,^CT$L+R/T\XI"7>-(B'O C7D-HYQVQOR/0_M MX7G3]LC,1F8VCG$;O[B-='=B=#>.<1N+V4^]+N)776M>R2L30%/Z1D_+<5;$ MR^FG2*(U<*|N:)6+ E2I4B>Q@EA
M :5$P/|(FFF92*&S*%HK\;I/K<%3<45*)QF-1[;XU%7/KT5;_^YZ/BUOM?9P MN!O@L\V$1=5=Z)F&W]:CA'H1$NJ)%9-7(YA\+H2?8*JN2E)0TD$F99+&1-(
M6\3"=]FCU/4F3:PAW%^UZ>[12Q+;KT!B$\:VYP*/U# RP?':1R:XVH"!YDF: M)SFA?LX)SF'&D9+M9XC7)3893GB>^O#;I\2"7P\9A@Q,8YI:.,_6C|8"_YM"E' M&T7/*'I&T;-
[8]641BSFC&!U-V']42_O?_2@,:C(@QNH8/UN RUW4-,@>4 MT5I7-X6$O:%KN,1RV)$OCWVIQ[[41]5M9<)!%94!27@,>FH.^)M*^#TG@D0'|B^?:$OH41$>&>XI(L;(<#N&&T0BRA-
- M6![CE!9%2:9X0O)0),)KS@$8;.L@],,OD> R73M+T=0YA>78>[['Y_N;K^5@N MP"CAZZU 1B$Y]H >>T _G<3D/! BR5(2A#PGC$>:".T'8*S03"6,9YRO17X? M.-=LI3?2GF5D/,EB.G:
'BV3D>F.3/?$F6ZB7\V9-[5V]*72 MH<@X$6F ?E69$!%(A(A"K6,N#9FE_U(:T=WV/W.T! CKU;SZN*SRY-!D'7 M3G1;;T?S\F&Q'>^V'7 Y<>&(M/H?=H? *]1R\
&$4.K&:V\,XO*VWN=&") M/KO&G/>"C/T!ON!M 69Y(;?"ZE\7OWD_%M)T66\A=;0;W'W7K.^O(=@\<W..DPT7I0=0!Q9F6E]CY+?2[<(,J->?Y719 OOSINX^>7.? MWJ=B<>75(%'--
]B$%72OZ]I^CBBPN.(+TZ:U>:/1SF#58@:O+&9>X-/HS/L- M7HL=P&$_[>*3P7-7' /2&S8#RUSSW_7$6];P1ZVGTXF-7.@(;@]:=?_P' MH=2/!BM?E5,LE'$!5RTL/&
(\[%.S2DU8=F]XB$'N]%|I6 MZO,2SP*(X"TJS1?FNS+WSG^\F."US\I%'Q3X!-[7VA6?O3[Z*+W?M9XC7"_+ M$M5.!/KLTMY2A_L23@(%*AF@*6*CUHL6M?HW
^\&FBIG+KB5BG&@Z&P)-W0- M/X6W\YG47]YU#:@QG1I% !5C_(5[F1$W0 N _T)K@V<>$; _71/S4P>\PLBL@_ MC5$40,'(."WM2S0AU?$G+
[QNK>0:.>,T+H"'>27H%I=&#X&+098YI/E>V";P ME:T*&K#82C?D.V@%C_!Y)37@)*P_VLR!8%,M,WO-F>8ZZKM1]:/IR'$DS^] M4T4IG_+;M_E4?^[#.X;C.K@UQS*_.344-*QW!K
$WUB_% M=N@I6<.)W@:2*(B#,$X"'"ISS!USK13-10,*^IBTTBAD>B!B@W $%F\H:Q*V] MWIO6X)(^_Z?5E8!)A]>"%]GFM$P3A61[<32ABO@698R$L?*SY-04)VL#1+B M*4_#(*?
$3V)%6!)H(F0>$ZY]7PF1R%3D [[>LFW'X.OS:QR/XJ:C_#8O9Q_Q M=#\ 2W_\]*'0/Q'^;O1K^LX[7X^QVLI'2915/7"]0;AJFI@QDMHL%4*9#47 M:!V!]?#=$F>4PN;A\0Y6B94O616?
^'-G3R)Y. MGCTEN621C#A)*;;DR7'P9A+F.$0S&&DD0F V]^Q)IXR#=]D(Y3(BC&8AR7C, MB!:YRH2@+([%/=G33[SZ72] #3B? UG=)MY!(.*3XU!X0E1!=7%W)@Z.NU>.=+:)&
[T*U;-Q/FGOG'*R8(LCZE,!IKFQW;VJO.73Q6US#=>%(N@# M0V=-<5DLS$HSL-#1 07W8IQBW06<""U+Z@>]#(N%46Z5(RD61R06 D_BC,9 M!>OMM7RLK4R
>.,HUP24E9BDG(+2(9,XIC3-?3XT(7_6BPL$PG>?]?5\\7U5 M7OI]8>=H^S&$2T^%L\G_5-WJVU/5NB1&K"$EJ+1$I47FM M]>S-WV;ET^.BY6"(9R#O5C$-W<_**Z4)0%C/Z#!.HTX$
337FC M/E@OU48;^;FB =K'S26W@JEL#PKG7(_9'7N/KR_&<:Y4L3"5(/|;U8@41Z_H M6CRJ#<]JZRK%,+J9HWFC;IO@7T_;A0?^K>7"Q(3;MW4JB7.0HY= >4LT4O#Y MWEO,B$[
#8LFQH*Y,1%?^)&\\I!?@KRZP+[S8|)99ZW290#7FUE@5:[,6CC$Y^'"AX9&&JP%A$:>HX3E.=[2R\P7-^:4FLU+I M9I$W ^?$'P;=/[\EX3OCSE!%I0W7P#&(N78[W&W/N
M,67NF8F'EDLW;-2F 7O,4GS ?1]8]=:MAXCZ5:25^8)(0MF07KF3F833+(M["FKGO9@M$B;2'QK&34?,/&3T![^LH)+0Z36EGLG!?/I=$TIWV?2NU)$^C[3%;0B0
MG'D!T!I*&0#W66N7!TJ8M!T+?ZE*J36F13UO(#T$:[XWJB9L$35+_.^0'X(MU-.@WA5E,O:FQJPS3NP(8L$Y:ZXKFV2)/P.>*%S)8,96,QX=0NTNZQJX_.1
M2!|J=0ULN9\]8>MB:^,1:CCLIRL]Z^_HS[4'0.0V =T3>HI)/.ZMQ0+W"X"] MPKT),TS>;]>W(')XDV[68^G6ZK?Z.VX/>%"-Z8F8LP$J3PTV@YC> B<" &%]
MAMUV+W$#]RJ0N>@^->R*N;|..QU"09!W4NV7@/?\|;\|L*]+C3"=&Y7_]1'DA]G#7$YO-DOU..2!B-,V/_%.]+!;? \W- M+K\%F]%#U6CF_9)K^/T5+D,4OR68Y4C0770T4/]S.=-
>$!D]D+:(MFK 'E>- MFWA@VH+66>1YO5=$4%$E<2HB$@490Q=R2H1*?!+D"5/*C](T$@= A)_ARP_Y M+\V9CBG9X#7_XAB# /[^#_S+WWEY(K?
LY<74N"+GRX6Q@[VZXW_&2^(Y]^_4 M$E(;'3^[./.^Q;3[D3R>Q"H79+\OT ^Z6K6?0WRYU^\OH*;P#1^?@EW4 \+ M&%8;]B#+T__!/O)Z J#0"3V_V MEN\#D/>HU<&;O@%
[;W%55!S3GX#K3+P?9O)LXF&&^?3H&;_3[^?RS O>@OTN M;XCOIS$|\WIR+S%4D!0#^Y>PZ4Z;'IW65X9'^*Y10":A6#B H;TOI!V],5W[[U?L1H#I_0!%^33*<;M+KLZ%Z5S
M/5,]22#N2N]7I&4<\-80%=7 MUI8V>GTQN\LH\KIR4T]1]6,/(578#3,,M"1N U=F[1Q^R(%-[XP=1WF)S78 MD[@1$"YP^^YI3]F^A2M
6%5*>!W<^*>R^MV#5,[KXK=^(9)1B_FLF"^G;XG+]:GA+,@(,P/XT"%*D_"M5HEU*09FF*!ST,PQ5A(MLCR%9S*J8DH5RWTVFE4'-
ZOVB@\.#IK*I_*J^4EA2^D_0$6;JBI_(#9^(237[I*?-E= +=&A:PRHOL$H6 M%6-G6$U:U>S:!*G:A($U7:8$S=DH328VCI]=4P2-*W?+4[9$9 H0PG"5+2HW MMN3GD[QO_@\?&8-D$\
1MC-:1EZ#?Z=O+$7G(KNV$+LV#!! M'=*P*F?=UMY-45K-WT5E&_N6&KV01ALV\Z@#0W&#K]:-U_Y9C, D1HLS[9S M06<\&'OG2R:NT)
(O,;;Q:.U;3$O"-8;&%6RUY03MRPWEU5B$W5I(K1$VYW-M MZ1@SDA!XL QRM-8"*Z[G6 Q13;&BU.6GG8K='K==;FB\Y=CA@;OL)XST;(", MSH'MV10C5^G?
=5LP+B'O?/K'E08&4[7(@)4)BKWNV6VCJ?;DY-:I.FBMU=O- MM1=HH=W+HCFJT?;%+++1?.NGAF+)_)Z--C^*P@#+@1C#/T'1$*ZBPJZM$4]U
MH$6V9K3Y*8_#)!6$^SK$)]\!25.EP.Z+A A8JI,X'HVV9Q8+BWQ!:<8UD5D. MEYK(@'#-(Z*UKY2?"8R'0 1GLYJ UHO%U>WWL7T=F95FH^-L\/ZD;M^&>9; M$T\S?J<'V'#P>-
_@0D/,'?,5]S.M]7!:]>EI=]>*Y: ME_-E-0=;"0VPNL:4-5,.O6[OK5MYSKRKK\KE5/6:GS7A.M40 .YVZTE=\='E M1JPGN]S.K.KKNFT4,,<\ $4\]T[S;%9#A-B"^:(/CB]M+P:UYCB0*L
M]0'X!58G1/W%5*.^:%Z5S^=E891,#ST@?:795.6;!AO:*"9%A4U%+=,SB:[X M>U-34? "4 3? #@Q?97W^$\^6V*:EF)[J'Y) MXFQ.Y1GD[ZQGZ=B/.JDU\6@PN5-T6>EP]Y9-
VG15+B^O%D>/:?SYGM&,/UM1 MB$<&"Z&<*;RR31&-"Q/1< IY\\C%2DC#U 6UO4P C6Y,@GL+&>2.%CRFM B- M!E0$W'VV#L_^IN%M*%O\"V+.-T&^Y]O>K/O-/[#&O&FL>FU
0,PYMO^9[;X8.5PEA_85=Q'5C8T;*7' MF9I/+(=R*8E8VX%OZ4XT3"WML]Y6/;UC?>B# MRDJ#%UET/>"B=R ML:M&#]HL:"L4QA(<-CMR=K#%+Z\[4^HI^[?T; MG57&.EIB#1

[SM9@7GLB=#=+O14B_8$8<1^B9 M7#I=@+RSCE$B\AA$6<$82#'!M&!Q3C=KH.QT.G\PH>?Y?M[2>A]Y_O3 (3FO MCYT"BK[*;7\U*.K23&C&"\3.'"OH6ZR53DDADU@6SN0TS9X3BA[)?OB.#Y/'-MY_Z_5*8+!Q![MA!^4&/C1J-@(P3]HG*DVYX+W^2<\4 8 0_"M@<\'"@0?+;'-MI:^_^].* +^AIDRH*7,@%OOFJ5K."9l.9;/$IYRHL5L=HUEN%)Y$fJ\AMJ$.S#A;A@@ZE0VTLZH6>/PU[.7%$X,XT^ M5[.1C2X4C%8f-XY BI>DG\#-5>X>M-6A\-T3%+Y+)Y)"+G2O?I<P-V!3X*?'0K'!WX&[&HQ#7YJ 3:3*KS85]W(HW*1P4AZRVY+5=H1S67VGMSC*45#*#3=@6IDBUWBC_9JEC0EM&3)*E1&3.$)FZVIA#BU0HDRL3KWOT'^G'/|L$ MD)S>$7%#3Z0[X.MCEX"2KW+;7PU*.BHE-[H@7!I /*8H48))DMO"B$1PG/V+ ^Q M25\3Q%405T%UE**$:$U8QH#8](C8X9I:E47)PB0,8L'L1Q M<'D$/_V1M/EWEY-1=>U.DG(S4.0X23,0D2POAF$I >IF-RA:*"IO$BL0ZT42XPI$\-P5V>3&QLY(;>9(>_GR0 M41FJ402#(0#QB1!& ,(Y$"LC8RXI3+ MB6#"DMRE"=%*YR95-#? QAOUB"S8]1#B,TT*=(D9=G M&UB(`>6A1L_1<00<4PZ5+QY2&"N4P0BEL$%S5_KE .0W58^9;=&2 ')0$+ H0)L MT+Y4-1CT:%;=^5&U01-H=ZN"N>| (;DM)+7=/V;&.EKD+'"68H.MC,=$8E$? MEHI\CV6F&=V(F3$LTW&F-;$)7"X2*HB.>4(839)<.A=;EVQXBQPV3AD;APZA M9KL7,U[Q8L9W1<$,* U):D\>#/I:9,_/;@Os//*B1UFX[FRFM?*]#X+T"1D2 M(4/B23(DBL087B1$)!A>)HDSDBMG2:I=FM),.6$VVLL8RJ@6W!#*K21":T6T M225A:49S[##&C3R6! (M#\MGSL+!"RL,M*0]1TI-'$(4AX#8$W#Z9.,Q2PPIC M"Z(I!7%(02:J6#)BI2R43:G$I6'<7B%2!UHO*!3JN ?VU6 MD"2/F7(9XT9MU&][=%1>%^WS0QO6N+?8M.U)P$]#+LPL9YF M.F6G >(9N|ZG?$!OL@A*Q0< MP\3,"*CS0[^,]'-'QI5U_>;:EC0EM&>2IQD2/RV&+DOQ):URN*T36SR_%_M6S.3D;I^@[_ZU>CT9K 3RO'.CE?I9_NKB!O;MY.]*? UCVHB*W=/Q&1\][CF MQQV-I4(%G*]L1IL6N-^$BWI-J2_'2 2DF;JZBW!;_0'6K?W:IUEK;Z@"IO1& MC3ZKZ28+Y=FR?1M[L^L6'$E'WE.VQ#&R'I])>1R%V5S^@_\#;E!MZ_#F"\A M9M8TL-+_@&]'UTW9_*/8URGL+JOT'L88\6'TU_D@_^,/.6?9VR;Z<3Y6#UQG MW7@1F&Y'T.,,_^Z=R##@'5T0_.!!ZTO6#_,V',/HQ_CIQM0]T;(9//MQH-53R MY'K_/@KPV@OP>6]*L-Y+LW49_]^;@63R;7,1L-:C5AJ&@@^B -|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f'(5?:C_0*>6UU,IY%$?)H M,4@8NW^;]RN.6T5Z67!YO)X!.M7 51L+VX_OE@WK9,@@TK,%\(_*2R^>IM5@-M10)IS-ZZ(16_\RJA&4Q&("V(&_E;/#$!%+Y:\WGX@TP 4YY_O>9*6D!I"DAV MHR/)>TK>>LPD^;,F#4I|})5LH.1"JQ"YLZ\/#K<;<+\T@"P!'21/A>1Q)C*> M?+U\COR|](V/V).&K!VFOI"+:^ MW@!:&W#%0BD?=']HI_[6!:NR;.QKT%(3NG2=%HRKRTM7HRJ!Q3?P0;:>(>C# M?>@Z"6@;!F1SW1R'6%H1<6^-D/-MG\C9C^uQ\IG_//KSK).L@^LO[G_PO>**(#B44T..Q'N? U\#U.7E0G7TIP&S M::N9]H%D[2%H_R3_Y/YPH%PQOMJCBM.Y=8DD[WIGUUSB+ZL*_I@B"/__$8_F MB$[":_#=.%ET!NG/A#&:K"F:+1./KWT%3O>O&=+(@#>95\ MIW]VH-M MX_3'MKRK6;6I.2{CI4]AO<'L6W.3&=W@0ZK^G*:%9Y@!U,J4.6N M5+D(G|&84^*:,37V=.IWK,&:Q5C,](F6E=^.!FL@HS:>1W4'7$L:P:44\S? M/'!8(-% HCOZ^;"W"N%)>>]E! [XERT\X?1&57HOI*V4)>17Q>A5S@&R"E M F.]N8@:-4)::[U/O7BW6'NGU+/N1+2H57_@Z=:IUWG-=(UV_?E56QK^L^O/@ MMGIO0]#E0.N//$!5TRFFKW8G_)[?G? 77U!LSJY?.U1=-D18Q5'T(WV 1$'[E,+U@'L ^W',/7YODY M9UL!KVP;& Y7=.&KX_-P4A (=F>_:%V:7@.M77FI9W7CZ6/+2>BJA70/P@OE M' Y9SB$.Y1Q.I)Q#P-J M7?HK\ '91MD,NZZL]*BH%.K4.+X= ;ATS;8+@| M$6ACHY>TW"W7^TM#B%6@*,$_R$18L9FZ|S"O$50;-U2+GR%B>H^HQ)3?.=) M[('R N7M2'GML7N,/'NAT#7@;DRL.G@@%>*> P$>D@"70OF68I::OK3>W\8^ M8]G73>GJ>?A<{G_,@$0Q\QYS30+I!=+;6TI3Z_HLVRH$2|39'P=MTQ(?0K"# M>8A4G^Q78XK>_%>?J+\H;O"YCT/LW@$"W_EQX!-ZA\+:@)/!)]8@2AZ&U&# MPG'EZBWAB&W @C,7;;FS +^(@'NBMVW%W_?A\5]\PJ#WL,W:ER+_*OE0P/S %:.BGU93\>5@ (L=32OS^T4ULIZPESBHXY])@HN0FP:=/-CDIP'2>SV; M^,*7;049+$/9%IF0OL :QOZ>]M'"N>EB>9Q$CW/Z5F#&!/!CQCH?*\Z M.L:M>5_)Y:0[O9[!2GY1C57_BD:=\EW/1N$$)9#? {DIVF]A@H_.Z^@PDMI*R MVX8Y8+Y$,R_4=5MHFK]HX6D!86 M]3P4<=G@5]U[MF_.@*4SRZ)PZ J;^MS&T?5R"8WE*@B]8;]U<,/H)]7ZP_QK M+|'SV[VV+9;0O75GUX-V "N^LN4V.?!GUR!B58-VUGG0?H,EZ0=T+!?9 M9BN)@;]EYAMNK/1K6+YK$#43P"G@(.Q3U'1<2%EC)0A.%_ L6LDQ5;C-*.I*M WFU_(R<,K&^[P4&3E^5S68+"7SAR*_EHKG&P/UA|ADK34#\ MHO9M9ES4M?-9)O$&^&BDZN6;,E?@V4SK1%OJP55-RG%[P#CN*NJ.W!703(\R M-S186;3YFDW66G:M-.I"K_EM=-6%5O6];193;2EF^;GX"9Z&S6N:.NQ? ",H M6R/97[W,M1NWMU'8@+N4AJ0 M$Q"T:C^9B!GTS UT5A4#CR=S"VJEN|E\|6_O<*,|=B&$^>YH<|CW M,|$64G@'_ ^>WK8?\|L!POSYN(OK=N,V>M6\1B;I#")3O$QJ/#6 FS_+^(@'NBMVW_?A\5]\PJ#WL,W:ER+_*OE0P/S %:.BGU93\>5@ (L=32OS^T4ULIZPESBHXY])@HN0FP:=/-CDIP'2>SV; M^,*7;049+$/9%IF0OL :QOZ>]M'"N>EB>9Q$CW/Z5F#&!/!CQCH?*\Z M.L:M>5_)Y:0[O9[!2GY1C57_BD:=\EW/1N$$)9#? {DIVF]A@H_.Z^@PDMI*R MVX8Y8+Y$,R_4=5MHFK]HX6D!86 M]3P4<=G@5]U[MF_.@*4SRZ)PZ J;^MS&T?5R"8WE*@B]8;]U<,/H)]7ZP_QK M+|'SV[VV+9;0O75GUX-V "N^LN4V.?!GUR!B58-VUGG0?H,EZ0=T+!?9 M9BN)@;]EYAMNK/1K6+YK$#43P"G@(.Q3U'1<2%EC)0A.%_ L6LDQ5;C-*.I*M WFU_(R<,K&^[P4&3E^5S68+"7SAR*_EHKG&P/UA|ADK34#\ MHO9M9ES4M?-9)O$&^&BDZN6;,E?@V4SK1%OJP55-RG%[P#CN*NJ.W!703(\R M-S186;3YFDW66G:M-.I"K_EM=-6%5O6];193;2EF^;GX"9Z&S6N:.NQ? ",H M6R/97[W,M1NWMU'8@+N4AJ0 M$Q"T:C^9B!GTS UT5A4#CR=S"VJEN|E\|6_O<*,|=B&$^>YH<|CW M,|$64G@'_ ^>WK8?\|L!POSYN(OK=N,V>M6\1B;I#")3O$QJ/#6 FS_+^(@'NBMVW%W

*[,2HT|99K_?#DNPH2J7:<)O_*?,B M&LXV/76SGO6I\7F51PK^,,@$5;SU9][+JU;/@\?&49KXWC!+)}[+[D6KJ_[F M#=/,*\8"_C\3PIO>\:Y)X!VH?=%3 LQZ8O,Z[5]#Q3CGE>DWLO.1>MJHY^?*MMKRO\%6U/N\N@,5FT:UO&D6 9EA||AF]876T-],JY M\D1U%K4-WW,[%GWJ5$%^R +8D790IMDH2**_J+J15J6ID -/[>;<1_$:.^",\L M+3/OTQ@7U?VIY_WVX?W?DYNWYC<%\B#3!38P2#-XSS1-J-0RA;V=Q$%?Q$RJ M7/&|]4SOY@T!$)^PZC6\\S.+)_%7085L>K\@D:40_J7,<"F&<&>M,_5S(GHN M+(+=B4PH$'DL.?4LU$)P"$/>V>0YIXUO&XB1)0Z&^4Z=/ M!|^\M5_470[?WZ MI/=Z&(OO)\Y25Z'43Z-@]DU?DKOEP[^-%K6&\]Y2GX'4+3/+IF^=@$2^MGJ; O@8XE)@JS4O@4VWUU>.MY7;Y38!/X'*ZI=#C,18&X#&^.$H-4=$]TVF<-X-YMG1](R_-T M$-%E<1<58X)9!LI.#1Y]#_8 #]()W#/#^ \|;/|>BY@8:WWQ(6!=<6O(*N MV!KN[/TR1)4R=*L/093X,+OH)H5 G@>E*9N79>\;%T^0)6\;)UO3Y,L!3ZS MHB;-Y(9!@9FFL%-KGZP$GE9T#OA%0\P!] .\6;7F'_66:QK>&BBQ6&6LOX,/ MJ_;K+!W"&N%35.[$=AL-X(>U)W3T*ATBO/A_QOD1TJ8A?\#:=:$)JY+FTGDK MD%V)S8%O_IGKK&B"3W0KXMQ&9$W #"3 T!NA:1,4\)EI*=B-N.S7Y^]_N^QVNJ+M=]EZ4-(-%KR%PNEX%YGOK$8MN# =ZR+K2GN!R?M'\GH M_Y" SB1\V$AQC +/1(@D$1)1^#774&?^.N],:@GS_Z[RJ[6-(7=YQ>]>7S"L* M!K!B))?]@^]2,D%U&G!&\ L$!X ,*B"]\(L2>@=]L,R^X#:(878PGL*.3/(B%]=)Y!0 > M5,9XG|/]^07|(Z2 5 ,,2Q_']fPO@%)C]R 3M+ ^U#\QH!;"6-T2Y*%?7B_#^ M .W/^YU)!VX1P9%WD(;'B"]H=P_3&#B;F!19VV\W6N;_]L%19?D^5\N3?-??[3#O!MYO2ZPS2[MRRW! M=7-$X0F;WA[>=G7#X\|IBH|'FY9F[I8Z&RN5:Q%OA8:X&1-M7I/X3!G-X9?# MKYWCUZJ&[8>W=;?=0]ZN8VRWW8/<[EXS]F[5R;?H;\D<(QSE=H^8[W]P/:_, M(<]0XV7&RW[\])SL.-EXDG_V7DS#1^1<+CL=)CY,> M9S!*1<+CL=)CY,> M9S!*1<+CL=)CY,>\;LF0:!]=`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|E F'O[ARS4J<->@@QD',SB#FK.W^0!S$ M.(AQ$+,CB.EB>W6OFIP,8!5_#[]JRM@L13^]P;4FVVI8D$[D(LL&8/%.A MN!5Q.IW %SSQ'1.)A'-1[>8N|K:Z>!F';=F/Q5.]=YNZF_N3,|K)LT!@OEY MQ^]U=M66KD9%9I^XYR'&0<_20<|'V.YU=]1APD,.@QT&.@YRYMB875Y>'#SDN M6>NIL>=([IG#]6Z]MBX]>&P,,V\8BR\)$]$-X'7C'-/ .E'[XN8%F+2%YG7;_M>M]WM>47JO3SOM'J; M_/]TY7V%;ZK5>7A,_/1VD"!U*DB1IMQ;EA M7CKT7G:Z9B<<^?& !&8#5/QZ(?l2]_E-[$:]9;^.[^$PU|KQA,>U65WYW MMM7!.<2F3)T>R +9--Q1CLDT&P5))!>5--(*-0ER#0O-ID_R[!A?8.5EYGT. MXZ*$Z_6\WSZ_WIR\!.\ID#>H\?@J0I2#- XS31.JKTR!+B=QT!D.?I(*,NXN*.=&;*=;ITPND=QSGZ:1RN MQE?^_K[@.BK@!8.%B/N+2$0FI>(FA&]%,?!D ?++IO9N/ AS-1623):B29<%5 M=-XZK5|%W?/-+A.^BCI71OH? >A69.R@L!8N/#43],H?GYGGSE8O"W37@X=+=^ M/)*D CR=ID C4?UEI_++.0P$'!G"F^%3!'61W48#^&'MFKHRP'43AE%!WXYG M/F# *(CUMWWX-U4OKY\ \IZ.X YA9!G@=3B@ZT0#TUN!P$=[AM?]$YE@M&N[M%?!O(]H[_-IA=|UA.Q2!M?Q&YW#,@/'A ;QU)XA+,Q3GH,K3) "GEOH4LHZP M/A:\|^28!!F^%$!D(E^9"Z%N65HPO*881R@M(..%5T1%#.]|\0D6[WWXX'L?.MX+E>Y^]_N^QVNJ_YM#]EZ4 (%+;\A1,"O#.R ([Y0P*JC#A&$>#]1[1_&W;O MQ[*]NKF!/(D&08+,)#XD$Y, .+F1X9#^(]9[7OQ7L.LAI>=,^O'P11NF%OX MY8A6%TS2$OIQ&T0QFM9>4-!//^P((2<^4SY)Z)!VE&5^B22H?\M MGBX4EWNQ MQ\;^BP6\L5UNF/-YK8D+!*3%@CP82/%,6+#1VE_,1$24>>T=#N!3PK\3E.[?>3W! -.K+LLPR@>()<"QIBH[*-GV'=K5W&\3P8-1_QR(T"Q:N8OS!<Z/ZH7@>0 YJ!>]\ (L@2>@]\L M,P-.)["ADSR(A?72>9,>'E3&B)FT>GZ!!$S2]Y<^CE=Y3UBC#E1!)FA[ZYY6 M'0O#Z-8;Q$&>_^/%-!B)DR0-A6(D8%C\6/+K7R0LWZ]/>J^'L?A^PK8]'- U M<'(Y25[# (4WC8'-.GQ)GRES!=NLL2EY+*5#/IF^=P"I?3]. <3(QKF M/[G3W5PDC1?_L22R5W6W-UWE_^(AC'5ZI5QSE,1PE@!X<"M>]V61OJY^ '3C M/].9<8YE,(0M?0?Q73#+7[_X29_N_/'- G&V@>3+D+2I*$*/_MEE&HT.Y-,,5+T_LL<@"VP6*+\?D39'TI%ON3_I%94^L85B#QS:GT)=V^<%TH M$WD5&>E\ID0)=SBEM* M\!H\M-XIF(A& 6QB*#*\R/2'YJM@"V1H!N3LSK)_EZ2%R!>YJ'DU%0L"O\C/ M3&F?\$V1#:(_2C4096>B%0U_(&06Y1 MA5P*[0M+03+TTQ2S"86KJ%#@E?&SU1?^XQ8IJ56#QV(|IQCE[88X8B%/A=[+ M\TM+$'T:(,4W])41WENOW^3`\8@F(J M!=4(=,M;"@*AN$WQ27G9!X4DD3$K^|_%K)FZ5U ,Y1\6Q)6'H/S"6O,2/X1_ M3O QD50&33@6I-!B.0GK^\"=,S!>TL1$(0N0 AEBJL7_?'S0WR+Q(P?8FFMOR5N(5/0V,[AF[W4&Z1E)/X'B4Y6@@=<'. M@\"?D5|0/P&HZW2F_7WXT47,1*RN_T/P"SO0B%2 MF00 '=SJ&3F!&S@G5*!+,#F,$KA_(P(9^$.%? *$GXE52PN7:<]_R_@2U M(A.46P +@E\!-/);"C:,[7@:4F2:XM'ABX,,RO 9H%*:,!I2(VJ]=WP&ZE/Y M";>=5E^B\\K261 SL]&FQND3(% 4RPA)Z&-.-W__/^OEO=)_5]B$@OYK"&4 MSA)U'&D"'Y13=.@.QA$ N_JI# . 2UM4$?$@Q,I8V(C1C|:L-D9\OIG'I!.^M.\6#"#C-*Z()(V>"EU;?%)@P&@#I6B#:H,K@[NDDSQIVDL-UN F7!E2:)V] M#|JN1N5YJG JR=$4,Y'TIYA&"Y?C."@TV"?X_MC6]NE^P+202O!8IF;8Q^@NAFS5QX3.$]\SS.*$6,42BF_G+K#B3/R2L0T(-(:D/>! ME0?1%#*5?VM[RVU\%B6F)\,TE5Z/^]AV(3B6$S>0(LA- OOG>]H'TO2EU!+Y, M*T2.F09EGF9,QNE;UF+@RY4*FE%@&8PY&T,T?5Y*|>;:UC9JCU).K[>D]W4-MXIQ+,O2K M4A)2

*M{^':X+U/H$R#FFU8-M]HMP>4,,K>;L*=@>X5672-V<>DK7P-(!X\Z-L7N^.DEN/EV<$L4Y2[8(9O*OM$YE!-433#HTZ^K&=@F-Y_CJ7RGNQ5K2-/1OLB<2LMB4AK&KDK6+^S>,\31A3-MRN\2AK36,U,*0H#,8W.A9%"$EX;L3DIH;_*'}4"W=.J.OC6B:Q6?E)I)5M^8-MB6KC%QNR'514K1.;\;O!*

M&3N222N2NHE]>VA3NI+CKE[88&=B&%8G-+B,KT>;,#0-HE"6RS1I<)4X(R8B-M+?456&QD\;K'@O^-P%N-X/(<*0P"^D2Q-U/E-/PHCKVXZ\\S[8"?$]\U1[#P/O-M370+]I-%)AQ.*":D>*..RUBR0!Y&YED+,.SK6X%@4!$R"2^+,#]X&?RI-MR.=)Y{306F:0C20+HH(ZYXZY{*^-.MM'-E"B+_.^/"KK\&3R#'!EPRK{C^2SZ.?HLOK3GEHQ2$4UL3^OD0C\;<.]92JA-M(VXAPO*-C;:\3/4@4W4^4+YY-MS/B]S"P$I:W.,,V-MHVZZ,YC.?.5R9UPOV35//R&S$_P[B_)O_\8$]C3;@\D-RTNW9S'>1V1@3S*P-M3Y()90(,ROBN%KIH64@]Z M4)_.,L;TG<\&_C]J^)}A)}I$!D,D49^\F)4":R-M]<)B;)TH!95"76C3GL1I^JW6AU_.K;49)W(7W%U0*O7HW.!AG[#CDKMYT-)Y

M(6&$#5$]74782$FIM8@<36F3<>%*@FIJI:*P/717$KP+R-S.@[9G-M@+,<'J^N?STM?03:!\&J,FRZ)\K9?OIB)D4\\3W*"SD5DIQ&.:>YV)Q$%AS?-MK/C4ON-Q=[.5*D:,*5HZ'$9T<=+C-9_FM]$H^\#2SWTU]*CV1'2I.%/9Y+D[*-M,XIE)<-F.N?3==3:BC+WF0CVV;*+\9A_EH*LX>"M.54(O^$[;]-RY+V\+Q+\M;2DA\IE0?WA=_.R-M#Y1*I)$(+:!P.XL%;$";A?DT)A\EAIT%2-LP@/\8TNDT+I*DDNE?@(?G2.8!!-MH"#{)KAJ2$4I*#*8%]-]QZ0.%#S[.12GQ"BPSV>-M.A$9:S/P9#'W?8GA/+XE-M#]1T=NN-V.N*RQ75L/

*9O5U2$RRSVD.MET9_6<>G#HLN;,4_>&HY{83JR'(% M?30*JL1MZ&/#==Uj+XQ5X&L/9C,*R(SXK,.HP[%*&K7"VF]BAC]PVG9*JV(.[]OLD!+&OH8H!F#7(K?;,C 221_B& MU#H5]NJ]>96OB?E+,7R-$A>K;ZN4<)+#_3O$NWUDA(2R2C9HTC,VIL+TLJU-MJ<1[_8&?X)U6HD0.K%!3,+V

I&X"6>8$&VU=/GBX\,HF_%]I{(%O7:":X K.Z M-&7F<,D!V3XS%7-9[RCX5F+6I62W"O_&NBQ RHA-!505,(X05BX3=,67V0"S M3[D:%'\FV3>X!1%3Y"]Y9%2-,K-*4.N!(:WECA-D411+?V@D:CO;D7B1.#6IQ2XZP@+# OSBUV$CI+7HMZD#!-9/,7N)8U(E>HU!,P!^(\W!A$^5 H[#]MAA M P32'(ZH)U-:'BUXLCZ577,GTV1WGK9==N&X'V*H]G]/B5^BPA] RMN?OO" M@:;WI+.8>QS=B4M@3)VI2^HK_XO<=[''W^Q M?+)? 5.(*7_)<'Z@2W5B5C]G* 3QP$K%>T:A_8&NPA;2D-CB4934,)E.N8 -:!1GL M)).OD15U*!UQ,/B&+R+IB%2A2)

*(BWM\&.3T9Bs!|%:0I\.:/+WPT*PY>AGZ MDR7M8;'D:Z&G_/SSSVP$)V-*T%'%AK=2(H.FO?M>ORR:L:$B[?QD)?#-\DU) M FR4H TO!3+2&2JSCPSB)LN6"FQ"0=X923.!?^!=R%\J,U)EUJUQ MC$&F^2A-8,L%|S*!+U&E*T7'!,>\2T< 01P'!5O>#?F1V16)TQ\+,YP.],=6 M4(]NF@"U[Q-3% F_'8%I,)6:N>.)II+H>U0JO#[*'WT>T>S-^]P%3E=,[[JPD M@@30<%G&S/)DEAL/2"0927'[-@CANN!0QI$X'\3[UVV\,8>2+OO4$ZDM.>_M 1HH-06YECRHT@BG>H1^BK,>N=-.-('FOTV.*P,3!T82[(BD)9&B$&C&YSBK M(:\K@=ESU:M)2LIQJGSS9=?;SZ]fJ,-K.+3Vf?<2_:WGZF(?!6[O%6&'!V)[J6MA)U8+NUC MV85T#.#B3MO>9%3EB!"#[LPZY,*:NU34L?E A$2^D5:J[QO%D&>Q<0f\ADE"! M R!S(/O/#>G8%5-*

*()D(?,N(5*A;VMR?TT^?/WJP[9TK29}!%^F159VP)O" M'HP@'5B(F =W=;\>7OSY>1-.NKTK"8+L>Q%#]2ED4)4JRY_&!K.Y%(+R9NO

MDG]?]HN'!<G@KL8P3)4146&76t(W&

M5QJ}XOOZ/0?XHS62/K#0:|!V !-.OK#N+|SI?6[;=CSE+!GWL)T277)-:H(E"9C.WQ0.RX/G"K=ZW&SP@H?T M-_%@R)&+ >PDA1-(Q3\GK?*
*5B+IRW%D8A\5|\37F5Z0#MG1>3XJU_5(-,@+2 M)O^YDJ=55XT_Y/X'DC>*3[P-^ M)DYB2W;#05VYN99#_&BBH@W%DU5H-GGX:18VOXTTGM6!,$YT0M02:94K\!B0*
*M7@RR:JE14(S-)[$^(IHEXV>S=S&Q^-FXF$\C75S%Z.QHBU7I-4M<[2,2?N0I MQZS8K%)_S4^&UXUN2X[O+8V*0;"VYG'<"0#0[_SRC6B@PNJ?9Z_/5L}10Y9P M_'NF?*
*^#3[_^EO_I*_UEM5Z^%OEVF42(4VOB=:N+,Z+!OFW32V<I/EC:EP"FP"I8(\AFXP.9#=,= M+-.STX!5G|C?*B+16R/2"2DESCH&"W)B.7HU!?TZG;5,8.\;,K0#IV*MPG=V*
MT\5HY2QJB#=.NT({ERQ&"L",\C|"";]K."W. ^8LF7M#[&9H:>5YI>S@%A9% M-UMDN&/N5-Z\7]#[2GC@:F1CM))Y32:Z4OYFBHG^U#0M?8;B:2 M] X'(V0L^@J+)%9L*
L5"0"&>L&O)C/3BQKQ"[.F] %K-??L#A,,843+5%Z6 M:]E=9R1@W1^*]H$ZG%AEIXC@Q/=;%8&;=P::9.S,-A(3^R MMG#)@V3?)\QSF]^@@G&E9%^))W(].Q%HX5_"8]T:B<7-
*7)ZVM=[N/QM HUX?-MW9%-!VGD)KB'E#^5>[V.,.@/39QN%Y3%\D)2F<*E.5E;@O^N' S=MJKX?XGV(-MA(N'1L?#*Z?KEZ$H:=LIRJQ!6 M&@2?*
*LI\NZ"XV^N:=M.,]^ZF(33*P'IK(VP!(7T@&*-*7"PCI8P,A_6Z.8U?= -MU2I4UGV6B "UR$@&G%O>#IE],EE_M8A+W+]JGS^@ EDG(:-%YV(5Q%IHJ],H _XB"JW>L/OP],*
8M[UW7+1M9=)1 M5DY)4@+/AZ=P6XEBY)1?-&DAF&I:"=^;X[O@T1:9%,[!4-#OR]M%/H%D_/B%Q M$G9]7/?A*-.VI:IONF]18_]D_>1]Y=:G'.K%*
M9OJ<]A\EYO1T8=L_J.5[K[,TKM+8N(U=UQ:LAN$]Y"9J;#84LY-<@%%XKX1 ML')" (R[?G&N,_DU!OJ8:1+]A)+7+XFN;-*QFAL6Z4K>XZ($-IC0[=::|\ALU M$Q3T&[(5C #'?4O>:R,-*
#GC&0B4GX'EI)ES-ERB0S035T CV6&UW=#BZ MM:,?]_ ;-*S/ Z:7.KR>6 &YMRF$2O_(" 4C& M6!D^S+ z]M#[#(*KPY@:7,$^*?1(*[MJ/9/D]-
*L>6!0MYR_.ZU M3:T*X5]'<7C Y#1\?L2!"LM.?QKQ.[U)AC#" HZW:A+:,CER# .44Z58FL!N1+.,6W'H0<%6&-_N7IE[_RWKV!GXO7_@@^^O/-IL6W3BEWY}, M+
*(@]ZM9XQS%^PIF]_2%.3]<0 ZMH0R86I<|>%XE)B?DKV?46XH!Y4U]"/4M2 M!:%_%LXXNLA__?6+LR]7]) UML+7P(./!VT=VQ&?C)K',F63**F-Y]S2TO$M MO]W KPZ]/7-:T/7B-A?
V30D.\$-:QR%!>3=Z/>/&7 Q_&B M=VRF.A}@-?NH?FQG_3WLGD96_2A2]MRP,AL6!Q*AW2&'!*V0;)7+%(B_$_L M<:#8+%O/V+-,&L6U9&Q#=3R?
*DC)Q.@60[MHD^[!]X^HODJ?LW]4T\9Z%&H\ M/Z*ML;_,ZH^@F3S[_XZY^_?/K9YW_^_,E?_O#5%7EBJ;W_ M]YL0#G1C=5P.K<-
C56Y8!B73_VLL1+N"O'SQD\>/_S"ZZH<\;P25)\/XA80A M$V5#8UYT) #3/9;%H9K4G2Y9@5,A1J(9,N7&4',=KBG$Y6BUD&(!4,/7GR5 MC#[OJRS&OQC_.XR?(P>R2(.@^O':;*
fY_!A"$/~% Q_O#N%E3#,&B4V85Y-$ ME8':,IH4\C04LA 4ZJG4X*Kf]8A4ZR&?X7-.YYM^5EAOD(YI*9
*MBV7>V3)UGA>97YR4ZS'IHH7CIN8$7B3P6NUOL[D[(C!PTG^J'6:WB/P.7(6B[OK03O?S>C#1F :(,OTXRW3 M;HSP+WALQZ8\B:!=,:.QS5]LFUS"VG
*5&&T\&117!)%]6DHCQ8;'P%P^PUGC M:1@6]URL\I=896%Y1IS2B+:.!)FAU/= MYB3=-'>FWMIKHR-A8Z)RA._NZTR^W /F2[Y.K'ZQ^E\A,1*BK,+"5(E,='I'+ ME_VF/<3.VSP[
*O=:=VU=M6-LI&Q?D#?5H;S6!0S4LI1I+1Q9Q.$K_1H?.BKDV M.W19/$L*GF(UXGC>D@)RP3/U01G#@3\S#([DABKRYH58*=E3SYNA7DRO
*,L.M/,,RIGB/[_,OCY=QOX]DW"QO(OGO66)N&*L@AS\!)+M &XW_H[_N^6TJ^'+7E?VQ&]#+R*.]<5Y').)-_TL__15^O 0)BZG>,4B@?[,[M:N.YZ$+'XS<^M]O:1++E5^(Y4^-+#D,9U3
&BFJ.CCB;&76H]3ROLZ_19K*AA-3H]T MPZB42.GIM)T?EN\I'3V_H/?K+&0R$NCF"8()ELHCC]\H^]'XXR\)#DY[DQ_M*O9)XRK.W*V,KJ?Q=*TQ90/[/&/TL4\(W(L#80K'LA$^-[
X\CYE3W],GL. M)26&7"S>#HILSVD#LO!#=?SY,5?MDK\^;P]$ZK(}>]E3.OKGU[^K5A]!|US M_)\BS?GS)-W#'I/<'!AB\\,/[[0?WW^ ME[/'-OQ2%T&
*[P3F@ZKV8"_581(RG^,C,LU'8F6XH6<_?5[@P@4TK+N GJ?N MN8QZ=/KX]G1" ;BQ>3%;0
*!Q\G^%Q!S1M[58N6L48",7C=)7T3:C&XHWWL50*X\X_:|SF^DZJ7+-#!BJ$/2L_(S/-0SNT4:KZ[/5LT.5,_REO%!Y/9A M#=[&!=VXR SO(P,B(|?"^@A;R*:TV2
*.Z6VNVK7M74X"L_NZ'@S(^&P(PQ. MK)%IYOA##\"I0_O0$R1IT,Q>"V3J(:MT+0CD4R(D^1%,QG5DK1=^XS/2,KK= M'#?X[%PU;!>$*E&.*?M*GI@5YQXWF(_DE(T^1G^7HH?
*20!/)RV!*AIO%@:.MNZ'U!>1?KF-LT$0;AKIOXSK5+EV-Z2O>8]A+5*RSV.KA5]H[C%D,+/#\30D^9R M/>4!Y@;/9H3!E?!YO!R!ONES!$,V#DMD&SO4Y)$V"(\$L_>+C;A<-UQ=_?
*M^Z0DL^!QH5.5%C]WG'U@%%)Z;3./^-=8FFVQ?.-&&O@9DU5J;36*A<&>T!WG M%B0N>C5M'4L/'-@Q!9_96&B,\O,!T8=)E#!2SCT1P".4E0%&]M&Q\E+,9D^W-N-U6]M%$FW@1=
*CJ1X0J1< M0'E II.?S[U9QYV8"4&*XT\: ?=8<6E-:9_&!*QWP;=\\,I60V)R%-%P6? M+NT@!J+[F6,)5L>OG%\7")5&D1;X3:Z"IGP785] ?1RG3%0C\K%8"R'(&(R=
*M.M'A&_3C-.AEE/%3>*8BQ-!{3P5 \JHABK?24<"]J842<6F?;IGS-C4.-1 MQ#Z+X-X%8?4D+A+&3(*/N8##;=P58F#C9Q#2]OFGL*27SV#..0C7)G.7(<606
*M,2<,.5H[R["O3.6>;E8S[RP(LEC\A::RZ91>H[H3V08!9.L2X#? MSGD>.RPD$=`9]MFOEW$S.3IE+/3DEXYEOT=-H^N'@1N\P"8X@9.4N<'[H0X6 MYT?1/S5% WUXV5(>/&(5(9-
*";\"FUX)X%]3CKQ]]HC+?E*IW[BB7F27+DC[Y MH^C^>*9@F] U8_Q/UN5N4/].997($]$]DV#56!7.WHB4)/GGC MZV0.D2^>) X1W-9_??GX[,_Q)_;&&Q;X508."G^8&GM"88*/\;/NV
*MC^7A&9$U2=CG P,?EF3*F^,1;\!3?' *DQB\G*U^:L$FPDC?=,=$Z#IJ569 MEFZL34,*7]BCHFO;@*Q^AW'2E[*])7R#6/RKOF M/T=N)^B/4,YE9F"0Z$/F2K2D^*^/(EKM$<@UVX-
*R<'&(U^.#MI?7)68'GD9 M.9V :DLMOC^MJCS"Y.AA0G%RI@"JF*H%CC>P1P71.M)[EJ+/(C6!=&Z>."/-MWP-
'EF57I'!Q@"LJQVKRV"CTSG5LBLJC0&188G^'=PTHKK8V&)C=YB3.HA\^8P4 MPV)1BT7=P.,\T^Z6>5&V:U4A6V]PO. MQ2737VF-
*UB=G>I/K. ^8\B1FIZT8SRO/AI2OU'T5%'N(/-8K':QSKLTZ3)QUADV MQ3}5L_,Z@SZTTWO>-1CAKSP0\/#K=G\H4&5KAXN8_YM MGX8NTI11FL@X@P#
*JH:MH+05G6N@TK&ZBPTQE85,[=A? :_,Z'YH,X_G.62. M[;$QLDC\)Y4P/^K/3NS)YU_I"-$G#PN^I_F;9[:.ET&Y8\G:=.@<-9G>YB-[N]T ML,TMU#;L2EF|IFT>J4\21'Y,-
*_5E>CI+|P[34E<-/=%QB(.F4"8WMQNYJ[:M M&\P<6093FG1&DRPI,T_W7)?D6ZO^C>UC'5V1B9/=_"\/ZEVOOBZ;-[CAU__[=;&Z*IG+ MO.V3C-
*X&)@:5CKGK+ZJ#\GZM>_(6<&4Y7=VE"YN))+/-KY?_=IW?-\.U^N_1SMI M^?N7I/A&GXAPD??QO@C1BIOO(.4A2-"&_X2TS-&3! T>-'&8(\|^/KO43A8S
*MO8.9FH$E, ^V"J6XD,7HRQ>KH.[?1#%FT556+,#AO\XEJR62DGG6=J1V*5==2 ME,SJ'$BF>&A.I@CV)4L@(2LK),\2)DKZ:$.O[#WN(LY)+KMBV15WV!6IWM)V
*MQJO(C\SD7;N<;2U5#?YY]OILM0M;)JO3D4\.?:ZXWU>75P98;8#@TA@D,9!< MA+V7!Z%(\WA4S*P:?K1V_;>5-#TETE*G7&S^CC8?N5V$L@6AOQ?(\$Q=1A:# MH9)>R],/5 M3Q?\
*(? AK\Z'DB?V@]8)>5G&KP#5/7L/0@JLK!_IV])2BN7GU0/!%ZI7<2R] MK.I!>9IFEL4>,,DS@7/D"@6L+1,T"L68DE;N:'O1GX,9#T_.O$B7((685DT^ MHEGW9:#S/@UY^[<^
*MAQZ$S3R+[>D^2--#[8"9/OF3.1*2]5PV/^]K(14 MZC,2Z6G[3;IXH"9_@$W9>P%?_ ',0;Q:>(.],.C@UCW:>DTM!V6]PC MLIC)7=),D+QN^F.0$3;
*"&VR64VU8DF.T)1*L;D1#%!3D;NK4B2$G+"_/D" M2*?3"EX?0K':#J:Z]) ^AC&X_.O:H8P6JW1,20N M#\,)5PT?S+(^2/'H,"X[S ^6*\7:!H@.JC39BG$9PSQKVA|HUQ(2V2^W(.(%K
M67;K^^_6=_GI\/8 4 !:-XW>VMI3VWY=[Z 5B4!=G5[98'!.DRQQ\NHU M/>(V@] X;JBZ1.+O3H>AB7|MF5X_8N?[[^SDT:>Z;#D;K''#)P^.[%?C0T=D MM16$4JJDND7=PSR0DB*
*<1MFK0;DKA2::Y6=MYO(\"P,\1'T6Z5YBN-[L& M]D)]_\/JXQ!O2Z93A>; 6 ..M(-W!._)5H_?0JL+*8]H0IK$(A:UN,3')M MKW<9&]#11+G1GJ^.]810/?2M6Q86[;*S6]&[@ P?M?
QE4@)F=V(:D5@857.JH\%:-BC2=-'T M(8GA=&%M#A:L^QG?%2H\MJ28.'HA(VR M:3\IDMP< Y2M.YUO&/B\3=EUUW387)7=5CH-__CAN[YXIX%P,.G4.&]-]^^-
MOCS[2\9L:F]!0#.ONRF4L\>9I8T"TQI.@'0[>,&2DY5ZG:+7_T"[[%)W]> M78>R8|2E?AO?/0C'GWSVQ=GG\88<4SS7JW%:/'W\Y'/<'5]" =Q\@RN]0\8, M<^)0X>8BR#O?%GRA+Q[_
2=00D)HH"]<3SQ=]#YQ;I(/QF\[^>'RV" $$ M.TL:W$LQCO5+^YJ]. .;]?.0+L.6C1B.]K)+DDF=MKS=D^^^^I'<(O34KY ME?+0/V=WL)3O.&]16EBAA_[X M*XIM%
*DKP1=^_,2K44'#>2D^>AD^-_P_&,L^3NL'>C8=,C7'&9>NR&1,2Z[M,KI#6KD7T"_22V2I\$X^X0.9[815[3QD1&2FO\LK@(IXU%U8;6 M<&U?0G\%2 M,?Q2G(;
*(AIW19M2QO.'V:B*H5Z+7H(HH4%C[K%U^W%1_7^CPW M/@Z43<70A\9N=61Y)12;8N\X4>'N=E)YLK^/&GAKO]5C7VT3?6T+8:A"LZ"D
*MTN@@UI/+T3V*XE^\=K1(F+|_LZ:&A.;T$^.;(AT) V]A;3B$RAI0 :A+]>+ M6.9_5E_Y$ZWK\T%5L?]HU_W]&8_B\H:3'$T-0[<MQT]VF75 MT:M_5M$>?
*<5O=B=)YC>FA/5:0NEOKGK2W>P"UVC8 %?,@(;T0*5DF7|=Q1M7 M2,SL6VD4C)2?[4.:L5N9IQ&T@D8AQUC&.,59#=+CYO$J.]"B.NH:\3R07'F) MM$^TF-+&XM>
I/5]:D:I%"/E<<6)S?MYFH2G_R;N:,TP@=7XN@FL8R|\<++ M3LGN1S&U"JH7=6G!'9|C_R9OT&|5;_9L-6-!Q=0A1[$^,2XY) 8[FS^TI=!-MS=?
S17W_6GXE5.1QW!Z[QPHVD8P=E>B M$11GV*)C'G<LZPZ\-L$YT^MP3@AGI<-?!P1,A_):H-J=5H&#U3WB&P^^^*

3(\D:T%-566?VC7DL='F2:D!=NQB8X23H1 MN6MR[<3ZKI\9#F*5^/T^G5W,_T'V4$&WBLT!+1CGF[A/+3)#"'BU'5 .,=(> M&P4(S&-4;MZ(1$\C-+7F_#Q%@U9_;\+NI";ERVH8[&ZY@,"^8KOF]\^Q&2!2CC'\<*C)6#TMLM!Z$%F@!#\0U-C,Z/IXZH#,QX_1D:GY23R MHJ$2E@@'\,FZ0AX4* (N(D;2EV:G0](%";O(3*,YOG,T_<5PW+97LO"Z+%D5 M9)3*E,)6#$;8Q%GK*!IF M_;<_(.;+*0R9.K(^F7+<\@KUST^*J_/Z_?]'V1AU==YV3'W.6/YTN_E(M0\; M^Q#>H%N1\ZRS] !Z4/CZ2Y$?C$+RTLCEA9QP6-TE0Z!1:Y9]60#PIN7W>E?O< M6E1"=`{OF6X#97$V<8,R^>`,LVR|@DWS.3Y\$WLLL@?B_"RK&II,#*5R*(JLMEM76V6&V'-F*M">; [5#>A@ZADSTIX+88GXYN=,O MSK5+7PS)9&$&P[TSH8NEFY+VZ0_CL]\A@/[M#2LLXC"5RB\?^U#OP#LC%_(" MX_&5/&O>]:ZK["WE)] E1_V&+;B#*^P[WK_>T&ZQT+>5]O>`^:M(LF[7'F[*1 M3$>)Z=Z8/C&72J.$N1019)B9";G-;]GKK)*QDB@^L^]XN?@]2V_D@O=E+X5. MYJ68C"]I&;I_GLBYR(M%&% +-QE%0B ,OGUEXKVK#K(Y1FAE#B>V-TC21U01?,G368!4ZTH1<@0 (\ M]WQI_9[*=.A=;3&5WI73$IGY&)^S12&#CI\^4!@!4'0TC2^=@)\+*S"Y9K9A< MEYL.K#1%,? X6",X,U&BPHLX]V.N*WAXSNL.*W_V,#+X")=(1*QT?SAXEEM:R MARE!PW%/#YXHV?IA"4%4!4RA;Z-M4D."PO+(>+?L.5V\,D;fS@:3.-NU56Y M)/:3Z_PQG)V? D,'EN[_[TRDNL7>^'/BS5,4=P4 39[<1&"-B*0WZ M>*,W"[Y"R:L'SV)A'Y8FD#C4=&0_R MD(O-C^-K7YH5B_(A^]7=(6G M7O;<:WPJL=1SCB%KV.!6,.AI? VM\QG'C_2GGXUQ"M^VK72)7[1_[!OJC7Y MC%TK8^138.G<% MI/NQS_#XM!3AJNW>9+J;GK\O8@XZW&)_|WN5A,,S>1H%E4. L'V@:F9E!'G3 MTSAW9%X 283C4=DLCQ>> [W^GV;U[^1RJ{5)>Y)C\$<13@ MRGC)0 M&F2(F2HZ@P&0+!.'L N+6Q. ?<<=M=8:5X_6*.88ZTB?QO%GQF-]# MWJO.QFIR87)0+.]2;&LYL>'0W:"5S MK'Q\#O1F7N$!V8;1,- -+#O!]_%>Y2HJ8___VU_PDP>@FO-MB8[;T=Y,5*O3E=F7QPWD37ET+;54_!/&QE([' VI)6:T&[JFZB\$19J2/ZF M3Z9I4^?IA?@6VE]SE;PA-C;L) ;9GLE1IV_HR&":F ^/MA];- SIV[+ ^(=TQ MBU1<5MN!\>"AZ=CY %WOQW:[IP,]&8A;-'5<(TPP_W11 M(6?+1<&(-;%7GS_^P^J/R=, 5U,VL1/\=05BEYYL]VN9JT[^^XM"]P>*W+W^ M],L_K8#2? -3N'D$&0C@^D:F FCYO,*C8RL(A:UIR&)=U#IV7](Y#81E[F%T M<%)(&K+%$"3#[ZZ_;.0$Q?7#,'3^DT>)\"C3QGR]M!Y(6 M9@E+3&68.W6$) YN51/S9? %5\%- ^:_I[&B*<,V@3?{ON)3 M=I-<;*:D*B[T.]*E9:< Q33LI;N1/LAO\6O:(G1_^6,AE-5Q.=T+C&NC:-D, MD!Z\'],<.57M'6H?CH1SJSDED^?>+-\G_HD7G Y D:^W^62"?1 MA&W@8MKF76> (GIERDOL-=2@%Z,?.>7H(1TQ3|$'9 W*Y, 2_{X]/H>1T%Q(B M"!|H78<5?RTF$-_FB7??\)+"O'@!1@0U;$,J&$EW|3+PHUZO|M6)[<\I9AB>IKFC&?I1QTR OX]0*[0]GW<".Q# %R < M;K0@CFU9P(40&2XA>5D_5BNQ081FF7'A?&ZFMT!802!\!T#A&NQ@C. M3KuI;.0%,!/^.*AM2PJOK(UTMRX;@(_^GZ$)NGZ3QO&S=G@:1;J6N_8D2)4]M M&%)O0*XHN*7X.B? 2H!9G\4.XD&R+4[1*4.X8XDEAEG/IIZV*S&-D3"D1XJ0$ M.!"5\GW^1,(QN5,,P-C- 53%AVN*;MN&@E5\4T< MA>9984W!.41&I9"$@]6WB&;IQ7+@GFOB(9YW/[TKVI?M9F6? Z.).Q%I/OBQX^XR2OOG,($Y?6>IW8P!T==$] MVR1$E591>S;9%Z MQVH(P6<;QT.#1+]C^QAQ3/$'>4STQ%+2Y7B4TFHAY\B0NQ4W+"JH0$HU!V3 M"W^,7-CPI^2P-Q=|PM@=9_4_Q[NK9Y;4 _2% (RO-V^13 B9P?Z3_XFM!9AF=!/Y5NR M(KK.*5H=M[GG6G_W$Y_K<,.ZVR6W;@+@%&?>L7!RN M&J%{X\ [HI5^X01&=FC]TU:4(YO90UM%1OID\&?T24, B/SO@WYB=JA@>,,2?5.4R8S#E

*M&!*EHG32>1*+29+8KP]_%/DEM5XUY0+S.R)*LO1%1D"PX29:^"2B3*DHLGC ML99Y92$!PTUJ0W&0N"L/(@KQA&_WL>\0RDA2+9T^*N;RL!;0L!'LQ?R/-^N MZO:S+MS=,,,9/V"&=5[2'"O=E/-#YJHM1B%^3N8CF><-^;(0O$WON=L4&I3$PW"WY-D;STTX7ZW>FP>? M<#+<*%Q 1#,53#;/L>VT"X=PL0S$W+NVQ[!JYNY'(!VH$^<; ,O,]ZL#&.L_O M9]0_,M7!LP_\,>O+4?C\D]23M^4>.QK$L8>1<)\02PU2$%_[.?N9XH^W=S0[M4$RX*?]9=ENJ748N *"^&,ZUBJID;/RUPT8,#(SFU*C+8^@<^21'V%S!EXO7 M^/6_]\?$0S_"=EFN38CM<^1C@1!6+ IGB""(4ATR>;RR"8)*$^L;MX43# -M"RUR UB)*7#W)+6.2:PA7)N%,&W2H|0M?4V64[/*E00XHv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{S32P(RKI1,#24>5V

*MVQ@#VEW>^+8P0*F|/3Y6BU)GQ_(4IOZHVK>J6^^V.B:4F@X\RA=EY^CD/)V7I>,C);I*N6S:7FMQEUC%INO++S8X\R=QF0U%!-$P2·MCA%GO -+WMF368|TQ4$ S3I9G,G:9,ZC(@(J:N(F*\'JW+."J.1LKKLI#[U@ MOA+O.:2,)#5\Y*M^SZ8TD90VES]>3$}IOO)IZ>F_6';Z6+6J!V^W7(@SW6V: M^NM^4.<%'.Y3O1#NQ$PDSX>1$P$U8!H#343O: (H5FXL2}NG,>1*2GAL M2A@^Z%X@Y_V2H|6L*,ED$/9|SO4=%5HHH*(|G_13+[_1%>KUZ&# M""_1>0S&[=%;2T%#H@X$P99IN6K!77TA MW-5_+KBKYX:[^J?QG5_TR*;(A#5]74, <28$3]\F:IH^0M/|,-+%AV MZDMK6RHHB!?WT^B>Q=D7VYT!AJ3STG3-S2IHT7VDB_4-$;X(Z~KG- MCA2CK-+LRB0B\%7&P,EI-JUM[AV\T'V5_KNYV6J%%>I=`$1UQ=@[+1%!>S@ M,\=QXW05%041AC%VZ0+9F1^)]77.HJP=6 8-*AWF4:W""><EH .P$U143Z,!=?WDB MT'/>4PD+.+>2B$"=HK%X@9S6.? E]^MX]+, MM0+F=#:/JQ%TI,C9Q9_ 7A,I6K*S:<.+A6]KO^J1WS(|8)L9L](#]-C$+[(D MT%)SQ?UD__C\M-57]H_$WCG[3T@Z-X$/O*3 MRQ,2]H[0?-9=JG8VG89 M3!2*;&[-O1@(K\R_WC@O)DY&:J5Z\A?A!9A+1MO)#)^A&Q^HJI*)%20H8\0]=ZHD>ON')D$QFOHB%|.XG-SIZQ50#C*/06K55_: DNHT69L\'4^LOI> M.R8"7@0AL11D:Z .C_9OBI:3KKW:B=G;^,F3^W[!K\GA_B:2*DVI?>C++SY>C,$XI[D^CGQY*U M\5"!H8.K/#*F=/*7BO7MD^E3VV58$F8C90X;((?\L81M'#X6[F. M0%BOM&;W.AV(H:>C6]N>U>Z.-<2-0%W9]"@\GZ/51CW.4'2"C->/VMO;.09:W M,:)-B>?K587GD@I-2_:1'BT<_F MG&MF<5#?|/6M M]W&>>-/ZS?1/VDK7K4B?T7-J[01CA@6XC>R 8C\3&ZE)W0L4]%+(5'#;I)\ M6YX(C[?# 3IL:'B&1?8C*#".2HSL[:#4?G9D#G@.D.:$Q,)2_@K1<"WOJO M!;RU@+!<^(WC+N!IVIWJ,UL(DD3B?]\7[BKI6N5@C-](H*G^]GMD8:^P0ZJ,: M/M/.2S7SY(Q37]V);(V5P+"\@QOY-TH:-QK&!H&+TWMZZY4SY14 ^1HDVCQ&[;Q M$0WABK1&/U?>Nn?]\8^4\H1B JQVE0T9$M%@=I=8@RPPH!CF]SXW4>K9RK"OI'P@[Q=6O'#>45\3 # IQ&S\H(KVD&/0SQ3(B=]/+!"K M_0Q3QPAL3Q?$RY_1NKW(XO5KF7HAB+7?HVC=L67,-=;#] 1':M)M9!FU\M9_ ME]2AX"R:3CEYC60T=:?A1")O3=D1T^+ (%X49(^/J82&GHNC3,9HW;>,-JS=(,:5% M":U(BD7;,>#Z+/T?A^K^&D#P]H)[(&)*%^B,_K!$I? JND$>S\>J!'CUYYB M,V(=Z$9J8A"T3FBC-)2$0#SQ73HJJY.KJ0H1,;984WK[/*IU2EZ7FZR+ SLT M:R!EGTW5;<8#)1,,;@,<7?G!-0%_(D2?X7KMD1 |@-H^N1NEHF*-2+,;$,' 1 MQ>++N.BD&AX&0[9E&059:O> I N_DUIK^^EMSW'ND)=Q@>F:,;^[H ^JF,>\T3;V*F#(@2%'^)*'-&U@$/L] MQ)^%*<^0)KQN%]R327&OIXC,]\#[TM73,@^J$*3Y!;\AL\L>^/WD(V9VX33 M,D!/U>LEY#D@1&7L,;E:&^EHD_?H4R|ZKK@K_CR2;RZ;K#MMVF/(/ND:K9";-MC0? ,KBT8NHPH 58.V\C.*QPA%#V^TY^RU%]U0<1*3$)N_Q:6TP_RUL5K_*7 M=V] 0[CG\GD_1"8=SA1\%'EQ!VOSS_)KG*6\' ^1;_WKMQI*^=$"L=)N)MH\R'-P-B'-W =.%TX KC=XIX8 3V<'6\T#N%)NIGP:T#*73')FO?\,..//9R> MDJ>,VN_>7$WOK.;U'QU5C.=,;.^$IXY]?[K M%NS:E6R*=%Y_(HUVZ14^*$U&_P+]D]N9E:18 \|'9&+-.MD&.8L MTU6:E!S*$_1/B;V,IBMHA%KF*I+?]W MY(,%= (+$B'+23%M-.4"%GB0SE6^F;0^7BKPCE& N0=PSV:/O)*B2<*&N]NAU MU-7.T2V@FCKK@;"PM4_P *)V#5+-G1-P(+U?-*!(O((^VY0^=_1{UWT\5%W4 M>PP,IKUV/OVGOOL|5Y8%^.WOS/!??5#8B.(FY;=AG(+ AXPP/WL_U=VI"K@-MOV@@%0_*0[5-H65G)K_ET?R=2TM5V.-2#0_;=RM458&9MM^VAPR'+$Z.E6/P4//Y% MR0L"<-*;? E#"KZV/T4W135DK!7]190S\6%?$XF/>/,)69[9EF%2/6*[L+K5 M9B52ZV&&/AEMOUK]H6(0S'2O1GH@KX?]O MSA(@"Z=K#= .Z[#HLG$1EQ=*1PVH@'W3=@,*4H0PG7Y(A31"#6W+95XY3A(@ MV<%?;-?651N@J%K@'7L=M0QHGSC8*HEU_TGQ:0^U NL+W'TN@?Z);>P=NDS?&GJ.#2DSV.WWX)_- APL;Y^_KV MC__U!f1__EH.FYM7OY8?_;ND&4C6\!!-SC._))C^OC+Z4_;N<+NDQW3@.2M_MG/!97#(*U#^XJ-I$,#L^4].<0)2G -'45(J2'IK>UOR($"%3&JG;EQ^K_8B; MH%^EG^&7 I?MTN-$*R]VD.U!F]3N;,|W^?>4G5FBH^^.?5ZJ`.@4EG4K13B ZQ/E]D M5IQ(P>R$}(+Z28>#*Z)5)HE1Z029*W^2-4C#W*E=8S>RV'?:#DU?H"B]IQ,7&+D,\ ^ZW} B#J,_V@!YVZ@A MK)"S(&E,-3-?//5[;_)Q/,^J3Q/^A/[>)UU18K@<2H;Z\5)Q9I-P#'+&UO&K M$2A&,-JU"YC()?0]VUA!^U0X?6XFY0{(:'=]6$MUCV]5+F/MY18M-MP[K$V. =? _$\3I%45'?AY1W8FBFBC_P:XTP4LABZB_,H8P#[>CK2&J"?C^=< M@A.,"MM*1?PX(7DU-ZJS%WE^:2GOH8OUKM9!WFI/99-YC0/L#QQ/9KZO$;.5 M[%=PK3XQWZN0%>DY- _8N<^4YH_ DHD@NBD#*MY3!3T K7%Z;[.IX,*DA6J+EA>GSQ=RURAC&C. MF@O/K$Y2R2FPI//X03:FK)IZ[N\A8' MS"4%GNU@W"8L8P15A7..=4E#SU&>4@ !KXXGV1W6)#EGB+>:;@ '"XV[#)+*(@\; M>#NO4IWPW11 \D!!063$@6#;)@_ICB,ZF:H-ZJK\K?YY_+H Y[&0C7=FOG:"M;DZ&G,.^^D7OW2/TASQ&CH[Q-?DPSI4WL'_|+*'GV3V\ |3A'*%.XX3!?Q88Z" MA-3 ZP]D=!4UL4N150[#,/X_>9Z@/DV\TP5YH@=+}$IG;@9)ZWX^Z791B'12A MD\-U:$5*3JLNVLT>4[D0E:"3R7@ZZ<=*.=R/@2O:Q;.38("LG,C>8=A%Z)^X M[=:[EU)U:,=6$_FBJT%3 SNHDLZ74*#P\W9M)3 MHQ&2^U9=`"/N)!*KO_@*5)CV4+7P@;(8SKB421+7B^1

BV0@>9&1HL+@=^1NJ\FS%&/&8!TJ'G MXEIR&FP<@GAQEK7<$9.-KR/(((("86#$H#5=G,H&.CG-!5!F$,;14-U18G4S M$-BD@#XQ6!EVMP>

<5:/Y9]5,H$+NX,A_H#>FO^L,AC[XY@[*SU5!'J;NB<27 M0U!((("80@B5ZU!)1/QR!IT-A8 O4' ,; #Sl. @-?N$Q7+P5&PP8^?85#,+% M6#%8AH_N/=,N>CK4@{(1

F#"ZT6NDPG7EU#TE+=>K]$\&&DQ=8\%8Q,[";RHM^JF]PE.1B)I(/&",XQMH81''\H)O<>?]Y 6U MG4M=#@!#ZOG!I(IKB)/D8)@X3?G '&Y0W(HWVWKU] QHJM!I\\!

<#=).IM@A3'%=N^MNNGKWlF3V$4R^]-EYC8H-@3)W|VD7 M@F($5UWZMD)Z2GI,VS_]E/H9=T4YP:#=$n_(Q7^UBl..!$(GDBB84+ZECE@6X M'-;>HLOA

7,1X1L/20;Z0[Q0-.8.E3^XJ31!NO%ABC2&[BL=$)!ZF;A('!O8 M$3_W=S=(2@L&((KJH M95Z>B&]6^3FG[,H!6IJ]#?8)BT2^2__-P_^ XBEV M&.''0Q[Z6(F=]44H_^.GIP;YO

*J8)6'*5E;VAD2_< 7PX%;8-.+R291?\0GV&EOS=+&QN?V94X(9! $\|/UPO!O_^_]_R?0^Z-= M!#73RPR1M$<",#!;B9*WG>*

M,ZW)1H\2[,X#%D2@6%/AVF"}H/P>Y8MP:M3T[)#_)U\;'CB6M+H<-$UP,NL M[*6@E3A^]X1,E.?GQO((]1"*$A6U"P);8R!!//[>1^&M02@uN\l&_;JJ;Y M(=.//NUU\Q-*

JV/F^KX[N[5&A<<03W#K@QKB\-5?HJ4GXGV#EGSH+E$ VTBPAY M,X9D237(OMNK}'--LZI[%WFM<&,NWRPQC1%F!:25&\%IKDQ'%SF8828-[%#% MPR2-,XL 3X>,V/TZ?

#3NW;G)]T!V!%PV2Z+I4$2)NDF61C3\;02A!5^P)'9 MH%CF6965*VE5/A:7; M5&R\)1];7["U@/^1+ =:2+C0,BLH14$,AFC#F7I+0"V%5D7FO3S]X0=?!,;P

M2@!EHUHMSG(_NVO#I/(>]C:++/7#A]PQU-N.M[%GPW2 JAZ@5=/'HR?>#9(?7 MQ$?VJ293'1C++/T>5VX,[ML\`)AO.CY%R^G<.Q7__:UKZVBW] =X?'IT^/C) MHY.G1\>/3QX?

G7[__+IN'#P_>"]Y7W'!^7=@JBM7CGI[1=6XD%7L\UA+F=]8A1T38H&@*Y](R(M.XN^A;"H*9,W!.)R42(C M.0U!7X5T@PTFMCF(=M<0AJ&WZ.U M(;/R1>7;JLS")1;*

*M4+B3PC.G>XQW4S4MZAO7R0#(&7;-)+QA)*QC,'M5Z@)2C6P*BAYBO@;3,@G<.4O; ,4WA%I4A'@,;HU'H+>?C#&-Y'3=[*A#ME M*

*B8Y1(<,P!&GP%Q4O<=!DT53&A5P&P4,E(TC\K'C]*7:.Q11LW\0G9Q@/C#RJ7/YE$B/6PTC@%V5,2M%%$AWSB^[MS! M:MF & [K!64<6T;+9P9QET/7B76 MBB)]J)!KF7P-*

*O/,H@*S?;K/`W5*%O M:FK4uE0T5"`)_K>K47L&0.EJ%]&/NK>=]EUEC=#Y\<#M MZ 0G]$=&O!P0!&,0 ,*P21D$]1'@?]J+]Y79=FE,NYHU!QA1@UVSTG@H8VA4?*

MUV@RHTY&G?Q$G:2<>P,C:51I)&S^&=K#;(4^)V.(WT3;(F[.;>+F/(FX.3N" MFQ,-;#2P&S2'YX 5EHQ]`2C[U'WV&S,F(.%[6;8$,? +N%X\$>]6Z+(,B#

*M1#G$J_.L0C8..L6CRQ@U:]M"CF^N$ QZ<1<3LRQRLRAFCKE'<+)C(8OJMDVK M+(@8&U){#_TTZ-U(P2BJV/33L"MD]915##H@^AQ?*C0P47>S3&T(6I@?N(3F> M/0]G)V*

*7O:G;MLCV?GO7 `!"4CCF^AXQ>F0L9 8_]46|L)vB!,.|VF8 MQ&WD1#/'|'T=EB\JVW?D=P"8!6]*I*_V!=*7KU*0V-59-# M8E\|>@Y<*

\E/I&^YN%SC%:0Y&-4GX3'%:O*H3:KKID93++!HQ/<*MS"0&M# MFUTAF7O0P0\&A;Y6 1R,<*#-^C)K4N)N?@\0?@8;^S6_&(%0P<6N(+=F'/-4*

MS1!".AG!X^MYA|#B]G_Z2GK&>=#H&%L;+`YWA*8,)@X]]8W]#V08]68.)LL_M]#?67!R>HGM@.E'ALXW/NI_\I:FSW$,&YLY0.F6&5K46D S[UO/NW 212Y@1 M2P:=0:!:*

fA69>CL@QBS+^K<`N^W5"\3O-@^ MCR95)!EAOI0%N/? ?;>?R0OH8$0O]H@0Z,`7CA6,AGO?.^FDM%[CP:)9 OU.'_M_AA".9]):VR!5 ;M$PIE/$_?*

B]477:O@SZ!R4:6^Q$N?:,_$E*VYM@Z+ MRKLJ/P#)XM_\51QJ;@KUY/Z.*&!!6BIM?P$&OT+1N8:E(_MTCX^\^% 8K8]Z:R>>(HU]W9,86\-3_\;"CPX?XC?.CIXD#T4Z_[R/1W.P(&.*

*MG[H2V._?+YW"LVSB[Z\H&YP$"FU?<&W_&4/T^3PB';J[@RL[M!B$H:HD@PDPEVTL/V;XBFC*C2]HHHRJ[%1= "!P2=#2B%%XJYHZ+HKX.R8U1 M6/D5A7YCP*I4AH\T3O?-U&#-?*

*>I/0S;^1W7'GKN-4 M:)8=AR@G,[=F1V0X-EK6;<=C(KT/!2!YT3;]LA NTRDR.HK5GH'#N,T*X#)HL M<6U/LC9W9^GNPH.M_K:V)(4:!:,??9K M*VOK,1(:\[POTTEINP ;C"4|-*

EFPZ@,&/9UF&J'=-F'>!E+/Z)AN^7"G@EQ M217_[?-DF"'#O)X]V6C[9A<7$&M860:4B[.LO4SQ?Q-@!,*?N=%"QK@QE-E/ M7N.",,C-HB#;@C.7)*

*U'PXC9U!8OA.'T1FJ!4)XT%5D6]AEPP>G.MQ:GT#&! D##.[ETB"*ZH;Q8^@(QR7PE@E(?A'4X88F8M M):EJ@\.KPEQSA+PL*O]34-6+.J-QfNJ29H(93$R D:V8!__K;XV%!\.]K&+*

*M,YQ5.C=6+0LP%-H7F[JR/>PA-)B1HB)6-W>YNDFPE3ESH&,@6)76">%7MV$#;[-1P=D'J"F(K_"QUBZR7^^J"0G MUD:M2*5X#71H&80I5N:<@(+T=C9[1_.P".%O_YJB?*

^D.&TZMF??+LD;<, YU M!7C[\'5?9L5T:4T-%;[KP!UL1)+RBUAQ,/Q;"LL9AY40XK$OQ%!-79;:13?$ M>9<$S22C,;@"1+,ID10XIQ^R 3%501R@#'1 ^PYQ[9>(.1C605W+-,/;/8^*9UH

MS^4Y%/MAMJJA/:NF8:M!&R55;M8[Z(`M;E7 VOF,X-ZA]MR3'^FZXMQAIB"U W)-)O2N#"0AL\;^E#7B\U)Z^W'"E"LX M'>;VOS/0;$BO,6$QW-++#CKF!%/@X;IFX9;;@XICC-,I5D?

>H9M888SJ> $/6 MN'!DWQ/NO9@E-C:SJCKT#@=I,\NH3%) =IQ HG1%A=,(G,^H MDYE=),@M^RJJ3RP.^KE;=5:YIJ,9(%[6HHX]1]!XT%U"R'',,29[7V80@N

*M6#60LP=8@;?0&QC6.3^,3HW$$4#WHHS[#*A8CZ*UIS \)82/D3111T2 M;P5H+>R1]WID=(#]2CHU!0#2X]"6'[Z(3-0HWJ&=-P.XQ%(?4LW(0*1B82? M%60APCD'-*

&WP;_$A\0E+&!Z8?+;!<]F7RQUQ.WTK=17FO)_=3,.'S6%T-Z9P MZ9=U):U1S:R0XBZ?RVNJ-[;'AX1ZL+8L0-98NRY+#/R6S%US\U2'*)EU]9H MM\E%8_^,*;/<2$#?G9=V#?*

*D%K_1*BM*Z+'HG8(K!-7@+99\?I M&**QK^UQ1&|P%_X:Z-Q$&'(P,]"5VI?2D:6^P3? MZ[GU'|06I'L]4OKKC2& M.GE3U55\Q?KO& M8-*

*CZJ9E@?!@FY>K|*0VIO/K1L,+89VQSO*47HVY=RR+, ,[@\|=("P:,? =' MFT+)8].UDKW)WYYZB_1F)RU9+CYLXT[8#7_AM6[33-?-%&@'1B*UL*-?5X-!% M':HZZX=/SQ=[/PVU.5D-*

*@C@UKF@/'SP4F/+)1@-V:\JD@NJWE\P_)^Z;NKSW MSOBVK8,,%S,-5E*Y)5CV5R=|L',Y'BNPG+ZD %O9&VL=*F.O6> @R%@CL@4P*

*M%7[X+O@@GHCK^'!%,J[!Y,PG!U*QMDH)$102;56&MO+ "0$2,.LLE%K*HYC.P ME[!L0=^Y?9VL8&V'>H],$#1P$C0TQ*,_ IA =]1B?OJ*4QBARB_0P5)K,*L, MR K"/+%2;G*

T"R;BJH6@=5M;X=]'NBR6>&AAJO++>EL,A|]:FS#=?)Y8@X@= MP0:A3BW8()3*QT@#'IP5.#U|W'A:,,9WQ(R#S]-@0Z,^GDM%[CAY[Z^3.0HWJ&=(#]2CHU!0#2X]"6'[Z(3-0HWJ&=-P.XQ%(?4LW(0*1B82? M%60APCD'-*

*@KI/*R[Q:X&1,7|7@=6L.<_L,NR]?E_:|]$M MP8%?@0%7TAL|$YP8ZOXD!D[997F]5)'X+R2R%WS.G,V0N!@N_AJ2^7CD_ 73 MNG[NUGZ07'BV[8LG\Z)9)$TM+ \T#+F4_#ZG*

EA&;EJ=YZ-IB!)/01\&65\ M$"RH,\5-/-#-Q#3Z#D$_OYM.&)9M[+ 0&]LJN8 _(WA-KOL.P=N3&-< MX#D(=@C^T.1C+RR0X;618=4P/A ?#++103,,:4HU^CNIC'1Z7 _"$M8W=S_?;#*

*M(>%AXOX2_3]_R-!#V-7/,WPX64\230^9CFZP:3&R:B$@\1>_V76S@?:XW8+ M?V#@<,8AE,0)ZC(S7PU;?AC/Y.Z#L-@X^Y7D_00-L[N2./LO?,6 M;\+ E+, LD. XTF8KXH^;=*6*0*

*MDN+ ^W.#*7>*.7+R"K9U\M7Q^RH|:E|(4;Q+?QBAZ&|; ,P5? =S'OJ3,#1]AW M#CL-$[6%0_UP,0$[^!-!A@0W$*O8!6DO*=LGJ:[..?Z$EF O2"L4,D/\WMI- MJU[?;5MN=;/^N?VS?*

8>7T@\TL<4Q:.-6NA7N<5I=HM9$)!! 5W3X)S0&R)# M7)IR*3DW1MKW/H<_=2%W1."G<>VS# ^P=0$--]YY||WC0B6GW<8OL%8ZD$,' M4+Y@OJ]6>$@JOB;2D'|W?PFV$.O-*

>%&T2?)P;JI'J71-Z@CJH",9I/KO49[M0WR|;]'8_7IG-[@D%S!P:(Z905 2FWM8C32MU1&< NZ&=4K"D^6N MN8|SW9!MNJ"VK$SVUH:QP,!@ -SH -7 PSA)?

*W#C)VE'"G75P&A:@BJ)_K MNO:@(7"/@WAFI9&#K?@M?7"X=F,;S*FMZSG7JQ^;=%"^75?8R"G40$5XLJB M:%WN0V$S%#D'W-^-[??*

J$N2:3#$XYF,#!8'BB^F:6I5BV$3>N:N2Z\.>2]N MTR27UMKA1$]N0!U99?GHSU.LR$\N"HJZP<5JPO"C=E9VW-M#L $ZA%10:U\}3 MWME&0-*

%=4FI#UV\!SF7Y>#+;Z2.@=\/;.-7D&>=OBP M>KW:)*=]BM($":,RIO0G3@%D7/ UV0XA5@&K=C-HGU 4@IX,+9O)OT@"_ MFDOVF;2'DL1#SW"[%"WN06147C$\D[1I\"W]2F[HH(BI*

TV ,0|/>Z7%VA3\ M)KG%Y^&;LO7HT5F;WN_T_B[U1FJYP67R]4C2HG2,FC4]J^V0:\!,&VQ!D=0; M-Q'4-"HWMT] \;2@CMD;&WW>]4E?1) P5U>M-FTFQV(M6427WK6.#KGPJ3CD*

*MO@5:Q1!9WUTR"MF]WQVWU15L3Z8]F.?"0T*UZ\EDHUUOL.QY/>M]$$(=6C^: M$GH*$6;S]PRCBX[_!'E!L1*)V$-V _FQ4NO@N\,[Y>X3.#\6RZZ5. M@: ^,H.PL-%M8,(=&B*

*M/!L9\JXD.3?61R7^8(K."H):3LZF^Q_4&VT,?:&1KI[E#58X\13B^_: MEN>S$9PLV>O/OMI/UE<\XLA<')E;P$U8%*2]T[''KW(>\A/^VSYH>T/^O6ICM*

M0\RN1V\RUU#IZO&P]:RBTS<,,NT4IQ57!:.S$5X#.,1E8)R>IRG)B.NKR- M+K/3[2)=D2D=GK_VZJFGVXQP3OL*4 G6$Y1^*FFER&490]M>F=$#8T:`]D:"OF- MJVP&H6

(#5V9Z]^'XX!*_3\RV))8"Q0<8'Y+FQ05AZ33WU;1R!EN.72ET6@-M01JCS2O#W3IS3*W1"8'A:F#Y+PT.CU&?MI\]"'=6?*OOF[Z1=P*<2ML12#)*

M.V'2|>#YVL88TB$3+6Y4LT^WN$[#\.RG]|P%B7WC8\3"LDF-(@L(2+%O'K4 MS:B;6X&B4KF2=+-.'04))2<@$UE-Y@"Q;'\N!7-(.Z!]]R6,>>!SZCB#.M3 MK*

*<8#PA8]$VO&^A?)O1E- JHX5'#/]'Z!GK7&O...T/L,5]8>P/? M=EM?PA#&.&OG8;FV0)4*GFP4.&O,7MB M/.7O6.X*GR*H;&F(F1'Z#M^ M^%EUB]-XT1QH\/)B,.TVWU6?*

Y:KH"+XK%]SW:.OBZVEF]]D/+B\)CST^NDR M0.U-UD#SH"_9M!Q3%^0-"!4;_7SYI43)"D8\G#U+Q^"9GYN@.S;]?EZFAQNP MPE'+&A+7%0K(?SZP@Z%G"6M7*

*M4/'*7>*9]A)N^4;&^XI?4B=+=:%,ZP,3/FHI^AI:@>:G%:\4AGY@R;C.!5\&PG:WF=P>RZIMN;.!9OPR>5/IW@Z65/ M^<8P?S35Z^@N[GFE*=(=X&\Q)R) 5UTC3H[&"LOI)*

*(+ORU7Q+ANWF=]4. MUWA]*WN8E>G.]8.("VOX3$'5'C^%@=O)^@V?N6F7J/?3P'&XGKQ.@6?L:F M)C$<S9U|S07YWKX:]&\SKD/KA@G\7CA:/[&Y_]*

M6[O:7$0IQMQPUBDQW?);)&%=-!;VWU1TS$BPQ@.D(S_-G]L,C+?8\;](YC M@UYLT-NI>.C5)A*YCP2T61!^Z0C&+,J.(]4!7E*X0< MS.1$U_9'4F2;STZUZ]GDX>K 5+ ^* C5M@E[5?*

[VI3;]IW1C3':XE[_RD_B94 M!U<7;?AOCIM#JAQC+"(W92#N!6=#0W9K#4/@.FYNRD<+\T#.]F6;%MVW"03I M#AF@YMJA<'5CC]6V/B)85M#OO'#C.8A>C/_^$'N42.*

*DI^=W#9.Q_TAMGS1U MT3=*M9@1&I0HQN^!9(G/NAQ:I%/:)R40Y&5$'$\!=9IDZ.]_DU.7^=GZ!\M9=__I8.B;*O&3>ZS2DJM&=0-;;=#P:.?PVAD+A6D -MBU"U\$^\OZ&JO/F+B*

M^L/.8=R/. ^+UPBFLNOAP:7&M+DU66JTS2]LM%L5LS,DYT2.CK3#\O:HK$'B MH$?;]9"IH7R8_+&#I[W_K37;VDJ%.@BR#9 /P\)AACD!%8+Y3R/T8J\{CO*

M,'0!KE3JASG1=OT2]6HRX-:QMY[!3K?=&6I.TS?@M.95DM,I%'=H#T1DGC4 M>0T$R^322IZ_H*/25/;X*L=#;TM[V. A*Y3*H79&$I"HAUM- 3:Q[43T+<\ MZS/Z3'0-E5)\39;V?*

&6+:7!L@LTV=<7E2.QQ\B8$C(MZSNY>E&OHU[?MGWU M1WW1^?;@L)5[^!LU-CG\.2"N04; =74'G^.0<%3AJ,++;#F>U;#+)'YYE.,/+ M>:

*DNP.8%GVA9G8GB#:C!S0FT+L.KURW2XBK6IH[H..\L2%&2>;.^.O^"1^ 9 MM$=A\LAC1;>]\+GV0OHF7#8!9H%H]T#_?1!0VDB@W 3*DQ^#3>[8!J.71D<*

MVY'^Z0JZO^@J8N3Q3C$0&WAW.4A")JU8#U3YA\38>E@V L#5YIU&+S(\ FY M3 7=&-P>!1'IBO)\>0_L(&[.SSY*W<[[92%MB6 => 37QK1ID#7'5,C# "Z M0F !%,X0*F^Y-*

S=EC!]%K=PW,?OH6AE(,>&N>)5*F= X2??CSS M Y>Z96H\'JS4&AJ9<)(C)]2[*^X,A[=MGR=)U-VHNY]_*2A_CIBJ!1]H;(P MKDR?-_U%P#;KXNF:D "@O-*

0#@%52S4@H@NRTBCK9]%8K55M=&3,!H#Y[+F3+Z%PE=*5:!;L' H-VU8+.14L>=\,G[@;4]ZD$>BZ(CX15 M3RZ4C$9K,#3*QI?9.?3T(@X$' '0H2$;MC-*

*JYA78, '@':.'#9IH!P<{0>A= M- 85*L0F11++]4#VAE6B !' .:%MIB]D_XMC_I&3?!%D^:%/%>XO6,ZG(4S_*

M9>C_OZH+H@6'HP,KZ25@4\"44[^D"IJIEZ5Y'AV=N'D^U;2G81[4^SR";\,9 M>_.>A]$F,"YQ]L)> (<)PDE0G/8A![98UI9 6.&FIX6-.!6Q\,@ZO/G'SH9 MJ)..A)PX,- O#@RZSRA%*

*[N&H@5MJ('603U2>5$9OA.2ED"I5Y%W.:,]4^ME*5L(H=C/:U KJZ;%7#L%4Y.L^'+5O#]M.+U_]MU8|AT^=0];NMW3C.XQP8A0@E@=3OJ>3YI-*

*$M%?,DGUE>!Z540$,SYW#B":W M**B>,F2XA9=R?[SK[LXVZOB%14UX]XJCCKHTZ?C666HR? DM"&.0@PFHRBJMF M&=77NTND[$:K%QC"[%>>>2;?@#K(.?)N[Y7GBX.AHA;-*

*H8]YHB1HPE!_$R"@^&W MNZB?0+E1H/8!F(4'2Q$@(IH6\O(79ZINW;9X|>8UHJDNK->#-JA0:*2UHM_ MOFX'\+@>P%W!E'W0'&%_<_FO/GN'E:SZ&NR- M+VUU*

*%AD'[U&"CE5D?T DP%OK;\[*NUOA2\P)_93FTO>C"1MA%.107_IT8-JLS*BGH\K.SV@H"V9S7#.LO6<(BF52)1?]VB 'MI5V_6X(*

MBA&3X5[EO0JAVM=^96L_0++HGTJ]+.FR[_YPN:7!JJ,.#1Q-";|\^]?D@:FNBJ;&-M.SV@H"_56,,\1!.YJ'#J0'A44HEA'/$H&I# _"%BSZG=U!07$#D[(C'LB#]RADAQ MAAO+@,2/B)"Y3J5]#

<=9G;H&.E:5'N")U-\&)U;6!#4[CPMW$ ^7# \^J:JJA MX\!&@?JZ/[GI'1#D&Y[Y]F_L3LKS4IG];P/4L^RV4H*=]0!K.-F M%TSA?;'#%(ZK;7O7]$=%U@W83[*

OP&'5]DSE:"NJ]@>%.4Q2!O1ATKY4<_M_77.MZ>]9T):MR<2(73Q4_]\V@'KV0*5G#]&B4O* 3N+BQK PP80M8%+G_RS M;@RL'$+EP@*W_3*DQ^#3>[8!J.71D<*

$2BK(`NJ4=#8Z1P00_,!2I0B76>!O?TGZ/:L[2EF=QI35_4E9W>_G'T1U\U MYJ(9]SD?V!>ZP^PW-WJ#T:IO4M2^5?V&9.C >0W]9#)ETG/O;3/^<5XIY:F_,6# _6H&:_P255!)|KX+*

<1O5 M^KE6'/PWMQ"?Y2V]B3C^(S?S#&\8_NBM>VK-0E74S1\)>P_K.#<3Q?O(C/V+R MVI^#4-QUD<*K.H^/#_R-P? 1=!W3'B!_WO2E20X?*

M97N'#^8/920PQ&.=6ND//K451/^6557/P.U1C%#E?IC\?S)X^>G#Q#]M'=P M_O4\[R2;Y7M/GY[F>_GL.)N=G#\|/CA^!/UFC:QLWYCY?WSWXH^G^7P^,X^. M]XX.\|=

[)\>/9GOG)R>`>X=/\D>/]G1:?,2DT+NDRA;VN0TEC)_*[.[A/3%[JSWG97E>Y;/1RY;L^91GQZ<'C_.3D[WYD^.S:-\Q[M[&B^]V0^>]1W?C@_?G(XST\A2>?*

^JC6T=OB:,^4AF7T.&YS!5:^/<7;M^J MIXW0MJHY/Yl;Y/]9.>'I[L/3EZL*&7+\UN%SXM1>R8\ 5. #/TSE MER8CD)ET\FS/"@"YOR-8_1(WN[]??A0QOSQ%\H?/XKYXV\I?*

^P=^$=_F/>7 MQ7G1W7VL^6@_>7GG7CL+8XO(ZDNJVS 2V"*CWQ'AVW@<"7?N>=WDIL$'L(8= MGA>^OF<-:-WSJ?KQ $/!J_H7L>]8K$[\Z_/B?G![O'V!QIZ?[-MQ[O]HZ-

*"_K5O_0><.E8H/Q&.K=>39[!#T*5;[':W.._]_TSE2C7700P'\K>7#C&\)/3S5!>D_#$#W_#=42_Q'@V/[QRO3X;+,Q[:4.ZKLK_LEQ^I*S1\ MG-!U_>Q/Y^\HFV]_HOGZ#:WN*

=/F="O5VA?AQ-O>BO#KUTMK,."3_ CN MY+LU D99?KJ ^3AR?WU\NNR2MBZ+/!%'8K0&>)==6(.M'9X;YB5=@QPVPMH MW&##*\=2]?*

45GP38JL3/\G95XB5YO5H!OK(W_+D'3M2[,?:,%(^W2SQ2X_:^ M/>7_T;2SIL#!A8|[T^;]\>$?AZ?' M^Y?=8KWJK[,0^(RYF=4$(_#,&A;3(^[JS9?RC(F08+[PC4$"1#QY 0L".$L=

M#ASZBI/B?7Q!H-!.",+/'\Y_]vERLT#]&RG&IT7]-UJ>PX.]__NVLB51O/]I MM^7>|=/3@^.HXUN3\<SBC1-$HT:]2HC']=X_2?T<{[DG$]-^N"7!3^]JX M_W_E]>P_)M.*

@=\\/3TX/#QP=')P:/3IX>< SR"2Y\>W6$.<)#NPY0@S_#_M1":D^CXU1PA4Y/87_\Q6R=$Q1JDG.6UXJ[:NR=[?][F9?Y^D&!.&.6MXOZ6+_#IQCIP!3'A&'TLJ+\HOQBZB

*F8Z)$HT2C1&/"\!{D9;Y0PO!C@[VO2J[?@BMV MY_V"$XE"&Y^=GIP6)'IU507=8O? M..LNBR9+?KG,FD66 DSA/L,1OIYUD*1,&)$P9BACAO+ ^2C=F*&.[XCT7K]CC MF)*

*[\^M)#47*C%1B>1<&-Z/CZE)T]B>C*FO)^^ # &-Z,GF3 MS2Y-F?S#0%-D9[!^LPSE89 \Q MV7=XFO._\%%P.OJMO4A3=(7]\LOW.QJV/IMU<*O#I\+R$EJ*]O M?*

*X>/=!QP) 0L;[/F/*M,N_?Z?6E6?B,;.0HP"C *76B_*+\ M=E1^.7B/\HORB_+[JN47DV_W)-EVM\8QV*_RU^WP2?+;_MO]`M%_LN,79X?'KPP>S9TX-',7NVD_LJ"C ^*_IP]P48LV>[O#I1?*

E%^.RJ_&'U' M^47Y1?E]U?+V;/[E#T[BMFSK]R)^@+9LZ^@=RTFT[ZR;18%& 48!;C[HS) MM%U>G2B_*+\=E5\,O[/\HORB_+Y]^<5DVDXGTPX/#O=?_?QVQT_^^QD8?"L"*

M_*P^;]"_%GN_SES3^25U7;9=7.)#_6LO[Y$?[G_WAB+'CX'--5A7R:RZ=Y M:5^C]KLD6RY-UMAOX!=?,;&B:^E&77;1)EEC$K,X M-WEN\N2ZZ"[=S_T3R:UV_*3XZO9+%&*

48!3@[@LPYL)V>76B_*+\=E1^,9;. M\HORB_+[JN47]%=YF\E,35/XKJW3G0ATK.K-UQ2_[5Z7,48!1@%.#N"S#F

MJG9Y=:+\HOQV5'XQUHWRB_*+\ONJY1=S53N=&C@\F&22_U9D^2VX3?=`&5_4 M5S",F%VLZ[5Z,^;1=;!#&)1!0U5,-=85+.RS^FSE^\OB_.B2PX/#A_NN%G_ MZA0\"C *,*

C:/?NK0J3EDU4[D)IA#!4(TF0:A77F39TZ)E,LX?^6)L.P"?!@ M"1AKUU7VKHY#K%8098.#K89#+:N8(1G=9+*F&=BQW"P-2HM ?S),& I:F7VQ M>89K7K7F7SUA?#CZ/E>)T_Q|<)*

*<%0.7]ET=ZOV99):*H=U\.8M!,5!([^_M.14JT3_L,RK7H?C%7B>IFY!<27 P+C*1 -I,^ISHUCP&%2>5%03+M%K" MP0S.F=T<)9@L'U:-4\CA:/[&Y_]*

I_N'U(1"6L@5AKT11\--[X5)?;U>(];!=_A MB8QO5'E+UA77),E @S.IDU)&M%%4*0\OJD,3:E0(&(50UBE[#V\M7VIK+#V MTH:Q8C]A0(.G.6S$TBNFFB!\0-*

*6(EAV()"IW,6Q1[FUKK*L0@H!DUTD MPGX3!QWX&.$ZW%L)L$\RCD;-%'PY^ISZ?(+W[^OI\^*_$=_;.G#).*+GUH;3 MEU(5+"](4)L(GE-08TMN6YP ,+]2^C)9+]:2O-*

*25=9/,C050^8Y%"T:H\[= M]H#%1K<-U,7K*8KPSQH]'(EW[6QG[R%M6?A#.&OG8;FV0)4*GFP4.&O,7MB M/.7O6.X*GR*H;&F(F1'Z#M^ M^%EUB]-XT1QH\/)B,.TVWU6?*

Y:KH"+XK%]SW:.OBZVEF]]D/+B\)CST^NDR M0.U-UD#SH"_9M!Q3%^0-"!4;_7SYI43)"D8\G#U+Q^"9GYN@.S;]?EZFAQNP MPE'+&A+7%0K(?SZP@Z%G"6M7*

*M4/'*7>*9]A)N^4;&^XI?4B=+=:%,ZP,3/FHI^AI:@>:G%:\4AGY@R;C.!5\&PG:WF=P>RZIMN;.!9OPR>5/IW@Z65/ M^<8P?S35Z^@N[GFE*=(=X&\Q)R) 5UTC3H[&"LOI)*

*(+ORU7Q+ANWF=]4. MUWA]*WN8E>G.]8.("VOX3$'5'C^%@=O)^@V?N6F7J/?3P'&XGKQ.@6?L:F M)C$<S9U|S07YWKX:]&\SKD/KA@G\7CA:/[&Y_]*

M6[O:7$0IQMQPUBDQW?);)&%=-!;VWU1TS$BPQ@.D(S_-G]L,C+?8\;](YC M@UYLT-NI>.C5)A*YCP2T61!^Z0C&+,J.(]4!7E*X0< MS.1$U_9'4F2;STZUZ]GDX>K 5+ ^* C5M@E[5?*

[VI3;]IW1C3':XE[_RD_B94 M!U<7;?AOCIM#JAQC+"(W92#N!6=#0W9K#4/@.FYNRD<+\T#.]F6;%MVW"03I M#AF@YMJA<'5CC]6V/B)85M#OO'#C.8A>C/_^$'N42.*

*DI^=W#9.Q_TAMGS1U MT3=*M9@1&I0HQN^!9(G/NAQ:I%/:)R40Y&5$'$\!=9IDZ.]_DU.7^=GZ!\M9=__I8.B;*O&3>ZS2DJM&=0-;;=#P:.?PVAD+A6D -MBU"U\$^\OZ&JO/F+B*

M^L/.8=R/. ^+UPBFLNOAP:7&M+DU66JTS2]LM%L5LS,DYT2.CK3#\O:HK$'B MH$?;]9"IH7R8_+&#I[W_K37;VDJ%.@BR#9 /P\)AACD!%8+Y3R/T8J\{CO*

M,'0!KE3JASG1=OT2]6HRX-:QMY[!3K?=&6I.TS?@M.95DM,I%'=H#T1DGC4 M>0T$R^322IZ_H*/25/;X*L=#;TM[V. A*Y3*H79&$I"HAUM- 3:Q[43T+<\ MZS/Z3'0-E5)\39;V?*

&6+:7!L@LTV=<7E2.QQ\B8$C(MZSNY>E&OHU[?MGWU M1WW1^?;@L)5[^!LU-CG\.2"N04; =74'G^.0<%3AJ,++;#F>U;#+)'YYE.,/+ M>:

*DNP.8%GVA9G8GB#:C!S0FT+L.KURW2XBK6IH[H..\L2%&2>;.^.O^"1^ 9 MM$=A\LAC1;>]\+GV0OHF7#8!9H%H]T#_?1!0VDB@W 3*DQ^#3>[8!J.71D<*

MVY'^Z0JZO^@J8N3Q3C$0&WAW.4A")JU8#U3YA\38>E@V L#5YIU&+S(\ FY M3 7=&-P>!1'IBO)\>0_L(&[.SSY*W<[[92%MB6 => 37QK1ID#7'5,C# "Z M0F !%,X0*F^Y-*

S=EC!]%K=PW,?OH6AE(,>&N>)5*F= X2??CSS M Y>Z96H\'JS4&AJ9<)(C)]2[*^X,A[=MGR=)U-VHNY]_*2A_CIBJ!1]H;(P MKDR?-_U%P#;KXNF:D "@O-*

0#@%52S4@H@NRTBCK9]%8K55M=&3,!H#Y[+F3+Z%PE=*5:!;L' H-VU8+.14L>=\,G[@;4]ZD$>BZ(CX15 M3RZ4C$9K,#3*QI?9.?3T(@X$' '0H2$;MC-*

*JYA78, '@':.'#9IH!P<{0>A= M- 85*L0F11++]4#VAE6B !' .:%MIB]D_XMC_I&3?!%D^:%/%>XO6,ZG(4S_*

M9>C_OZH+H@6'HP,KZ25@4\"44[^D"IJIEZ5Y'AV=N'D^U;2G81[4^SR";\,9 M>_.>A]$F,"YQ]L)> (<)PDE0G/8A![98UI9 6.&FIX6-.!6Q\,@ZO/G'SH9 MJ)..A)PX,- O#@RZSRA%*

*[N&H@5MJ('603U2>5$9OA.2ED"I5Y%W.:,]4^ME*5L(H=C/:U KJZ;%7#L%4Y.L^'+5O#]M.+U_]MU8|AT^=0];NMW3C.XQP8A0@E@=3OJ>3YI-*

*$M%?,DGUE>!Z540$,SYW#B":W M**B>,F2XA9=R?[SK[LXVZOB%14UX]XJCCKHTZ?C666HR? DM"&.0@PFHRBJMF M&=77NTND[$:K%QC"[%>>>2;?@#K(.?)N[Y7GBX.AHA;-*

*H8]YHB1HPE!_$R"@^&W MNZB?0+E1H/8!F(4'2Q$@(IH6\O(79ZINW;9X|>8UHJDNK->#-JA0:*2UHM_ MOFX'\+@>P%W!E'W0'&%_<_FO/GN'E:SZ&NR- M+VUU*

*%AD'[U&"CE5D?T DP%OK;\[*NUOA2\P)_93FTO>C"1MA%.107_IT8-JLS*BGH\K.SV@H"V9S7#.LO6<(BF52)1?]VB 'MI5V_6X(*

MBA&3X5[EO0JAVM=^96L_0++HGTJ]+.FR[_YPN:7!JJ,.#1Q-";|\^]?D@:FNBJ;&-M.SV@H"_56,,\1!.YJ'#J0'A44HEA'/$H&I# _"%BSZG=U!07$#D[(C'LB#]RADAQ MAAO+@,2/B)"Y3J5]#

<=9G;H&.E:5'N")U-\&)U;6!#4[CPMW$ ^7# \^J:JJA MX\!&@?JZ/[GI'1#D&Y[Y]F_L3LKS4IG];P/4L^RV4H*=]0!K.-F M%TSA?;'#%(ZK;7O7]$=%U@W83[*

OP&'5]DSE:"NJ]@>%.4Q2!O1ATKY4<_M_77.MZ>]9T):MR<2(73Q4_]\V@'KV0*5G#]&B4O* 3N+BQK PP80M8%+G_RS M;@RL'$+EP@*W_3*DQ^#3>[8!J.71D<*

$2BK(`NJ4=#8Z1P00_,!2I0B76>!O?TGZ/:L[2EF=QI35_4E9W>_G'T1U\U MYJ(9]SD?V!>ZP^PW-WJ#T:IO4M2^5?V&9.C >0W]9#)ETG/O;3/^<5XIY:F_,6# _6H&:_P255!)|KX+*

<1O5 M^KE6'/PWMQ"?Y2V]B3C^(S?S#&\8_NBM>VK-0E74S1\)>P_K.#<3Q?O(C/V+R MVI^#4-QUD<*K.H^/#_R-P? 1=!W3'B!_WO2E20X?*

M97N'#^8/920PQ&.=6ND//K451/^6557/P.U1C%#E?IC\?S)X^>G#Q#]M'=P M_O4\[R2;Y7M/GY[F>_GL.)N=G#\|/CA^!/UFC:QLWYCY?WSWXH^G^7P^,X^. M]XX.\|=

[)\>/9GOG)R>`>X=/\D>/]G1:?,2DT+NDRA;VN0TEC)_*[.[A/3%[JSWG97E>Y;/1RY;L^91GQZ<'C_.3D[WYD^.S:-\Q[M[&B^]V0^>]1W?C@_?G(XST\A2>?*

^JC6T=OB:,^4AF7T.&YS!5:^/<7;M^J MIXW0MJHY/Yl;Y/]9.>'I[L/3EZL*&7+\UN%SXM1>R8\ 5. #/TSE MER8CD)ET\FS/"@"YOR-8_1(WN[]??A0QOSQ%\H?/XKYXV\I?*

*^P=^$=_F/>7 MQ7G1W7VL^6@_>7GG7CL+8XO(ZDNJVS 2V"*CWQ'AVW@<"7?N>=WDIL$'L(8=

*IP]P4HKIG[O]EY:?_ET.}\E,>VA?\7.][;GTVTWA¥GRZ[I*W+_M(I=ODLB?/-I_],CO[UH\?_9M5\Q7-Y<0/NTC>?;MY!6(9;T,C@9W^8A57_-:_M-SU.\7&>?-1+_EORZZ5)9AHRH$WF]HC-H9^9#\\V 5!9/%H!'P.,FZ$K.C=F M8;\(/=1'=N7A5_C?A\\3>SXGR[Y9UJU]WKN(02>.'" S90W>#>Y45U(LE_/6F/#O'27U#.I[K M2V._UR2++#?VT>S;&OAM-N_X1KE]R.1^P]B?%$UCVJ4A'\;^&Q[IPE36K2G5 M.X%T@I_]IU_M^LOYB#MMMGS.P.5E;*V.\/WP%G M$]9R9I7'5&W6UPC7(U]7N3V0>T5URX$BJ^HX&O/]DfV'Y\|_3X_$_V3X^/-MQ_]LYI.>/D4-=7"6S.FM%)@NS%\5YT07>8Y\+/N;' M^F^4TOMG>}^/NZ5Y0V<7#1U.S^SFZA?5{QH[7Y?/8-/\2$X364=%.OX\Z;*G]NSKL#+-*;.P-.;?T$<_0K,3,0'G^2D1@MPV8E?/HX\""M7/E_M81$N76:/G[G R'ROI;*F>Y;U7?T_,#*C?Z.:T:9/#Q$GV7E=;9JGW_W@UO= M\?*-UF;,,)?A';OHV\|[PVD7:M_EBHEA)D?_'=ZW]2];UUHO94M&N:9'.ZS+?M7A)O7_WUYS,1Q)T]Q:^_O7GY}B8V^(F]G!H_;^P=_"1+ZZQOLBS_%=O+2=V MA-W0IT^'+NFE/>3SWK]CZ#_DY&P'UD^,,.3<7&;E')Q5N!"Z M]?P%,9-#V$7L_:EnZL6^9;^&UW?4YN(47@"[P/;BH8_&E>-I> +K#< S MP?]W[!E7]_8 *]Z;_#G=ZO#@8/_@>_F!5,-^5[9_XV>G^?PA9EA%,_^)2zY,:`MHB__]9X5G97,,.#K]7/OJV'6_\X5>1M=@Q9^1.9EZ^&@N[PP8UBNO>2%B2C:F9&-*=K=D"'"G9-[7=CEWRQE25?3_OS49[>>_W?A3/?0HE MOL:TQ"[(ZT;BB59P-]24]R=9MARRO8F#_#!G8CTNYWGCD?W='(^*(X'T8$7SRY4<$__V'\SI?_>?_|>_7':+ M\C__?U!+ P04 " #1@6=97GTN ^,* 0#$#P\ $0 &%T:&$M.C R-# Y M,S N>'-D[+UI<^0XDB#Z?7\%MMZ839:]4%[5U=U5.SUK.K/U1IG2ZLC:WK*U M,8I$2)O&D-$D0U+TKW]P7 1O1A R4RMV4YG*4B_}^^[_]SY<504\X2<,X M^LL/']Z^_P'AR(^#,'KXRP]W-P>'\!?GYS_]SW__.VWP\.I.G3^1:?I'3^C M0S\+G_)\6B4Z#1_QRD.GL_]9X2A#[^^@QR]:_OGOW M_/S\-EB&41]3]N#6GO&3+(.,1*I?(X,<)S2+X_*-:/&%S7"0IQ>8S^F_R A8^UR>1<%]+5X$U'1 M7[J[9I1H]7&"]VQQ[Z>,9B9_3V[CXPT7HW5, V?;*VS(<)SCS0I}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Ç[?_M6%FZ5E?RZPKV?\3$MD2+QA63OW>LT$^U*T0-*/;VZX+T/_%]6$<-\+RHK86.[V7DI?XFOBC7"EGZW=#6OZXG$K<(.!

MR;:7]R1\&-R!50!#L8(V;=I)D>S+!F9!=BG=7I6X|5]VN>!ZR-K|O'+$&2 .3 M544(+ 6)[>QE<;/K!=TV$-3-[12O!3:(AL2 7*5_DQ?\4I.*G%}-)B03O/71W4CD-053%#FL3;!PRN*7.%(E"3P0NV\C M#,U28": 2#/EB:5.,F&,\2)628>G4B0%2.LYLGG+POI(TNF+3S8!#LZ2> 6'-MRR83TT[*G3&-3&N]V:Q67K(%'>&D&GU"DABTI-0@C1SU-OT-$E'8=%L5,46'*

*MI5;ON@XH6KU^^W*6MX5LN4E%UA#E;Y=SM8VI;!*)7,ZEW?=*5IDSAU2C7?&+ M[3I,_WZ68.@;C4$UO:8VZZ"@!X5WL(3YFZ& B.C7/=TR;5LR,;>?;-WP-1H7 M"*A&0+}KBY+F-EIEF,U==!|"-113CZZQCZG63K^:Q0=FW>NV6AQ&,\C,=*E0XI77]ND89DILV7S6)%)S5]'$%SUQH!0V;25!A2|!.2*-%M$K+YT1+IM\$RT;GE\|8UMCBE*C6/P*@NL2*%U$S9V)H_2G$\U9':&,".X\F[ZM\%*,;!]S0OTP[LI*.M29E-44A[D?.9 M_[>>+QX$(4C1(U=>&)Q'HC&3%E4=S;-?S$Q6C,.4W0/*N,\1S(\OMLM:NAZCDOMIBP-5S!S&A8DQ]MO%N&-2 MK&JOP3#NCN,O,,NI;Y@9<3=IDLM-RUP0S+Y22&#!P0DKC^3!;YX7HR?2R"2; M@1-S5)-6"6[&#!|/8G.6LV%=)N84AH=AABL70WK]:7%.# ;Y/'4^=!5, ME;RO=+SINV/*P=[WQ(?NNG'N7^,4>XG_>!@%)_@)DYCEVHAL#A-]CAXELJC M(7 W%L4X>\4#H(G!&3)&^BV9L]X:I7]VX87OY.JV63! ZFFW7M/.ZH7A #-1 M=4=/Q#1C#G6M M1#OK)?)1SCQ"/V^#X-5&(70> +RG@SD(0K0[,O M I??N*-R)=,\;GM.Y]$K)\94Z3OFCEI=533AU,Y))9QDA9<(7DK =FG\XJf MQ/7\QMOXRAOJ!-+&X#YXT$T\0E[!30)TH50!]IV)]JBQ:,+B;6U?9=9Q7O9H M#7M8%9V6GYI36FRE*^BMY/MRDAT=PA,3/-E3YC=&9.Y$V.;*"_2HI.NR L.L M5+ZWUC(#E]^&Z?)'NQ93; I32SY>I+\A_?LI4;2:*J36+ZBD^0M8ABLY$]=T6D*BI6-;$^]PPX_)%3O+C94F&.8 M$W>US8-J6)L33Z2;'6H'"">!,M"6J(.L7@'< 4&%1{JW*B&!EAIA": M5LR$.*

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iO M 2(&<18,D'K.W96U%2MGILN6>9Z!S;0T>JR5_@)3O--#<)D9 _>*UFADM"9SK MO1+;]R2;&O=#;6%615AP.53^"(0ME!SG-**3-VH5*Y+]`77F##$RFRO-8^)4 MMT^XF\5U"M^T)%29^]8@H_E,?3,LIFJCYCPKA0F(A22_%VF8//!B M,56)VDF))*

*1M(O5OYK++%[FWZ#2:AWS[Z]:*0+GK@2+ZUPQM,9OK+(A;2&5])WPVM8AM3^],'C>?WQN6@:Z.3/AR&."B,@-(YBK0WF/%@A M'>LRZB0!GKMOP~"Q.RDNXA|KL$,#)2+&CH%%TG M,^)'"Z!S'J@F+_B28!?25G258.RECRPG/WW.AW /R9=F!F:>9$__H<%TO!:O M63&\[-M-4X_[J)71'RTLKH-.)X O\F8Z!OOG9O.1?.P,1"[53[UC(% M#.1S&(6KS>HZWGHDV\HX M^N&24G06)FF6QS.AH'851[@0RN.$"4<(UI;#MT[XY44V!2XD$"F,A000X<8 M/[0%BVV6:SH303G9I7W%D<=$L62B\'-10-FO],P7%DG=^]G+_P.3-'G"|C*V M9'X/4:DI5|>/*5MPS#V'V2-*=,0SXC*WWG.(2(!TUF3O"WZF$H9D(<@N3>*(M_I.WSDQ-IF;@:%."-!Q41C>F?L U_*56+PB5;=!C$;^,K;9*(_1*QPR"@SZ3' MJ)^7R6W\/&R@>2)1$S#IWH7_BA,$<&? "AF/"V7Y^_ 2'E$O-^%RM9^A)0[6-6;!*-0U2>X9*7N-@,Z5CAJ]**IG8%U;K!+VX=8)"_ MQ:L>P)US$4,X/,.K?0^DHH^(Y8:)X@6 CGX'^(@AL&X=G&!JIOF\VFS(0:/# M<93R-8ATO8>,!L=59>\0VDF5,+N.\8>'A!EJLC*=#0T:Y+F0$%7l.%H#S!FP M0W+1ZM.)DZ2-3S(.%A7SDS+*"*;1BB.P.,Z_M1W*WCB.Y#ZIP@W"!4+T' M@O=@DRSKRCX')7XV=1_9K-EEW#[REVE-3YPV>";)JS\%%*#OVY,+8=;Y5;FDZ(5!ZW5 MX,7YW"Z:H;56)J83EPH! QR%+-E3CK/1 ZHXN^PH8;396L[*PPW-+=+&A96 MS:%VU]Z.]>=@X^! ;TG*KA7=RI*?U2#*[E6&VU.@\(4]+QA1'5.QINY"M28]& MN4)HO7N?L.H.U8;?5T4IV MBDCK)H?\Z'T[$HFD 53*W U6KW2W2ZO?@783L M?;Z=7(@TY1/*;D4W9S5;N4LW<;%|SL=1[T.0@RF|&+-#LYS'K0&KN.\|. <^DFX MYH/&CC9I&%&K_V+?L'XQFJP@=Q=5PG82U+? &ODFN2IM69T[NC'O!7AK6U-? M(G-+'QQ6F*L&R "HJ9),'-(JE8"[FT\Q%57$3.0''/EB0JG)47MW;V_>HAP- M'SH):CU#N'4X7=$6MV+E[FYT-B6"\!!-ZXY3V(<"W?;#Q_O;,-N]"K-4UYY# M0PSA:/JP\L_S9J%\<@3++8>U M;^?\;Z"!.D3PF?>OOJ)2&3S^$G'YX\D5QXN63&[6-,LJ!D?K-0G\W"2]_M(F>EG;HR?D,7?R.RNZF_&6:\2O6<0\5>&XLV"L$&8XY,-4 $/JZ>U7-CB73 MGT=9$D9IZ ^^>_*$WU#"K(Z5QIYX#*Z!G\0Q)4IV6%Z%\7W4%@<)OAYM-YD MO1ES1UOV^C'QTG2_8IR"=@&P$ /VO:!/*IQ;+S^2(KA*H$X_VUY1.%"?"A8(M.\|W^C+*GC@)?8$8?)Z.)3&(/>[:V>#8]WUUH]GYRXWLVSKREL_AITH<(:9 M+,Z)99 9=SCGSLN<##4QRQCIOW#VV^?3(Q?V/YRI5**!R:<2'!L' V%M]5: MD="/#3N:]6" +5+F* ?E9@8K<[BE!ML=F:%=U6 M3RX$A8;KQ'FS=O-^7Y7XKF%1K7].TRQ<\0],*S&(EPA[U&XUSRG*(2+8CU$S 90WE#M";FU)KPKiO M 2(&<18,D'K.W96U%2MGILN6>9Z!S;0T>JR5_@)3O--#<)D9 _>*UFADM"9SK MO1+;]R2;&O=#;6%615AP.53^"(0ME!SG-**3-VH5*Y+]`77F##$RFRO-8^)4 MMT^XF\5U"M^T)%29^]8@H_E,?3,LIFJCYCPKA0F(A22_%VF8//!B M,56)VDF))*

*1M(O5OYK++%[FWZ#2:AWS[Z]:*0+GK@2+ZUPQM,9OK+(A;2&5])WPVM8AM3^],'C>?WQN6@:Z.3/AR&."B,@-(YBK0WF/%@A M'>LRZB0!GKMOP~"Q.RDNXA|KL$,#)2+&CH%%TG M,^)'"Z!S'J@F+_B28!?25G258.RECRPG/WW.AW /R9=F!F:>9$__H<%TO!:O M63&\[-M-4X_[J)71'RTLKH-.)X O\F8Z!OOG9O.1?.P,1"[53[UC(% M#.1S&(6KS>HZWGHDV\HX M^N&24G06)FF6QS.AH'851[@0RN.$"4<(UI;#MT[XY44V!2XD$"F,A000X<8 M/[0%BVV6:SH303G9I7W%D<=$L62B\'-10-FO],P7%DG=^]G+_P.3-'G"|C*V M9'X/4:DI5|>/*5MPS#V'V2-*=,0SXC*WWG.(2(!TUF3O"WZF$H9D(<@N3>*(M_I.WSDQ-IF;@:%."-!Q41C>F?L U_*56+PB5;=!C$;^,K;9*(_1*QPR"@SZ3' MJ)^7R6W\/&R@>2)1$S#IWH7_BA,$<&? "AF/"V7Y^_ 2'E$O-^%RM9^A)0[6-6;!*-0U2>X9*7N-@,Z5CAJ]**IG8%U;K!+VX=8)"_ MQ:L>P)US$4,X/,.K?0^DHH^(Y8:)X@6 CGX'^(@AL&X=G&!JIOF\VFS(0:/# M<93R-8ATO8>,!L=59>\0VDF5,+N.\8>'A!EJLC*=#0T:Y+F0$%7l.%H#S!FP M0W+1ZM.)DZ2-3S(.%A7SDS+*"*;1BB.P.,Z_M1W*WCB.Y#ZIP@W"!4+T' M@O=@DRSKRCX')7XV=1_9K-EEW#[REVE-3YPV>";)JS\%%*#OVY,+8=;Y5;FDZ(5!ZW5 MX,7YW"Z:H;56)J83EPH! QR%+-E3CK/1 ZHXN^PH8;396L[*PPW-+=+&A96 MS:%VU]Z.]>=@X^! ;TG*KA7=RI*?U2#*[E6&VU.@\(4]+QA1'5.QINY"M28]& MN4)HO7N?L.H.U8;?5T4IV MBDCK)H?\Z'T[$HFD 53*W U6KW2W

!4B0'./C^_/Q-MO)@,NN"L9Q+6C>;R>C(=ZS;++UVVQL@V$T;76>AV);.[D>"N8R# 1"S)K>^Z M_L?&>XR_4WTX(\X'N S,'3%A(HBZVQ9;8?V>QXO2'$*)4$KC7A^_TCN3)*

*M!O4\C=2HE6PP*W5YFQ]%LLF"(3\D)U'>Z_7E8.H[75]V*Z]S&6L5Y(:4G.R MG6]"9[5=P'&??K+^7-9%?7*(:2J#.4D]XSDA7+U\1.257BO(1]/]E=E$_5! MB4]65D5W14AV>?*

B]>&W*M^4\"OD.^TUG5>$WQK;F),.1^Y$#M&08#XKQ4)] MSZ;:-N1R7+A<&4@F.JK&!;<18L#[11?&CTD1M E+3480],T'60Z>1NX\NSO*+*%R;)A!D-3'?Q$-*

*:>]#*DB>)5AM0%0!5AM0%0!-B/_M%GU>'7:,A V/2H+:.2\3ERY:*O9M" M67AQ ISY5{.? HF2@N^2'1+9F\%\,!?G.R&&@>6)#0F%[&]@J38C)"F MKQP3PDM_*K(PTX*_6I07*

Y'A9H$OQ-9$,DUW\7M>#'G2S3S1ALJAY<5N\NK+ MDVI#M5XJ#]:!4/&>[(AG6QI;Q,"Z276W=.5YP55I5I""8D\%2EBSA2747KE6 M& X-

\F0K_<"6FLW^W<;6)PJ=K/6&V'R/+"K$4SG5YG.[A\<#PDKUIZ[FC2)B M^IBP\I4_^.FG(2V#I!]G :4>^2A56YXX%7E"_+@UU.0]-'[8E%!54T9-+:9] M_+S9!N'S$LZ&UTXVFT:G#R97

L[HI:;5J!>I Q:N5R BQ!.A>IP#@9;PVSAY M=:,#R[_GU(HK/L!\7@PJWAH5-%RQ.F0W.6(DQ1"W#$';6B$9AJ"@0!#\/KY+ ML,+1:RK;$X%KF_T(?*

J$O6M/M@FS]!*UC#J'_<2)6$/[/N0.>N4[JL< -33/_M5OJRC9F$P"Y1!1'?>&IX%&1568;J@U_^#2=__5C3S_ :]27"P5=;IK 5#U MU-A-S9]?>,74ZWT\1HZ6365\HG;5NF!J&I>22*

*Z)DO. P*AC62B7K%7?3_^X M\THYHX'C;9TCLQ;E?WH&8YX5V.'KT8:VPX<#_?_ L=R;W8[T=ADDGP9U!Q2 MFGW]]^6_YAOX(=G:[W\HJO!#LHD?*

*_K\HB*E"8[DAF:!^8,B$FM0_/RB@.4G= M*733M+OCZ&:'H3#D;LLPE:]N1MYX4=,F+/<;2*ILLQZ@+*:LU#$K:9F';E###1RHL6.[_=8Y7ODW*FY>/- H$NSEIXX=RKPDJ*

M.LEK6@#++I,X;'$DYPBQ[<&1%;"&.'YZ1;Y@M\%)?#2*2CN5%@C*3)UCU42@+V+XR< MN_F,*)T]H(;?.R'W452)% _[PF)O@9^?*3,3S=+3=WI-'O=HY M5VY=*

*[[E/H>>^Y8AY8O0@#W*UXQSX"O_G;X&'!FR M\2.*<[^Q L@V".ESGKW^SI9W9-R!'$ HV02Y\DL:'A=`>S\ R85%Q)7J_8$+ M.+P\532N)R!$%2OD"%]$@52NWT2F&DDGH "I'")QI-*

*K\CUZSFMOT5E3N<^'TOEJ.=TEV?D"/YV/I .I8V+S",#0.H)(QEQ,,=\"(6A%I5 MQL;.&@IZRTT#692Y[/H((1YNGBTN?*CBN^RL55>G^(M\3F*P$XU"<1.K#IBWC*

*M&F27(HJN95FH@#RB23\ME37>(\5&MUM@Z'\MIGH0 NBQ$5Q;B4?T>Q88VU MDY(OC%"M_C-D$RC+C&FLED.J]0'@#"A)*A,:4,D/T(A])@+WHF=)VEDE:9;*

MK)5JBYA_+'ZEA,>/U6^\%^*A$Y04(]Y:4F@2,@]J;&^K#I M&I8.1$%G)>&"'0>:<:4#V8"9\}TD5:8A-8*TZ1-I6MR50@,T+Q(-P$F@OX E? MM_99*("C%$>W&)U*

HL@.Y=>/-8WE1X!WU(@'H\"(:7>+9--NJ^" GA>-2@] M<&RIC)7W2)-:P2?S4 #(F$:I)KY<-Y?.0 &4(-A3C5*5)Z, M204/UK!)F". M%9N17F:,;I&E1=-0@)?{B9*]5+>N_R$]/-EX%

!=>)%C.VX,V=V%552>$-HV M!P5@60)E2/OR1O5S4@4N428A2<9;ERZ?"+O3L@"/$IF_%HV16'5;SX"?=

<;=P)=@F_<>]XU7=X]!^,@N"QA+1812V>O4",=U';=-,D]^ M_'YO1{#O2_O$08=V*C2EV3957U1BJVM0{'B?0D$AX]EKF%4FO/.2EV5:6U'U MVR@0+52C[V7!2NVS4 #7[%\F<=$)!Z,*

I0@6X4NU-Y],-[:)#5TB@6SC(VU MK4?M'\%!+ ZWNC<'\%'TAN<1/3OB/VX! R!B:RKI/|#?2RD94/XK@ MO6N&-[JZ|%%V(4:%,H8GLB7...X2T<&>2X:GYI;GSE<6-X&R'0CE)?*

*8([MFN'S=/ M48\@=[-$I2OZDI.UW)? R;B0?T'W8K/R M^:Y5*2S2^!"%U9!D,U5+!?!(6WDR"E %>Z.W:"O66UHGH0"-ZH@.W K+?;0< M^\Y+(P5*.@37PM8Z"P=PM=#*0J"I!EG*#[+-*

[^BB ?R!1X<\4N)B 2BV+,*W M559H,V67K\=U7@4'\/KJ;(T7\=7X" K40403'0Z9V]=0P\EG.FFJQDF3P=NF MH0^O9G,5.SZX :V!:X"V:!%,_XB<4E/Y*//HNY0@+NP#E1[!$0:.L,1\T#(%*

M!5BB2)?\9=OY05AYV0I72O8)\PC]MRFKB+ ^4U?VAGXSI;O0S#$3UCU42@+V+XR< MN_F,*)T]H(;?.R'W452)% _[PF)O@9^?*3,3S=+3=WI-'O=HY M5VY=*

*[[E/H>>^Y8AY8O0@#W*UXQSX"O_G;X&'!FR M\2.*<[^Q L@V".ESGKW^SI9W9-R!'$ HV02Y\DL:'A=`>S\ R85%Q)7J_8$+ M.+P\532N)R!$%2OD"%]$@52NWT2F&DDGH "I'")QI-K\CUZSFMOT5E3N<^'TOEJ.=TEV?D"/YV/I .I8V+S",#0.H)(QEQ,,=\"(6A%I5 MQL;.&@IZRTT#692Y[/H((1YNGBTN?*CBN^RL55>G^(M\3F*P$XU"<1.K#IBWC*

*M&F27(HJN95FH@#RB23\ME37>(\5&MUM@Z'\MIGH0 NBQ$5Q;B4?T>Q88VU MDY(OC%"M_C-D$RC+C&FLED.J]0'@#"A)*A,:4,D/T(A])@+WHF=)VEDE:9;*

MK)5JBYA_+'ZEA,>/U6^\%^*A$Y04(]Y:4F@2,@]J;&^K#I M&I8.1$%G)>&"'0>:<:4#V8"9\}TD5:8A-8*TZ1-I6MR50@,T+Q(-P$F@OX E? MM_99*("C%$>W&)U*

HL@.Y=>/-8WE1X!WU(@'H\"(:7>+9--NJ^" GA>-2@] M<&RIC)7W2)-:P2?S4 #(F$:I)KY<-Y?.0 &4(-A3C5*5)Z, M204/UK!)F". M%9N17F:,;I&E1=-0@)?{B9*]5+>N_R$]/-EX%

!=>)%C.VX,V=V%552>$-HV M!P5@60)E2/OR1O5S4@4N428A2<9;ERZ?"+O3L@"/$IF_%HV16'5;SX"?=

<;=P)=@F_<>]XU7=X]!^,@N"QA+1812V>O4",=U';=-,D]^ M_'YO1{#O2_O$08=V*C2EV3957U1BJVM0{'B?0D$AX]EKF%4FO/.2EV5:6U'U MVR@0+52C[V7!2NVS4 #7[%\F<=$)!Z,*

I0@6X4NU-Y],-[:)#5TB@6SC(VU MK4?M'\%!+ ZWNC<'\%'TAN<1/3OB/VX! R!B:RKI/|#?2RD94/XK@ MO6N&-[JZ|%%V(4:%,H8GLB7...X2T<&>2X:GYI;GSE<6-X&R'0CE)?*

*8([MFN'S=/ M48\@=[-$I2OZDI.UW)? R;B0?T'W8K/R M^:Y5*2S2^!"%U9!D,U5+!?!(6WDR"E %>Z.W:"O66UHGH0"-ZH@.W K+?;0< M^\Y+(P5*.@37PM8Z"P=PM=#*0J"I!EG*#[+-*

[^BB ?R!1X<\4N)B 2BV+,*W M559H,V67K\=U7@4'\/KJ;(T7\=7X" K40403'0Z9V]=0P\EG.FFJQDF3P=NF MH0^O9G,5.SZX :V!:X"V:!%,_XB<4E/Y*//HNY0@+NP#E1[!$0:.L,1\T#(%*

M!5BB2)?\9=OY05AYV0I72O8)\PC]MRFKB+ ^4U?VAGXSI;O0S#$3UCU42@+V+XR< MN_F,*)T]H(;?.R'W452)% _[PF)O@9^?*3,3S=+3=WI-'O=HY M5VY=*

*[[E/H>>^Y8AY8O0@#W*UXQSX"O_G;X&'!FR M\2.*<[^Q L@V".ESGKW^SI9W9-R!'$ HV02Y\DL:'A=`>S\ R85%Q)7J_8$+ M.+P\532N)R!$%2OD"%]$@52NWT2F&DDGH "I'")QI-K\CUZSFMOT5E3N<^'TOEJ.=TEV?D"/YV/I .I8V+S",#0.H)(QEQ,,=\"(6A%I5 MQL;.&@IZRTT#692Y[/H((1YNGBTN?*CBN^RL55>G^(M\3F*P$XU"<1.K#IBWC*

*M&F27(HJN95FH@#RB23\ME37>(\5&MUM@Z'\MIGH0 NBQ$5Q;B4?T>Q88VU MDY(OC%"M_C-D$RC+C&FLED.J]0'@#"A)*A,:4,D/T(A])@+WHF=)VEDE:9;*

MK)5JBYA_+'ZEA,>/U6^\%^*A$Y04(]Y:4F@2,@]J;&^K#I M&I8.1$%G)>&"'0>:<:4#V8"9\}TD5:8A-8*TZ1-I6MR50@,T+Q(-P$F@OX E? MM_99*("C%$>W&)U*

HL@.Y=>/-8WE1X!WU(@'H\"(:7>+9--NJ^" GA>-2@] M<&RIC)7W2)-:P2?S4 #(F$:I)KY<-Y?.0 &4(-A3C5*5)Z, M204/UK!)F". M%9N17F:,;I&E1=-0@)?{B9*]5+>N_R$]/-EX%

!=>)%C.VX,V=V%552>$-HV M!P5@60)E2/OR1O5S4@4N428A2<9;ERZ?"+O3L@"/$IF_%HV16'5;SX"?=

<;=P)=@F_<>]XU7=X]!^,@N"QA+1812V>O4",=U';=-,D]^ M_'YO1{#O2_O$08=V*C2EV3957U1BJVM0{'B?0D$AX]EKF%4FO/.2EV5:6U'U MVR@0+52C[V7!2NVS4 #7[%\F<=$)!Z,I0@6X4NU-Yl;-[:)#5TB@6SC*(VU MK4?M'\%!+ZWNC<'\%'TAN<1/3OB/VX! R!B:RKI/|#?2RD94/XK@ MO6N&-[JZ|%%V(4:%,H8GLB7...X2T<&>2X:GYI;GSE<6-X&R'0CE)?*

8([MFN'S=/ M48\@=[-$I2OZDI.UW)? R;B0?T'W8K/R M^:Y5*2S2^!"%U9!D,U5+!?!(6WDR"E %>Z.W:"O66UHGH0"-ZH@.W K+?;0< M^\Y+(P5*.@37PM8Z"P=PM=#*0J"I!EG*#[+-*

[^BB ?R!1X<\4N)B* 2BV+,*W M559H,V67K\=U7@4'\/KJ;(T7\=7X" K40403'0Z9V]=0P\EG.FFJQDF3P=NF MH0^O9G,5.SZX :V!:X"V:!%,_XB<4E/Y*//HNY0@+NP#E1[!$0:.L,1\T#(%*

M!5BB2)?\9=OY05AYV0I72O8)\PC]MRFKB*+ ^4U?VAGXSI;O0S#$3UCU42@+V+XR< MN_F,*)T]H(;?.R'W452)% _[PF)O@9^?*3,3S=+3=WI-'O=HY M5VY=*

[[E/H>>^Y8AY8O0@#W*UXQSX"O_G;X&'!FR M\2.*<[^Q L@V".ESGKW^SI9W9-R!'$ HV02Y\DL:'A=`>S\ R85%Q)7J_8$+ M.+P\532N)R!$%2OD"%]$@52NWT2F&DDGH "I'")QI-K\CUZSFMOT5E3N<^'TOEJ.=TEV?D"/YV/I .I8V+S",#0.H)(QEQ,,=\"(6A%I5 MQL;.&@IZRTT#692Y[/H((1YNGBTN?*CBN^RL55>G^(M\3F*P$XU"<1.K#IBWC*

M&F27(HJN95FH@#RB23\ME37>(\5&MUM@Z'\MIGH0 NBQ$5Q;B4?T>Q88VU MDY(OC%"M_C-D$RC+C&FLED.J]0'@#"A)*A,:4,D/T(A])@+WHF=)VEDE:9;*

MK)5JBYA_+'ZEA,>/U6^\%^*A*$Y04(]Y:4F@2,@]J;&^K#I M&I8.1$%G)>&"'0>:<:4#V8"9\}TD5:8A-8*TZ1-I6MR50@,T+Q(-P$F@OX E? MM_99*("C%$>W&)U*

HL@.Y=>/-8WE1X!WU(@'H\"(:7>+9--NJ^" GA>-2@] M<&RIC)7W2)-:P2?S4 #(F$:I)KY<-Y?.0 &4(-A3C5*5)Z, M204/UK!)F". M%9N17F:,;I&E1=-0@)?{B9*]5+>N_R$]/-EX%*

!=>)%C.VX,V=V%552>$-HV M!P5@60)E2/OR1O5S4@4N428A2<9;ERZ?"+O3L@"/$IF_%HV16'5;SX"?=*

6DNV/;_[{'VWB)!BC_U(@B_[';S=4KXM.D"J;"UP]ZCD ML:ME5_E3;?X>)4Z"9%[?<-MJ/.+QV]SXQ3O;\M1U[*V]A8?C-.?B-.D]MH?>5388;;F?3\& M_I80.P3S3)9 !:+J8]TZ"R*'7X#$3K3*C<,G*^:L%)NF(R[OT+&R,@$MUZ-,J M_@)]Y PTV(4E2C+ZP48MV&]UC,FM JXHE;P[5#2]/+V&T-@CR5.-J2"5YO32 M^RT&1'D%W4+BVUM WMCU3*0^Y]KB2HC\D>;:>%KA=4B*1/9?=.BF0(< O'#D^#%00=^$[SXR9-0#;!I86FIH M9 =E!?#21458]#52U#X]MC&QI+]H5"EK.A5D*7#T56!-JW*5OWXRRETT6COR MN\ [JW}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|#_H8?5N MN6G,4%$R#'Z;9;8Z7A]4%R,AQ7X.PE4^H.C*"H(3W2G4%A.:.1?F(NBVP$@P M#H(6!TYC+)*M/_C>ML/N2\.-DE6-+]J;.+" TL@[#T]!40*BO.,HAY,[-?#C M(YT!O^>)"B-V:][?1%N8DY&LX]5?M-VG'^8$G&?1!@<=F"HSLD6;"?I?R.F8 MYBBV!#^R7"R%TVXM)V \K)!%\S\E8FE5)'W>^T%$2>A0BFZ? I6":0WEYRO_U-M;PX]^6"[/]V3=^)*BH0H3C8F6>2;^D8L..7$+]:8J;1<5+:_U?% M;F(]EC0]3:I"B&SKQ76R7,C6>MX3$C'63%EU,^WRRDIJ_#=,$\);VG/9L\(Y M&6AB7mB90)Y@BX>,T:XAG6(>D,L3]Y+(.A0K334/V48%B+M=2]^>,(?";;IY%3 M4K_E-O9I^7LB&&QI\ZR8 17)F<3*.@Y"AER1P7_G@3,Q*8]*MQ'R?)Y*>N-9/ MZ&Y?#$+Z2T5(%]?=% \V?WG9'0F90/U%2H"R&>,.:ZX3*<0C#9_"I>GD@IP M&Y#_CHFW/:FI1*9YL'B;,VS1E2?:1ZL\B.B=D:U\>9!*&N<^0.J=O]E4S5S M68%@NMW&AYC%IE!1**1/?D L%SHT?:.7T<4EV?D!>K$|>)QZVH#F)WC\3HRE9BC,';2D'GSS.55 >)/BB! M2UV^,2Q!3=S@!X/X;?='B4-UNE+V4E,GN[C%N+Q3ZGU:US4?R5]51KO(M,,* M1(_A&LIS6B6.EU4@MU?<$94E]-XZ00ZB!XI,1NL'60 MIKI#L$U#:CC9X >BT)=U(;J_T:6N*:\,;_J80/*

V%S $ZK<4D#JQ9=2DTC2Y"&:*P,B9/QAXYFFF4V'}-'Q'W/;67H-4_> M?(U93Y' &6C,(YY :U3E=*WF5HHI3JVAORZ[GU\A[6'IW7>NGM$[J3G\9D$] MZ.@$? ^9E/+7.F;2M&>O7+>QE5OYUTFU] MRX\@+P-RSF%7GXD+ P)X/W8JO4I9ZN5WY"G*-[$J-HT1$(;H3>S+T6IO MZ3G><]?RP2!6B9-HX^!?R1!=+KP; @2.@(R'DA4% ;G#9BEQ30#Y-&%MCPE M:-ILH@H3C2G/PKTQ?U97@)))^("Y/$$JF\1NHS(3'UBP-:G=1F6F,;":+**Y M38D)47FZ9H\"Y;X0C.,'I_P[XC*IXL'XJ*G%!MT^SUPEFL(-?TWH*{)U4K_< MT25,U/#L-%"_.5'(B0!R;?>4?CG&5A1HL\MT M?-1*98RNA I3C %R3U4W85==^^YP#/SW1(>3&]=E,8MX;35>)- ;P;$D{MV916A379:M$+>0^92PEU9IED% KN*04I8+"_.%5CL("/G M;B:))+=NG,D<"NKDNFX<2E\,70*K5AL>WL#249ADTU:W;%-H'Q[92<=8-Q:[MR8I,CQG%5(PM9:HC^2DI3JM(ANZ),+FJ-EU")$+OQ'+"N!=HS2M+1(+=5X8@ MOZ0R8;H*ZG0"LZ&VP53L#6*Z<00T%,8A!9;EML MMVR&9H-QBN,GBD'(?X4.UI !ZS,ZO? D\$B\45:?O/M\8 .[@Y'W_1,@3806 MB;+DA??;YYESE9&{$\B9"U"(YTR#EU1%5HKBS@;C4TEE2+,45FVA/@G;J4IEM MTL-4XTXM31R$XY&\5NUL*E/UU@3,7.2,....X^.>)97@O>K? 9RF1ET M2Q[K\U]$\I9)QN20 M.X_>,A)&V85.MB@ 0C#8V:,9)AXH_5%%F5*+[Y;B578&O.'&_"AO)D&F' +Q M>!P,4NUJE'FDB/Y6(?5U1Y>8XE?BM^N.,LD=F\Y+8M)D_>R\> <[.V8(9\2T@ MB,\#N<&Z);F9BJ1VO(TV02]/"FHS<(=-FGV=[J;HC4)";GRU?*PY*T400'9/ M0C&>3.^25?R%]7VQF#>]H9%NQU4T&Y-^M<(]O? N1[!'DFE?/>.A96S.5/>ZMD+Q\^%=T*TM7'HS'?HZT&>" ML?[-3OV^1%T*0>K(E> ^Z21@?O>--5K45_%QF8VD))MH^9$[!"MXL+XTH@\@ MWW5L*XTV>RP)#:6&7WEZ8ZN^K&5M@U'M@P_WOB4)4.LG=+,2ZP3?VG@*75)0G M28C-9E=B==_)EUGS_%U:,T=U+.VYB-]L#)U(:1Z01Q:'[^_$\WZ+*89]ISNTQL"U=)C+TK-T]'WWL)6*N*;&,\ M.+HO,CD425-8*G!?'"%"#Y3P/G TE]'MIO:\V'+3\DE/_HD2]2G?S2XBP:T3 MA%'1WPIJH'(=UGW6T7V_203+AC>?Y"',@._MA'NU6Z,8Y JOQ.O)F(.F_ZL M&8DI^>0O>8K<@.*EFA#XDM8^2-E6WO:07)/:E3Q*+-WTJ&L2*I M2F#6#2*E.PG%5]5PSPI=:]?TVG!RBNQM*%D@SL.FTVH5W55'):5F.)TYKRU0\U+!T=[_9PH MPR.H'50Z(-X6FLO..N;[W+:.P%\8F;EO8LJ5{2H#)?;P"LX4IH3E8Z5'MXN/?V MRP6[9H||B]Z*.V\KBP07CL97TOA.QHI?(A7W"W<[;DUMJFR=4J1?/%TS3OM'B&ZZ\P+SI<:.8I! M1BT@5E68E4{9]@=#M7YHUR4.Y)7E9#-,%B8A#YMT":?OB6S]=Q(X MPF!NWDCSVRY0"8TUB?,,,IR\QIO;7"QW.*V =&4%P8G^B;4VE,/?80'-=WN3 M%8!@M9\I;3L!H_=O=#?@L_| [L;A77&F>P0Y 84A(=8_0S1R<8IY,JE28B JH M&ZI91)1DH'X4,]2^^#?,!-D!/O$;J$!](A[YL-RD*;TR<.59FJ_.-3GZH1,E ML:1NP9E2U\^+7_SI-F9UTFN8L@NI?Z(S=S%H-Q]GMDYAK%XVD'1X"3KLNB35Y MT=CK8]H^MXF3OP6\)6RE^>)

:MP<1&&\2%)(8 K#PD"U\ZI-M8]-[^$29B&ZR4O{N)%$N"AM.TRM8R&IXYR5O< Z%>F#+\|$^AP4BT)\'+WO+* M^X7JE"-AI?US9J_?]W;@O@N.&M)UB-TX:E'?LM$^-S_^MBW]

(/T3C!.Q@HDW,5O;HC|!6A"G-U0RG;D2/A)^QQ=K9ZfGZ\7[-MN"+RS"-!4%.0?9>>F9B?XXRBJ0^T^JJ2!EX)lE^IO5W[7/&.77L7/IS6NYH-MEO12KDLB;&2I5M=*

*(9O3V[Z+Q>^6%UCBUU-)2;F/X ^4?G 5V0LJB=L2A M?]I"#!C7):8F0#*I%lD29=!=G" ,?9PLW%[WKRUN=G+6]5OU"C>W5)\GT*(^A1 M#Z6I M"=L0_C CR(S<_6&1F*P'.-+>M&6!E>9)9?2_"G3E|-*Y5[LZKY-NZQOES(?X M(-Q8|?2!,<8AB>IOOGP%6I7.1(9)?72SQ/KXOA^K_0{HQXA M'.K*(LMC9WN,)25KU&-L?F=ACB1=2EX7Y)0C6@5-G-]:F[.f:7.@;H7Y+"2V M-8$"!>CB*#&H@92ZF;AJ3P9E!0&H8>QK)-4B@>964Y%.])+ MAI SZE1U/?WVF$7&1XQ)MF7CSQEY$Q&NQP(UBP@'M;K_69A#+%$\H/-T5VSV^93)POB-@+]GM*Y]>VDOB2.>8:&.3H%-[):+V=RAE#[__(1G$>;&L-Q\DL-Y(:^%55%M;X,%462B^T^FZOP4>4^\^FZOX6_IQSR"%F:!DP5BP=_P-L#K4.,S(5'346 ME>*

*(2N(lJ)YKLA6G,B,.1U%X{F$6Z)_'RR{HH9V%.-KSHYQAZSBG=DYV W09T MKLQK1EY3T*:A7L-/@Y&SNCX<;0:B.4;8/)#HW@1#"B/# MTD5$5R3;F.#LDO/G_(-791HRU"L3SN6)OX LM>&3$+R)#XV *JF\P73T<7'P8V&Q=3UKZRX64BH.]N(_QL%V3V6CT@LLONBJ M4S7OF&J8O_ 8##-QB%.BK,DUWW8.L!PM)\,/O.![VY39~O5T2U!\[YX>X0.S*

*MC5]!M5)ESGF*AM)#CQHI:AZC\=_^BA^D}1AF@E)9>BHRG(Z,]X2SZ)70U!_EC_.;#(;.M'XM9OW7X]R\]Y":,/NU9I*A|]4*Z!V?G$)MK69./-,+E6S\@6RN,A.5"!0-Q M$%#*::*

fB("!"2YYLQFPM-%U8-M_ZHL 1%Z8T+\|6=D; 8_%C!8%R;POZ:BS M;M0(:BUK*'U9<|(0LWS4T,M+0+4^9'7PZ|_'S%5<+5>C_B@M0F_)HT<85L+0*

*MWSIP^7'UHOT+"0Z.QQ292^+1'49IK$Z-XYZUG+,6,P3,.X_2+M!]WV)LOFX$-#*DK7CI",$1B*CSMH21ATAGJX\R]3H0^ACL*5E?TSVY_A&0";*+*

M%_+W>9;0RLKY3I\I9+/W9A4T;LT ML@=5-!3"UN6E9L0\IAKE#5AH;%V#OO94^RY 4K25[(.I>G7E16OI14 MZM:TCE6#%OJV/L+))8D8%_9_Q6'$,C;*

*B60TTJ)\#5L3@5;F"D!I_VK*6N^% MC2&EEHJ347.#CB^MT-D*X. ^VQK2-(`M$B]!:UD:8VI[0/!4<@W^+9AKM93;0 MQX"\.WXK>U"BRC%-VKT%TAFKK)IQVE' M>08U^MK[O?&EF[P+3O/IG@FO)CY(@#//!=*H'5?;!BN02B=I(2R+\S#ZX?'4VYK*W1[K]UW&WL6F,8 M7G-[\Y5/5_%811DQ)W*%AA)R2-)%(W2P2A^_M4KY&W<^0Q?*

(!%Y;Z_W:@7^.%V%(M\0[D.27/(:H> 0_&(]D;*]5;B>'IUP%)BG2 MPX.ME &4EM^9"7CWCO7=<9,,+L]6 Y8W:G[@\B K_3PW.]W=+(@Z)6B&XZ> ?*

*M<&COE@O<|"'ZLH+@1!GE;.E6 O/%=@NYHN&C=0+I=9YG*HS.9%EV<)X/OK>M M@?8%.6AJG*9(+7NT'/O.N[*.3F2Y)6X[&X#[.,H*MYH?G#R0-E15I4MX;_?$*

M"DDV^#1#"FYEN-4)6N<|V,%38|!00X_%7(@Q-N>*\+\-8GH_RT_*W 7.IW" MP*74&YT@@Q>|\'$83_W!&-.$SCG UTRD)1$!.;(NMBAU-\1:O/ MRQ/ L-F]AH3-*)U4..G=D>?(##*

(W9FZ"C=V6NR<[;.? 67LNT/!0E5)?8 MK,KM$]D2jKQPI'GL0*K=3H& -#=@Q5?TWO?>1 SVS[. 2G)ZCP$Y4DTEC?2D M,@)\[/2F6KWD RZ71 BB.X/ZOLX!+46Q32ALY

\U1MYH=FT_R2G/-,4.!N9K/(?F#$5:QX9]DN=L7#C>'?05C M,_\DVB<: TK!WL]%]?1>$D)3)34&&N.X78PE_(9L?H"QH"4FTFY8$FGF&3' MW8R@(C[=.16#S:UYID^^M,L;;O*<1 9-T8D(QB-ATPV[!0*+KL\QR)I;S9(" M7MTZ47N>&;EAL;)-E1E(Z*=I>SRQAL'AFLA%#R'WH]5],D-FZ$_\[6W!=2 MFX<;VJLL2M/*8B"1JRE2 4D9ZS\^G0#O D"(=3(2:?(@*

MR&XT^OC0:+1,3FCW'+"_#O-G[SF=:.G:/KU$;=M.6)?("V>'@]^6 T6IA+X*E Q)@8F"=9^7>G\,M=,-`$MR3FCY.AWD91&_Q M.NI0%%E-M/QR6@#]22#_]P$'ZN.V#4VW%%V/?

*J/NOGK0-+^'8"):9.=PJ|/7 MT WC*YF1G@0W;8MK=YH$=LMK?VH[QZ+F[_1S=$AI;W.^'?_$T7NTR:M09B5HT MB7$DJ<,*

*-26:Y1L52;S42A;@+Y)A30VC35]%F\@O%$GC9%@U2M6BD,O M^;B/$'8C?;7;A_9K)>9I>LJ(50D'**M6+Q(TD"VU^N<35@@E_D0*5[MF;6?*

*S41V+FX9*IGSQ7=8,!LB+2+I[&LVVPHM5L?5,D0J$9UE=2D MDWHZI,N,6FK2T?;DM1/9\'J;.9W3*T?K&LY9TR+55W2Q^I& MO2]XU@FE0J|86J+0:#9A0HO!K=+'O88>*

(^\VU#RB]M9"]3'->N+=>^R&/M/J M H-QfUf"W9VH%D3OH,.6BQ+ ^\01__,<=!"G0:6IX!WI8HXA>?6#%S>D92+@/ M"U, \(#IG6Q:^\"=0"G>[\?>TN?QI5N2\90E M@[B$CD"'RM?-

:8?H"'D@U75-KF&;J.5[0/R.1[''>X]UM[_PF271>Z3L_M#I)=DUIE.1.FGK="7IF)_'#4R@Y0)C*^L$BY[J):!%5NY$?_/00 MZTYY_VFFW!D:S76>;I@1RSR(MWMN'J2*

(N!>3/WR8[RM32)D>R!.!,ON-" M<'TB<,&=O_S>N-.XZ8APN4L$!&=OW[3=]C-'%M]YD|X8RK[>CVY$)/N]=U-M@"D/PA5XKI.(2@-J,V$ 5-QF0C? E#-A

Y]HLC2C]I\&?P4MWG3#3#=O/4% MQO6SV'.424L;7!\FT-1(N.)'3'C<50^$;YG2T7CD#(%+(]3MI(,+OW&RR:TC M]MHIK34A89G.P$&MUFOXV-.GTCDC=/]4CK[#D) %-^S-[K2X##-

*=5HLCJJ9/M;G'K/&E5@B$@F9;8@8/1<=P,&)B;S]8]P,A&N]>U3:H/7I/> "QZ&/ZDG:B! M@Q$BW@U>:3!"Q/<[2.G>GU)]87DP_I/_$OH[WT,5HB8*OOPQ"GP\&E_>*

*MC]<)@5]3_>UI//:72YB, ^#2,8I9!*N(TB/F\]D:M00:E164 " 1TH.2W=;/, MU-R<|I41M+BGJ4Y,\H#3%%P;$_;I^PG?BX=^+XA)R2)?.%(W2P2A^_M4KY&W<^0Q?*

*62>E4K8MZ&\Q*RNPD%*T]&S<95:.(JB*94#OFI4!TAXSC!2UK-MN33F,*!2L;H'^-T!#HPQPV>+.,35^W=F<2*%E_3(]+JC5T_F_$2=.5/*_M$T)!1I:1Y-*

AUQ$G/&^KYL9>0ICIR7/YO=C=(79$WFB"DY^T]WWWCBY"F=3UZ MD?K/]UVPT');FXT]!V&*L&NOL$0+CB./?+&Q)E.4'NOXKP!9S?Q#2L^ZL37 MQYYXXDV$CC*

@F8FW.B-.4VP;A3RY5KQDP$*4D!19&:(TL?E<&,&=Q_S>N-.XZ8APN4L$!&=OW[3=]C-'%M]YD|X8RK[>CVY$)/N]=U-M@"D/PA5XKI.(2@-J,V$ 5-QF0C? E#-A

Y]HLC2C]I\&?P4MWG3#3#=O/4% MQO6SV'.424L;7!\FT-1(N.)'3'C<50^$;YG2T7CD#(%+(]3MI(,+OW&RR:TC M]MHIK34A89G.P$&MUFOXV-.GTCDC=/]4CK[#D) %-^S-[K2X##-

*=5HLCJJ9/M;G'K/&E5@B$@F9;8@8/1<=P,&)B;S]8]P,A&N]>U3:H/7I/> "QZ&/ZDG:B! M@Q$BW@U>:3!"Q/<[2.G>GU)]87DP_I/_$OH[WT,5HB8*OOPQ"GP\&E_>*

*MC]<)@5]3_>UI//:72YB, ^#2,8I9!*N(TB/F\]D:M00:E164 " 1TH.2W=;/, MU-R<|I41M+BGJ4Y,\H#3%%P;$_;I^PG?BX=^+XA)R2)?.%(W2P2A^_M4KY&W<^0Q?*

*62>E4K8MZ&\Q*RNPD%*T]&S<95:.(JB*94#OFI4!TAXSC!2UK-MN33F,*!2L;H'^-T!#HPQPV>+.,35^W=F<2*%E_3(]+JC5T_F_$2=.5/*_M$T)!1I:1Y-*

AUQ$G/&^KYL9>0ICIR7/YO=C=(79$WFB"DY^T]WWWCBY"F=3UZ MD?K/]UVPT');FXT]!V&*L&NOL$0+CB./?+&Q)E.4'NOXKP!9S?Q#2L^ZL37 MQYYXXDV$CC*

@F8FW.B-.4VP;A3RY5KQDP$*4D!19&:(TL?E<&,&=Q_S>N-.XZ8APN4L$!&=OW[3=]C-'%M]YD|X8RK[>CVY$)/N]=U-M@"D/PA5XKI.(2@-J,V$ 5-QF0C? E#-A

Y]HLC2C]I\&?P4MWG3#3#=O/4% MQO6SV'.424L;7!\FT-1(N.)'3'C<50^$;YG2T7CD#(%+(]3MI(,+OW&RR:TC M]MHIK34A89G.P$&MUFOXV-.GTCDC=/]4CK[#D) %-^S-[K2X##-

*=5HLCJJ9/M;G'K/&E5@B$@F9;8@8/1<=P,&)B;S]8]P,A&N]>U3:H/7I/> "QZ&/ZDG:B! M@Q$BW@U>:3!"Q/<[2.G>GU)]87DP_I/_$OH[WT,5HB8*OOPQ"GP\&E_>*

*MCJ<)@5]3_>UI//:72YB, ^#2,8I9!*N(TB/F\]D:M00:E164 " 1TH.2W=;/, MU-R<|I41M+BGJ4Y,\H#3%%P;$_;I^PG?BX=^+XA)R2)?.%(W2P2A^_M4KY&W<^0Q?*

*62>E4K8MZ&\Q*RNPD%*T]&S<95:.(JB*94#OFI4!TAXSC!2UK-MN33F,*!2L;H'^-T!#HPQPV>+.,35^W=F<2*%E_3(]+JC5T_F_$2=.5/*_M$T)!1I:1Y-*

AUQ$G/&^KYL9>0ICIR7/YO=C=(79$WFB"DY^T]WWWCBY"F=3UZ MD?K/]UVPT');FXT]!V&*L&NOL$0+CB./?+&Q)E.4'NOXKP!9S?Q#2L^ZL37 MQYYXXDV$CC*

@F8FW.B-.4VP;A3RY5KQDP$*4D!19&:(TL?E<&,&=Q_S>N-.XZ8APN4L$!&=OW[3=]C-'%M]YD|X8RK[>CVY$)/N]=U-M@"D/PA5XKI.(2@-J,V$ 5-QF0C? E#-A

*Y]HLG2CI]

{6K8C_;/D+/_3-0\KH)VAH) M<%[UY3BD^GL)/E7E7=N.'\F?22A]L93]"(B07:T] D%F4SNOE84#'6!-0 MA&O]74J5,^.$>KR+S^QNM:.9FJ/16R(RYDUB!

{=2*%E2S7BAHB_^RCQHG2DB MA/RYIF1_6F09DH#Y?S.9NUG8 [5;D]RQ_&9;>LFF3D^5H72[$;AD&R9 M1!GF$X^[2$C4?=4C,&:E >]"8^[[$W+<1R V^A$XQNE2DJ8' MU3P-7[,>=8/V"&SDB-Q)DOTE32E[*)\B2=D=4QFQ[ZCM(T#!\A%8H_MW-/;[M2OU^~4-]5L-OZ02#O]2N,1P!3^B)&$*_1:HB6CT"%8]9&=$CT"?C,]5[,A? MD.BJ83MD"AC\I2I*_XYDK2[\@:R"/P=]8D+T&?^4MEW,OV,2>5,>-=C4$B'\-R*I1EQ%[/10#Z^Q.OFWW\WW^-1'$0E)63[#M*? MF&]LGIFPOMC\2]5!%/QF3;*

<\P2=U5'-2VW5]TK*M{)U0GCBXI:JZ1%0]QI8 MO!-ZY[/L35_')P/[V$H@O=3.Z)>IH M1"^Y&!&XU>8SZ#^IO=9!#C>C=7'U0(_WU#O"F4Y:E[-%G=,-FT\)DI)%]=$D MJGPGI0# .DHWPOT]]@X&(816I5E6'}91B-)T%#X.V%L>52N5+O^ RUE9GR'3 M:UY//0H)SNCR.-GYN:'=2>&>5_^J62]4?YU2<,7Y4+H1!H?5O+SRC]I8.]BNY

M3BR+6(6+CTBQDKSRWO0_S!#P:E.66<9UD^(]-AJ5E*JJ\T@A\,,2*8^4P7-MNX(7C+:+)<[E!%'T+_]YRO%,._'NKB&Y3\]/_?=H:1Y?/2*5UP!BAR7DAL,:G5M&~=?

6Z'SCX#E3/4T^T(.MI*D##RVDNC_!""X M6;[SWWX$_|Z/?^-U-_M@D4?@R6Y&@^S/_"5)[+\ ]66(SU FA"<&M<$% M/YX'I]_X#1U(?!A 9]%A2'WA_K+%:C\> ^I/.SNMV-X*,#/: -)Z]6=

MN;LHM0D%%L:5#?;G.R/A$A1W!1ND$6?(I_2D&'(T<^HK_^#1_#$ MT233$$OT?#N1W]G;]/-&GMO"NRY#)5$2XQG=K(24RWO M(8//]H>:."$G]H.@=2QV&I5@-

;I"7)01W9TL3:U^(GU)AH*=4H$%@=5=W,.T M\(F+@.ZQ!$]"Y771RSI)X5].?@39NA:%]9[DE//$R@:K_&;'(?RR,BZ";P_R7I=HY=W.UA M$,!Y6\+P[O@\:%]?;9!0]3.%#5HUU(;]&4*UE\

,7S/349GDV#!\MIY3,]?1 M-_9K(^^!\OI*!>03?CK]>M**X^"EIGGOHU0/(X3R5X[4#?HI^-UM&._1(&:0[M4AKRPH[WWK3+@+TQ3X*)K$EW29HI)PL"\+=-

'4NL'=+Q$0" M6M!9;NX_'JG?!(-.W(S.M$%M0Q8FJ1.+Y'I?(\RL4R6/<<)N-,.7;_;GD7RQU1B)@PP]9+=""%E!B M1SR?IN0*=S0:I=

{N4IS&5S]GC$2PME50HK:=430[A#+"72;$[5S.X&K(;B[H M](Z]24*T>M5.0$PJ,1D02O_QR9]!OP6>&G]N_S-A7L CD!3VL-AZ4>(I_T'D MTS_L#G

R%&IB!]JU3/EHG_PFH>V%2<;=4UC4$W4UU4@'E_GV(]+)-'0-#W M>]V!Z\Q4@Y'=N3T"$3K?_.C _)YL+L'WM. =4(=595_^5B95O MIUOI_]ZA4"/>]4-

0U)PD5;;E&BSP[711{3,,'NKW-$2]&!^]!;@'0=_NI"(^ M.;[WMQ@9ST>^]MU9=:N^N'(2PL#Q^]^BPC^'^D>&8G M QJW\]EW-V*/@$\7V2NG-

"!#1N1PM@A;$=ZW_+=!D*YH;L"_DM=+0\"M@$;'D,T 'E3 ME;!P@. G9+N/ZWNZ@WA_B_VG66D>M$I_->U;AFPQK?T(7'CN\HLVUJ?LV\LU MBK*_&T?

@@/KK+!%/M=J?3BO5ABW7_1A>CG4%#L-%FH*T?Q{41)].W# MS'C_GL@XOR]TJ\]:-#]F70@WM#EYQM\FXBEW$?V'!O83NV"1L) ,R+,B^U-P4FVW\'W!Z:VB

M/+$_/]!:IR=J,+VU-F_,7@M#3R08_6[*/_RR&PWK[NU8UM2/[NGDI+I;@]G6 M:LFZ&Y:4T=*[TV'I=W,!0X"S[^]PWE:ZDTJ1/<;[##FT^\)93K*VL-Z!F+,'I M:A;3-

759]^53)4]E='$L7.V]KiLH"_QU"3%.U-2MD\LYZ+ ^^,$] MH4S"P;P4-WW"8MI" /9*^]E4+ ^+/%^B'>3!S_+#*'TVE3P+ M;T$-;C>H48,5LJI.%'TS[DR8Y"W(P>@H8H'P'

\"DZM!(.=7W_]:=/DM6H&SS.J#N8L$?@<_9? M$H&5)&?Q6_\=I?E3)B/007;&;$%V!?I*:U!H]"JY(+#@3;\!MUJMDD57THYY[E&3I!Z#K*4"2GL+6\W\: LDU6.27!KC($0++

TW4E40SVR,@ MOA7S%/>R^1YSU4CB_5.H?PKU/UDHDKS/N7.[<3H0BX3I>^W9>F#YE%,RI/-8V/F;K+BX9F00$VP'TY^3_=P86 M?\/,HI/>UPK+'T+ZX M@91X\RF#@PP._Y%S?

%JN1BXH,417#TVI;5ZG7'8+[U4ES3!K M#R\B%2KAZ3+1E8+"4<_/1P!3]+I.@T?#%K2@MR2W)4=#\]:DG-_XHL!+(WO' M@_+]S>ZZ7(07F_7@38"$[1]^3D+RS#8^0<,)

HLQWFAK?S*4HA M^CH6\]+#!9'TN(=IL3]7[\KM!*01HZVZ&;Y$LEL__R#1]4VR_ -\/CA#9XB? MUBGPE DO73=L-8Y\?"^=9:68B8*M?U0.PXOZ23[&>&?]6#H=H>5AS2% M.

!8[.,;8?0F/X^$>2# DNO2_]U=]J5+!*+|^1KT.S^AN-A$3"9$8/=8H "6- MWYE8N#N6Y/X*5 B1:[Y]F>[IARLQ>P+HWAA/3^65Y>WBO="9L\1-Y!"U9[0; M+!U+7=|"-ASW]"G7]#$RKZ

*$F52(L?K>N@EV6*Y7F]Q2YC_9W/\-^ M1*,=ODYUYD/L\N4UBF[NGPW3MHO\(K)^959:V2_^6J3WBCN"",@A)R.SJ @ M-Z-]LZXN]PE$Z/514%I$5'PI9%>)

M^O;^:W;6DD/IAE=G3#2['?;9CHYV6LGF4M@Q#!-%@F+C>/-Q5]K0<'LZ4%G9 MJBAIGU'13F..LES^+FZB?;<=U):]%_LV^AW]]ZML\83IW;5ES?+ZR&D.QB7) M?

NNDF,L@=<;6CS1CX1*NJRRD\G9]>=8-L70; 8O1T9_BR8,?C57]@ M/U[-)37F=+M,,'>5K>]>,W\; F9+GLOU4/)_?BT?6(<(*CC;QL_$,&Z>=FH1 M5L$YR#4#DT<-O>+

<_4ACWP1W-D)0"&5A*H/&;@VO$86Y#O=]L-N=Y>6E#.SE MVDAV^7S12GJEW-.I7NC(*4R*(&.CRKM T(.*+D9.>M]ME7DE540:6-P6BDOG MG/)I76E,%:Z-+

TDA/"W"D/_#I#YRX>2[U(> 5],2B,>XS)>E8R>S%VWH:=% M^U<>9,(VCW3H4UQ]7DO#8E+O%D'I@0OOQW6N1XOG%825MM4^Z[^^[=#&#;+Z M)HGWR8?

TZMNA.NK\5L#^_(4^-XS[/J_Y6MFLD:XBLY@S1QI[(M(X6>P8B]=$PU"\7(RIUL=EU-HQ#08G'67)>$#"ES[GF=Q)4E!4)1LH<7]\$PBAF MN$@.#XB\R;2#^_T_?

1((%jJ]!&L@2AVP;-7R+Z,S>P1_+718*==,YFO)XQ#2>Y MQ$ L)HJ'F)KH@AZL$7]O%?+,.4=W?#&93"/6Z%\'P+E:I*7&&03'"\A$DHL[

M?'6=B*,S74M+Y:T4PG3#)*VBKK[*/4M[B=1S^3ZF/IH508PX>=<7PJ&:XRO<8 MO7]WW#R[U4T^I(),36]*L^B5X',B&WN%*XV+%KNEJS)E$/2%-$ZXX/;&9U$7 MTL&[>[%,- -LM|:

[G2F\3,26'"&/D^XV,16+5;N[48RL5^6+67ASD4"$6;2 MQZB$$J4E%N\O+V:>7T> &=^3RFP>(6T3I]OQ$@1VG>KM9&">,9D^D:E.,H&A M-+++*B+FBY+6B)"&^VL,M55-

>&@5N@9W24JT5-6'B&0I5=8TAX*I.\&+9679I M6M_)4D:I-NZ*CA6W8JQHPE&Y*+3"\KAOlC#W?Q\^$E:?KB2T?XSF?+70<.SCBDC]LV2^)*(K$\1 M>"_&"V"V\VZ.

{N;H7'5I7.J3QNF']?KMQ"I@<)BXE#|@Y=@L3]"$IX.#8M2* M[SQ7(R3DFB=+G%43(.F*Y\R/-#YYNKLB<|I)-YHA!H>O:."$9IDP\CED4"E@6_ M4I5+Q?;D1\"MV0& L'-T&5\I=/

L0SQP(K;2UFKJ)VR\=B*Z^G,_PI/QA6T(MG/Y"&W/GHd;XBLY@S1QI[(M(X6>P8B]=$PU"\7(RIUL=EU-HQ#08G'67)>$#"ES[GF=Q)4E!4)1LH<7]\$PBAF MN$@.#XB\R;2#^_T_?

9]F5Z&$$;TTFB&5E'"(W?P M]NZ*[6@MHX /S_64O574@-HHZT:A!D3Z-UAZ/^HA';N<,+LUTI]&R?(=SP0K M 8'F[JA_*S0\.8 .['$;?-G-:)C%+4ZW#5^L .D5.@/)Z>!+]]>D[4^JE1

MN C^QRV#)]].@MXN=]4K9-9W"OH_Z_N$B?9>>+%.0,?G]Q\HRCF^=U,K+$DR ML!HSHB^I53560X9LR:V->]&X Q&MJ0^!QDC6BK-*K;VS MA\9H-

IH&GI=X=A)&MI:UTS0P3HO_G$81R#P53ZGCN/8SXAMFVW40\KS91$FUY ;7FT?-%89:0>T7BQ8G.0$ MBSH5R6_*'X$@)?EC;26%F;OI#=(<9<0R5D:Z1;&Q_3NO'GO[4IL

M6I(,G'YN9BE.(0LYSLT8R>DCTO>GQZ"#5_2\6\1X.V\BNQ*%O\O!F!R<<%DW MW?@IR9F BW7)6.#'AM*+&KRKAG8H5']9MSMNW5/(9KQ[M^?M%%7PP2;T$@GF

M>7RWMCA^D+[*&5<_5/$D+N!Q.PMT'&T-&^%KDYKU;MN0,O)F/!*C8"&S[JXK&Z3+-XLQ_H,Y G:+@VNWS

MH7%O)ZF3H5Z_1A*"3C#01E:30[H>"%K(CM)W\6:K)PXI:SP]@\&K@R8.R*6: MCMTRA^GQ>V=SE+)&YAN2;@LX)A^BV\[A%'$%'26/X6="?:BN!';-K;.X+^(-

M(B%0,W+\3PM=/ENR^"]H[2/;%H9'I)V^>6C:-)RY[2:PCETYG-,0K+H$2SO M 1QI:<,)2^ 'M(X*9HL#?/TB4GK@<2(=D)D[C>V1Z5]XDC/>)OM3OHT'3^A)8X M*O$7N\ YC1_+;

!TF#8:U$=PE-T_E<+[$=0YH\)?8=.$+N?;JS#EF=S?R%;35M2JH9 MD6/J.B1!SU8V4%%/&*S<+S!#SE2U0!X=-X'\SKTL_.:TM;FYNE&3J9CE_;1_ M8U5HW!VLX\OKS0:'=X[=;:*?

I(6;EU.MV38>TRUS8-7'@)8!)@<]Q:GD*2K@UO[5.%D.-$^^U%?BS?!9@W8O"VU6KGF.C MQBH &@%NPUA>5L5#9?KT!T4:2TB*?@RGJD54F9R,3+T/EUM;/G4C$2I"&$5.99;JK\?

@-)0%(T M2@=^_T3E!+ZsNW%N<6IC7/;/GL$+'Q-&QDK'P'S!%0!UZ3"Z%G.WI#[E(I MJR/0IUR:E./UW!%WC76O&\O_U[?*0^E]#Z?:1PGA\/DS!uA/M9)EBY-$@5W

MKI>U::262XH9_LC1W:)W*_+>_KDVCO\M[-: 8G5#W:<8]O+!'T@+1OCY$4*35 MD)?6[AZM#.FS47!)7P7_5RUK MMHIF&&BL&P8E]K4Q.=K@.Z3#>4ZD"Q(1[?$;(_09P&!#E*>,

{MI^8:=M)SU MK)SRZ,,T9>DHA2G&THUPD^FE52IZH39:G#4?/!V+.X/OWFE#0_$'0?P%$XS" M:?58("KZV26-:/S46+X=Z0"J2#)LS,E?ALLJ*?N." VX+&:VIBZ8M8KY_9-

MY@NNQ.DMI/_C-F%;X]N39 HARE6Q%X*M;*3O?5[\8B4.!)=/M1A/R'B2T+5 MB2KR[//S]UV)O%5-8ZS=NYEF$=YR;&[-]0IEAIL>^]7#\;3]N:%VZ]?:8) M#OV#7P4W:CDBFI$O#

{BO:LD0KIS/$<+EF$"';IT>G!]?C)0#<=>NF49>;&M]M-4,22N/G)/3R+*KE=''9U%A_[E8)50Q1A;KSY3R/3F[=7@PYBO&FR79)'+O):-MW6L]KP43)

<7&E%SIKC7RR7]1SRS_HE<:NNM;I2TOO+BD:GWK&+YBAK/-YJ4P MG2(;U;27![MT<:M3WY$DVA?L'LSF5"98#81M,44.:<3\;47D6!E6W!#$=',=KU$6.'Y\LXE

M#8]Z/%IU_HFB@2/CG,S'3= 1>8?]R+I=0911.,!>1VQM%WSQ'&@]HY M\&ND&*$2C^H\'1T2LL;^X^8)YI\:)]U))5 MN\=<^]BWVI9IHR%R]L#:D%I

KX4'5JB>$^E2I<1"XBUATN3^(U-U(EIAV+IJ#06&YUZ[EG83W)P=7IR" %>T]I6XI?AC !98KJ:KDS%<& MCAWIM!

{BGV4LM'$A1[!RD'H1RQ88V(UNIYMWJGAEOP8W86UXBZIQU;>TE $7 M1C)I)+ @O@T4(FFITD>)(IBCI$,_%.[<%#-QIWF#W;%JISW=$R012Y\INV^H MTWZ^DR\TCY-

&3UF=3U.\9A(("Y;#P:WHX2E,C5?N,D@FTQ@=89\LNSV(V(A MD+[VM:>],=D7XFI2=K9D!&=^A"K$3TX,0M!+?)2AFSP?H[T&AI'NVDOH-WV(-M2O/2@=?

$X=0V=^/#OQ6'!F,$OV446>U8CSZ<4822Q%>&QR8Z%DFI]!RK1YHDR MDJX6T_)_(4BYKX2VJ"K^U0K8'_NR.#B#RV8U">#P!VV\V>RMF'%CDEW>NM

M;8/*KUW='9L$8G1$Q#:@H2%#N1WY!O1++,YC+(U?5DZ4=HY)@!7A;Q\IZTT@G-(6P$58]XR/ZA_L-Y'B&Q9.*BDBPS?GC!43RKW%6INPYQVH@O^G&AGHY'.U[.5O*L

MIY;@@.862K;?5J?A\1$O6GSFI_(NZYOK2 3]64I>-M7$F!0E@7HH4H-51F>^+%ZI&-2. M 22LO)FF\'7^E,8I-54(Z8C!VX-1T9E9;KU>^O1+^7 QO\CG&JF8RAE_U/:*J

MO/2MA.HDLV%(KW_9@5<[LBL2@%_Z_3^>T/@-LO!*I{G@KY2 _N%_+\R3_|C MZ8^H#V46L3N0M/KT<;VfI86!U.?2]&++$_DLY$]5f\K0* 3]_P@5,P\116XUB

M,"DX*%"=6$YA__MC/3 :2A,ESF!^3Y1?S?-,\;?ZTM7S^$PKU0I*+R?VD[M>?@D629.5VQ\?T4;-QGK3KLPM4L'_&X207^N-(V?%V?W4X'1# V0+;N"\NH+ ME@B,*%[!'\[

=#=KWKP_IOU4QKGH7BVOCF3O:5{@2216X)?!W$D5W+_]/=85 M%:9/>$##K\@8WZGM_Y2Z_6L3&IR:U Z9Q<41=V+9C45(19]OLW:571Z39Q9HZ

M%A>7TXQF48.LG<@O3RY.N$M=HA%U_8$NPRLR M'5Y>07M1\;WT%_-0AG=3<$_F6M.$2)V_PTGfL,Y 2(.W /&'.I+4]IV-EU M_E=P@A933+)8#ZfLWR_^&V0X]['*YI"0L.*2.QTW\-

DM&/F9TR/-OIHENL&\ MK8PTL$%6.M;>5ER&8G3+T3:O^12YV"@$>,218N*]EQX=_'R71ZGISKG M+9E[O.MR2M1HU(L?ZGP/EV#EY*J(+@H7'BDK$@%C",;?T-IQ2125@3O*^1H-

M=#@$#@NZ4)F:K(7XL3>_^P#U\WN?U>LS)/8*T3\[4;G9^A44- M8. R'PN<$M3>?>ZAW+Q!C;R7S429_#M'9?[?@)+8(_!B+L7LKHE\L:+A.B-B M#N+C9VR6CE0T)8EXIV

SCC9#W3HWM[RX3&SN(&)27>C/N77>0? 3@IPV>D MJBS+, ,^<[ML/;G+7&,>%YIE(S:>/@"U7[^XL]2F@<4V1? 1&GOF^_M_*]E"^)@IW>N4BAD%-

GEOORP+7.$#>2+5Z9'GY\I*2OW:1X0O=S>O MOO.E#2Q_$V4J%6NY/?U%-2^M_$.KMH"2;W MG:HL > U/_C;5K$1U5\\Q:05:N%8[OT1Y M0]_.N_[!^;HH0&_^>D_*]@73"K

M,YIU]YD(CQ;D[UM>!QXZ1-(F7K)95JHR691YN\|VT",P99BV]OL(&R0V7NX M,(]0^#]NMO])^O\,XW(51V]KY^H1N;B,IBJ+C-^_):TG*^$CO[!'6G5^OG^ ME'9P.,V0N8,;C$"

[GW\:U%FG 9&$16.Z(5ISW2>2 .E_I$M0#<9+ MD*C!E&/KMD.DR:YI"E2L]&N!\65?6N-*?UO_;-^/1OQ4W5*

MBLQ!5HM4J)QKH\&78+:7,"D6!&U4+D73,VSZVAW.H,-@8RU*:|QX2O*5T]%1-MF#\PC/J#Y^=BPH,!^R-'P3^,/%FM",(8_Z)T]K\

M(!%M@HF>OM;+,2QN#E_"TR"^.P_T_%!OCM__]]^-P'#DU_V3=??))(@!>2T8T M?&2=F3'7:I#<(C9Y9A>,M(?)>2$<=/UKU"GY;U\GEA_SF.1_2&O^JP!&?13C2N;@W9)/'YF M04,;[?

W(P-.3768=@VM\[:OH_)6-=N-4>\HW*EM14QCDHK&QF^?IC>_M//4XDK30U1%$!8DYHC]*/P(>?-CLZ7>]HOBQAYY69Y&S"7?M>5MS7CK9<", MR5CC@'B":*)KP+-

LJQ#S<.M*KV^,4'Q(MLW_]=ER*4!8E9!IKD[=TTL2M>K=P MZQ*2DQIJ6J*+ZM7]*S;7W_=\8>4(7P^%&AY=?(;;<@M5&5)P;2AF3_,O+-

D_+DO3%9$YSG>Q023,4$)2W<&50[X88YWL*7^KXVR01M(S<\$;.MB#*!C^\]NX,[EXUF=CI>_ML/FX3(YR:61FT:N5 PE41Q.VVL8BT?@'KV,#@?]30.,-

QOKXKR.,MY';PR=QM2,6],F/6CI9?'%* M\RDQ+Z!]>OF'[_ 4@/(3I_RXK6N$+&QO ML;&IE]

W\:DRU/NRT1URE3M+4P@V$[S"QKS[CB56W27AT=X>]U<5]FJZC/4 M:2?L';Z;_G&;U@+SZU#A7[R4<=VL[YYMH#HUHK),\)"B:]K;&NN)]W7UR]L= M1'R*G_R.I<8JA3#**

[C5>#G&F82U2"97:5R+6OZJ3IP"]3+@^&3[!_^4OXEY MWD*8IE@MT7L*MMNL\ ^^33W$+IFOSY0D0?_H5]+_=)__7W.?KI^YB$HH)3*4 MJB.HN7--

DKF57<7QW;^VKP8/0(6S0I6L M/=I!AC/VQ5BU%96M'1X\P=73+:."B?U]6!X,@R M55,E,3=_)+",C\^W%7SDG/I@G.B:6*>A/-(WXLQ-[KA1;BR*(QXT[(;,$3?L

MGHGL>)5WPX*V"PGMLMW6Q@6;$<:#<-^'V2!6$[!36(=\'UB(<&_,P*@SY*&@B MRMS!+UY:4G6; -\GGQ.=<|!_PFY?(_*1<3OA0[%F2?JB*+=9B8C\A%8-

M94O*99N*KM=0(ZX;35@!I=)/GIS]_.M%,I08/O-ZT/)O/:[(O/*0=K:2*+"ZKTPF1RLOHHO.2%V)GO1G<\[1D-3U(Z9-M][*74W3V6MBGL*4H&OL]DY@.TNJP?I@[E+]']9]/=._F+?GLQ4

R*6E;H_?N M>/!HF%3K.9B-U00&1QPFI@\E+KV%C3E_]1#*9X-B".?F">|GV*;\V^#5;,SWY MND/%V\# \E*/\RT_O.ID9HA4% DT.U3*,\7MA]V;.^%@U<3?**F)UD4]W&@4[M/(W5N-';?

1=R.K+;PL(*)DK7"K2$+#)7'IO.(M#/%F33E.R@5V!N^'YVS MYOW/%OOV-G#@S(3XAHS[5E+D$EL2#4FF%%L!/1$16\ MDH%LW1#]W4HHWB"2K(-

>!3 ,P<,"C+N5(*=R$9{JK4O MR6Q&(XTUE!$D$/@0A4)PE}KQS.SM7>T+#):7!YRMF=+RG?2^SG8WX/>ADL M1G*=B6I51F!%Z)-6.'C1:L!%P]=1(.F"AP6V/[X.,/ER&NV

]&'T>,_AL%-[M*88+FG8S.^(R+2L4%??B6W4)>=C >[VP#TO,4AQ-N>8+;O(LU;<#0A):4[98 MN\O{&P.,5A6.16I*.'),UU]?'/8-+2{(5DW5D'#?K/133VRR2U;XH.7:+3BP M?

_=T^,;'^O(X;&H?C:EA CK.Q/W]@+K9(;=GA*,/)0>5G/2(MO6NZ?U*.S.L[@UX!(;TA#UMV1=Z7[=K&+[#QD5_IL]/N@@:56U&+]Z

MINW'OFXTXM>AN@U!C*646/7 TOH7]G_E&J_QM+R&K5H ?U9R0TRBIX-8+U!')5W-_-QU5OEN)(

MZW*&/E!%X9Z4QF8293N_[^\0M&LC=MT1)4CT>3EYUBLSR6G>-5@IC98\OW@= M,T(9"YM@K/RU6Y9>BM_X6(VEV'T)-M!#@&WJV)&X4?

LH[,DAU2HGHA>/1*059$QG_^%>XUHU!M^5D*"6]W41ZOZ\-MNY*,B3NU7%T0"Q&$F,ZRY&8&->OTW4D1]05+MMXT7_-&Q GYV+:DVH7%(\OT;X0_MUBO:"4;LP=C\@&5\8'

MZQ>Z$$GC1#Q2U3?&?B*,"Q0KN+1D_EP(1>LI18L46T*OBH7GP;[F<4(E5\DT MD5H $=6SU%0IUJ)7?1YPK#N0Y(M*ROGARK+5YXJ4]5%85,WIK1I6\'F;]4]*3YVK_;T-

5<91SH\?.WA PH1/\IQ M,Q=#SRIBE.-4K7A78X^3N4V"|%R7^KVJD160W\/:!H@9'1@,ZE L,T3Y"R;Q MNN5,&NYGV2GY9.CF^Z,1?!2E!>W8CU>?Q6K9&D[&<+%

0;ZHRV:#YMK4G\?B M7 =S7CV02TD+,FP>A4?9XT"GOU&W/HS)6OJ' M=;F>_U_W=FYB*:A/O41Z.P2GO0!W3BWS:U0A;KMGHLIP("2/;JN3SS8 M1=HVU6RJ^+N[^A)

{4/Z7I=/B8EY6B5* VZK*0$6 <?-KY/7P$:D>%)HNO"K$A>"7>N1 M16G?ON.'IBEWW+68X&\{J2B_!4,7QR6HAXZ"F6+ZV\,.%!^)Z0 V05*^[K2, M2!652'S.>1W/$BFV)*:

{ZF8$C,4"4WLZY3=@DW;4U-3G?!TES62NA@E#%D6O MX^9T=64M#\TUW57X7"/%FFVW\4U>74J36"X\D$WFWU*O[]%!:HK'!1U3Q#8^ MVH&D-

X/1Z@!GA[EMWC4_BB.3Z/GQ#.2.7PW^_&G9!6*3C@EK^^^3;$R*\[# M,%0:"II+)&.T8T:3:$-'S>DWQZ6+G<*:RDIXY@2",*F.H^NIQONC_TA##)Y$

MJU^K"'''6ZRK8JUMA79\],Z,CZY=;T92IND."9?1%F?#+#+.X]YGP MJC?QZD MI.> F<%>HVFBMXF)NU.%[C*?G!-]CWLOB6C;IM\VLT1?,Q=_:.0)@> M_0W44+)BX@"\|+Q"

[H6M:4=O_KVY4C3&LRNU]OJ>8_6FU7R=@0%@2%VIU{F M."DIR7"Q7R&]&+R.8 &_B\9GU3@ M")NU\?#TM?N"F/7EBMK..9HXD_C>3RM/QXN&L'6S_?'AYS)B<"_V1

M96+O>.&D-2N)%-2K.2CZ$3QO)P?K8[-@)*!H49QU?%$"YEJL60F O*;84HAN MMNP!4NW^R"DH^5<9>2.%5?K:A1BV B7-9 MR:.N+031YC'@\V-B6<4!?)TIX6QRO#@RV+=E9-

DN6?1O\L17)L10%N).5"DE;.WZXV53\YCA ML6F&B;_7R^*Z2V$V -9]J"Y_MH90TU8/,L, VW@#%)4;,F=+)4F=' \O2T8 MY8R>.L#:Y3]+U${(MIY.[!Z?8V+6QD3^QF

#09]AU.Q(9>U& M8%.Y>PW00VPEEN*(HHO;S>[EXG^/32K9*DT+9\6XM":<$7*4/R.0G;SVU/!6M;-=^MMDO!&8?# MA)G# QI8*DQYN(MK4RQ_1@/IF>(I-GDI^H.?4ZR-F

OCE42^CDNO@^M/!P+ M/1;.E1HGQQ\UW/$,-P+$RV_S)Z?FFUI4=1X!4Z&N^U0)W9H HV SO-;7@%RR?5OSL324ZIO&5_!//($T>PJH(+=^*_XNOG+U_FVZENT:!,U

MFR8X+Z9L<7]"6#&=75$9U;{TA UPG5(6B^(3:0*(A=^7T":9G?5\.R|K8@EL M3(XV\J0IX;.R\/ON"D#UD55A)%0_ZQO$DO@HZ+*"-F?HJ85^%4 5KQMA^\F MG*V8M/E(A]6-

7NPG\%&;;T2T$. CZ/-M./ 51SC*I9]VXB8VQN 3Z@ VZRT M70#*=[]*0K({W%VPB9;;B#.L9V9$C MVFQ&!"/0.V3SD3R-#]U[G:JBLPK6BX2NF5 ?L]V);5+7W1{T%OXH$^9!-

PJ MQM)&XI@SEZ8[HU(;L)1^V_#@2)330L6ERV3TT8^'62':9U:V^BC\(%M*8*7 MY@<4VQH%OY-1'8!W.RQ N8"'/,[VA49B(N2@]D!W0?>%49ZV71<9 /PGKYF(MV:.(${

)1@.Q4AQ5)VX&!G2@=^?D:(>WH3I2'+##?;DV2JF3!09IAC MB(*=5&%3%8&IAVI#N0<@C97N:MZDO3^U?A$HBEDIV84#!.T&2]=E=57]8C6E-77_-0WDK7L M^],V!Q$806F]7?

6]^B[RYVSL.#4R[O,_'?Q8'WOH[[CP=?_;R$K_@KOR3]3?M12WQ76=XM9\;B633&8XP42^]?-L6RQ#Z+0HJ*.U\B7BA3E9U.WS[\,*;Y\%- MQ%81GD$NI2>'/F/E$= D/D1. QZ!-

:*_/^)_[\17\W*@$!+DGHL@:B2*L7!-MJ_U![SO_BY,3#%#D_9'|ZQ_HU;8P_7/8+SRMURF<2\{>VY'_W5EP7!=_-M"',-W6O)U5JK;<"ZT+4R99$W&8E#>^TX M>&'[S.

[W6144%?U'"#9,((68T"1{64LT8+53IR1#"4 M8"E(/_I#M)6{^-?2YI%E6W-E'"QT.&NI>QZHB^XC.S<>%&T,%;@&\,QG?&A; MTS=YH((<-QKV=V/Z= -I#+7#^2RX6D J3P3Y#6V#]2DI?

6TGI"28*$]PEC|0M9J.RZ)&I=#*@SDS.;7? M4.MCPA8*WB!3=:PG3!?]HK6;]N! [M>WS3)5<;P?1KN(U 8_]ZZ='H:Z7HQ8Y;CYK.TRF#O+3>*QR[*)EK]$W8B; M2*L?

{6K8C_;/D+/_3-0\KH)VAH) M<%[UY3BD^GL)/E7E7=N.'\F?22A]L93]"(B07:T] D%F4SNOE84#'6!-0 MA&O]74J5,^.$>KR+S^QNM:.9FJ/16R(RYDUB!

{=2*%E2S7BAHB_^RCQHG2DB MA/RYIF1_6F09DH#Y?S.9NUG8 [5;D]RQ_&9;>LFF3D^5H72[$;AD&R9 M1!GF$X^[2$C4?=4C,&:E >]"8^[[$W+<1R V^A$XQNE2DJ8' MU3P-

7[,>=8/V"&SDB-Q)DOTE32E[*)\B2=D=4QFQ[ZCM(T#!\A%8H_MW-/;[M2OU^~4-]5L-OZ02#O]2N,1P!3^B)&$*_1:HB6CT"%8]9&=$CT"?C,]5[,A? MD.BJ83MD"AC\I2I*_XYDK2

[\@:R"/P=]8D+T&?^4MEW,OV,2>5,>-=C4$B'\-R*I1EQ%[/10#Z^Q.OFWW\WW^-1'$0E)63[#M*? MF&]LGIFPOMC\2]5!%/QF3;*

<\P2=U5'-2VW5]TK*M{)U0GCBXI:JZ1%0]QI8 MO!-ZY[/L35_')P/[V$H@O=3.Z)>IH M1"^Y&!&XU>8SZ#^IO=9!#C>C=7'U0(_WU#O"F4Y:E[-%G=,-FT\)DI)%]=$D MJGPGI0#

.DHWPOT]]@X&(816I5E6'}91B-)T%#X.V%L>52N5+O^ RUE9GR'3 M:UY//0H)SNCR.-GYN:'=2>&>5_^J62]4?YU2<,7Y4+H1!H?5O+SRC]I8.]BNY

M3BR+6(6+CTBQDKSRWO0_S!#P:E.66<9UD^(]-AJ5E*JJ\T@A\,,2*8^4P7-MNX(7C+:+)<[E!%'T+_]YRO%,._'NKB&Y3\]/_?=H:1Y?/2*5UP!BAR7DAL,:G5M&~=?

6Z'SCX#E3/4T^T(.MI*D##RVDNC_!""X M6;[SWWX$_|Z/?^-U-_M@D4?@R6Y&@^S/_"5)[+\ ]66(SU FA"<&M<$% M/YX'I]_X#1U(?!A 9]%A2'WA_K+%:C\> ^I/.SNMV-X*,#/: -)ZJ6=

MN;LHM0D%%L:5#?;G.R/A$A1W!1ND$6?(I_2D&'(T<^HK_^#1_#$ MT233$$OT?#N1W]G;]/-&GMO"NRY#)5$2XQG=K(24RWO M(8//]H>:."$G]H.@=2QV&I5@-

;I"7)01W9TL3:U^(GU)AH*=4H$%@=5=W,.T M\(F+@.ZQ!$]"Y771RSI)X5].?@39NA:%]9[DE//$R@:K_&;'(?RR,BZ";P_R7I=HY=W.UA M$,!Y6\+P[O@\:%]?;9!0]3.%#5HUU(;]&4*UE\

,7S/349GDV#!\MIY3,]?1 M-_9K(^^!\OI*!>03?CK]>M**X^"EIGGOHU0/(X3R5X[4#?HI^-UM&._1(&:0[M4AKRPH[WWK3+@+TQ3X*)K$EW29HI)PL"\+=-

'4NL'=+Q$0" M6M!9;NX_'JG?!(-.W(S.M$%M0Q8FJ1.+Y'I?(\RL4R6/<<)N-,.7;_;GD7RQU1B)@PP]9+=""%E!B M1SR?IN0*=S0:I=

{N4IS&5S]GC$2PME50HK:=430[A#+"72;$[5S.X&K(;B[H M](Z]24*T>M5.0$PJ,1D02O_QR9]!OP6>&G]N_S-A7L CD!3VL-AZ4>(I_T'D MTS_L#G

R%&IB!]JU3/EHG_PFH>V%2<;=4UC4$W4UU4@'E_GV(]+)-'0-#W M>]V!Z\Q4@Y'=N3T"$3K?_.C _)YL+L'WM. =4(=595_^5B95O MIUOI_]ZA4"/>]4-

0U)PD5;;E&BSP[711{3,,'NKW-$2]&!^]!;@'0=_NI"(^ M.;[WMQ@9ST>^]MU9=:N^N'(2PL#Q^]^BPC^'^D>&8G M QJW\]EW-V*/@$\7V2NG-

"!#1N1PM@A;$=ZW_+=!D*YH;L"_DM=+0\"M@$;'D,T 'E3 ME;!P@. G9+N/ZWNZ@WA_B_VG66D>M$I_->U;AFPQK?T(7'CN\HLVUJ?LV\LU MBK*_&T?

@@/KK+!%/M=J?3BO5ABW7_1A>CG4%#L-%FH*T?Q{41)].W# MS'C_GL@XOR]TJ\]:-#]F70@WM#EYQM\FXBEW$?V'!O83NV"1L) ,R+,B^U-P4FVW\'W!Z:VB

M/+$_/]!:IR=J,+VU-F_,7@M#3R08_6[*/_RR&PWK[NU8UM2/[NGDI+I;@]G6 M:LFZ&Y:4T=*[TV'I=W,!0X"S[^]PWE:ZDTJ1/<;[##FT^\)93K*VL-Z!F+,'I M:A;3-

759]^53)4]E='$L7.V]KiLH"_QU"3%.U-2MD\LYZ+ ^^,$] MH4S"P;P4-WW"8MI" /9*^]E4+ ^+/%^B'>3!S_+#*'TVE3P+ M;T$-;C>H48,5LJI.%'TS[DR8Y"W(P>@H8H'P'

\"DZM!(.=7W_]:=/DM6H&SS.J#N8L$?@<_9? M$H&5)&?Q6_\=I?E3)B/007;&;$%V!?I*:U!H]"JY(+#@3;\!MUJMDD57THYY[E&3I!Z#K*4"2GL+6\W\: LDU6.27!KC($0++

TW4E40SVR,@ MOA7S%/>R^1YSU4CB_5.H?PKU/UDHDKS/N7.[<3H0BX3I>^W9>F#YE%,RI/-8V/F;K+BX9F00$VP'TY^3_=P86 M?\/,HI/>UPK+'T+ZX M@91X\RF#@PP._Y%S?

%JN1BXH,417#TVI;5ZG7'8+[U4ES3!K M#R\B%2KAZ3+1E8+"4<_/1P!3]+I.@T?#%K2@MR2W)4=#\]:DG-_XHL!+(WO' M@_+]S>ZZ7

*\D!SN%Q"J9EZ6H!#:IDMM9$3^T>S0]8$S[>1^Z@"/"X.H:+$RQV_G Z? MNXFH'$5F4WE$U*8YO1]T2*OL:/6R)D"WC^=MAX9NGQG 77G(M1(V65R#:4QO M,4]S[J>G3,FZ3AT0=6>^[:2CUHYY&=B76$2AY>8.E0?H((s#\E8<3KY[J,Y/0)9G+Y@ M7-]?"Q77==OY/QC&O1A*=KA_X!UM!G47FJ!M)#L7R+DS8QH:CA7@*SLX>"AW MK1RRK*X>9#S/AG0GFE_ES,U9?+;_8.+J_L$6|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f'Q;!YT4>]+?1'7-14XPI\I_D(>G MDQ8KFPQ!<<;\2]{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uG6@4TRAC8O(NB'R$R#MIS MTZEI)CGL0M_>+X-8%*MB 9I]?#369D+U-8\ 7==/Y1V@J#BQ3I&93WX_X=U9'B M++");M&|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|L__F_4"=IXZ/ETQE)R:^59%T[UT#/1O$WD_ CXJ'GW MBP.:R>V,6U+B@?8_Z5Y_-XL|f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l7,JI7=,@Z8>D6&O!!#A&4S;[N4'Z,ORJZ-W9)/..7R+K(SK8"6QM2 M'V)_LW1UF6':0$9>XURM5VO@2Q?B2B$BE@LSCI PE#9$U@(&|!);&15P5F MSNKTNEEDJPLY4[CWKE8K,_?V]L-$1P\";'6(P,\? ;65XA-@85W@T)D%LPRT MM$\2R3_C:0AAQ(O0>HEUXSIBPIU8C4]^%Z\9Z,;L+UDZ|/2V M\O&H9#4%9VGH]GJ"L]5%7%\;D'? 84/=LA,F](2>SAEVRYKR2P1KW&*LC(MJ>YS(?&=D$<&$X7E+=_?_0((HO["#T*+M7/DM!B?&"HMZ&3WS9GV MRD6!2#;+FBQ;,,=O!0_T6P-[X9LL?;V8M@EB(^(B9PF= B^^(<\Y,;F+ M-_>P?-X<)TE0!CX)!,DO*39XMHAGV6N$++MS=#%ZD!W)$=''V25E;?3^QGZ5LX MT@8/ Y)2>)(NBI?DQAZZ/7)\U^]D25D_E.WM LP0AI*ARLK)NL91A@*2=*KK7 M7V8UOQ(H,-ECK/<@P&X1NZ#"[4!VH_7)*V+]VYT(?3&596Q.'Y;,|>_^(X9@ M<###1BHFY4A;9$]3IN(3==G"H?% ^F G%&9:IJW9YT@F2;4S>7>S:LX)F3Q!:B M/-D :PXHZFQ+.,#LW"?1+%&0\7SWK%FV0FWV?"#QO+%'+..@3EDJ#<,&4ANV1H6/^8 N;YRX)V& M.5-FV(;<=SN&S]-MR7U&#CQ^=CRX%&!*G?:@7\\QL/,+ [+2P^0.UZO;?2-V+1. Q& M8GH0Rf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lNC7O\(1=%Y:HK\WONB9W:D*0M!PCKS,_M.O'V_WR<_I3]3ZG<VZ7*I67SX% &Z$+B=3F(%5B13 P_[']P$>! ?Y^5^>VIO>$_3 @=%@S.KTR$4H4\G/JOC)KBJ""Z\:-EK0HX%_M$))Y0E^7VX[*?',M^ MV=GM'KM[7WI.?#F6-3\9_^$AONWRQA-_Y_LN?Z1CF$"-^TWX5XFRIJ=_W.D M)-;O++\J_TXZ^<0? JC6E\O;F-6@ET@ YR$;6E2W#WI8HJR(.(TF<(-9 QUH@-MF.16R7?_^\&\ZS5+M6KBUWYL/-&5V[U[%@WF],O)E0]\E1;.'DTUKB#&^?A!5*6SS,\ZC*X]<@D&[0L'=W@6%)Z M3)6$I;NMOE0398^>W30.Y6?%>B(fF<(QP+X2V1=[-'-&"%6KI2]+0(53P2:XM M((.P-YV ML:NA]YO1HDHZ$95:Y>R,#)>6$\ 5Y"CL>N2/^FH/rEM?=]+g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|_!PB)S;N7HN&S3DDV0^0=DV(-MZ8]BB@X@V+ C T,>S_M/ M9*/IMOQ,QEG[#>?AD)%75V(K;\LBV #M B(N&NS>,NO*'-HQ@:)-S&C2) MKGQ!N'.31Y1.WXU35?T0D)@+*$K[f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fJ1[.3E51=P]NLU7AM1Z.FE0L9 MJ=34E):1EIG >6^4^R,_="[7C-0!W-.J"1/@0D;FFW0R%!M=O T!S="%/JCA M(/'3MN7_V3A+6.NXC1$INAZ7.H:CE?EV3S5[L*+WZ&DX"?^>L,_72,5EI^N6KT0LZ\HJ]<@_S :Z&):.G@,C;09&1O2U6E%"PRN# MMN>*Z\ (;X@8,G_?'#MVQ9E8LZJR0$1AJ2H^(T0:JQ.O5*(1#0P"(VG/.V9 M='1S.!*;MT 'I2]*#_/2P#1;[._A=WD2=*8G!(DH2.PPRTDY>-EH4:FAT6@/[1K6U!Q;U -BQ@OTAF$.(E.UNU3Y4GT] MF85NN"VIU^&/@+GFA\F2]R4OKS ? 4P_O,4?3SVD6^ B$P(>>>U$C?*!GAQF],L@TRR):=",,P< MROIGIR 99@_Q277PE=D=;/[_KU:'=$P9 5 3XT8F|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|\R']LZ<+]9K"]LTSK-Y'#./H5LK.(OA]@'50N+8>FEH"'\T$SO-M61'WD>+XQLAAWVY9T3!NN;GS<6/]\'8!>!^Q=+KE"@'CJIVS5',&"}BTY+1V9=I\$I;UO*^H2FE-]SK/ +>3*ZEZG+7 MX4XXB>9JZES\1F7Z^84NT]V6^>"^XC]&=&;[>E]0[+T]?7,NOYI.Y:E]R\)V MQSC(}K)'7NRDHL4]==P(1;T,L"+3[9<4W<<4P1L5MR\]O6M.KFL5.R@%A:? M)"4>N(X>(6KB1*7OR ?,#B5PGY9O M686ZN>E[%3(NB_$[*:=Z-#X"O$80)>D;LT6^>5KQC3P.GKYY<%$1>+5M@^!V MWF7^E%)LY&7X%{C90BRU_Y$$^^6+5,*3DZU6]*7'$<>@3+W'\;TI MI,?%!CNYN;B:Q:V-4E34?!KR,9'8D"FVRVH1L/A)K+ M6ZWUO%).07X$?.-XD)%Y\'1.:_]V? F:>E+0Q*V1FK7E%Q87EP6OIFHWC$8 K M?D<|C. Y0O@(H,A^:!*SNE:6G5]0Z\;LZ!W*X\+YP,_Y]KHWYS4?/[D7?R4[?L3[]?Z)0M'_!=N.VL\L_] M2%]#Z>=]KPB5EN_;4SP>&C\Y_UZ]C3ZL#U%>\CZ =O$5V ;Y1$0_<[SQ,&S MK?#8Y!ZF^=3<^H&^GH#];U0\?U+]2?7O4 UX(+75,01\'+V/-():5X#//#\< MU5O97@9V+_ +Q6>@'46N"%Z(6+G^8Q&_M9>(#?YM<&;1AY!?21FHW ;D"\S*.M>UHEZ[fGFK*W35N)#=97F^ -V7F87_QR*_&=(M6:B:&H2F0U%RQ\&*#@A/@_M PMK>;%?KA??-B8;I6R?$R!Z[#8KXPA$5I :$BPE8Q6WP_G15'S=]M0Q@M8!^[M!GDLI3DDA\ M"A&;LN-VLX44AJ+)(F7G5]^]Q:NXGKOTI!C6^?@NS%[CQ\N4E1]f[%N#9OP! M'K.4B43(&)ZB2&JR/EV99G2/UG]T8OO* O7B(4UND=,@=1O:O+ M=DB.*-%2)0L+)H[RDT.>)8.ESC3[=`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|K8ISEWY$V@GW I*H^_EEF!O\#)_K%7 M8F6/]AG^K4D'U;Z?@"1#P%$FH\ 6,,_N-.*.^1N:L?$'H?6#V4+|'T;E/_MV=BC%ZKS? +Z"]JB|GD_(6D"!,;?3S8?!\O|!?^&X3G27N"Y,)FZ)CZI:,_ MS:)2I?'KK*%6Z O$P4UF@\@[J6?$,>[M_Z=S_7^!8O]5%G\GB;HDWO,7P_]R MS)N"PY>ME_P%Z4U*OQK^5V/NEM2X(<[?% ==O_OE\|+J62W!3RCZQ_6X=S8;< MKS7T*[7PYJ]^*O48SM\NB1'XD\7_G%$7]Z'%:.D'^41;*; MW]@VRC8)K:]1!78+5=+NJQ1O<:LHEA+&?YHF7[E'^MD=-EZ9_*;0E;WZ'D&+ MHG0>TZOK3?M*W(<;4B_*<;9!#K6H0S[^'1,+R;M<8+$&#H;LMP;KVU]\6% ? 5_ZTT16(AE5"X+DV%DD0/TXWO-6O'}&^_M,(NBC]1[5)RMMP634#Y8^^G QWF9(0U$6\-JQGS*P+.!!KRWL"964]]@.05B M;'#+EW95-*H#+<\M9C=O|;7-+DV/784)W7.7>YN1> <=1&]ZJ38+7E DKT)MPU MBQ?GV+?IZ6B-0AN5HX0%Q&.51S0NN0QIK'O:*=.0S)*UH4.GY+XH/WXL6[3 M'QPFO(?K?14@@I4HZU0#B.&_"VHY#I8=M|B4!\[*?- HEG*1MI'6OSY$#GH$ M?&;K4\]0U],2Z'1TAJ]\! 0:5M9^T9:L(1'N2PLV0F+'*FT'>]?$ RZ>%[GF M:NRLPCHRQ3T-E{?1M?.?5NVO>!533:O=L.I/MM!M^ H,QO=A48$^SH,@O25 M/)D96*-D^=_U@]Q>^F^8HY W-=_'$2UT#L84E^6PZK@/LKPYJBSUE<[1B^5 M[+H!G&NZ^=6&]!+T /1KHMA#UH$O\6##./G0%#]E=4B2;=.5.96XCI9+2M?[^Z)$W4=W%OW M#X[KG$]TXHBCJ1BI0N)OAO+Z)@]?9FEH/\X$[Q>BH2TUT?(-MDS^<>[=8T_Y#<\]U;DE&3$58IA]M.#++/FYA;F%0)F&7JH@L< ^H-=;_M;$ M2[2TG@,=$]O\^> BW"? E#T{$_?"+BP^%?MP0FO!C^(/! M #)%QH|-]V9Y#4R/@*S*M&93WJ1+<; V/6SN4JGGZ,;5]P.-=:|\, /2A^* MPST+- !X!QF7L552#KWCF$)_WV?!7P.Q5]":T%NPTH1U'2;XT(R^1+>PZMTU! M^A460\896YR0!YR.N=%3K2H_3'=Q0Q/S=KD%/CO,<57B.5Q.T,DF#'|?P0V- MMRRU|'T@8H995- Q62[Y7)=2;]>MR,T:VVSBJKG/S"R#1#6OG!%9S4>)L2[_>/XFN?[^'*+FE5ZTM @:/+/6A4C5N%;4\7^?]f QKJS$QT MH88D.X-Z&5*Q4/_K#:%W%L82U08O6FK%%ES26.? X7A6>4X@YUV @&NJY -B1,*>]F)98 M87:Q5)-W/O)-Z79P.VD?^HX(O6T5=N@/N%(I<'-W- MBBQ(QPX)W:,#U%8C+RN'+R-4G>(@.,D\+[T.B98_[^ZfU?!&*1.M,,2^79[MNB":")X+W,7J(&0Y7N|N_(M|F(51'5&S$YK.HI4^8V'0CG6,*VYMM<0XSF M09^>9Z_$K22YX.:P|RK^> G /Q3Z*J9^?H>F3J102J[Q9?7-M^>]R^F4NP'OWKMB.CP!T>96& M:&E-

4XV: 2VVW3/:12]4R1O55VM$J-#;5@8+*">'.M57(A/:CMSK,/:0*),% MVL!*5],Z(UAMV[YDB^_W2S4"=&&8W=8 M1K+F1{^1KU&(#KF$YC9PE(BNRKQRQ'OEHI <,:1$A1RQ55@3/37>)2"?,//U4P>YVDK6&BX(DL"-GD>%2$/92MN]S M>'&]\FGO2KOE^I^D58\5@@W%@P#X""]BZ:IWHKM7WCD8&>Q_&P 2QY6/.(IR M_TT $M5"!QE-I<"-\?/^N9HU3N?J:K.GJ<*"G/ELLZ8$7TYM0A"_TX,_2^>+/HV/%7) M.2'K]GO!:/OIVDK:>A>H@CN^--G3!C68X",TIV8F0&#L>&,)"$OY/""L,ED M4'C) 89CQ8<*EIG!|M:(WC UUI*((} \#/4@&>?4=9OR\)\CFFSXNH[*K+ ML@I'K!D>]5B0^M? =D?:E#<1BB]12]MAIN%:%07U;(UZRN=[+\(@:\))U>W!E<(6:&QL@87ER8(H2UT>]/S:JE726[_!!0^XQE:?UYRZ MYEO<7CCK:31L,]7[D.]H+E&ROZ9] \3EL<+MG_H@Y$]#\DF9^(@]YFIU*5,1L7SMR,JIK81,,U'}4 H.MW:HR|:. ^:E_64*7QDW[^?I M,3PG_)VR2@?$C(+|\7V+$9[2Z4Y132[4]C3U-KW6W4YPC-ZV(;WV#;AVEO"* M=Q< 4T=9S9YH"&8]V&+HQ7K87]&\F)0%=%7KH1=]S"PC;HG[A 1,XV8[#B^ M-+ ^]CY8*FCV%[\AB4MYW/(% 9-0DAYSAHD^#>0/I^$QA"PO64PUDIRY$R&J M%'14Q2Q1$EU.B^5KT1EA\V"6>]69/KE3W#]&@O/ M@A?Y"W!CW.:4(*S$^(.$SK=T|_/H07?]6H]>\NN;X^^%9[>G=%%M=G"_JH MCS"SEH%\3C95_CODV5<%RK6CO!S.N;/=6"HEC-16V:TNPUK>X($SCA5EZ:! M]M98?6$@!5*$YRWKC,/":'+*5JQTI(?7UL4.!?@E+WRJ,30S)# (=VM%3>%0Y MW%,YC,>5P22#5E9ZU>1;M9_$:VN$M4K?H'>MESSO*.?@U7-L-5ME>+*%[$Y,5 M4U24G7"JYI%O72U$P\P8&6WZ-JVUA23I!0]P!%&7KP*7.IB7]0]]2A2#"ER8 M0]W.]Y37%Y+IH"HF+M_7#B_10UJSP-%)4-7,BJ."/JNN35Y2*+A(!4(_U8G"AIL"WY^'#F /I*_)M6O8<>T$E*-M]_$WU#%"%[J#*,A3@R X^4 ,*F5EH!Y,R\O_A[VO (MKV=)M)$"P!(){ @2"M!7=-< (=7!W:/HG #!_@&"$UR#N\L[P=T:=W?WE\PY9^;>=<^]|<^L,W/?> MS+O]??>U\INW>M^M>]6KMJ5U4O&8^E\>'GX1SD$AY)UO^D-0/%-5.6%ZX*Q;B!N MCZM,_F9662H7C:\ZJ=K')-@BT.)/&>MMS#U5%M[TN.#G+"2^.4*Q_RB5,.L M!)91<7OQ3+R*2\56@KB#*(]0A8;N](@"MO J13)+$PP%+C.1L.G-G6 >1CZ@8 MG+(&,:"+FGW-&?VJEM6LTM*R&9\Z17'#(/->T,)EXHGG_6A3N]=)#Q>"FO7Z MTS:<,>E M:[A/$ V"V81)D3*6M 3/6SM;T5Q (!P1378L$J'21@!Z4T; C)T4"?#5"3= M+&IB&"22I2&&J/#8((;5YG\IAG.PVTG=H@=PM4.L^,*U-7<7>$0GF-EQ#N M %%*Q21/$F,0 ^'7#!7;4]_1'+1,PR/<=RTN<@*|P^8$F.F4#MB)CN]E4\G9*4" M8*D! ZG-4%=DU*LF9@ LP0>[>>059'|%YN7 MS[:(7%_=$4O]&OXX93/>@US,Y54'M-3*PL"&CUT/78RA|I M+CH X#8!N,; &N\62B@6BQZ=9=9^G#@&J92#$]-#6H;"WWE>&*P-H*X(,&.* M?]A^Q7=*A_GJF>#>-#G&HEXQ@S'M;4X+0*7>+X8BJO00B@SZ9A)Y%((4E. M?@&7V"L7EQSSZZB*G.UHE4X8<36C6$GP3(Z35_)7[XB|E3 ?OD8KB=3(C-G) ML:CCES1U3F%<[17 AM>K3@:U8C$ Q-9T8WP M/;#\K^KI">NXW6-+>UGQ !%Q>P@KJ;*M,Z+#"WE> R0E*]\$@INT,,_O_76R WV&W B5/Z&90S.*L,C?JGS1!'PA5=1)DZ2I(? D[V<./*+!M0 1J:E09DKH6<]-M&X<)7$^W60KZKVXL2SGLZ/62Y[S:5S96T6]85E =4:LXO=`]EUO#%Y(O)951-M(24TO4$("!17C7HG=E>@3+A9^A'3U)%]DM.FB*/]IJ*V <6W5?? #A^.CQ%MI MP_D:0Z(,(=>:X]\9>C /OCK.|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ko>O<+]YH;\ 4!<&)(_RGX^ MS(\7<%%TJ:!-_ !(W@/=W_]8"73^]/VD7FJZNA]O.MAUO[7\0?D$\]S%M.C# M[PM^7_&ZG_G_"\@\G5NBP[6,KV4%YQE?">]6-_&+;"AI3M-VV-MF1 ^WZ>>; M_KRST_Y"&X)E[P3*_Y"B?@75^:"?HGQ?D3C0AU?/Q1TM/PJ+WC8\INT./*H \M@;,#%L$)PV=Q>GNI3O.X!S]'Z?5<#P A6-7=7<@#(&CX]\.&7#V3#$;C-.Q] M]A#NU?I.SN_.O!TQ-U1+TU1M9&]!5% Q0R @#V1 MKM28.T7V'ZG\32,2A)T1KM$G'>Z!5]K;*Q)!9ZJPVPQ95]5",E,H)@@F%=P+4TXM7U4 ,8-O6 MBJ>R8VXW4S?"'W9Z!P]V5#%[&MXN%)-/L$]=%KB:Y,QA('O8F9RAK;$)B_VQ M?3&L4#;9)>+#+R3]-;O3=BH^?D2C!P0"=:"]-;*UFD^U)01R,\>W]Z(2A+ M74,QI$HBX;)TPN5/P@^0H)C+-1<_?QSG=!"8;Z2BYP6@+WY% D&K:F3KMQP6 M9M0@\!T'RQH6]M;6UOG!\N6W&L,;&[J.LM0A /L%D27!],L:Q6WA, ^M+,L&*R M0F1#SB2&=X8ETK]!MI.TW6&G>5& EI<6(6'Q W3Z(D MG90*,KB2" [#&>0RWTZ_@O73+_&,97%B1?>7PK*&C9 .!=!=)_4+\;36?GSX< M<8-S86L 8.-U_4M86(E+@8M2..A5X!$/R/8D%$#M6!!>Q"?'^IA&@-ZX(=U=?#6,?O GYYUE:S^> M/($? DU>+\MG?"N+*"BY$Q%0)@&M&;HK7*FEM/\;7ZZL\ROBJF,5H.;7*Z5LIHPP'05.:A"AA*YD4X& L:N+XTI /HDP9'05.:A"UA4HVEOL2YI ORKKX"V5\(RH\6QNWD@:@S/HC;IW>0"L>(4P65T=/ ""47U[54;M MN:F2VMZ7U_JR?0Y_'"6F&'@LLA)@E%F5OC#3#S7)5===L_25OK4.+@DT6;=8 MM'ZB 2C[RV;]5$YC[TEE0G4A.]5.99<2O*O8IZFB@X 4N-\|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

*M#]7$]%P6RP.&R/KB3FO^RP+2&X*$D5M#Q_8 M$_>"_?6-&NVQ<4(P+W"CPYH9LPI.8*UAV.CV M.8CQS>+TX*/^T5E !^GPV/>.KT'I3S%1!%@?*8#[6ZQMYRY27E_1J+G",BE== M? WG4;HM#(:D<.Y7TQK/Y'$<-5%D6-_O=-9M4?-WDZZM62 NRI=PB M2T2++J\TO3_0K](_.*GAP$J@V;0 "0W[,X5MJ#6B!0";M);NP M((N**RJ4NAW:8KLNP6XQ S>O++UT:5$$\&*; 4F.OJYPC.]%>1Z8VOVHHV"J M.L"(L@RB\$1NBB+PV0 :7(X8CL)OUA (Q!T4R9BSM_$UVIQL!NLDM_4_4SIV M@@?`P_4*CP_W!KOK(E<,. 7U!GO_9;MD7+|>E5&"C4J;6D'U!^3" >T;AR83 M7[+@4A4%]9Y;`^;A!U!5U@|&B9QS6?7AV9;0V5 |W?ZGBQ'X3P5N6S(NG-B'\ M-:<5=X GYBN[W1M\UB,HJ"(M_M'S)XXK+X!M_D- ,1*OX^!Z'* MI**3$<\G=`^I9!,RBKT8\ "9B[OSFG4/.M?:>$;1@H*C-4'HMXEIR&5C?69NN-MHY","-JE^[XE*2FWY,T+Q+I4SJL#SRV9D>@6J..3"8E9S#I336KS87-R0>D]# [EUIZ]5@1#XCK%3]B?PI\?X;_MVIP]. &;#L'C%$]\;,%D[<)Y$WT,CIE7^.$E*1S6?)W8;1\%LJ#[(B6\WA_W M>I:TBBT4EO, *+.]+^+;5174GIN¥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`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|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

srt:MinimumMemberatha:ExercisePriceThreeMember 2024-01-012024-09-30 0001620463
atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember 2024-09-30
0001620463 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberatha:ShortTermInvestmentMember
2023-12-31 0001620463 us-gaap:CommonStockMember 2023-03-31 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001620463 us-
gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001620463 atha:EmployeeStockPurchasePlanMember 2023-01-012023-09-30 0001620463 us-
gaap:CommonStockMember 2023-12-31 0001620463 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001620463
srt:MinimumMemberatha:ExercisePriceOneMember 2024-01-012024-09-30 0001620463 atha:StockOptionsToPurchaseCommonStockMember 2024-01-012024-09-30
0001620463 atha:TowThousandAndTwentyEmployeeStockPurchasePlanMember 2024-01-01 0001620463 atha:TwoThousandAndTwentyEquityIncentivePlanMember 2024-01-
012024-09-30 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001620463
atha:BothellWashingtonMemberatha:LaboratoryAndOfficeFacilitiesMember 2024-01-012024-09-30 0001620463 atha:AtTheMarketOfferingMember 2023-01-012023-01-31
0001620463 2023-01-012023-09-30 0001620463 atha:TwoThousandAndTwentyFourInducementEquityIncentivePlanMember 2024-01-012024-09-30 0001620463 us-
gaap:CommonStockMember 2023-01-012023-03-31 0001620463 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001620463
atha:BothellWashingtonMemberatha:LaboratoryAndOfficeFacilitiesMember 2024-09-30 0001620463 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001620463
atha:WashingtonStateUniversityLicenseAgreementMember 2015-12-31 0001620463 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001620463 us-
gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001620463 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMemberatha:ShortTermInvestmentMember 2023-12-31 0001620463 us-gaap:CommonStockMember 2022-12-31 0001620463
atha:FurnitureFixturesAndComputerEquipmentMember 2023-12-31 0001620463 us-gaap:CommonStockMember 2024-09-30 0001620463 2024-01-012024-03-31 0001620463
us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001620463
srt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMember 2024-01-012024-09-30 0001620463 us-gaap:CommonStockMember 2024-01-012024-03-31
0001620463 us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001620463 us-gaap:CommonStockMember 2024-06-30
0001620463 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001620463 atha:ExercisePriceThreeMember 2024-09-30 0001620463 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001620463 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001620463 us-
gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001620463 atha:SlyneVAthiraPharmaIncMember 2024-01-012024-09-30 0001620463 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001620463 atha:WashingtonStateUniversityLicenseAgreementMember 2015-01-012015-12-31
0001620463 us-gaap:RetainedEarningsMember 2023-09-30 0001620463 2022-12-31 0001620463 us-
gaap:FairValueMeasurementsRecurringMemberatha:ShortTermInvestmentMember 2023-12-31 0001620463 us-gaap:RetainedEarningsMember 2023-12-31 0001620463 us-
gaap:AdditionalPaidInCapitalMember 2023-12-31 0001620463 2023-04-012023-06-30 0001620463 atha:AthiraPharmaIncVDrKawasMember 2024-01-012024-09-30
0001620463 us-gaap:CommonStockMember 2023-04-012023-06-30 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30
0001620463 us-gaap:RetainedEarningsMember 2023-03-31 0001620463 2022-10-012022-12-31 0001620463 2024-03-31 0001620463
atha:EmployeeStockPurchasePlanMember 2024-01-012024-09-30 0001620463 srt:MaximumMemberatha:AtTheMarketOfferingMember 2023-01-31 0001620463 us-
gaap:RetainedEarningsMember 2022-12-31 0001620463 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001620463 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001620463
atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember 2024-09-30 0001620463
atha:SharesAvailableForFutureGrantUnderTwoThousandTwentyEquityIncentivePlanMember 2023-12-31 0001620463 2023-07-012023-09-30 0001620463 us-
gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001620463 atha:TwoThousandAndTwentyFourInducementEquityIncentivePlanMember 2024-02-29 0001620463
us-gaap:RetainedEarningsMember 2024-03-31 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001620463
srt:MaximumMemberatha:BothellWashingtonMemberatha:LaboratoryAndOfficeFacilitiesMember 2024-09-30 0001620463 2023-10-012023-12-31 0001620463 2023-06-30
0001620463 us-gaap:CommonStockMember 2024-03-31 0001620463 2024-06-30 0001620463 atha:NonVestedRestrictedStockUnitsMember 2024-01-012024-09-30
0001620463 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001620463
atha:PhaseTwoClinicalTrailInitiationOfLicenseAgreementMemberatha:WashingtonStateUniversityLicenseAgreementMember 2020-01-012020-12-31 0001620463 2023-03-31
0001620463 us-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2024-09-30 0001620463 2023-01-012023-12-31 0001620463 us-gaap:RetainedEarningsMember 2024-09-30 0001620463
atha:SharesIssuableUponTheExerciseOfOutstandingCommonStockOptionsAndTheVestingOfOutstandingCommonRestrictedStockUnitsGrantedMember 2023-12-31
0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001620463 atha:StockOptionsToPurchaseCommonStockMember 2023-01-012023-09-30
0001620463 atha:LaboratoryEquipmentMember 2023-12-31 0001620463 atha:LaboratoryEquipmentMember 2024-09-30 0001620463 2024-04-012024-06-30 0001620463 us-
gaap:CashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001620463 atha:NonVestedRestrictedStockUnitsMember 2023-01-012023-09-30 0001620463
atha:LicensedProductsMemberatha:WashingtonStateUniversityLicenseAgreementMember 2024-01-012024-09-30 0001620463 us-gaap:AdditionalPaidInCapitalMember 2023-
03-31 0001620463 srt:MaximumMemberatha:ExercisePriceThreeMember 2024-01-012024-09-30 0001620463 atha:ExercisePriceTwoMember 2024-09-30 0001620463 us-
gaap:CommonStockMember 2023-09-30 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001620463
atha:FurnitureFixturesAndComputerEquipmentMember 2024-09-30 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001620463
atha:WashingtonStateUniversityLicenseAgreementMember 2024-09-30 0001620463 us-gaap:CommonStockMember 2023-06-30 0001620463
srt:MinimumMemberatha:BothellWashingtonMemberatha:LaboratoryAndOfficeFacilitiesMember 2024-09-30 0001620463 2024-01-012024-09-30 0001620463 2024-09-
152024-09-15 0001620463 2024-11-04 0001620463 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001620463 us-
gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001620463 us-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001620463 us-gaap:RetainedEarningsMember 2023-01-012023-03-31
0001620463 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001620463 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001620463 us-
gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30
0001620463 atha:TwoThousandAndTwentyEquityIncentivePlanMember 2024-01-01 0001620463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-
03-31 0001620463 srt:ScenarioForecastMember 2024-12-31 0001620463 us-gaap:RetainedEarningsMember 2023-06-30 0001620463 us-gaap:RetainedEarningsMember 2024-
06-30 pure shares atha:Segment iso4217:USD shares iso4217:USDQ30001620463--12-31false10-Qtrue2024-09-302024false001-39503Athira Pharma, Inc.DE45-3368487187066
North Creek ParkwaySuite 104BothellWA98011425620-8501Common Stock, $0.0001 par value per shareATHANASDAQYesYesNon-accelerated
Filertruetruefalsefalse3866907368856000905840008373000568350003145000568200016280001628000820020001547290006310006310002687000338800087100010490005
349000-391143000-
309206000575830001301880008624600016024500017922000272020006131200070110000757200078400001989700002634200041270004127000296210003504200085336000
29621000-35042000-85336000-96452000157000880000207200033990005908000-28741000-32970000-81937000-90387000410002610003520001278000-28700000-
32709000-81585000-89109000-0.75-0.75-0.87-0.87-2.13-2.13-2.38-
2.38385176023851760238054583380545833840670938406709379930023799300238172603400043973900 0-349000-
309206000130188000154049267900026790002120002120002633700026337000383266524000442418000-137000-
335543000106742000200011072314800014800032050003205000990000990000-26859000-26859000384393754000445771000-38000-
362402000833350007566012000120001540382936000293600041000410000-28741000-28741000386690734000448719000 3000-
391143000575830003787738740004282300 0-1956000-191534000235137000732139900099000027820002782000927000927000-27820000-
278200003795060040004315040000-1029000-219354000211250007882110000961012310003110000311900090000900000-29597000-
295970003805458340004348650000-939000-248951000184979000249400024940002610002610000-32970000-32970000380545834000437359000-678000-
281921000154764000-81937000-90387000882000083950007270007240001780001580004880001131000-7000-1227000-2930000366000-112300071590000-271000-239000-
71157000-744600001132200027671000689970001166730003300030400005764200088698000160000341000160000341000-
133550001457900091215000963860007786000011096500 0
1. Description of Business <p
style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-
wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Organization <p style="text-indent:4.533%;font-size:10pt;margin-
top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-
content;">Athira Pharma, Inc., or the Company, was incorporated as M3 Biotechnology, Inc. in the state of Washington on <span style="font-size:10pt;font-
family:Arial;">March 31, 2011<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and reincorporated in the state of Delaware on <span style="font-
size:10pt;font-family:Arial;">October 27, 2015
. In April 2019, the Company changed its name to Athira Pharma,
Inc. The Company currently has office and laboratory space in Bothell, Washington. The Company is a clinical-stage biopharmaceutical company focused on developing small
molecules to restore neuronal health and slow neurodegeneration. <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New
Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-
content;">Liquidity and Capital Resources <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-
align:justify;">Since the Company's inception, it has funded its
operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser
extent from grant income and stock option exercises. From the Company's inception through September 30, 2024, it has raised aggregate net cash proceeds of $
407.4<span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million primarily from the issuance of its common stock (excluding option exercises), convertible preferred
stock, common stock warrants, and convertible notes.
<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of September 30, 2024, the Company had cash, cash equivalents and
investments of $68.9<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million. The Company's net loss for the nine months ended September 30,
2024 was $81.9<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and cash used in operations for the nine months ended September 30, 2024 was $
71.2<span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million. Since the Company's inception, it has devoted substantially all of its resources to its research and
development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the
Company's intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. <p style="text-
indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Arial;min-width:fit-content;">Based upon the Company's current operating plan, it estimates that its $<span style="font-size:10pt;font-
family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">68.9<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-
width:fit-content;"> million of cash, cash equivalents and investments at September 30, 2024<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Arial;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date
of this report. Historically, the Company has incurred net losses from continuing operations and negative operating cash flows. The Company has not yet established an
ongoing source of revenue sufficient to cover its operating costs; therefore, the Company will need to continue to raise additional capital to accomplish its operating plan. The

Company has a sales agreement in place with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and BTIG, LLC, or BTIG, for an "at the market" equity offering facility through which it may offer and sell shares of its common stock equaling an aggregate amount up to $75.0 million. The Company has not sold any securities pursuant to this ATM offering. Should it be determined to be strategically advantageous, the Company could pursue public and private offerings of its equity securities similar to those the Company has previously completed, debt financings, or other strategic transactions, which could include income from collaboration, licensing or similar arrangements with third parties, or receiving research contributions, or grants. 2011-03-312015-10-27407400000689000000-81900000-712000006890000007500000000 2: Significant Accounting Policies Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP. The unaudited condensed consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation. Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated balance sheet as of September 30, 2024, and condensed consolidated statements of operations and comprehensive loss, cash flows, and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, are unaudited. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of September 30, 2024, and the unaudited condensed consolidated results of its operations and its cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year ending December 31, 2024 or any other period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 22, 2024. Fair Value Measurements The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts. Restricted Cash Restricted cash consists of $8.4 million paid into a settlement fund account pending resolution of the securities class action settlement discussed in Note 7, as well as collateral pledged in connection with the Company's corporate credit cards. The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows.</p><div style="font-size:10pt;font-family:Arial;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 68,856 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,373 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash, non-current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 631 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span style="font-family:Arial;min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 631 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash, cash equivalents and restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">77,860</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 91,215 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Short-term Investments The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, and short-term investments on the unaudited condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net. The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. Research and Development Expenses Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company's drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company's research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables. Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. General and Administrative Expenses General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. Leases The Company adopted Accounting Standards Codification, or ASC, Topic 842 – Leases effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use, or ROU, assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company's use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company's leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company's incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date. The Company's leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company's lease agreements do not contain residual value guarantees or covenants. The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company's leases include variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term. Lease expense is recognized within operating expenses on a straight-line basis over the terms of the leases. Incentives granted under the Company's facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease. Stock-based Compensation The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company's common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur. The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Net Loss Per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. Segments <span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company's chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Corporate Restructuring On September 15, 2024, the Company committed to a workforce reduction that is expected to result in the termination of approximately 70% of the Company's workforce, or the Restructuring. In connection with the Restructuring, the Company currently estimates it will incur costs of approximately $2.8 million, consisting primarily of cash severance costs and termination benefits, which the Company expects to recognize in the third and fourth quarters of 2024. The Company expects to substantially complete the Restructuring by December 31, 2024. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently Adopted Accounting Pronouncements In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures. Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP. The unaudited condensed consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation. Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated balance sheet as of September 30, 2024, and condensed consolidated statements of operations and comprehensive loss, cash flows, and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, are unaudited. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements as of and for the year ended December 31, 2023. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of September 30, 2024, and the unaudited condensed consolidated results of its operations and its cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year ending December 31, 2024 or any other period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 22, 2024. Fair Value Measurements The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts. Restricted Cash Restricted cash consists of $8.4 million paid into a settlement fund account pending resolution of the securities class action settlement discussed in Note 7, as well as collateral pledged in connection with the Company's corporate credit cards. The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows.</p><div style="font-size:10pt;font-family:Arial;"><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 68,856 </td><td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">90,584</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash, current</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,373</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash, non-current</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash, cash equivalents and restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 77,860 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">91,215</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div>8400000The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 68,856 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash, current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,373 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-

space:pre-wrap;vertical-align:top;"> Restricted cash, non-current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 631 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 631 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash, cash equivalents and restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">77,860</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 91,215 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>6885600090584000837300063100063100077860000912150000 Short-term Investments The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, and short-term investments on the unaudited condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net. The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. Research and Development Expenses Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company's drug discovery efforts and the development of its drug candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company's research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables. Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. General and Administrative Expenses General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. Leases The Company adopted Accounting Standards Codification, or ASC, Topic 842 – Leases effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use, or ROU, assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company's use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company's leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company's incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date. The Company's leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company's lease agreements do not contain residual value guarantees or covenants. The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company's leases include variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term. Lease expense is recognized within operating expenses on a straight-line basis over the terms of the leases. Incentives granted under the Company's facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease. Stock-based Compensation The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company's common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur. The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Net Loss Per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the

*period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. Segments The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company's chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. 1 Corporate Restructuring On September 15, 2024, the Company committed to a workforce reduction that is expected to result in the termination of approximately 70% of the Company's workforce, or the Restructuring. In connection with the Restructuring, the Company currently estimates it will incur costs of approximately $2.8 million, consisting primarily of cash severance costs and termination benefits, which the Company expects to recognize in the third and fourth quarters of 2024. The Company expects to substantially complete the Restructuring by December 31, 2024. 0.7028000002800000 Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company and (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently Adopted Accounting Pronouncements In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for the fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. The Company does not expect the adoption of this new guidance to have a material impact on its consolidated financial statements and is currently evaluating the effect of adopting the ASU on its disclosures. 3. Fair Value The Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are: Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2—Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Level 3—Inputs are generally unobservable and reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies. The determination of a financial instrument's level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The following tables reflect the Company's financial asset balances measured at fair value on a recurring basis (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:44.8%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:9.96%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;border-bottom:0.5pt solid #000000;"> Cash equivalents: </td><td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> <span*

*style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td>

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,136</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,139 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:9.96%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"> Cash equivalents: </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Commercial paper</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">59,227</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(30</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 59,260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"> Short-term investments: </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,431 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,427 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government debt and agency
  securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,723 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 315 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">57,154</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(319</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,835 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> All the commercial paper, U.S. government debt and agency securities, U.S. treasury bills, and corporate bonds designated as short-term investments have an effective maturity date that is equal to or less than one year from the respective balance sheet date. As of September 30, 2024, the Company does not intend to sell any securities in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell such securities prior to the recovery of the amortized cost basis. Based on the Company's assessment, the Company concluded all impairments as of September 30, 2024 to be due to factors other than credit loss, such as changes in interest rates. A credit loss allowance was not recognized and the unrealized losses for available-for-sale securities were recorded in other comprehensive loss. The following tables reflect the Company's financial asset balances measured at fair value on a recurring basis (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:9.96%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td

style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"> Cash equivalents: </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government debt and agency
 securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,120 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,125 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23,983 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23,981 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,136</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,139 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:9.96%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">

 </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"> Cash equivalents: </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Commercial paper</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">59,227</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(30</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">59,197</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 59,290 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(30</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 59,260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"> Short-term investments: </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,431 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,427 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> U.S. government debt and agency
  securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,723 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (315 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,408 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 57,154 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <span style="font-family:Arial;min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (319 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 56,835 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr>
</table>3300033000181200005000181250002398300010003000239810004213600060003000421390006300063000592270003000059197000592900003000059260000064310(
style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">4. Property and Equipment, Net Property and equipment consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Lab equipment </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">705</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 688 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Office furniture, fixtures, and
computer equipment </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 712 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 712 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvement </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,322 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,322 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Property and equipment, at cost </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,739 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,722 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,052 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,334 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,687</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,388 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Depreciation expense was $243,000 and $727,000 for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $244,000 and $724,000 for the three and nine months ended September 30, 2023, respectively. Property and equipment consisted of the following (in thousands):
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Lab equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">705</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 688 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Office furniture, fixtures, and
computer equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 712 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 712 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-

wrap;font-family:Arial;min-width:fit-content;">Leasehold improvement </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,322 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,322 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Property and equipment, at cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,739 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,722 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,052 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,334 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,687</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,388 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>705000688000712000712000432200043220005739000572220003052000233400026870003388000243000727000244000724000 5. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,644</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,916 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-

width:fit-content;">Employee compensation and benefits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,440 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,545 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Legal expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Professional services and other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 750 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,882 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total accrued liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,961</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 18,343 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accrued liabilities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,644</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,916 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Employee compensation and benefits </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,440 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,545 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Legal expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Professional services and other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 750 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,882 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total accrued liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,961</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 18,343 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>764400011916000444000045450004127000750000188200016961000018343000 6. Significant Agreements WSU License Agreement The Company is party to an amended and restated exclusive license agreement with sublicensing terms with WSU that the Company entered into in 2015. Under this agreement, the Company has an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration. ATH-1105, the Company's small molecule drug candidate currently in development for the potential treatment of ALS, is not covered by the WSU license agreement. To keep in good standing, the agreement requires the Company to meet certain development milestones and pay annual maintenance fees. All contractual requirements have been met as of September 30, 2024. During the year ended December 31, 2020, the Phase 2 clinical trial milestone was reached and a payment of $50,000 to WSU was recorded. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company may also be obligated to pay the following if the related milestones are reached:</p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">•<div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$300,000 - At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product; and • $600,000 - Upon receipt of marketing approval in the United States, European Union or Japan for the first licensed product. Under the terms of the agreement, the Company will pay a royalty in the mid-single digits of net sales, with the first $100,000 of net sales being exempt from royalty payment, and annual minimum royalty payments of $25,000 beginning after the first commercial sale of a licensed product. As of September 30, 2024, no sales of any licensed products had occurred and the Company had not incurred a royalty obligation under this agreement. Additionally, the agreement allows the Company to sublicense the rights conveyed by the agreement, subject to additional payments to WSU based upon the sublicense consideration received in such event. Such amounts are dependent on the terms of the underlying sublicense and range from the mid-single digits to mid-teens of any non-sales based payments received, and low twenties of net sales based sublicense royalties. As of September 30, 2024, the Company has not entered into or incurred any liability from a sublicense agreement. 5000030000060000010000002500000 7. Commitments and Contingencies Legal Proceedings From time to time, the Company is subject to various legal proceedings or claims that arise in the ordinary course of business. The Company accrues a liability when the Company's management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. The following is a brief description of the more significant legal proceedings. Securities Class Actions On June 25, 2021, plaintiffs <span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fan Wang and Hang Gao filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company and the Company's former chief executive officer Dr. Leen Kawas, captioned Wang v. Athira Pharma, Inc., et al., No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, or Exchange Act, and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding the Company's business. Specifically, the Wang plaintiffs allege that the Company failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU, including the manipulation of data, and that as a result, the defendants' positive statements about the Company's business, operations, and prospects were materially misleading. The Wang plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys' fees.   That same day, on June 25, 2021, plaintiff Harshdeep Jawandha filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company's then chief financial officer, certain members of the Company's board of directors at the time of the Company's initial public offering, or IPO, as well as the IPO underwriters, captioned Jawandha v. Athira Pharma, Inc., et al., No. 2:21-cv-00862. The Jawandha complaint asserts violations of Sections 11 and 15 of the Securities Act of 1933, or Securities Act, alleging that that the Company's IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawas's published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to the Company's efforts to develop treatments for Alzheimer's disease, and that the defendants' positive statements about the Company's business, operations, and prospects were materially misleading. The Jawandha plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneys' fees.   Also on June 25, 2021, plaintiffs Timothy Slyne and Tai Slyne filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company's then chief financial officer, and the same members of the Company's board of directors and underwriters as in the Jawandha complaint, captioned Slyne v. Athira Pharma, Inc. et al., No. 2:21-cv-00864. The Slyne complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawas's doctoral research at WSU should have been disclosed in the Company's IPO registration statement. The Slyne plaintiffs seek unspecified compensatory damages, reasonable costs and expenses, including attorneys' fees, and injunctive and other equitable relief. On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel. On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against the Company, Dr. Kawas, the Company's then chief financial officer, certain members of the Company's board of directors at the time of the Company's IPO and secondary public offering, or SPO, and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawas's published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffs' consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint. On August 12, 2022, defendant Dr. Kawas filed a motion for partial reconsideration of the court's July 29, 2022 order. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, the Company and Dr. Kawas filed their individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery. On March 10, 2023, following a mediation and the parties' agreement in principle to settle the securities class action, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. On May 31, 2023, the court issued a minute order requiring the parties to file a joint status report on or before June 30, 2023 addressing several aspects of the proposed settlement, including revision of certain notices to putative class members regarding the settlement, which the parties filed on that date. On September 27, 2023, the court issued an order denying plaintiffs' motion for preliminary approval without prejudice, citing the motion's failure to satisfy the court's questions and concerns regarding traceability of certain Securities Act claims. The court permitted plaintiffs to file a renewed motion for preliminary approval, which plaintiffs filed on December 15, 2023. On February 15, 2024, the court issued an order granting in part and deferring in part plaintiffs' renewed motion for preliminary approval and ordered the parties to submit a joint status report by March 15, 2024. In its order, the court preliminarily approved the proposed settlement and certified a class with two subclasses. The court deferred ruling in part as to the proposed notices and claim form relating to the settlement. On March 29, 2024, the court issued a minute order (i) granting the portion of plaintiffs' renewed motion for preliminary approval that the court had previously deferred ruling on, (ii) setting a final approval hearing, and (iii) ordering plaintiffs' motion for final approval of the proposed settlement to be filed on or before September 26, 2024. On September 26, 2024, plaintiffs filed a motion for final approval of class action settlement and plan of allocation. On September 30, 2024, the court issued a minute order requiring additional information related to the claims administration process, to which plaintiffs responded. On October 25, 2024, the court held a settlement final approval hearing and ruled that the terms of the settlement are fair, reasonable and adequate and that notice was reasonable. On November 1, 2024, the court entered a final written judgment and order granting final approval of the settlement and closed the case. As a result of the foregoing, the Company recorded a legal settlement expense of $10.0 million in operating expenses in the fourth quarter of 2022 and an accrued liability of $10.0 million on the accompanying condensed consolidated balance sheets. Additionally, the Company recorded an insurance recovery of $1.6 million in operating expenses in the fourth quarter of 2023 and an insurance recovery receivable of $1.6 million on the accompanying condensed consolidated balance sheets. This insurance recovery represents the amount of the settlement to be covered by the Company's insurers. The Company has deposited $8.4 million into a settlement fund account pending final payment of the settlement amount, and such funds are legally restricted for use and are included within restricted cash, current on the condensed consolidated balance sheets. Shareholder Derivative Actions On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of the Company's board of directors, captioned Bushansky v. Kawas et al., No. 2:22-cv-497. Plaintiff purported to bring the action derivatively on behalf of the Company, which was a nominal defendant to the action. The derivative complaint alleged that the

*Company's board of directors breached its fiduciary duties by failing to prevent alleged misstatements in the Company's public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint sought unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys' fees. On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain current and former directors and officers of the Company, captioned Houlihan v. Kawas et al., No. 2:22-cv-620. Plaintiff purported to bring the action derivatively on behalf of the Company, which was a nominal defendant to the action. The derivative complaint alleged that certain of the Company's current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in the Company's public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserted claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint sought unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneys' fees. On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. On March 18, 2024, following a mediation and the parties entering into a stipulation of settlement to settle the consolidated derivative action for certain corporate governance reforms and the Company's payment of a fee and expense award to plaintiffs' counsel, plaintiffs filed an unopposed motion for preliminary approval of a settlement of the derivative action. On May 3, 2024, the court entered an order preliminarily approving the settlement. On May 17, 2024, plaintiffs filed an unopposed motion for approval of attorneys' fees and expenses and service awards to plaintiffs. On July 3, 2024, plaintiffs filed an unopposed motion for final approval of derivative settlement. The settlement final approval hearing took place on July 18, 2024, and no Company shareholders objected to the proposed settlement or attorneys' fees or service awards sought by plaintiffs. After the hearing, on July 18, 2024, the court entered an order and judgment granting plaintiffs' motion for final approval of derivative settlement, finding the settlement to be fair, reasonable, and adequate to the settling parties and the Company's shareholders, and dismissing the derivative action with prejudice. The Company paid the fee and expense award related to this shareholder derivative action settlement during the third quarter of 2024. Government Investigation In November 2022, the Company received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand sought documents and information relating to the Company's relationship with WSU, certain of its grant applications in 2016 and 2019 with the NIH, and the Company's receipt of an NIH grant in 2020. The Company has been cooperating with the Department of Justice with respect to the Demand. The Company recorded a legal expense of $4.1 million based on developments in the third quarter of 2024 and a corresponding accrued liability on the accompanying condensed consolidated balance sheets. Failure by the Company to obtain a favorable resolution could have a material adverse effect on its business, results of operations and financial condition. Operating Leases The Company has operating leases for laboratory and office facilities in Bothell, Washington that expire in August 2027. The initial terms of the leases range from 6.3 to 7 years and the Company has options to extend the leases for an additional five years that it is not reasonably certain to exercise. As of September 30, 2024, the Company was not party to any finance leases. The following table reconciles the Company's undiscounted operating lease cash flows to its operating lease liability (in thousands):
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.823%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Remaining 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 123 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 494 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 509 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 346 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Total undiscounted lease payments </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,472 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Present value adjustment for minimum lease
  commitments </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <span style="font-family:Arial;min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (158 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Net lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,314</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.924%;box-sizing:content-box;"></td> <td style="width:1.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.756999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,
2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted average remaining lease term (years)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.2</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted average discount rate</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Operating lease expense and variable lease expense consisted of the following (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.34%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.195%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.195%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.195%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.195%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 89 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-family:'Helvetica LT Pro',sans-serif;color:#000000;white-space:pre-wrap;min-

width:fit-content;">265 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">265</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Variable lease expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">108</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">144</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p>2021-06-25Fan Wang and Hang Gao2021-06-25Harshdeep Jawandha2021-06-25Timothy Slyne and Tai Slyne2022-08-12Dr. Kawas10000000100000001600000160000084000004100000202708P6Y3M18DP7YtrueP5Y<p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table reconciles the Company's undiscounted operating lease cash flows to its operating lease liability (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,
2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Remaining 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">123</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">494</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">509</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">346</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total undiscounted lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,472</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value adjustment for minimum lease
  commitments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(158</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,314 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>12300049400050900034600014720001580001314000 The weighted average remaining lease

term and the weighted average discount rate used to determine the operating lease liability were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.924%;box-sizing:content-box;"></td> <td style="width:1.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.756999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average remaining lease term (years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> Operating lease expense and variable lease expense consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.34%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.195%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.195%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.195%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">89</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 265 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">89</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 265 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 42 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 108 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 144 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>P3Y2M12D0.08189000890002650002650004100042000108000144000 8. Common Stock Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and if declared by the Company's board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception. The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.568%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.557%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.716%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares issuable upon the exercise of outstanding
  common stock options and the vesting of
  outstanding common restricted stock
  units granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,785,447 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,130,956 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for future grant under the 2020
  Equity Incentive Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,426,486 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,158,094 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for future grant under the
  Employee Stock Purchase Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,399,735 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,128,732 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for future grant under the 2024
  Inducement Equity Incentive Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 350,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-

*align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,961,668 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,417,782 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company's 2020 Equity Incentive Plan, or the 2020 Plan, provides for annual increases in the number of shares that may be issued under the 2020 Plan on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) 3,230,000 shares, (2) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company's board of directors. The Company's 2020 Employee Stock Purchase Plan, or the ESPP, provides for annual increases in the number of shares that may be issued under the ESPP on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (1) 646,000 shares, (2) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (3) an amount determined by the Company's board of directors. Effective January 1, 2024, the Company's 2020 Plan and ESPP reserves increased by 1,908,630 shares and 381,726 shares, respectively. In February 2024, the board of directors adopted the Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan, or the 2024 Inducement Plan, and, subject to the adjustment provisions of the 2024 Inducement Plan, reserved 750,000 shares of the Company's common stock for issuance pursuant to equity awards granted under the 2024 Inducement Plan. The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.568%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:16.557%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.716%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares issuable upon the exercise of outstanding
  common stock options and the vesting of
  outstanding common restricted stock
  units granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,785,447 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,130,956 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for future grant under the 2020
  Equity Incentive Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,426,486 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,158,094 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-*

wrap;font-family:Arial;min-width:fit-content;">Shares available for future grant under the
  Employee Stock Purchase Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,399,735 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,128,732 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for future grant under the 2024
  Inducement Equity Incentive Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 350,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,961,668 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,417,782 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1078544771309561426486315809413997351128732350000139616681141778232300000.056460000.011908630381726750000 9. Stock-based Compensation Stock-based compensation expense recognized was as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 944 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,228</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,812</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,550</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,557</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,167</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,936 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,494</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,820 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,395 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Valuation Assumptions The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally required significant judgment. • Fair Value of Common Stock—The fair value of each share of common stock is based on the closing price of the Company's common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. • Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. • Expected Volatility—Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. • Expected Term—The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity. • Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of zero. The fair value of each stock option was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.739999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96.93 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 99.18 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.48 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The grant date fair value of restricted stock units is based upon the fair market value of the Company's common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. The fair value of options granted during the nine months ended September 30, 2024 and 2023 was $10.2 million and $9.8 million, respectively. The fair value of restricted stock units granted during the nine months ended September 30, 2024 and 2023 was less than $0.1 million and $0.4 million, respectively. Stock Option Activity Changes in shares available for grant under the 2020 Plan and the 2024 Inducement Plan during the nine months ended September 30, 2024 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares
Available
for Grant </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for grant at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,158,094 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2020 Plan reserve increase on January 1, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,908,630 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares reserved upon adoption of the
  2024 Inducement Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 750,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options and restricted stock units granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,090,804 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options and restricted stock units forfeited,
  cancelled, or expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for grant at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,776,486 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> A summary of stock option activity under the 2020 Plan and the 2024 Inducement Plan for the nine months ended September 30, 2024 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:36.853%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.138%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.158%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Exercise
price
per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Remaining
Contractual
Term
(in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic
Value
(in
thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,820,869 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.97</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.24</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 387 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,088,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (75,660 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Forfeited/expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (50,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.48 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,783,447 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.18</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.27</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected to vest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,905,187 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.27 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.86 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercisable</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,878,260</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.49 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.56 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The total fair value of options granted that vested during the nine months ended September 30, 2024 and 2023 was $9.2 million and $8.3 million, respectively. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company's common stock underlying all options that were in-the-money at September 30, 2024. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2024 and 2023 was $0.2 million and $0.2 million, respectively, determined as of the date of option exercise. As of September 30, 2024, there was $17.7 million of total unrecognized compensation cost related to non-vested stock options. The Company expects to recognize this cost over a remaining weighted-average period of 2.2 years. The Company utilizes newly issued shares to satisfy option exercises.</p><div style="font-size:10pt;font-family:Arial;"><p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Stock options outstanding and exercisable under the 2020 Plan and the 2024 Inducement Plan consisted of the following at September 30, 2024:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.88%;box-sizing:content-box;"></td> <td style="width:1.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#fffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-family:Arial;min-width:fit-content;">Exercise Price ($) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> Shares
Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares
Exercisable </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 0.16 to 4.22 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,703,393 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,515,358 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 8.93 to 19.94 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-

family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,727,806 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,084,154 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 20.55 to 29.41 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 352,248 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 278,748 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,783,447 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,878,260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Restricted Stock Unit Activity A summary of restricted stock unit, or RSU, activity for the nine months ended September 30, 2024 is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.879999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Share
Equivalent </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Grant Date
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 310,087 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.44 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.51 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">(310,087 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11.44 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.51</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Stock-based compensation expense recognized was as follows (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">944</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,228 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,812 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times

*New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,557 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,167 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,936</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,494 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,820</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,395 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>1124000944000326300032280001812000155000055570005167000293600024940008820000833950000 The fair value of each stock option was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.739999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96.93 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 99.18 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> *<span*

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.48 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>0.04260.03540.96930.9918P6YP5Y5M23D1020000098000001000004000000 Changes in shares available for grant under the 2020 Plan and the 2024 Inducement Plan during the nine months ended September 30, 2024 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.22%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares
Available
for Grant </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for grant at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,158,094 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2020 Plan reserve increase on January 1, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,908,630 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares reserved upon adoption of the
 2024 Inducement Plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 750,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options and restricted stock units granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,090,804 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options and restricted stock units forfeited, <br/> cancelled, or expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for grant at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,776,486 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>3158094190863075000040900804505661776486 A summary of stock option activity under the 2020 Plan and the 2024 Inducement Plan for the nine months ended September 30, 2024 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:36.853%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.138%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.158%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Exercise
price
per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Remaining
Contractual
Term
(in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-wrap;font-family:Arial;min-

width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic
Value
(in
thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,820,869 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.97</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.24</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 387 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,088,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (75,660 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Forfeited/expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (50,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.48 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="font-family:Arial;color:#000000;white-

space:pre-wrap;min-width:fit-content;">10,783,447 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.18</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.27</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,905,187 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.27</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.86</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr></table>68208697.97P8Y2M26D38700040888043.16756600.165056611.48107834476.18P8Y3M7D59051874.27P8Y10M9D48782608.49P7Y6M21D9200000830000020000020000

style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Stock options outstanding and exercisable under the 2020 Plan and the 2024 Inducement Plan consisted of the following at September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.88%;box-sizing:content-box;"></td> <td style="width:1.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:bottom;"> Exercise Price ($) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares
Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares
Exercisable </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 0.16 to 4.22 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,703,393 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="font-

family:Arial;min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,515,358 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 8.93 to 19.94 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,727,806 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,084,154 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 20.55 to 29.41 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 352,248 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 278,748 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,783,447 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,878,260 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>0.164.2277033932515358 8.9319.942727806208415420.5529.413522482707481078344748782 60 A summary of restricted stock unit, or RSU, activity for the nine months ended September 30, 2024 is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.98%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.879999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Share
Equivalent </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Grant Date
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 310,087 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.44 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.51 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 310,087 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11.44 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2.51 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>31008711.4420002.5131008711.4420002.51 10. Net Loss Per Share Attributable to Common Stockholders The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.248%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.777%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.777%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,783,447 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,019,311 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested Restricted Stock Units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313,337 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,709 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,373 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-

word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,794,156 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,344,021 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.248%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.777%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.777%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,783,447 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,019,311 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested Restricted Stock Units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313,337 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,709 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,373 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,794,156 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,344,021 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>10783447701931120003133378709113731079415673440 21 11. Corporate Restructuring The Company currently estimates that it will incur costs of approximately $2.8 million for termination benefits relating to the Restructuring, substantially all of which the Company expects to recognize in the third and fourth quarters of 2024 and pay out in cash during the fourth quarter of 2024 and first quarter of 2025. <span

style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company expensed the following costs associated with the termination benefit payments resulting from the Restructuring (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:70.86%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:25.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,007 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,309 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total severance expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of September 30, 2024, the accrued liability balance associated with the Restructuring is $2.3 million and is included in the accrued expenses line of the accompanying unaudited condensed consolidated balance sheet. 28000002800000 The Company expensed the following costs associated with the termination benefit payments resulting from the Restructuring (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:70.86%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:25.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,007 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,309 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"> Total severance expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>10070001309000231600023000000falsefalsefalsefalse